PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Barroso, MR; Bernd, KK; DeWitt, ND; Chang, A; Mills, K; Sztul, ES				Barroso, MR; Bernd, KK; DeWitt, ND; Chang, A; Mills, K; Sztul, ES			A novel Ca2+-binding protein, p22, is required for constitutive membrane traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; ESCHERICHIA-COLI; PLASMA-MEMBRANE; RECOVERIN; FUSION; CELLS; FAMILY; MYRISTOYLATION; RECONSTITUTION; SYNAPTOTAGMIN	We have identified a novel protein, p22, required for ''constitutive'' exocytic membrane traffic. p22 belongs to the EF-hand superfamily of Ca2+-binding proteins and shows extensive similarity to the regulatory subunit of protein phosphatase 2B, calcineurin B. p22 is a cytosolic N-myristoylated protein that undergoes conformational changes upon binding of Ca2+. Antibodies against a p22 peptide block the targeting/fusion of transcytotic vesicles with the apical plasma membrane, but recombinant wild-type p22 overcomes that inhibition. Nonmyristoylated p22, or p22 incapable of undergoing Ca2+-induced conformational changes, cannot reverse the antibody-mediated inhibition. The data suggest that p22 may act by transducing cellular Ca2+ signals to downstream effecters. p22 is ubiquitously expressed, and we propose that its function is required for membrane trafficking events common to many cells.	UNIV ALABAMA, MED CTR, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham			Bernd, Karen K/K-2774-2012; Barroso, Margarida/A-9901-2010	Bernd, Karen K/0000-0002-0743-2848; Barroso, Margarida/0000-0002-0407-3181				AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BABU A, 1992, J BIOL CHEM, V267, P15469; BARROSO M, 1988, EUR J BIOCHEM, V172, P363, DOI 10.1111/j.1432-1033.1988.tb13895.x; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; CHAKRAVARTI S, 1990, J BIOL CHEM, V265, P10597; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; LEW DJ, 1991, J MEMBRANE BIOL, V123, P261, DOI 10.1007/BF01870409; LI E, 1987, J BIOL CHEM, V262, P13773; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MORIMOTO T, 1995, CELL, V15, P689; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHELLER RH, 1995, NEURON, V14, P893; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TURNER MD, 1992, J CELL BIOL, V117, P269, DOI 10.1083/jcb.117.2.269; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405	48	71	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10183	10187		10.1074/jbc.271.17.10183	http://dx.doi.org/10.1074/jbc.271.17.10183			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626580	hybrid			2022-12-25	WOS:A1996UG25700052
J	Kamada, Y; Qadota, H; Python, CP; Anraku, Y; Ohya, Y; Levin, DE				Kamada, Y; Qadota, H; Python, CP; Anraku, Y; Ohya, Y; Levin, DE			Activation of yeast protein kinase C by Rho1 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION; SYSTEM; GENE	We have investigated the role of the essential Rho1 GTPase in cell integrity signaling in budding yeast. Conditional rho1 mutants display a cell lysis defect that is similar to that of mutants in the cell integrity signaling pathway mediated by protein kinase C (Pkc1), which is suppressed by overexpression of Pkc1. rho1 mutants are also impaired in pathway activation in response to growth at elevated temperature. Pkc1 co-immunoprecipitates with Rho1 in yeast extracts, and recombinant Rho1 associates with Pkc1 in vitro in a GTP-dependent manner. Recombinant Rho1 confers upon Pkc1 the ability to be stimulated by phosphatidylserine. indicating that Rho1 controls signal transmission through Pkc1.	JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA; UNIV TOKYO, GRAD SCH SCI, DEPT BIOL SCI, TOKYO 113, JAPAN	Johns Hopkins University; University of Tokyo				Levin, David/0000-0003-0696-2860	NIGMS NIH HHS [GM48533] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OHYA Y, 1994, GENETICS, V138, P1041; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; QADOTA H, 1996, IN PRESS SCIENCE; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WATANABE M, 1994, J BIOL CHEM, V269, P16829; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	33	259	261	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9193	9196		10.1074/jbc.271.16.9193	http://dx.doi.org/10.1074/jbc.271.16.9193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621575	hybrid			2022-12-25	WOS:A1996UG04400006
J	Miyata, KS; McCaw, SE; Patel, HV; Rachubinski, RA; Capone, JP				Miyata, KS; McCaw, SE; Patel, HV; Rachubinski, RA; Capone, JP			The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT; SYSTEM; ACID	The yeast two-hybrid system was used to isolate novel cellular factors that interact with the mouse peroxisome proliferator-activated receptor alpha (PPAR alpha). One of the interacting clones isolated encoded LXR alpha, a recently described human orphan nuclear hormone receptor. LXR alpha bound directly to PPAR alpha, as well as to the common heterodimerization partner 9-cis-retinoic acid receptor (RXR alpha). LXR alpha did not form a DNA binding complex with PPAR alpha on synthetic hormone response elements composed of direct repeats of the TGACCT consensus half-site or on naturally occurring peroxisome proliferator response elements (PPREs) or LXR alpha response elements, However, LXR alpha inhibited binding of PPAR alpha/RXR alpha heterodimers to PPREs, and coexpression of LXR alpha in mammalian cells antagonized peroxisome proliferator signaling mediated by PPAR alpha/RXR alpha in vivo, These findings identify a novel partner for PPAR alpha and suggest that LXR alpha plays a role in modulating PPAR-signaling pathways in the cell.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA	McMaster University; University of Alberta								APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; AUSUBEL GM, 1995, CURRENT PROTOCOLS MO, V2; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MIYATA KS, 1994, GENE, V148, P327, DOI 10.1016/0378-1119(94)90707-2; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	28	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9189	9192		10.1074/jbc.271.16.9189	http://dx.doi.org/10.1074/jbc.271.16.9189			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621574	hybrid			2022-12-25	WOS:A1996UG04400005
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: Possible involvement of Tax1 in the altered expression of cyclin D2, p18(Ink4) and p21(Waf1/Cip1/Sdi1)	ONCOGENE			English	Article						HTLV-I; Tax1; cyclin; cdk; cdk-inhibitor; immortalization	PRIMARY HUMAN-LYMPHOCYTES; LEUKEMIA-VIRUS TYPE-1; DEPENDENT KINASES; TRANS-ACTIVATION; PROTEIN; LEUKOCYTES	To understand how the growth of T-cells transformed by Human T-cell leukemia virus type I(HTLV-I) is deregulated, we analysed the expression of cell-cycle regulatory genes in HTLV-I infected and non-infected T-cell lines, We investigated the gene for 6 cyclins, 4 cyclin-dependent kinases, and 5 cyclin-dependent kinase inhibitors, and found the following: (1) HTLV-I infected T-cell lines preferentially expressed cyclin D2, whereas cyclin D3 was the major D-type cyclin in HTLV-I negative T-cell lines; (2) HTLV-I infected T-cell lines expressed strikingly low levels of p18(Ink4) compared with those that were HTLV-I negative; (3) HTLV-I infected T-cell lines expressed high levels of p21(Waf1/Cip1/Sdi1), whereas p21(Waf1/Cip1/Sdi1) was undetectable in HTVL-I negative T-cell lines, These features were also found in T-cells immortalized by Tax1, which we established, Therefore, it is strongly suggested that Tax1 alters the expression of these cell-cycle regulatory genes.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1991, GENE, V106, P255, DOI 10.1016/0378-1119(91)90207-R; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GAZDAR AF, 1980, BLOOD, V55, P409; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JIANG HP, 1994, ONCOGENE, V9, P3397; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	118	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1645	1652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622884				2022-12-25	WOS:A1996UG45800006
J	Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G				Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G			Retinoblastoma protein inhibits IFN-gamma induced apoptosis	ONCOGENE			English	Article						retinoblastoma protein; IFN-gamma; apoptosis	TUMOR-NECROSIS-FACTOR; B-CELL LINES; INTERFERON-GAMMA; FLOW-CYTOMETRY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HUMAN CANCER; DEATH; INDUCTION; ALPHA	Regulation of apoptosis (programmed cell death) is critical for maintaining tissue homeostasis. Recent studies indicate a tight coupling between cellular proliferation and apoptosis as cell cycle regulators such as Cyclin D, E1A and E7 appear to influence both events, Each of these modulators is able to bind to and inhibit the function of the retinoblastoma tumor suppressor protein (RE), RE functions, in part, by binding to and inactivating E2F transcription factors, preventing expression of E2F-activated genes associated with G1/S cell-cycle progression, Loss of functional RB deregulates E2F activity and, depending on cell type and environmental factors, promotes tumorigenesis or apoptotic death, To determine the effect of RB on IFN-gamma induced apoptosis, we treated RB-defective carcinoma cell lines and their respective RB-reconstituted sister clones with IFN-gamma and examined the cells for alterations characteristic of apoptosis, We observed that RB-defective cells, but not the RB-reconstituted clones, decreased in size following IFN-gamma treatment, IFN-gamma treatment caused increased cell detachment in the RB-defective lines but did not affect adherence of the RB-reconstituted clones, Assays for DNA fragmentation revealed lower molecular weight DNA and the apoptosis- associated oligo-nucleosomal ladder following IFN-gamma treatment of the RB-defective cells while higher molecular weight DNA was present in the IFN-gamma treated, RB-reconstituted lines, IFN gamma-induced apoptosis in RB-defective cells was enhanced by serum stimulation, which is also characteristic of p53-dependent E2F-1-mediated apoptosis, However, IFN-gamma induced apoptosis in RB-defective lines does not require wild-type p53 suggesting that, upon IFN-gamma induction, deregulated E2F-mediated apoptosis can also proceed via p53-independent pathways.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; UNIV S FLORIDA, H LEE MOFFITT CANC CTR, COLL MED, TAMPA, FL 33612 USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Baylor College of Medicine					NEI NIH HHS [EY06195] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARTEK J, 1990, ONCOGENE, V5, P893; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN PA, 1993, J IMMUNOTHER, V14, P242, DOI 10.1097/00002371-199310000-00012; DETRICK B, 1991, INVEST OPHTH VIS SCI, V32, P1714; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOON DSB, 1991, CANCER RES, V51, P2002; HOOPER ML, 1994, J CELL SCI, P13; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1994, EXP CELL RES, V212, P161, DOI 10.1006/excr.1994.1131; IBRAHIM L, 1993, IMMUNOLOGY, V79, P119; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISHII H, 1994, ACTA MED OKAYAMA, V48, P73; JO TS, 1995, ANAT RECORD, V241, P70, DOI 10.1002/ar.1092410110; KARASAKI Y, 1992, J INTERFERON RES, V12, P185, DOI 10.1089/jir.1992.12.185; Kelso A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026930; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOTEM J, 1995, LEUKEMIA, V9, P685; LU Y, 1994, J IMMUNOL, V153, P1495; LU Y, 1996, IN PRESS J IMMUNOL; LU YM, 1994, ONCOGENE, V9, P1015; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOVELLI F, 1994, J IMMUNOL, V152, P496; OKUBO K, 1991, Kurume Medical Journal, V38, P57; OSBORNE BA, 1994, IMMUNOL REV, V142, P301, DOI 10.1111/j.1600-065X.1994.tb00894.x; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; PANG YB, 1992, BLOOD, V80, P724; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHER RL, 1993, ARCH OTOLARYNGOL, V119, P432; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shimada Shinya, 1993, In Vivo (Attiki), V7, P1; SHINAGAWA T, 1991, J PATHOL, V165, P247, DOI 10.1002/path.1711650309; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOMITA Y, 1993, AM J PATHOL, V143, P191; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	76	80	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1809	1819						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622902				2022-12-25	WOS:A1996UG45800024
J	Tulchinsky, EM; Georgiev, GP; Lukanidin, EM				Tulchinsky, EM; Georgiev, GP; Lukanidin, EM			Novel AP-1 binding site created by DNA-methylation	ONCOGENE			English	Article						AP-1; DNA-methylation; gene expression; mts1 gene	GLOBIN GENE-EXPRESSION; MESSENGER-RNA; MTS1 GENE; PROTEIN; CELLS; FOS; JUN; IDENTIFICATION; SEQUENCES; PROMOTER	DNA-methylation is known to repress transcription either by inactivation of positive regulatory cis-elements containing CpG dinucleotides or via the sequence-nonspecific and methylation-specific binding of inhibiting methyl-CpG binding protein 1 (MeCP1). In the present work we describe the novel way DNA-methylation can influence gene expression: a binding site for transcription factors AP-1 might be created by DNA-methylation. Such a DNA-methylation-dependent AP-1 binding site was found in the first intron of the metastasis-associated mts1 gene, The expression level of this gene correlates with the hypomethylation of the mts1 first intron sequence in mouse adenocarcinoma cells. The DNA methylation-dependent AP-1 binding site was found to be functionally active in the nucleotide context of the mts1 gene. When methylated, this site reproducibly repressed transcription of CAT-containing DNA that had been transiently transfected into mouse adenocarcinoma CSML100 cells.	INST GENE BIOL, MOSCOW 117334, RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Tulchinsky, EM (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49 43, DK-2100 COPENHAGEN, DENMARK.		Tulchinsky, Eugene/ABD-7070-2021					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAHLER DW, 1985, J IMMUNOL, V134, P2790; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; FORD HL, 1995, ONCOGENE, V10, P1597; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HEIZMANN CW, 1991, NOVEL CALCIUM BINDIN; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HU JM, 1994, MOL CELL BIOL, V14, P1531, DOI 10.1128/MCB.14.3.1531; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JOEL P, 1993, NUCLEIC ACIDS RES, V21, P5786, DOI 10.1093/nar/21.24.5786; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SINGERSAM J, 1993, DNA METHYLATION MOL, P359; SUETAKE I, 1993, NUCLEIC ACIDS RES, V21, P2125, DOI 10.1093/nar/21.9.2125; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; ZHANG XY, 1989, NUCLEIC ACIDS RES, V17, P1459, DOI 10.1093/nar/17.4.1459; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	43	33	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1737	1745						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622894				2022-12-25	WOS:A1996UG45800016
J	Kalluri, R; Sun, MJ; Hudson, BG; Neilson, EG				Kalluri, R; Sun, MJ; Hudson, BG; Neilson, EG			The Goodpasture autoantigen - Structural delineation of two immunologically privileged epitopes on alpha 3(IV) chain of type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; NONCOLLAGENOUS DOMAIN HEXAMER; ALPORT SYNDROME; GLOBULAR DOMAIN; IDENTIFICATION; ANTIGEN; PROTEINS; GENE; AUTOANTIBODIES; LOCALIZATION	The family of type IV collagen comprises six chains numbered alpha 1 through alpha 6. The alpha 3(IV) NC1 domain is the primary target antigen for autoantibodies from patients with anti-basement membrane disease and Goodpasture syndrome. Earlier peptide studies suggested that the last 36 amino acids of the alpha 3 NCI domain probably contains one recognition site for Goodpasture autoantibodies, and an algorithm analysis of secondary structure from a later study predicted a second possible upstream epitope near the triple helix junction. me have used several analytic approaches to evaluate the likelihood of two immunologic epitopes for the Goodpasture antigen, In our first set of studies, peptide antibodies directed against these two putative regions co-inhibited Goodpasture autoantibodies binding to denatured human alpha 3(IV) NC1 monomer by nearly 80%, with the helix junction region of the alpha 3 NC1 domain contributing 26% of the binding sites and the C-terminal region contributing the remaining 50%, Second, both of these candidate regions are normally sequestered within the associated alpha 3(IV) NC1 hexamer but become more visible for binding by anti-peptide antibodies upon their dissociation, a property that is shared by the Goodpasture autoantibodies, Third, segment deletions of recombinant alpha 3 NC1 domain further confirmed the presence of two serologic binding sites. Finally, we looked more closely at the C-terminal binding region of the alpha 3(IV) NC1 domain. Since the lysines in that region have been previously advanced as possible contact sites, we created several substitutions within the C-terminal epitope of the alpha 3 NCI domain, Substitution of lysines to alanines revealed lysines 219 and 229 as essential for antibody binding to this distal site; no lysines were present in the NC1 part of the helix-NC1 junction region. Substitutions involving arginine and cysteines to alanines in the same C-terminal region did not produce significant reductions in antibody binding, In summary, our findings characterize two Goodpasture epitopes confined to each end of the alpha 3 NC1 domain; one is lysine-dependent, and the other is not. We propose, as a hypothetical model, that these two immunologically privileged regions fold to form an optimal pathogenic structure within the NC1 domain of the alpha 3 chain, These sites are subsequently concealed by NC1 hexamer assembly of type IV collagen.	UNIV PENN,DEPT MED,PENN CTR MOL STUDIES KIDNEY DIS,PHILADELPHIA,PA 19104; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160	University of Pennsylvania; University of Kansas; University of Kansas Medical Center			Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030280, R37DK030280, T32DK007006, R01DK018381, R37DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07006, DK-30280, DK-18381] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; COUSER WG, 1988, AM J KIDNEY DIS, V11, P449, DOI 10.1016/S0272-6386(88)80079-9; COUSER WG, 1991, PRINCIPLES PRACTICES, P283; DEVITO LD, 1993, HUM IMMUNOL, V37, P165, DOI 10.1016/0198-8859(93)90182-Z; DOWNIE GH, 1982, J IMMUNOL, V129, P2647; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1993, KIDNEY INT, V43, P135, DOI 10.1038/ki.1993.22; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LIOTTA LA, 1992, SCI AM, V266, P34; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1258; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; QUINONES S, 1992, J BIOL CHEM, V267, P19780; REGENMORTAL MHV, 1989, IMMUNOL TODAY, V10, P266; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; SAUS J, 1988, J BIOL CHEM, V263, P13374; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1986, KIDNEY INT, V30, P293, DOI 10.1038/ki.1986.183; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TIMPL R, 1985, ANN NY ACAD SCI, V460, P58, DOI 10.1111/j.1749-6632.1985.tb51157.x; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; Wilson C B, 1981, Aust N Z J Med, V11, P94, DOI 10.1111/j.1445-5994.1981.tb03570.x; WILSON CB, 1973, KIDNEY INT, V3, P74, DOI 10.1038/ki.1973.14; WILSON CB, 1988, IMUNOLOGIC DIS LUNG, P675; WILSON CB, 1981, P 8 INT C NEPHR, P910; WILSON CB, 1991, THERAPY RENAL DIS RE, P333; WILSON CB, 1991, KIDNEY, P1062; YOUNG SG, 1994, J LIPID RES, V35, P399; YUDOH K, 1994, JPN J CANCER RES, V85, P1263, DOI 10.1111/j.1349-7006.1994.tb02939.x; YURCHENCO PD, 1986, J HISTOCHEM CYTOCHEM, V34, P93, DOI 10.1177/34.1.3510247; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1992, J BIOL CHEM, V267, P12475	54	70	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9062	9068		10.1074/jbc.271.15.9062	http://dx.doi.org/10.1074/jbc.271.15.9062			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621555	hybrid			2022-12-25	WOS:A1996UE73000086
J	Nakamoto, T; Sakai, R; Ozawa, K; Yazaki, Y; Hirai, H				Nakamoto, T; Sakai, R; Ozawa, K; Yazaki, Y; Hirai, H			Direct binding of C-terminal region of p130(Cas) to SH2 and SH3 domains of Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASES; V-CRK; MONOCLONAL-ANTIBODIES; CYTOPLASMIC PROTEIN; STABLE ASSOCIATION; HOMOLOGY REGION-2; PHOSPHOLIPASE-C; IDENTIFICATION; RECEPTOR	p130(Cas) is a major tyrosine-phosphorylated protein that tightly binds v-Crk in v-crk-transformed cells and v-Src in v-src-transformed cells. The ''substrate domain'' of p130(Cas) contains 15 possible Src homology (SH) a-binding motifs, most of which conform to the binding motif for the Crk SH2 domain. Another region near its C terminus contains possible binding motifs for the Src SH2 domain and proline-rich sequences that are candidates for SH3-binding sites. Using GST fusion proteins, we revealed that both SH2 and SH3 domains of Src bind p130(Cas), whereas v-Crk binds p130(Cas) through its SH2 domain. We located the binding site of p130(Cas) for the Src SH3 domain at the sequence RPLPSPP in the region near its C terminus. Mutations within this sequence or at Tyr(762) Of p130(Cas) caused a significant reduction in the association of p130(Cas) with Src, and no association was detected when both of them were deleted. The kinase activity in v-Crk-transformed cells was also associated with p130(Cas) through this region. On the other hand, the deletion of the substrate domain abolished the binding with v-Crk, The association through the C-terminal region of p130(Cas) with Src kinase may facilitate effective hyperphosphorylation of tyrosine residues in the substrate domain of p130(Cas), resulting in the binding of SH2-containing molecules to p130(Cas).	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; JICHI MED SCH, DIV MOLEC BIOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	University of Tokyo; Jichi Medical University								BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OGAWA S, 1994, ONCOGENE, V9, P1669; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUDOL M, 1994, ONCOGENE, V9, P2145; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZAITSU H, 1988, BIOMED RES-TOKYO, V9, P181; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	219	220	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8959	8965		10.1074/jbc.271.15.8959	http://dx.doi.org/10.1074/jbc.271.15.8959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621540	hybrid			2022-12-25	WOS:A1996UE73000071
J	Thorogood, H; Grasby, JA; Connolly, BA				Thorogood, H; Grasby, JA; Connolly, BA			Influence of the phosphate backbone on the recognition and hydrolysis of DNA by the EcoRV restriction endonuclease - A study using oligodeoxynucleotide phosphorothioates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; CRYSTAL-STRUCTURE; NUCLEOSIDE PHOSPHOROTHIOATES; ABSOLUTE-CONFIGURATION; STEREOCHEMICAL COURSE; CHARGE LOCALIZATION; TRP REPRESSOR; BASE ANALOG; BOND ORDER; CLEAVAGE	A set of phosphorothioate-containing oligonucleotides based on pGACGATATCGTC, a self-complementary dodecamer that contains the EcoRV recognition sequence (GATATC), has been prepared. The phosphorothioate group has been individually introduced at the central nine phosphate positions and the two diastereomers produced at each site separated and purified. The K-m and V-max values found for each of these modified DNA molecules with the EcoRV restriction endonuclease have been determined and compared with those seen for the unmodified all-phosphate-containing dodecamer, This has enabled an evaluation of the roles that both of the non-esterified oxygen atoms in the individual phosphates play in DNA binding and hydrolysis by the endonuclease, The results have also been compared with crystal structures of the EcoRV endonuclease, complexed with an oligodeoxynucleotide, to allow further definition of phosphate group function during substrate binding and turnover, For further study, see the related article ''Probing the Indirect Readout of the Restriction Enzyme EcoRV: Mutational Analysis of Contacts to the DNA Backbone'' (Went, A., Jeltsch, A, and Pingoud, A, (1996) J. Biol, Chem, 271, 5565-5573).	UNIV NEWCASTLE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV SOUTHAMPTON,DEPT BIOCHEM,SOUTHAMPTON SO9 3TU,HANTS,ENGLAND	Newcastle University - UK; University of Southampton								AIKEN CR, 1991, METHOD ENZYMOL, V208, P433; ALVES J, 1995, BIOCHEMISTRY-US, V34, P11191, DOI 10.1021/bi00035a026; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; BARANIAK J, 1988, J AM CHEM SOC, V110, P4059, DOI 10.1021/ja00220a067; BECKER MM, 1988, P NATL ACAD SCI USA, V85, P6247, DOI 10.1073/pnas.85.17.6247; BOUGUELERET L, 1985, NUCLEIC ACIDS RES, V13, P3823, DOI 10.1093/nar/13.11.3823; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; CONNOLLY BA, 1984, BIOCHEMISTRY-US, V23, P3443, DOI 10.1021/bi00310a010; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P4771; CRUSE WBT, 1986, J MOL BIOL, V192, P891, DOI 10.1016/0022-2836(86)90035-5; DARCY A, 1985, J BIOL CHEM, V260, P1987; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Fersht A., 1985, ENZYME STRUCTURE MEC; FLIESS A, 1988, NUCLEIC ACIDS RES, V16, P11781, DOI 10.1093/nar/16.24.11781; FLIESS A, 1986, NUCLEIC ACIDS RES, V14, P3463, DOI 10.1093/nar/14.8.3463; FREEMONT PS, 1991, BIOCHEM J, V278, P1; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; GALLO KA, 1986, NUCLEIC ACIDS RES, V14, P7405, DOI 10.1093/nar/14.18.7405; GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016; HALFORD SE, 1993, NUCLEIC ACIDS MOL BI, V7, P47; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HOGREFE RI, 1993, PROTOCOLS OLIGONUCLE, P143; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KOZIOLKIEWICZ M, 1992, BIOCHEMISTRY-US, V31, P9460, DOI 10.1021/bi00154a019; Koziolkiewicz M, 1993, PROTOCOLS OLIGONUCLE, P207; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LESSER DR, 1992, J BIOL CHEM, V267, P24810; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIANG CX, 1987, J AM CHEM SOC, V109, P6449, DOI 10.1021/ja00255a034; MATTHEWS BW, 1988, NATURE, V335, P294, DOI 10.1038/335294a0; MAYER AN, 1994, J BIOL CHEM, V269, P29067; MAZZARELLI J, 1989, BIOCHEMISTRY-US, V28, P4616, DOI 10.1021/bi00437a016; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; MILLER PS, 1991, OLIGONUCLEOTIDES ANA, P137; MILLIGAN JF, 1989, BIOCHEMISTRY-US, V28, P2849, DOI 10.1021/bi00433a016; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; OLSEN DB, 1990, BIOCHEMISTRY-US, V29, P9546, DOI 10.1021/bi00493a008; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAHO CO, 1992, ANNU REV BIOCHEM, V61, P1053; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; POTTER BVL, 1984, J BIOL CHEM, V259, P4243; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEC WJ, 1985, J CHROMATOGR, V326, P263, DOI 10.1016/S0021-9673(01)87452-5; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEITZ TA, 1993, STRUCTURAL STUDIES P; STOVER T, 1993, J BIOL CHEM, V268, P8645; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3729; VANWAZER JR, 1958, PHOSPHORUS ITS COMPO, V1, P348; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; VIPOND IB, 1993, MOL MICROBIOL, V9, P225, DOI 10.1111/j.1365-2958.1993.tb01685.x; WATERS TR, 1992, ANAL BIOCHEM, V204, P204, DOI 10.1016/0003-2697(92)90162-Z; WATERS TR, 1994, BIOCHEMISTRY-US, V33, P1812, DOI 10.1021/bi00173a026; WENZ A, 1996, J BIOL CHEM, V271, P5565; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87; ZON G, 1993, PROTOCOLS OLIGONUCLE, P165	75	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8855	8862		10.1074/jbc.271.15.8855	http://dx.doi.org/10.1074/jbc.271.15.8855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621526	hybrid			2022-12-25	WOS:A1996UE73000057
J	Beaumont, C; Torti, SV; Torti, FM; Massover, WH				Beaumont, C; Torti, SV; Torti, FM; Massover, WH			Novel properties of L-type polypeptide subunits in mouse ferritin molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY SUBUNIT; RAT-LIVER; GENE-EXPRESSION; LIGHT SUBUNIT; CDNA CLONES; H-CHAIN; HETEROGENEITY; IRON; IDENTIFICATION; HETEROPOLYMERS	Properties of the L- and H-type polypeptide subunits forming ferritin 24-mer molecules in mice were investigated, using the products of in vitro transcription and translation from the two cloned genes, and recombinant ferritin molecules (H(24)L(0) or H(0)L(24) produced by transformation in Escherichia coli, Several different conditions for analytical electrophoresis reproducibly show that the relative migration position of the two mouse ferritin subunits is reversed from that reported for ferritin H- and L-subunits in all other mammals; since mouse and human H-polypeptides almost co-migrate, this unusual relative mobility is due largely to novel properties of the murine L-subunit. This unusual electrophoretic property of the mouse L-subunit has led to conflicting reports about the subunit composition of natural mouse ferritin. Here, we show that the single major electrophoretic band given by liver ferritin purified from mice having a short-term iron overload matches that produced by the genetically defined L-polypeptide and that some bona fide H-subunits are also detected. In conclusion, it is reasonable to assume that, when mouse ferritin samples will be analyzed under the same conditions as those described here, the slower species will correspond to the L-type subunit. However, when dealing with ferritin from species other than human or mouse, it should be kept in mind that upon electrophoretic analysis of ferritin polypeptide, the designation of an electrophoretic band as being H or L-type subunits will be very uncertain without corroboration hom genetic, immunological, or amino acid sequencing data.	BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, DEPT BIOCHEM, WINSTON SALEM, NC 27157 USA; BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, DEPT CANC BIOL, WINSTON SALEM, NC 27157 USA; UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT ANAT & CELL BIOL, NEWARK, NJ 07103 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Beaumont, C (corresponding author), UNIV PARIS 07, FAC MED XAVIER BICHAT,INSERM,U409, 16 RUE HENRI HUCHARD, BP 416, F-75870 PARIS 18, FRANCE.				NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412, R01DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [CA12197] Funding Source: Medline; NIDDK NIH HHS [DK42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS SC, 1987, BIOCHEM J, V245, P447, DOI 10.1042/bj2450447; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BOYD D, 1985, J BIOL CHEM, V260, P1755; BROWN AJP, 1983, P NATL ACAD SCI-BIOL, V80, P1265, DOI 10.1073/pnas.80.5.1265; BROXMEYER HE, 1992, J LAB CLIN MED, V120, P367; Dean B, 1989, Biol Met, V2, P77, DOI 10.1007/BF01129204; DRYSDALE JW, 1988, PROG NUCLEIC ACID RE, V35, P127, DOI 10.1016/S0079-6603(08)60612-1; HARRISON PM, 1991, ADV INORG CHEM, V36, P449; HONDA T, 1981, BRIT J HAEMATOL, V49, P653, DOI 10.1111/j.1365-2141.1981.tb07277.x; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1984, J BIOL CHEM, V259, P4327; LEVI S, 1988, J BIOL CHEM, V263, P18086; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; MASSOVER WH, 1993, MICRON, V24, P389, DOI 10.1016/0968-4328(93)90005-L; MASSOVER WH, 1979, BIOCHIM BIOPHYS ACTA, V579, P169, DOI 10.1016/0005-2795(79)90096-5; MASSOVER WH, 1985, BIOCHIM BIOPHYS ACTA, V829, P377, DOI 10.1016/0167-4838(85)90248-1; MIYAZAKI Y, 1988, NUCLEIC ACIDS RES, V16, P10373, DOI 10.1093/nar/16.21.10373; MUNRO H, 1993, NUTR REV, V51, P65, DOI 10.1111/j.1753-4887.1993.tb03072.x; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; REISER PJ, 1985, J BIOL CHEM, V260, P4403; RENAUDIE F, 1995, CR ACAD SCI III-VIE, V318, P431; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; SANTAMBROGIO P, 1989, BRIT J HAEMATOL, V71, P281, DOI 10.1111/j.1365-2141.1989.tb04268.x; STIEFEL EI, 1994, ADV EXP MED BIOL, V356, P157; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638	32	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7923	7926		10.1074/jbc.271.14.7923	http://dx.doi.org/10.1074/jbc.271.14.7923			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626471	hybrid			2022-12-25	WOS:A1996UD60000011
J	Knudsen, ES; Wang, JYJ				Knudsen, ES; Wang, JYJ			Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CELL-CYCLE; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION; BINDING PROTEIN; REPRESSION; REGIONS; DOMAINS; KINASE; PRB	The retinoblastoma tumor suppressor protein, RE, contains at least three distinct protein binding domains. The A/B pocket binds proteins with the LXCXE motif, the C pocket binds the nuclear c-Abl tyrosine kinase, and the large A/B pocket binds the transcription factor E2F. Dissociation of RE from its targets is observed as RE becomes phosphorylated during G(1)/S progression. There are 16 Cdk consensus phosphorylation sites in RE. It was previously unknown whether the many phosphorylation sites had redundant or distinct functions in the regulation of RE. Using RE mutant proteins lacking specific phosphorylation sites, we show that each of the binding domains is inhibited by different sites. Thr-821/826 phosphorylation is required to inhibit the binding to LXCXE containing proteins. Mutation of these two sites does not interfere with the hyperphosphorylation of RE. However, this phosphorylated mutant retains the ability to bind T-Ag, E7, and Elf-1, all of which contain the LXCXE motif. In contrast, Ser-807/811 phosphorylation is required to disrupt c-Abl binding. Mutation of Ser-807/811 and Thr-821/826 does not abolish the regulation of E2F binding. Taken together, these results show that the protein binding domains of RE are each regulated by distinct Cdk phosphorylation sites.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [CA58320, R01 CA058320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEYERLE KL, 1989, J VIROL, V63, P356, DOI 10.1128/JVI.63.1.356-365.1989; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN BTY, 1992, CIBA F SYMP, V170, P227; MELENDY T, 1991, J BIOL CHEM, V266, P1942; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	29	274	277	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8313	8320		10.1074/jbc.271.14.8313	http://dx.doi.org/10.1074/jbc.271.14.8313			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626527	hybrid			2022-12-25	WOS:A1996UD60000067
J	Sakane, F; Imai, S; Kai, M; Wada, I; Kanoh, H				Sakane, F; Imai, S; Kai, M; Wada, I; Kanoh, H			Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those the EPH family of protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; REGULATORY DOMAIN; CDNA-CLONING; ZINC-FINGER; HAND MOTIFS; RAT-BRAIN; GENE; EXPRESSION; PURIFICATION	A fourth member of the diacylglycerol kinase (DGK) gene family termed DGK delta was cloned from the human testis cDNA library. The cDNA sequence contains an open reading frame of 3,507 nucleotides encoding a putative DGK protein of 130,006 Da. Interestingly, the new DGK isozyme contains a pleckstrin homology domain found in a number of proteins involved in signal transduction. Furthermore, the C-terminal tail of this isozyme is very similar to those of the EPH family of receptor tyrosine kinases. The primary structure of the delta-isozyme also has two cysteine-rich zinc finger-like structures (C3 region) and the C-terminal C4 region, both of which have been commonly found in the three isozymes previously cloned (DGKs alpha, beta and gamma). However, DGK delta lacks the EF-hand motifs (C2) and contains a long Glu- and Ser-rich insertion (317 residues), which divides the C4 region into two portions. Taken together, these structural features of DGK delta indicate that this isozyme belongs to a DGK subfamily distinct from that consisting of DGKs alpha, beta, and gamma. Increased DGK activity without marked preference to arachidonoyl type of diacylglycerol was detected in the particulate fraction of COS-7 cells expressing the transfected DGK delta cDNA. The enzyme activity was independent of phosphatidylserine, which is a common activator for the previously sequenced DGKs. Northern blot analysis showed that the DGK delta mRNA (similar to 6.3 kilobases) is most abundant in human skeletal muscle but undetectable in the brain, thymus, and retina. This expression pattern is different from those of the previously cloned DGKs. Our results show that the DGK gene family consists of at least two subfamilies consisting of enzymes with distinct structural characteristics and that each cell type probably expresses its own characteristic repertoire of DGKs whose functions may be regulated through different signal transduction pathways.			Sakane, F (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,SOUTH-1,WEST-17,SAPPORO,HOKKAIDO 060,JAPAN.		Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKCROFT S, 1992, BIOCHEM J, V288, P1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KATO M, 1990, J BIOL CHEM, V265, P794; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOHTAK V, 1991, MOL CELL BIOL, V11, P2496; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARU Y, 1990, ONCOGENE, V5, P445; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SDAMBROOK J, 1989, MOL CLONING LAB MANU; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YADA Y, 1990, J BIOL CHEM, V265, P19237; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	62	133	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8394	8401		10.1074/jbc.271.14.8394	http://dx.doi.org/10.1074/jbc.271.14.8394			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626538	hybrid			2022-12-25	WOS:A1996UD60000078
J	Liu, J; Blin, N; Conklin, BR; Wess, J				Liu, J; Blin, N; Conklin, BR; Wess, J			Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; ADENYLATE-CYCLASE; COUPLED RECEPTORS; BINDING; HYDROLYSIS; SUBTYPES; IDENTIFICATION; SPECIFICITY; G(Q)ALPHA	We have recently shown that a four-amino acid epitope (VTIL) on the m2 muscarinic receptor (corresponding to Val(385), Thr(386), Ile(389), and Leu(390)) is essential for G(i/o) coupling specificity and G(i/o) activation (Liu, J., Conklin, B. R., Blin, N., Yun, J., and Wess, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11642-11646). Because this sequence element is thought to be located at the junction between the third intracellular loop and the sixth transmembrane helix (TM VI), we speculated that agonist binding to the m2 receptor protein results in conformational changes that enable the VTIL motif to interact with G(i/o) proteins. To test the hypothesis that such structural changes might involve a relative movement of TM VI toward the cytoplasm, we created a series of mutant m2 muscarinic receptors in which one to four extra Ala residues were inserted into TM VI immediately after Leu(390). Based on the geometry of an alpha-helix, such mutations are predicted to ''push'' the VTIL sequence away from the lipid bilayer. Consistent with our working hypothesis, second messenger assays with transfected COS-7 cells showed that all mutant m2 receptors containing extra Ala residues C-terminal of Leu(390) could activate the proper G proteins even in the absence of agonist. However, replacement of the VTIL motif in such constitutively active m2 receptors with the corresponding m3 muscarinic receptor sequence (AALS) or deletion of Ala(391) from the wild type m2 receptor completely abolished G protein coupling. Interestingly, introduction of extra Ala residues C-terminal of the AALS motif in the m3 muscarinic receptor completely abolished functional activity. Mutant m2 and m3 receptors that contained extra Ala residues immediately N-terminal of the VTIL and AALS motif, respectively, displayed wild type-like coupling properties. Our data are consistent with a model in which agonist binding to the m2 muscarinic receptor leads to a relative movement of TM VI toward the cytoplasm, thus enabling the adjacent VTIL sequence to interact with the C terminus of G alpha(i/o) subunits.	NIDDK,NIH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT PHARMACOL,SAN FRANCISCO,CA 94141	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P18870; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; REN Q, 1993, J BIOL CHEM, V268, P16483; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1996, IN PRESS CRIT REV NE	47	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6172	6178		10.1074/jbc.271.11.6172	http://dx.doi.org/10.1074/jbc.271.11.6172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626406	hybrid			2022-12-25	WOS:A1996UA36300035
J	MatsunoYagi, A; Hatefi, Y				MatsunoYagi, A; Hatefi, Y			Ubiquinol-cytochrome c oxidoreductase - The redox reactions of the bis-heme cytochrome b in ubiquinone-sufficient and ubiquinone-deficient systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; MITOCHONDRIAL ELECTRON-TRANSPORT; PROTONMOTIVE Q-CYCLE; YEAST COMPLEX-III; RHODOBACTER-SPHAEROIDES; OXIDATIVE-PHOSPHORYLATION; RESPIRATORY-CHAIN; SACCHAROMYCES-CEREVISIAE; BINDING PROTEINS; ANTIMYCIN	Antimycin and myxothiazol are stoichiometric inhibitors of complex III (ubiquinol-cytochrome c oxidoreductase), exerting their highest degree of inhibition at 1 mol each/mol of complex III monomer. Phenomenologically, however, they each inhibit three steps in the redox reaction of the bis-heme cytochrome b in submitochondrial particles (SMP), and all three inhibitions are incomplete to various extents. (i) In SMP, reduction of hemes b(H) and b(L) by NADH or succinate is inhibited when the particles are treated with both antimycin and myxothiazol. Each inhibitor alone allows reduced b(H) and b(L) to accumulate, indicating that each inhibits the reoxidation of these hemes, (E)-Methyl-3-methoxy-2-(4'trans-stilbenyl)acrylate in combination with antimycin or 2-n-heptyl-4-hydroxyquinoline-N-oxide in combination with myxothiazol causes less inhibition of b reduction than the combination of antimycin and myxothiazol. (ii) Reoxidation of reduced b(L) is inhibited by either antimycin or myxothiazol (or 2-n-heptyl-4-hydroxyquinoline-N-oxide, (E)-methyl-3-methoxy-2-(4'-trans-stilbenyl)acrylate, or stigmatellin). (iii) Reoxidation of reduced b(H) is also inhibited by any one of these reagents. These inhibitions are also incomplete, and reduced b(L) is oxidized through the leaks allowed by these inhibitors at least 10 times faster than reduced b(H). Heme b(H) can be reduced in SMP via cytochrome c(1) and the Rieske iron-sulfur protein by ascorbate and faster by ascorbate + TMPD (N,N,N',N'-tetramethyl-p-phenylenediamine). Energization of SMP by the addition of ATP affords reduction of b(L) as well. Reverse electron transfer to b(H) and b(L) is inhibited partially by myxothiazol, much more by antimycin, Ascorbate + TMPD also reduce b(H) in ubiquinone-extracted SMP in which the molar ratio of ubiquinone to cytochrome b has been reduced 200-fold from 12.5 to similar to 0.06. Reconstitution of the extracted particles with ubiquinone-10 restores substrate oxidation but does not improve the rate or the extent of b(H) reduction by ascorbate + TMPD. These reagents also partially reduce cytochrome b in SMP from a ubiquinone-deficient yeast mutant. The above results are discussed in relation to the Q-cycle hypothesis.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BEATTIE DS, 1993, J BIOENERG BIOMEMBR, V25, P233, DOI 10.1007/BF00762585; BEATTIE DS, 1986, BIOCHEMISTRY-US, V25, P1395, DOI 10.1021/bi00354a031; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CHANCE B, 1974, DYNAMICS ENERGY TRAN, P553; CLEJAN L, 1986, BIOCHEMISTRY-US, V25, P7984, DOI 10.1021/bi00372a029; CLEJAN L, 1983, BIOCHEMISTRY-US, V22, P52, DOI 10.1021/bi00270a007; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; DEGLIESPOSTI M, 1990, ARCH BIOCHEM BIOPHYS, V283, P258, DOI 10.1016/0003-9861(90)90640-K; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DEVRIES S, 1980, FEBS LETT, V122, P143; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; ERNSTER L, 1969, EUR J BIOCHEM, V9, P299, DOI 10.1111/j.1432-1033.1969.tb00609.x; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; HATEFI Y, 1962, J BIOL CHEM, V237, P1681; HATEFI Y, 1982, BIOCHEMISTRY-US, V21, P6614, DOI 10.1021/bi00268a045; HATEFI Y, 1963, ADV ENZYMOL REL S BI, V25, P275; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HATEFI Y, 1961, BIOCHEM BIOPH RES CO, V4, P441, DOI 10.1016/0006-291X(61)90305-9; HATEFI Y, 1959, BIOCHIM BIOPHYS ACTA, V34, P183, DOI 10.1016/0006-3002(59)90246-X; HE DY, 1994, J BIOL CHEM, V269, P2292; LESTER RL, 1961, BIOCHIM BIOPHYS ACTA, V47, P358, DOI 10.1016/0006-3002(61)90297-9; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P10561, DOI 10.1021/bi00201a001; OHNISHI T, 1989, J BIOL CHEM, V264, P735; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; RIESKE JS, 1971, ARCH BIOCHEM BIOPHYS, V145, P179, DOI 10.1016/0003-9861(71)90025-7; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; SZARKOWSKA L, 1966, ARCH BIOCHEM BIOPHYS, V113, P519, DOI 10.1016/0003-9861(66)90228-1; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI A, 1986, BIOCHIM BIOPHYS ACTA, V852, P100, DOI 10.1016/0005-2728(86)90061-7; TSAI AL, 1987, J BIOL CHEM, V262, P8677; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU CA, 1978, BIOCHEM BIOPH RES CO, V82, P1070, DOI 10.1016/0006-291X(78)90296-6; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1986, BIOCHIM BIOPHYS ACTA, V848, P305, DOI 10.1016/0005-2728(86)90204-5; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014	53	27	27	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6164	6171		10.1074/jbc.271.11.6164	http://dx.doi.org/10.1074/jbc.271.11.6164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626405	hybrid			2022-12-25	WOS:A1996UA36300034
J	HillEubanks, D; Burstein, ES; Spalding, TA; Brauner-Osborne, H; Brann, MR				HillEubanks, D; Burstein, ES; Spalding, TA; Brauner-Osborne, H; Brann, MR			Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ACETYLCHOLINE-RECEPTOR; AMINO-ACIDS; BETA-2-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; ESCHERICHIA-COLI; EXPRESSION; SUBTYPES; IDENTIFICATION; SELECTIVITY	The third intracellular loop (i3) plays a critical role in the coupling of many receptors to G-proteins. In muscarinic receptor subtypes, the N- and C-terminal regions (Ni3 and Ci3) of this loop are sufficient to direct appropriate G-protein coupling. The relative functional contributions of all amino acids within Ni3 was evaluated by constructing libraries of m5 muscarinic receptors containing random mutations in Ni3 and screening them using high throughput assays based on ligand-dependent transformation of NIH 3T3 cells, In receptors that retained a wild type phenotype, the pattern of functionally tolerated substitutions is consistent with the presence of three turns of an alpha helix extending from the transmembrane domain. All of the amino acid positions that tolerate radical substitutions face away from a conserved hydrophobic face that ends with an arginine, and helix-disrupting proline substitutions were not observed, All of the mutant receptors with significantly compromised phenotypes had amino acid substitutions in residues predicted to form the hydrophobic face. Similar data from the Ci3 region (Burstein, E. S., Spalding, T. A., Hill-Eubanks, D., and Brann, M. R. (1995) J. Biol, Chem, 270, 3141-3146) are consistent with the presence of a single helical turn extending from the transmembrane domain, with an alanine that defines G-protein affinity, Functionally critical residues of Ni3 and Ci3 are predicted to be in close proximity where they form the G-protein-coupling domain.	UNIV VERMONT, DEPT PSYCHIAT, MOLEC NEUROPHARMACOL SECT, BURLINGTON, VT 05405 USA; UNIV VERMONT, DEPT PHARMACOL, BURLINGTON, VT 05405 USA; UNIV VERMONT, VERMONT CANC CTR, BURLINGTON, VT 05405 USA; RECEPTOR TECHNOL INC, WINOOSKI, VT 05404 USA	University of Vermont; University of Vermont; University of Vermont			Bräuner-Osborne, Hans/D-7260-2011	Bräuner-Osborne, Hans/0000-0001-9495-7388	NIGMS NIH HHS [GM52737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P111; ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANN MR, 1992, MOL BIOL G PROTEIN C; BREYER RM, 1990, EMBO J, V9, P2679, DOI 10.1002/j.1460-2075.1990.tb07453.x; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; DUERSON K, 1993, FEBS LETT, V324, P103, DOI 10.1016/0014-5793(93)81541-7; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JONES SVP, 1992, MOL BIOL G PROTEIN C, P170; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OLIPHANT AR, 1989, P NATL ACAD SCI USA, V86, P9094, DOI 10.1073/pnas.86.23.9094; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; Sambrook J, 1989, MOL CLONING LABORATO; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG SKF, 1990, J BIOL CHEM, V265, P6219	43	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3058	3065		10.1074/jbc.271.6.3058	http://dx.doi.org/10.1074/jbc.271.6.3058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621701	hybrid			2022-12-25	WOS:A1996TU69100030
J	Thomas, CE; Ohlweiler, DF; Carr, AA; Nieduzak, TR; Hay, DA; Adams, G; Vaz, R; Bernotas, RC				Thomas, CE; Ohlweiler, DF; Carr, AA; Nieduzak, TR; Hay, DA; Adams, G; Vaz, R; Bernotas, RC			Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERT-BUTYL-NITRONE; ADDUCTS; BRAIN; OXIDATION; ISCHEMIA; DAMAGE; RATS	alpha-Phenyl-tert-butyl nitrone (PEN) is a nitrone spin trap, which has shown efficacy in animal models of oxidative stress, including stroke, aging, sepsis, and myocardial ischemia/reperfusion injury. We have prepared a series of novel cyclic variants of PBN and evaluated them for radical trapping activity in vitro. Specifically, their ability to inhibit iron-induced lipid peroxidation in liposomes was assessed, as well as superoxide anion (O-2) and hydroxyl radical ((OH)-O-.) trapping activity as determined biochemically and using electron spin resonance (ESR) spectroscopy. All cyclic nitrones tested were much more potent as inhibitors of lipid peroxidation than was PBN. The unsubstituted cyclic variant MDL 101,002 was approximately 8-fold more potent than PBN. An analysis of the analogs of MDL 101,002 revealed a direct correlation of activity with lipophilicity. However, lipophilicity does not solely account for the difference between MDL 101,002 and PBN, in as much as the calculated octanol/water partition coefficient for MDL 101,002 is 1.01 as compared to 1.23 for PBN. This indicated the cyclic nitrones are inherently more effective radical traps than PBN in a membrane system. The most active compound was a dichloro analog in the seven-membered ring series (MDL 104,342), which had an IC50 of 26 mu M, which was 550-fold better than that of PBN. The cyclic nitrones were shown to trap (OH)-O-. with MDL 101,002 being 20-25 times more active than PBN as assessed using 2-deoxyribose and p-nitroso dimethylaniline as substrates, respectively. Trapping of (OH)-O-. by MDL 101,002 was also examined by using ESR spectroscopy. When Fenton's reagent was used, the (OH)-O-. adduct of MDL 101,002 yielded a six-line spectrum with hyperfine coupling constants distinct from that of PEN. Importantly, the half-life of the adduct was nearly 5 min, while that of PBN is less than 1 min at physiologic pH. MDL 101,002 also trapped the O-2, radical to yield a six-line spectrum with coupling constants very distinct from that of the (OH)-O-. adduct. In mice, the cyclic nitrones ameliorated the damaging effects of oxidative stress induced by ferrous iron injection into brain tissue. Similar protection was not afforded by the lipid peroxidation inhibitor U74006F, thus implicating radical trapping as a unique feature in the prevention of cell injury. Together, the in vivo activity, the stability of the nitroxide adducts, and the ability to distinguish between trapping of (OH)-O-. and O-2 suggest the cyclic nitrones to be ideal reagents for the study of oxidative cell injury.			Thomas, CE (corresponding author), HOECHST MARION ROUSSEL INC,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							ABE Y, 1991, J CHEM SOC PERK T 2, P897, DOI 10.1039/p29910000897; BOLLI R, 1990, AM J PHYSIOL, V259, pH1901, DOI 10.1152/ajpheart.1990.259.6.H1901; BORS W, 1979, EUR J BIOCHEM, V95, P621, DOI 10.1111/j.1432-1033.1979.tb13003.x; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Carr A. A., 1994, US Patent, Patent No. [5,292,746, 5292746]; CHING TL, 1993, CHEM-BIOL INTERACT, V86, P119, DOI 10.1016/0009-2797(93)90116-G; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DOWNS TR, 1995, INT J IMMUNOPHARMACO, V17, P571, DOI 10.1016/0192-0561(95)00042-Z; FRENCH JF, 1994, CIRC SHOCK, V43, P130; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P761; HAMBURGER SA, 1989, CIRC SHOCK, V29, P329; HINTON RD, 1992, J ORG CHEM, V57, P2646, DOI 10.1021/jo00035a020; JANZEN EG, 1992, TETRAHEDRON LETT, V33, P1257, DOI 10.1016/S0040-4039(00)91595-8; JANZEN EG, 1994, J AM CHEM SOC, V116, P3738, DOI 10.1021/ja00088a009; KADIISKA MB, 1993, MOL PHARMACOL, V44, P222; KNECHT KT, 1988, DRUG METAB DISPOS, V16, P813; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; LARSEN RD, 1991, J ORG CHEM, V56, P6034, DOI 10.1021/jo00021a014; LEO AJ, 1993, CHEM REV, V93, P1281, DOI 10.1021/cr00020a001; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; Murahashi S.-I., 1998, ORG SYNTH, V70, P265; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PHILLIS J W, 1990, Medical Science Research, V18, P403; THOMAS CE, 1992, LIPIDS, V27, P543, DOI 10.1007/BF02536138; THOMAS CE, 1994, ANN NY ACAD SCI, V738, P243; THOMAS CE, 1994, J LIPID RES, V35, P610; THOMAS CE, 1994, J BIOL CHEM, V269, P28055; TORTOLANI AJ, 1993, FREE RADICAL BIO MED, V14, P421, DOI 10.1016/0891-5849(93)90091-8; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; 1994, PCMODELS VERSION 434; 1993, SYBYL VERSION 60; 1989, MOPAC VERSION 50; 1993, SPARTAN VERSION 30	38	83	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3097	3104		10.1074/jbc.271.6.3097	http://dx.doi.org/10.1074/jbc.271.6.3097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621707	hybrid			2022-12-25	WOS:A1996TU69100036
J	Yeh, TC; Ogawa, W; Danielsen, AG; Roth, RA				Yeh, TC; Ogawa, W; Danielsen, AG; Roth, RA			Characterization and cloning of a 58/53-kDa substrate of the insulin receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN; PROTEIN	A monoclonal antibody has been produced which immunoprecipitates 58- and 53-kDa proteins which are rapidly tyrosine phosphorylated in insulin-treated cells. These proteins can also be tyrosine phosphorylated in vitro by the isolated human insulin receptor. Increased tyrosine phosphorylation of these proteins is also observed in cells expressing a transforming chicken c-Src (mutant Phe-527) and in cells with the activated tyrosine kinase domains of the Drosophila insulin receptor, human insulin-like growth factor I receptor, and human insulin receptor-related receptor. P58/53 did not appear to associate with either the GTPase activating protein of Ras (called GAP) or the phosphatidylinositol 3-kinase by either co-immunoprecipitation experiments or in Far Westerns with the SH2 domains of these two proteins. Since p58/53 did not appear, by immunoblotting, to be related to any previously described tyrosine kinase substrate such as the SH2 containing proteins SHC and the tyrosine phosphatase Syp, the protein was purified in sufficient amounts to obtain peptide sequence. This sequence was utilized to isolate a cDNA clone that encodes a previously uncharacterized 53-kDa protein which, when expressed in mammalian cells, is tyrosine phosphorylated by the insulin receptor.	STANFORD UNIV, SCH MED, DEPT MOLEC PHARMACOL, STANFORD, CA 94305 USA	Stanford University			OGAWA, Wataru/AAQ-9586-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926, R01DK041765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41765, DK 34926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD ER, 1992, J BIOL CHEM, V267, P14138; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YANG SD, 1995, MOL IMMUNOL, V32, P733, DOI 10.1016/0161-5890(95)00035-D	34	84	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2921	2928		10.1074/jbc.271.6.2921	http://dx.doi.org/10.1074/jbc.271.6.2921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621681	hybrid			2022-12-25	WOS:A1996TU69100010
J	Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH				Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH			Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia	ONCOGENE			English	Article						adenocarcinoma; gastric cardia; microsatellite instability; replication errors; DNA mismatch repair	NONPOLYPOSIS COLORECTAL-CANCER; LYNCH SYNDROME-II; GENETIC INSTABILITY; CARCINOMA; MUTATIONS; HOMOLOG; HISTORY; FAMILY; TUMORS; COLON	Hereditary non-polyposis colorectal cancer (HNPCC) is associated with an increased predisposition to colorectal cancer and extra-colonic cancers of the gastro-intestinal, urological and female reproductive tracts, These tumours are characterised by an underlying defect in DNA mismatch repair and exhibit numerous replication errors throughout the genome (RER(+) phenotype), HNPCC-associated gastric tumours, and a subset of sporadic, distally-located gastric tumours exhibit this RER(+) phenotype, It is recognised that proximal gastric tumours exhibit distinct epidemiological features, In this study we investigated the occurrence of microsatellite instability in a series of 38 primary gastric adenocarcinomas, arising in the proximal stomach, A total of 138 microsatellite markers, comprising mainly dinucleotide and tetranucleotide repeat units and covering all autosomal arms, excluding acrocentric arms, were analysed, One tumour demonstrated somatic microsatellite alterations at 62% (26 of 42) of loci tested, A further 32 tumours demonstrated levels of microsatellite instability ranging from 0.8% (1 of 128)-11.4% (15 of 132) of loci tested, Five tumours demonstrated no microsatellite alterations at any of the loci tested, These findings suggest that a high percentage of proximal gastric carcinomas exhibit a low level of microsatellite alterations at dinucleotide and tetranucleotide repeat loci, However, ubiquitous somatic alterations at these loci, characteristic of HNPCC-associated tumours, occur in a relatively small proportion of tumours.	QUEENS UNIV BELFAST,BELFAST CITY HOSP,DEPT MED GENET,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,DEPT PATHOL,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,REG THORAC UNIT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449	Belfast City Hospital; Queens University Belfast					PHS HHS [NG00835] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CRISTOFARO G, 1987, CANCER, V60, P51, DOI 10.1002/1097-0142(19870701)60:1<51::AID-CNCR2820600110>3.0.CO;2-V; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUREN P, 1965, ACTA PATHOL MIC SC, V5, P145; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1988, AM J GASTROENTEROL, V83, P741; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OGASAWARA S, 1995, CANCER RES, V55, P891; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SERUCA R, 1995, INT J CANCER, V64, P32, DOI 10.1002/ijc.2910640108; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SIDONI A, 1989, TUMORI, V75, P605, DOI 10.1177/030089168907500619; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641	45	41	41	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1653	1662						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622885				2022-12-25	WOS:A1996UG45800007
J	Brooks, AR; Shiffman, D; Chan, CS; Brooks, EE; Milner, PG				Brooks, AR; Shiffman, D; Chan, CS; Brooks, EE; Milner, PG			Functional analysis of the human cyclin D2 and cyclin D3 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; CORONARY ANGIOPLASTY; EXPRESSION; GENES; RESTENOSIS; CLONING; GROWTH; G(1)	The D-type cyclins promote progression through the G(1) phase of the cell cycle and may provide a link between growth factors and the cell cycle machinery. We determined the nucleotide sequence of the 5'-flanking region of the human cyclin D2 and cyclin D3 genes and identified the transcription start sites. Analysis of the upstream sequences required for transcription of the cyclin D2 and cyclin D3 genes in continuously dividing cells revealed marked differences in their regulatory elements. In the cyclin D2 gene positive elements were localized between positions -306 and -114 relative to the ATG codon at +1. Additional positive elements were localized between -444 and -345, whereas sequences that reduced transcription were identified between nucleotides -1624 and -892. In the cyclin D3 gene all of the positive elements required for maximal transcription were localized between nucleotides -366 and -167, and no negative elements were found. The activities of a reporter gene linked to the upstream regulatory sequences of the cyclin D2 gene but not the cyclin D3 gene were induced when starved cells were serum stimulated. This suggests that although the abundance of both the cyclin D2 and cyclin D3 mRNAs is increased by serum stimulation, only the cyclin D2 gene is up-regulated at the transcriptional level. Sequences between nucleotides -306 and -1624 of the cyclin D2 gene were necessary for serum inducibility.	CV THERAPEUT, PALO ALTO, CA 94304 USA									ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GILMAN M, 1987, CURRENT PROTOCOLS MO; HANNA Z, 1993, ONCOGENE, V8, P1661; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HERMANS WRM, 1991, AM HEART J, V122, P171, DOI 10.1016/0002-8703(91)90775-D; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NEVINS JR, 1992, SCIENCE, V258, P424; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PALMERO I, 1993, ONCOGENE, V8, P1049; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAM SW, 1994, ONCOGENE, V9, P2663; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	38	105	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9090	9099		10.1074/jbc.271.15.9090	http://dx.doi.org/10.1074/jbc.271.15.9090			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621559	hybrid			2022-12-25	WOS:A1996UE73000090
J	Pei, DQ; Weiss, SJ				Pei, DQ; Weiss, SJ			Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; IV COLLAGENASE; GELATINASE; CARCINOMA; INHIBITOR; PRECURSOR; TIMP-2; FURIN	Membrane-type matrix metalloproteinase-l (MT-MMP-1) has been proposed to play a critical role in regulating the expression of tissue-invasive phenotypes in normal and neoplastic cells by directly or indirectly mediating the activation of progelatinase A. To bean characterizing MT-MMP-1 structure-function relationships, transmembrane-deletion mutants were constructed, and the processing of the zymogens as well as the enzymic activity of the mature proteinases was analyzed. We now demonstrate that pro-MT-MMP-1 mutants are efficiently processed to active proteinases following post-translational endoproteolysis immediately downstream of an Arg(108)-Arg-Lys-Arg basic motif by a proprotein convertase-dependent pathway. The secreted form of active MT-MMP-1 not only displays an N terminus identical with that described for the processed wild-type enzyme at Tyr(112) (Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grants, G. A., and Goldberg, G. I. (1995) J. Biol. Chem. 270, 5331-5338), but also directly mediated progelatinase A activation via a two-step proteolytic cascade indistinguishable from that observed with intact cells. Furthermore, although the only function previously ascribed to MT-MMP-1 is its ability to act as a progelatinase A activator, purified transmembrane deletion mutants also expressed proteolytic activities against a wide range of extracellular matrix molecules. Given recent reports that MT-MMP-1 ectodomains may undergo intercellular transfer in vivo (Okada, A., Bellocq, J.-P., Rouyer, N., Chenard, M.-P,, Rio, M.-C,, Chambon, P., and Basset, P. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 2730-2734), our data suggest that soluble forms of the proteinase confer recipient cells with the ability to not only process progelatinase A, but also directly degrade extracellular matrix components.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV HEMATOL ONCOL,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIAID NIH HHS [AI23876] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023876] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; BROWN PD, 1993, CLIN EXP METASTAS, V11, P183, DOI 10.1007/BF00114976; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; DAVIES B, 1993, CANCER RES, V53, P2087; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TOURNIER JM, 1994, J BIOL CHEM, V269, P25454; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YOUNG TN, 1995, J BIOL CHEM, V270, P999, DOI 10.1074/jbc.270.3.999	35	347	361	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9135	9140		10.1074/jbc.271.15.9135	http://dx.doi.org/10.1074/jbc.271.15.9135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621565	hybrid			2022-12-25	WOS:A1996UE73000096
J	Park, DS; Farinelli, SE; Greene, LA				Park, DS; Farinelli, SE; Greene, LA			Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR DEPRIVATION; PHEOCHROMOCYTOMA CELLS; PROTEIN-SYNTHESIS; SENSORY NEURONS; DEATH; RAT; APOPTOSIS; SYSTEM; NGF	Previous studies have demonstrated that multiple agents that promote survival of PC12 cells and sympathetic neurons deprived of trophic support also block cell cycle progression. Presently, we address whether inhibition of cell cycle-related cyclin-dependent kinases (CDKs) prevents neuronal cell death. We show that two distinct CDK inhibitors, flavopiridol and olomoucine, suppress the death of neuronal PC12 cells and sympathetic neurons. In addition, we demonstrate that inhibitor concentrations required to promote survival correlate with their ability to inhibit proliferation. Promotion of survival, however, does not correlate with inhibition of extracellular signal-regulated kinase or c-Jun kinase activities or with interference with the activation of c-Jun kinase that accompanies serum/nerve growth factor deprivation. In contrast to their actions on nerve growth factor-differentiated PC12 cells, the CDK inhibitors do not prevent the death of proliferation-competent PC12 cells and, in fact, promote their cell death. These findings support the hypothesis that post-mitotic neuronal cells die after removal of trophic support due to an attempt to re-enter the cell cycle in an uncoordinated and inappropriate manner. We speculate that cycling PC12 cells are not saved by these agents due to a signaling conflict between an inherent oncogenic signal and the inhibition of CDK activity.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Park, DS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Park, David/0000-0002-4490-3784				BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BONIECE IR, 1993, J NEUROSCI, V13, P4220; Brooks Susan F., 1993, Society for Neuroscience Abstracts, V19, P885; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; COLOMBEL M, 1992, CANCER RES, V52, P4313; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GORIN PD, 1980, BRAIN RES, V198, P27, DOI 10.1016/0006-8993(80)90341-8; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1996, IN PRESS PERSPECT DE; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; KAUR G, 1992, J NATL CANCER I, V84, P1736, DOI 10.1093/jnci/84.22.1736; LEE VM, 1980, NEUROSCIENCE, V5, P2239, DOI 10.1016/0306-4522(80)90140-2; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LINDENBOIM L, 1995, CANCER RES, V55, P1242; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TSAL L, 1994, SCIENCE, V371, P419; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN GZ, 1995, J NEUROSCI, V15, P6200; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; 1995, MESSENGER, V4	51	231	240	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8161	8169		10.1074/jbc.271.14.8161	http://dx.doi.org/10.1074/jbc.271.14.8161			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626506	hybrid			2022-12-25	WOS:A1996UD60000046
J	Pollock, JD; Rane, SG				Pollock, JD; Rane, SG			p21(ras) signaling is necessary but not sufficient to mediate neurotrophin induction of calcium channels in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; MAP KINASE; PHEOCHROMOCYTOMA CELLS; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; SODIUM-CHANNELS; RAS; EXPRESSION; CAMP	Nerve growth factor and basic fibroblast growth factor bind to and activate receptor tyrosine kinases, causing sequential signaling via the p21(ras)/extracellular signal-regulated kinase pathway. The necessity and sufficiency of this signaling pathway in transducing neuronal differentiation have been tested in the PC12 cell model. Although necessary for morphological changes, the sufficiency of p21(ras)-mediated signaling in these events has come into question. We report that growth factor induction of voltage-gated calcium channels, a hallmark of physiological differentiation, also requires p21(ras)-mediated signaling, but cannot be driven by p21(ras) activation alone. Thus, constitutive expression of the dominant negative N17(ras) mutant blocks growth factor-induced increases in Omega-conotoxin GVIA-sensitive, nimodipine-sensitive, and Omega-conotoxin GVIA/ nimodipine-resistant calcium currents, but it does not block sodium current induction. However, manipulations that produce sustained activation of the p21(ras) signaling pathway and the neurite extension characteristic of morphological differentiation fail to increase calcium channel current densities. These results indicate the existence of distinct signaling requirements for morphological and physiological differentiation and further emphasize the importance of p21(ras)-independent signaling pathways in growth factor-mediated neuronal development.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Pollock, Jonathan D/B-1554-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043462] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM43462] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; GARBER SS, 1989, J NEUROSCI, V9, P3976; GINTY DD, 1992, J CELL BIOL, V116, P1465, DOI 10.1083/jcb.116.6.1465; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS DL, 1993, J PHYSIOL-LONDON, V465, P325, DOI 10.1113/jphysiol.1993.sp019679; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RANE SG, 1994, J NEUROSCI RES, V38, P590, DOI 10.1002/jnr.490380511; REUTER H, 1992, P ROY SOC B-BIOL SCI, V249, P211, DOI 10.1098/rspb.1992.0106; RYDEL RE, 1987, J NEUROSCI, V7, P3639; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOGARI A, 1985, J NEUROSCI, V5, P307; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Troy C. M., 1994, Molecular Biology of the Cell, V5, p25A; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	44	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8008	8014		10.1074/jbc.271.14.8008	http://dx.doi.org/10.1074/jbc.271.14.8008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626482	hybrid			2022-12-25	WOS:A1996UD60000022
J	MacKichan, ML; Logeat, F; Israel, A				MacKichan, ML; Logeat, F; Israel, A			Phosphorylation of p105 PEST sequences via a redox-insensitive pathway up-regulates processing to p50 NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; PROTEIN-KINASE; DNA-BINDING; C-REL; GENE; ACTIVATION; PRECURSOR; PROMOTER; ALPHA; IDENTIFICATION	The p105 Rel protein has dual functions; it is the precursor of the p50 subunit of NF-kappa B, and it acts as an I kappa B-like inhibitor to retain other Rel subunits in the cytoplasm. We have investigated the posttranslational regulation of p105 following activation of Jurkat T cells and find that a rapid and sustained phosphorylation of p105 is induced. The inducible phosphorylation occurs on multiple serines in the C-terminal-most 150 amino acids of the molecule, a region rich in Pro, Glu, Ser, and Thr residues. Phosphorylation of p105 in Jurkat cells treated with phorbol 12-myristate 13-acetate/ionomycin or with okadaic acid, another activator of NF-kappa B, is correlated with an increase in proteolytic processing to p50. Intact PEST sequences are required for the phorbol 12-myristate 13-acetate/ionomycin-induced p105 processing, as a 68-amino acid C-terminal deletion abolishes the response to stimulation. When compounds that block I kappa B alpha phosphorylation and degradation were tested, the serine protease inhibitors L-1-tosylamido-2-phenylethyl chloromethyl ketone and 1-chloro-8-tosyl-amido-7-amino-2-heptanone blocked inducible p105 phosphorylation, but the antioxidants pyrrolidine dithiocarbamate and butylated hydroxyanisol did not. Thus, while regulation of the p105 I kappa B resembles that of I kappa B alpha involving inducible serine phosphorylation and proteolysis of the inhibitory ankyrin repeat domain, it depends on a different, redox-insensitive, signaling pathway.	STANFORD UNIV, PROGRAM CANC BIOL, STANFORD, CA 94305 USA	Stanford University	MacKichan, ML (corresponding author), INST PASTEUR, UNITE BIOL MOL EXPRESS GEN, URA 1149 CNRS, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.				NCI NIH HHS [5T32 CA-09302, CA09302] Funding Source: Medline; NINR NIH HHS [NRSA 5732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; GRUMONT RJ, 1994, MOL CELL BIOL, V14, P8460, DOI 10.1128/MCB.14.12.8460; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ISRAEL N, 1992, J IMMUNOL, V149, P3386; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MACKMAN N, 1994, J BIOL CHEM, V269, P26363; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MOLITOR JA, 1991, NEW BIOL, V3, P987; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; RICE D, 1982, P NATL ACAD SCI-BIOL, V79, P7862, DOI 10.1073/pnas.79.24.7862; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEVENIN C, 1990, New Biologist, V2, P793; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	61	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6084	6091		10.1074/jbc.271.11.6084	http://dx.doi.org/10.1074/jbc.271.11.6084			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626394	hybrid			2022-12-25	WOS:A1996UA36300023
J	Bearne, SL				Bearne, SL			Active site-directed inactivation of Escherichia coli glucosamine-6-phosphate synthase - Determination of the fructose 6-phosphate binding constant using a carbohydrate-based inactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSAMINE SYNTHETASE; MECHANISM; DERIVATIVES; INHIBITION; ACID; ISOMERASE	Glucosamine-6-phosphate synthase (GlmS) catalyzes the formation of glucosamine B-phosphate from fructose 6-phosphate using glutamine as the ammonia source, Because N-acetylglucosamine is an essential building block of both bacterial cell walls and fungal cell wall chitin, the enzyme is a potential target for antibacterial and antifungal agents, N-Iodoacetylglucosamine 6-phosphate is an active site-directed irreversible inactivator of GlmS from Escherichia coli (k(inact)/K-I = 17 (+/-3) M(-1) s(-1)). Both fructose 6-phosphate and glutamine protect the enzyme from inactivation, indicating that this reagent is directed at both the sugar binding site and the glutamine binding site, Protection studies with fructose g-phosphate demonstrate that the value of the dissociation constant for fructose 6-phosphate is 3.3 (+/-0.5) x 10(-7) M, approximately 3 orders of magnitude less than the K-ia value for this substrate determined from initial velocity experiments (Badet, B., Vermoote, P., and Le Goffic, F. (1988) Biochemistry 27, 2282-2287).			Bearne, SL (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.		Bearne, Stephen/ABF-8338-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018325, R37GM018325] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTAMIRANO MM, 1987, ARCH BIOCHEM BIOPHYS, V258, P95, DOI 10.1016/0003-9861(87)90326-2; ANDRUSZKIEWICZ R, 1990, J MED CHEM, V33, P132, DOI 10.1021/jm00163a022; ANDRUSZKIEWICZ R, 1986, INT J PEPT PROT RES, V27, P449; AUVIN S, 1991, BIOORG CHEM, V19, P143, DOI 10.1016/0045-2068(91)90030-S; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADET B, 1988, BIOCHEMISTRY-US, V27, P2282, DOI 10.1021/bi00407a006; BADETDENISOT MA, 1995, BIOORG MED CHEM LETT, V5, P815, DOI 10.1016/0960-894X(95)00119-E; BADETDENISOT MA, 1993, B SOC CHIM FR, V130, P249; BEDNAR RA, 1982, BIOCHEMISTRY-US, V21, P3681, DOI 10.1021/bi00258a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHMARA H, 1985, J GEN MICROBIOL, V131, P265; CHMARA H, 1985, BIOCHIM BIOPHYS ACTA, V870, P357; CLARK JM, 1977, EXPT BIOCH, P167; CONNOLLY BA, 1979, EUR J BIOCHEM, V93, P375, DOI 10.1111/j.1432-1033.1979.tb12833.x; DIXON M, 1979, ENZYMES, P369; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERSHT A, 1985, ENZYME STRUCTURE MEC, P101; GHOSH S, 1962, METHOD ENZYMOL, V5, P414, DOI 10.1016/S0076-6879(62)05251-9; GHOSH S, 1960, J BIOL CHEM, V235, P1265; GOLINELLIPIMPANEAU B, 1989, J AM CHEM SOC, V111, P3029, DOI 10.1021/ja00190a042; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P564; KITZ R, 1962, J BIOL CHEM, V237, P3245; Kort M.J., 1970, ADV CARBOHYD CHEM BI, VVolume 25, P311, DOI DOI 10.1016/S0065-2318(08)60431-X; KUCHARCZYK N, 1990, BIOCHEMISTRY-US, V29, P3668, DOI 10.1021/bi00467a012; LUGTENBERG EJJ, 1971, J MICROBIOL SEROL, V37, P537; MEISLER MH, 1975, BIOCHIM BIOPHYS ACTA, V410, P347, DOI 10.1016/0005-2744(75)90236-3; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MIDELFORT CF, 1977, BIOCHEMISTRY-US, V16, P1590, DOI 10.1021/bi00627a010; MILEWSKI S, 1993, BIOCHIM BIOPHYS ACTA, V1161, P279, DOI 10.1016/0167-4838(93)90225-G; MILEWSKI S, 1992, BIOCHIM BIOPHYS ACTA, V1115, P225, DOI 10.1016/0304-4165(92)90058-3; OTIENO S, 1975, BIOCHEMISTRY-US, V14, P2403, DOI 10.1021/bi00682a021; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Segal I. H., 1975, ENZYME KINETICS, P560; WINDHOL M, 1976, MERCK INDEX, P579; WOLFENDEN R, 1987, ENZYME MECHANISMS, P97; ZALKIN H, 1985, METHOD ENZYMOL, V113, P278; 1990, ENZYMEKINETICS	39	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3052	3057						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621700				2022-12-25	WOS:A1996TU69100029
J	Launay, JM; Birraux, G; Bondoux, D; Callebert, J; Choi, DS; Loric, S; Maroteaux, L				Launay, JM; Birraux, G; Bondoux, D; Callebert, J; Choi, DS; Loric, S; Maroteaux, L			Ras involvement in signal transduction by the serotonin 5-HT2B receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA; MASTOMYS-NATALENSIS; MAP KINASE; PHOSPHOLIPASE-C; STOMACH FUNDUS; ALPHA-SUBUNITS; PROTEIN; EXPRESSION; ACTIVATION; FIBROBLASTS	The family of serotonin 5-HT2 receptors stimulates the phospholipase C second messenger pathway via the cu subunit of the G(q) GTP-binding protein. Here, we show that agonist stimulation of the 5-HT2B receptor subtype stably expressed in the mouse fibroblast LMTK(-) cell line causes a rapid and transient activation of the protooncogene product p21(ras) as measured by an increase in GTP-bound Pas in response to serotonin, Furthermore, 5-HT2B receptor stimulation activates p42(mapk)/44(mapk) (ERK2/ERK1) mitogen-activated protein kinases as assayed by phosphorylation of myelin basic protein, Antibodies against p21(ras), G alpha(q),-beta or-gamma(2) subunits of the GTP-binding protein inhibit MAP kinase-dependent phosphorylation. The MAP kinase activation is correlated with a stimulation of cell division by serotonin. In addition to this mitogenic action, transforming activity of serotonin is mediated by the 5-HT2B receptor since its expression in LMTK(-) cells is absolutely required for foci formation and for these foci to form tumors in nude mice. Finally, we detected expression of the 5-HT2B receptor in spontaneous human and Mastomys natalensis carcinoid tumors and, similar to the 5-HT2B receptor transfected cells, the Mastomys tumor cells are also responsive to serotonin with similar coupling to p21(ras) activation.	UNIV STRASBOURG 1,INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; INST PASTEUR,URA 1960 CNRS,F-75724 PARIS 15,FRANCE; FAC PHARM,BIOL CELLULAIRE LAB,F-75006 PARIS,FRANCE; HOP LARIBOISIERE,SERV BIOCHIM,FORMAT RECH ASSOC C BERNARD,F-75006 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite			loric, sylvain/F-7224-2011; Maroteaux, Luc/H-4585-2019; callebert, jacques/L-4569-2017; Choi, Doo-Sup/G-9474-2012	Maroteaux, Luc/0000-0002-9499-8603; Choi, Doo-Sup/0000-0002-6796-9938				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165-6147(00)88991-9; BERTHOU L, 1992, EUR J CELL BIOL, V58, P377; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOI DS, 1994, FEBS LETT, V352, P393, DOI 10.1016/0014-5793(94)00968-6; CHOI DS, 1994, CELL MOL BIOL, V40, P403; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLAS JF, 1995, P NATL ACAD SCI USA, V92, P5441, DOI 10.1073/pnas.92.12.5441; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVIVO M, 1994, J BIOL CHEM, V269, P16971; FAURE M, 1994, J BIOL CHEM, V269, P7851; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; GANEM YJ, 1989, BIOGENIC AMINES, V6, P495; GRAHAMESMITH DG, 1972, CARCINOID SYNDROME; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HOSODA S, 1970, SCIENCE, V170, P454, DOI 10.1126/science.170.3956.454; HUETHER G, 1992, BIOGENIC AMINES, V8, P421; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHAN C, 1992, EXP CELL RES, V200, P523, DOI 10.1016/0014-4827(92)90204-L; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KURSAR JD, 1994, MOL PHARMACOL, V46, P227; KURSAR JD, 1992, MOL PHARMACOL, V42, P549; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LORIC S, 1995, MOL PHARMACOL, V47, P458; LORIC S, 1992, FEBS LETT, V312, P203, DOI 10.1016/0014-5793(92)80936-B; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MORILAK DA, 1993, NEUROSCIENCE, V55, P869, DOI 10.1016/0306-4522(93)90447-N; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PEROUTKA SJ, 1995, TRENDS NEUROSCI, V18, P68; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SAXENA PR, 1991, TRENDS PHARMACOL SCI, V12, P223, DOI 10.1016/0165-6147(91)90556-8; SCHMUCK K, 1994, FEBS LETT, V342, P85, DOI 10.1016/0014-5793(94)80590-3; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; SNELL KC, 1969, SCIENCE, V163, P470, DOI 10.1126/science.163.3866.470; SUYAMA M, 1984, J NATL CANCER I, V72, P751; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; WILKINSON LO, 1991, SEROTONIN RECEPTOR S, V15, P147; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; XU NZ, 1994, ONCOGENE, V9, P597; YAVARONE MS, 1993, TERATOLOGY, V47, P573, DOI 10.1002/tera.1420470609	69	118	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3141	3147		10.1074/jbc.271.6.3141	http://dx.doi.org/10.1074/jbc.271.6.3141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621713	hybrid			2022-12-25	WOS:A1996TU69100042
J	Sasisekharan, R; Venkataraman, G; Godavarti, R; Cooney, CL; Langer, R				Sasisekharan, R; Venkataraman, G; Godavarti, R; Cooney, CL; Langer, R			Heparinase I from Flavobacterium heparinum - Mapping and characterization of the heparin binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SUBSTRATE-SPECIFICITY; LYASES; PROTEINS; GLYCOSAMINOGLYCANS; PURIFICATION; MECHANISM; SEQUENCE; CALCIUM; CLONING	In this study we have identified the primary heparin binding site of heparinase I (EC 4.2.2.7). Chemical and proteolytic digests of heparinase I were used in direct binding and competition assays, to map the regions of heparinase I that interact specifically with heparin. We find the heparin binding site contains two Cardin-Weintraub heparin binding consensus sequences and a calcium co-ordination consensus motif. We show that heparin binding to heparinase I is independent of calcium (K-d of 60 nM) and that calcium is able to activate heparinase I catalytically. We find that sulfhydryl selective labeling of cysteine 135 of heparinase I protects the lysines of the heparin binding sequence from proteolytic cleavage, suggesting the close proximity of the heparin binding site to the active site. Site-directed mutagenesis of H203A (contained in the heparin binding site) inactivated heparinase I; however, a H203D mutant retained marginal activity, indicating a role for this residue in catalysis. The above results taken together suggest that histidine 203 (hence the heparin binding site) is immediately adjacent to the scissile bond. We propose that the heparin binding site and active site are in close proximity to each other and that the calcium coordination motif, contained in the heparin binding site, may bridge heparin to heparinase I through calcium in a ternary complex during catalysis.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,E17-430,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM 25810] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025810] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; BAUGH RF, 1992, ANESTH ANALG, V74, P201, DOI 10.1213/00000539-199202000-00005; BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; BOYD J, 1980, J MOL BIOL, V137, P175, DOI 10.1016/0022-2836(80)90324-1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COHEN DM, 1990, BIOPOLYMERS, V30, P733, DOI 10.1002/bip.360300708; COLTRINI D, 1993, EUR J BIOCHEM, V214, P51, DOI 10.1111/j.1432-1033.1993.tb17895.x; COMFORT AR, 1989, BIOTECHNOL BIOENG, V34, P1383, DOI 10.1002/bit.260341106; COMPER WD, HEPARIN RELATED POLY; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DIETRICH CP, 1973, J BIOL CHEM, V248, P6408; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FAN BQ, 1994, FEBS LETT, V354, P84, DOI 10.1016/0014-5793(94)01083-8; Fersht A., 1985, ENZYME STRUCTURE MEC; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GREILING H, 1975, CONNECT TISSUE RES, V3, P135, DOI 10.3109/03008207509152171; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HUNTER GK, 1988, ARCH BIOCHEM BIOPHYS, V260, P161, DOI 10.1016/0003-9861(88)90437-7; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; Kretsinger RH, 1975, CALCIUM TRANSPORT CO, P469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER R, 1982, SCIENCE, V217, P261, DOI 10.1126/science.7089564; LECKBAND D, 1991, BIOTECHNOL BIOENG, V37, P227, DOI 10.1002/bit.260370305; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LERNER EA, 1992, J BIOL CHEM, V267, P1062; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LINHARDT RJ, 1989, BIOMIMETIC POLYM, P135; LINHARDT RJ, 1993, TRENDS GLYCOSCI GLYC, V5, P181; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MUNIER H, 1992, J BIOL CHEM, V267, P9816; NADER HB, 1990, J BIOL CHEM, V265, P16807; NIEDUSZYNSKI IA, 1985, POLYSACCHARIDES TOPI, P107; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; SASISEKHARAN R, 1991, THESIS HARVARD U CAM; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SMITH JW, 1987, J BIOL CHEM, V262, P11964; Stewart JM, 1984, SOLID PHASE PEPTIDE; TALPAS CJ, 1993, J PROTEIN CHEM, V12, P303, DOI 10.1007/BF01028192; TEJIDOR L, 1993, THROMB HAEMOSTASIS, V69, P866; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YANG VC, 1985, J BIOL CHEM, V260, P1849; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YOSHIDA K, 1991, 1991 INT S HEP REL P	65	36	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3124	3131		10.1074/jbc.271.6.3124	http://dx.doi.org/10.1074/jbc.271.6.3124			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621711	hybrid			2022-12-25	WOS:A1996TU69100040
J	Aqvist, J; Fothergill, M				Aqvist, J; Fothergill, M			Computer simulation of the triosephosphate isomerase catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC ANHYDRASE-I; FREE-ENERGY; ENZYME CATALYSIS; REACTION PATHWAY; MODEL; ENERGETICS; MECHANISM; LOOP; STEP; PKA	A major challenge for theoretical simulation methods is the calculation of enzymic reaction rates directly from the three-dimensional protein structure together with some idea of the chemical reaction mechanism. Here, we report the evaluation of a complete free energy profile for all the elementary steps of the triosephosphate isomerase catalyzed reaction using such an approach. The results are compatible with available experimental data and also suggest which of the possible reaction intermediates is kinetically observable. In addition to previously identified catalytic residues, the simulations show that a crystallographically observed active site water molecule plays an important role during catalysis and an intersubunit interaction that could explain the low activity of the monomeric enzyme is also observed. The calculations clearly demonstrate the important catalytic effects associated with stabilization of charged high energy intermediates and reduction of reorganization energy, which are likely to be general principles of enzyme catalyzed charge transfer and separation reactions.			Aqvist, J (corresponding author), UPPSALA UNIV,BIOMED CTR,DEPT BIOL MOLEC,BOX 590,S-75124 UPPSALA,SWEDEN.							ALAGONA G, 1984, J AM CHEM SOC, V106, P3623, DOI 10.1021/ja00324a035; ALAGONA G, 1995, J AM CHEM SOC, V117, P9855, DOI 10.1021/ja00144a011; ALBERY WJ, 1980, ANNU REV PHYS CHEM, V31, P227, DOI 10.1146/annurev.pc.31.100180.001303; AQVIST J, 1992, J MOL BIOL, V224, P7, DOI 10.1016/0022-2836(92)90572-2; AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; AQVIST J, 1993, J AM CHEM SOC, V115, P631; AQVIST J, 1993, CHEM REV, V93, P2523, DOI 10.1021/cr00023a010; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BLACKLOW SC, 1990, BIOCHEMISTRY-US, V29, P4099, DOI 10.1021/bi00469a012; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; BROWN FK, 1987, J MOL BIOL, V198, P533, DOI 10.1016/0022-2836(87)90298-1; CHIANG Y, 1984, J AM CHEM SOC, V106, P460, DOI 10.1021/ja00314a055; COHEN AO, 1968, J PHYS CHEM-US, V72, P4249, DOI 10.1021/j100858a052; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; DAGGETT V, 1989, J AM CHEM SOC, V111, P8247, DOI 10.1021/ja00203a028; DAVENPORT RC, 1991, BIOCHEMISTRY-US, V30, P5821, DOI 10.1021/bi00238a002; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; GUTHRIE JP, 1979, CAN J CHEM, V57, P1177, DOI 10.1139/v79-193; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; LODI PJ, 1993, BIOCHEMISTRY-US, V32, P4338, DOI 10.1021/bi00067a024; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MENGER FM, 1992, BIOCHEMISTRY-US, V31, P5368, DOI 10.1021/bi00138a018; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5939, DOI 10.1021/bi00416a018; PAGE MI, 1987, ENZYME MECH, pCHY; Pauling L., 1945, NATURE CHEM BOND; RICHARD JP, 1984, J AM CHEM SOC, V106, P4926, DOI 10.1021/ja00329a050; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; WARSHEL A, 1992, FARADAY DISCUSS, V93, P225, DOI 10.1039/fd9929300225; Warshel A, 1991, COMPUTER MODELING CH; YADAV A, 1991, J AM CHEM SOC, V113, P4800, DOI 10.1021/ja00013a013	40	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10010	10016		10.1074/jbc.271.17.10010	http://dx.doi.org/10.1074/jbc.271.17.10010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626554	hybrid			2022-12-25	WOS:A1996UG25700026
J	Mery, L; Mesaeli, N; Michalak, M; Opas, M; Lew, DP; Krause, KH				Mery, L; Mesaeli, N; Michalak, M; Opas, M; Lew, DP; Krause, KH			Overexpression of calreticulin increases intracellular Ca2+ storage and decreases store-operated Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-BINDING PROTEIN; HL-60 CELLS; ENDOPLASMIC-RETICULUM; CALSEQUESTRIN; LIVER	The widely distributed and highly conserved Ca2+ binding protein calreticulin has been suggested to play a role as a Ca2+ storage protein of intracellular Ca2+ stores. To test this hypothesis, we have generated a mouse L fibroblast cell line stably transfected with a calreticulin expression vector, The calreticulin content of the overexpressers was increased by 1.6 +/- 0.2-fold compared with mock-transfected cells. The total cellular Ca2+ content of calreticulin-overexpressing and control cells, as assessed by equilibrium Ca-45(2+) uptake, was 141 +/- 8 and 67 +/- 6 pmol of Ca2+/10(6) cells, respectively (i.e. a 2.1 +/- 0.2-fold increase in the Ca2+ content of calreticulin-overexpressing cells). Over 80% of the increased Ca2+ content was found within thapsigargin-sensitive Ca2+ stores, The pattern of calreticulin distribution, revealed by immunofluorescence microscopy, showed an endoplasmic reticulum-like pattern and was identical in overexpressers and control cells. In overexpressers, cytosolic free [Ca2+] elevations due to Ca2+ release were enhanced when either ATP or a combination of ionomycin and thapsigargin was used as a stimulus. In contrast, thapsigargin-induced Ca2+ and Mn2+ influxes from the extracellular space were markedly diminished in calreticulin-overexpressing cells, suggesting an active involvement of calreticulin in the regulation of store-operated Ca2+ influx.	UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL GRP MOLEC BIOL MEMBRANES,EDMONTON,AB T6G 2S2,CANADA; UNIV TORONTO,DEPT ANAT & CELL BIOL,TORONTO,ON M5S 1A8,CANADA	University of Alberta; University of Toronto	Mery, L (corresponding author), UNIV HOSP GENEVA,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND.		Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Mesaeli, Nasrin/0000-0003-1456-4643				BAKSH S, 1991, J BIOL CHEM, V266, P21458; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CLEMENTI E, 1994, EUR J IMMUNOL, V24, P1365, DOI 10.1002/eji.1830240619; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; FASOLATO C, 1993, PFLUG ARCH EUR J PHY, V423, P225, DOI 10.1007/BF00374399; FASTOLATO C, 1991, J BIOL HEM, V266, P20159; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; KRAUSE KH, 1991, FEBS LETT, V285, P225, DOI 10.1016/0014-5793(91)80806-E; LIU NG, 1994, J BIOL CHEM, V269, P28635; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PIZZO P, 1992, J IMMUNOL, V149, P3372; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651	25	220	224	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9332	9339		10.1074/jbc.271.16.9332	http://dx.doi.org/10.1074/jbc.271.16.9332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621597	hybrid			2022-12-25	WOS:A1996UG04400028
J	Wang, ZG; Namgoong, SY; Zhang, XS; Harshey, RM				Wang, ZG; Namgoong, SY; Zhang, XS; Harshey, RM			Kinetic and structural probing of the precleavage synaptic complex (type 0) formed during phage Mu transposition - Action of metal ions and reagents specific to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-PERMANGANATE; MECHANISM; PROTEIN; ENDS; RECOGNITION; JUNCTION; SYNAPSIS; ENHANCER; CLEAVAGE	In an earlier kinetic study (Wang, Z., and Harshey, R.M. (1994) Proc. Natl, Acad, Sci, U. S. A, 91, 699-703), we showed that supercoiling free energy was utilized during Mu transposition to lower the activation barrier of some rate-limiting step in the formation of the cleaved Mu end synaptic complex (type I complex), We report here results from kinetic studies on the assembled but uncleaved synaptic complex (type 0). Based on the estimated rate constants for the formation of type 0 and type I complexes, as well as their temperature and superhelicity dependence, we infer that the type 0 complex is an authentic intermediate in the pathway to Mu end cleavage. Our results are consistent with type 0 production being the rate-limiting step in the overall type I reaction. The conversion of type 0 to type I complex is a fast reaction, does not show strong temperature dependence, and is apparently independent of substrate superhelicity. We have explored the DNA structure within the type 0 complex using chemical and enzymatic probes, The observed susceptibility of DNA outside the Mu ends to single-strand-specific reagents suggests that a helix opening event is associated with type 0 formation. This structural perturbation could account, at least partly, for the high activation barrier to the reaction, There is a close correlation between the appearance of single strandedness near the Mu ends and the superhelicity of the DNA substrate, It is possible that supercoiling energy is utilized in effecting specific conformational transitions within DNA, We have found that Zn2+ and Co2+ ions, like Mg2+ and Mn2+ ions, can efficiently cleave the type 0 complex. However, unlike Mg2+ and Mn2+ ions, Zn2+ and Co2+ ions cannot support assembly of type 0. We discuss the implications of our findings for the mechanism of Mu transposition.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin					NIGMS NIH HHS [GM33247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKMAN SA, 1990, ARCH BIOCHEM BIOPHYS, V282, P202, DOI 10.1016/0003-9861(90)90105-8; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6645; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P1109; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FUJIMOTO M, 1974, AGR BIOL CHEM TOKYO, V38, P1555, DOI 10.1080/00021369.1974.10861384; HARSHEY RM, 1988, BACTERIOPHAGES, V1, P193; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; JIANG H, 1991, NUCLEIC ACIDS RES, V19, P6943, DOI 10.1093/nar/19.24.6943; KANG SM, 1994, J BIOL CHEM, V269, P9528; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PULLEYBLANK DE, 1988, UNUSUAL DNA STRUCTUR, P23; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; WU ZG, 1992, J BIOL CHEM, V267, P9552; YANG JY, 1995, GENE DEV, V9, P2545, DOI 10.1101/gad.9.20.2545; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; ZOU A, 1991, J BIOL CHEM, V266, P20476	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9619	9626		10.1074/jbc.271.16.9619	http://dx.doi.org/10.1074/jbc.271.16.9619			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621637				2022-12-25	WOS:A1996UG04400068
J	Najjar, SM; Boisclair, YR; Nabih, ZT; Phillippe, N; Imai, Y; Suzuki, Y; Suh, DS; Ooi, GT				Najjar, SM; Boisclair, YR; Nabih, ZT; Phillippe, N; Imai, Y; Suzuki, Y; Suh, DS; Ooi, GT			Cloning and characterization of a functional promoter of the rat pp120 gene, encoding a substrate of the insulin receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ECTO-ATPASE; LIVER-SPECIFIC GENES; RNA POLYMERASE-II; ENDOGENOUS SUBSTRATE; TRANSCRIPTION FACTOR; GROWTH-FACTOR; CARCINOEMBRYONIC ANTIGEN; ADHESION MOLECULE; PROTEIN-KINASE; LESS PROMOTER	Cloning of the 5'-flanking region of the rat pp120 gene has indicated that it is a housekeeping gene: it lacks a functional TATA bog and contains several Spl binding sites and multiple transcription initiation sites at nucleotides -101, -71, -41, and -27 spread over a GC-rich area, A fragment between nucleotides -21 and -1609 exhibited promoter activity when ligated in a sense orientation into a promoterless luciferase reporter plasmid and transiently transfected into rat H4-II-E hepatoma cells, 5' progressive deletion and block substitution analyses revealed that the three proximal Spl boxes (boxes 3, 5, and 6) are required for basal transcription of the pp120 gene. Promoter activity was stimulated 2-3-fold in response to insulin, dexamethasone, insulin plus dexamethasone, and cAMP. Although unaltered by phorbol esters alone, promoter activity was stimulated 4-5-fold in response to phorbol esters plus cAMP. Several motifs resembling response elements for insulin (in the rat phosphoenolpyruvate carboxykinase gene), glucocorticoids, cAMP, and phorbol esters as well as a number of putative binding sites for activating proteins-1 (Jun/Fos) and -2, and liver-specific factors were detected, The role of these sites in tissue-specific expression of pp120 remains to be investigated.	NIDDK,NIH,MOLEC & CELLULAR ENDOCRINOL BRANCH,BETHESDA,MD 20892; CORNELL UNIV,DEPT ANIM SCI,ITHACA,NY 14853	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cornell University	Najjar, SM (corresponding author), MED COLL OHIO,DEPT PHARMACOL & THERAPEUT,HLTH SCI BLDG,RM 270,TOLEDO,OH 43614, USA.		Najjar, Sonia M/GXW-2217-2022	Imai, Yumi/0000-0001-5046-4223				ACCILI D, 1986, ENDOCRINOLOGY, V119, P1274, DOI 10.1210/endo-119-3-1274; ARAKI E, 1995, MOL ENDOCRINOL, V9, P1367, DOI 10.1210/me.9.10.1367; ARAKI E, 1987, J BIOL CHEM, V262, P16186; BARTON CH, 1990, BIOCHEM J, V268, P161, DOI 10.1042/bj2680161; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOISCLAIR YR, 1995, DNA CELL BIOL, V14, P731, DOI 10.1089/dna.1995.14.731; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FABER PW, 1993, J BIOL CHEM, V268, P9296; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARNHAM PJ, 1990, CELL GROWTH DIFFER, V1, P179; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FROMONTRACINE M, 1993, NUCLEIC ACIDS RES, V21, P1683, DOI 10.1093/nar/21.7.1683; GAO JP, 1993, ARCH BIOCHEM BIOPHYS, V303, P90, DOI 10.1006/abbi.1993.1259; GIGUERE V, 1985, EMBO J, V4, P2017, DOI 10.1002/j.1460-2075.1985.tb03886.x; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALING M, 1991, MOL CELL BIOL, V11, P93, DOI 10.1128/MCB.11.1.93; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN SH, 1989, J BIOL CHEM, V264, P14408; MAMULA PW, 1988, DIABETES, V37, P1241, DOI 10.2337/diabetes.37.9.1241; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PLESNER L, 1995, INT REV CYTOL, V158, P141; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SEHGAL A, 1988, MOL CELL BIOL, V8, P1360; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2088; SUH DS, 1994, MOL ENDOCRINOL, V8, P794, DOI 10.1210/me.8.6.794; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	55	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8809	8817		10.1074/jbc.271.15.8809	http://dx.doi.org/10.1074/jbc.271.15.8809			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621519	hybrid			2022-12-25	WOS:A1996UE73000050
J	Baek, SH; Seo, JK; Chae, CB; Suh, PG; Ryu, SH				Baek, SH; Seo, JK; Chae, CB; Suh, PG; Ryu, SH			Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; PHOSPHOLIPASE-C; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; COMBINATORIAL LIBRARIES; MEMBRANE IG; AMINO-ACIDS; BETA-GAMMA; G-PROTEINS; ACTIVATION	Peptides which stimulate the formation of inositol phosphates (InoPs) in lymphocyte cell lines were identified by screening synthetic peptide libraries composed of random sequences of hexapeptides. The peptides containing the consensus sequence XKYX(P/V)M were found to be most active in the phospholipase C (PLC)-mediated formation of InoPs in a human B myeloma cell line, U266, The peptides also stimulated the phosphoinositide hydrolysis and the release of [Ca2+](i) in HL60 and U937 cell lines, On the other hand, these peptides showed no effect in the following cell lines: NIH3T3, PC12, Daudi, Sp2, Jurkat, H9, Molt-4, SupT-1, K562, and RBL-2H3. The result suggests the possibility that the peptides may have cell type specificity. Experiments with one of the active peptides, WKYMVM-NH2 showed that its action mimics the effect of AlF4- which is a G-protein activator in the InoPs generation, and pertussis toxin partially blocked the InoPs accumulation and [Ca2+](i) release induced by the peptide in the U266 cells, Binding assays with the peptide labeled with I-125 showed that U266 cells have a saturable number of binding sites for the peptide, Taken together, these results suggest that the peptides could activate PLC-mediated signal transduction via a pertussis toxin-sensitive G-protein coupled receptor in certain cell types.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA	Pohang University of Science & Technology (POSTECH)			Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIANCHINI L, 1993, J BIOL CHEM, V268, P3357; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMBIER JC, 1990, J IMMUNOL, V145, P13; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYASHI S, 1995, J IMMUNOL, V154, P814; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HULME EC, 1992, RECEPTOR LIGAND INTE, P1; JHON DY, 1993, J BIOL CHEM, V268, P6654; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LLORET S, 1995, J CELL PHYSIOL, V165, P89, DOI 10.1002/jcp.1041650112; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MIN DS, 1993, FEBS LETT, V331, P38, DOI 10.1016/0014-5793(93)80293-4; MOUSLI M, 1992, J IMMUNOL, V148, P2456; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V312, P315; OSTRESH JM, 1994, P NATL ACAD SCI USA, V91, P11138, DOI 10.1073/pnas.91.23.11138; OWENS RA, 1991, BIOCHEM BIOPH RES CO, V181, P402, DOI 10.1016/S0006-291X(05)81433-0; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P3710; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SENGELOV H, 1990, BIOCHEM J, V295, P11123; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; ZUCKERMANN RN, 1992, P NATL ACAD SCI USA, V89, P4505, DOI 10.1073/pnas.89.10.4505	53	90	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8170	8175		10.1074/jbc.271.14.8170	http://dx.doi.org/10.1074/jbc.271.14.8170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626507	hybrid			2022-12-25	WOS:A1996UD60000047
J	Betton, JM; Hofnung, M				Betton, JM; Hofnung, M			Folding of a mutant maltose-binding protein of Escherichia coli which forms inclusion bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY FORMATION; EXPORT; TRANSPORT; MEMBRANE; STEP; AGGREGATION; CHEMOTAXIS; SECRETION; BACTERIA; RECEPTOR	The maltose-binding protein (MalE) of Escherichia coli is the periplasmic component of the transport system for malto-oligosaccharides. We have examined the characteristics of a Mal(-) mutant of malE corresponding to the double substitution Gly(32) --> Asp/Ile(33) --> Pro, MalE31, previously obtained by random mutagenesis. In vivo, the MalE31 precursor is efficiently processed, but the mature protein forms inclusion bodies in the periplasm. Furthermore, the accumulation of insoluble MalE31 is independent of its cellular localization; MalE31 lacking its signal sequence forms inclusion bodies in the cytoplasm, The native MalE31 protein can be purified by affinity chromatography from inclusion bodies after denaturation by 8 M urea, The renatured protein exhibits full maltose binding affinity (K-d = 9 x 10(-7) M), suggesting that its folded structure is similar to that of the wild type protein. Unfolding/refolding experiments show that MalE31 is less stable (-5.5 kcal/mol) than the wild-type protein (-9.5 kcal/mol) and that folding intermediates have a high tendency to form aggregates, In conclusion, the observed phenotype of cells expressing malE31 can be explained by a defective folding pathway of the protein.			Betton, JM (corresponding author), INST PASTEUR,DEPT BIOTECHNOL,UNITE PROGRAMMAT MOL & TOXICOL GENET,CNRS,URA 1444,25 RUE DR ROUX,F-75015 PARIS,FRANCE.							BASSFORD PJ, 1990, J BIOENERG BIOMEMBR, V22, P401, DOI 10.1007/BF00763175; BETTON JM, 1994, EMBO J, V13, P1226, DOI 10.1002/j.1460-2075.1994.tb06372.x; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; CHRUNYK BA, 1993, J BIOL CHEM, V268, P18053; CHUN SY, 1993, J BIOL CHEM, V268, P20855; DUPLAY P, 1984, J BIOL CHEM, V259, P606; DUPLAY P, 1988, J BACTERIOL, V170, P4445, DOI 10.1128/jb.170.10.4445-4450.1988; DUPLAY P, 1987, J MOL BIOL, V194, P669; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GEORGIOU G, 1994, PROTEIN SCI, V3, P1953, DOI 10.1002/pro.5560031107; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LIU G, 1989, J BIOL CHEM, V263, P14790; MARTINEAU P, 1992, GENE, V113, P35, DOI 10.1016/0378-1119(92)90667-E; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MESCAS J, 1993, GENE DEV, V7, P2618; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NOSAKI Y, 1970, METHOD ENZYMOL, V26, P43; Pace C N, 1986, Methods Enzymol, V131, P266; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; PRESS WH, 1986, NUMERICAL RECIPES AR; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schein C H, 1991, Curr Opin Biotechnol, V2, P746, DOI 10.1016/0958-1669(91)90046-8; SCHIMMEL PR, 1968, J MOL BIOL, V34, P105, DOI 10.1016/0022-2836(68)90237-4; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; UFER R, 1992, PROTEIN SCI, V1, P31; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILD J, 1993, J BACTERIOL, V175, P3992, DOI 10.1128/JB.175.13.3992-3997.1993; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x	49	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8046	8052		10.1074/jbc.271.14.8046	http://dx.doi.org/10.1074/jbc.271.14.8046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626487	hybrid			2022-12-25	WOS:A1996UD60000027
J	Gladyshev, VN; Boyington, JC; Khangulov, SV; Grahame, DA; Stadtman, TC; Sun, PD				Gladyshev, VN; Boyington, JC; Khangulov, SV; Grahame, DA; Stadtman, TC; Sun, PD			Characterization of crystalline formate dehydrogenase H from Escherichia coli - Stabilization, EPR spectroscopy, and preliminary crystallographic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTORS; HYDROGEN-LYASE; SELENOCYSTEINE; SEQUENCE; BIOCHEMISTRY; SELENIUM; ENZYMES	The selenocysteine-containing formate dehydrogenase H (FDH) is an 80-kDa component of the Escherichia coli formate-hydrogen lyase complex. The molybdenum-coordinated selenocysteine is essential for catalytic activity of the native enzyme, FDH in dilute solutions (30 mu g/ml) was rapidly inactivated at basic pH or in the presence of formate under anaerobic conditions, but at higher enzyme concentrations (greater than or equal to 3 mg/ml) the enzyme was relatively stable, The formate-reduced enzyme was extremely sensitive to air inactivation under all conditions examined. Active formate-reduced FDH was crystallized under anaerobic conditions in the presence of ammonium sulfate and PEG 400. The crystals diffract to 2.6 Angstrom resolution and belong to a space group of P4(1)2(1)2 or P4(3)2(1)2 with unit cell dimensions a = b = 146.1 Angstrom and c = 82.7 Angstrom. There is one monomer of FDH per crystallographic asymmetric unit. Similar diffraction quality crystals of oxidized FDH could be obtained by oxidation of crystals of formate-reduced enzyme with benzyl viologen. By EPR spectroscopy, a signal of a single reduced FeS cluster was found in a crystal of reduced FDH, but not in a crystal of oxidized enzyme, whereas Mo(V) signal was not detected in either form of crystalline FDH. This suggests that Mo(IV)- and the reduced FeS cluster-containing form of the enzyme was crystallized and this could be converted into Mo(VI)- and oxidized FeS cluster form upon oxidation. A procedure that combines anaerobic and cryocrystallography has been developed that is generally applicable to crystallographic studies of oxygen-sensitive enzymes. These data provide the first example of crystallization of a substrate-reduced form of a Se- and Mo-containing enzyme.	NHLBI, NIH, LB, BETHESDA, MD 20892 USA; NIAID, MOLEC STRUCT LAB, NIH, ROCKVILLE, MD 20852 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA				Gladyshev, Vadim/0000-0002-0372-7016				[Anonymous], 1993, ADV INORGANIC CHEM, DOI DOI 10.1016/S0898-8838(08)60181-6; AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; AXLEY MJ, 1991, J BIOL CHEM, V266, P13731; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; GEWIRTH D, 1993, HKL VERSION 1 0 MANU; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P232, DOI 10.1073/pnas.91.1.232; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1989, PREPARATION ANAL PRO, P82; MOURA JJG, 1994, METHOD ENZYMOL, V243, P24; Pilato R. S., 1993, BIOINORGANIC CATALYS, P131; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; POSTON JM, 1971, METHOD ENZYMOL, V22, P49; RAJAGOPALAN KV, 1993, ACS SYM SER, V535, P38; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; *RIG CORP, 1994, R AX 2 C INSTR MAN; ROMAO MJ, 1993, EUR J BIOCHEM, V215, P729, DOI 10.1111/j.1432-1033.1993.tb18085.x; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; STADTMAN TC, 1991, BIOFACTORS, V3, P21; STIEFEL EI, 1993, ACS SYM SER, V535, P1; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; ZINONI F, 1987, P NATL ACAD SCI USA, V84, P3156, DOI 10.1073/pnas.84.10.3156; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	26	43	44	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8095	8100		10.1074/jbc.271.14.8095	http://dx.doi.org/10.1074/jbc.271.14.8095			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626495	hybrid, Green Submitted			2022-12-25	WOS:A1996UD60000035
J	Malecz, N; Foisner, R; Stadler, C; Wiche, G				Malecz, N; Foisner, R; Stadler, C; Wiche, G			Identification of plectin as a substrate of p34(cdc2) kinase and mapping of a single phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT REORGANIZATION; CULTURED-CELLS; PROTEIN-KINASE; NUCLEAR LAMINA; P34CDC2; VIMENTIN; MITOSIS; CYCLE; EXPRESSION; SUBUNIT	Plectin is an in vitro substrate for various kinases present in cell lysates from mitotic and interphase Chinese hamster ovary cells. Sensitivity of plectin kinase activity to the inhibitor olomoucine, and two-dimensional tryptic peptide mapping of plectin phosphorylated by various kinase preparations suggested that the major plectin kinase activity in mitotic extracts is related to the cell cycle regulator kinase p34(cdc2). Bacterial expression of various truncated plectin mutant proteins comprising different domains of the molecule and their phosphorylation by purified p34(cdc2) kinase revealed that the target site of this kinase resided within plectin's C-terminal globular domain. Among the subdomains of the C-terminal region (six repeats and a short tail sequence), only repeat 6 and the tail were phosphorylated by p34(cdc2) kinase. As shown by two-dimensional phosphopeptide mapping, repeat 6, but not the tail, contained a mitosis-specific phosphorylation site targeted by p34(cdc2) kinase in intact plectin molecules. By performing site-directed mutagenesis of a potential p34(cdc2) recognition sequence motif within the repeat 6 domain, threonine 4542 was identified as the major target for the kinase. Protein kinase A, phosphorylating plectin also within repeat 6, targeted sites that were clearly different from those of p34(cdc2) kinase.			Malecz, N (corresponding author), UNIV VIENNA, BIOCTR, INST BIOCHEM & MOL CELL BIOL, DR BOHRGASSE 9, A-1030 VIENNA, AUSTRIA.		WICHE, Gerhard/AAA-3227-2021; Foisner, Roland/AAD-1833-2019	Wiche, Gerhard/0000-0001-9550-5463; Foisner, Roland/0000-0003-4734-4647				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; FOISNER R, 1987, J MOL BIOL, V198, P515, DOI 10.1016/0022-2836(87)90297-X; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HERRMANN H, 1983, J BIOL CHEM, V258, P4610; HERRMANN H, 1987, J BIOL CHEM, V262, P1320; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMON MN, 1988, PLASMID, V19, P94, DOI 10.1016/0147-619X(88)90048-0; TERASIMA T, 1963, EXP CELL RES, V30, P344, DOI 10.1016/0014-4827(63)90306-9; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WICHE G, 1982, EXP CELL RES, V138, P15, DOI 10.1016/0014-4827(82)90086-6; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; WICHE G, 1989, CRIT REV BIOCHEM MOL, V24, P41, DOI 10.3109/10409238909082551; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607	26	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8203	8208		10.1074/jbc.271.14.8203	http://dx.doi.org/10.1074/jbc.271.14.8203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626512	hybrid			2022-12-25	WOS:A1996UD60000052
J	Keegan, K; Cooper, JA				Keegan, K; Cooper, JA			Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7	ONCOGENE			English	Article						SHPT2; Syp; Grb 2; Grb 7; 8H2 domain; two hybrid system	FACTOR RECEPTOR-BETA; PHOSPHOTYROSINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; KINASE; PHOSPHORYLATION; ACTIVATION; CLONING; DOMAINS; SPECIFICITY; CORKSCREW	SHPTP2 is a ubiquitously-expressed SH2-containing tyrosine phosphatase that is tyrosine phosphorylated in response to activation of various receptor and nonreceptor tyrosine kinases. SHPTPZ associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTPZ to this receptor promotes tyrosine phosphorylation of SHPTP2. The yeast two-hybrid system was modified to identify partners of tyrosine-phosphorylated proteins. Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTPZ interacts with another signaling protein, Grb7. We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy-terminus of Grb7. We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine-phosphorylated. These experiments show that this modified two hybrid technique may be useful for the identification of proteins involved in tyrosine kinase signal transduction cascades.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OOI J, 1995, ONCOGENE, V10, P1621; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; Rose M, 1990, LAB COURSE MANUAL ME; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221	47	89	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622870				2022-12-25	WOS:A1996UF07600018
J	Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A				Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A			The adenovirus E1A-associated 300 kDa adaptor protein counteracts the inhibition of the collagenase promoter by E1A and represses transformation	ONCOGENE			English	Article						adenovirus E1A; CBP; cJun; collagenase promoter; p300	E2F TRANSCRIPTION FACTOR; CELL-CYCLE; 5 DNA; REGION; GENE; COMPLEXES; BINDING; PRODUCT; JUN; TRANSACTIVATION	Adenovirus E1A proteins modulate the expression of a large variety of genes in transformed cells by either stimulating or repressing their promoters. For example, the E1A proteins inhibit the collagenase promoter, whereas they activate the c-jun promoter. Both effects are mediated through AP-1/ATF-binding sites. Repression of transcription of the collagenase gene requires the amino-terminus and conserved region 1 (CR1) of Ad5 E1A, two regions that are also crucial for interaction of E1A with the recently isolated transcriptional adaptor protein p300. We show here that overexpressed p300 can counteract the repressive effect of E1A on the collagenase promoter. Using the CREB-binding protein (CBP), which is highly homologous to p300, the same results were obtained. The domains in E1A required for binding to p300 are also essential for E1A-mediated cell transformation. We therefore tested the effect of p300 and CBP on the transforming potential of Ad5 El in baby rat kidney (BRK) cells. It was found that E1A-induced focus formation was strongly inhibited by overexpression of p300 or CBP. Moreover the BRK cell colonies, obtained after cotransfection with Ad5E1 and p300, could not be established. These results indicate that one of the mechanisms by which E1A modulates transcription and transforms cells is via transcriptional adaptors like p300 and CBP.			Smits, PHM (corresponding author), LEIDEN STATE UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1994, ONCOGENE, V9, P359; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DORMAN JC, 1995, J VIROL, V69, P2962; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maniatis T, 1989, DECONTAMINATION DILU; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS J, 1992, SCIENCE, V258, P242; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	40	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622869				2022-12-25	WOS:A1996UF07600017
J	Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T				Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T			Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinomas and underlying disease	ONCOGENE			English	Article						genomic imprinting; IGF2; H19; hepatocellular carcinoma; hepatocarcinogenesis	II GENE; HEPATITIS-C; WILMS-TUMOR; P53 GENE; INTERFERON; TISSUES; RELAXATION; IGF2; RNA	It has been well documented that the liver is an exceptional organ in which the monoallelic expression of insulin-like growth factor 2 (IGF2) due to genomic imprinting is relaxed during the postnatal period, resulting in biallelic expression thereafter. In the present study, changes in the status of genomic imprinting were examined in 15 hepatocellular carcinomas (HCCs) as well as in 29 liver biopsies of chronic hepatitis or liver cirrhosis without clinical evidence of HCC, following screening for heterozygotes with an ApaI polymorphism in IGF2 in 34 HCCs and 80 such non-HCC cases. Extreme allelic-expression imbalance, leading to restoration of monoallelic IGF2 expression, was observed in 15 (100%) of 15 informative HCCs for the polymorphism with this monoallelic IGF2 expression appearing to be non-random from the paternal allele. Interestingly, the same allelic-expression imbalance was also present in a significant fraction of noncancerous liver specimens of patients with underlying disease known to be associated with HCC development. In contrast, the status of genomic imprinting of H19, another gene closely mapped at 11p15 under opposite imprinting, was strictly maintained in seven (100%) of seven cases informative for an RsaI polymorphism of H19. Together with the previous reports on altered genomic imprinting of IGF2 and H19 in embryonal lesions such as Wilms tumors as well as in lung cancers, the results suggest that perturbations of imprinting status occur as locus and tumor-type specific events in the development of human cancers.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT PATHOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT CLIN LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OGAKI MUNICIPAL HOSP,DEPT INTERNAL MED,OGAKI 503,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University; Ogaki Municipal Hospital			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROWN AL, 1986, J BIOL CHEM, V261, P3144; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1994, CANCER RES, V54, P2560; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMA T, 1994, J GASTROENTEROL, V29, P450, DOI 10.1007/BF02361242; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NISHIDA N, 1993, CANCER RES, V53, P368; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANAKA K, 1991, CANCER RES, V51, P2842; TSAI JF, 1994, INT J CANCER, V56, P619, DOI 10.1002/ijc.2910560502; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZHANG X, 1994, CANCER RES, V54, P4177	33	51	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1589	1592						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622877				2022-12-25	WOS:A1996UF07600025
J	Biel, M; Zong, XG; Ludwig, A; Sautter, A; Hofmann, F				Biel, M; Zong, XG; Ludwig, A; Sautter, A; Hofmann, F			Molecular cloning and expression of a modulatory subunit of the cyclic nucleotide-gated cation channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD PHOTORECEPTOR CELLS; GMP-ACTIVATED CHANNEL; AMINO-ACID-SEQUENCE; FUNCTIONAL EXPRESSION; OLFACTORY TRANSDUCTION; BIPOLAR CELLS; PROTEIN; CONDUCTANCE; CALMODULIN; NEURONS	The cDNA of three variants of a cyclic nucleotidegated (CNG) channel modulatory subunit (CNG4c-CNG4e) has been cloned, CNG4c, CNG4d, and CNG4e differ slightly from each other within an amino-terminal sequence that was originally reported as part of the bovine retinal glutamic acid-rich protein (GARP). The core region of CNG4 is homologous to the second subunit of the human rod photoreceptor channel (hRCNC2b), suggesting that both proteins are alternatively spliced products of the bovine and human homologue of the same gene, CNG4 transcripts are present in retina, testis, kidney, heart, and brain. Expression of CNG4 in HEK293 cells did not lead to detectable currents, Coexpression of CNG4 with the principal subunit of the bovine testis CNG channel (CNG3) resulted in currents which differed in several aspects from that induced by CNG3 alone. The heterooligomeric CNG3/CNG4 and the homooligomeric CNG3 channels were modified by Ca2+-calmodulin and some calmodulin antagonists, The results suggest that CNG4 forms functional heterooligomeric channels with CNG3 in vitro and probably also in intact tissues.			Biel, M (corresponding author), TECH UNIV MUNICH,INST PHARMAKOL & TOXIKOL,BIEDERSTEINER STR 29,D-80802 MUNICH,GERMANY.		Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; AHMAD I, 1994, NEURON, V12, P155, DOI 10.1016/0896-6273(94)90160-0; BAUMANN A, 1994, EMBO J, V13, P5040, DOI 10.1002/j.1460-2075.1994.tb06833.x; BIEL M, 1993, FEBS LETT, V329, P134, DOI 10.1016/0014-5793(93)80209-D; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DISTLER M, 1994, NEUROPHARMACOLOGY, V33, P1275, DOI 10.1016/0028-3908(94)90027-2; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; EISMANN E, 1993, CELL PHYSIOL BIOCHEM, V3, P332, DOI 10.1159/000154697; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HSU YT, 1994, J BIOL CHEM, V269, P29765; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KLEENE SJ, 1994, BRIT J PHARMACOL, V111, P469, DOI 10.1111/j.1476-5381.1994.tb14760.x; KORSCHEN HG, 1995, NEURON, V15, P327; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NICOL GD, 1993, J PHARMACOL EXP THER, V265, P626; PITTLER SJ, 1992, J BIOL CHEM, V267, P6257; QUANDT FN, 1991, NEUROSCIENCE, V42, P629, DOI 10.1016/0306-4522(91)90032-J; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZIMMER M, 1987, EUR J BIOCHEM, V164, P411, DOI 10.1111/j.1432-1033.1987.tb11073.x	41	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6349	6355		10.1074/jbc.271.11.6349	http://dx.doi.org/10.1074/jbc.271.11.6349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626431	hybrid			2022-12-25	WOS:A1996UA36300060
J	Hines, MD; AllenHoffmann, BL				Hines, MD; AllenHoffmann, BL			Keratinocyte growth factor inhibits cross-linked envelope formation and nucleosomal fragmentation in cultured human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; PROGRAMMED CELL-DEATH; ENDOGENOUS ENDONUCLEASE; TRANSGENIC MICE; APOPTOSIS; DIFFERENTIATION; EXPRESSION; TRANSGLUTAMINASE; PROTEIN; KGF	Keratinocyte growth factor (KGF) exhibits paracrine action on numerous epithelia, including skin. We leave found that cultures of normal human keratinocytes must attain confluence before KGF promotes an increase in cell number relative to untreated controls. In postconfluent cultures, treatment with KGF promoted tight packing of keratinocytes with a small basal cell morphology. Based on these observations, we hypothesized that KGF increased cell number in postconfluent cultures by affecting the ability of normal keratinocytes to undergo terminal differentiation and/or programmed cell death. In support of this hypothesis, keratinocytes treated with KGF produced fewer cross-linked envelopes and exhibited reduced membrane-associated transglutaminase activity relative to cells treated with epidermal growth factor or untreated controls. We also found that nucleosomal fragmentation was reduced in postconfluent cultures of KGF-treated keratinocytes. Furthermore, KGF-treated keratinocytes were more resistant to suspension-induced nucleosomal fragmentation than control or epidermal growth factor-treated cultures. Therefore, it appears that KGF modulates aspects of keratinocyte terminal differentiation which share features with programmed cell death. We propose that stromally-derived KGF may act as a paracrine survival factor in skin and perhaps other renewal tissues.	UNIV WISCONSIN, DEPT PATHOL, MADISON, WI 53706 USA; UNIV WISCONSIN, PROGRAM DEV BIOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R43AR040285, R29AR040284, R01AR040284] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29-AR40285-S1, AR40284] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALISON MR, 1992, J ROY COLL PHYS LOND, V26, P25; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIANCHI L, 1994, J INVEST DERMATOL, V103, P829, DOI 10.1111/1523-1747.ep12413590; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BUDTZ PE, 1989, CELL TISSUE RES, V256, P475; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUCHS E, 1993, J CELL SCI, P197; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; JETTEN AM, 1990, METHOD ENZYMOL, V190, P42; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P239; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P807; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; NAKAGAWA K, 1994, CANCER, V74, P1720, DOI 10.1002/1097-0142(19940915)74:6<1720::AID-CNCR2820740613>3.0.CO;2-T; Paus R, 1993, Exp Dermatol, V2, P3, DOI 10.1111/j.1600-0625.1993.tb00192.x; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; Polakowska R R, 1994, Cell Death Differ, V1, P19; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Reichert Uwe, 1993, P107; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SAYAMA K, 1994, J INVEST DERMATOL, V103, P330, DOI 10.1111/1523-1747.ep12394858; SCHURER NY, 1991, DERMATOLOGICA, V183, P77, DOI 10.1159/000247644; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEVEN AC, 1994, J CELL SCI, V107, P693; TARCSA E, 1992, J BIOL CHEM, V267, P25648; THATCHER SM, 1985, CELL, V40, P685; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	62	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6245	6251		10.1074/jbc.271.11.6245	http://dx.doi.org/10.1074/jbc.271.11.6245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626417	hybrid			2022-12-25	WOS:A1996UA36300046
J	Smith, CD; Zhang, XQ				Smith, CD; Zhang, XQ			Mechanism of action of cryptophycin - Interaction with the Vinca alkaloid domain of tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE ASSEMBLY INVITRO; COLCHICINE-BINDING-SITE; MULTIDRUG-RESISTANCE; DYNAMIC INSTABILITY; CELL-PROLIFERATION; VINBLASTINE; INHIBITION; AGENTS; POLYMERIZATION; DOLASTATIN-10	Cryptophycin is a potent antitumor agent that depletes microtubules in intact cells, including cells with the multidrug resistance phenotype. To determine the mechanism of action of cryptophycin, its effects on tubulin function in vitro were analyzed. Cryptophycin reduced the in vitro polymerization of bovine brain microtubules by 50% at a drug:tubulin ratio of 0.1. Cryptophycin did not alter the critical concentration of tubulin required for polymerization, but instead caused substoichiometric reductions in the amount of tubulin that was competent for assembly. Consistent with its persistent effects on intact cells, cryptophycin-treated microtubule protein remained polymerization-defective even after cryptophycin was reduced to sub-inhibitory concentrations. The effects of cryptophycin were not due to denaturation of tubulin and were associated with the accumulation of rings of microtubule protein. The site of cryptophycin interaction with tubulin was examined using functional and competitive binding assays. Cryptophycin blocked the formation of vinblastine-tubulin paracrystals in intact cells and suppressed vinblastine-induced tubulin aggregation in vitro. Cryptophycin inhibited the binding of [H-3]vinblastine and the hydrolysis of [gamma-P-32]GTP by isolated tubulin, but did not block the binding of colchicine. These results indicate that cryptophycin disrupts the Vinca alkaloid site of tubulin; however, the molecular details of this interaction are distinct from those of other antimitotic drugs.			Smith, CD (corresponding author), FOX CHASE CANC CTR, DEPT PHARMACOL, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.				NATIONAL CANCER INSTITUTE [R01CA064631] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64631] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREU JM, 1984, BIOCHEMISTRY-US, V23, P1742, DOI 10.1021/bi00303a025; ANDREU JM, 1983, BIOCHEMISTRY-US, V22, P1556, DOI 10.1021/bi00276a006; BAI R, 1991, J BIOL CHEM, V266, P15882; BAI R, 1990, J BIOL CHEM, V265, P17141; BAI R, 1990, BIOCHEM PHARMACOL, V39, P1941, DOI 10.1016/0006-2952(90)90613-P; BAI RL, 1993, MOL PHARMACOL, V44, P757; BARROW RA, 1995, J AM CHEM SOC, V117, P2479, DOI 10.1021/ja00114a011; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BORISY GG, 1972, ANAL BIOCHEM, V50, P373, DOI 10.1016/0003-2697(72)90046-2; Cleveland Don W., 1993, P101; CORTESE F, 1977, J BIOL CHEM, V252, P1134; DAHLLOF B, 1993, CANCER RES, V53, P4573; DECONTI RC, 1975, CATHARANTHUS ALKALOI, P237; DEINES C, 1994, CANCER RES, V54, P75; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENGELBORGHS Y, 1990, MICROTUBULE PROTEINS, P1; ENGLEBORGHS Y, 1993, CELL PHARM S1, V1, pS23; FARRELL KW, 1984, BIOCHEMISTRY-US, V23, P3741, DOI 10.1021/bi00311a027; FRIDEN B, 1991, BIOCHEM PHARMACOL, V42, P997, DOI 10.1016/0006-2952(91)90281-9; GERWICK WH, 1994, J ORG CHEM, V59, P1243, DOI 10.1021/jo00085a006; Gerzon K, 1980, ANTICANCER AGENTS BA, P271; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAMEL E, 1983, BIOCHEM PHARMACOL, V32, P3864, DOI 10.1016/0006-2952(83)90163-6; Hamel E., 2018, MICROTUBULE PROTEINS, P89, DOI [10.1201/9781351074643-4, DOI 10.1201/9781351074643-4]; HEUSELE C, 1981, BIOCHEM BIOPH RES CO, V103, P332, DOI 10.1016/0006-291X(81)91697-1; HIMES RH, 1976, CANCER RES, V36, P3798; IWASAKI S, 1989, NOVEL MICROBIAL PROD, P79; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KOBAYASHI M, 1995, CHEM PHARM BULL, V43, P1598; LUDUENA RF, 1994, BIOCHEM PHARMACOL, V47, P1593, DOI 10.1016/0006-2952(94)90537-1; LUDUENA RF, 1995, DRUG DEVELOP RES, V35, P40, DOI 10.1002/ddr.430350107; LUDUENA RF, 1989, ARCH BIOCHEM BIOPHYS, V272, P32, DOI 10.1016/0003-9861(89)90191-4; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; OLMSTED JB, 1973, BIOCHEMISTRY-US, V12, P4282, DOI 10.1021/bi00745a037; PEYROT V, 1989, J BIOL CHEM, V264, P21296; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P739, DOI 10.1021/bi00351a035; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHIFF PB, 1978, BIOCHEM BIOPH RES CO, V85, P737, DOI 10.1016/0006-291X(78)91223-8; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SMITH CD, 1994, CANCER LETT, V79, P213, DOI 10.1016/0304-3835(94)90262-3; SMITH CD, 1984, J BIOL CHEM, V259, P1890; SMITH CD, 1994, CANCER RES, V54, P3779; TAKAHASHI M, 1987, BIOCHIM BIOPHYS ACTA, V926, P215, DOI 10.1016/0304-4165(87)90206-6; TAYLOR EW, 1965, J CELL BIOL, V25, P145, DOI 10.1083/jcb.25.1.145; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; TRIMURTULU G, 1994, J AM CHEM SOC, V116, P4729, DOI 10.1021/ja00090a020; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VANDECANDELAERE A, 1994, BIOCHEMISTRY-US, V33, P2792, DOI 10.1021/bi00176a007; VANDERGRAAF WTA, 1994, CANCER RES, V54, P5368; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; Wilson L., 1993, Cellular Pharmacology, V1, pS35; YORK J, 1981, BIOCHEM PHARMACOL, V30, P3239, DOI 10.1016/0006-2952(81)90524-4	56	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6192	6198		10.1074/jbc.271.11.6192	http://dx.doi.org/10.1074/jbc.271.11.6192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626409	hybrid			2022-12-25	WOS:A1996UA36300038
J	Varlamov, O; Fricker, LD				Varlamov, O; Fricker, LD			The C-terminal region of carboxypeptidase E involved in membrane binding is distinct from the region involved with intracellular routing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; INSULIN-SECRETORY-GRANULE; TRANS-GOLGI NETWORK; REGULATED PATHWAY; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CELL-LINE; CDNA; PURIFICATION; CONVERTASE	Carboxypeptidase E (CPE) is involved in the biosynthesis of numerous peptide hormones and neurotransmitters. Previously, the C-terminal region of CPE has been shown to participate in the binding of the protein to membranes and to also contribute to the sorting of CPE into the regulated pathway. In this study, the role of the C-terminal region of CPE was further examined using several approaches. A series of CPE mutants with C-terminal deletions was expressed in the baculovirus system; constructs with a deletion of 14 or 23 residues were expressed at levels comparable to wild-type CPE. In contrast, deletion of 33 or more residues eliminated CPE activity, and the resulting protein was not secreted from the cells. Even though CPE mutants with a deletion of 14 or 23 residues were expressed normally, the resulting protein was mainly soluble, whereas approximately 55% of wild-type CPE was membrane associated. When expressed in AtT-20 cells, CPE with a deletion of 43 C-terminal amino acids was not secreted, whereas CPE with a deletion of 23 residues was secreted via the regulated pathway. Pulse-chase analysis revealed the protein with a deletion of 43 residues to be degraded in a non-acidic intracellular compartment. To investigate whether the C-terminal region of CPE can confer membrane binding and regulated pathway sorting to another protein, portions of the CPE C-terminal region were attached to the C terminus of albumin and the fusion proteins expressed in AtT-20 cells. Of the constructs examined, only the protein containing 51 amino acids of CPE was sorted to the regulated pathway, although with reduced efficiency compared to endogenous CPE. Although the C terminal 14 amino acids of CPE are sufficient to target albumin to membranes, this fusion protein is not sorted into the regulated pathway. Taken together, these results indicate that the C-terminal 14 amino acids of CPE are important for membrane binding and that membrane binding and sorting require distinct signals.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine			Varlamov, Oleg/AAK-6980-2020	Varlamov, Oleg/0000-0003-0294-215X	NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, R01DA004494] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00194, DA-04494] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADELI K, 1994, J BIOL CHEM, V269, P9166; [Anonymous], 1995, METH NEUROSCI; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BEAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DOCHERTY K, 1983, FEBS LETT, V162, P137, DOI 10.1016/0014-5793(83)81065-5; EATON DL, 1991, J BIOL CHEM, V266, P21833; Fricker L D, 1991, NIDA Res Monogr, V111, P171; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1990, NEUROENDOCRINOLOGY, V51, P658, DOI 10.1159/000125407; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; FRICKER LD, 1994, NEUROPROTOCOLS, V5, P151; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; GORR SU, 1992, J BIOL CHEM, V267, P21595; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KLEIN RS, 1992, J NEUROCHEM, V58, P2011, DOI 10.1111/j.1471-4159.1992.tb10941.x; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MANSER E, 1991, BIOCHEM J, V280, P695, DOI 10.1042/bj2800695; MITRA A, 1994, J BIOL CHEM, V269, P19876; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PARKINSON D, 1993, MOL CELL ENDOCRINOL, V86, P221; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; Porath J, 1976, Methods Enzymol, V44, P19; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMYTH DG, 1989, J NEUROCHEM, V53, P489, DOI 10.1111/j.1471-4159.1989.tb07360.x; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; SUPATTAPONE S, 1984, J NEUROCHEM, V42, P1017, DOI 10.1111/j.1471-4159.1984.tb12705.x; TAN FL, 1989, J BIOL CHEM, V264, P13165; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAMASHITA Y, 1994, J VIROL, V68, P7933, DOI 10.1128/JVI.68.12.7933-7943.1994; ZHENG M, 1994, J NEUROSCI, V14, P4656	57	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6077	6083		10.1074/jbc.271.11.6077	http://dx.doi.org/10.1074/jbc.271.11.6077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626393	hybrid			2022-12-25	WOS:A1996UA36300022
J	Zhou, JH; FernandezVelasco, JG; Malkin, R				Zhou, JH; FernandezVelasco, JG; Malkin, R			N-terminal mutants of chloroplast cytochrome f - Effect on redox reactions and growth in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; RHODOBACTER-CAPSULATUS; PHENOTYPIC SELECTION; POLYACRYLAMIDE GELS; ELECTRON-TRANSFER; PHOTOSYSTEM-I; BC1 COMPLEX; DNA; TRANSFORMATION; GENE	The N-terminal tyrosine of cytochrome f, which provides the sixth ligand to the heme group, has been changed by site-directed mutagenesis in Chlamydomonas reinhardtii to evaluate the role of this amino acid in assembly and function. The second and third residues, proline and valine, respectively, have also been mutated, Y1P is the only strain that did not grow photoautotrophically. The other strains show cytochrome b(6)f complex/photosystem I reaction center chlorophyll, photosystem I unit size and chlorophyll a+b/cell ratios comparable with wild-type cells. Rates of cytochrome f photooxidation in all strains were similar (t(1/2) congruent to 300 mu s), whereas the rate of re-reduction sensitive to stigmatellin (at E(h) = 0 mV, (where E(h) is the ambient redox potential) for wild-type, Y1W, Y1F, Y1S, P2V, and V3P had a t(1/2) of 3, 4, 5, 9, 40, and 2 ms, respectively. Rates of oxygen evolution by whole cells of P2V, Y1F, and Y1S were 67, 80, and 80% of wild-type rates, respectively. At low light intensity, all competent strains had the same growth rate whereas at saturating intensities, only P2V showed a significant inhibition. These results are considered in relation to structure function relationships in the cytochrome f molecule.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20571] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JM, 1992, PHOTOSYNTH RES, V34, P341, DOI 10.1007/BF00029810; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENDALL DS, 1987, METHOD ENZYMOL, V148, P259; Bendall DS, 1971, METHOD ENZYMOL, V23A, P327, DOI DOI 10.1016/S0076-6879(71)23109-8; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; BERTSCH J, 1991, PLANT MOL BIOL, V17, P131, DOI 10.1007/BF00036814; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUCE BD, 1991, PLANT CELL, V3, P203, DOI 10.1105/tpc.3.2.203; CRAMER WA, 1987, LIGHT REACTIONS, P447; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; DAVIS DJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P61, DOI 10.1016/0005-2728(88)90251-4; DELOSME R, 1991, PHOTOSYNTH RES, V29, P45, DOI 10.1007/BF00035205; DEWOLF FA, 1988, BIOCHIM BIOPHYS ACTA, V936, P487, DOI 10.1016/0005-2728(88)90026-6; Dutton P L, 1978, Methods Enzymol, V54, P411; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HAUSKA G, 1989, Z NATURFORSCH C, V44, P462; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JOLIOT P, 1993, BIOCHIM BIOPHYS ACTA, V1141, P151, DOI 10.1016/0005-2728(93)90039-I; KALLAS T, 1988, METHOD ENZYMOL, V167, P779; KONISHI K, 1991, J BIOL CHEM, V266, P14270; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALKIN R, 1992, PHOTOSYNTH RES, V33, P121, DOI 10.1007/BF00039175; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; NEWMAN SM, 1990, GENETICS, V126, P875; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOGASKAKI RK, 1992, RES PHOTOSYNTHESIS, V3, P939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WILLEY DL, 1984, CELL, V36, P555, DOI 10.1016/0092-8674(84)90248-4; WURTZ EA, 1977, P NATL ACAD SCI USA, V74, P4552, DOI 10.1073/pnas.74.10.4552; ZER H, 1994, J BIOL CHEM, V269, P17670	48	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6225	6232		10.1074/jbc.271.11.6225	http://dx.doi.org/10.1074/jbc.271.11.6225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626414	hybrid			2022-12-25	WOS:A1996UA36300043
J	Orita, M; Vinayak, R; Andrus, A; Warashina, M; Chiba, A; Kaniwa, H; Nishikawa, F; Nishikawa, S; Taira, K				Orita, M; Vinayak, R; Andrus, A; Warashina, M; Chiba, A; Kaniwa, H; Nishikawa, F; Nishikawa, S; Taira, K			Magnesium-mediated conversion of an inactive form of a hammerhead ribozyme to an active complex with its substrate - An investigation by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNUSUALLY STABLE RNA; HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-MAGNETIC-RESONANCE; SECONDARY STRUCTURE; SELF-CLEAVAGE; HAIRPIN; MISMATCHES; MECHANISM; STABILITY; ENZYMES	The effects of magnesium ions on a 32-mer ribozyme (R32) were examined by high resolution NMR spectroscopy, In solution, R32 (without its substrate) consisted of a GAAA loop, stem II, a non-Watson-Crick 3-base pair duplex and a 4-base pair duplex that included a wobble G:U base pair, When an uncleavable substrate RNA (RdC11) was added to R32 without Mg2+ ions, a complex did not form between R32 and RdC11 because the substrate recognition regions of R32 formed intramolecular base pairs (the recognition arms were closed), By contrast, in the presence of Mg2+ ions, the R32-RdC11 complex was formed. Moreover, titration of mixtures of R32 and RdC11 with Mg2+ ions also induced the ribozyme-substrate interaction, Elevated concentrations (1.0 hi) of monovalent Na+ ions could not induce the formation of the R32-RdC11 complex. These data suggest that Mg2+ ions are not only important as the true catalysts in the function of ribozyme-type metalloenzymes, but they also induce the structural change in the R32 hammerhead ribozyme that is necessary for establishment of the active form of the ribozyme-substrate complex.	UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, TSUKUBA, IBARAKI 305, JAPAN; PERKIN ELMER CORP, APPL BIOSYST, FOSTER CITY, CA 94404 USA; MINIST INT TRADE & IND, AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN; IBARAKI UNIV, FAC AGR, AMI, IBARAKI 30003, JAPAN; UNIV TSUKUBA, SCH BIOSYST, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; Astellas Pharmaceuticals; Thermo Fisher Scientific; Applied Biosystems; National Institute of Advanced Industrial Science & Technology (AIST); Ibaraki University; University of Tsukuba								ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CHOWRIRA BM, 1994, J BIOL CHEM, V269, P25856; CLORE GM, 1983, J MAGN RESON, V54, P170, DOI 10.1016/0022-2364(83)90160-9; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FREIER SM, 1986, BIOCHEMISTRY-US, V25, P3209, DOI 10.1021/bi00359a019; GUTELL RR, 1990, P NATL ACAD SCI USA, V87, P663, DOI 10.1073/pnas.87.2.663; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HEUS HA, 1990, NUCLEIC ACIDS RES, V18, P1103, DOI 10.1093/nar/18.5.1103; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JOHNSTON PD, 1981, BIOCHEMISTRY-US, V20, P1147, DOI 10.1021/bi00508a016; KATAHIRA M, 1994, NUCLEIC ACIDS RES, V22, P2752, DOI 10.1093/nar/22.14.2752; ODAI O, 1990, NUCLEIC ACIDS RES, V18, P5955, DOI 10.1093/nar/18.20.5955; OHKAWA J, 1995, J BIOCHEM-TOKYO, V118, P251, DOI 10.1093/oxfordjournals.jbchem.a124899; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; PEASE AC, 1990, BIOCHEMISTRY-US, V29, P9039, DOI 10.1021/bi00490a022; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SAKATA T, 1990, NUCLEIC ACIDS RES, V18, P3831, DOI 10.1093/nar/18.13.3831; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; SARMA RH, 1995, FEBS LETT, V357, P317, DOI 10.1016/0014-5793(94)01388-H; SAWATA S, 1993, NUCLEIC ACIDS RES, V21, P5656, DOI 10.1093/nar/21.24.5656; SAWATA S, 1995, J AM CHEM SOC, V117, P2357, DOI 10.1021/ja00113a028; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SPROAT B, 1995, NUCLEOS NUCLEOT, V14, P255, DOI 10.1080/15257779508014668; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUGIMOTO N, 1986, BIOCHEMISTRY-US, V25, P5755, DOI 10.1021/bi00367a061; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; TAKAGI Y, 1995, FEBS LETT, V361, P273, DOI 10.1016/0014-5793(95)00192-C; UCHIMARU T, 1993, FASEB J, V7, P137, DOI 10.1096/fasebj.7.1.8422960; UEBAYASI M, 1994, J ORG CHEM, V59, P7414, DOI 10.1021/jo00103a038; UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P233; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	47	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9447	9454		10.1074/jbc.271.16.9447	http://dx.doi.org/10.1074/jbc.271.16.9447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621614	hybrid			2022-12-25	WOS:A1996UG04400045
J	Vinson, M; vanderMerwe, PA; Kelm, S; May, A; Jones, EY; Crocker, PR				Vinson, M; vanderMerwe, PA; Kelm, S; May, A; Jones, EY; Crocker, PR			Characterization of the sialic acid-binding site in sialoadhesin by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; INFLUENZA-VIRUS HEMAGGLUTININ; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; ADHESION MOLECULE; CELL-ADHESION; CDNA CLONING; RECOGNITION; RECEPTOR; DOMAINS	The sialoadhesins are a distinct subgroup of the immunoglobulin superfamily, comprising sialoadhesin, CD22, the myelin-associated glycoprotein, and CD33. They can all mediate sialic acid-dependent binding to cells with distinct specificities. Sialoadhesin is a murine macrophage-restricted cell-surface molecule with 17 extracellular immunoglobulin-like domains that recognizes NeuAc alpha 2-3Gal in N- and O-glycans and interacts preferentially with cells of the granulocytic lineage, Its sialic acid-binding site is located within the NH2-terminal (membrane-distal) V-set domain, Here we have carried out site-directed mutagenesis in an attempt to identify the binding site of sialoadhesin. A subset of nonconservative mutations disrupted sialic acid-dependent binding without affecting binding of three monoclonal antibodies directed to two distinct epitopes of sialoadhesin, A CD8 alpha-based molecular model predicts that these residues form a contiguous binding site on the GFCC'C '' beta-sheet of the V-set domain centered around an arginine in the F strand. A conservative mutation of this arginine to lysine also abolished binding, This amino acid is conserved among all members of the sialoadhesin family and is therefore likely to be a key residue in mediating sialic acid-dependent binding of sialoadhesins to cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND; CHRISTIAN ALBRECHTS UNIV KIEL,INST BIOCHEM,D-24098 KIEL,GERMANY; UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Cancer Research UK; University of Oxford; University of Oxford; University of Kiel; University of Oxford; University of Oxford			Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016; Kelm, Soerge/C-5403-2013; van der Merwe, P. Anton/F-8539-2011	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Kelm, Soerge/0000-0001-5277-9421; Crocker, Paul/0000-0001-6230-0293				ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1990, BLOOD, V76, P1131; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; JANAKIRAMAN MN, 1994, BIOCHEMISTRY-US, V33, P8172, DOI 10.1021/bi00193a002; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SAUTER NK, 1992, P NATL ACAD SCI USA, V89, P324, DOI 10.1073/pnas.89.1.324; SIMMONS D, 1988, J IMMUNOL, V141, P2797; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SPAGNOL G, 1989, J NEUROSCI RES, V24, P137, DOI 10.1002/jnr.490240203; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; TCHILIAN EZ, 1994, BLOOD, V83, P3188; TORRES RM, 1992, J IMMUNOL, V149, P2641; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; WATOWICH SJ, 1994, STRUCTURE, V2, P719, DOI 10.1016/S0969-2126(00)00073-3; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WHITAKER PB, 1993, J MOL BIOL, V232, P1069; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345	49	101	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9267	9272		10.1074/jbc.271.16.9267	http://dx.doi.org/10.1074/jbc.271.16.9267			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621587	hybrid			2022-12-25	WOS:A1996UG04400018
J	Chen, F; Mosher, DF				Chen, F; Mosher, DF			Formation of sodium dodecyl sulfate-stable fibronectin multimers - Failure to detect products of thiol-disulfide exchange in cyanogen bromide or limited acid digests of stabilized matrix fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; CELL-SURFACE; CROSS-LINKING; BINDING; MODULES; GLYCOPROTEIN; MOLECULES; LAYERS	Fibronectin exists in a soluble form in body fluids and as a fibrillar component of the extracellular matrix. Matrix fibronectin associates as large complexes in SDS unless a reducing reagent is also present, This observation suggests that complex formation is due to interprotomeric disulfides that form by thiol-disulfide exchange, To localize the presumptive new disulfides, we labeled protomeric fibronectin by the chloramine-T method or with I-125-Bolton-Hunter reagent, incorporated I-125-fibronectin into the matrix of cultured fibroblasts, and subjected matrix fibronectin to acid or cyanogen bromide digestion, When cyanogen bromide digests of matrix I-125-fibronectin and protomeric I-125-fibronectin labeled with Bolton-Hunter reagent were analyzed by two-dimensional polyacrylamide gel electrophoresis in SDS, with the first dimension being nonreducing and the second reducing, we were not able to identify any fragments of matrix fibronectin that migrated as high molecular weight complexes in the first dimension. Limited acid digestion of matrix I-125-fibronectin also dissociated the majority of the high molecular weight complexes. Since we could account for all of the parts of fibronectin that contain cysteine or cystine, we conclude that matrix fibronectin is not stabilized by interprotomeric disulfides. We propose, instead, that stabilization is mediated by noncovalent protein-protein interactions that are sensitive to reduction, cyanogen bromide digestion, or limited acid digestion.	UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN RA, 1994, BIOMATERIALS, V15, P457, DOI 10.1016/0142-9612(94)90225-9; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CHOI MG, 1979, J BIOL CHEM, V254, P2050; COLVIN RB, 1989, FIBRONECTIN, P213; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GOLD LI, 1979, P NATL ACAD SCI USA, V76, P4803, DOI 10.1073/pnas.76.10.4803; Gros E., 1967, METHOD ENZYMOL, V11, P238; HAYMAN EG, 1979, J CELL BIOL, V83, P255, DOI 10.1083/jcb.83.1.255; HEDMAN K, 1989, FIBRONECTIN, P123; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; Hynes RO, 1990, FIBRONECTIN; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; Landon, 1977, Methods Enzymol, V47, P145; LITVINOVICH SV, 1992, BIOCHIM BIOPHYS ACTA, V1119, P57, DOI 10.1016/0167-4838(92)90234-5; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; MALCHEREK G, 1995, J EXP MED, V181, P527, DOI 10.1084/jem.181.2.527; MCCONNELL MR, 1978, J BIOL CHEM, V253, P7522; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MIYAMOTO S, 1993, P NATL ACAD SCI USA, V90, P8402, DOI 10.1073/pnas.90.18.8402; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; OH E, 1981, P NATL ACAD SCI-BIOL, V78, P3218, DOI 10.1073/pnas.78.5.3218; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAKAI K, 1994, J BIOCHEM-TOKYO, V115, P415, DOI 10.1093/oxfordjournals.jbchem.a124353; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; THIERY JP, 1989, FIBRONECTIN, P181; WILLIAMS MJ, 1994, J MOL BIOL, V235, P1302, DOI 10.1006/jmbi.1994.1083; YAMADA KM, 1977, BIOCHEMISTRY-US, V16, P5552, DOI 10.1021/bi00644a025	47	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9084	9089		10.1074/jbc.271.15.9084	http://dx.doi.org/10.1074/jbc.271.15.9084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621558				2022-12-25	WOS:A1996UE73000089
J	Gabbitas, B; Pash, JM; Delany, AM; Canalis, E				Gabbitas, B; Pash, JM; Delany, AM; Canalis, E			Cortisol inhibits the synthesis of insulin-like growth factor-binding protein-5 in bone cell cultures by transcriptional mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT CALVARIAE; FACTOR-I; EXTRACELLULAR-MATRIX; COLLAGEN-SYNTHESIS; MOLECULAR-CLONING; IGF-I; STIMULATION; BASAL; GENE	Glucocorticoids inhibit the synthesis of insulin-like growth factor-binding protein-5 (IGFBP-5) in osteoblasts, but the mechanisms involved are unknown. IGFBP-5 stimulates bone cell growth, and its inhibition by glucocorticoids may be relevant to the action of this binding protein on bone formation, We tested the effects of cortisol on IGFBP-5 expression in cultures of osteoblast-enriched cells from fetal rat calvariae (Ob cells), Cortisol decreased IGFBP-5 polypeptide levels in the extracellular matrix and caused a time- and dose-dependent decrease in IGFBP-5 mRNA. IGFBP-5 transcripts were markedly decreased by cycloheximide, and further suppressive effects of cortisol could not be determined, Cortisol did not modify the decay of IGFBP-5 mRNA in transcriptionally arrested Ob cells. Cortisol decreased IGFBP-5 hnRNA, the rate of IGFBP-5 transcription, and the activity of the murine IGFBP-5 promoter by 35% in transient transfection experiments, Deletion analysis showed that the region responsive to cortisol is from base pairs -70 to +22, and E-box-binding proteins or c-Myb-related nuclear factors may be involved in its regulation. In conclusion, cortisol inhibits IGFBP-5 transcription in Ob cells through the Myb-binding domain. This effect may be partly responsible for the effect of glucocorticoids on bone formation.	ST FRANCIS HOSP & MED CTR,DEPT RES,HARTFORD,CT 06105; ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06030	Saint Francis Hospital & Medical Center; Saint Francis Hospital & Medical Center; University of Connecticut					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45227] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BIRNBAUM RS, 1994, ENDOCRINOLOGY, V135, P223, DOI 10.1210/en.135.1.223; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; CANALIS E, 1993, ENDOCRINOLOGY, V133, P33, DOI 10.1210/en.133.1.33; Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1152; DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEYEN JHM, 1991, J BIOL CHEM, V266, P19469; FROLIK CA, 1988, BIOCHEM BIOPH RES CO, V151, P1011, DOI 10.1016/S0006-291X(88)80466-2; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HASSAGER C, 1992, J CLIN ENDOCR METAB, V75, P228, DOI 10.1210/jc.75.1.228; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; RAISZ LG, 1993, ENDOCRINOLOGY, V133, P1504, DOI 10.1210/en.133.4.1504; REISS K, 1991, CANCER RES, V51, P5997; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; Sokal R. R, 1981, BIOMETRY; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALL FJ, 1986, STATISTICAL DATA ANA; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9033	9038		10.1074/jbc.271.15.9033	http://dx.doi.org/10.1074/jbc.271.15.9033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621551	hybrid			2022-12-25	WOS:A1996UE73000082
J	Sharma, PK; Kuchumov, AR; Chottard, G; Martin, PD; Wall, JS; Vinogradov, SN				Sharma, PK; Kuchumov, AR; Chottard, G; Martin, PD; Wall, JS; Vinogradov, SN			The role of the dodecamer subunit in the dissociation and reassembly of the hexagonal bilayer structure of Lumbricus terrestris hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT EXTRACELLULAR HEMOGLOBIN; AMINO-ACID-SEQUENCES; QUATERNARY STRUCTURE; REASSOCIATION; MYOGLOBIN; PROTEIN; PH; ALKYLUREAS; EARTHWORM; TRIMER	The dissociation of the similar to 3500-kDa hexagonal bilayer (HBL) hemoglobin (Db) of Lumbricus terrestris upon exposure to Gdm salts, urea and the heteropolytungstates [SiW11O39](8-) (SiW), [NaSb9W21O86](18-) (SbW) and [BaAs4W40O140](27-) (AsW) at neutral pH was followed by gel filtration, SDS-polyacrylamide gel electrophoresis, and scanning transmission electron microscopy. Elution curves were fitted to sums of exponentially modified gaussians to represent the peaks due to undissociated oxyHb, D (similar to 200 kDa), T+L (similar to 50 kDa), and M (similar to 25 kDa) (T = disulfide-bonded trimer of chains a-c, M = chain d, and L = linker chains). OxyHb dissociation decreased in the order Gdm . SCN > Gdm . Cl > urea > Gdm . OAc and AsW > SbW > SiW. Scanning transmission electron microscopy mass mapping of D showed similar to 10-nm particles with masses of 200 kDa, suggesting them to be dodecamers (a + b + c)(3)d(3). OxyHb dissociations in urea and Gdm . Cl and at alkaline pH could be fitted only as sums of 3 exponentials. The time course of D was bell-shaped, indicating it was an intermediate. Dissociations in SiW and upon conversion to metHb showed only two phases. The kinetic heterogeneity may be due to oxyHb structural heterogeneity. Formation of D was spontaneous during HBL reassembly, which was minimal (less than or equal to 10%) without Group IIA cations. During reassembly, maximal (similar to 60%) at 10 mM cation, D occurs at constant levels (similar to 15%), implying the dodecamer to be an intermediate.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,DETROIT,MI 48201; UNIV PARIS 06,CHIM MET TRANSIT LAB,URA 419,F-75252 PARIS,FRANCE; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Wayne State University; UDICE-French Research Universities; Sorbonne Universite; United States Department of Energy (DOE); Brookhaven National Laboratory					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01777] Funding Source: Medline; NIDDK NIH HHS [DK38674] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI F, 1978, J MOL BIOL, V119, P191, DOI 10.1016/0022-2836(78)90433-3; CHIANCONE E, 1980, BIOCHIM BIOPHYS ACTA, V670, P84; CHOTTARD G, 1992, BIOCHIM BIOPHYS ACTA, V1122, P113, DOI 10.1016/0167-4838(92)90312-2; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; DEHAAS F, 1996, IN PRESS BIOPHYS J; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; GOTOH T, 1990, ZOOL SCI, V7, P1; HARRINGTON JP, 1994, COMP BIOCHEM PHYS A, V109, P799, DOI 10.1016/0300-9629(94)90224-0; HERVE M, 1983, NOUV J CHIM, V7, P515; KAPP OH, 1987, P NATL ACAD SCI USA, V84, P7532, DOI 10.1073/pnas.84.21.7532; KAPP OH, 1990, J MOL BIOL, V213, P141, DOI 10.1016/S0022-2836(05)80127-5; KAPP OH, 1984, J BIOL CHEM, V259, P628; KLEMPERER WG, 1990, INORG SYN, V27, P71, DOI 10.1002/9780470132586.ch14; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPANJE S, 1986, BIOPHYS CHEM, V24, P179, DOI 10.1016/0301-4622(86)80012-6; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; Novak J., 1987, CHROMATOGRAPHIC THEO, P103; OCHIAI T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P310, DOI 10.1016/0167-4838(93)90100-6; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; POLIDORI G, 1984, ARCH BIOCHEM BIOPHYS, V233, P800, DOI 10.1016/0003-9861(84)90509-5; POLIDORI G, 1988, COMP BIOCHEM PHYS A, V89, P541, DOI 10.1016/0300-9629(88)90830-4; REH E, 1995, TRAC-TREND ANAL CHEM, V14, P1, DOI 10.1016/0165-9936(95)91139-J; SAID AS, 1981, THEORY MATH CHROMATO, P69; SHISHIKURA F, 1986, BIOCHIM BIOPHYS ACTA, V869, P314, DOI 10.1016/0167-4838(86)90071-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SZAHO ZG, 1969, COMP CHEM KINETICS, P1; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1994, METHOD ENZYMOL, V231, P112; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; VINOGRADOV SN, 1985, BIOCHIM BIOPHYS ACTA, V828, P43, DOI 10.1016/0167-4838(85)90007-X; Von Hippel P. H., 1969, STRUCTURE STABILITY, P417; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; ZEROVNIK E, 1986, BIOPHYS CHEM, V24, P53, DOI 10.1016/0301-4622(86)85059-1	42	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8754	8762		10.1074/jbc.271.15.8754	http://dx.doi.org/10.1074/jbc.271.15.8754			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621510	hybrid			2022-12-25	WOS:A1996UE73000041
J	Toyoshige, M; Basi, NS; Rebois, RV				Toyoshige, M; Basi, NS; Rebois, RV			Chloride effects on G(s) subunit dissociation - Fluoroaluminate binding to G(s) does not cause subunit dissociation in the absence of chloride ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; REGULATORY COMPONENT; G-PROTEINS; CONFORMATIONAL-CHANGES; GUANINE-NUCLEOTIDES; ALPHA-SUBUNIT; RECEPTOR; PURIFICATION	The stimulatory guanine nucleotide binding protein (G(s)) is heterotrimeric (alpha beta gamma), and mediates activation of adenylyl cyclase by a ligand-receptor complex. The cu subunit of G(s) (G(s) alpha) has a guanine nucleotide binding site, and activation occurs when tightly bound GDP is displaced by GTP. Together, GDP and fluoroaluminate (AlF4-) form a transition state analog of GTP that activates G(s). The work of other investigators suggests that AlF4- causes subunit dissociation when it activates G(s). We have observed that in solution AlF4- did not cause G(s) subunits to dissociate unless NaCl was also present. The effect of NaCl was concentration dependent (10-200 mM). Omitting F-, Al3+, or Mg2+ prevented the NaCl-induced dissociation of G(s) subunits. Na2SO4 could not substitute for NaCl in causing subunit dissociation, but KCl could, suggesting that the anion was responsible for the effect. G(s) subunit reassociation occurred when the concentration of Cl- was reduced even though the concentrations of AlF4- and Mg2+ were maintained. The absence of Cl- did not prevent AlF4- binding to G(s) alpha. We have concluded that AlF4- a ligand which is capable of activating G proteins, can bind to G(s) in solution without causing subunit dissociation.	NINCDS,NIH,MEMBRANE BIOCHEM SECT,LAB MOL & CELLULAR NEUROBIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BASI NS, 1996, IN PRESS CELL SIGNAL, V8; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1984, J BIOL CHEM, V259, P1408; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HANSKI E, 1981, J BIOL CHEM, V256, P2911; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; HOWLETT AC, 1980, J BIOL CHEM, V255, P2861; HOWLETT AC, 1979, P NATL ACAD SCI USA, V79, P4888; HUDSON TH, 1981, J BIOL CHEM, V256, P1459; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KAHN RA, 1984, J BIOL CHEM, V259, P6235; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; RALL TW, 1958, J BIOL CHEM, V232, P1065; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SONDEK J, 1994, NATURE, V371, P429; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TOYOSHIGE M, 1994, BIOCHEMISTRY-US, V33, P4865, DOI 10.1021/bi00182a014; Warner DR, 1996, CELL SIGNAL, V8, P43, DOI 10.1016/0898-6568(95)02017-9	29	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8791	8795		10.1074/jbc.271.15.8791	http://dx.doi.org/10.1074/jbc.271.15.8791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621516	hybrid			2022-12-25	WOS:A1996UE73000047
J	Zal, F; Lallier, FH; Wall, JS; Vinogradov, SN; Toulmond, A				Zal, F; Lallier, FH; Wall, JS; Vinogradov, SN; Toulmond, A			The multi-hemoglobin system of the hydrothermal vent tube worm Riftia pachyptila .1. Reexamination of the number and masses of its constituents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPE; LUMBRICUS-TERRESTRIS HEMOGLOBIN; SUBUNIT STRUCTURE; EXTRACELLULAR HEMOGLOBIN; ANNELID HEMOGLOBIN; SULFIDE-BINDING; GALAPAGOS RIFT; JONES; BLOOD; VESTIMENTIFERA	The deep-sea tube worm Riftia pachyptila Jones possesses a well developed circulatory system and a large coelomic compartment, both containing extracellular hemoglobins, Fresh vascular blood is heterogeneous and contains two different hemoglobins (V1 and V2), whereas the coelomic fluid is homogeneous and comprises only one hemoglobin (C1), Their molecular weights have been determined by scanning transmission electron microscopy mass mapping (STEM) and by multi-angle laser light scattering (MALLS). Both methods yielded approximately the same molecular weights with masses significantly higher than the literature data for V1, V1, V2, and C1 had M(r) of 3396 +/- 540 x 10(3), 393 +/- 71 x 10(3), and 410 +/- 51 x 10(3) by STEM, and 3503 +/- 13 x 10(3), 433 +/- 8 x 10(3), and 380 +/- 4 x 10(3) by MALLS, respectively, Transmission electron micrographs of V1 are typical of an hexagonal bilayer hemoglobin (HBL Hb), When submitted to dilution or osmotic shock, V1 dissociates into halves and one-twelfth subunits like annelid HBL Hbs, V1 is resistant to urea treatment, indicating that hydrophobic interactions play a small role in its quaternary structure, Conversely, V1 Hb is rather unstable in solution without denaturant, a property which seems to be characteristic of vestimentiferan HBL Hbs and could be explained by an important number of hydrogen bonds.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	United States Department of Energy (DOE); Brookhaven National Laboratory; Wayne State University	Zal, F (corresponding author), UNIV PARIS 06,CNRS,INSU,EQUIPE ECOPHYSIOL,BIOL STN,PL GEORGES TEISSIER,BP 74,F-29682 ROSCOFF,FRANCE.				NIDDK NIH HHS [DK38674] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARP AJ, 1981, SCIENCE, V213, P342, DOI 10.1126/science.213.4505.342; ARP AJ, 1983, SCIENCE, V219, P295, DOI 10.1126/science.219.4582.295; ARP AJ, 1987, J EXP BIOL, V128, P139; ARP AJ, 1990, RESP PHYSIOL, V80, P323, DOI 10.1016/0034-5687(90)90092-D; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V30, P337; CHILDRESS JJ, 1991, BIOL BULL-US, V180, P135, DOI 10.2307/1542437; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; FISHER CR, 1988, SYMBIOSIS, V5, P229; HARRINGTON JP, 1975, BIOCHEMISTRY-US, V14, P4972, DOI 10.1021/bi00693a028; HERSKOVI.TT, 1970, J BIOL CHEM, V245, P4544; HERSKOVITS TT, 1975, BIOCHEMISTRY-US, V14, P4964, DOI 10.1021/bi00693a027; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; JONES ML, 1981, SCIENCE, V213, P333, DOI 10.1126/science.213.4505.333; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUZUKI T, 1989, ZOOL SCI, V6, P915; SUZUKI T, 1988, BIOCHEM J, V255, P541; TERWILLIGER NB, 1984, MAR BIOL LETT, V5, P191; TERWILLIGER R, 1985, BIOCHIM BIOPHYS ACTA, V829, P27, DOI 10.1016/0167-4838(85)90064-0; TERWILLIGER RC, 1980, COMP BIOCHEM PHYS B, V65, P531, DOI 10.1016/0305-0491(80)90307-7; TERWILLIGER RC, 1987, J MAR BIOL ASSOC UK, V67, P219, DOI 10.1017/S002531540002645X; TOULMOND A, 1994, DEEP-SEA RES, V10, P1447; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; VINOGRADOV SN, 1980, COMP BIOCHEM PHYS B, V67, P1, DOI 10.1016/0305-0491(80)90262-X; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALL JS, 1982, ULTRAMICROSCOPY, V8, P397, DOI 10.1016/0304-3991(82)90062-6; WALL JS, 1979, ANAL ELECT MICROSCOP, P339; WHILHEM PP, 1980, INT J BIOL MACROMOL, V2, P383; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Zal F, 1996, J BIOL CHEM, V271, P8875, DOI 10.1074/jbc.271.15.8875	33	49	51	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8869	8874		10.1074/jbc.271.15.8869	http://dx.doi.org/10.1074/jbc.271.15.8869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621528	hybrid			2022-12-25	WOS:A1996UE73000059
J	Zufferey, R; Preisig, O; Hennecke, H; ThonyMeyer, L				Zufferey, R; Preisig, O; Hennecke, H; ThonyMeyer, L			Assembly and function of the cytochrome cbb(3) oxidase subunits in Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; C-OXIDASE; GENE; COMPLEX; PROTEINS; MUTANTS; HEMOPROTEINS; BIOGENESIS; SYMBIOSIS	The Bradyrhizobium japonicum cbb(3)-type cytochrome oxidase, which supports microaerobic respiration, is a multisubunit enzyme encoded by the genes of the fixNOQP operon, We investigated the contribution of the individual subunits to function and assembly of the membrane-bound complex, In-frame deletion mutants of fixN, fixO, and fixQ, and an insertion mutant of fixP were constructed. All mutants, except the fixQ mutant, showed clearly altered absorption difference spectra of their membranes and decreased oxidase activities, and they were unable to fix nitrogen symbiotically, The presence of the individual subunits was assayed by Western blot analysis, using subunit-specific antibodies, and by heme staining of the c-type cytochromes FixO and FixP. These analyses led to the following conclusions: (i) FixN and FixO are necessary for assembly of the multimeric oxidase, (ii) FixN and FixO assemble independently of FixP, and (iii) FixQ is not required for complex formation and, therefore, does not seem to be an essential subunit, The possible oxidase biogenesis pathway involves the formation of a primary core complex consisting of FixN and FixO, which allows the subsequent association with FixP to form the complete enzyme.	ETH ZURICH, INST MIKROBIOL, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								BOTT M, 1991, J BACTERIOL, V173, P6766, DOI 10.1128/jb.173.21.6766-6772.1991; BOTT M, 1990, MOL MICROBIOL, V4, P2147, DOI 10.1111/j.1365-2958.1990.tb00576.x; COX GB, 1987, CURR TOP BIOENERG, V15, P163; DANIEL RM, 1972, BIOCHIM BIOPHYS ACTA, V275, P347, DOI 10.1016/0005-2728(72)90215-0; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; DEGIER JWL, 1995, TERMINAL OXIDASES PA; FRANCIS RT, 1984, ANAL BIOCHEM, V136, P509, DOI 10.1016/0003-2697(84)90253-7; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; GOTTFERT M, 1992, MOL PLANTMICROBE INT, V5, P308; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HAHN M, 1984, MOL GEN GENET, V193, P46, DOI 10.1007/BF00327412; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAHN D, 1993, NEW HORIZONS NITROGE, P474; KEEFE RG, 1993, BIOCHIM BIOPHYS ACTA, V1183, P91, DOI 10.1016/0005-2728(93)90008-4; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFERER H, 1993, EMBO J, V12, P3373, DOI 10.1002/j.1460-2075.1993.tb06011.x; MANDON K, 1994, J BACTERIOL, V174, P6444; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINTON NP, 1984, GENE, V31, P269, DOI 10.1016/0378-1119(84)90220-8; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PREISIG O, 1996, IN PRESS J BACTERIOL; REGENSBURGER B, 1983, ARCH MICROBIOL, V135, P103, DOI 10.1007/BF00408017; RITZ D, 1993, MOL MICROBIOL, V9, P729, DOI 10.1111/j.1365-2958.1993.tb01733.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER A, 1995, MOL GEN GENET, V247, P206, DOI 10.1007/BF00705651; Schluter A, 1993, NEW HORIZONS NITROGE, P493; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1994, MOL MICROBIOL, V14, P705, DOI 10.1111/j.1365-2958.1994.tb01308.x; THONYMEYER L, 1991, P NATL ACAD SCI USA, V88, P5001, DOI 10.1073/pnas.88.11.5001; Turner G. L., 1980, Methods for evaluating biological nitrogen fixation., P111	40	92	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9114	9119		10.1074/jbc.271.15.9114	http://dx.doi.org/10.1074/jbc.271.15.9114			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621562	hybrid			2022-12-25	WOS:A1996UE73000093
J	Hwang, MCC; Sung, YJ; Hwang, YW				Hwang, MCC; Sung, YJ; Hwang, YW			The differential effects of the Gly-60 to Ala mutation on the interaction of H-Ras p21 with different downstream targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; BINDING DOMAIN; MOLECULAR MECHANISM; CATALYTIC DOMAIN; PROTEIN; GTPASE; GAP; EXCHANGE; MUTANTS; IDENTIFICATION	We examined the effects of the Gly-60 to Ala mutation on the interaction of H-Ras with Pas GTPase activating protein (GAP), neurofibromin 1 (NF1), Raf-1, and ral guanine nucleotide dissociation stimulator (ralGDS), factors that interact with GTP-bound form of H-Ras. Previous study has shown that the G60A mutation perturbs GTP-induced conformational changes of H-Ras. We found that the G60A mutation decreases GTPase activity of H-Ras without significantly affecting GTP/GDP binding. The reduction in GTPase activity is most dramatic in the presence of GAP or NF1. Interestingly, the G60A mutation does not appear to alter the affinity of H-Ras for GAP or NF1. The G60A mutation moderately reduces the binding of H-Ras to Raf-1 Ras binding domain; however, the binding of H-Ras to ralGDS Ras binding domain was more significantly affected by the same mutation. These results indicate that although GAP, NF1, Raf-1, and ralGDS all interact with H-Ras in a GTP-dependent manner and they are able to compete against each other for binding to H-Ras, these factors share overlapping but not identical binding domains on H-Ras. The significance of our findings is discussed in the light of the GTP-induced conformational change model.	NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT BIOL MOLEC, STATEN ISL, NY 10314 USA; CUNY, CSI IBR, CTR DEV NEUROSCI, NEW YORK, NY 10036 USA; CUNY, GRAD PROGRAM BIOL, NEW YORK, NY 10036 USA	Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System					NCI NIH HHS [CA53782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Crystal R G, 1974, Methods Enzymol, V30, P101; CUNNINGHAM PR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P18, DOI 10.1016/0167-4781(90)90135-O; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE E, 1992, J BIOL CHEM, V267, P1212; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Miller JH., 1972, EXPT MOL GENETICS; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	60	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8196	8202		10.1074/jbc.271.14.8196	http://dx.doi.org/10.1074/jbc.271.14.8196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626511				2022-12-25	WOS:A1996UD60000051
J	Sasaguri, T; Ishida, A; Kosaka, C; Nojima, H; Ogata, J				Sasaguri, T; Ishida, A; Kosaka, C; Nojima, H; Ogata, J			Phorbol ester inhibits the phosphorylation of the retinoblastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MEDIATED INHIBITION; GENE-PRODUCT; DNA-SYNTHESIS; GROWTH-INHIBITION; DEPENDENT KINASE; TGF-BETA; EXPRESSION; PROLIFERATION; ACTIVATION; ARREST	To elucidate the role of protein kinase C in vascular smooth muscle cell proliferation, we examined the effects of phorbol 12-myristate 13-acetate (PMA) on G(1) events in human arterial cells. About 15 h after G(0) cells were stimulated with fetal bovine serum and basic fibroblast growth factor, [H-3]thymidine incorporation started. PMA (10 nM) inhibited the incorporation over 90% when added earlier than 3 h after stimulation, but had no effect when added 12 h or later. PMA inhibited the phosphorylation of the retinoblastoma protein (pRb), which normally began at about 9 h. PMA did not inhibit the gene expression of Cdk2, Cdk3, Cdk4, Cdk5, and cyclins G, C, and D, all of which began at 0-3 h. However, PMA reduced the expression of cyclins E and A, which usually began at 3-9 h and about 15 h, respectively. PMA inhibited the histone H1 kinase activity of Cdk2, which increased from about 9 h, whereas PMA did not inhibit the pRb kinase activities of cyclin D-associated kinase(s) and Cdk4, detectable from 0-3 h. These results suggested that the PMA-induced inhibition of pRb phosphorylation is not mediated by suppressing cyclin D-associated kinase(s) including Cdk4, but involves the suppression of Cdk2 activity that results hom the reduced expression of cyclins E and A.	OSAKA UNIV, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN	Osaka University	Sasaguri, T (corresponding author), NATL CARDIOVASC CTR, RES INST, DEPT BIOSCI, 5-7-1 FUJISHIRO DAI, SUITA, OSAKA 565, JAPAN.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COPPOCK DL, 1992, CELL GROWTH DIFFER, V3, P485; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; KARIYA K, 1987, EXP CELL RES, V173, P504, DOI 10.1016/0014-4827(87)90290-4; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; KOSAKA C, 1993, BIOCHEM BIOPH RES CO, V193, P991, DOI 10.1006/bbrc.1993.1723; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLASHAW NE, 1988, ADV SEC MESS PHOSPH, V22, P139; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SASAGURI T, 1992, EXP CELL RES, V200, P351, DOI 10.1016/0014-4827(92)90182-8; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SASAGURI T, 1994, INT CONGR SER, V1051, P177; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SING GK, 1990, CELL GROWTH DIFFER, V1, P549; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TOKER A, 1994, J BIOL CHEM, V269, P32358; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOKOTA T, 1992, ARTERIOSCLER THROMB, V12, P1393, DOI 10.1161/01.ATV.12.12.1393	56	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8345	8351		10.1074/jbc.271.14.8345	http://dx.doi.org/10.1074/jbc.271.14.8345			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626531	hybrid			2022-12-25	WOS:A1996UD60000071
J	Sasaoka, T; Langlois, WJ; Bai, F; Rose, DW; Leitner, JW; Decker, SJ; Saltiel, AR; Gill, GN; Kobayashi, M; Draznin, B; Olefsky, JM				Sasaoka, T; Langlois, WJ; Bai, F; Rose, DW; Leitner, JW; Decker, SJ; Saltiel, AR; Gill, GN; Kobayashi, M; Draznin, B; Olefsky, JM			Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; RAS; PROTEIN; GRB2; KINASE; TRANSFORMATION	To investigate the mechanisms underlying the enhanced mitogenic activity of the truncated epidermal growth factor receptor (EGFR) lacking the C-terminal autophosphorylation sites (Delta 973-EGFR), we studied the intracellular signaling pathways in NR6 cells expressing human wild type EGFR and Delta 973-EGFR. Microinjection of dominant/negative p21(ras) (N17) completely inhibited EGF-induced DNA synthesis in both cell types. EGF stimulated Shc phosphorylation as well as the formation of mild type EGFR . Shc complexes. In contrast, EGF stimulated Shc phosphorylation without formation of Delta 973-EGFR . Shc complexes. Tyrosine-phosphorylated Shc formed complexes with Grb2 . Sos, and microinjection of anti-ghc antibody and Shc-SH2 GST fusion protein inhibited EGF stimulation of DNA synthesis in both cell lines. EGF markedly increased ErbB2 tyrosine phosphorylation in wild type EGFR cells. In Delta 973-EGFR cells, ErbB2 was tyrosine phosphorylated in the basal state and EGFR stimulated further phosphorylation of ErbB2. In addition to ErbB2, additional proteins were tyrosine phosphorylated in Delta 973-EGFR cells, mostly in the molecular mass range of 120-170 kDa. Taken together with our findings indicating coupling of ErbB2 to Shc, these data suggest the importance of an alternative signaling pathway in Delta 973-EGFR cells mediated by the formation of heterodimeric structures between the truncated EGFR and ErbB2, followed by coupling through Shc to Grb2 . Sos and the p21(ras) pathway, ultimately leading to mitogenesis.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; TOYAMA MED & PHARMACEUT UNIV,DEPT MED 1,TOYAMA 93001,JAPAN; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO 80220	University of California System; University of California San Diego; University of Toyama; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pfizer; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK13149, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK033651, R37DK013149, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MASUI H, 1991, CANCER RES, V51, P6170; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QIAN XL, 1994, ONCOGENE, V9, P1507; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SOLER C, 1994, J BIOL CHEM, V269, P12320; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLICH A, 1984, NATURE, V309, P418; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	52	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8338	8344		10.1074/jbc.271.14.8338	http://dx.doi.org/10.1074/jbc.271.14.8338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626530	hybrid			2022-12-25	WOS:A1996UD60000070
J	Sekar, MC; Sambandam, V; Grizzle, WE; McDonald, JM				Sekar, MC; Sambandam, V; Grizzle, WE; McDonald, JM			Dissociation of cyclic inositol phosphohydrolase activity from annexin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BINDING-PROTEINS; 1,2-CYCLIC 4,5-TRISPHOSPHATE; PHOSPHATE 2-PHOSPHOHYDROLASE; BILAYER-MEMBRANES; HUMAN NEUTROPHILS; CELLS; CALCIUM; STIMULATION; MYOINOSITOL; EXPRESSION	Cyclic inositol phosphohydrolase is a phosphodiesterase that cleaves the cyclic bond of cyclic inositol monophosphate, In 1990, Boss ct at (Boss, T. S., Tait, J. F., and Majerus, P. W. (1990) Science 248, 605-607) purified this enzyme from human placenta and reported that cyclic inositol phosphohydrolase is identical to annexin III, Independent confirmation of this finding has not been provided. The relative distribution of annexin III and cyclic inositol phosphohydrolase activity in rat kidney and spleen indicated that annexin III can be dissociated hom cyclic inositol phosphohydrolase activity, Rat spleen contains large quantities of annexin III, but has very little cyclic inositol phosphohydrolase activity, In contrast, rat kidney, one of the richest sources of cyclic inositol phosphohydrolase activity, possesses very little (immunohistochemistry) or no (Western blot) annexin IIIm. similar to cytosol of human placenta, cytosol of guinea pig kidney contains both annexin III and cyclic inositol phosphohydrolase. On SDS-gel electrophoresis, guinea pig kidney annexin III has a slightly different mobility than the human placental annexin III. Human placental annexin III co-migrates with cyclic inositol phosphohydrolase on ion exchange chromatography, while guinea pig kidney annexin III is clearly dissociated from cyclic inositol phosphohydrolase on ion exchange chromatography. Both guinea pig kidney annexin III and human placental annexin III pellet with the addition of calcium and centrifugation, while cyclic inositol phosphohydrolase activity in both of these tissues remains in the supernatant. Our studies clearly show that cyclic inositol phosphohydrolase and annexin III are two different proteins.			Sekar, MC (corresponding author), UNIV ALABAMA,DEPT PATHOL,LHRB 528,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA57381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BINDER H, 1985, ANAL BIOCHEM, V148, P220, DOI 10.1016/0003-2697(85)90649-9; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAWSON RMC, 1972, BIOCHEM J, V127, P113, DOI 10.1042/bj1270113; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DIXON JF, 1987, BIOCHEM BIOPH RES CO, V149, P1208, DOI 10.1016/0006-291X(87)90536-5; DOLHOFER R, 1987, J CLIN CHEM CLIN BIO, V25, P733; ERNST JD, 1989, BIOCHEM BIOPH RES CO, V161, P959, DOI 10.1016/0006-291X(89)91336-3; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HULLIN F, 1989, J BIOL CHEM, V264, P3506; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; ISHII H, 1986, P NATL ACAD SCI USA, V83, P6397, DOI 10.1073/pnas.83.17.6397; JUNGALWALA FB, 1971, BIOCHEM J, V123, P19, DOI 10.1042/bj1230019; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KOCH MA, 1974, BIOCHEM BIOPH RES CO, V58, P361, DOI 10.1016/0006-291X(74)90373-8; LECABEC V, 1992, BIOCHEM BIOPH RES CO, V189, P1471, DOI 10.1016/0006-291X(92)90240-L; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MYERS RB, 1993, MODERN PATHOL, V6, P733; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1991, J BIOL CHEM, V266, P9086; ROSS TS, 1991, J BIOL CHEM, V266, P851; ROSS TS, 1992, J BIOL CHEM, V267, P19924; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SEKAR MC, 1987, J BIOL CHEM, V262, P340; SHAYMAN JA, 1986, BIOCHIM BIOPHYS ACTA, V888, P171, DOI 10.1016/0167-4889(86)90018-2; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TARVER AP, 1987, J BIOL CHEM, V262, P17268; WILSON DB, 1985, P NATL ACAD SCI USA, V82, P4013, DOI 10.1073/pnas.82.12.4013; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WIRL G, 1990, J CELL PHYSIOL, V144, P511, DOI 10.1002/jcp.1041440320	36	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8295	8299		10.1074/jbc.271.14.8295	http://dx.doi.org/10.1074/jbc.271.14.8295			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626524	hybrid			2022-12-25	WOS:A1996UD60000064
J	Arai, T; Clarke, J; Parker, A; Busby, W; Nam, T; Clemmons, DR				Arai, T; Clarke, J; Parker, A; Busby, W; Nam, T; Clemmons, DR			Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I in response to heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-III; HUMAN FIBROBLASTS; 2 FORMS; IDENTIFICATION; MECHANISMS; THROMBIN; CELLS	Heparin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decrease in its affinity for IGF-I, and a region that contains several basic amino acids (Arg(201)-Arg(218)) may be involved in this affinity shift. In the present study, mutagenesis was used to analyze the effect of substitutions for basic amino acids in the Arg(201)-Arg(218) region of IGFBP-5 on heparin-binding and the heparin-induced affinity shift. Nine mutant forms were prepared, Their association constants (K-alpha) for IGF-I were similar to native IGFBP-5, When 10 mu g/ml of heparin was added, the K-alpha of native IGFBP-5 decreased 17-fold, and the K-alpha of the K134A/R136A mutant decreased 16-fold. In contrast, substitutions for specific basic amino acids in the Arg(201)-Arg(218) region decrease the affinity shift to 1.1-3.2-fold, Lys(211) was especially important. When a mutant containing that single substitution was tested, heparin caused only a 2.5-fold reduction in IGF-I affinity. Affinity cross-linking studies showed that heparin was equipotent in inhibiting the formation of I-125-IGF-I . K134A/R136A mutant complexes compared to native IGFBP-5. In contrast, heparin had minimal effects on the formation of complexes between I-125-IGF-I and the other mutants. The heparin-binding activity of each mutant was determined. Four mutants, R201A/K202N, K202A/K206A/R207A, R201A/K202N/K206N/K208N, and K211N/R214A/K217A/R218A, had reduced heparin binding compared to native IGFBP-5. The other five mutants, including the K211N mutant, showed no change in heparin binding. The four mutants with reduced heparin binding could be dissociated from heparin-Sepharose with much lower NaCl concentrations, indicating that they had reduced affinity. These findings suggest that Arg(201), Lys(202), Lys(206), and Arg(214) are important for heparin binding. In contrast, Lys(211) , not important for the binding of IGFBP-5 to heparin, but substitution for it reduced the heparin-induced affinity shift.	UNIV N CAROLINA,DEPT MED,SCH MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26309] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAR R, 1993, 75 ANN M LAS VEG; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG JY, 1989, J BIOL CHEM, V264, P3111; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1993, THROMB HAEMOSTASIS, V70, P361; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MERRIFIELD RB, 1964, J AM CHEM SOC, V86, P304, DOI 10.1021/ja01056a056; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OLSON ST, 1981, J BIOL CHEM, V256, P1065; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; RAGG H, 1990, J BIOL CHEM, V265, P5211; Sambrook J, 1989, MOL CLONING LABORATO; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SMITH EP, 1994, ENDOCRINOLOGY, V135, P359, DOI 10.1210/en.135.1.359; WU YI, 1994, BLOOD COAGUL FIBRIN, V5, P83, DOI 10.1097/00001721-199402000-00012	29	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6099	6106		10.1074/jbc.271.11.6099	http://dx.doi.org/10.1074/jbc.271.11.6099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626396	hybrid, Green Published			2022-12-25	WOS:A1996UA36300025
J	Fay, PJ; Beattie, TL; Regan, LM; OBrien, LM; Kaufman, RJ				Fay, PJ; Beattie, TL; Regan, LM; OBrien, LM; Kaufman, RJ			Model for the factor VIIIa-dependent decay of the intrinsic factor Xase - Role of subunit dissociation and factors IXa-catalyzed proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; A1/A3-C1-C2 DIMER; PROCOAGULANT ACTIVITY; A2 SUBUNIT; FACTOR-X; THROMBIN; ACTIVATION; PROTEIN; RECONSTITUTION; INACTIVATION	The intrinsic factor Xase complex (FXase) is comprised of a serine protease, FIXa, and a protein cofactor, FVIIIa, assembled on a phospholipid surface. Activity of FXase decays with time and reflects the lability of FVIIIa. Two mechanisms potentially contribute to this decay: (i) a weak affinity interaction between the FVIIIa A2 subunit and A1/A3-C1-C2 dimer and (ii) FVIIIa inactivation resulting from FIXa-catalyzed proteolysis of the A1 subunit. At low reactant concentrations (0.5 nM FVIIIa; 5 nM FIXa), FXase decay is governed by the inter-FVIIIa subunit affinity and residual activity approaches a value consistent with this equilibrium, as judged by reactions containing exogenous A2 subunit. Analysis using a mutant form of FVIII (FVIIIR336I) possessing an altered FIXa cleavage site, showed similar rates of FXase decay (0.12 min(-1)) and confirmed the lack of contribution of proteolysis under these conditions. When the concentration of FIXa was increased 10-fold, the initial rate of decay of FXase containing native FVIIIa increased (0.82 min(-1)) and paralleled the rate of proteolysis of A1 subunit. However, the rate of decay of FXase containing the FVIIIa(R336I) was reduced (0.048 min(-1)) consistent with the elevated concentration of FIXa stabilizing the labile subunit structure of the cofactor. Reconstitution of FVIII with FIXa-cleaved light chain showed that cleavage at the alternate FIXa site (A3 domain) was not inhibitory to FXase. The presence of substrate FX resulted in a 10-fold reduction in the rate of FIXa-catalyzed proteolysis of FVIIIa. These results suggest a model whereby decay of FXase results from both FVIIIa subunit dissociation and FIXa-catalyzed cleavage, dependent upon the relative concentration of reactants, with greater contribution of the former at low values and, in the absence of substrate, greater contribution of the latter at high values.	UNIV ROCHESTER,SCH MED,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Rochester; University of Rochester; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL52173, HL38199, HL30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173, P01HL030616, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1991, J BIOL CHEM, V266, P20819; JESTY J, 1990, J BIOL CHEM, V265, P17539; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; NEUENSCHWANDER P, 1992, ANAL BIOCHEM, V184, P347; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510	35	91	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6027	6032		10.1074/jbc.271.11.6027	http://dx.doi.org/10.1074/jbc.271.11.6027			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626386	hybrid			2022-12-25	WOS:A1996UA36300015
J	Pietravalle, F; LecoanetHenchoz, S; Blasey, H; Aubry, JP; Elson, G; Edgerton, MD; Bonnefoy, JY; Gauchat, JF				Pietravalle, F; LecoanetHenchoz, S; Blasey, H; Aubry, JP; Elson, G; Edgerton, MD; Bonnefoy, JY; Gauchat, JF			Human native soluble CD40L is a biologically active trimer, processed inside microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED IMMUNODEFICIENCY; HYPER-IGM; MOLECULAR-CLONING; T-CELLS; B-CELLS; LIGAND; EXPRESSION; PROTEIN; GP39; FORM	CD40 ligand (CD40L) is a glycoprotein expressed on the surface of activated helper T cells, basophils, mast cells, and eosinophils. Binding of CD40L to its receptor CD40 on the B cell surface induces B cell proliferation, adhesion, and immunoglobulin class switching. We have identified soluble cleavage products of human CD40L in the supernatant of a stimulated human T cell clone. Subcellular fractionation experiments have shown that the transmembrane CD40L is processed inside the microsomes and that its cleavage is stimulation-dependent. The native human soluble CD40L is trimeric and, when used in conjunction with interleukin-4, induces B cell proliferation.	GLAXO INST MOLEC BIOL SA, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND	GlaxoSmithKline								ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FACCHETTI F, 1995, J IMMUNOL, V154, P6624; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1995, EUR J IMMUNOL, V25, P863, DOI 10.1002/eji.1830250335; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Notarangelo L D, 1993, Immunodeficiency, V4, P225; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; TUCCI A, 1992, J IMMUNOL, V148, P2778	23	97	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5965	5967		10.1074/jbc.271.11.5965	http://dx.doi.org/10.1074/jbc.271.11.5965			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626375	hybrid			2022-12-25	WOS:A1996UA36300004
J	Ross, SA; Scott, HM; Morris, NJ; Leung, WY; Mao, F; Lienhard, GE; Keller, SR				Ross, SA; Scott, HM; Morris, NJ; Leung, WY; Mao, F; Lienhard, GE; Keller, SR			Characterization of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 GLUCOSE TRANSPORTERS; HEXOSE-TRANSPORT; PHOSPHORYLATION; EXPRESSION; SEQUENCE; CELLS; GLUT4	A novel membrane aminopeptidase has been identified as a major protein in vesicles from rat adipocytes containing the glucose transporter isotype Glut4. In this study we have characterized this aminopeptidase, referred to as vp165, in 3T3-L1 adipocytes, The subcellular distributions of vp165 and Glut4 were determined by immunoisolation of vesicles with antibodies against both proteins, by immunofluorescence, and by subcellular fractionation and immunoblotting, Relative amounts of vp165 at the cell surface in basal and insulin-treated cells were assayed by cell surface biotinylation, These experiments showed that vp165 and Glut4 were entirely colocalized and that vp165 increased markedly at the cell surface in response to insulin, in a way similar to Glut4, When intact cells were assayed with a novel, membrane-impermeant fluorogenic substrate for vp165, we found that insulin stimulated aminopeptidase activity at the cell surface, This observation provides direct evidence for the functional consequence of vp165 translocation.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; MOLEC PROBES INC,EUGENE,OR 97402	Dartmouth College			Mao, Feng/B-8280-2019	Morris, Nicholas/0000-0002-8389-7508	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK025336, R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32 AR07576] Funding Source: Medline; NIDDK NIH HHS [DK 25336] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BROWN SJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P339, DOI 10.1016/S0005-2728(88)80049-5; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1986, J BIOL CHEM, V261, P3944; HANPETER D, 1995, MOL MEMBR BIOL, V12, P263, DOI 10.3109/09687689509072426; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANG J, 1993, J BIOL CHEM, V268, P4600	25	140	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3328	3332		10.1074/jbc.271.6.3328	http://dx.doi.org/10.1074/jbc.271.6.3328			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621739	hybrid			2022-12-25	WOS:A1996TU69100068
J	Faurobert, E; Chen, CK; Hurley, JB; Teng, DHF				Faurobert, E; Chen, CK; Hurley, JB; Teng, DHF			Drosophila neurocalcin, a fatty acylated, Ca2+-binding protein that associates with membranes and inhibits in vitro phosphorylation of bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; COUPLED RECEPTOR KINASES; MOLECULAR-CLONING; NERVOUS-SYSTEM; S-MODULIN; RECOVERIN; FAMILY; HIPPOCALCIN; MECHANISM; TERMINUS	Neurocalcins belong to a family of neuronal specific EF hand Ca2+-binding proteins defined by recoverin. Previously, we reported the cloning and initial characterization of neurocalcin in Drosophila melanogaster (Teng, D. H.-F., Chen, C.K., and Hurley, J. B. (1994) J. Biol. Chem. 269, 31900-31907). We showed that the Drosophila neurocalcin protein (DrosNCa) is expressed in neurons and that bacterially expressed recombinant DrosNCa (rDrosNCa) can be myristoylated. Here, we present two lines of evidence that DrosNCa is fatty acylated its vivo. First, the mobility of affinity-purified native DrosNCa on two-dimensional gel electrophoresis is identical to that of myristoylated rDrosNCa and distinct from that of nonacylated rDrosNCa. Second, the membrane binding properties of native DrosNCa are similar to those of myristoylated rDrosNCa; both of these proteins bind to membranes at 0.2 mM Ca2+, whereas nonacylated rDrosNCa always remains soluble. It has been shown that recoverin inhibits the phosphorylation of rhodopsin when Ca2+ is present (Kawamura et al., 1993) and that a dependent recoverin/rhodopsin kinase interaction underlies the inhibitory effect of recoverin (Chen ct at, 1995). Given the similarities between recoverin and neurocalcin, we examined the effect of DrosNCa on rhodopsin phosphorylation. We find that rDrosNCa is capable of inhibiting bovine rhodopsin phosphorylation in vitro in a Ca2+-dependent manner. The inhibitors activity of rDrosNCa is enhanced by myristoylation, and the potency of its effect is similar to that of recoverin. Two other related EF hand proteins, guanylate cyclase-activating protein-2 and calmodulin, are only poor inhibitors in these phosphorylation assays. in vitro inhibition of rhodopsin phosphorylation therefore appears to be an assayable property of a subset of recoverin-like proteins.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Faurobert, Eva/M-2735-2013	Faurobert, Eva/0000-0002-2714-8537	PHS HHS [E406641] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; COX JA, 1994, J BIOL CHEM, V269, P32807; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HIDAKA H, 1993, NEUROSCI RES, V16, P73, DOI 10.1016/0168-0102(93)90074-Z; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; OKAZAKI K, 1995, BIOCHEM J, V306, P551, DOI 10.1042/bj3060551; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TENG DHF, 1994, J BIOL CHEM, V269, P31900; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; YAMAGATA K, 1990, NEURON, V2, P459; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	34	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10256	10262		10.1074/jbc.271.17.10256	http://dx.doi.org/10.1074/jbc.271.17.10256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626592				2022-12-25	WOS:A1996UG25700064
J	Hu, ZZ; Zhuang, L; Dufau, ML				Hu, ZZ; Zhuang, L; Dufau, ML			Multiple and tissue-specific promoter control of gonadal and non-gonadal prolactin receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OVARY; CELLS	Prolactin receptors (PRLRs) are widely expressed, and multiple mRNA transcripts encoding PRLRs are present in prolactin target tissues. The molecular basis for the control of the PRLR gene expression is currently unknown. Analyses of the 5'-untranslated regions of PRLR mRNAs expressed in gonadal and non-gonadal tissues and their genomic organization revealed three alternative first exons designated as El(1), El(2), and El(3). Each of these exons is alternatively spliced to a common noncoding exon (exon 2, nucleotides -115 to -56) that precedes the third exon containing the translation initiation codon. Alternative utilization of exons El(1), El(2), and El(3), as well as alternative splicing of exon 2, generates multiple 5'-untranslated regions in PRLR transcripts. These alternative first exons (El(1), El(2), and El(3)) were found to be utilized in a tissue-specific manner in vivo. El(1) is predominantly expressed in the ovary, El(2) is specifically expressed in the liver, and El(3) is expressed as a predominant form in the Leydig cell and as a minor form in the ovary and liver. Genomic 5'-flanking regions containing the three putative PRLR gene promoters (PI, PII, and PIII) that initiate the transcription of El(1), El(2), and El(3), respectively, were identified. El(1) was found to initiate from a single site at -549, El(2) from multiple sites at -405, -461, and -506, and El(3) from two major sites at -340 and -351. These findings indicate that multiple promoters control transcription of the PRLR gene and provide a molecular basis for the differential regulation of PRLR expression in diverse tissues.	NICHHD, SECT MOL ENDOCRINOL, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AQUILANO DR, 1984, ENDOCRINOLOGY, V114, P499, DOI 10.1210/endo-114-2-499; Bonifacino J.S., 1984, Serono Symposia Publications from Raven Press, V9, P149; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; DAVIES TF, 1980, NATURE, V283, P863, DOI 10.1038/283863a0; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HU ZZ, 1990, FEBS LETT, V274, P181, DOI 10.1016/0014-5793(90)81359-V; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	19	58	59	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10242	10246		10.1074/jbc.271.17.10242	http://dx.doi.org/10.1074/jbc.271.17.10242			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626590	hybrid			2022-12-25	WOS:A1996UG25700062
J	Mikus, P; Ny, T				Mikus, P; Ny, T			Intracellular polymerization of the serpin plasminogen activator inhibitor type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MONOCYTES-MACROPHAGES; SEMLIKI FOREST VIRUS; HAMSTER OVARY CELLS; ALPHA-1-PROTEINASE INHIBITOR; SITE LOOP; ALPHA-1-ANTITRYPSIN; PROTEIN; SECRETION; U-937; BETA	Plasminogen activator inhibitor type 2 (PAI-2) is synthesized in two molecular forms: an intracellular, nonglycosylated form and an extracellular, glycosylated form. The bitopological distribution of PAI-2 is caused by an inefficient internal secretion signal. In addition, the secretion efficiency of PAI-2 seems to differ, depending on the cell type, differentiation state, and culture conditions. In recombinant cell clones designed for the synthesis of the secreted form of PAI-2, the fraction of secreted PAI-2 decreased with increasing expression levels. Subcellular fractionation of cell clones with higher expression levels revealed that PAI-2 accumulating in the cell was mainly associated with the organelles of the secretory pathway. Electrophoresis under nondenaturating conditions revealed that the PAI-2 retained at higher expression levels was mainly polymerized. Polymers of PAI-2 were also detected in cytosolic extracts prepared from human placenta and phorbol ester-stimulated U 937 cells, indicating that intracellular polymerization of PAI-2 may occur in the cytosols of cells that normally express PAI-2 under physiological conditions. When purified PAI-2 or cellular extracts were incubated at 37 degrees C for 24 h most of the PAI-2 protein was found to polymerize. Polymer formation was prevented by the addition of synthetic peptides with sequences corresponding to residues P2 to P14 in the reactive center loop of PAI-2 and antithrombin. These synthetic peptides also caused dissociation of prepolymerized purified PAI-2 and PAI-2 polymers in cellular extracts. Incubation with unrelated peptides of the same size had no effect on polymer formation or dissociation of preformed polymers, indicating that polymerization of PAI-2 occurs by the loop-sheet mechanism. Taken together, our data suggest that the wild-type form of PAI-2, like some natural pathological genetic variants of alpha(1)-antitrypsin, antithrombin, and C1 inhibitor readily polymerizes intracellularly and that polymerization may lead to a reduced secretion efficiency.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; SAS BRATISLAVA,INST MOLEC PHYSIOL & GENET,BRATISLAVA,SLOVAKIA	Umea University; Slovak Academy of Sciences								ASTEDT B, 1985, THROMB HAEMOSTASIS, V53, P122; ASTEDT B, 1987, Fibrinolysis, V1, P203, DOI 10.1016/0268-9499(87)90037-3; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARELL R, 1985, TRENDS BIOCHEM SCI, V10, P20; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CARRELL RW, 1992, CURR OPIN STRUC BIOL, V2, P488; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVANS DL, 1991, THESIS CAMBRIDGE U U; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; KAWANO T, 1968, NATURE, V217, P253, DOI 10.1038/217253a0; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LAWRENCE DA, 1995, J BIOL CHEM, V270, P1; LECANDER I, 1984, BRIT J HAEMATOL, V57, P407, DOI 10.1111/j.1365-2141.1984.tb02914.x; LECANDER I, 1986, BRIT J HAEMATOL, V62, P221, DOI 10.1111/j.1365-2141.1986.tb02925.x; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NY T, 1989, FIBRINOLYSIS, V3, P189, DOI 10.1016/0268-9499(89)90045-3; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SHARP HL, 1969, J LAB CLIN MED, V73, P934; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; YE RD, 1988, J BIOL CHEM, V263, P4869; ZETTLMEISSL G, 1987, BIO-TECHNOL, V5, P720, DOI 10.1038/nbt0787-720	46	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10048	10053		10.1074/jbc.271.17.10048	http://dx.doi.org/10.1074/jbc.271.17.10048			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626560	hybrid			2022-12-25	WOS:A1996UG25700032
J	Nagayama, Y; Tanaka, K; Hara, T; Namba, H; Yamashita, S; Taniyama, K; Niwa, M				Nagayama, Y; Tanaka, K; Hara, T; Namba, H; Yamashita, S; Taniyama, K; Niwa, M			Involvement of G protein-coupled receptor kinase 5 in homologous desensitization of the thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID CELL-LINE; MOLECULAR-CLONING; MULTIGENE FAMILY; RNA ISOLATION; RAT; EXPRESSION; MECHANISM; REFRACTORINESS; STIMULATION; MEMBER	Homologous desensitization of G protein-coupled receptors involves agonist-dependent phosphorylation of receptors by G protein-coupled receptor kinases (GRKs). To identify GRK(s) that play a role in homologous desensitization of the thyrotropin (TSH) receptor, thyroid cDNA was amplified by polymerase chain reaction using degenerate oligonucleotide primers from highly conserved regions in GRK family. GRK5 is found in the predominant isoform expressed in the thyroid. Rat GRK5 cDNA was then isolated, which encodes a 590-amino acid protein with 95% homology to human and bovine homologs. Northern blot identified GRK5 mRNA of similar to 3, 8, and 10 kilobases with highest expression levels in lung > heart, kidney, colon > thyroid. In functional studies using a normal rat thyroid FRTL5 cells, overexpression of GRK5 by transfecting the plasmid capable of expressing the sense GRK5 RNA suppressed basal cAMP levels and augmented the extent of TSH receptor desensitization, whereas suppression of endogenous GRK5 expression by transfecting the antisense GRK5 construct increased basal cAMP levels and attenuated the extent of receptor desensitization. Although exogenously overexpressed GRK6 also enhanced TSH receptor desensitization, we conclude that GRK5, the predominant GRK isoform in the thyroid, appears to be mainly involved in homologous desensitization of the TSH receptor.	NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,INST ATOM DIS,DEPT CELL PHYSIOL,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University			Yamashita, Shunichi/GVS-9508-2022	Yamashita, Shunichi/0000-0001-6399-6261				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FOTI D, 1991, J ENDOCRINOL INVEST, V14, P213, DOI 10.1007/BF03346791; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARAGUCHI K, 1994, J MOL ENDOCRINOL, V13, P283, DOI 10.1677/jme.0.0130283; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HIRAYU H, 1985, MOL CELL ENDOCRINOL, V42, P21, DOI 10.1016/0303-7207(85)90003-6; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KANEKO Y, 1976, HORM METAB RES, V8, P202, DOI 10.1055/s-0028-1093660; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1994, ENDOCRINOLOGY, V135, P1060, DOI 10.1210/en.135.3.1060; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAPOPORT B, 1976, J BIOL CHEM, V251, P6653; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI Y, 1993, ENDOCR J, V1, P157; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SHUMAN SJ, 1976, J CLIN INVEST, V57, P1132, DOI 10.1172/JCI108380	42	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10143	10148		10.1074/jbc.271.17.10143	http://dx.doi.org/10.1074/jbc.271.17.10143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626574	hybrid			2022-12-25	WOS:A1996UG25700046
J	BeitnerJohnson, D; Blakesley, VA; ShenOrr, Z; Jimenez, M; Stannard, B; Wang, LM; Pierce, J; LeRoith, D				BeitnerJohnson, D; Blakesley, VA; ShenOrr, Z; Jimenez, M; Stannard, B; Wang, LM; Pierce, J; LeRoith, D			The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS - Modulation by insulin growth factor-1 (IGF) and enhanced IGF-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS; IRS-1; SH2; PHOSPHORYLATION; PROTEINS; ELEMENTS; PATHWAYS; DOMAINS; BINDING	The Crk proto-oncogene product is an SH2 and SH3 domain-containing adaptor protein which we have previously shown to become rapidly tyrosine phosphorylated in response to stimulation with insulin-like growth factor I (IGF-I) in NIH-3T3 cells, In order to further characterize the role of Crk in the IGF-I signaling pathway, NIH-3T3 and 293 cells were stably transfected with an expression vector containing the Crk cDNA, The various resultant 3T3-Crk clones expressed Crk at approximately 2-15-fold higher levels than parental 3T3 cells, In 3T3-Crk cells, Crk immunoreactivity was detected in insulin receptor substrate-1 (IRS-1) immunoprecipitates, Stimulation with IGF-I resulted in a dissociation of Crk protein from IRS-1, In contrast, the association of the related adaptor protein Grb2 with IRS-1 was enhanced by IGF-I stimulation. Similar results were obtained in stably transfected 293-Crk cells, which express both IRS-I and the IRS-1-related signaling protein 4PS. In these cells, IRS-1 and 4PS both associated with Crk, and this association was also decreased by IGF-I treatment, whereas the association of Grb2 with IRS-1 and 4PS was enhanced by IGF-I. Overexpression of Crk also enhanced IGF-I-induced mitogenesis of NIH-3T3 cells, as measured by [H-3]thymidine incorporation. The levels of IGF-I-induced mitogenesis were proportional to the level of Crk expression, These results suggest that Crk is a positive effector of IGF-I signaling, and may mediate its effects via interaction with IRS-1 and/or 4PS.	NIDDK, DIABET BRANCH, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; CASE RD, 1994, J BIOL CHEM, V269, P10467; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; KATO H, 1993, J BIOL CHEM, V268, P2655; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9287	9290		10.1074/jbc.271.16.9287	http://dx.doi.org/10.1074/jbc.271.16.9287			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621590	hybrid			2022-12-25	WOS:A1996UG04400021
J	DiasKadambi, BL; Drum, CL; Hanck, DA; Blumenthal, KM				DiasKadambi, BL; Drum, CL; Hanck, DA; Blumenthal, KM			Leucine 18, a hydrophobic residue essential for high affinity binding of anthopleurin B to the voltage-sensitive sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL NA+ IONOPHORE; SEA-ANEMONE; 3-DIMENSIONAL STRUCTURE; SCORPION NEUROTOXINS; EXCITABLE CELLS; AP-A; POLYPEPTIDE; EXPRESSION; PROTEINS; CLONING	Anthopleurin B is a potent anemone toxin that binds with nanomolar affinity to the cardiac and neuronal isoforms of the voltage-gated sodium channel, A cationic cluster that includes Arg-12, Arg-14 and Lys-49 has been shown previously to be important in this interaction, In this study, we have used site-directed mutagenesis to determine the contribution to activity of two aliphatic residues, Leu-18 and Ile-43, that have previously been experimentally inaccessible, Leu-18, a residue proximal to the cationic cluster, plays a critical role in defining the high affinity of the toxin, In ion flux studies, this is exemplified by the several hundredfold loss in affinity (231-672-fold) observed for both L18A and L18V toxins on either isoform of the sodium channel, When analyzed electrophysiologically, L18A, the most severely compromised mutant, also displays a substantial loss in affinity (34-fold and 328-fold) for the neuronal and cardiac isoforms, This difference in affinities may reflect an increased preference of the L18A mutant for the closed state of the neuronal channel, In contrast, Ile-43, a residue distal to the cationic cluster, plays at most a very modest role in affinity toward both isoforms of the sodium channel, Only conservative substitutions are tolerated at this position, implying that it may contribute to an important structural component, Our results indicate that Leu-18 is the most significant single contributor to the high affinity of Anthopleurin B identified to date. These results have extended the binding site beyond the cationic cluster to include Leu-18 and broadened our emphasis from the basic residues to include the crucial role of hydrophobic residues in toxin-receptor interactions.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Cincinnati; University of Chicago; University of Chicago			Drum, Chester/A-6089-2015	Drum, Chester/0000-0001-6327-4584	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543, HL-PO1-20592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CATTERALL WA, 1975, P NATL ACAD SCI USA, V72, P1782, DOI 10.1073/pnas.72.5.1782; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cleland W W, 1979, Methods Enzymol, V63, P103; DOGGRELL S, 1994, CLIN EXP PHARMACOL P, V21, P833, DOI 10.1111/j.1440-1681.1994.tb02454.x; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; ELAYEB M, 1986, EUR J BIOCHEM, V155, P289; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1980, P NATL ACAD SCI-BIOL, V77, P6496, DOI 10.1073/pnas.77.11.6496; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KHERA PK, 1995, BIOCHEMISTRY-US, V34, P8533, DOI 10.1021/bi00027a003; KHERA PK, 1994, J BIOL CHEM, V269, P921; Maniatis T., 1982, MOL CLONING; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MIYAMOTO S, 1993, P NATL ACAD SCI USA, V90, P8402, DOI 10.1073/pnas.90.18.8402; MONKS SA, 1995, STRUCTURE, V3, P791, DOI 10.1016/S0969-2126(01)00214-3; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1981, FED PROC, V40, P21; PALLAGHY PK, 1995, BIOCHEMISTRY-US, V34, P3782, DOI 10.1021/bi00011a036; RUFFOLO RR, 1983, J PHARMACOL EXP THER, V224, P46; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIBATA S, 1976, J PHARMACOL EXP THER, V199, P298; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; WASSERSTROM JA, 1983, CIRC RES, V52, P697, DOI 10.1161/01.RES.52.6.697; YOUNG L, 1994, PROTEIN SCI, V3, P717; Zeng D., 1993, Society for Neuroscience Abstracts, V19, P284	36	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9422	9428		10.1074/jbc.271.16.9422	http://dx.doi.org/10.1074/jbc.271.16.9422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621610	hybrid			2022-12-25	WOS:A1996UG04400041
J	Frosina, G; Fortini, P; Rossi, O; Carrozzino, F; Raspaglio, G; Cox, LS; Lane, DP; Abbondandolo, A; Dogliotti, E				Frosina, G; Fortini, P; Rossi, O; Carrozzino, F; Raspaglio, G; Cox, LS; Lane, DP; Abbondandolo, A; Dogliotti, E			Two pathways for base excision repair in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPAIR; APURINIC ENDONUCLEASE; SITES	Abasic sites (apurinic/apyrimidinic, AP sites) are the most common DNA lesions generated by both spontaneous and induced base loss, In a previous study we have shown that circular plasmid molecules containing multiple AP sites are efficiently repaired by Chinese hamster extracts in an in vitro repair assay. An average patch size of 6.6 nucleotides for a single AP site was calculated, To define the exact repair patch, a circular DNA duplex with a single AP site was constructed, The repair synthesis carried out by hamster and human cell extracts was characterized by restriction endonuclease analysis of the area containing the lesion, The results indicate that, besides the repair events involving the incorporation of a single nucleotide at the lesion site, repair synthesis occurred also 3' to the AP site and involved a repair patch of approximately 7 nucleotides, This alternative repair pathway was completely inhibited by the presence in the repair reaction of a polyclonal antibody raised against human proliferating cell nuclear antigen, These data ave the first evidence that mammalian cell extracts repair natural AP sites by two distinct pathways: a single nucleotide gap filling reaction targeted at the AP site and a proliferating cell nuclear antigen-dependent pathway that removes a short oligonucleotide containing the abasic site and 3'-flanking nucleotides.	IST SUPER SANITA,COMPARAT TOXICOL & ECOTOXICOL LAB,I-00161 ROME,ITALY; IST NAZL RIC CANC,IST SCI TUMORI,LAB CTR STUDI TUMORI AMBIENTALI MUTAGENESIS,I-16132 GENOA,ITALY; UNIV DUNDEE,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	Istituto Superiore di Sanita (ISS); University of Genoa; IRCCS AOU San Martino IST; University of Dundee			Lane, David P/C-4920-2008; Fortini, Paola/K-1197-2018; Frosina, Guido/Z-2382-2019; Cox, Lynne/AAT-2047-2021; Raspaglio, Giuseppina/Y-2339-2019	Fortini, Paola/0000-0001-6206-8498; Frosina, Guido/0000-0002-6717-5097; Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545				BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	23	422	434	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9573	9578		10.1074/jbc.271.16.9573	http://dx.doi.org/10.1074/jbc.271.16.9573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621631				2022-12-25	WOS:A1996UG04400062
J	Grifantini, R; Pratesi, C; Galli, G; Grandi, G				Grifantini, R; Pratesi, C; Galli, G; Grandi, G			Topological mapping of the cysteine residues of N-carbamyl-D-amino-acid amidohydrolase and their role in enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; L-ASPARAGINASE; MICROBIAL TRANSFORMATION; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; PURIFICATION; HYDANTOINS; EXPRESSION; CATALYSIS; SEQUENCE	The N-carbamyl-D-amino-acid amidohydrolase from Agrobacterium radiobacter NRRL B11291, the enzyme used for the industrial production of D-amino acids, was cloned, sequenced, and expressed in Escherichia coli, The protein, a dimer constituted by two identical subunits of 34,000 Da with five cysteines each, was susceptible to aggregation under oxidizing conditions and highly sensitive to hydrogen peroxide, To investigate the role of the cysteines in enzyme stability and activity, mutant proteins were constructed by site directed mutagenesis in which the five residues were substituted by either Ala or Ser, Only the mutant carrying the Cys(172) substitution was catalytically inactive, and the other mutants maintained the same specific activity as the wild type enzyme, The crucial role of Cys(172) in enzymatic activity was also confirmed by chemical derivatization of the protein with iodoacetate, Furthermore, chemical derivatizations using both acrylamide and Ellman's reagent revealed that (i) none of the five cysteines is engaged in disulfide bridges, (ii) Cys(172) is easily accessible to the solvent, (iii) Cys(193) and Cys(250) appear to be buried in the protein core, and (iv) Cys(243) and Cys(279) seem to be located within or in proximity of external loops and are derivatized under mild denaturing conditions, These data are discussed in light of the possible mechanisms of enzyme inactivation and catalytic reaction.	ENIRICERCHE SPA, GENET ENGN & MICROBIOL LABS, I-20097 MILAN, ITALY	Eni SpA			Renata, Grifantini/AAB-9969-2022	Renata, Grifantini/0000-0003-0024-3355; Grandi, Guido/0000-0001-9724-2185				AIDA K, 1986, PROGR IND MICROBIOLO, V24, P269; BELLINI AV, 1991, J BIOTECHNOL, V18, P177, DOI 10.1016/0168-1656(91)90246-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; Bucherer HT, 1934, J PRAKTISCHE CHEMIE, V140, P291; Capozzi G., 1974, CHEM THIOL GROUP 2; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; EDMAN P, 1972, PROTEIN SEQUENCE DET, P232; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPATPOLASKO L, 1993, BIOCHEMISTRY-US, V29, P9561; LUBKOWSKI J, 1994, BIOCHEMISTRY-US, V33, P10257, DOI 10.1021/bi00200a005; MAKRYALEAS K, 1990, Patent No. 4980284; MEYER P, 1993, FEMS MICROBIOL LETT, V109, P67, DOI 10.1111/j.1574-6968.1993.tb06145.x; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; MISRA HP, 1974, J BIOL CHEM, V249, P2151; OGAWA J, 1993, EUR J BIOCHEM, V212, P685, DOI 10.1111/j.1432-1033.1993.tb17706.x; OLIVIERI R, 1981, BIOTECHNOL BIOENG, V23, P2173, DOI 10.1002/bit.260231002; POLGAR L, 1982, BIOCHEM J, V207, P1; RUNSER S, 1990, APPL MICROBIOL BIOT, V33, P382; SOUBRIER F, 1992, GENE, V116, P99, DOI 10.1016/0378-1119(92)90635-3; STARK GR, 1963, J BIOL CHEM, V238, P214; SWAIN AL, 1993, P NATL ACAD SCI USA, V90, P1474, DOI 10.1073/pnas.90.4.1474; SYLDATK C, 1990, ADV BIOCHEM ENG BIOT, V41, P30; TAKAHASHI S, 1979, J FERMENT TECHNOL, V57, P328; WEATHERBURN MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WRISTON JC, 1973, ADV ENZYMOL RAMB, V39, P185	32	58	62	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9326	9331		10.1074/jbc.271.16.9326	http://dx.doi.org/10.1074/jbc.271.16.9326			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621596	hybrid			2022-12-25	WOS:A1996UG04400027
J	Honkakoski, P; Moore, R; Gynther, J; Negishi, M				Honkakoski, P; Moore, R; Gynther, J; Negishi, M			Characterization of phenobarbital-inducible mouse Cyp2b10 gene transcription in primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; TISSUE-SPECIFIC EXPRESSION; CYTOCHROME-P-450 GENE; GROWTH-HORMONE; MESSENGER-RNA; TESTOSTERONE 16-ALPHA-HYDROXYLASE; CHROMOSOME LOCALIZATION; INVITRO TRANSCRIPTION; GLYCOPROTEIN GENE; LIVER-MICROSOMES	The mouse phenobarbital (PB)-inducible Cyp2b10 gene promoter has been isolated and sequenced, and control of its expression has been characterized, The 1405-base pair (bp) Cyp2b10 promoter sequence is 83% identical to the corresponding region from the rat CYP2B2 gene. In addition to the lack of CA repeats, differences include insertion of 42 base pairs (-123/-82 bp) into the middle of a consensus sequence to the so called ''Barbie box.'' In this report, we have developed a primary mouse hepatocyte culture system in which endogenous 2B10 mRNA as well as Cyp2b10-driven CAT activity were induced by PB and 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), but not by the 3-chloro derivative of TCPOBOP, Deletion analysis of the Cyp2b10 promoter identified a basal transcription element at -64/-34 bp and a negative element at -971/-775 bp. Sequences contained within the -1404/-971 bp region are responsible for the induced CAT activity. DNase I protection and gel shift assays detected five major protein binding sites within the -1404/-971 bp fragment, one of which shared high sequence identity with a portion of a regulatory element in CYP2B2 gene (Trottier, E,, Belzil, A., Stoltz, C,, and Anderson, A, (1995) Gene 158, 263-268). Our results indicate that sequences important for PB-induced transcription of Cyp2b10 gene are located in the distal promoter.	NIEHS,PHARMACOGENET SECT,REPROD & DEV TOXICOL LAB,NIH,RES TRIANGLE PK,NC 27709; UNIV KUOPIO,DEPT PHARMACEUT CHEM,SF-70211 KUOPIO,FINLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Eastern Finland			Negishi, Masahiko/F-7805-2019; Honkakoski, Paavo/AAJ-1278-2020	Negishi, Masahiko/0000-0002-2076-8928; Honkakoski, Paavo/0000-0002-4332-3577				ABDELRAZZAK Z, 1995, FEBS LETT, V366, P159, DOI 10.1016/0014-5793(95)00513-9; AIDA K, 1991, BIOCHEMISTRY-US, V30, P8041, DOI 10.1021/bi00246a023; AKRAWI M, 1993, BIOCHEM PHARMACOL, V45, P1583, DOI 10.1016/0006-2952(93)90298-B; AUBRECHT J, 1993, BIOCHEM BIOPH RES CO, V190, P1023, DOI 10.1006/bbrc.1993.1151; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MA, 1995, BIOCHEM PHARMACOL, V49, P97, DOI 10.1016/0006-2952(94)00438-R; CONNEY AH, 1967, PHARMACOL REV, V19, P317; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DOGRA SC, 1993, ARCH BIOCHEM BIOPHYS, V300, P531, DOI 10.1006/abbi.1993.1073; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HASHIMOTO T, 1988, J BIOCHEM-TOKYO, V103, P487, DOI 10.1093/oxfordjournals.jbchem.a122297; HE JS, 1991, J BIOL CHEM, V266, P7864; HONKAKOSKI P, 1992, BIOCHEM J, V285, P979, DOI 10.1042/bj2850979; HONKAKOSKI P, 1992, BIOCHEM PHARMACOL, V43, P2121, DOI 10.1016/0006-2952(92)90170-N; HONKAKOSKI P, 1989, ARCH BIOCHEM BIOPHYS, V273, P42, DOI 10.1016/0003-9861(89)90160-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INGRASSIA R, 1994, DNA CELL BIOL, V13, P615, DOI 10.1089/dna.1994.13.615; ISSHIKI H, 1991, NEW BIOL, V3, P63; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; JEAN A, 1994, DNA CELL BIOL, V13, P781, DOI 10.1089/dna.1994.13.781; KENDE AS, 1985, MOL PHARMACOL, V28, P445; KOCAREK TA, 1993, TOXICOL APPL PHARM, V120, P298, DOI 10.1006/taap.1993.1115; KOCAREK TA, 1994, BIOCHEM PHARMACOL, V48, P1815, DOI 10.1016/0006-2952(94)90468-5; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LAKSO M, 1991, EUR J BIOCHEM, V195, P477, DOI 10.1111/j.1432-1033.1991.tb15728.x; LARSEN MC, 1995, ARCH BIOCHEM BIOPHYS, V321, P467, DOI 10.1006/abbi.1995.1419; LECAM A, 1994, J BIOL CHEM, V269, P21532; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; LIANG QW, 1995, J BIOL CHEM, V270, P18606, DOI 10.1074/jbc.270.31.18606; Maniatis T, 1989, DECONTAMINATION DILU; MEEHAN RR, 1988, BIOCHEM J, V254, P789, DOI 10.1042/bj2540789; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEMOTO N, 1995, ARCH BIOCHEM BIOPHYS, V316, P362, DOI 10.1006/abbi.1995.1048; NEMOTO N, 1995, ARCH BIOCHEM BIOPHYS, V319, P286, DOI 10.1006/abbi.1995.1294; NOSHIRO M, 1988, BIOCHEMISTRY-US, V27, P6434, DOI 10.1021/bi00417a035; OHMORI S, 1993, XENOBIOTICA, V23, P419, DOI 10.3109/00498259309057030; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; PAQUEREAU L, 1992, ANAL BIOCHEM, V204, P147, DOI 10.1016/0003-2697(92)90154-Y; PASCO DS, 1989, DNA-J MOLEC CELL BIO, V8, P535, DOI 10.1089/dna.1.1989.8.535; POLAND A, 1981, MOL PHARMACOL, V20, P442; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; SALONPAA P, 1994, BIOCHEM BIOPH RES CO, V205, P631, DOI 10.1006/bbrc.1994.2712; SCHUETZ EG, 1990, J BIOL CHEM, V265, P1188; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SIDHU JS, 1995, J BIOL CHEM, V270, P12762, DOI 10.1074/jbc.270.21.12762; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; SMITH G, 1993, BIOCHEM J, V289, P807, DOI 10.1042/bj2890807; SUWA Y, 1985, J BIOL CHEM, V260, P7980; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WONG G, 1989, J BIOL CHEM, V264, P2920; YAMAZOE Y, 1987, J BIOL CHEM, V262, P7423; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612	68	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9746	9753		10.1074/jbc.271.16.9746	http://dx.doi.org/10.1074/jbc.271.16.9746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621653	hybrid			2022-12-25	WOS:A1996UG04400084
J	Igarashi, P; Whyte, DA; Li, K; Nagami, GT				Igarashi, P; Whyte, DA; Li, K; Nagami, GT			Cloning and kidney cell-specific activity of the promoter of the murine renal Na-K-Cl cotransporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; RAT-TISSUES; EXPRESSION; PROTEINS	The murine Nkcc2/Slc12a1 gene encodes a bumetanide sensitive Na-K-Cl cotransporter that is expressed exclusively in the kidney in the thick ascending limb of the loop of Henle, Nuclear run-off assays demonstrated that kidney-specific expression of Nkcc2 was due, at least in part, to kidney-specific gene transcription, To begin study of the gene promoter, a genomic clone that contained 13.5 kilobases of the 5'-flanking region of Nkcc2 was isolated. A single transcription initiation site was located 1330 base pairs (bp) upstream of the start codon. The sequence of the proximal 5'-flanking region contained typical eukaryotic promoter elements including a TATA box, two CCAAT boxes, and an initiator, A (G-A)(28) (C-T)(28) microsatellite and consensus binding sites for hepatocyte nuclear factor 1, cAMP-response element binding protein, CCAAT/enhancer-binding proteins, and basic helix-loop-helix proteins, were also identified, To functionally express the promoter, 2255 bp of the proximal 5'-flanking region was ligated to a luciferase reporter gene and transfected into thick ascending limb (TAL) cells, a stable cell line derived from microdissected loops of Henle of the Tg(SV40E)Bri7 mouse. TAL cells exhibited furosemide-sensitive Na-K(NH4+)-Cl cotransport activity and endogenously expressed the 5.0-kilobase Nkcc2 transcript. Luciferase activity was 130-fold greater following transfection into TAL cells compared with transfection into cells that did not express Nkcc2 (NIH 3T3 fibroblasts). Deletion analysis revealed that promoter activity in TAL cells was similar in constructs extending from the transcription initiation site to -1529 to -469, whereas further deletion to -190 resulted in a 76% decrease in activity, We conclude that the Nkcc2 promoter exhibits kidney cell-specific activity. Regulatory elements required for maximal promoter activity are located in a 280-bp DNA segment that contains consensus binding sites for several transcription factors expressed in the kidney.	YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06520; W LOS ANGELES DEPT VET AFFAIRS,MED CTR,MED & RES SERV,LOS ANGELES,CA 90073	Yale University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Igarashi, P (corresponding author), YALE UNIV,SCH MED,NEPHROL SECT,DEPT INTERNAL MED,333 CEDAR ST,NEW HAVEN,CT 06520, USA.			Igarashi, Peter/0000-0001-8698-1185	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044122, R01DK042921, T32DK007276] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK-07276, R01 DK-44122, R01 DK-42921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BLAUROCK MC, 1995, BBA-GENE STRUCT EXPR, V1262, P159, DOI 10.1016/0167-4781(95)00075-R; CELANO P, 1989, BIOTECHNIQUES, V7, P942; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUNCAN MK, 1994, KIDNEY INT, V46, P324, DOI 10.1038/ki.1994.278; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAGNON ML, 1992, DEVELOPMENT, V114, P457; GAMBA G, 1994, J BIOL CHEM, V269, P17713; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Igarashi P., 1995, Journal of the American Society of Nephrology, V6, P697; IGARASHI P, 1992, AM J PHYSIOL, V263, pF83, DOI 10.1152/ajprenal.1992.263.1.F83; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; KARIN M, 1993, GENE EXPRESSION GEN; KAUNITZ JD, 1993, J CLIN PHARMACOL, V33, P63, DOI 10.1002/j.1552-4604.1993.tb03905.x; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; LAZZARO D, 1992, DEVELOPMENT, V114, P469; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MANDON B, 1995, PFLUG ARCH EUR J PHY, V430, P12, DOI 10.1007/BF00373834; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MOLONY DA, 1987, AM J PHYSIOL, V252, pF177, DOI 10.1152/ajprenal.1987.252.1.F177; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAGAMI GT, 1992, J CLIN INVEST, V89, P925, DOI 10.1172/JCI115673; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRICE PM, 1983, J AM SOC NEPHROL, V4, P474; QUAGGIN SE, 1995, MAMM GENOME, V6, P557, DOI 10.1007/BF00356178; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; VANDENHOFF MJB, 1994, HISTOCHEM J, V26, P20; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; Yu Heron, 1994, Gene Expression, V4, P63	43	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9666	9674		10.1074/jbc.271.16.9666	http://dx.doi.org/10.1074/jbc.271.16.9666			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621642	hybrid			2022-12-25	WOS:A1996UG04400073
J	Mulrooney, SB; Fishel, RA; Hejna, JA; Warner, RC				Mulrooney, SB; Fishel, RA; Hejna, JA; Warner, RC			Preparation of figure 8 and cruciform DNAs and their use in studies of the kinetics of branch migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATIVE FORM DNA; ECORI ENDONUCLEASE; PALINDROMIC DNA; STRANDED DNA; CIRCULAR DNA; DIFFUSION; JUNCTION; RECOMBINATION; TRANSITIONS; SEQUENCES	We have re-examined the kinetics of the branch migration of double-stranded DNA that is mediated by the stepwise movement of the Holliday junction. This work revises and extends our previous treatment (Thompson, B. J., Camien, M. N., and Warner, R. C. (1976) Proc, Natl, Acad, Sci, U. S. A. 73, 2299-2303). New methodology and new highly purified substrates have been used, The latter include figure 8s prepared from phage G4 DNA by annealing single-stranded components and two sizes of a novel cruciform, We treat the process as a one-dimensional diffusion based on the random walk, the mathematical basis of which is discussed in detail, The step rate is shown to be 3 orders of magnitude slower than we reported previously, The most important contribution to the erroneously high rate was a result of the presence of EDTA in the spreading solution used for electron microscopy at that time, A second contribution of about 4-fold resulted from catalysis by EcoRI and other proteins. The rates reported here are for the uncatalyzed reaction.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine					NIGMS NIH HHS [GM28769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Carslaw H.S., 1959, CONDUCTION HEAT SOLI, V2nd ed., P97; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; CLAYTON DA, 1970, J MOL BIOL, V47, P137, DOI 10.1016/0022-2836(70)90335-9; CLEGG RM, 1994, BIOPHYS J, V66, P99, DOI 10.1016/S0006-3495(94)80765-9; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; COUREY AJ, 1983, CELL, V33, P817, DOI 10.1016/0092-8674(83)90024-7; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; ERIE DA, 1989, BIOCHEMISTRY-US, V28, P268, DOI 10.1021/bi00427a037; Feller W., 1968, INTRO PROBABILITY TH, VI; FISHEL RA, 1986, VIROLOGY, V148, P198, DOI 10.1016/0042-6822(86)90415-0; FISHEL RA, 1980, THESIS U CALIFORNIA; GELLERT M, 1983, P NATL ACAD SCI-BIOL, V80, P5545, DOI 10.1073/pnas.80.18.5545; GREENE PJ, 1974, METHODS MOLECULAR BI, V7, P87; HAMMES GG, 1978, PRINCIPLES CHEM KINE, P16; HAMMING RW, 1991, ART PROBABILITY SCI, P50; HARNETT DL, 1982, STAT METHODS, P228; ISAACS ST, 1977, BIOCHEMISTRY-US, V16, P1058, DOI 10.1021/bi00625a005; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; MESELSON M, 1972, J MOL BIOL, V71, P795, DOI 10.1016/0022-2828(72)90048-X; MIZUUCHI K, 1982, J MOL BIOL, V156, P229, DOI 10.1016/0022-2836(82)90325-4; MODRICH P, 1976, J BIOL CHEM, V251, P5866; NOYES RM, 1961, PROG REACT KINET MEC, V1, P129; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; ROBINSON BH, 1987, BIOPHYS J, V51, P611, DOI 10.1016/S0006-3495(87)83386-6; RUSH MG, 1970, J BIOL CHEM, V245, P2704; SCHWARZENBACH G, 1969, COMPLEXOMETRIC TITRA, P160; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SINDEN RR, 1984, J BIOL CHEM, V259, P6593; Smith H O, 1980, Methods Enzymol, V65, P371; SPITZER F, 1976, PRINCIPLES RANDOM WA, P244; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THOMPSON BJ, 1976, P NATL ACAD SCI USA, V73, P2299, DOI 10.1073/pnas.73.7.2299; THOMPSON BJ, 1975, J MOL BIOL, V91, P409, DOI 10.1016/0022-2836(75)90269-7; WARNER RC, 1979, COLD SPRING HARB SYM, V43, P957, DOI 10.1101/SQB.1979.043.01.105; WARNER RC, 1978, SINGLE STRANDED DNA, P417; WEMMER DE, 1985, NUCLEIC ACIDS RES, V13, P8611, DOI 10.1093/nar/13.23.8611; WHEELER FC, 1977, ANAL BIOCHEM, V78, P260, DOI 10.1016/0003-2697(77)90031-8; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; 1954, TABLES ERROR FUNCTIO	45	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9648	9659		10.1074/jbc.271.16.9648	http://dx.doi.org/10.1074/jbc.271.16.9648			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621640	hybrid			2022-12-25	WOS:A1996UG04400071
J	Shi, WP; Dong, J; Scott, RA; Ksenzenko, MY; Rosen, BP				Shi, WP; Dong, J; Scott, RA; Ksenzenko, MY; Rosen, BP			The role of arsenic thiol interactions in metalloregulation of the ars operon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE OPERON; PROTEINS; EXPRESSION; OXIDE	The ars operon of the Escherichia coli plasmid R773 that confers arsenical and antimonial resistance is negatively regulated by the ArsR repressor, ArsR residues Cys-32 and Cys-34 were previously identified as involved in induction by arsenite and antimonite, suggesting coordination between As(III) and the two cysteine thiolates, However, in small molecule thiolate-As(III) complexes, arsenic is frequently three-coordinate. A site-directed mutagenic approach was employed in a search for a third arsenic ligand, ArsR proteins with C32G, C34G, and C32G/C34G substitutions were active repressors, but were not inducible in vivo. In vitro, the altered repressor-ars DNA complexes could not be dissociated by inducers, Alteration of Cys-37 and Ser-43, residues located in or near the putative helix-turn-helix DNA-binding region of the protein, had no effect on the inducibility of the operon. While these results indicated that neither the thiolate of Cys-37 nor the hydroxyl oxygen of Ser-43 is required for induction, they did not eliminate either atom as a potential arsenic ligand. Another approach involved reaction with an alternative inducer, phenylarsine oxide, which can form only two coordinations, Phenylarsine oxide was shown to be as effective as or more effective than arsenite or antimonite in induction in vivo, In vitro, the organic arsenical was more effective than either arsenite or antimonite in dissociating the repressor-promoter complex, Thus, two ArsR-arsenic bonds are sufficient for induction. The interaction of ArsR proteins with As(III) was examined using a phenylarsine oxide affinity resin. ArsR proteins containing any two of the three cysteine residues Cys-32, Cys-34, and Cys-37 bound to the resin, Alteration of any two of the three resulted in loss of binding, Arsenic x-ray absorption spectroscopy of ArsR treated stoichiometrically with arsenite confirmed the average arsenic coordination as AsS3. These results suggest that all three cysteine thiolates are arsenic ligands, but binding to only two, the Cys-32 and Cys-34 thiolates, is required to produce the conformational change that results in release of the repressor from the DNA and induction.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, DETROIT, MI 48201 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA	Wayne State University; University System of Georgia; University of Georgia				Scott, Robert/0000-0003-2236-1336; Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NIEHS NIH HHS [1 P30-ES06639] Funding Source: Medline; NIGMS NIH HHS [GM42025] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; Chen YX, 1996, J BACTERIOL, V178, P911, DOI 10.1128/jb.178.3.911-913.1996; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CRUSE WBT, 1972, ACTA CRYST SECT B, V28, P1326; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; FREEMAN HC, 1975, INORGANIC BIOCH, P153; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SHI WP, 1994, J BIOL CHEM, V269, P19826; Silhavy T.J., 1984, EXPT GENE FUSIONS; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x; WU JH, 1993, J BIOL CHEM, V268, P52; WU JH, 1992, J BIOL CHEM, V267, P12570; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427	27	140	157	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9291	9297		10.1074/jbc.271.16.9291	http://dx.doi.org/10.1074/jbc.271.16.9291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621591	hybrid			2022-12-25	WOS:A1996UG04400022
J	Sugiyama, S; Vassylyev, DG; Matsushima, M; Kashiwagi, K; Igarashi, K; Morikawa, K				Sugiyama, S; Vassylyev, DG; Matsushima, M; Kashiwagi, K; Igarashi, K; Morikawa, K			Crystal structure of PotD, the primary receptor of the polyamine transport system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ACTIVE-TRANSPORT; SALMONELLA-TYPHIMURIUM; RESOLUTION STRUCTURE; FUNCTIONAL-CHANGES; CHEMOTAXIS; PUTRESCINE; CHROMOSOME; RIBOSE; MAPS	PotD protein is a periplasmic binding protein and the primary receptor of the polyamine transport system, which regulates the polyamine content in Escherichia coli. The crystal structure of PotD in complex with spermidine has been solved at 2.5-Angstrom resolution. The PotD protein consists of two domains with an alternating beta-alpha-beta topology. The polyamine binding site is in a central cleft lying in the interface between the domains. In the cleft, four acidic residues recognize the three positively charged nitrogen atoms of spermidine, while five aromatic side chains anchor the methylene backbone by van der Waals interactions. The overall fold of PotD is similar to that of other periplasmic binding proteins, and in particular to the maltodextrin-binding protein from E. coli, despite the fact that sequence identity is as low as 20%. The comparison of the PotD structure with the two maltodextrin-binding protein structures, determined in the presence and absence of the substrate, suggests that spermidine binding rearranges the relative orientation of the PotD domains to create a more compact structure.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN	Chiba University			Vassylyev, Dmitry/A-9005-2008	Igarashi, Kazuei/0000-0003-3751-3187				AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BINNIE RA, 1992, PROTEIN SCI, V1, P1642, DOI 10.1002/pro.5560011212; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DUPLAY P, 1987, J MOL BIOL, V194, P675, DOI 10.1016/0022-2836(87)90244-0; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GIGLIO E, 1966, ACTA CRYSTALLOGR, V20, P683, DOI 10.1107/S0365110X66001609; HUSE Y, 1969, ACTA CRYSTALL B-STRU, VB 25, P498, DOI 10.1107/S0567740869002470; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG CH, 1991, J BIOL CHEM, V266, P23893; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1988, P DAR STUD WEEK 5 6, P25; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MATSUO Y, 1994, FEBS LETT, V345, P23, DOI 10.1016/0014-5793(94)00435-8; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; OH BH, 1993, J BIOL CHEM, V268, P11348; PEGG AE, 1988, CANCER RES, V48, P759; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARFF AJ, 1995, J MOL BIOL, V246, P8, DOI 10.1006/jmbi.1994.0059; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SUGIYAMA S, 1996, IN PRESS ACTA CRYS D; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; VERMERSCH PS, 1990, J BIOL CHEM, V265, P16592; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	46	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9519	9525		10.1074/jbc.271.16.9519	http://dx.doi.org/10.1074/jbc.271.16.9519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621624	hybrid			2022-12-25	WOS:A1996UG04400055
J	vanderMerwe, PA; Crocker, PR; Vinson, M; Barclay, AN; Schauer, R; Kelm, S				vanderMerwe, PA; Crocker, PR; Vinson, M; Barclay, AN; Schauer, R; Kelm, S			Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE COMMON ANTIGEN; MONOCLONAL-ANTIBODY; ADHESION MOLECULE; STRUCTURAL CHARACTERIZATION; T-CELLS; RECEPTOR; SIALYLTRANSFERASE; GANGLIOSIDES; EXPRESSION; SEQUENCE	B-lymphocyte antigen CD22 is a member of the recently described sialoadhesin family of immunoglobulin-like cell-surface glycoproteins that bind glycoconjugates terminating in sialic acid. One prominent ligand for CD22 is the highly glycosylated leukocyte surface protein CD45, Using surface plasmon resonance spectroscopy, we characterized the interaction of recombinant mouse CD22 with native CD45 purified from rat thymus (CD45-thy), By in situ desialylation and resialylation of immobilized CD45-thy, we show that mouse CD22 binds to the sialoglycoconjugate NeuGc alpha 2-6Gal beta 1-4GlcNAc carried on CD45-thy N-glycans, Previous studies have shown that the sialic acid-binding site lies within the two membrane-distal domains of CD22 (domains 1 and 2), which are V-set and Ca-set immunoglobulin superfamily domains, respectively. To further localize the binding site, we have made 42 single amino acid substitutions throughout both domains, All 12 mutations that abrogated binding to CD45-thy without disrupting antibody binding were of residues within the GFCC'C '' beta-sheet of domain 1, These residues are predicted to form a contiguous binding site centered around an arginine residue in the F strand that is conserved in all members of the sialoadhesin family, Our results provide further evidence that immunoglobulin superfamily cell adhesion molecules use the GFCC'C '' beta-sheet of membrane-distal V-set domains to bind structurally diverse ligands, suggesting that this surface is favored for cell-cell recognition.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; CHRISTIAN ALBRECHTS UNIV KIEL,INST BIOCHEM,D-24098 KIEL,GERMANY	Cancer Research UK; University of Oxford; University of Kiel	vanderMerwe, PA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND.		van der Merwe, P. Anton/F-8539-2011; Kelm, Soerge/C-5403-2013	Kelm, Soerge/0000-0001-5277-9421; Crocker, Paul/0000-0001-6230-0293				ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P10242, DOI 10.1073/pnas.89.21.10242; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; CAMPBELL DG, 1981, BIOCHEM J, V195, P15, DOI 10.1042/bj1950015; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HAZLEWOOD M, 1993, CLIN EXP IMMUNOL, V93, P157; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LAW CL, 1993, J IMMUNOL, V151, P175; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LAW CL, 1995, J IMMUNOL, V155, P3368; LEPRINCE C, 1993, P NATL ACAD SCI USA, V90, P3236, DOI 10.1073/pnas.90.8.3236; MCCALL MN, 1992, IMMUNOLOGY, V76, P310; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUTHING J, 1987, EUR J BIOCHEM, V163, P407, DOI 10.1111/j.1432-1033.1987.tb10813.x; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1358, DOI 10.1002/eji.1830230626; PEDRAZA L, 1990, J CELL BIOL, V111, P2651, DOI 10.1083/jcb.111.6.2651; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PORTNER A, 1993, BIOCHEMISTRY-US, V32, P12685; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; REUTER G, 1994, METHOD ENZYMOL, V230, P168; SATO T, 1993, BIOCHEMISTRY-US, V32, P12694, DOI 10.1021/bi00210a019; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHAUER R, 1991, CARBOHYD RES, V213, P353, DOI 10.1016/S0008-6215(00)90623-2; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SCHLENZKA W, 1994, GLYCOBIOLOGY, V4, P675, DOI 10.1093/glycob/4.5.675; SCHULTE RJ, 1992, SCIENCE, V258, P1001, DOI 10.1126/science.1279802; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; SUNDERLAND CA, 1979, EUR J IMMUNOL, V9, P155, DOI 10.1002/eji.1830090212; SYMINGTON FW, 1982, IMMUNOGENETICS, V16, P381, DOI 10.1007/BF00372098; TORRES RM, 1992, J IMMUNOL, V149, P2641; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137	73	124	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9273	9280		10.1074/jbc.271.16.9273	http://dx.doi.org/10.1074/jbc.271.16.9273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621588	hybrid			2022-12-25	WOS:A1996UG04400019
J	Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU				Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU			Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma	ONCOGENE			English	Article						p53; adenoviral constructs; tumorigenicity; gene therapy	WILD-TYPE P53; CANCER CELLS; GROWTH; EXPRESSION; PROTEIN; MECHANISMS; MUTATIONS; APOPTOSIS	Mutations of p53 gene are reported in 50-60% of human cancers and reintroduction of wild-type p53 can suppress cell proliferation, In this study, replication deficient recombinant adenovirus encoding wild-type p53 (ACN53) under the control of the human cytomegalovirus (CMV) promoter was constructed. A specific incorporation of the p53 gene with ACN53 in SK-OV-3 (deleted p53 gene) cells was observed, ACN53 reduced the colony-forming ability of SK-OV-3 cells thereby supporting that 95-98% of cells are susceptible to infection by recombinant adenovirus. ACN53 inhibited the growth of 71-98% of SK-OV-3 cells 72-216 h after single infection, A highly aggressive ovarian xenograft model was established in which animals die between 25-45 days, A localization study with the adenovirus-containing beta galactosidase reporter gene showed effective gene transfer in the tumor tissues, Ex vivo treatment of SK-OV-3 cells with ACN53 followed by injection into nude mice, increased the survival of the p53 treated mice by more than 50% compared with control animals, Gene therapy with ACN53 in intraperitoneal model of SK-OV-3 cells in two independent experiments revealed that there were some long-term survivors in the group of mice [2/5 (66 and 120 days) and [2/8 (166 and 423 days)] treated with ACN53. These findings demonstrate the potential of the p53 tumor suppressor gene therapy in human ovarian carcinoma.	CANJI INC,SAN DIEGO,CA 92121		Mujoo, K (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC ONCOL,HOUSTON,TX 77030, USA.		Mujoo, Kalpana/S-9933-2019	Mujoo, Kalpana/0000-0002-4275-1051				BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOSARI S, 1993, HUM PATHOL, V24, P1175, DOI 10.1016/0046-8177(93)90212-Y; BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CLAYMAN GL, 1995, CANCER RES, V55, P1; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GOODING LR, 1990, CRIT REV IMMUNOL, V10, P53; HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V9, P7491; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; OKAMOTO A, 1991, CANCER RES, V51, P5171; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROEMER K, 1994, ANN NY ACAD SCI, V716, P265, DOI 10.1111/j.1749-6632.1994.tb21718.x; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIEGFRIED W, 1993, EXP CLIN ENDOCRINOL, V101, P7, DOI 10.1055/s-0029-1211201; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAGINUMA Y, 1992, CANCER RES, V52, P4196; ZHANG WW, 1994, CANCER GENE THER, V1, P1	39	98	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1617	1623						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622881				2022-12-25	WOS:A1996UG45800003
J	Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T				Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T			Zinc finger protein GFI-1 cooperates with MYC and PIM-1 in T-cell lymphomagenesis by reducing the requirements for IL-2	ONCOGENE			English	Article						oncogene cooperation; MoMuLV mutagenesis; proviral integration; zinc finger; IL-2 independence; tumour progression	MURINE LEUKEMIA-VIRUS; E-MU-MYC; C-MYC; TRANSGENIC MICE; N-MYC; PROVIRAL INSERTION; GENE; DNA; RNA; EXPRESSION	The clonality of lymphomas that originate in myc/pim-1 bitransgenic mice due to synergistic action of both oncogenes indicates the requirement of additional events for progression to full malignancy, To isolate genes that cooperate with both myc and pim-1, we have used provirus tagging with E mu L-myc/pim-1 double transgenic mice, We find accelerated tumour formation in infected animals and show that the gfi-1 gene and neighbouring loci on mouse chromosome 5 are occupied by proviruses in about 53% of the tumours leading in all cases to high level gfi-1 expression. In agreement with data from Gilks et al, (1993) we find that forced expression of the gfi-1 encoded zinc finger protein in IL-2 dependent T-cells provokes increased survival upon IL-2 depletion and we present evidence that this occurs at least in part through stimulation of proliferation, Our data suggest that gfi-1 is a proto-oncogene and very efficiently engages in a tripartite oncogene cooperation with both mye and pim-1 genes in T-cell lymphomagenesis.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, Current Biology, V1, P28, DOI 10.1016/0960-9822(91)90118-G; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GOTO Y, 1992, J BIOL CHEM, V267, P15252; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	50	94	98	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1789	1801						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622900				2022-12-25	WOS:A1996UG45800022
J	BudhramMahadeo, V; Morris, PJ; Lakin, ND; Dawson, SJ; Latchman, DS				BudhramMahadeo, V; Morris, PJ; Lakin, ND; Dawson, SJ; Latchman, DS			The different activities of the two activation domains of the Brn-3a transcription factor are dependent on the context of the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED DNA; FUNCTIONAL-ANALYSIS; GENE; PROTEIN; DISTINCT; ELEMENT; IDENTIFICATION; PROMOTER; NEURONS; CELLS	The POU (Pit-Oct-Unc) family transcription factor Brn-3a contains two distinct activation domains, one at the N terminus of the molecule and one at the C terminus coincident with the DNA binding domain, These different activation domains have been shown previously to differ in their ability to activate an artificial test promoter containing a Brn-3a binding site and the naturally occurring alpha-internexin gene promoter, Here we identify the target site for Brn-3a in the alpha-internexin gene promoter and show that it can confer responsiveness to Brn-3a on a heterologous promoter, One of the single-stranded DNA sequences derived from either this novel Brn-3a binding site or from the previously characterized site in the test promoter are shown to bind Brn-3a preferentially compared with the complementary single strand or the corresponding double-stranded sequence. The pattern of responsiveness of these two sequences when cloned upstream of the same test promoter and co-transfected with constructs encoding various portions of Brn-3a indicates that the activity of the two Brn-3a activation domains is dependent upon differences in the context of the target sequence in each promoter rather than on differences in the target sequence itself.	UCL, SCH MED, MED MOLEC BIOL UNIT, DEPT MOLEC PATHOL, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School				Dawson, Sally/0000-0002-4421-2043				BAUKNECHT T, 1995, J VIROL, V69, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; BUDHRAMMAHADEO V, 1995, NEUROSCI LETT, V185, P48, DOI 10.1016/0304-3940(94)11222-5; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHING GY, 1991, J BIOL CHEM, V266, P19459; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FALKNER FG, 1986, NUCLEIC ACIDS RES, V13, P7847; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LILLYCROP KA, 1995, BIOCHEM J, V307, P581, DOI 10.1042/bj3070581; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; PAN WT, 1990, J BIOL CHEM, V265, P7022; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7	38	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9108	9113		10.1074/jbc.271.15.9108	http://dx.doi.org/10.1074/jbc.271.15.9108			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621561	hybrid			2022-12-25	WOS:A1996UE73000092
J	Czernik, PJ; Peterson, CA; Hurlburt, BK				Czernik, PJ; Peterson, CA; Hurlburt, BK			Preferential binding of MyoD-E12 versus Myogenin-E12 to the murine sarcoma virus enhancer in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKI ONCOGENE; DNA-BINDING; MUSCLE DIFFERENTIATION; SUBUNIT GENE; MYOD1; FIBROBLASTS; MYOGENESIS; ACTIVATION; SEQUENCE; REGION	The MyoD family of transcription factors regulates muscle-specific gene expression in vertebrates. In the adult rat, MyoD mRNA accumulates predominately in fast-twitch muscle, in particular type IIb and/or IIx fibers, whereas Myogenin mRNA is restricted to slow-twitch type I muscle fibers, Transgenic mice expressing the avian v-ski oncogene from the murine sarcoma virus (MSV) promoter-enhancer display preferential hypertrophy of type IIb fast-twitch muscle apparently because of the restricted expression of the transgene. We tested the hypothesis that preferential interactions of MyoD, as a heterodimer with E12, with the MSV enhancer, which has six E-box targets for MyoD family proteins, could contribute to v-ski gene expression in IIb muscle fibers, A series of quantitative binding studies was performed using an electrophoretic mobility shift assay to test MyoD-E12 versus Myogenin-E12 binding to the MSV enhancer. Our results indicate that MyoD-E12 binds the MSV enhancer with higher affinity and higher cooperativity than Myogenin-E12. Interestingly, MyoD-E12 bound all of the individual E-boxes tested with positive cooperativity indicating DNA-mediated dimerization of the protein subunits.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET ADM MED CTR,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences								AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BLACKWELL KT, 1990, SCIENCE, V23, P1104; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOLEMIS EA, 1990, J VIROL, V64, P534, DOI 10.1128/JVI.64.2.534-542.1990; HASTY P, 1993, NATURE, V364, P532; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LAWRENZSMITH SC, 1995, J VIROL, V69, P4142, DOI 10.1128/JVI.69.7.4142-4148.1995; LEFEROVICH JM, 1995, J NEUROSCI, V15, P596; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MURRE C, 1989, CELL, V56, P1351; NABESHIMA Y, 1993, NATURE, V364, P501; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; PETROPOULOS CJ, 1992, J VIROL, V66, P3391, DOI 10.1128/JVI.66.6.3391-3397.1992; Ptashne M., 1986, A GENETIC SWITCH; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SEENE T, 1994, J STEROID BIOCHEM, V50, P1, DOI 10.1016/0960-0760(94)90165-1; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; VAIDYA TB, 1992, GENE, V116, P223, DOI 10.1016/0378-1119(92)90519-U; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VOYTIK SL, 1993, DEV DYNAM, V198, P214, DOI 10.1002/aja.1001980307; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZINGG JM, 1991, NUCLEIC ACIDS RES, V19, P6433, DOI 10.1093/nar/19.23.6433	42	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9141	9149		10.1074/jbc.271.15.9141	http://dx.doi.org/10.1074/jbc.271.15.9141			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621566	hybrid			2022-12-25	WOS:A1996UE73000097
J	Perez, RG; Squazzo, SL; Koo, EH				Perez, RG; Squazzo, SL; Koo, EH			Enhanced release of amyloid beta-protein from codon 670/671 ''Swedish'' mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CULTURED-CELLS; PEPTIDE; IDENTIFICATION; CLEAVAGE; DERIVATIVES; COMPARTMENT; RECEPTOR; TERMINUS; FRAGMENT	The mutation at codons 670/671 of beta-amyloid precursor protein (beta PP) dramatically elevates amyloid beta-protein (A beta) production, Since increased A beta may be responsible for the disease phenotype identified from a Swedish kindred with familial Alzheimer's disease, evaluation of the cellular mechanism(s) responsible for the enhanced A beta release may suggest potential therapies for Alzheimer's disease, In this study, we analyzed Chinese hamster ovary cells stably transfected with either wild type beta PP (beta PP-wt) or ''Swedish'' mutant beta PP (beta PP-sw) for potential differences in beta PP processing, We confirmed that increased amounts of A beta and a beta-secretase-cleaved COOH-terminally truncated soluble beta PP (beta PPs) were secreted from beta PP-sw cells, As shown previously for beta PP-wt cells, A beta was released more slowly than the secretion of beta PPs from surface-labeled beta PP-sw cells, indicating that endocytosis of cell surface beta PP is one source of A beta production, In contrast, by [S-35]methionine metabolic labeling, the rates of A beta and beta PPs release were virtually identical for both cell lines. In addition, the identification of intracellular beta PPs and A beta shortly after pulse labeling suggests that A beta is produced in the secretory pathway. Interestingly, more A beta was present in medium from beta PP-sw cells than beta PP-wt cells after either cell surface iodination or [S-35]methionine labeling, indicating that beta PP-sw cells have enhanced A beta release in both the endocytic and secretory pathways, Furthermore, a variety of drug treatments known to affect protein processing similarly reduced A beta release from both beta PP-wt and beta PP-sw cells, Taken together, the data suggest that the processing pathway for beta PP is similar for both beta PP-wt and beta PP-sw cells and that increased A beta production by beta PP-sw cells arises from enhanced cleavage of mutant beta PP by beta-secretase, the as-yet unidentified enzyme(s) that cleaves at the NH2 terminus of A beta.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Perez, Ruth G./AAK-9844-2020; Perez, Ruth/A-7388-2009		NATIONAL INSTITUTE ON AGING [R01AG012376, T32AG000222] Funding Source: NIH RePORTER; NIA NIH HHS [AG12376, 5T32AG00222, R01 AG012376] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LO ACY, 1994, J BIOL CHEM, V269, P30966; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513	42	115	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9100	9107		10.1074/jbc.271.15.9100	http://dx.doi.org/10.1074/jbc.271.15.9100			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621560	hybrid			2022-12-25	WOS:A1996UE73000091
J	Galang, CK; GarciaRamirez, JJ; Solski, PA; Westwick, JK; Der, CJ; Neznanov, NN; Oshima, RG; Hauser, CA				Galang, CK; GarciaRamirez, JJ; Solski, PA; Westwick, JK; Der, CJ; Neznanov, NN; Oshima, RG; Hauser, CA			Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappa B-dependent gene expression, and inhibiting ets activation blocks neu-mediated cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; TYROSINE KINASE; FACTOR RECEPTOR; SIGNAL TRANSDUCTION; MAMMARY-TUMORS; POINT MUTATION; DNA-BINDING; AMPLIFICATION; PROTOONCOGENE	Overexpression of Neu (ErbB-2/HER2) is found in similar to 20% of breast tumors. Activation of Neu by a point mutation (Neu(T)) causes constitutive tyrosine kinase activity of this transmembrane receptor and transforming activity in fibroblasts. To identify downstream targets of Neu, we have analyzed the ability of Neu to activate gene expression. Expression of Neu(T), but not normal Neu, caused transcriptional activation of Ets, AP-1, or NF-kappa B-dependent reporter genes. Dominant inhibitory Ras or Raf mutants blocked the Neu-mediated transcriptional activation, confirming that Ras signaling pathways were required for this activation. Analysis with Ets2 mutants indicated that activation of Ets2 transcriptional activity mediated by Neu(T) or oncogenic Ras required phosphorylation of the same Ets2 residue, threonine 72. Cotransfection of dominant inhibitory Ets2 mutants specifically blocked Neu(T)-mediated activation of Ets-dependent reporter genes. Furthermore, in focus formation assays using NIH 3T3 cells, the transforming activity of Neu(T) was inhibited 5-fold when Neu(T) was cotransfected with a dominant negative Ets2 mutant. However, parallel colony formation assays showed that the Ets2 dominant negative mutant did not inhibit the growth of normal cells. Together, these data show that Neu(T) activates a variety of transcription factor families via the Ras signaling pathway and that Ets activation is required for Neu(T)-mediated cellular transformation. Thus, downstream targets of Neu, including Ets transcription factors, may be useful points for therapeutic intervention in Neu/ErbB-2-associated cancers.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; University of North Carolina Chapel Hill			Garcia-Ramirez, Jose J/L-2153-2014	Garcia-Ramirez, Jose J/0000-0002-8348-3727; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042302, R01CA042978, R01CA063130] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130, CA42978, CA42302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRYSCH W, 1994, CANCER GENE THER, V1, P99; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DER CJ, 1988, ONCOGENE, V3, P105; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GALANG CK, 1994, ONCOGENE, V9, P2913; GALIEN R, 1994, ONCOGENE, V9, P1101; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JANES PW, 1994, ONCOGENE, V9, P3601; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEMOINE NR, 1990, ONCOGENE, V5, P237; LI X, 1994, J BIOL CHEM, V269, P6263; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NEBL G, 1994, J BIOL CHEM, V269, P7371; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEGATTO O, 1993, ONCOGENE, V8, P2105; SETH A, 1990, ONCOGENE, V5, P1761; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STANCOVSKI I, 1992, J STEROID BIOCHEM, V43, P95, DOI 10.1016/0960-0760(92)90192-L; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; XIE YM, 1995, ONCOGENE, V10, P2409; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang BS, 1996, MOL CELL BIOL, V16, P538	65	124	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7992	7998		10.1074/jbc.271.14.7992	http://dx.doi.org/10.1074/jbc.271.14.7992			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626480	hybrid			2022-12-25	WOS:A1996UD60000020
J	Hurtubise, Y; Barriault, D; Sylvestre, M				Hurtubise, Y; Barriault, D; Sylvestre, M			Characterization of active recombinant His-tagged oxygenase component of Comamonas testosteroni B-356 biphenyl dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENES; PROTEINS	Biphenyl (BPH) dioxygenase oxidizes BPH to 2,3-dihydro-2,3-dihydroxybiphenyl in Comamonas testosteroni B-356, The enzyme comprises a two-subunit iron-sulfur protein (ISPBPH), a ferredoxin FER(BPH), and a ferredoxin reductase RED(BPH). RED(BPH) and FER(BPH) transfer electrons from NADH to an Fe-S active center of ISPBPH which activates molecular oxygen for insertion into the substrate, In this work B-356 ISPBPH complex and its alpha and beta subunits were purified from recombinant Escherichia coli strains using the His-bind QIAGEN system. His-tagged B-356 ISPBPH construction carrying a single His tail on the N-terminal portion of the alpha subunit was active. Its major features were compared to the untagged enzyme. In both cases, the native form is an alpha(3) beta(3) heteromer, with each alpha beta unit containing a [2Fe-2S] Rieske center (epsilon(455) = 8,300 M(-1) cm(-1)) and a mononuclear Fe2+. Although purified His-tagged alpha subunit showed the characteristic absorption spectra of Rieske-type protein, reassociation of this enzyme component and His-tagged beta subunit to reconstitute active ISPBPH was weak. However, when His-tagged alpha and beta subunits were reassembled in vitro in crude cell extracts from E. coli recombinants, active ISPBPH could be purified on Ni-nitrilotriacetic acid resin.	INST NATL RECH SCI SANTE,POINTE CLAIRE,PQ H9R 1G6,CANADA	University of Quebec				Sylvestre, Michel/0000-0002-6942-3373				AHMAD D, 1990, GENE, V86, P53, DOI 10.1016/0378-1119(90)90113-6; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; BATIE CJ, 1990, CHEM BIOCH FLAVOENZY, P544; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; HIROSE J, 1994, GENE, V138, P27; HURTUBISE Y, 1995, J BACTERIOL, V177, P6610, DOI 10.1128/jb.177.22.6610-6618.1995; KING TE, 1967, METHOD ENZYMOL, V10, P634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; NEIDLE EL, 1991, J BACTERIOL, V173, P5385, DOI 10.1128/jb.173.17.5385-5395.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SUEN WC, 1994, GENE, V143, P67; SUEN WC, 1993, J BACTERIOL, V175, P5877, DOI 10.1128/JB.175.18.5877-5881.1993; SYLVESTRE M, 1982, J GEN APPL MICROBIOL, V28, P61, DOI 10.2323/jgam.28.61; SYLVESTRE M, 1996, IN PRESS GENE AMST; TAIRA K, 1992, J BIOL CHEM, V267, P4844	22	52	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8152	8156		10.1074/jbc.271.14.8152	http://dx.doi.org/10.1074/jbc.271.14.8152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626504	hybrid			2022-12-25	WOS:A1996UD60000044
J	Szczesna, D; Guzman, G; Miller, T; Zhao, JJ; Farokhi, K; Ellemberger, H; Potter, JD				Szczesna, D; Guzman, G; Miller, T; Zhao, JJ; Farokhi, K; Ellemberger, H; Potter, JD			The role of the four Ca2+ binding sites of troponin C in the regulation of skeletal muscle contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; MUTATION; CALCIUM; EXPRESSION; AFFINITY; 4-MALEIMIDOBENZOPHENONE; CYSTEINE-98; MUTAGENESIS; RESOLUTION; PROTEINS	In order to study the role of the Ca2+-specific sites (I and II) and the high affinity Ca2+-Mg2+ sites (III and IV) of TnC in the regulation of muscle contraction, we have constructed four mutants and the wild type (WTnC) of chicken skeletal TnC, with inactivated Ca2+ binding sites I and II (TnC1,2-), site III (TnC3-), site IV (TnC4-), and sites III and TV (TnC3,4C-), All CdC binding site mutations were generated by replacing the Asp at the X-coordinating position of the Ca2+ binding loop with Ala. The binding of these mutated proteins to TnC-depleted skinned skeletal muscle fibers was investigated as well as the rate of their dissociation from these fibers. The proteins were also tested for their ability to restore steady state force to TnC-depleted fibers. We found that although the NH2-terminal mutant of TnC (TnC1,2-) bound to the TnC-depleted fibers (with a lower affinity than wild type TnC (WTnC)), it was unable to reactivate Ca2+-dependent force. This supports earlier findings that the low affinity Ca2+ binding sites (I and II) in TnC are responsible for the Ca2+-dependent activation of skeletal muscle contraction. All three COOH-terminal mutants of TnC bound to the TnC-depleted fibers, had different rates of dissociation, and could restore steady state force to the level of unextracted fibers, Although both high affinity Ca2+ binding sites (III and IV) are important for binding to the fibers, site III appears to be the primary determinant for maintaining the structural stability of TnC in the thin filament, Moreover, our results suggest an interaction between the NH2- and COOH-terminal domains of TnC, since alteration of sites I and II lowers the binding affinity of TnC to the fibers, and mutations in sites III and IV affect the Ca2+ sensitivity of force development.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701, R01AR040727] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40727, AR37701] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRITO RM, 1993, J BIOL CHEM, V168, P966; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FRANCOIS JM, 1995, J BIOL CHEM, V270, P19287, DOI 10.1074/jbc.270.33.19287; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GUTH K, 1987, J BIOL CHEM, V262, P13627; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NEGELE JC, 1992, J BIOL CHEM, V267, P825; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REINACH FC, 1988, J BIOL CHEM, V263, P2371; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT HG, 1982, J BIOL CHEM, V257, P7678	26	57	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8381	8386		10.1074/jbc.271.14.8381	http://dx.doi.org/10.1074/jbc.271.14.8381			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626536	hybrid			2022-12-25	WOS:A1996UD60000076
J	Wang, JP; Needleman, DH; Seryshev, AB; Aghdasi, B; Slavik, KJ; Liu, SQ; Pedersen, SE; Hamilton, SL				Wang, JP; Needleman, DH; Seryshev, AB; Aghdasi, B; Slavik, KJ; Liu, SQ; Pedersen, SE; Hamilton, SL			Interaction between ryanodine and neomycin binding sites on Ca2+ release channel from skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE; H-3 RYANODINE; PURIFICATION; RECEPTOR; RECONSTITUTION; MEMBRANES	Neomycin is a potent inhibitor of skeletal muscle sarcoplasmic reticulum (SR) calcium release. To elucidate the mechanism of inhibition, the effects of neomycin on the binding of [H-3]ryanodine to the Ca2+ release channel and on its channel activity when reconstituted into planar lipid bilayer were examined. Equilibrium binding of [H-3]ryanodine was partially inhibited by neomycin. Inhibition was incomplete at high neomycin concentrations, indicating noncompetitive inhibition rather than direct competitive inhibition. Neomycin and [H-3]ryanodine can bind to the channel simultaneously and, if [H-3]ryanodine is bound first, the addition of neomycin will slow the dissociation of [H-3]ryanodine from the high affinity site. Neomycin also slows the association of [H-3]ryanodine with the high affinity binding site. The neomycin binding site, therefore, appears to be distinct from the ryanodine binding site. Dissociation of [H-3]ryanodine from trypsin-treated membranes or from a solubilized 14 S complex is also slowed by neomycin. This complex is composed of polypeptides derived from the carboxyl terminus of the Ca2+ release channel after Arg-4475 (Callaway, C., Seryshev, A. Wang, J. P., Slavik, K. Needleman, D. H., Cantu, C., Wu, Y., Jayaraman, T., Marks, A. R., and Hamilton, S. L. (1994) J. Biol. Chem. 269, 15876-15884). The proteolytic 14 S complex isolated with ryanodine bound produces a channel upon reconstitution into planar lipid bilayers, and its activity is inhibited by neomycin. Our data are consistent with a model in which the ryanodine binding sites, the neomycin binding sites, and the channel-forming portion of the Ca2+ release channel are located between Arg-4475 and the carboxyl terminus.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369; Pedersen, Steen E./0000-0001-8755-8899	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001618] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41801] Funding Source: Medline; NINDS NIH HHS [NS01618] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo-128-6-3047; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; WYSKOVSKY W, 1990, EUR J BIOCHEM, V194, P549, DOI 10.1111/j.1432-1033.1990.tb15651.x; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	18	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8387	8393		10.1074/jbc.271.14.8387	http://dx.doi.org/10.1074/jbc.271.14.8387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626537	hybrid			2022-12-25	WOS:A1996UD60000077
J	Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S				Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S			Back-mutation of the v-Ets to the c-Ets carboxy-terminal amino acids in the P135(gag-myb-ets) results in chicken neuroretina cells transformation and loss of basic fibroblast growth factor responsiveness	ONCOGENE			English	Article						neuroretina; bFGF; ets; myb	AVIAN-MYELOBLASTOSIS VIRUS; LEUKEMIA-VIRUS; MYB ONCOGENE; DNA-BINDING; NUCLEOTIDE-SEQUENCE; ERYTHROID-CELLS; C-ETS-1 LOCUS; MYELOID CELLS; GENE FAMILY; E26 VIRUS	The v-Myb, v-Ets containing E26 retrovirus (called in this work E26ABC) induces the proliferation of chicken neuroretina (CNR) cells in minimal medium, strongly stimulated by basic Fibroblast Growth Factor (bFGF) which confers on them the ability to form colonies in soft agar. V-Ets differs from its cellular counterpart c-Ets-l by two point mutations and by the replacement of the 13 last C-terminal amino acids by 16 unrelated residues as a consequence of DNA segment inversion in the viral sequence. It has been documented that this different C-terminal sequence influences DNA binding activity and specificity. Replacement in E26ABC virus of the sequence encoding the 16 v-Ets last C-terminal amino acids by the sequence encoding the 13 c-Ets-l derived C-terminus (virus E26ABO), results in the production of a P135(gag-myb-ets) with modified biological properties on CNR cells. E26ABO infected CNR cells proliferate in minimal medium more efficiently than E26ABC, are unresponsive to bFGF and able to grow in soft agar. In contrast, CNR cells infected by viruses encoding Myb and Ets proteins either in the E26ABO or in the E26ABC configuration are bFGF responsive. Since Myb alone is sufficient to induce bFGF responsiveness on CNR cells, these results suggest that the c-Ets-l C-terminus interferes with the Myb activity of the E26ABO P135(gag-myb-ets) protein in CNR cells.	INST PASTEUR,CNRS EP56,F-59019 LILLE,FRANCE; INST PASTEUR,CNRS UA 1160,F-59019 LILLE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022	Aumercier, Marc/0000-0002-0370-3452				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frykberg L, 1988, Oncogene Res, V3, P313; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GARRIDO C, 1992, ONCOGENE, V8, P2713; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LI RP, 1989, ONCOGENE RES, V5, P137; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; QUEVA C, 1993, ONCOGENE, V8, P2511; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	49	0	0	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1449	1456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622861				2022-12-25	WOS:A1996UF07600009
J	Atkinson, EA; Ostergaard, H; Kane, K; Pinkoski, MJ; Caputo, A; Olszowy, MW; Bleackley, RC				Atkinson, EA; Ostergaard, H; Kane, K; Pinkoski, MJ; Caputo, A; Olszowy, MW; Bleackley, RC			A physical interaction between the cell death protein Fas and the tyrosine kinase p59(fynT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; T-LYMPHOCYTES; MICE; EXPRESSION; APOPTOSIS; ANTIGEN; SIGNALS; DOMAIN	The Fas antigen (Apol/CD95) is a transmembrane protein belonging to the nerve growth factor receptor family. It is expressed on a variety of cells, including activated T lymphocytes. Ligation of Fas with its natural ligand or with anti-Fas antibodies often results in the apoptotic death of the cell, making Fas an important mediator of down-regulating immune responses. The signal transduction pathways utilized by Fas are currently unknown, although tyrosine kinase activity has recently been strongly implicated. Here, we report that the tyrosine kinase p59(fyn) physically associates with Fas in Fas sensitive cells. In addition, we show that activated T lymphocytes from fyn knockout mice exhibit elevated lifespans and reduced apoptosis in vitro compared to their normal counterparts. Furthermore, activated T lymphocytes from the fyn- deficient mice are less sensitive to killing by both anti-Fas antibody and Fas-ligand cytotoxic T cells. These results suggest that p59(fyn) plays an important role in Fas signal transduction.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT IMMUNOL, EDMONTON, AB T6G 2H7, CANADA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	University of Alberta; University of Alberta; Washington University (WUSTL); Washington University (WUSTL)								ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CRISPE IN, 1994, IMMUNITY, V1, P347; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GARNER R, 1994, J IMMUNOL, V153, P5413; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HELGASON CD, 1993, EXP CELL RES, V206, P302, DOI 10.1006/excr.1993.1150; HENKART PA, 1994, CURR BIOL, V4, P923, DOI 10.1016/S0960-9822(00)00207-4; ITOH N, 1993, J BIOL CHEM, V268, P10932; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KIM MY, 1991, J BIOL CHEM, V266, P484; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WEISS A, 1995, NATURE, V377, P17, DOI 10.1038/377017a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5968	5971		10.1074/jbc.271.11.5968	http://dx.doi.org/10.1074/jbc.271.11.5968			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626376	hybrid			2022-12-25	WOS:A1996UA36300005
J	Chang, LF; Thompson, MA				Chang, LF; Thompson, MA			Activity of the distal positive element of the peripherin gene is dependent on proteins binding to an Ets-like recognition site and a novel inverted repeat site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; NERVE GROWTH-FACTOR; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTORS; DNA-BINDING; C-FOS; FUNCTIONAL-ANALYSIS; SILENCER ELEMENT; MAMMALIAN-CELLS; SCG10 GENE	The peripherin gene, encoding a neuron-specific intermediate filament protein, is transcriptionally induced when PC12 cells begin to terminally differentiate into neurons in response to nerve growth factor. Previously we identified two regulatory sequences of the peripherin gene: a proximal negative element (centered at -173), which prevents peripherin expression in undifferentiated PC12 cells, and a distal positive region (-2660 to -2308) necessary for full induction of peripherin in differentiated PC12 cells (Thompson, M., Lee, E. Lawe, D., Gizang-Ginsberg, E., and Ziff, E. (1992) Mol. Cell, Biol, 12, 2501-2513). Here we define a distal positive element (DPE, -2445 to -2337) within the distal positive region. Methylation interference footprinting of the DPE identified DNA-protein contact points at a novel inverted repeat sequence (AACCACTGGTT)and an Ets-like recognition sequence (CAGGAG). Functional analysis using site-directed mutagenesis demonstrates that both sites are necessary for the activity of the DPE. In addition, ternary complex formation at the DPE is dependent on both sites. Antibody competition assays confirm that an Ets family member participates in the DNA-protein complex. We have indirect evidence that the inverted repeat binding protein and the Ets related protein interact directly with each other. Finally, we demonstrate that the DPE is constitutively active and that neuron specific regulation of peripherin expression may be due to interaction with distal and proximal negative regulatory elements.	VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NIMH NIH HHS [MH-19732] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BALDWIN AS, 1987, CURRENT PROTOCOLS MO; BELECKYADAMS T, 1993, J NEUROSCI, V13, P5056, DOI 10.1523/JNEUROSCI.13-12-05056.1993; BRODY BA, 1989, J NEUROSCI, V9, P2391; CHING GY, 1991, J BIOL CHEM, V266, P19459; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; ESCURAT M, 1990, J NEUROSCI, V10, P764; FLUG F, 1987, J BIOL CHEM, V262, P6373; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JBA, 1994, CELL, V77, P317, DOI 10.1016/0092-8674(94)90145-7; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; Liem RKH, 1990, CURR OPIN CELL BIOL, V2, P86, DOI 10.1016/S0955-0674(05)80036-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MANIATIS T, 1989, MOL CLONING, V2; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; RAO VN, 1992, ONCOGENE, V7, P2335; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	64	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6467	6475		10.1074/jbc.271.11.6467	http://dx.doi.org/10.1074/jbc.271.11.6467			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626448				2022-12-25	WOS:A1996UA36300077
J	Chen, Y; Chafin, D; Price, DH; Greenleaf, AL				Chen, Y; Chafin, D; Price, DH; Greenleaf, AL			Drosophila RNA polymerase II mutants that affect transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-SII; DMS-II; MELANOGASTER; INVITRO; IDENTIFICATION; TERMINATION; TEMPLATE; COMPLEX; LOCUS; TFIIS	We have examined the properties of two Drosophila RNA polymerase II mutants, C4 and S1, during elongation, pyrophosphorolysis, and DmS-II-stimulated transcript cleavage. The C4 and S1 mutants contain a single amino acid substitution in the largest and second largest subunits, respectively. Compared with wild type, C4 had a lower elongation rate and was less efficient at reading through intrinsic elongation blocks. S1 had a higher elongation rate than wild type and was more efficient at reading through the same blocks. During elongation, C4 and wild type responded similarly to DmS-II and NH4+, whereas the S1 mutant was less responsive to both. Differences between the two mutants also appeared during DmS-II-mediated transcript cleavage and pyrophosphorolysis. During extended pyrophosphorolysis, S1 polymerase was fastest and S1 polymerase was slowest at generating the final pattern of shortened transcripts. S1 and wild type were equal in the rate of extended DmS-II-mediated transcript cleavage, and C4 was slower. Our results suggest that the S1 mutation increases the time spent by the polymerase in elongation competent mode and that the C4 mutation may affect the movement of the polymerase.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa	Chen, Y (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X				ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CHEN Y, 1995, THESIS DUKE U; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; COULTER DE, 1982, J BIOL CHEM, V257, P1945; COULTER DE, 1985, J BIOL CHEM, V260, P1390; GREENLEAF AL, 1979, CELL, V18, P613, DOI 10.1016/0092-8674(79)90116-8; GREENLEAF AL, 1980, CELL, V21, P785, DOI 10.1016/0092-8674(80)90441-9; GUO HL, 1993, J BIOL CHEM, V268, P18762; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KIM WJ, 1994, J MOL BIOL, V244, P13, DOI 10.1006/jmbi.1994.1700; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MORTIN M, 1990, P NATL ACAD SCI USA, V887, P4864; MORTIN MA, 1988, GENETICS, V119, P863; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	30	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5993	5999		10.1074/jbc.271.11.5993	http://dx.doi.org/10.1074/jbc.271.11.5993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626382	hybrid			2022-12-25	WOS:A1996UA36300011
J	Chu, YF; Solski, PA; KhosraviFar, R; Der, CJ; Kelly, K				Chu, YF; Solski, PA; KhosraviFar, R; Der, CJ; Kelly, K			The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TYROSINE PHOSPHATASE; T-CELLS	Mitogen-activated protein (MAP) kinases can be grouped into three structural families, ERK, JNK, and p38, which are thought to carry out unique functions within cells. We demonstrate that ERK, JNK, and p38 are activated by distinct combinations of stimuli in T cells that simulate full or partial activation through the T cell receptor. These kinases are regulated by reversible phosphorylation on Tyr and Thr, and the dual specific phosphatases PAC1 and MKP-1 previously have been implicated in the in vivo inactivation of ERK or of ERK and JNK respectively. Here we characterize a new MAP kinase phosphatase, MKP-2, that is induced in human peripheral blood T cells with phorbol 12-myristate 13-acetate and is expressed in a variety of nonhematopoietic tissues as well. We show that the in vivo substrate specificities of individual phosphatases are unique, PAC1, MKP-2, and MKP-1 recognize ERK and p38, ERK and JNK, and ERK, p38, and JNK, respectively. Thus, individual MAP kinase phosphatases can differentially regulate the potential for cross-talk between the various MAP kinase pathways. A hyperactive allele of ERK2 (D319N), analogous to the Drosophila sevenmaker gain-of-function mutation, has significantly reduced sensitivity to all three MAP kinase phosphatases in vivo.	NCI,PATHOL LAB,NIH,BETHESDA,MD 20892; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHABRE O, 1995, ENDOCRINOLOGY, V136, P956, DOI 10.1210/en.136.3.956; CHARLES CH, 1992, ONCOGENE, V7, P187; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; KELLY K, 1992, ONCOGENE, V7, P1463; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YI HF, 1995, GENOMICS, V28, P92, DOI 10.1006/geno.1995.1110; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	34	384	390	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6497	6501		10.1074/jbc.271.11.6497	http://dx.doi.org/10.1074/jbc.271.11.6497			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626452	Green Published, hybrid			2022-12-25	WOS:A1996UA36300081
J	Kalkhoven, E; Wissink, S; vanderSaag, PT; vanderBurg, B				Kalkhoven, E; Wissink, S; vanderSaag, PT; vanderBurg, B			Negative interaction between the RelA(p65) subunit of NF-kappa B and the progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; GLUCOCORTICOID RECEPTOR; P65 SUBUNIT; TRANSCRIPTION FACTORS; CELLULAR PROLIFERATION; NUCLEAR RECEPTORS; MESSENGER-RNA; C-JUN; FOS; ACTIVATION	Interactions between transcription factors are am important means of regulating gene transcription. The present study describes the mutual repression of two transcription factors, the RelA(p65) subunit of NF-kappa B and the progesterone receptor (PR). This trans-repression is shown to occur independent of PR isoform, reporter construct, or cell type used. Together with the demonstration of an interaction between PR and RelA in vitro, these findings suggest that the mutual repression is due to a direct interaction between these proteins. Furthermore, activation of NF-kappa B by tumor necrosis factor-alpha also results in repression of PR, while PR is able to repress tumor necrosis factor-alpha-induced NF-kappa B activity. Since NF-kappa B-regulating cytokine receptors are expressed in progesterone target tissues, like breast and endometrium, the mutual repression of PR and RelA could play an important role in a wide variety of physiological processes in these tissues, including maintenance of pregnancy, immunosuppression, and tumorigenesis.	NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHALBOS D, 1986, NUCLEIC ACIDS RES, V14, P965, DOI 10.1093/nar/14.2.965; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; INOUE T, 1994, HUM REPROD, V9, P2411, DOI 10.1093/oxfordjournals.humrep.a138460; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; ITO A, 1994, BIOCHEM J, V301, P183, DOI 10.1042/bj3010183; JIKIHARA H, 1994, ENDOCRINOLOGY, V134, P353, DOI 10.1210/en.134.1.353; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KELLY RW, 1994, ENDOCR REV, V15, P684, DOI 10.1210/er.15.5.684; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIITERI PK, 1982, BIOL REPROD, V26, P1, DOI 10.1095/biolreprod26.1.1; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TABIBZADEH S, 1991, ENDOCR REV, V12, P272, DOI 10.1210/edrv-12-3-272; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	64	291	298	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6217	6224		10.1074/jbc.271.11.6217	http://dx.doi.org/10.1074/jbc.271.11.6217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626413	hybrid			2022-12-25	WOS:A1996UA36300042
J	Mao, QK; Fulmer, P; Li, WB; DeRose, EF; Petering, DH				Mao, QK; Fulmer, P; Li, WB; DeRose, EF; Petering, DH			Different conformations and site selectivity of HO2-Co(III)-bleomycin A(2) and Co(III)-bleomycin A(2) bound to DNA oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; BLEOMYCIN; BINDING; NMR; SPECTROSCOPY; DIOXYGEN; COMPLEX; CO(II)BLEOMYCIN; MECHANISM; EXCHANGE	Conformational properties of HO2--Co(III)-bleomycin A(2) (Form I) and Co(III)-bleomycin (Form II) bound to DNA oligomers offering either principal cleavage site for the drug, d(GGAAGCTTCC)(2) or d(AAACGTTT)(2), have been studied by MMR methods. Form I binds in slow exchange to these oligomers. It retains most of its solution nuclear Overhauser effects (NOEs) upon binding to either oligomer. Pyrimidinyl methyl protons from the metal domain of the drug make an NOE connection with a G5 2-amino proton on DNA. The bithiazole intercalates between base pairs involving either C6 and T7 or T6 and T7 of the two DNA molecules, according to NOE connections between the bithiazole protons and protons from these bases and changes in the positions of their chemical shifts. Form II also retains most of its solution NOEs upon association with the first oligomer. However, in contrast to Form I it binds to DNA in fast exchange on the NMR time scale over the temperature range of 5-35 degrees C and does not break the degeneracy of the DNA proton chemical shifts. No intermolecular NOEs between Form II and the 10-mer have been detected. Likewise, the major perturbation in chemical shift of the histidine H2 and guanine G5 protons seen in Form I-DNA adducts is absent in Form II-DNA. The association constant of Form II with d(GGAAGCTTCC)(2) in 20 mM HEPES buffer at pH 7.4 and 25 degrees C is 1.7 x 10(5) M(-1), and 1.0 mol of Form II bind per mol of 10-mer.	UNIV WISCONSIN, DEPT CHEM, MILWAUKEE, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee					PHS HHS [22184] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKKERMAN MAJ, 1988, EUR J BIOCHEM, V173, P211, DOI 10.1111/j.1432-1033.1988.tb13987.x; ALBERTINI JP, 1984, BIOCHEMISTRY-US, V23, P47, DOI 10.1021/bi00296a008; ANTHOLINE WE, 1981, P NATL ACAD SCI-BIOL, V78, P7517, DOI 10.1073/pnas.78.12.7517; ANTHOLINE WE, 1979, BIOCHEM BIOPH RES CO, V91, P528, DOI 10.1016/0006-291X(79)91554-7; BAX A, 1989, METHOD ENZYMOL, V176, P151; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; CHIKIRA M, 1989, J BIOL CHEM, V264, P21478; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2178, DOI 10.1021/bi00431a032; FULMER P, 1994, BIOCHEMISTRY-US, V33, P5319, DOI 10.1021/bi00183a040; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; LEUPIN W, 1986, BIOCHEMISTRY-US, V25, P5902, DOI 10.1021/bi00368a010; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANDERVILLE RA, 1995, J AM CHEM SOC, V117, P7891, DOI 10.1021/ja00135a007; MANDERVILLE RA, 1994, J AM CHEM SOC, V116, P10851, DOI 10.1021/ja00102a087; MAO QK, 1995, FASEB J, V9, pA1349; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; McLean M J, 1989, J Mol Recognit, V1, P184, DOI 10.1002/jmr.300010407; *MILL CORP, 1989, MILL CYCL PLUS DNA S; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; PETERING DH, 1990, CHEM-BIOL INTERACT, V73, P133, DOI 10.1016/0009-2797(90)90001-4; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P665, DOI 10.1021/bi00506a034; ROY SN, 1981, CANCER RES, V41, P4471; SAM JW, 1994, J AM CHEM SOC, V116, P5250, DOI 10.1021/ja00091a032; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; WU W, 1994, J AM CHEM SOC, V116, P10843, DOI 10.1021/ja00102a083; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P269; XU RX, 1994, BIOCHEMISTRY-US, V33, P907, DOI 10.1021/bi00170a009; XU RX, 1992, J BIOL CHEM, V267, P944; XU RX, 1992, J BIOL CHEM, V267, P950	35	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6185	6191		10.1074/jbc.271.11.6185	http://dx.doi.org/10.1074/jbc.271.11.6185			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626408	hybrid			2022-12-25	WOS:A1996UA36300037
J	Whitley, P; Nilsson, I; vonHeijne, G				Whitley, P; Nilsson, I; vonHeijne, G			A nascent secretory protein may traverse the ribosome endoplasmic reticulum translocase complex as an extended chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT-CHAINS; MEMBRANE; SIGNAL; SITE; ENVIRONMENT; MUTAGENESIS; TRANSLATION; SEQUENCES; CHANNEL; EXIT	We have measured the minimum number of residues in a translocating polypeptide required to bridge the distance between the P-site in endoplasmic reticulum-bound ribosomes and the lumenally disposed active site of the oligosaccharyl transferase. The results suggest that a nascent chain may traverse the ribosome/translocase complex in a largely extended conformation, and that hydrophobic stop-transfer segments have a more compact, possibly alpha-helical conformation in the translocase.	UNIV STOCKHOLM, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Stockholm University			Nilsson, IngMarie/H-2887-2012; von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROIWA T, 1993, J BIOCHEM-TOKYO, V114, P541, DOI 10.1093/oxfordjournals.jbchem.a124213; LILJESTROM P, 1991, J VIROL, V65, P147; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MILLIGAN RA, 1986, NATURE, V319, P693, DOI 10.1038/319693a0; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NILSSON I, 1993, J BIOL CHEM, V268, P5798; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; YONATH A, 1989, TRENDS BIOCHEM SCI, V14, P329, DOI 10.1016/0968-0004(89)90166-7; [No title captured]	31	128	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6241	6244		10.1074/jbc.271.11.6241	http://dx.doi.org/10.1074/jbc.271.11.6241			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626416	hybrid			2022-12-25	WOS:A1996UA36300045
J	Xiao, CY; Hubner, S; Elliott, RM; Caon, A; Jans, DA				Xiao, CY; Hubner, S; Elliott, RM; Caon, A; Jans, DA			A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site of simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; LATERAL MOBILITY; TRANSPORT; RECEPTOR; TRANSCRIPTION; TRANSLOCATION; LOCALIZATION; V2-RECEPTOR	The regulation of nuclear protein transport by phosphorylation plays a central role in gene expression in eukaryotic cells. We previously showed that nuclear import of SV40 large tumor antigen (T-ag) fusion proteins is regulated by the CcN motif, comprising phosphorylation sites for casein kinase II and the cyclin-dependent kinase cdc2, together with the nuclear localization signal. Regulation of nuclear uptake by CcN motif kinase sites also holds true for the yeast transcription factor SW15 and the Xenopus nuclear phosphoprotein nucleoplasmin. To test directly whether a kinase site other than those of the CcN motif could regulate nuclear import of T-ag, the CcN motif casein kinase II site, which markedly increases the rate of T-ag nuclear import, was replaced by a consensus site for the cAMP-dependent protein kinase (Ph-A) using site-directed mutagenesis. The resultant fusion protein could be specifically phosphorylated by PK-A in vitro and in cell extracts. Nuclear import of the fluorescently labeled protein was analyzed in the HTC rat hepatoma cell line both in vivo (microinjected cells) and in vitro (mechanically perforated cells) in the presence and the absence of cAMP and/or PK-A catalytic subunit using confocal laser scanning microscopy. In vitro PK-A-prephosphorylated protein was also tested. All results indicated that the rate of nuclear import was increased by phosphorylation at the PK-A site (2-5-fold), demonstrating that kinases other than those of the CcN motif can regulate nuclear import in response to stimulatory signals. The phosphorylation-regulated nuclear localization signal derived here represents an important first step toward developing a signal conferring inducible nuclear targeting of molecules of interest.	AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOLEC BIOL, NUCL SIGNALLING LAB, CANBERRA, ACT 2601, AUSTRALIA; MAX PLANCK INST BIOPHYS, D-60528 FRANKFURT, GERMANY	Australian National University; John Curtin School of Medical Research; Max Planck Society								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; JANS DA, 1987, EXP CELL RES, V172, P76, DOI 10.1016/0014-4827(87)90094-2; JANS DA, 1989, EMBO J, V8, P2481, DOI 10.1002/j.1460-2075.1989.tb08384.x; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JANS DA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P271, DOI 10.1016/0304-4157(92)90001-Q; JANS DA, 1995, AMINO ACIDS, V9, P93, DOI 10.1007/BF00805831; JANS DA, 1996, IN PRESS PHYSL REV; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROSENKRANZ AA, 1992, EXP CELL RES, V199, P323, DOI 10.1016/0014-4827(92)90441-A; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VANCUROVA I, 1995, J CELL SCI, V108, P779; VANDROMME M, 1994, J CELL SCI, V107, P613	34	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6451	6457		10.1074/jbc.271.11.6451	http://dx.doi.org/10.1074/jbc.271.11.6451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626446	hybrid			2022-12-25	WOS:A1996UA36300075
J	Chi, JH; Roos, J; Dean, N				Chi, JH; Roos, J; Dean, N			The OST4 gene of Saccharomyces cerevisiae encodes an unusually small protein required for normal levels of oligosaccharyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE-ACTIVITY; YEAST MUTANTS; GLYCOSYLATION; DNA; BIOSYNTHESIS; INHIBITORS; CELLS	Sodium vanadate is an effective drug for the enrichment of yeast mutants defective in glycosylation reactions that are carried out in the Golgi complex (1). We have isolated vanadate-resistant, hygromycin B-sensitive mutants that act at very early steps of N-linked glycosylation, occurring in the endoplasmic reticulum, Here we describe the phenotypic characterization of ost4, a vanadate-resistant mutant that is defective in oligosaccharyltransferase (OTase) activity both in vivo and in vitro. The OST4 open reading frame is unusual in that it predicts a protein of only 36 amino acids, We demonstrate that the OST4 gene product is, in fact, an unusually small protein of approximately 3.6 kDa, predicted to lie almost entirely in the hydrophobic environment of the membrane. Strains carrying a disruption of the OST4 gene are viable but grow poorly at 25 degrees C. The null mutant is inviable at 37 degrees C, demonstrating that the OST4 gene product is essential for growth at high temperatures. Deletion of the OST4 gene greatly diminishes OTase activity but does not abolish it. These results suggest that the OST4 gene encodes a subunit or accessory component of OTase that is essential at high temperature.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033185, R01GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANIKENNULAT C, 1990, MOL CELL BIOL, V10, P898, DOI 10.1128/MCB.10.3.898; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; POSTER JB, 1996, IN PRESS J BIOL CHEM; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; YANNISCHPERRON C, 1985, GENE, V33, P103; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	34	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3132	3140		10.1074/jbc.271.6.3132	http://dx.doi.org/10.1074/jbc.271.6.3132			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621712	hybrid			2022-12-25	WOS:A1996TU69100041
J	CzyzykKrzeska, MF; Beresh, JE				CzyzykKrzeska, MF; Beresh, JE			Characterization of the hypoxia-inducible protein binding site within the pyrimidine-rich tract in the 3'-untranslated region of the tyrosine hydroxylase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; POLYPYRIMIDINE TRACT; SEQUENCE; ELEMENT; INTRONS	Reduced tension of O-2 slows the degradation rate of mRNA for tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis, in the pheochromocytoma (PC12) clonal cell line, The observed increase in half-life (30 h versus 10 h) correlates with enhanced binding of a 66-kDa protein (hypoxia inducible protein) to the pyrimidine-rich tract located between bases 1552-1578 in the S'-untranslated region of TH mRNA (hypoxia-inducible protein binding site (HIPBS)), The present study investigates the protein binding site within the 27-base HIPBS, first by using specific cleavages of HIPBS and its flanking sequences with antisense oligodeoxynucleotides and RNase H and then by using mutational analysis of the binding properties. We found that the 27-base HIPBS oligoribonucleotide was sufficient to bind the protein in vitro in a hypoxia-stimulated manner. We further identified the optimal hypoxia-inducible protein binding site that is represented by the motif (U/C)(C/U)CCCU, where the core binding site is indicated by the underlined cytidines, Substitutions of either one of the cytidines with purine or uridine abolished the protein binding, The mutations within HIPBS, which partially reduced binding, did not prevent stimulation of protein binding for extracts from hypoxic cells. The hypoxia-induced increase in complex formation was proportional to the strength of binding using proteins from normoxic cells, The HIPBS element is conserved in TH mRNAs derived from different species.			CzyzykKrzeska, MF (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC & CELLULAR PHYSIOL,POB 670576,CINCINNATI,OH 45267, USA.				NHLBI NIH HHS [HL 51078] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051078] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; FEINSILVER SH, 1987, BIOCHIM BIOPHYS ACTA, V928, P56, DOI 10.1016/0167-4889(87)90085-1; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; KASPAR RL, 1992, J BIOL CHEM, V267, P508; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; WATKINS BA, 1993, BIOTECHNIQUES, V15, P700; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHU H, 1996, IN PRESS AM J PHYSL	24	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3293	3299		10.1074/jbc.271.6.3293	http://dx.doi.org/10.1074/jbc.271.6.3293			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621733	hybrid			2022-12-25	WOS:A1996TU69100062
J	Shyur, LF; Aleshin, AE; Honzatko, RB; Fromm, HJ				Shyur, LF; Aleshin, AE; Honzatko, RB; Fromm, HJ			Site-directed mutagenesis of residues at subunit interfaces of porcine fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 2,6-BISPHOSPHATE; 1,6-BISPHOSPHATASE; BISPHOSPHATASE; BINDING; AMP; INHIBITION; MECHANISM; FORM	Mutation of Arg-15, Glu-19, Arg-22, and Thr-27 of porcine liver fructose-1,6-bisphosphatase was carried out by site-directed mutagenesis. These residues are conserved in all known primary sequences of mammalian fructose-1,6-bisphosphatase. On the basis of the crystal structure of the enzyme, Arg-15, Glu-19, and Arg-22 are located at the interface of the two dimers (C1-C2 and C3-C4), and Thr-27 is in the AMP binding site. The wildtype and mutant forms of the enzyme were purified to homogeneity and characterized by initial rate kinetics and circular dichroism (CD) spectrometry. No discernible differences were observed between the secondary structures of the wild-type and mutant forms of fructose-1,6 bisphosphatase on the basis of CD data. Kinetic analyses revealed similar k(cat) values for mutants R15A, E19Q, R22K, and T27A of fructose-1,6-bisphosphatase; however, a 2-fold increase of k(cat) was observed with R22M compared with that of the wild-type enzyme. Small changes in K-m values for fructose-1,6-bisphosphate were found in the five mutants, 4-6-fold decreases in K-i values for fructose 2,6-bisphosphate and 5-9-fold decreases in the binding affinity of Mg2+ relative to the wild-type enzyme were exhibited by R15A and E19Q. No alteration of Mg2+ cooperativity was found in the five mutants. Significant changes in R(i) values for AMP were obtained in the case of R22K (30 fold) and T27A (1300-fold) with a Hill coefficient of 2.0. Replacement of Arg-22 with methionine, however, caused the total loss of AMP cooperativity without changing AMP affinity. Modeling of the mutant structures was undertaken in an attempt 60 define the functional role of Arg-22. These studies link specific interactions between subunits in fructose-1,6-bisphosphatase to observed properties of cooperativity.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHEN LR, 1993, ARCH BIOCHEM BIOPHYS, V307, P350, DOI 10.1006/abbi.1993.1599; CHEN M, 1994, J BIOL CHEM, V269, P5554; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELMAGHRABI MR, 1992, J BIOL CHEM, V267, P6526; HERS HG, 1982, BIOCHEM J, V206, P1; KE H, 1989, J MOL BIOL, V212, P513; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KITAJIMA S, 1983, J BIOL CHEM, V258, P7352; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LIANG JY, 1992, P NATL ACAD SCI USA, V89, P2404, DOI 10.1073/pnas.89.6.2404; LIU F, 1988, J BIOL CHEM, V263, P10035; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RUDOLPH FB, 1971, J BIOL CHEM, V246, P6611; RUDOLPH FB, 1973, J THEOR BIOL, V39, P363, DOI 10.1016/0022-5193(73)90105-7; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHYUR LF, 1995, ARCH BIOCHEM BIOPHYS, V319, P123, DOI 10.1006/abbi.1995.1273; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; SOLA MM, 1993, INT J BIOCHEM, V25, P1963, DOI 10.1016/0020-711X(88)90332-1; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TASHIMA Y, 1975, J BIOCHEM, V78, P1161, DOI 10.1093/oxfordjournals.jbchem.a131012; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Ulm E H, 1975, Methods Enzymol, V42, P369; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P2861; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG R, 1995, J BIOL CHEM, V270, P54, DOI 10.1074/jbc.270.1.54; ZHANG RL, 1995, BIOCHEMISTRY-US, V34, P8190, DOI 10.1021/bi00025a026; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	38	15	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3005	3010		10.1074/jbc.271.6.3005	http://dx.doi.org/10.1074/jbc.271.6.3005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621693	hybrid			2022-12-25	WOS:A1996TU69100022
J	Sowden, M; Hamm, JK; Smith, HC				Sowden, M; Hamm, JK; Smith, HC			Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B MESSENGER-RNA; APOLIPOPROTEIN-B; INVITRO; LIPOPROTEINS; PROTEIN; REQUIREMENTS; INTESTINE; CELLS; SITE	Apolipoprotein B (apoB) RNA editing involves site-specific deamination of a cytidine to a uridine. A mooring sequence, a spacer region, and a regulator region are components of the apoB RNA editing motif of which only the mooring sequence is both necessary and sufficient for editosome assembly and editing. The catalytic component of the editosome is APOBEC-1. In rat hepatoma, stable cell lines, overexpression of APOBEC-1 resulted in 3-6-fold stimulation of the editing efficiency on either rat endogenous apoB RNA or transiently expressed human apoB RNA, In these cell lines, cytidines in addition to the one at the wild type site were edited, The occurrence and efficiency of this ''promiscuous'' editing increased with increasing expression of APOBEC-1, Promiscuous editing was restricted to cytidines 5' of the mooring sequence and only occurred on RNAs that had been edited at the wild type site, Moreover, RNAs with mutant editing motifs supported high efficiency but low fidelity editing in the presence of high levels of APOBEC-1. This study demonstrates that overexpression of APOBEC-1 can increase the efficiency of site specific editing but can also result in promiscuous editing.	UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester				Smith, Harold/0000-0001-6257-6791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK R0143739-04] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; [Anonymous], 1994, PROGRAM MANUAL WISCO; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BARNES C, 1993, BIOCHEM BIOPH RES CO, V197, P1410, DOI 10.1006/bbrc.1993.2634; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V19, P105, DOI 10.1016/0968-0004(94)90200-3; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Scott James, 1994, Current Opinion in Lipidology, V5, P87, DOI 10.1097/00041433-199404000-00004; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YAO ZM, 1992, J BIOL CHEM, V267, P1175; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	41	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3011	3017		10.1074/jbc.271.6.3011	http://dx.doi.org/10.1074/jbc.271.6.3011			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621694	hybrid			2022-12-25	WOS:A1996TU69100023
J	Takaha, T; Yanase, M; Takata, H; Okada, S; Smith, SM				Takaha, T; Yanase, M; Takata, H; Okada, S; Smith, SM			Potato D-enzyme catalyzes the cyclization of amylose to produce cycloamylose, a novel cyclic glucan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIPARALLEL DOUBLE HELIX; MOLECULAR-CLONING; ARABIDOPSIS LEAF; STARCH; WATER; 4-ALPHA-GLUCANOTRANSFERASE; GLUCOSE; GENES	Potato D-enzyme was purified from recombinant Escherichia coli, and its action on synthetic amylose (average M(r) of 320,000) was analyzed. D-enzyme treatment resulted in a decrease in the ability of the amylose to form a blue complex with iodine. Analysis of the products indicated that the enzyme catalyzes an intramolecular transglycosylation reaction on amylose to produce cyclic alpha-1,4-glucan (cycloamylose). Confirmation of the cyclic structure was achieved by demonstrating the absence of reducing and nonreducing ends, resistance to hydrolysis by glucoamylase (an exoamylase), and by ''time of flight'' mass spectrometry. The degree of polymerization of cycloamylose products was determined by time of flight mass spectrometry analysis and by highperformance anion-exchange chromatography following partial acid hydrolysis of purified cycloamylose molecules and was found to range from 17 to several hundred. The yield of cycloamylose increased with time and reached >95%, D-enzyme did not act upon purified cycloamylose, but if glucose was added as an acceptor molecule, smaller cyclic and linear molecules were produced. The mechanism of the cyclization reaction, the possible role of the enzyme in starch metabolism, and the potential applications for cycloamylose are discussed.	UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Takaha, T (corresponding author), EZAKI GLICO CO LTD, BIOCHEM RES LAB, NISHIYODOGAWA KU, UTAJIMA, OSAKA 555, JAPAN.		Smith, Steven M/G-7183-2015; Smith, Steven/HDM-9496-2022	Smith, Steven M/0000-0001-5661-9994; 				EISENHABER F, 1992, BIOPOLYMERS, V32, P1643, DOI 10.1002/bip.360321207; FRENCH D, 1957, ADV CARBOHYD CHEM, V12, P189; FRENCH D, 1965, ARCH BIOCHEM BIOPHYS, V111, P153, DOI 10.1016/0003-9861(65)90334-6; HINRICHS W, 1987, SCIENCE, V238, P205, DOI 10.1126/science.238.4824.205; HINRICHS W, 1990, J AM CHEM SOC, V112, P2789, DOI 10.1021/ja00163a048; HIZUKURI S, 1978, CARBOHYD RES, V63, P261, DOI 10.1016/S0008-6215(00)80950-7; JONES G, 1969, CARBOHYD RES, V9, P483, DOI 10.1016/S0008-6215(00)80033-6; KAINUMA K, 1972, BIOPOLYMERS, V11, P2241, DOI 10.1002/bip.1972.360111105; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Lee E. Y. C., 1971, ENZYMES, V5, P191; LIN TP, 1988, PLANT PHYSIOL, V86, P251, DOI 10.1104/pp.86.1.251; LIN TP, 1988, PLANT PHYSIOL, V86, P260, DOI 10.1104/pp.86.1.260; MANOR PC, 1972, NATURE, V237, P392, DOI 10.1038/237392a0; MIWA I, 1972, CLIN CHIM ACTA, V37, P538, DOI 10.1016/0009-8981(72)90483-4; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; PEAT S, 1956, J CHEM SOC, P44, DOI 10.1039/jr9560000044; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; STARNES RL, 1990, CEREAL FOOD WORLD, V35, P1094; SUNDARARAJAN PR, 1970, CARBOHYD RES, V13, P351, DOI 10.1016/S0008-6215(00)80592-3; TAKAHA T, 1993, J BIOL CHEM, V268, P1391; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; VISSER RGF, 1989, PLANT SCI, V64, P185, DOI 10.1016/0168-9452(89)90023-X; YOSHIO N, 1986, J JPN SOC STARCH SCI, V33, P244	23	161	169	5	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2902	2908		10.1074/jbc.271.6.2902	http://dx.doi.org/10.1074/jbc.271.6.2902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621678	hybrid			2022-12-25	WOS:A1996TU69100007
J	Popoff, MR; ChavesOlarte, E; Lemichez, E; vonEichelStreiber, C; Thelestam, M; Chardin, P; Cussac, D; Antonny, B; Chavrier, P; Flatau, G; Giry, M; deGunzburg, J; Boquet, P				Popoff, MR; ChavesOlarte, E; Lemichez, E; vonEichelStreiber, C; Thelestam, M; Chardin, P; Cussac, D; Antonny, B; Chavrier, P; Flatau, G; Giry, M; deGunzburg, J; Boquet, P			Ras, Rap, and Rac small GTP-binding proteins are targets for Clostridium sordellii lethal toxin glucosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFICILE; HYDROLYSIS; P21	Lethal toxin (LT) from Clostridium sordellii is one of the high molecular mass clostridial cytotoxins. On cultured cells, it causes a rounding of cell bodies and a disruption of actin stress fibers. We demonstrate that LT is a glucosyltransferase that uses UDP-Glc as a cofactor to covalently modify 21-kDa proteins both in vitro and in vivo. LT glucosylates Ras, Rap, and Rac. In Ras, threonine at position 35 was identified as the target amino acid glucosylated by LT. Other related members of the Ras GTPase superfamily, including RhoA, Cdc42, and Rab6, were not modified by LT. Incubation of serum-starved Swiss 3T3 cells with LT prevents the epidermal growth factor-induced phosphorylation of mitogen-activated protein kinases ERK1 and ERK2, indicating that the toxin blocks Ras function in vivo. We also demonstrate that LT acts inside the cell and that the glucosylation reaction is required to observe its dramatic effect on cell morphology. LT is thus a powerful tool to inhibit Ras function in vivo.	INST PASTEUR, UNITE TOXINES MICROBIENNES, F-75724 PARIS 15, FRANCE; KAROLINSKA INST, MICROBIOL & TUMORBIOL CTR, S-17177 STOCKHOLM, SWEDEN; CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; FAC MED NICE, INSERM, U452, F-06107 NICE 2, FRANCE; CTR IMMUNOL MARSEILLES LUMINY, F-13286 MARSEILLE, FRANCE; UNIV MAINZ, INST MED MIKROBIOL & HYG VERFUGUNGSGEBAUDE FORSCH, D-55101 MAINZ, GERMANY; INSERM, U248, F-75010 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm)			Antonny, Bruno/ABH-7434-2020; CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010; Lemichez, Emmanuel/G-3559-2013	Antonny, Bruno/0000-0002-9166-8668; CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Lemichez, Emmanuel/0000-0001-9080-7761				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; ARSECULERATNE SN, 1969, J MED MICROBIOL, V2, P37, DOI 10.1099/00222615-2-1-37; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; JOHN J, 1993, J BIOL CHEM, V268, P923; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MARTINEZ RD, 1992, J MED MICROBIOL, V36, P30, DOI 10.1099/00222615-36-1-30; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SANDVIG K, 1992, BIOCHEM SOC T, V20, P724, DOI 10.1042/bst0200724; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	29	177	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10217	10224		10.1074/jbc.271.17.10217	http://dx.doi.org/10.1074/jbc.271.17.10217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626586	hybrid			2022-12-25	WOS:A1996UG25700058
J	Wu, XJ; Zhou, MY; Huang, LS; Wetterau, J; Ginsberg, HN				Wu, XJ; Zhou, MY; Huang, LS; Wetterau, J; Ginsberg, HN			Demonstration of a physical interaction between microsomal triglyceride transfer protein and apolipoprotein B during the assembly of ApoB-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEP G2 CELLS; INTRACELLULAR DEGRADATION; COMBINED HYPERLIPIDEMIA; OLEIC-ACID; SECRETION; LIVER; OLEATE; ABETALIPOPROTEINEMIA; STIMULATION	Microsomal triglyceride (TG) transfer protein (MTP) is an endoplasmic reticulum lumenal protein consisting of a 97-kDa subunit and protein disulfide isomerase. It is believed that MTP delivers TG to nascent apoB molecules during the assembly of lipoprotein particles in the secretory pathway. Although in vitro studies have established the mechanism of TG transfer between donor and acceptor membranes, the mechanism of action of MTP in vivo remains unknown. The present studies were undertaken to examine whether or not the transfer of TG to nascent apoB in the endoplasmic reticulum involves the physical interaction between MTP and apoB. HepG2 cells were labeled with [H-3]leucine, lysed in a nondenaturing homogenizing buffer, and immunoprecipitated with anti-MTP antiserum. We found that labeled apoB and protein disulfide isomerase were co-immunoprecipitated by this procedure. In addition, we were able to detect the 97-kDa subunit of MTP in these immunoprecipitates by immunoblot. The association of MTP and apoB, as assessed in pulse-labeled cells by co-immunoprecipitation, was transient; apoB was prominent on fluorography at 10 min of chase but minimal thereafter. Oleic acid treatment, which protects apoB from rapid intracellular degradation by increasing TG availability, increased both the degree and the duration of association between MTP and apoB dramatically. Inhibition of TG synthesis by Triacsin D, on the other hand, significantly decreased the MTP-apoB binding. N-Acetyl-leucyl-leucyl-norleucinal, a cysteine protease inhibitor, which directly protects apoB from rapid intracellular degradation but does not affect TG synthesis, increased the interaction between MTP and apoB only slightly, although it did prolong it. Our results suggest that direct interaction between MTP and apoB occurs during the assembly of apoB-containing lipoproteins in HepG2 cells.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543	Columbia University; Bristol-Myers Squibb					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36000, HL21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ARAD Y, 1990, J LIPID RES, V31, P567; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; DASHTI N, 1989, J LIPID RES, V30, P1365; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELOVSON J, 1994, CIRCULATION, V90, P185; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KISSEBAH AH, 1981, METABOLISM, V30, P856, DOI 10.1016/0026-0495(81)90064-0; KROON PA, 1986, P NATL ACAD SCI USA, V83, P5071, DOI 10.1073/pnas.83.14.5071; KUSWAHA RS, 1991, J LIPID RES, V32, P1929; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; THRIFT RN, 1986, J LIPID RES, V27, P236; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WU XJ, 1994, J LIPID RES, V35, P1200; WU XJ, 1994, J BIOL CHEM, V269, P12375	31	125	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10277	10281		10.1074/jbc.271.17.10277	http://dx.doi.org/10.1074/jbc.271.17.10277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626595				2022-12-25	WOS:A1996UG25700067
J	Kummer, JA; Kamp, AM; Citarella, F; Horrevoets, AJG; Hack, CE				Kummer, JA; Kamp, AM; Citarella, F; Horrevoets, AJG; Hack, CE			Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; CYTO-TOXIC LYMPHOCYTES; SERINE ESTERASE GENE; LEUCINE METHYL-ESTER; T-CELL; PROTEASE GRANZYME; VACCINIA VIRUS; CYTOTOXIC LYMPHOCYTES; THIOL PROTEASE; GRANULES	Human granzyme A is one of the serine proteinases present in the granules of cytotoxic T lymphocytes and natural killer cells. Granzymes are synthesized as inactive proenzymes with an amino-terminal prodipeptide, which is processed during transport of granzymes to the cytotoxic granules, where they are stored as active proteinases. In this study, we explored the possibility of producing recombinant granzymes. Recombinant human granzyme A zymogen was expressed in several eukaryotic cell lines (HepG2, Jurkat, and COS-l) after infection with a recombinant vaccinia virus containing full-length granzyme A cDNA, Immunoblot analysis of cell lysates showed that all infected cells produced a disulfide-linked homodimer of identical molecular weight as natural granzyme A. Infected HepG2 cells produced the largest amount of this protease (approximately 160 times more than lymphokine activated killer (LAK) cells). The recombinant protein only had high mannose type oligosaccharides as did the natural protein. Although infected HepG2 and COS cells contained high granzyme A antigen levels, lysates from these cells did not show any granzyme A proteolytic activity. However, the inactive proenzyme could be converted into active granzyme A by incubation with the thiol proteinase cathepsin C (dipeptidyl peptidase I). This study is the first to demonstrate expression of an active recombinant human cytotoxic lymphocyte proteinase and conversion of inactive progranzyme A into an active enzyme by cathepsin C, We suggest that a similar approach can be used for the production of other granzymes and related proteinases.	FREE UNIV AMSTERDAM,NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,LAB EXPT & CLIN IMMUNOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,1007 MB AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1007 MB AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam			Levi, Marcel/AAZ-8559-2020					BURKHARDT JK, 1989, P NATL ACAD SCI USA, V86, P7128, DOI 10.1073/pnas.86.18.7128; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CAPUTO A, 1988, J BIOL CHEM, V263, P6363; CITARELLA F, 1992, EUR J BIOCHEM, V208, P23, DOI 10.1111/j.1432-1033.1992.tb17155.x; COLEMAN PL, 1981, METHOD ENZYMOL, V80, P408; FRUTH U, 1988, FEBS LETT, V237, P45, DOI 10.1016/0014-5793(88)80168-6; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; HAMEED A, 1988, J IMMUNOL, V141, P3142; HANGGI M, 1986, EMBO J, V5, P1071, DOI 10.1002/j.1460-2075.1986.tb04324.x; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1991, J IMMUNOL, V147, P1360; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; KUMMER JA, 1993, J IMMUNOL METHODS, V163, P77, DOI 10.1016/0022-1759(93)90241-X; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; MASSON D, 1988, MOL IMMUNOL, V25, P1283, DOI 10.1016/0161-5890(88)90043-0; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MULE JJ, 1989, J IMMUNOL, V142, P726; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OKANO K, 1990, BIOCHEM BIOPH RES CO, V167, P1326, DOI 10.1016/0006-291X(90)90668-D; PODACK ER, 1984, J EXP MED, V160, P695, DOI 10.1084/jem.160.3.695; POE M, 1988, J BIOL CHEM, V263, P13215; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; THIELE DL, 1990, J EXP MED, V172, P183, DOI 10.1084/jem.172.1.183; THIELE DL, 1990, P NATL ACAD SCI USA, V87, P83, DOI 10.1073/pnas.87.1.83; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924	35	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9281	9286		10.1074/jbc.271.16.9281	http://dx.doi.org/10.1074/jbc.271.16.9281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621589	hybrid			2022-12-25	WOS:A1996UG04400020
J	Ueda, E; Ohno, S; Kuroki, T; Livneh, E; Yamada, K; Yamanishi, K; Yasuno, H				Ueda, E; Ohno, S; Kuroki, T; Livneh, E; Yamada, K; Yamanishi, K; Yasuno, H			The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; MESSENGER-RNA; INSITU HYBRIDIZATION; I TRANSGLUTAMINASE; RETINOIC ACID; NPKC-ETA; CELLS; EXPRESSION; DIFFERENTIATION; FAMILY	Transglutaminase 1 (TGase 1) is expressed during the terminal differentiation of keratinized squamous epithelium to form cornified cell envelope in differentiated keratinocytes by the epsilon-(gamma-glutamyl) cross linking reaction. The gene for human TGase I is responsible for autosomal recessive lamellar ichthyosis, a severe hereditary keratinizing disorder of the skin. We examined the transcriptional activity of the gene in FRSK, rat keratinocytic cells, transfected with the luciferase reporter gene under control of the 5' upstream region of human TGase 1 gene, Transfection of the reporter gene with an expression vector for the eta isoform of novel protein kinase C (nPKC eta), as well as exposure to 12-O-tetradecanoylphorbol-13-acetate, markedly increased the luciferase activity in FRSK, but not in HT-1080 fibrosarcoma cells, although exogenous nPKC eta was expressed in both. The induction was suppressed by deleting the TGase I upstream sequence from -95 to -67 and by deleting the kinase domain from exogenous nPKC eta. In comparison with other PKC isoforms, nPKC eta most effectively induced the luciferase activity. We suggest that nPKC eta, an epithelium-specific isoform of PKC, mediates the activation of the TGase 1 transcription.	KYOTO PREFECTURAL UNIV MED,DEPT DERMATOL,KAMIKYO KU,KYOTO 602,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOLEC,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Kyoto Prefectural University of Medicine; Yokohama City University; University of Tokyo; Weizmann Institute of Science			Yamanishi, Kiyofumi/R-2200-2019; Kuroki, Toshio/A-9500-2011; Ohno, Shigeo/B-1768-2010	Yamanishi, Kiyofumi/0000-0003-0484-2320; Kuroki, Toshio/0000-0001-6369-4351; Ohno, Shigeo/0000-0002-1294-5269				BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; INDO K, 1977, J NATL CANCER I, V59, P867, DOI 10.1093/jnci/59.3.867; INDO K, 1979, J NATL CANCER I, V63, P1017; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; KOYAMA Y, 1990, J INVEST DERMATOL, V94, P677, DOI 10.1111/1523-1747.ep12876255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTI U, 1988, CANCER RES, V48, P74; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NONOMURA K, 1993, BRIT J DERMATOL, V128, P23, DOI 10.1111/j.1365-2133.1993.tb00141.x; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; TAKAHASHI M, 1994, FEBS LETT, V340, P173, DOI 10.1016/0014-5793(94)80131-2; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YADA Y, 1993, BIOCHEM BIOPH RES CO, V190, P688, DOI 10.1006/bbrc.1993.1104; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1991, BIOCHEM BIOPH RES CO, V175, P906, DOI 10.1016/0006-291X(91)91651-R; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	48	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9790	9794		10.1074/jbc.271.16.9790	http://dx.doi.org/10.1074/jbc.271.16.9790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621660	hybrid			2022-12-25	WOS:A1996UG04400091
J	Brockmann, D; Schafer, D; Kirch, HC; Esche, H				Brockmann, D; Schafer, D; Kirch, HC; Esche, H			Repression of c-Jun-induced mouse major histocompatibility class I promoter (H-2K(b)) activity by the Adenovirus type 12-unique 52R E1A protein	ONCOGENE			English	Article						adenovirus type 12; E1A; MHC class I; oncogenicity; transformation	NF-KAPPA-B; TRANSFORMED RAT-CELLS; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GEL-ELECTROPHORESIS; NEGATIVE REGULATION; RESPONSE ELEMENT; FACTOR BINDING; AP-1 ACTIVITY	Down-regulation of major histocompatibility (MHC) class I gene expression by protein products of the early region 1A (E1A), which might allow transformed cells to escape the host immune system, is discussed as one cause for the oncogenicity of Adenovirus (Ad) subtype 12-transformed cells, The MHC class I promoter is activated through several cellular transcription factors among them AP-1, whose target sequences are located in the enhancers A and B, and NF kappa B, In this report we present evidence that the Ad12-unique 52R E1A protein inhibits c-Jun-induced activation of MHC class I gene expression, Repression occurs through both AP-1 recognition sequences with the AP-1 binding site of Enhancer A, which can be bound by c-Jun dimers irt vitro, being the main target for c-Jun activation as well as 52R-mediated down-regulation, Furthermore our data revealed that both promoter elements of Enhancer A, the AP-1 and NF kappa B binding sites, are necessary for full promoter activity, As NF kappa B is down-regulated by the 266R protein of Ad12 E1A our results suggest a model in which two Ad12 E1A proteins co-operate in the repression of MHC class I gene expression.			Brockmann, D (corresponding author), UNIV ESSEN GESAMTHSCH, SCH MED, INST MOL BIOL CANC RES, HUFELANDSTR 55, D-45122 ESSEN, GERMANY.							ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMANN D, 1994, VIROLOGY, V198, P717, DOI 10.1006/viro.1994.1085; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; BROCKMANN D, 1995, MOL REPERTOIRE ADENO, V3, P81; BYRD PJ, 1988, ONCOGENE, V2, P477; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FLINT SJ, 1981, STRUCTURE GENOMIC OR, P383; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JOCHEMSEN H, 1982, VIROLOGY, V122, P15, DOI 10.1016/0042-6822(82)90373-7; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LIU XH, 1994, ONCOGENE, V9, P2183; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIROKI K, 1977, VIROLOGY, V82, P462, DOI 10.1016/0042-6822(77)90019-8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TANG XR, 1995, J BIOL CHEM, V270, P2327, DOI 10.1074/jbc.270.51.30428; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; WHITE E, 1995, MOL REPERTOIRE ADENO, V3, P33; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILLIAMS J, 1995, MOL REPERTOIRE ADENO, V3, P149; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	66	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1715	1725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622892				2022-12-25	WOS:A1996UG45800014
J	Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG				Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG			Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer	ONCOGENE			English	Article						chromosome 8p; colorectal cancer; mapping; YAC isolation; TSG	HEPATOCELLULAR-CARCINOMA; ALLELIC LOSS; SHORT ARM; CHROMOSOME-8; MUTATIONS; GENE	Loss of heterozygosity (LOH) of markers at chromosome 8p is frequently noted in many different tumour types, including colorectal cancer, Numerous investigations indicate the presence of more than one tumour suppressor gene (TSG) located on 8p. In this study, we describe a detailed LOH map in colorectal cancer and relate this to physical mapping data from reduced radiation 8p hybrids, yeast artificial chromosome (YAC) co-localisation of markers and fluorescence in situ hybridisation data,;These data indicate the presence of two regions harbouring putative TSG's between the polymorphic markers for the LPL gene-D8S298 (similar to 4 Mb) and the markers D8S136-D8S137 (similar to 8 Mb), Yeast Artificial Chromosomes (YAC) have been isolated from these regions of interest to aid the localisation of the putative TSG's.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Farrington, SM (corresponding author), MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BOVA GS, 1993, CANCER RES, V53, P3869; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MACOSKA JA, 1994, CANCER RES, V54, P3824; Maniatis T., 1982, MOL CLONING; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SAPRU M, 1994, GENOMICS, V21, P208, DOI 10.1006/geno.1994.1244; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; SENGUPTA DN, 1993, SCIENCE, V260, P816; STEINBRUECK T, 1992, SCIENCE, V258, P67; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wood S, 1993, Cytogenet Cell Genet, V64, P134; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	38	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1803	1808						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622901				2022-12-25	WOS:A1996UG45800023
J	Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS				Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS			Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro	ONCOGENE			English	Article						hepatitis B virus; X gene; liver carcinogenesis; incomplete oncogenes; transactivation	B VIRUS-DNA; HUMAN HEPATOCELLULAR-CARCINOMA; WOODCHUCK LIVER-TUMORS; X-GENE; INSITU HYBRIDIZATION; CELL-LINES; T-ANTIGEN; TRANSACTIVATOR; EXPRESSION; MECHANISMS	The hepatoma-derived hepatitis B virus (HBV) DNA insert HU-a has recently been shown to contain two viral transactivator genes, X and preS2/S-t, We report here that HU-a induces malignant transformation after stable transfection of the fetal mouse hepatocyte line FMH202, as indicated by soft agar growth and nude mouse tumorigenicity, Transfections with HU-a subclones, containing the X gene or the preS2/S-t gene alone or sequences without transactivator gene, respectively, suggested that the X gene is essential for transformation, Sequential stages of transformation and tumor progression were analysed by injection of the stably transfected FMH202 lines into nude mice, explantation of the resulting tumors and re-establishment of cell lines from the tumors, Comparison of two HU-a-transformed cell lines by HBV mRNA hybridization, Southern analysis and chromosomal in situ hybridization revealed that integrated HBV DNAs were involved in major chromosomal rearrangements in both cases, Interestingly, recombination of the HBV DNA insert during the nude mouse passage had completely abolished HBV-specific transcription in one case, indicating that expression of integrated HBV genes, while presumably involved in early transformation, is dispensable at later stages of tumor progression, The sequential transformation observed in this experimental system suggests that expression of the X gene by integrated viral DNA and subsequent hepatocyte genome mutations might both contribute to HBV-associated liver carcinogenesis.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; INST ANTHROPOL & HUMAN GENET,D-80333 MUNICH,GERMANY; INST MED VIROL,D-35392 GIESSEN,GERMANY; INST PATHOL,D-55131 MAINZ,GERMANY	Max Planck Society			Arnold, Norbert/E-3012-2010; Stürzl, Michael/B-3019-2015	Arnold, Norbert/0000-0003-4523-8808; Stürzl, Michael/0000-0002-9276-2824				ARNOLD N, 1992, BIOTECH HISTOCHEM, V67, P59, DOI 10.3109/10520299209110009; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRECHOT C, 1987, J HEPATOL, V4, P269, DOI 10.1016/S0168-8278(87)80090-9; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUH N, 1981, GANN, V72, P178; KEKULE A, 1994, PRIMARY LIVER CANC E, P191; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KOCH S, 1984, EMBO J, V3, P2185, DOI 10.1002/j.1460-2075.1984.tb02111.x; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; MATSUBARA K, 1991, MOL BIOL HEPATITIS B; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1993, GENOMICS, V18, P381, DOI 10.1006/geno.1993.1479; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J., 1989, MOL CLONING; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SETO E, 1991, J VIROL, V65, P2351, DOI 10.1128/JVI.65.5.2351-2356.1991; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TUCKER RW, 1977, CANCER RES, V37, P1571; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	54	39	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1597	1608						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622879				2022-12-25	WOS:A1996UG45800001
J	Yuan, WC; Condorelli, G; Caruso, M; Felsani, A; Giordano, A				Yuan, WC; Condorelli, G; Caruso, M; Felsani, A; Giordano, A			Human p300 protein is a coactivator for the transcription factor MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DIFFERENTIATION; ACTIVATION; DOMAINS; PRODUCT; BINDING	Human p300 protein is a cellular target of adenoviral E1A oncoprotein and a potential transcriptional coactivator. Both p300 and Rb family protein-binding regions of E1A are required for the repression of muscle gene expression, which is regulated by MyoD family transactivators, This implies that p300 is involved in MyoD-dependent transactivation, We show that the repression of MyoD mediated E box (MyoD consensus) reporter activity by E1A is correlated with its interaction with p300, indicating that p300 participates in MyoD-dependent transactivation, In addition, p300 is able to interact both in vivo and in vitro with MyoD through a portion at the carboxyl-terminal cysteine/histidine-rich domain and associates with the components of the basal transcriptional complex through its two separate transactivation domains at the amino and carboxyl termini, Consistent with its role as a coactivator, p300 potentiates MyoD-activated transcription.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL IMMUNOL & PATHOL,PHILADELPHIA,PA 19107; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY; CNR,INST TECNOL BIOMED,I-0158 ROME,ITALY	Jefferson University; Jefferson University; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)			Felsani, Armando/D-1784-2010; Caruso, Maurizia/G-8895-2013; Giordano, Antonio/F-1927-2010; Condorelli, Gianluigi/Q-6736-2017	Felsani, Armando/0000-0001-8851-6295; Caruso, Maurizia/0000-0001-5445-6343; Giordano, Antonio/0000-0002-5959-016X; Condorelli, Gianluigi/0000-0003-0481-6843	NCI NIH HHS [R01 CA60999-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CARUSO M, 1993, ONCOGENE, V8, P267; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GIORDANO A, 1991, ONCOGENE, V6, P481; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	34	280	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9009	9013		10.1074/jbc.271.15.9009	http://dx.doi.org/10.1074/jbc.271.15.9009			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621548	hybrid			2022-12-25	WOS:A1996UE73000079
J	Hwa, J; Graham, RM; Perez, DM				Hwa, J; Graham, RM; Perez, DM			Chimeras of alpha(1)-adrenergic receptor subtypes identify critical residues that modulate active state isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1B-ADRENERGIC RECEPTOR; 3-DIMENSIONAL STRUCTURE; BACTERIORHODOPSIN; PROTEIN	We have identified previously two amino acids, one in each of the fifth and sixth transmembrane segments of both the alpha(1a)-adrenergic receptor and the alpha(1b)-adrenergic receptor (AR), that account almost entirely for the selectivity of agonist binding by these receptor subtypes (Hwa, J., Graham, R. M., and Perez, D. M. (1995) J. Biol. Chem. 270, 23189-23195). Thus reversal of these two residues, from those found in the native receptor of one subtype to those in the other subtype, produces complementary changes in subtype selectivity of agonist binding. Here we show that mutating only one of these residues in either the alpha(1b)-AR or the alpha(1a)-AR to the corresponding residue in the other subtype (Ala(204) --> Val for the alpha(1b); Met(292) --> Leu for the alpha(1a)-AR) results in chimeras that are constitutively active for signaling by both the phospholipase C and phospholipase A(2) pathways. This is evident by an increased affinity for agonists, increased basal phospholipase C and phospholipase A(2) activation, and increased agonist potency. Although mutation of the other residue involved in agonist binding selectivity, to the corresponding residue in the other subtype (Leu(314) --> Met for the alpha(1b)-AR; Val(185) --> Ala for the alpha(1a)-AR) does not alter receptor binding or signaling, per se, when combined with the corresponding constitutively activating mutations, the resulting chimeras, Ala(204) --> Val/Leu(314) --> Met (alpha(1b)-AR) and Val(185) --> Ala/Met(292) --> Leu ((alpha(1a)-AR), display wild type ligand binding and signaling. A simple interpretation of these results is that the alpha(1a)- and alpha(1b)-ARs possess residues that critically modulate isomerization from the basal state, R, to the active state R*, and that the native receptor structures have evolved to select residues that repress active state isomerization. It is likely that the residues identified here modulate important interhelical interactions between the fifth and sixth transmembrane segments that inhibit or promote receptor signaling.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; ST VINCENTS MED CTR,VICTOR CHANG CARDIAC RES INST,DARLINGHURST,NSW 2010,AUSTRALIA	Cleveland Clinic Foundation; Case Western Reserve University; Victor Chang Cardiac Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLB52544] Funding Source: Medline; NINDS NIH HHS [NS19853] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; ENGEL G, 1981, EUR J PHARMACOL, V73, P221, DOI 10.1016/0014-2999(81)90095-9; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; HWA J, 1996, IN PRESS AUTONOMIC N, V8; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Sambrook J., 2002, MOL CLONING LAB MANU; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SUBRAMANIAM S, 1993, EMBO J, V12, P1; SUNG SS, 1991, FASEB J, V5, pA804; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHOU W, 1994, MOL PHARMACOL, V45, P165	24	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7956	7964		10.1074/jbc.271.14.7956	http://dx.doi.org/10.1074/jbc.271.14.7956			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626475	hybrid			2022-12-25	WOS:A1996UD60000015
J	Leone, G; Coffey, MC; Gilmore, R; Duncan, R; Maybaum, L; Lee, PWK				Leone, G; Coffey, MC; Gilmore, R; Duncan, R; Maybaum, L; Lee, PWK			C-terminal trimerization, but not N-terminal trimerization, of the reovirus cell attachment protein is a posttranslational and Hsp70/ATP-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPTAD REPEAT REGION; HEAT-SHOCK PROTEINS; FUNCTIONAL DOMAINS; SIGMA-1; PROTEIN-SIGMA-1; TRANSLOCATION; HEMAGGLUTININ; SEQUENCE; INVITRO; PORTION	The C-terminal globular head of the lollipop-shaped sigma 1 protein of reovirus is responsible for interaction with the host cell receptor. Like the N-terminal fibrous tail, it has its own trimerization domain, Whereas N-terminal trimerization (formation of a triple alpha-helical coiled coil) occurs at the level of polysomes (i.e. cotranslationally) and is ATP-independent, C-terminal trimerization is a posttranslational event that requires ATP. Coprecipitation experiments using anti-Hsp70 antibodies and truncated sigma 1 proteins synthesized in vitro revealed that only regions downstream of the N-terminal alpha-helical coiled coil were associated with Hsp70. Hsp70 was also found to be associated with nascent al chains on polysomes as well as with immature postribosomal sigma 1 trimers (hydralike intermediates with assembled N termini and unassembled C termini). These latter structures were true intermediates in the al biogenetic pathway since they could be chased into mature al trimers with the release of Hsp70. Thus, unlike N-terminal trimerization, C-terminal trimerization is Hsp70- and ATP-dependent. The involvement of two mechanistically distinct oligomerization events for the same molecule, one cotranslational and one posttranslational, may represent a common approach to the generation of oligomeric proteins in the cytosol.	UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba			Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300; Duncan, Roy/0000-0002-5162-5081				BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BANERJEA AC, 1990, VIROLOGY, V179, P460, DOI 10.1016/0042-6822(90)90315-I; BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; DUNCAN R, 1994, VIROLOGY, V203, P149, DOI 10.1006/viro.1994.1465; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; FERNANDES J, 1994, J BIOL CHEM, V269, P17043; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; NAGATA L, 1987, VIROLOGY, V160, P162, DOI 10.1016/0042-6822(87)90056-0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	44	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8466	8471		10.1074/jbc.271.14.8466	http://dx.doi.org/10.1074/jbc.271.14.8466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626547	hybrid			2022-12-25	WOS:A1996UD60000087
J	Parent, JL; LeGouill, C; deBrumFernandes, AJ; RolaPleszczynski, M; Stankova, J				Parent, JL; LeGouill, C; deBrumFernandes, AJ; RolaPleszczynski, M; Stankova, J			Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX MODEL; MOLECULAR-CLONING; PHOSPHOLIPASE-C; HYDROLYSIS; PHOSPHORYLATION; EXPRESSION; REGION; CDNA	We have mutated two residues, Ala(230) and Leu(231), in the C-terminal portion of the third intracellular loop of the human platelet-activating factor (PAF) receptor into Glu(230) and Arg(231), respectively. The Leu(231) --> Arg(231) substitution. led to two major modifications: 1) increased constitutive activity of the PAF receptor resulting in agonist-independent production of inositol phosphates and 2) increased affinity of the receptor for binding PAF (agonist) but not WEB2086 (antagonist). The L231R mutant was able to adopt at least two conformations: (i) a higher affinity state than the corresponding state of the wild-type receptor (WT), dependent on G protein coupling, and (ii) a low affinity state, higher than the one for the uncoupled WT receptor. The Ala(230) --> Glu(230) substitution also resulted in two major modifications: 1) unresponsiveness in terms of phosphatidylinositol hydrolysis in response to PAF and 2) a marked decrease in affinity of the receptor for binding the agonist but not the antagonist. Competition binding studies of transient receptor expression in COS-7 cells and the inability of guanosine 5'-O-(3-thiotriphosphate) to modulate the decrease in affinity of a stable A230E mutant in Chinese hamster ovary cells suggest an inherent low affinity conformation for this mutant. Alternatively, mutation of Ala(230) to Gln(230) suggested that the residue 230 has a fundamental effect on receptor affinity and its charge is determinant in G protein coupling of the PAF receptor. In this report, we show that substitution of two immediately adjacent residues of the PAF receptor, Ala(230) and Leu(231), surprisingly leads to an inactive and a constitutively active phenotype, respectively. These results further support the concept of constitutively active G protein-coupled receptors as adopting ''active'' state conformations similar to those induced by agonist binding to WT receptors.	UNIV SHERBROOKE,FAC MED,DEPT PEDIAT,DIV IMMUNOL,SHERBROOKE,PQ J1H 5N4,CANADA; UNIV SHERBROOKE,FAC MED,DEPT MED,RHEUMAT DIS UNIT,SHERBROOKE,PQ J1H 5N4,CANADA	University of Sherbrooke; University of Sherbrooke								ALI H, 1994, J BIOL CHEM, V269, P24557; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOONE C, 1993, P NATL ACAD SCI USA, V90, P9921, DOI 10.1073/pnas.90.21.9921; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; FRANKLIN RA, 1995, BIOCHEM BIOPH RES CO, V209, P1111, DOI 10.1006/bbrc.1995.1612; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONDA Z, 1994, J BIOL CHEM, V269, P2307; JAGADEESH G, 1990, J PHARMACOL EXP THER, V252, P1184; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	27	34	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7949	7955		10.1074/jbc.271.14.7949	http://dx.doi.org/10.1074/jbc.271.14.7949			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626474	hybrid			2022-12-25	WOS:A1996UD60000014
J	Smith, PL; Gersten, KM; Petryniak, B; Kelly, RJ; Rogers, C; Natsuka, Y; Alford, JA; Scheidegger, EP; Natsuka, S; Lowe, JB				Smith, PL; Gersten, KM; Petryniak, B; Kelly, RJ; Rogers, C; Natsuka, Y; Alford, JA; Scheidegger, EP; Natsuka, S; Lowe, JB			Expression of the alpha(1,3)fucosyltransferase Fuc-TVII in lymphoid aggregate high endothelial venules correlates with expression of L-selectin ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWIS-X; DETERMINES EXPRESSION; EMBRYONIC ANTIGEN; MOLECULAR-CLONING; HOMING RECEPTOR; CELL LINES; GENE; DIFFERENTIATION; VIRUS; IDENTIFICATION	Lymphocyte homing to lymph nodes and Peyer's patches is mediated, in part, by adhesive interactions between L-selectin expressed by lymphocytes and L-selectin ligands displayed at the surface of the cuboidal endothelial cells lining the post capillary venules within lymphoid aggregates, Candidate terminal oligosaccharide structures thought to be essential for effective L-selectin ligand activity include a sulfated derivative of the sialyl Lewis x tetrasaccharide. Cell type-specific synthesis of this oligosaccharide is presumed to require one or more alpha(1,3)fucosyltransferases, operating upon common 3'-sialylated and/or sulfated N-acetyllactosamine-type precursors, The identity of the alpha(1,3)fucosyltransferase(s) expressed in cells that bear L-selectin ligands has not been defined, We report here the molecular cloning and characterization of a murine alpha(1,3)fucosyltransferase locus whose expression pattern correlates with expression of high affinity ligands for L-selectin. In situ hybridization and immunohistochemical analyses demonstrate that this cDNA and its cognate alpha(1,3)fucosyltransferase are expressed in endothelial cells lining the high endothelial venules of peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches, These expression patterns correlate precisely with the expression pattern of L-selectin ligands identified with a chimeric L-selectin/IgM immunohistochemical probe and by the high endothelial venule-reactive monoclonal antibody MECA-79. Transcripts corresponding to this cDNA are also detected in isolated bone marrow cells, a source rich in the surface-localized ligands for E- and P-selectins. Sequence and functional analyses indicate that this murine enzyme corresponds to the human Fuc-TVII locus, These observations suggest that Fuc-TVII participates in the generation of alpha(1,3)fucosylated ligands for L-selectin and provide further evidence for a role for this enzyme in E- and P-selectin ligand expression in leukocytes.			Smith, PL (corresponding author), UNIV MICHIGAN, SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,MSRB I, RM 3510, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		Natsuka, Shunji/L-9330-2018	Natsuka, Shunji/0000-0003-1726-8946	NCRR NIH HHS [M01RR00042] Funding Source: Medline; NIGMS NIH HHS [1R01GM47455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW ME, 1984, J IMMUNOL, V132, P839; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BRACIALE TJ, 1981, J EXP MED, V153, P910, DOI 10.1084/jem.153.4.910; CHANDRASEKARAN EV, 1994, BIOCHEM BIOPH RES CO, V201, P78, DOI 10.1006/bbrc.1994.1671; CHIA D, 1985, CANCER RES, V45, P435; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GESTEN KM, 1995, THESIS U MICHIGAN AN; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAMANO T, 1983, J IMMUNOL, V130, P2027; Harlow E., 1988, ANTIBODIES LAB MANUA; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HUMMEL M, 1987, J IMMUNOL, V138, P3539; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOREN HS, 1975, J IMMUNOL, V114, P894; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Maniatis T., 1982, MOL CLONING; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OLD LJ, 1965, CANCER RES, V25, P813; OWEN RL, 1977, GASTROENTEROLOGY, V72, P440; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; RALPH P, 1977, J IMMUNOL, V119, P950; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SINGER D, 1974, P NATL ACAD SCI USA, V71, P2668, DOI 10.1073/pnas.71.7.2668; SMITH PL, 1994, J BIOL CHEM, V269, P15162; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILKINSON DG, IN SITU HYBRIDIZATIO; ZANNETTINO ACW, 1995, BLOOD, V85, P3466, DOI 10.1182/blood.V85.12.3466.bloodjournal85123466	64	131	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8250	8259		10.1074/jbc.271.14.8250	http://dx.doi.org/10.1074/jbc.271.14.8250			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626519	hybrid			2022-12-25	WOS:A1996UD60000059
J	Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB				Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB			Linking protein kinase C to the cell cycle: Ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis	ONCOGENE			English	Article						protein kinase C; cell cycle; cyclins; Cdk inhibitors; adipogenesis	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT REGULATION; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; NPKC-ETA; DIFFERENTIATION; PHOSPHORYLATION; ACTIVATION; EPSILON	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, very little is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that ectopic expression of PKC eta in NIH3T3 fibroblasts blocks the normal phosphorylation of the Rb protein in quiescent cultures restimulated to enter the cell cycle; PKC eta activates a cellular program that includes increased expression of cyclins E (but not cyclin D), as well as the induced expression of the cyclin-dependent kinase inhibitors p21(WAF1) and p27(KIP1). The increased expression of the latter inhibitors and their association with the cyclin E-Cdk2 complex results in decreased cyclin E associated kinase activity. Furthermore, in contrast to the control NIH3T3 cells, the cells that express PKC eta can be induced to undergo adipocyte differentiation in response to adipogenic hormones. Thus, PKC eta induces altered expression of several cell cycle related functions, which may contribute to its ability to promote cellular differentiation.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032	Columbia University	Livneh, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CACACE AM, 1993, ONCOGENE, V8, P2095; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TIBS, V17, P310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOKER A, 1994, J BIOL CHEM, V269, P32358; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WIMMEL A, 1994, ONCOGENE, V9, P995; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	63	75	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1545	1555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622871				2022-12-25	WOS:A1996UF07600019
J	Chen, D; Waters, SB; Holt, KH; Pessin, JE				Chen, D; Waters, SB; Holt, KH; Pessin, JE			SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCTION PATHWAY; KINASE; PROTEIN; INTERACTS; DOMAIN; RAF-1; SHC	Insulin activation of Ras is mediated by the plasma membrane targeting of the guanylnucleotide exchange factor SOS associated with the small adapter protein Grb2, SOS also lies in an insulin-stimulated feedback pathway in which the serine/threonine phosphorylation of SOS results in disassociation of the Grb2-SOS complex thereby limiting the extent of Ras activation, To examine the relative role of the mitogen-activated protein kinases in the feedback phosphorylation of SOS we determined the signaling specificity of insulin, osmotic shock, and anisomycin to activate the ERK (extracellular-signal regulated kinase) and JNK (c-Jun kinase) pathways. In Chinese hamster ovary cells expressing the human insulin receptor and murine 3T3L1 adipocytes, insulin specifically activated ERK with no significant effect on JNK, whereas anisomycin specifically activated JNK but was unable to activate ERK. In contrast, osmotic shock was equally effective in the activation of both kinase pathways. Insulin and osmotic shock, but not anisomycin, resulted in SOS phosphorylation and disassociation of the Grb2-SOS complex, demonstrating that the JNK pathway was not involved in the insulin-stimulated feedback uncoupling of the Grb2-SOS complex, Both the insulin and osmotic shock-induced activation of ERK was prevented by treatment of cells with the specific MEK inhibitor (PD98059). However, expression of dominant-interfering Ras (N17Ras) inhibited the insulin- but not osmotic shock-stimulated phosphorylation of ERK and SOS. These data demonstrate that activation of the ERK pathway, but not JNK, is responsible for the feedback phosphorylation and disassociation of the Grb2-SOS complex.	UNIV IOWA,PROGRAM MOLEC BIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25925, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; UEKI K, 1994, J BIOL CHEM, V269, P15756; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	39	143	144	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6328	6332		10.1074/jbc.271.11.6328	http://dx.doi.org/10.1074/jbc.271.11.6328			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626428	hybrid			2022-12-25	WOS:A1996UA36300057
J	Kaptein, A; Paillard, V; Saunders, M				Kaptein, A; Paillard, V; Saunders, M			Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; GENE; CELLS	Interleukin-6 (IL-6) induces tyrosine phosphorylation and activation of the latent transcription factor Stat3 in HepG2 cells. Mutation of Stat3 tyrosine 705 to phenylalanine (Y705F) inhibits IL-6-induced tyrosine phosphorylation of this Stat3 mutant in transfected HepG2 cells. In cotransfections of HepG2 cells, the Stat3 mutant Y705F causes a reduction of the tyrosine phosphorylation of wild type Stat3-FLAG. Moreover, Y705F inhibits the action of endogenous Stat3 in cotransfected cells, reducing IL-6 induction of a Stat3-responsive reporter construct. Y705F therefore acts as a dominant negative mutation of Stat3.	LABS GLAXO WELLCOME, ZA COURTABOEUF, CTR RECH, F-91951 LES ULIS, FRANCE	GlaxoSmithKline								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	196	201	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5961	5964		10.1074/jbc.271.11.5961	http://dx.doi.org/10.1074/jbc.271.11.5961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626374	hybrid			2022-12-25	WOS:A1996UA36300003
J	Sangameswaran, L; Delgado, SG; Fish, LM; Koch, BD; Jakeman, LB; Stewart, GR; Sze, P; Hunter, JC; Eglen, RM; Herman, RC				Sangameswaran, L; Delgado, SG; Fish, LM; Koch, BD; Jakeman, LB; Stewart, GR; Sze, P; Hunter, JC; Eglen, RM; Herman, RC			Structure and function of a novel voltage-gated, tetrodotoxin-resistant sodium channel specific to sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; DEPENDENT PROTEIN-KINASE; RAT SKELETAL-MUSCLE; ALPHA-SUBUNIT; MOLECULAR-CLONING; NA+ CHANNELS; HUMAN BRAIN; EXPRESSION; CURRENTS; CDNA	Small neurons of the dorsal root ganglia (DRG) are known to play an important role in nociceptive mechanisms. These neurons express two types of sodium current, which differ in their inactivation kinetics and sensitivity to tetrodotoxin. Here, we report the cloning of the alpha-subunit of a novel, voltage-gated sodium channel (PN3) from rat DRG. Functional expression in Xenopus oocytes showed that PN3 is a voltage-gated sodium channel with a depolarized activation potential, slow inactivation kinetics, and resistance to high concentrations of tetrodotoxin. In situ hybridization to rat DRG indicated that PN3 is expressed primarily in small sensory neurons of the peripheral nervous system.			Sangameswaran, L (corresponding author), ROCHE BIOSCI, INST PHARMACOL, NEUROBIOL UNIT, 3401 HILLVIEW AVE, MAILSTOP R6E-6, PALO ALTO, CA 94304 USA.			Jakeman, Lyn/0000-0002-1760-8819; Koch, Bruce/0000-0003-1713-2301				AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CAFFREY JM, 1992, BRAIN RES, V592, P283, DOI 10.1016/0006-8993(92)91687-A; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; ELLIOTT AA, 1993, J PHYSIOL-LONDON, V463, P39, DOI 10.1113/jphysiol.1993.sp019583; FELIPE A, 1994, J BIOL CHEM, V269, P30125; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GEORGE AL, 1992, P NATL ACAD SCI USA, V89, P4893, DOI 10.1073/pnas.89.11.4893; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; IKEDA SR, 1986, J NEUROPHYSIOL, V55, P527, DOI 10.1152/jn.1986.55.3.527; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KIEFFER BL, 1991, GENE, V109, P115, DOI 10.1016/0378-1119(91)90595-3; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MCLEAN MJ, 1988, MOL CELL BIOCHEM, V80, P95; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OGATA N, 1993, J PHYSIOL-LONDON, V466, P9; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; PATTON DE, 1994, J BIOL CHEM, V269, P17649; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROY ML, 1992, J NEUROSCI, V12, P2104; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; WHITE JA, 1993, NEURON, V11, P1037, DOI 10.1016/0896-6273(93)90217-F; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7	40	386	401	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5953	5956		10.1074/jbc.271.11.5953	http://dx.doi.org/10.1074/jbc.271.11.5953			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626372	hybrid			2022-12-25	WOS:A1996UA36300001
J	Scholze, H; Frey, S; Cejka, Z; BakkerGrunwald, T				Scholze, H; Frey, S; Cejka, Z; BakkerGrunwald, T			Evidence for the existence of both proteasomes and a novel high molecular weight peptidase in Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYSIS; PURIFICATION; COMPLEXES	To screen for high molecular weight proteases in Entamoeba histolytica, we subjected a soluble amebal extract to density gradient centrifugation and tested the fractions for activity against the chymotryptic peptide substrate, Suc-leucyl-leucyl-valyl-tyrosyl-4-methylcoumaryl-7-amide. Two peaks of activity, of approximately 11 and 20 S, were clearly separated. Based on SDS-electrophoretic pattern and immunoblot analysis, we ascribe the 20 S activity to proteasomes. The 11 S protein was purified from amebal homogenates by a series of chromatographic steps. As determined by molecular sieve chromatography and nondenaturing gel electrophoresis, the native complex had an apparent M(r) of 385,000 +/- 10%. On SDS gels, the purified enzyme exhib ited a single band of M(r) 62,000 that yielded a single N-terminal sequence, indicating that the preparation was homogeneous and that the native complex consisted of six very similar or identical subunits. The enzyme preferred peptides with aromatic residues at the P-1 position and had low but distinct activity toward azocasein. We conclude that the 11 S enzyme is a novel high molecular weight protease that is distinct from proteasomes.	UNIV OSNABRUCK, DEPT BIOL CHEM, D-49069 OSNABRUCK, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; UNIV OSNABRUCK, DEPT BIOCHEM, D-49069 OSNABRUCK, GERMANY	University Osnabruck; Max Planck Society; University Osnabruck	Scholze, H (corresponding author), UNIV OSNABRUCK, DEPT MICROBIOL, FACHBEREICH BIOL CHEM BIOCHEM, POSTFACH 4469, BARBARASTR 11, D-49069 OSNABRUCK, GERMANY.							Bakker-Grunwald T., 1991, P367; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Diamond L.S., 1988, P27; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DOUGLAS M, 1979, METHOD ENZYMOL, V56, P734; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HENDIL KB, 1995, BIOCHEM J, V305, P245, DOI 10.1042/bj3050245; HUA SB, 1995, J BIOL CHEM, V270, P10264, DOI 10.1074/jbc.270.17.10264; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LOHDEN U, 1989, ANAL BIOCHEM, V182, P77, DOI 10.1016/0003-2697(89)90721-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; McKerrow J.H., 1991, P245; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Scholze H., 1991, P251; SCHOLZE H, 1994, METHOD ENZYMOL, V244, P512; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SOGIN ML, 1989, AM ZOOL, V29, P487; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J BIOCHEM-TOKYO, V106, P495, DOI 10.1093/oxfordjournals.jbchem.a122880; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; WALSH JA, 1986, REV INFECT DIS, V8, P228	31	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6212	6216		10.1074/jbc.271.11.6212	http://dx.doi.org/10.1074/jbc.271.11.6212			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626412	hybrid			2022-12-25	WOS:A1996UA36300041
J	Tamir, H; Liu, KP; Adlersberg, M; Hsiung, SC; Gershon, MD				Tamir, H; Liu, KP; Adlersberg, M; Hsiung, SC; Gershon, MD			Acidification of serotonin-containing secretory vesicles induced by a plasma membrane calcium receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID PARAFOLLICULAR CELLS; NITRIC-OXIDE SYNTHASE; NUCLEOTIDE-BINDING PROTEIN; NEURONAL NADPH DIAPHORASE; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; GRANULES; 5-HYDROXYTRYPTAMINE; ACTIVATION; INDUCTION	Parafollicular (PF) cells secrete B-hydroxytryptamine in response to increased extracellular Ca2+ (up arrow[Ca2+](e)). This stimulus causes Cl- channels in PF secretory vesicles to open, leading to vesicle acidification. PF cells express a plasmalemmal heptahelical receptor (CaR) that binds Ca2+, Gd3+, and Ba2+. We now report that the CaR mediates vesicle acidification, Ca2+, Gd3+, and Ba2+ induced vesicle acidification, which was independent of channel-mediated Ca2+ entry. Agonist-induced vesicle acidification was blocked by pertussis toxin, inhibitors of phosphatidylinositol-phospholipase C, calmodulin, NO synthase, guanylyl cyclase, or protein kinase G. PF cells contained NO synthase immunoreactivity, and vesicles were acidified by NO donors and dibutyryl cGMP. [Ca2+]e, and Gd3+ mobilized thapsigargin-sensitive internal Ca2+ stores. [S-35]G(alpha i) and [S-35]G(alpha q) were immuno-precipitated from PF membranes incubated with agonists in the presence of [S-35]adenosine 5'-O-(thiotriphosphate). Labeling of G(alpha i) but not G(alpha q) was antagonized by pertussis toxin. Vesicles acidified in response to activation of protein kinase C; however, protein kinase C inhibition blocked calcium channel- but not CaR-dependent acidification. We propose the following signal transduction pathway: CaR --> G(i) --> phosphatidylinositol-phospholipase C --> inositol 1,4,5-trisphosphate --> up arrow [Ca2+](i) --> Ca2+/calmodulin --> NO synthase --> guanylyl cyclase --> cGMP --> protein kinase G --> opens vesicular Cl- channel.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University	Tamir, H (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,DIV NEUROSCI,NEW YORK,NY 10032, USA.				NIDDK NIH HHS [DK19743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BARASCH JM, 1987, J NEUROSCI, V7, P4017; BERND P, 1981, J CELL BIOL, V88, P499, DOI 10.1083/jcb.88.3.499; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERT D, 1989, P NATL ACAD SCI USA, V86, P9030; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CIDON S, 1991, J BIOL CHEM, V266, P4392; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DICKENSON JM, 1995, EUR J PHARM-MOLEC PH, V288, P393, DOI 10.1016/0922-4106(95)90055-1; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GLUCK S, 1984, J CLIN INVEST, V73, P1704, DOI 10.1172/JCI111378; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HSIUNG SC, 1993, NEUR ABS, V19, P1333; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Le Douarin N.M., 1982, NEURAL CREST; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; NEMETH EF, 1995, NEWS PHYSIOL SCI, V10, P1; Nunez E A, 1978, Int Rev Cytol, V52, P1, DOI 10.1016/S0074-7696(08)60753-6; NUNEZ EA, 1976, AM J ANAT, V147, P375, DOI 10.1002/aja.1001470309; NUNEZ EA, 1972, ENDOCRINOLOGY, V90, P1008, DOI 10.1210/endo-90-4-1008; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PARK DG, 1993, J BIOL CHEM, V268, P4573; PRZYWARA DA, 1993, P NATL ACAD SCI USA, V90, P557, DOI 10.1073/pnas.90.2.557; RACKE K, 1993, N-S ARCH PHARMACOL, V347, P1; SHIELDS D, 1994, BIOCHIMIE PARIS, V76, P257; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAMIR H, 1994, J NEUROCHEM, V63, P97; TAMIR H, 1990, J NEUROSCI, V10, P3743; TAMIR H, 1994, ENDOCRINOLOGY, V135, P2045, DOI 10.1210/en.135.5.2045; Thureson-Klein A K, 1990, Int Rev Cytol, V121, P67, DOI 10.1016/S0074-7696(08)60659-2; WANG HY, 1993, J PHARMACOL EXP THER, V267, P1002; WEILER R, 1989, FEBS LETT, V257, P457, DOI 10.1016/0014-5793(89)81595-9; WU DQ, 1992, J BIOL CHEM, V267, P1811; YOUNG HM, 1993, NEUROSCIENCE, V55, P583, DOI 10.1016/0306-4522(93)90526-L; YULE DI, 1992, J BIOL CHEM, V267, P13830	49	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6441	6450		10.1074/jbc.271.11.6441	http://dx.doi.org/10.1074/jbc.271.11.6441			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626445	hybrid			2022-12-25	WOS:A1996UA36300074
J	Cao, YH; Chen, H; Zhou, L; Chiang, MK; AnandApte, B; Weatherbee, JA; Wang, YD; Fang, FY; Flanagan, JG; Tsang, MLS				Cao, YH; Chen, H; Zhou, L; Chiang, MK; AnandApte, B; Weatherbee, JA; Wang, YD; Fang, FY; Flanagan, JG; Tsang, MLS			Heterodimers of placenta growth factor vascular endothelial growth factor - Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; FACTOR FAMILY; ANGIOGENESIS; RECEPTOR; IDENTIFICATION; MITOGEN; VEGF	Here we show that the Escherichia coli expressed monomers of placenta growth factor (PLGF)(129) and vascular endothelial growth factor (VEGF)(165) can be refolded in vitro to form PLGF/VEGF heterodimers. The purified recombinant PLGF/VEGF heterodimers and VEGF homodimers have potent mitogenic and chemotactic effects on endothelial cells. However, PLGF/VEGF heterodimers display 2050-fold less mitogenic activity than VEGF(165) homodimers. In contrast, PLGF(129) homodimers have little or no effect in these in vitro assays. We also demonstrate the presence of natural PLGF/VEGF heterodimers in the conditioned media of various human tumor cell lines. While PLGF/VEGF heterodimers bind with high affinity to a soluble Flk-1/KDR receptor, PLGF(129) homodimers fail to bind to this receptor, Cross-linking of I-125-ligands to human umbilical vein endothelial cells reveals that PLGF/VEGF heterodimers and VEGF(165) homodimers, but not PLGF(129) homodimers, form complexes with membrane receptors. VEGF(165) homodimers and PLGF/VEGF heterodimers stimulate tyrosine phosphorylation of a 220-kDa protein, the expected size for the KDR receptor in human umbilical vein endothelial cells, whereas PLGF(129) homodimers are unable to induce tyrosine phosphorylation of this protein, These data indicate that PLGF may modulate VEGF-induced angiogenesis by the formation of PLGF/VEGF heterodimers in cells producing both factors.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; R&D SYST INC, MINNEAPOLIS, MN 55413 USA	Harvard University; Harvard Medical School	Cao, YH (corresponding author), HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA.		Flanagan, John/AAM-2995-2020		NCI NIH HHS [P01-CA-45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; CHIANG MK, 1995, GROWTH FACTORS, V12, P1, DOI 10.3109/08977199509003208; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SENGER DR, 1990, CANCER RES, V50, P1774; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEINDEL K, 1994, NEUROSURGERY, V35, P439, DOI 10.1227/00006123-199409000-00012	46	241	262	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3154	3162		10.1074/jbc.271.6.3154	http://dx.doi.org/10.1074/jbc.271.6.3154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621715	hybrid			2022-12-25	WOS:A1996TU69100044
J	Yamazaki, T; Komuro, I; Kudoh, S; Zou, YZ; Shiojima, I; Hiroi, Y; Mizuno, T; Maemura, K; Kurihara, H; Aikawa, R; Takano, H; Yazaki, Y				Yamazaki, T; Komuro, I; Kudoh, S; Zou, YZ; Shiojima, I; Hiroi, Y; Mizuno, T; Maemura, K; Kurihara, H; Aikawa, R; Takano, H; Yazaki, Y			Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; GENE-EXPRESSION; PROTEIN-KINASE; FUNCTIONAL EXPRESSION; SIGNAL TRANSDUCTION; CELL HYPERTROPHY; RECEPTOR; CLONING; CDNA; PHOSPHORYLATION	We have recently shown that mechanical stress induces cardiomyocyte hypertrophy partly through the enhanced secretion of angiotensin II (ATII), Endothelin-1 (ET-1) has been reported to be a potent growth factor for a variety of cells, including cardiomyocytes, In this study, we examined the role of ET-1 in mechanical stress-induced cardiac hypertrophy by using cultured cardiomyocytes of neonatal rats, ET-1 (10(-8)similar to 10(-7) M) maximally induced the activation of both Raf-1 kinase and mitogen-activated protein (MAP) kinases at 4 and 8 min, respectively, followed by an increase in protein synthesis at 24 h, All of these hypertrophic responses were completely blocked by pretreatment with BQ123, an antagonist selective for the ET-1 type A receptor subtype, but not by BQ788, an ET-1 type B receptor-specific antagonist, BQ123 also suppressed stretch-induced activation of MAP kinases and an increase in phenylalanine uptake by approximately 60 and 50%, respectively, but BQ788 did not, ET-1 was constitutively secreted from cultured cardiomyocytes, and a significant increase in ET-1 concentration was observed in the culture medium of cardiomyocytes after stretching for 10 min, After 24 h, an similar to 3-fold increase in ET-1 concentration was observed in the conditioned medium of stretched cardiomyocytes compared with that of unstretched cardiomyocytes. ET-1 mRNA levels were also increased at 30 min after stretching, Moreover, ET 1 and ATII synergistically activated Raf-1 kinase and MAP kinases in cultured cardiomyocytes, In conclusion, mechanical stretching stimulates secretion and production of ET-1 in cultured cardiomyocytes, and vasoconstrictive peptides such as ATII and ET-1 may play an important role in mechanical stress-induced cardiac hypertrophy.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,HLTH SCI CTR,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo								AHN NG, 1990, J BIOL CHEM, V265, P11487; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; HAMAOKI M, 1990, HYBRIDOMA, V9, P63, DOI 10.1089/hyb.1990.9.63; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NAKAMURA S, 1990, HISTOCHEMISTRY, V94, P475, DOI 10.1007/BF00272609; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO Y, 1993, ANAT REC, V237, P482, DOI 10.1002/ar.1092370407; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1991, BIOCHEM BIOPH RES CO, V175, P44, DOI 10.1016/S0006-291X(05)81197-0; SASAKI T, 1993, ANAT REC, V237, P332, DOI 10.1002/ar.1092370306; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TOBE K, 1991, J BIOL CHEM, V266, P24793; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	46	331	343	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3221	3228		10.1074/jbc.271.6.3221	http://dx.doi.org/10.1074/jbc.271.6.3221			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621724	hybrid			2022-12-25	WOS:A1996TU69100053
J	Glaasker, E; Konings, WN; Poolman, B				Glaasker, E; Konings, WN; Poolman, B			Glycine betaine fluxes in Lactobacillus plantarum during osmostasis and hyper- and hypo-osmotic shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MECHANICAL-PROPERTIES; MEMBRANE-VESICLES; ION CHANNELS; TRANSPORT; BACTERIA; EFFLUX; CELLS; GADOLINIUM; CHOLINE	Bacteria respond to changes in medium osmolarity by varying the concentrations of specific solutes in order to maintain constant turgor. The primary response of Lactobacillus plantarum to an osmotic upshock involves the accumulation of compatible solutes such as glycine betaine, proline, and glutamate. We have studied the osmotic regulation of glycine betaine transport in L. plantarum by measuring the overall and unidirectional rates of glycine betaine uptake and exit at osmostasis, and under conditions of osmotic upshock and downshock. At steady state conditions, a basal flux of glycine betaine (but no net uptake or efflux) is observed that amounts to about 20% of the rate of ''activated'' uptake (uptake at high osmolarity). No direct exchange of C-14-labeled glycine betaine in the medium for unlabeled glycine betaine in the cytoplasm was observed in glucose metabolizing and resting cells, indicating that a separate glycine betaine efflux system is responsible for the exit of glycine betaine. Upon osmotic upshock, the uptake system for glycine betaine is rapidly activated (within seconds), whereas the basal efflux is inhibited. These two responses account for a rapid accumulation of glycine betaine until osmostasis is reached. Upon osmotic downshock, glycine betaine is rapidly released by the cells in a process that has two kinetic components, i.e. one with a half-life of less than 2 s which is unaffected by the metabolic status of the cells, the other with a half-life of 4-5 min in glucose-metabolizing cells which is dependent on internal pH or a related parameter. We speculate that the former activity corresponds to a stretch-activated channel, whereas the latter may be facilitated by a carrier protein. Glycine betaine uptake is strongly inhibited immediately after an osmotic downshock, but slowly recovers in time. These studies demonstrate that in L. plantarum osmostasis is maintained through positive and negative regulation of both glycine betaine uptake and efflux, of which activation of uptake upon osmotic upshock and activation of a ''channel-like'' activity upon osmotic downshock are quantitatively most important.	UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT MICROBIOL,9751 NN HAREN,NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013					BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BOCH J, 1994, J BACTERIOL, V176, P5364; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Glaasker E, 1996, J BACTERIOL, V178, P575, DOI 10.1128/jb.178.3.575-582.1996; GLAZER AN, 1992, NATURE, V359, P859, DOI 10.1038/359859a0; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HALLETT FR, 1993, BIOPHYS J, V64, P435, DOI 10.1016/S0006-3495(93)81384-5; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; KANESHIRO ES, 1993, J MICROBIOL METH, V17, P1, DOI 10.1016/S0167-7012(93)80010-4; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; LAMARK T, 1992, FEMS MICROBIOL LETT, V96, P149; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCFEETERS R F, 1986, Food Microbiology (London), V3, P73, DOI 10.1016/S0740-0020(86)80029-6; MCLAUGHLIN S, 1982, MEMBRANES TRANSPORT, V1, P51; MEURY J, 1985, EUR J BIOCHEM, V151, P613, DOI 10.1111/j.1432-1033.1985.tb09148.x; MILNER JL, 1988, J BIOL CHEM, V263, P14900; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; SMALL DL, 1995, BRIT J PHARMACOL, V114, P180, DOI 10.1111/j.1476-5381.1995.tb14923.x; SPEED D, 1968, J CHROMATOGR, V35, P497, DOI 10.1016/S0021-9673(01)82415-8; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X	34	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10060	10065		10.1074/jbc.271.17.10060	http://dx.doi.org/10.1074/jbc.271.17.10060			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626562	hybrid, Green Published			2022-12-25	WOS:A1996UG25700034
J	Just, I; Selzer, J; Hofmann, F; Green, GA; Aktories, K				Just, I; Selzer, J; Hofmann, F; Green, GA; Aktories, K			Inactivation of Ras by Clostridium sordellii lethal toxin-catalyzed glucosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA EXOENZYME-S; TRIPHOSPHATE CONFORMATION; CROSS-REACTIVITY; DIFFICILE; PROTEINS; PURIFICATION; P21	The lethal toxin (LT) from Clostridium sordellii belongs to the family of large clostridial cytotoxins causing morphological alterations in cultured cell lines accompanied by destruction of the actin cytoskeleton. C. sordellii LT exhibits 90% homology to Clostridium difficile toxin B, which has been recently identified as a monoglucosyltransferase (Just, I., Seizer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503). We report here that LT too is a glucosyltransferase, which uses UDP-glucose as cosubstrate to modify low molecular mass GTPases. LT selectively modifies Rac and Ras, whereas the substrate specificity of toxin B is confined to the Rho subfamily proteins Rho, Rac, and Cdc42, which participate in the regulation of the actin cytoskeleton. In Rac, both toxin B and LT share the same acceptor amino acid, threonine 35. Glucosylation of Ras by LT results in inhibition of the epidermal growth factor stimulated p42/p44 MAP-kinase signal pathway. LT is the first bacterial toxin to inactivate Ras in intact cells.	UNIV STRASBOURG 1, FAC MED, LAB TOXINOL BACTERIENNE, F-67000 STRASBOURG, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Just, I (corresponding author), UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, HERMANN HERDER STR 5, D-79104 FREIBURG, GERMANY.		Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BALDACINI O, 1992, TOXICON, V30, P129, DOI 10.1016/0041-0101(92)90466-I; BALDACINI O, 1990, J CHROMATOGR-BIOMED, V528, P357, DOI 10.1016/S0378-4347(00)82394-4; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; CIESIELSKITRESKA J, 1991, EUR J CELL BIOL, V56, P68; COBURN J, 1989, J BIOL CHEM, V264, P9004; COBURN J, 1992, CURR TOP MICROBIOL, V175, P133; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFMANN F, 1995, MOL GEN GENET, V247, P670, DOI 10.1007/BF00290398; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ RD, 1992, J MED MICROBIOL, V36, P30, DOI 10.1099/00222615-36-1-30; MARTINEZ RD, 1988, INFECT IMMUN, V56, P1215, DOI 10.1128/IAI.56.5.1215-1221.1988; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1993, ONCOGENE, V8, P655; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONEICHELSTREIBER C, 1990, GENE, V96, P107, DOI 10.1016/0378-1119(90)90348-U; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; VONEICHELSTREIBER C, 1992, MOL GEN GENET, V233, P260, DOI 10.1007/BF00587587	39	158	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10149	10153		10.1074/jbc.271.17.10149	http://dx.doi.org/10.1074/jbc.271.17.10149			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626575	hybrid			2022-12-25	WOS:A1996UG25700047
J	Nomanbhoy, TK; Cerione, RA				Nomanbhoy, TK; Cerione, RA			Characterization of the interaction between RhoGDI and Cdc42Hs using fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; BOVINE BRAIN CYTOSOL; ACTIVATING PROTEIN; SUBSEQUENT BINDING; RAS P21; IDENTIFICATION; PURIFICATION; HYDROLYSIS; CLONING	The GDP-dissociation-inhibitor (GDI) for Rho-like GTP-binding proteins is capable of three different biochemical activities. These are the inhibition of GDP dissociation, the inhibition of GTP hydrolysis, and the stimulation of the release of GTP-binding proteins from membranes, In order to better understand how GDI interactions with Rho-like proteins mediate these different effects, we have set out to develop a direct fluorescence spectroscopic assay for the binding of the GDI to the Rho-like protein, Cdc42Hs. We show here that when the GDI interacts with Cdc42Hs that contains bound N-methylanthraniloyl GDP (Mant-GDP), there is an similar to 20% quenching of the Mant fluorescence. The GDI-induced quenching is only observed when Mant-GDP is bound to Spodoptera frugiperda-expressed Cdc42Hs and is not detected when the Mant nucleotide is bound to Escherichia coli-expressed Cdc42Hs and thus shows the same requirement for isoprenylated GTP-binding protein as that observed when assaying GDI activity. A truncated Cdc42Hs mutant that lacks 8 amino acids from the carboxyl terminus and is insensitive to GDI regulation also does not show changes in the fluorescence of its bound Mant-GDP upon GDI addition. Thus, the GDI-induced quenching of Mant-GDP provides a direct read out for the binding of the GDI to Cdc42Hs. Titration profiles of the GDI-induced quenching of the Mant-GDP fluorescence are saturable and are well fit to a simple 1:1 binding model for Cdc42Hs-GDI interactions with an apparent K-d value of 30 nM. A very similar K-d value (28 nM) is measured when titrating the GDI-induced quenching of the fluorescence of Mant-guanylyl imidotriphosphate, bound to Cdc42Hs. These results suggest that the GDI can bind to the GDP-bound and GTP-bound forms of Cdc42Hs equally well. Ne also have used the fluorescence assay for GDI interactions to demonstrate that the differences in functional potency observed ed between the GDI molecule and a related human leukemic protein, designated LD4, are due to differences in their binding affinities for Cdc42Hs. This, together with the results from studies using GDI/LD4 chimeras, allow us to conclude that a limit region within the carboxyl-terminal domain of the GDI molecule is responsible for its ability to bind with higher affinity (compared with LD4) to Cdc42Hs.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University; Cornell University					NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRA CN, 1993, GENE CHROMOSOME CANC, V8, P253, DOI 10.1002/gcc.2870080408; ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOMANBHOY TK, 1996, IN PRESS BIOCHEMISTR; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; UEDA T, 1990, J BIOL CHEM, V265, P9373; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	27	105	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10004	10009		10.1074/jbc.271.17.10004	http://dx.doi.org/10.1074/jbc.271.17.10004			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626553	hybrid			2022-12-25	WOS:A1996UG25700025
J	Mark, MR; Chen, J; Hammonds, RG; Sadick, M; Godowsk, PJ				Mark, MR; Chen, J; Hammonds, RG; Sadick, M; Godowsk, PJ			Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING GLOBULIN; LAMININ-A; TYROSINE KINASE; RECEPTOR; DROSOPHILA; ENCODES; GENE; EXPRESSION; MEMBRANES; CELLS	Rse, Axl, and c-Mer comprise a family of cell adhesion molecule-related tyrosine kinase receptors. Human Gas6 was recently shown to act as a ligand for both human Rse (Godowski et al., 1995) and human Axl (Varnum et al., 1995). Gas6 contains an NH2-terminal Gla domain followed by four epidermal growth factor-like repeats and tandem globular (G) domains, The G domains are related to those found in sex hormone-binding globulin and to those utilized by laminin and agrin for binding to the dystroglycan complex. A series of Gas6 variants were tested for their ability to bind to Rse and Axl. The Gla domain and epidermal growth factor-like repeats were not required for receptor binding, as deletion variants of Gas6 which lacked these domains bound to the extracellular domains of both Rse and Axl, A deletion variant of Gas6 containing just the G domain region was shown to activate Rse phosphorylation. These results provide evidence that G domains can act as signaling molecules by activating transmembrane receptor tyrosine kinases. Furthermore, they provide a structural link between the activation of cell adhesion related receptors and the control of cell growth and differentiation by the G domain-containing superfamily of proteins.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT RES IMMUNOCHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech				Hammonds, Glenn/0000-0003-0727-121X				BIESECKER LG, 1995, ONCOGENE, V10, P2239; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GERSHAGEN S, 1987, FEBS LETT, V220, P129, DOI 10.1016/0014-5793(87)80890-6; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; HRYB DJ, 1985, BIOCHEM BIOPH RES CO, V128, P432, DOI 10.1016/0006-291X(85)91697-3; HRYB DJ, 1989, J BIOL CHEM, V264, P5378; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; LAI C, 1994, ONCOGENE, V9, P2567; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; OHASHI K, 1994, ONCOGENE, V9, P669; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; PATTHY L, 1991, FEBS LETT, V289, P99, DOI 10.1016/0014-5793(91)80917-R; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	36	157	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9785	9789		10.1074/jbc.271.16.9785	http://dx.doi.org/10.1074/jbc.271.16.9785			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621659	hybrid			2022-12-25	WOS:A1996UG04400090
J	Oakley, RH; Sar, M; Cidlowski, JA				Oakley, RH; Sar, M; Cidlowski, JA			The human glucocorticoid receptor beta isoform - Expression, biochemical properties, and putative function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; HUMAN PROGESTERONE-RECEPTOR; 3' UNTRANSLATED REGION; GENE-EXPRESSION; DNA-BINDING; MULTIPLE; TRANSCRIPTION; LOCALIZATION; ACTIVATION; RESISTANCE	Alternative splicing of the human glucocorticoid receptor (hGR) primary transcript produces two receptor isoforms, hGR alpha and hGR beta, which differ at their carboxyl termini. The hGR alpha isoform conveys endocrine information to target tissues by altering patterns of gene expression in a hormone-dependent fashion, In contrast to hGR alpha, very little is known about the hGR beta splice variant. Using hGR alpha- and hGR beta-specific riboprobes on human multiple tissue Northern blots, we show that the hGR beta message has a widespread tissue distribution. We also prove by reverse transcriptase-polymerase chain reaction that the alternative splicing event underlying the formation of the hGR beta message occurs in these tissues. Because the hGR beta protein differs from hGR alpha at the extreme COOH terminus, we investigated several of the biochemical properties of hGR beta expressed in transfected cells. hGR beta does not bind the glucocorticoid agonist dexamethasone nor the glucocorticoid antagonist RU38486 in vivo. Moreover, in contrast to hGR beta, hGR beta is located primarily in the nucleus of transfected cells independent of hormone administration, Finally, in the absence of hGR alpha, hGR beta is transcriptionally inactive on a glucocorticoid-responsive enhancer. However, when both isoforms are expressed in the same cell, hGR beta inhibits the hormone-induced, hGR alpha-mediated stimulation of gene expression. Thus, hGR beta potentially functions as a dominant negative inhibitor of hGR alpha activity.	NIEHS,LAB INTEGRAT BIOL,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BRANDON DD, 1989, CANCER RES, V49, pS2203; BRONNEGARD M, 1991, J STEROID BIOCHEM, V39, P693, DOI 10.1016/0960-0760(91)90369-G; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; DAHLMANWRIGHT K, 1992, BIOCHEMISTRY-US, V31, P9040, DOI 10.1021/bi00152a047; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMIN WS, 1991, BIOCHEMISTRY-US, V30, P2570, DOI 10.1021/bi00224a002; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABER PW, 1991, J BIOL CHEM, V266, P10743; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; JONAT G, 1990, CELL, V62, P1189; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUIPER GGJM, 1989, J MOL ENDOCRINOL, V2, pR1, DOI 10.1677/jme.0.002R001; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TULLY DB, 1989, BIOCHEMISTRY-US, V28, P1968, DOI 10.1021/bi00431a003; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WEBSTER JC, 1994, ENDOCRINE, V2, P967; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YEN HFY, 1990, CELL, V62, P1205; ZEINER M, 1993, CANCER RES, V53, P3513	53	457	506	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9550	9559		10.1074/jbc.271.16.9550	http://dx.doi.org/10.1074/jbc.271.16.9550			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621628	hybrid			2022-12-25	WOS:A1996UG04400059
J	Shen, BH; Nolan, JP; Sklar, LA; Park, MS				Shen, BH; Nolan, JP; Sklar, LA; Park, MS			Essential amino acids for substrate binding and catalysis of human flap endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; RAD2; GENE; RNA; COMPLEMENTATION; EXONUCLEASE	Human flap endonuclease 1 (FEN-1) is a member of the structure-specific endonuclease family and is involved in DNA repair, Eight restrictively conserved amino acids in FEN-1 have been converted individually to an alanine to elucidate their roles in specific DNA substrate binding and catalysis. Flap endonuclease activity of the wild type and mutant enzymes was measured by kinetic flow cytometry. Mutants D34A, D86A, and D181A lost their cleavage activity completely but retained substrate binding ability, as measured by their ability to inhibit the wild type enzyme in a competition assay. This indicates that these amino acids contribute to integrity of the enzyme active site. Loss of both binding and cleavage competency for the flap substrate by mutants E156A, G231A, and D233A suggests that these amino acids are involved in substrate binding. Mutants R103A and D179A retained wild type-like enzyme activity.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,NATL FLOW CYTOMETRY RESOURCE,LOS ALAMOS,NM 87545; UNIV NEW MEXICO,SCH MED,DEPT CYTOMETRY,ALBUQUERQUE,NM 87131	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico			Park, Min Sung/HCH-2207-2022	Shen, Binghui/0000-0002-4408-407X				BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BEEZE LS, 1991, EMBO J, V10, P25; BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; LOPEZ P, 1989, J BIOL CHEM, V264, P4255; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Saenger W, 1991, CURR OPIN STRUC BIOL, V1, P130, DOI 10.1016/0959-440X(91)90021-K; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004	30	98	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9173	9176		10.1074/jbc.271.16.9173	http://dx.doi.org/10.1074/jbc.271.16.9173			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621570	hybrid			2022-12-25	WOS:A1996UG04400001
J	Xu, ZC; Yang, YH; Hebert, SC				Xu, ZC; Yang, YH; Hebert, SC			Phosphorylation of the ATP-sensitive, inwardly rectifying K+ channel, ROMK, by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; CYSTIC-FIBROSIS; APICAL MEMBRANE; ION CHANNELS; TYROSINE; CAMP; IDENTIFICATION	Activity of the recently cloned ATP-sensitive epithelial K+ channel, ROMK (He, K., Nichols, C. G., Lederer, W. J., Lytton, J., Vassilev, P. M., Kanazirska, M. V., and Hebert, S. C. (1993) Nature 362, 31-38), is regulated by phosphorylation-dephosphorylation processes with cAMP-dependent protein kinase (PKA)-dependent phosphorylation events being required for maintenance of channel activity in excised membrane patches (McNicholas, C. M., Wang, W., Ho, K., Hebert, S. C., and Giebisch, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8077-8081; Kubokawa, M., McNicholas, C. M., Higgins, M. A., Wang, W., and Giebisch, G. (1995) Am. J. Physiol. 269, F355-F362). To determine whether this channel is a substrate for PKA, ROMK tagged with the hemagglutinin epitope was transiently transfected into HEK293 cells. lit vitro labeling of immunoprecipitated proteins from transfected cells showed that ROMK could be phosphorylated by PKA. Metabolic labeling of ROMK resulted in a significantly increased phosphorylation upon pretreatment of the cells with forskolin, consistent with an action of cAMP-dependent protein kinase. Phosphoamino acid analyses of the ROMK phosphoproteins revealed that phosphate was attached exclusively to serine residues. Three putative PKA phosphorylation sites containing serine residues in the predicted ROMK proteins are shown directly to be substrates for PKA. Site-directed mutagenesis of each of these sites or double mutation of any two sites showed that ROMK proteins retained the ability to be phosphorylated by PKA both in vivo and in vitro to a variable extent, while triple mutation of all three PKA sites abolished the phosphorylation induced by cAMP agonists in transfected cells. Two-electrode voltage clamp experiments showed that PKA-dependent phosphorylation was required for ROMK channel activity and that at least two of the three sites were required for channel function when expressed in X. laevis oocytes. Taken together, these results provide strong evidence that direct phosphorylation of the channel polypeptide by PKA is involved in channel regulation and PKA-dependent phosphorylation is essential for ROMK, channel activity.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,LAB MOLEC PHYSIOL & BIOPHYS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 37605] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BIOM MA, 1995, AM J PHYSIOL, V268, pF1132; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; GOTTARDI GJ, 1995, AM J PHYSIOL, V268, pF285; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HEBERT S, 1984, AM J PHYSIOL, V252, pC121; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V269, pF355, DOI 10.1152/ajprenal.1995.269.3.F355; KUBOKAWA M, 1995, AM J PHYSIOL-RENAL, V268, pF211, DOI 10.1152/ajprenal.1995.268.2.F211; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Misler S, 1992, Curr Opin Nephrol Hypertens, V1, P21, DOI 10.1097/00041552-199210000-00005; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; WANG W, 1994, AM J PHYSIOL, V267, pF1076; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	44	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9313	9319		10.1074/jbc.271.16.9313	http://dx.doi.org/10.1074/jbc.271.16.9313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621594	hybrid			2022-12-25	WOS:A1996UG04400025
J	Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M				Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M			Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: Possible roles of AP-1	ONCOGENE			English	Article						H-ras; EGF receptor; AP-1; dominant negative c-jun	DENSITY-LIPOPROTEIN RECEPTOR; TRANSCRIPTION FACTOR AP-1; TUMOR-NECROSIS-FACTOR; MIDDLE T-ANTIGEN; C-FOS GENE; PROTO-ONCOGENE; MALIGNANT TRANSFORMATION; CHEMICAL CARCINOGENS; MOLECULAR-CLONING; TYROSINE KINASE	We previously reported that introduction of H-ras oncogene decreases the epidermal growth factor (EGF) binding activity to cell surface EGF receptor in mouse Balb/3T3, In this study, we have further isolated four H-ras transfectants, four v-myc transfectants and three both H-ras and v-myc (H-ras/v-myc) transfectants of mouse Balb/3T3 cells. In comparison with introduction of v-myc alone or both H-ras and v-myc oncogenes, introduction of H-ras alone resulted in a loss of [I-125]EGF binding activity to the cell surface EGF receptor, RT-PCR analysis also showed much lower levels of EGF receptor gene expression in H-ras transfectants compared to that of parental untransformed cells (Balb-Neo1), v-myc and H-ras/v-myc transfectants, Our results demonstrated the activated binding of a transcription factor, Stat1 p84/p91, which directly interacts with EGF receptor, to c-sis-inducible element (SIE) in both v-myc and H-ras/v-myc transfectants, but not in H-ras transfectants, Among transcription factors which we have analysed, activator protein 1 (AP-1) but not SP-1 was modulated by H-ras. Gel shift assays demonstrated the mobility pattern of TPA-responsive element (TRE) binding complex with AP-1 derived from H-ras transfectants migrated faster than those from Balb-Neo1, v-myc and H-ras/v-myc. Expression of c-Jun and Fra-1 was increased more than threefold in H-ras transfectants compared with Balb-Neo1, v-myc and H-ras/v-myc transfectants, but that of c-Fos, Jun B and SP-1 was unchanged, Both transient and permanent expression of H-ras enhanced AP-1 activity in mouse cells, but further co-introduction of dominant negative c-jun mutant encoding a transcriptionally inactive product inhibited the H-ras dependent AP-1 induction, Transfection of the dominant negative c-jun mutant also restored down-regulation of EGF binding by activated H-ras oncogene, Down-regulation of EGF receptor by activated H-ras and the possible involvement of a transcription factor, AP-1, will be discussed.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN; SOROKA MED CTR,LAB ONCOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,DEPT MICROBIOL & IMMUNOL,IL-84105 BEER SHEVA,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,FREDERICK,MD 21702	Kyushu University; Ben Gurion University; Soroka Medical Center; Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Gopas, Jacob/0000-0001-9289-8898				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROWN PH, 1993, ONCOGENE, V8, P877; CARBONE A, 1991, ONCOGENE, V6, P731; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DELAGE SB, 1994, J BIOL CHEM, V269, P18686; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DONG ZG, 1994, CARCINOGENESIS, V15, P1001, DOI 10.1093/carcin/15.5.1001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRISCH SM, 1990, ONCOGENE, V5, P75; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOPAS J, 1992, CELL MOL BIOL, V38, P605; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURATOMI Y, 1987, J CELL PHYSIOL, V130, P51, DOI 10.1002/jcp.1041300109; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; ONO M, 1992, EXP CELL RES, V203, P456, DOI 10.1016/0014-4827(92)90021-Y; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHITE S, 1988, J BIOL CHEM, V263, P19286; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEM DF, 1986, MOL CELL BIOL, V6, P870; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TANIGUCHI S, 1986, JPN J CANCER RES, V77, P1193; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMITA K, 1987, J BIOL CHEM, V262, P1398; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YASUTAKE C, 1987, CANCER RES, V47, P4894	59	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1625	1633						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622882				2022-12-25	WOS:A1996UG45800004
J	Azakie, A; Larkin, SB; Farrance, IK; Grenningloh, G; Ordahl, CP				Azakie, A; Larkin, SB; Farrance, IK; Grenningloh, G; Ordahl, CP			DTEF-1, a novel member of the transcription enhancer factor-1 (TEF-1) multigene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAT BINDING-FACTOR; FACTOR-I TEF-1; GENE-EXPRESSION; MYOD FAMILY; ACTIVATION; ELEMENT; MOUSE; SEQUENCE; HOMOLOGY; PROMOTER	M-CAT motifs mediate muscle-specific transcriptional activity via interaction with binding factors that are antigenically and biochemically related to vertebrate transcription enhancer factor-1 (TEF-1), a member of the TEA/ATTS domain family of transcription factors. M-CAT binding activities present in cardiac and skeletal muscle tissues cannot be fully accounted for by existing cloned isoforms of TEF-1. TEF-1-related cDNAs isolated from heart libraries indicate that at least three classes of TEF-1-related cDNAs are expressed in these and other tissues. One class are homologues of the human TEF-1 originally cloned from HeLa cells (Xiao, J. H., Davidson, I., Matthes, H., Garnier, J. M., and Chambon, P. (1991) Cell 65, 551-568). A second class represents homologues of the avian TEF-1-related gene previously isolated (Stewart, A. F., Larkin, S. B., Farrance, I. K., Mar, J. H., Hall, D. E., and Ordahl, C. P. (1994) J. Biol. Chem. 269, 3147-3150). The third class consists of a novel, divergent TEF-1 cDNA, named DTEF-1, and its preliminary characterization is described here. Two isoforms of DTEF-1 (DTEF-1A and DTEF-1B) were isolated as 1.9-kilobase pair clones with putative open reading frames of 433 and 432 amino acids whose differences are attributable to alternative splicing at the C terminus of the TEA DNA binding domain. Cardiac muscle contains high levels of DTEF-1 transcripts, but unexpectedly low levels are detected in skeletal muscle, DTEF-1 transcripts are present at intermediate levels in gizzard and lung, and at low levels in kidney. DTEF-1A is a sequence-specific M-CAT-binding factor. The distinct spatial pattern of expression, and unusual amino acid sequence in its DNA binding domain, may indicate a particular role for DTEF-1 in cell-specific gene regulation. Recent work also suggests that at least one more TEF-1-related gene exists in vertebrates. We propose a naming system for the four TEF-1 gene family members identified to date that preserves existing nomenclature and provides a means for extending that nomenclature as additional family members may be identified.	UNIV CALIF SAN DIEGO, CARDIOVASC RES INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN DIEGO, CARDIOVASC RES INST, DEPT SURG, SAN FRANCISCO, CA 94143 USA; GLAXO INST MOLEC BIOL SA, CH-1211 GENEVA, SWITZERLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline					NHLBI NIH HHS [HL-43821, HL-35561] Funding Source: Medline; PHS HHS [FO5 24892] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035561, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Farrance IKG, 1996, J BIOL CHEM, V271, P8266, DOI 10.1074/jbc.271.14.8266; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GULICK J, 1991, J BIOL CHEM, V266, P9180; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MIRABITO PM, 1989, CELL, V57, P859, DOI 10.1016/0092-8674(89)90800-3; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	32	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8260	8265		10.1074/jbc.271.14.8260	http://dx.doi.org/10.1074/jbc.271.14.8260			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626520	hybrid			2022-12-25	WOS:A1996UD60000060
J	McGwire, BS; Chang, KP				McGwire, BS; Chang, KP			Posttranslational regulation of a Leishmania HEXXH metalloprotease (gp63) - The effects of site-specific mutagenesis of catalytic, zinc binding, N-glycosylation, and glycosyl phosphatidylinositol addition sites on N-terminal end cleavage, intracellular stability, and extracellular exit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SURFACE GLYCOPROTEIN; MEXICANA-AMAZONENSIS; PROTEINASE GP63; EXPRESSION; GENES; VIRULENCE; PROTEASE; ANTIGEN; PROMASTIGOTES; MACROPHAGES	Leishmanolysin (EC 3.4.24.36) (gp63) is a HEXXH metalloprotease, encoded by multicopied genes in Leishmania and implicated in the infectivity of these parasitic protozoa. We examined posttranslational regulation of gp63 expression by site-specific mutagenesis of the predicted catalytic/zinc-binding sites in the H(264)EXXH motif, the potential sites of N-glycosylation and glycosyl phosphatidylinositol addition. Mutant and wild-type genes were cloned into a Leishmania-specific vector for transfecting a deficient variant, which produced gp63 similar to 20-fold less than wild-type cells. The selective conditions chosen fully restored this deficiency in transfectants with the wild-type gene. Under these conditions, all transfectants were found comparable in both the plasmid copy number per cell and elevation of gp63 transcripts. Mutant and wild-type products in the transfectants were then compared quantitatively and qualitatively by specific immunologic and protease assays. The results indicate the following. 1) Glu-265 in the HEXXH motif is indispensable for the catalytic activity of gp63. The propeptide of the inactive mutant products was cleaved, suggestive of a non-intramolecular event. 2) Substitution of either His residue in HEXXH leads to apparent intracellular degradation of the mutant products, pointing to a role for zinc binding in in vivo stability of gp63. 3) The three potential sites of N-glycosylation at Asn-300, Asn-407, and Asn-534 are all utilized and contribute to intracellular stability of gp63. 4) Substitution of Asn-577 causes release of all mutant products, indicative of its specificity as a glycosyl phosphatidylinositol addition site for membrane anchoring of gp63. It is suggested that expression of gp63 as a functional protease is regulated by these posttranslational modification pathways.	UNIV HLTH SCI CHICAGO MED SCH,DEPT MICROBIOL IMMUNOL,N CHICAGO,IL 60064	Chicago Medical School					NIAID NIH HHS [AI-20486] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020486] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; BUTTON LL, 1993, GENE, V134, P75, DOI 10.1016/0378-1119(93)90176-4; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ETGES R, 1986, J BIOL CHEM, V261, P9098; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; GEHM BD, 1993, J BIOL CHEM, V268, P7943; IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97; KINK JA, 1988, MOL BIOCHEM PARASIT, V27, P181, DOI 10.1016/0166-6851(88)90037-0; KINK JA, 1987, P NATL ACAD SCI USA, V84, P1253, DOI 10.1073/pnas.84.5.1253; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAFRANCE MH, 1994, BIOCHEM J, V302, P451, DOI 10.1042/bj3020451; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; LIU X, 1994, MOL BIOCHEM PARASIT, V66, P201, DOI 10.1016/0166-6851(94)90147-3; MABROUK T, 1994, J VIROL, V68, P5287, DOI 10.1128/JVI.68.8.5287-5290.1994; MCGWIRE B, 1994, MOL BIOCHEM PARASIT, V66, P345, DOI 10.1016/0166-6851(94)90160-0; MCMASTER WR, 1994, PARASITOLOGY, V108, pS29, DOI 10.1017/S0031182000075697; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SU B, 1989, MOL CELL BIOL, V9, P3369, DOI 10.1128/MCB.9.8.3369; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WATANABE S, 1992, VIROLOGY, V190, P872, DOI 10.1016/0042-6822(92)90928-I; WEBB EC, 1992, RECOMMENDATIONS NOME, P415; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WEI L, 1991, J BIOL CHEM, V266, P9002; WILSON ME, 1993, J BIOL CHEM, V268, P15731	48	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7903	7909		10.1074/jbc.271.14.7903	http://dx.doi.org/10.1074/jbc.271.14.7903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626468	hybrid			2022-12-25	WOS:A1996UD60000008
J	Reedquist, KA; Fukazawa, T; Panchamoorthy, G; Langdon, WY; Shoelson, SE; Druker, BJ; Band, H				Reedquist, KA; Fukazawa, T; Panchamoorthy, G; Langdon, WY; Shoelson, SE; Druker, BJ; Band, H			Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ZETA-CHAIN; LEUCINE ZIPPER; V-CBL; ONCOGENE; BINDING; DOMAIN; IDENTIFICATION; CD4	We and others have recently identified Cbl, the protein product of the c-cbl protooncogene, as an early tyrosine kinase substrate upon T cell activation and have shown that Cbl forms in vivo complexes with Src family tyrosine kinases, Grb2 adaptor protein, and the p85 subunit of PI-3 kinase. Here we show that Cbl associates with all three forms of the human Crk protein, predominantly CrkL, following T cell receptor activation of Jurkat T cells. Association between Cbl and Crk proteins was confirmed in normal human peripheral blood-derived T cells. In vitro, Cbl was able to interact with the Crk SH2 domain but not the SH3 domain. A phosphopeptide corresponding to a potential Crk SH2 domain-binding motif in Cbl (pYDVP) specifically inhibited binding between Cbl and Crk SH2 domain. Anti-Cbl antibody completely immunodepleted the CrkL-associated 120-kDa phosphotyrosyl polypeptide, suggesting that the recently described p130(cas)-related Crk-associated p116 of T cells may be Cbl. Consistent with this possibility, the 4F4 antibody used to characterize the p116 polypeptide cross-reacted with Cbl protein when it was resolved on one- or two-dimensional gels. CrkL was constitutively associated with a substantial amount of the guanine nucleotide exchange protein C3G, and a fraction of the C3G protein was coimmunoprecipitated with Cbl in activated Jurkat T cells. These results suggest the possibility that Cbl may participate in a signaling pathway that regulates guanine nucleotide exchange on small G-proteins in T cells.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,LYMPHOCYTE BIOL SECT, DIV RHEUMATOL & IMMUNOL,DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR, DEPT MED, BOSTON, MA 02115 USA; UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Western Australia; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022	Druker, Brian/0000-0001-8331-8206	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	168	172	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8435	8442		10.1074/jbc.271.14.8435	http://dx.doi.org/10.1074/jbc.271.14.8435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626543	hybrid			2022-12-25	WOS:A1996UD60000083
J	Roesler, WJ; Crosson, SM; Vinson, C; McFie, PJ				Roesler, WJ; Crosson, SM; Vinson, C; McFie, PJ			The alpha-isoform of the CCAAT/enhancer-binding protein is required for mediating cAMP responsiveness of the phosphoenolpyruvate carboxykinase promoter in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 C/EBP ISOFORMS; GTP GENE; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENT; KINASE-C; EXPRESSION; ACTIVATION; ENHANCER; FAMILY; IDENTIFICATION	The gene coding for phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) is expressed in all gluconeogenic tissues, but stimulation of its rate of transcription by cAMP is robust only in liver, Evidence has accumulated which suggests that a liver-enriched transcription factor, likely a member of the CCAAT/enhancer binding protein (C/EBP) family, is required along with other ubiquitously expressed transcription factors to mediate this liver-specific response to cAMP. In this study, we examined the ability of C/EBP to participate in the cAMP-mediated activation of phosphoenolpyruvate carboxykinase (PEPCK) gene transcription in hepatoma cells, Expression of a dominant repressor of C/EBP in hepatoma cells significantly inhibited the protein kinase A-stimulated transcription of the PEPCK promoter, suggesting that a C/EBP family member was required for maximal transcriptional activation by protein kinase A. To provide additional support for this hypothesis, we prepared GAL4 fusion proteins containing C/EBP domains. Both C/EBP alpha and C/EBP beta GAL4 fusion proteins were capable of stimulating transcription from promoters containing binding sites for the DNA-binding domain of GAL4, However, only the GAL4-C/EBP alpha fusion protein demonstrated the ability to synergize with the other transcription factors bound to the PEPCK promoter which are required to mediate cAMP responsiveness, The DNA-binding domain of C/EBP alpha was not required for this activity in hepatoma cells, although in non-hepatoma cells the basic region leucine zipper domain appeared to inhibit the ability of C/EBP alpha to participate in mediating cAMP responsiveness, These results suggest that the liver-specific nature of the cAMP responsiveness of the PEPCK promoter involves the recruitment of C/EBP alpha to the cAMP response unit.	NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roesler, WJ (corresponding author), UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON,SK S7N 5E5,CANADA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1875; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124	43	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8068	8074		10.1074/jbc.271.14.8068	http://dx.doi.org/10.1074/jbc.271.14.8068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626491	hybrid			2022-12-25	WOS:A1996UD60000031
J	Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N				Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N			Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q-associated leukemias	ONCOGENE			English	Article						tumor suppressor; translation	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; CELL-GROWTH; BETA GENES; INDUCTION; CHROMOSOME; ELEMENTS; DELETION; SYSTEM	The transcription factor IRF-1 (interferon regulatory factor 1) is an activator of type I interferon and interferon-inducible genes. IRF-1 manifests tumor suppresser activity. Its overexpression results in inhibition of cell growth, and gene were demonstrated in leukemias and myelodysplasias. Although the mechanism by which IRF-1 affects cell growth is unknown, it is believed that IRF-1 activates a Set of genes that negatively regulate cell growth. The double-stranded RNA-dependent protein kinase (PKR), which is an interferon-inducible gene, contains a promoter element for the binding of IRF-1 and exhibits antiproliferative properties. Consequently, we investigated the role of IRF-1 in PKR expression. Here, we show that in IRF-1-deficient embryonic fibroblasts, PKR expression is reduced relative to wildtype cells. This result predicts diminished expression of PKR as a potential consequence of deletion of the IRF-1 gene in human leukemias. We show that cells of the human leukemic U937 cell line contain a deletion of one IRF-1 gene and express low levels of PKR. We demonstrate that upregulation of IRF-1 expression in U937 cells by transfection is sufficient to induce PKR expression. We also found a marked reduction in the expression of PKR in blood samples from two patients with myelodysplasias, carrying a deletion of chromosome 5q, a locus to which IRF-1 was mapped. These results show that IRF-1 activates PKR expression and suggest that loss of one allele of the IRF-1 gene is sufficient to affect PKR expression. Therefore, PKR is a strong candidate for a mediator of the tumor suppressor activity of IRF-1.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; HOP ST LOUIS,INST MOLEC GENET,INSERM U301,F-75010 PARIS,FRANCE; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Michigan System; University of Michigan				Laura, Beretta/0000-0002-2054-684X				CHANG CH, 1992, IMMUNOGENETICS, V35, P378; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KIRCHHOFF S, 1995, NUCLEIC ACIDS RES, V11, P439; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MITELMAN F, 1994, HUMAN GENE MAPPING 1, P773; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532	28	65	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1593	1596						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622878				2022-12-25	WOS:A1996UF07600026
J	Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD				Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD			Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability	ONCOGENE			English	Article						replication errors (RER); repetitive sequences; nucleic acid; genomic instability; colon cancer; HPRT	GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; MISMATCH REPAIR; COLORECTAL-CANCER; HUMAN FIBROBLASTS; HPRT GENE; MUTATIONS; DNA; FRAMESHIFT	Colon cancer and an increasing number of other cancers have been found to exhibit instability of DNA microsatellite sequences. Such tumors have been designated as replication errors (RER) tumors. However, as microsatellites are only rarely found within coding regions of the genome, instability of these sequences cannot directly contribute to carcinogenesis. Recently, we have shown RER colon cancers also demonstrate a marked 100-fold increase in mutation rates measured within an expressed gene, hprt, suggesting the mutator phenotype in these tumors extends beyond microsatellite sequences. To determine whether the RER phenotype indeed destabilizes non-repetitive DNA sequences we have sequenced hprt gene mutations recovered from the RER colon cancer cell line RKO. Greater than 10% of hprt mutants proved to be a single 3 bp deletion located in a nonrepetitive ATTAT sequence motif. Additionally, 1-4 bp deletions or insertions were found to be randomly located throughout the hprt gene. Lastly, one third of hprt mutations proved to be transitions or transversions. The microsatellite instability demonstrated in RKO is thus a global mutator phenotype which destabilizes DNA sequences both inside and outside of repetitive sequence elements and which augments base substitutions as well as frameshifts. These findings extend the characteristics of mutations associated with RER tumors and suggest additional mechanisms by which mutator phenotypes may alter target oncogenes and tumor suppressor genes.	UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Case Western Reserve University; Duke University; Howard Hughes Medical Institute			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [P01CA051183, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA4370301, CA57208, P01 CA51183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSSON B, 1992, ENVIRON MOL MUTAGEN, V20, P89, DOI 10.1002/em.2850200204; BAO CY, 1995, MUTAT RES-FUND MOL M, V326, P1, DOI 10.1016/0027-5107(94)00152-U; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANKE M, 1994, BIOTECHNIQUES, V17, P858; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LITT M, 1989, AM J HUM GENET, V44, P397; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORRIS T, 1993, SOMAT CELL MOLEC GEN, V19, P9, DOI 10.1007/BF01233950; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1994, GENETICS, V138, P263; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARK MS, 1995, RADIAT RES, V141, P11, DOI 10.2307/3579084; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71	42	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1425	1432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622858				2022-12-25	WOS:A1996UF07600006
J	Beerli, RR; Hynes, NE				Beerli, RR; Hynes, NE			Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; TYROSINE PHOSPHORYLATION; PROTEIN; GENE; AMPHIREGULIN; EXPRESSION; MEMBER; FAMILY; LIGAND; EGF	Numerous epidermal growth factor (EGF)-related peptide binding members of the ErbB family of receptor tyrosine kinases have been described. While several EGF agonists bind and activate ErbB-1/EGF receptor, neu differentiation factor (NDF) functions as a ligand for ErbB-3 and ErbB-4. However, it is currently unknown which specific subsets of ErbB receptors become activated in response to each of these ligands. The present study addresses this issue using the T47D breast tumor cell line, which expresses moderate levels of all the presently known ErbB receptors. We show that all the EGF agonists, but not NDF, stimulated tyrosine phosphorylation of ErbB-1. In contrast, all the EGF-related factors except amphiregulin were able to induce tyrosine phosphorylation of ErbB-2. The ability to induce tyrosine phosphorylation of ErbB-3 varied dramatically among the different EGF-related peptides. While EGF, transforming growth factor (TGF)-alpha, and amphiregulin only had a moderate effect, NDF dramatically increased the ErbB-3 phosphotyrosine content. Most notably, heparin binding EGF-related growth factor (HB-EGF) and betacellulin (BTC) were more effective than other EGF agonists. Consequently, only NDF, HB-EGF, and BTC significantly stimulated association of phosphatidylinositol kinase activity with ErbB-3. Among the EGF agonists, HB-EGF induced a low level of ErbB-4 tyrosine phosphorylation, while BTC was as efficient as NDF in activating ErbB-4. The BTC activation of ErbB-4 appears to be independent of ErbB-1, as shown by pretreatment of cells with an antibody that inhibits binding of EGF agonists to ErbB-1. As a result of the differential activation of ErbB receptors, most of the EGF-related growth factors had distinguishable biological activities on cultured mammary epithelial cell lines.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RIESE DJ, 1996, IN PRESS ONCOGENE; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOULE HD, 1990, CANCER RES, V50, P6075; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WATANABE T, 1994, J BIOL CHEM, V269, P9966; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	49	265	275	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6071	6076		10.1074/jbc.271.11.6071	http://dx.doi.org/10.1074/jbc.271.11.6071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626392	hybrid			2022-12-25	WOS:A1996UA36300021
J	Waegemann, K; Soll, J				Waegemann, K; Soll, J			Phosphorylation of the transit sequence of chloroplast precursor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS NUCLEAR IMPORT; SV40 T-ANTIGEN; ESCHERICHIA-COLI; MITOCHONDRIAL; BINDING; TRANSPORT; ATP; TRANSLOCATION; PEPTIDES; KINASE	A protein kinase was located in the cytosol of pea mesophyll cells. The protein kinase phosphorylates, in an ATP-dependent manner, chloroplast-destined precursor proteins but not precursor proteins, which are located to plant mitochondria or plant peroxisomes. The phosphorylation occurs on either serine or threonine residues, depending on the precursor protein used. We demonstrate the specific phosphorylation of the precursor forms of the chloroplast stroma proteins ferredoxin (preFd), small subunit of ribulose-bisphosphate-carboxylase (preSSU), the thylakoid localized light-harvesting chlorophyll alb-binding protein (preLHCP), and the thylakoid lumen-localized proteins of the oxygen-evolving complex of 23 kDa (preOE23) and 33 kDa (preOE33). In the case of thylakoid lumen proteins which possess bipartite transit sequences, the phosphorylation occurs within the stroma-targeting domain. By using single amino acid substitution within the presequences of preSSU, preOE23, and preOE33, we were able to tentatively identify a consensus motif for the precursor protein protein kinase. This motif is (P/G)X(n)(R/K)X(n)(S/ T)X(n)(S*/T*), were n = 03 amino acids spacer and S*/T* represents the phosphate acceptor. The precursor protein protein kinase is present only in plant extracts, e.g. wheat germ and pea, but not in a reticulocyte lysate. Protein import experiments into chloroplasts revealed that phosphorylated preSSU binds to the organelles, but dephosphorylation seems required to complete the translocation process and to obtain complete import. These results suggest that a precursor protein protein phosphatase is involved in chloroplast import and represents a so far unidentified component of the import machinery, In contrast to sucrose synthase a cytosolic marker protein, the precursor protein protein kinase seems to adhere partially to the chloroplast surface. A phosphorylation-dephosphorylation cycle of chloraplast-destined precursor proteins might represent one step, which could lead to a specific sorting and productive translocation in plant cells.			Waegemann, K (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, AM BOT GARTEN 1-9, D-24118 KIEL, GERMANY.				NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOUTRY M, 1985, EMBO J, V4, P2159, DOI 10.1002/j.1460-2075.1985.tb03910.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DESHAIES RJ, 1988, NATURE, V322, P228; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; GEIGENBERGER P, 1993, PLANTA, V189, P329, DOI 10.1007/BF00194429; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HRACKY R, 1986, Z NATURFORSCH C, V41, P856; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; Innis MA, 1990, PCR PROTOCOLS GUIDE; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKINTOSH C, 1993, PROTEIN PHOSPHORYLAT, P197; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; REISS B, 1989, P NATL ACAD SCI USA, V86, P886, DOI 10.1073/pnas.86.3.886; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SOLL J, 1995, BOT ACTA, V108, P277, DOI 10.1111/j.1438-8677.1995.tb00495.x; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YASUNOBU KT, 1980, METHOD ENZYMOL, V69, P228; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x; [No title captured]	56	158	167	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6545	6554		10.1074/jbc.271.11.6545	http://dx.doi.org/10.1074/jbc.271.11.6545			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626459	hybrid			2022-12-25	WOS:A1996UA36300088
J	MacKenzie, AB; MahautSmith, MP; Sage, SO				MacKenzie, AB; MahautSmith, MP; Sage, SO			Activation of receptor-operated cation channels via P-2X1 not P-2T purinoceptors in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ATP	We have investigated the purinoceptor subtypes responsible for calcium signaling in human platelets, which previous studies have shown to involve both Ca2+ influx via receptor-operated cation channels and release of Ca2+ from intracellular stores. Fura-2 measurements of [Ca2+](i) in stirred platelet suspensions showed that both ADP (40 mu M) and the non-hydrolyzable ATP analogue alpha beta-meATP (alpha,beta-methyleneadenosine 5'-triphosphate, 10 mu M) activated a rapid Ca2+ influx whereas only ADP mobilized Ca2+ from internal stores. In ''nystatin'' whole cell patch clamp recordings, ATP, ADP, and the non-hydrolyzable ATP analogues, alpha beta-meATP and ATP gamma S (adenosine 5'-O-(3-thiotriphosphate), all activated a cation channel permeable to both monovalent and divalent cations with a single-channel conductance of 11 picosiemens in NaCl saline. The current response to ATP (40 mu M) was activated within 20 ms and desensitized with a time constant of 47-107 ms in the continued presence of agonist, which are characteristics of P-2X1 receptors in other tissues. We conclude that human platelets possess a P-2X1 purinoceptor, which mediates a rapid phase of ADP- or ATP-evoked Ca2+ entry via a cation channel, whereas one or more separate ADP-selective P-2 purinoceptors evoke release of calcium from intracellular stores.	PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	University of Cambridge				Sage, Stewart/0000-0001-8578-3558				BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BUELL G, 1995, IN PRESS SOC NEUR AB; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; KHAKH BS, 1995, BRIT J PHARMACOL, V115, P177, DOI 10.1111/j.1476-5381.1995.tb16336.x; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAHAUTSMITH MP, 1992, J BIOL CHEM, V267, P3060; PINTOR J, 1993, BRIT J PHARMACOL, V108, P1094, DOI 10.1111/j.1476-5381.1993.tb13510.x; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; STIENBERG TH, 1987, J BIOL CHEM, V262, P8884; SUPRENANT A, 1995, TRENDS NEUROSCI, V18, P224; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I	19	182	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2879	2881		10.1074/jbc.271.6.2879	http://dx.doi.org/10.1074/jbc.271.6.2879			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621673	hybrid			2022-12-25	WOS:A1996TU69100002
J	Befort, K; Tabbara, L; Kling, D; Maigret, B; Kieffer, BL				Befort, K; Tabbara, L; Kling, D; Maigret, B; Kieffer, BL			Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACETYLCHOLINE-BINDING; EXPRESSION; ACTIVATION; CLONING; M3-MUSCARINIC-RECEPTOR; DOPAMINE	In the present study we examine the role of transmembrane aromatic residues of the delta-opioid receptor in ligand recognition. Three-dimensional computer modeling of the receptor allowed to identify an aromatic pocket within the helices bundle which spans transmembrane domains (Tms) III to VII and consists of tyrosine, phenylalanine, and tryptophan residues. Their contribution to opioid binding was assessed by single amino acid replacement: Y129F and Y129A (Tm III), W173A (Tm IV), F218A and F222A (Tm V), W274A (Tm VI), and Y308F (Tm VII). Scatchard analysis shows that mutant receptors, transfected into COS cells, are expressed at levels comparable with that of the wild-type receptor. Binding properties of a set of representative opioids were examined. Mutations at position 129 most dramatically affected the binding of all tested ligands (up to 430-fold decrease of deltorphin II binding at Y129A), with distinct implication of the hydroxyl group and the aromatic ring, depending on the ligand under study. Affinity of most ligands was also reduced at Y308F mutant (up to 10-fold). Tryptophan residues seemed implicated in the recognition of specific ligand classes, with reduced binding for endogenous peptides at W173A mutant (up to 40-fold) and for nonselective alkaloids at W274A mutant (up to 65-fold). Phenylalanine residues in Tm V appeared poorly involved in opioid binding as compared with other aromatic amino acids examined. Generally, the binding of highly selective delta ligands (TIPP psi naltrindole, and BW373U86) was weakly modified by these mutations. Noticeably, TIPP psi binding was enhanced at W274A receptor by 5-fold. Conclusions from our study are: (i) aromatic amino acid residues identified by the model contribute to ligand recognition, with a preponderant role of Y129; (ii) these residues, which are conserved across opioid receptor subtypes, may be part of a general opioid binding domain; (iii) each ligand-receptor interaction is unique, as demonstrated by the specific binding pattern observed for each tested opioid compound.	UNIV NANCY 1,FAC SCI,CHIM THEOR LAB,F-54506 VANDOEUVRE NANCY,FRANCE	Universite de Lorraine	Befort, K (corresponding author), ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR 9050,LAB RECEPTEURS & PROT MEMBRANNAIRES,F-67400 ILLKIRCH GRAFFENS,FRANCE.							BARNARD EA, 1993, CURR BIOL, V3, P211, DOI 10.1016/0960-9822(93)90335-L; Befort K, 1996, MOL PHARMACOL, V49, P216; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FONG TM, 1993, NATURE, V362, P350; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; JOSEPH MP, 1995, J PROTEIN CHEM, V14, P381, DOI 10.1007/BF01886795; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KONG HY, 1994, P NATL ACAD SCI USA, V91, P8042, DOI 10.1073/pnas.91.17.8042; KONG HY, 1993, J BIOL CHEM, V268, P23055; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MINAMI M, 1995, FEBS LETT, V364, P23, DOI 10.1016/0014-5793(95)00340-F; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; OLAH ME, 1992, J BIOL CHEM, V267, P10764; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; PERLMAN JH, 1994, J BIOL CHEM, V269, P1610; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REES DC, 1990, OPIOID RECEPTORS, P805; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JB, 1994, J BIOL CHEM, V269, P25966; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; XUE JC, 1995, J BIOL CHEM, V270, P12977; XUE JC, 1994, J BIOL CHEM, V269, P30195; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024	35	151	155	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10161	10168		10.1074/jbc.271.17.10161	http://dx.doi.org/10.1074/jbc.271.17.10161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626577	hybrid			2022-12-25	WOS:A1996UG25700049
J	HellerHarrison, RA; Morin, M; Guilherme, A; Czech, MP				HellerHarrison, RA; Morin, M; Guilherme, A; Czech, MP			Insulin-mediated targeting of phosphatidylinositol 3-kinase to GLUT4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATABLE GLUCOSE TRANSPORTER; ISOLATED RAT ADIPOCYTES; PLASMA-MEMBRANE; GLUT4; TRANSLOCATION; PROTEIN; STIMULATION; CELLS; INTERNALIZATION; LOCALIZATION	Phosphatidylinositol (PI) 3-kinase is hypothesized to be a signaling element in the acute redistribution of intracellular GLUT4 glucose transporters to the plasma membrane in response to insulin. However, some receptors activate PI 3-kinase without causing GLUT4 translocation, suggesting specific cellular localization may be critical to this PI 3-kinase function. Consistent with this idea, complexes containing PI 3-kinase bound to insulin receptor substrate 1 (IRS-1) in 3T3-L1 adipocytes are associated with intracellular membranes (Heller-Harrison, R., Morin, M. and Czech, M. (1995) J. Biol. Chem. 270, 24442-24450). We report here that in response to insulin, activated complexes of IRS-1-PI 3-kinase can be immunoprecipitated with anti-IRS-1 antibody from detergent extracts of immunoadsorbed GLUT4-containing vesicles prepared from 3T3-L1 adipocytes. The targeting of PI 3-kinase to rat adipocyte GLUT4-containing vesicles using vesicles prepared by sucrose velocity gradient ultracentrifugation was also demonstrated, Insulin treatment caused a 2.3-fold increase in immunoreactive p85 protein in these GLUT4-containing vesicles while anti-p85 immunoprecipitates of PI 3-kinase activity in GLUT4-containing vesicle extracts increased to a similar extent. HPLC analysis of the GLUT4 vesicle-associated PI 3-kinase activity showed insulin-mediated increases in PI 3-P, PI 3,4-P-2, and PI 3,4,5-P-3 when PI, PI 4-P, and PI 4,5-P-2 were used as substrates. Our data demonstrate that insulin directs the association of PI 3-kinase with GLUT4-containing vesicles in 3T3-L1 and rat adipocytes, consistent with the hypothesis that PI 3-kinase is involved in the insulin-regulated movement of GLUT4 to the plasma membrane.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	HellerHarrison, RA (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.				NIDDK NIH HHS [DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; ISAOFF S, 1995, P NATL ACAD SCI USA, V92, P10247; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, J BIOL CHEM, V268, P14523; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKA Y, 1984, J BIOL CHEM, V259, P8125; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITE MF, 1994, J BIOL CHEM, V269, P1; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	40	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10200	10204		10.1074/jbc.271.17.10200	http://dx.doi.org/10.1074/jbc.271.17.10200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626583	hybrid			2022-12-25	WOS:A1996UG25700055
J	Maillet, I; Lagniel, G; Perrot, M; Boucherie, H; Labarre, J				Maillet, I; Lagniel, G; Perrot, M; Boucherie, H; Labarre, J			Rapid identification of yeast proteins on two-dimensional gels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; SACCHAROMYCES-CEREVISIAE; 2-DIMENSIONAL ELECTROPHORESIS; SEQUENCE DATABASES; POLYPEPTIDES	This work describes a rapid and sensitive technique for the identification of Saccharomyces cerevisiae proteins on two-dimensional gels based on the determination of their amino acid ratios. Specific double labeling with H-3 and C-14 or S-35-labeled amino acids, chosen among those that are specifically incorporated into proteins without interconversion, allowed an accurate measurement of different amino acid ratios for 200 proteins. A computer program was developed to screen a yeast data base containing 1700 protein sequences and to identify proteins matching the measured M(r), pI, and amino acid ratios. The method, tested with 45 reference proteins, allowed 79 new identifications corresponding to abundant proteins belonging to a few functional families. Some protein spots correspond to homologs of mammalian proteins or to uncharacterized open reading frames. Remarkably, among identified proteins of similar abundance, the organellar proteins have a markedly lower codon usage bias than the cytosolic ones. The double labeling technique is particularly suited to the analysis, on a single two dimensional gel, of the influence of physiological or genetic changes on yeast protein content.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE; INST BIOCHIM & GENET CELLULAIRES,CNRS,UPR 9026,F-33077 BORDEAUX,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)								BATAILLE N, 1988, ELECTROPHORESIS, V9, P774, DOI 10.1002/elps.1150091113; BATAILLE N, 1987, YEAST, V3, P11, DOI 10.1002/yea.320030104; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; GARRELS JI, 1994, ELECTROPHORESIS, V15, P1466, DOI 10.1002/elps.11501501210; GODEL H, 1984, J CHROMATOGR, V297, P49, DOI 10.1016/S0021-9673(01)89028-2; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HOBOHM U, 1994, ANAL BIOCHEM, V222, P202, DOI 10.1006/abio.1994.1474; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; JUNGBLUT P, 1992, J PROTEIN CHEM, V11, P603, DOI 10.1007/BF01024960; KLIER H, 1992, ELECTROPHORESIS, V13, P732, DOI 10.1002/elps.11501301157; LATTER GI, 1984, CLIN CHEM, V30, P1925; LUDWIG JR, 1982, MOL CELL BIOL, V2, P117, DOI 10.1128/MCB.2.2.117; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; MORTIMER RK, 1986, GENETICS, V113, P35; NEIDHARDT FC, 1989, ELECTROPHORESIS, V10, P116, DOI 10.1002/elps.1150100206; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NORBECK J, 1995, ELECTROPHORESIS, V16, P149, DOI 10.1002/elps.1150160124; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SHAW G, 1993, P NATL ACAD SCI USA, V90, P5138, DOI 10.1073/pnas.90.11.5138; SIBBALD PR, 1991, ANAL BIOCHEM, V198, P330, DOI 10.1016/0003-2697(91)90434-U	27	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10263	10270		10.1074/jbc.271.17.10263	http://dx.doi.org/10.1074/jbc.271.17.10263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626593	hybrid			2022-12-25	WOS:A1996UG25700065
J	Hogue, DL; Ellison, MJ; Young, JD; Cass, CE				Hogue, DL; Ellison, MJ; Young, JD; Cass, CE			Identification of a novel membrane transporter associated with intracellular membranes by phenotypic complementation in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NUCLEOSIDE TRANSPORT; HUMAN FIBROBLAST LYSOSOMES; FUNCTIONAL EXPRESSION; PYRIMIDINE NUCLEOSIDES; BROAD-SPECIFICITY; BINDING PROTEIN; LEUKEMIA-CELLS; XENOPUS-LAEVIS; CLONING; SYSTEM	A partial mouse cDNA was isolated by its ability to functionally complement a thymidine transport deficiency in plasma membranes of the yeast, Saccharomyces cerevisiae, The full-length cDNA encoded a previously unidentified 27-kDa protein (mouse transporter protein (MTP)) with four predicted transmembrane-spanning domains, MTP mRNA was detected in cells of several mammalian species, and its predicted protein sequence exhibited near identity (98%) with that of a human cDNA (HUMORF13), MTP and its homologs evidently reside in an intracellular membrane compartment because a protein (about 24 kDa) that was recognized by MTP-specific antibodies was observed in a subcellular fraction of rat hepatocytes enriched for Gels membranes. Deletion of the hydrophilic C terminus of MTP, which encompassed two putative signal motifs for intracellular localization (Tyr-X-X-hydrophobic amino acid), allowed expression of recombinant protein (MTP Delta C) in plasma membranes of Xenopus laevis oocytes, MTP Delta C-expressing oocytes exhibited greater fragility than nonexpressing oocytes, and those that survived the experimental manipulations were capable of mediated uptake of thymidine, uridine, and adenosine, Thymidine uptake by MTP Delta C-expressing oocytes was inhibited by thymine and dTMP. MTP may function in the transport of nucleosides and/or nucleoside derivatives between the cytosol and the lumen of an intracellular membrane-bound compartment.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT PHYSIOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta								Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARCLAY BJ, 1982, CAN J BIOCHEM CELL B, V60, P172, DOI 10.1139/o82-023; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERNSTIEL ML, 1985, CELL, V41, P349; CAPPASO JM, 1989, J BIOL CHEM, V264, P5233; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAWFORD CR, 1990, J BIOL CHEM, V265, P9732; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; GRIVELL AR, 1968, J GEN MICROBIOL, V54, P307, DOI 10.1099/00221287-54-2-307; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; JARVIS SM, 1991, BIOCHEM J, V278, P605, DOI 10.1042/bj2780605; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAISER C, 1989, METHODS YEAST GENETI, P15; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDLEY ER, 1993, BIOCHEM J, V290, P457, DOI 10.1042/bj2900457; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCNEIL JB, 1981, MOL GEN GENET, V184, P386, DOI 10.1007/BF00352510; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PISONI RL, 1989, J BIOL CHEM, V264, P4850; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO S, 1988, J BIOCHEM, V103, P678, DOI 10.1093/oxfordjournals.jbchem.a122328; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TSIFTSOGLOU AS, 1972, BIOCHIM BIOPHYS ACTA, V262, P239, DOI 10.1016/0005-2787(72)90259-6; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; WALKER LF, 1987, MOL CELL BIOCHEM, V77, P71; WOHLHUETER RM, 1979, BIOCHIM BIOPHYS ACTA, V553, P262, DOI 10.1016/0005-2736(79)90231-1; WU XC, 1992, J BIOL CHEM, V267, P8813	48	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9801	9808		10.1074/jbc.271.16.9801	http://dx.doi.org/10.1074/jbc.271.16.9801			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621662	hybrid			2022-12-25	WOS:A1996UG04400093
J	Morgan, RW; ElSayed, NMA; Kepa, JK; Pedram, M; Donelson, JE				Morgan, RW; ElSayed, NMA; Kepa, JK; Pedram, M; Donelson, JE			Differential expression of the expression site-associated gene I family in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE GLYCOPROTEIN GENES; RNA POLYMERASE-I; T-BRUCEI; TRANSCRIPTION UNIT; BLOOD-STREAM; ANTIGEN; IDENTIFICATION; IRRADIATION; RHODESIENSE; SEQUENCE	A minimum of 20 different mRNA species encoding related members of the expression site-associated gene I (ESAG-I) family occur in metacyclic variant antigen type 4 bloodstream trypanosomes, None of these ESAG-I mRNAs are derived from the metacyclic variant antigen type 4 variant surface glycoprotein (VSG) gene expression site, and some appear to come from pseudogenes, The ESAG-Is are transcribed in both procyclic and bloodstream trypanosomes, but their mRNAs accumulate to a detectable steady state level only in bloodstream trypanosomes. At least five different groups of 3'-untranslated regions (3'-UTRs) are represented among these ESAG-I mRNAs, suggesting that the 3'-UTR does not contribute to their differential expression, Some ESAG-I mRNAs completely lack a 3'-UTR or have only a single nucleotide as a 3'-UTR, Transcription of the ESAG-Is is sensitive to oc-amanitin, indicating that they are transcribed by a different RNA polymerase than the VSG genes, These results collectively demonstrate that ESAG-I's are a heterogeneous population that can be expressed independently of VSG genes, but like the VSG genes, their mRNAs are present in the bloodstream stage of the parasite and not in the procyclic stage.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010; Pedram, Mehrdad/L-4072-2016; El-Sayed, Najib M.A./K-7266-2015	Pedram, Mehrdad/0000-0002-7348-3475; El-Sayed, Najib M.A./0000-0001-7970-3312				ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; BARNES DA, 1990, MOL BIOCHEM PARASIT, V41, P101, DOI 10.1016/0166-6851(90)90101-Q; BARRELL BG, 1979, NATURE, V282, P189, DOI 10.1038/282189a0; BELIN D, 1979, P NATL ACAD SCI USA, V76, P700, DOI 10.1073/pnas.76.2.700; BERBEROF M, 1995, EMBO J, V14, P2925, DOI 10.1002/j.1460-2075.1995.tb07292.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COQUELET H, 1989, MOL CELL BIOL, V9, P4022, DOI 10.1128/MCB.9.9.4022; COQUELET H, 1991, MOL BIOCHEM PARASIT, V44, P33, DOI 10.1016/0166-6851(91)90218-U; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; CULLY DF, 1986, MOL BIOCHEM PARASIT, V21, P189, DOI 10.1016/0166-6851(86)90022-8; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ELSAYED NM, 1995, MOL BIOCHEM PARASIT, V473, P75; ESSER KM, 1982, J IMMUNOL, V129, P1715; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREDMAN P, 1983, J BIOL CHEM, V258, P1206; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; GRAHAM SV, 1991, MOL BIOCHEM PARASIT, V47, P31, DOI 10.1016/0166-6851(91)90145-V; HAJDUK S, 1992, AM J MED SCI, V303, P258, DOI 10.1097/00000441-199204000-00011; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; KEPA K, 1990, THESIS U IOWA; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1985, CELL, V42, P821, DOI 10.1016/0092-8674(85)90278-8; POULIS MI, 1981, BIOCHEMISTRY-US, V20, P4178, DOI 10.1021/bi00517a035; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SON HJ, 1989, MOL BIOCHEM PARASIT, V33, P59, DOI 10.1016/0166-6851(89)90042-X; THON G, 1990, GENE DEV, V9, P1374; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	39	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9771	9777		10.1074/jbc.271.16.9771	http://dx.doi.org/10.1074/jbc.271.16.9771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621657	hybrid			2022-12-25	WOS:A1996UG04400088
J	Tang, HY; Chaffotte, AF; Thacher, SM				Tang, HY; Chaffotte, AF; Thacher, SM			Structural analysis of the predicted coiled-coil rod domain of the cytoplasmic bullous pemphigoid antigen (BPAG1) - Empirical localization of the N-terminal globular domain-rod boundary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DESMOPLAKIN-I; CULTURED KERATINOCYTES; ERYTHROCYTE SPECTRIN; MOLECULAR-STRUCTURE; DESMOSOMAL PLAQUE; EPITHELIAL-CELLS; PROTEIN; EXPRESSION; HEMIDESMOSOMES	The bullous pemphigoid antigen BPAG1 is required for keratin filament linkage to the hemidesmosome, an adhesion complex in epithelial basal cells, BPAG1 structural organization is similar to the intermediate filament-associated proteins desmoplakin I (DPI) and plectin, All three proteins have predicted dumbbell-like structure with central alpha-helical coiled-coil rod and regions of N- and C-terminal homology, To characterize the size of the N-terminal globular domain in BPAG1, two polypeptides spanning possible boundaries with the coiled-coil rod domain of BPAG1 were expressed in Escherichia coli, BP-1 (M(r) = 111,000), containing amino acids 663-1581 of BPAG1 (Sawamura, D., Li, K., Chu, M.-L., and Uitto, J, (1991) J, Biol, Chem, 266, 17784-17790), and BP-1A, with a 186 amino acid N-terminal deletion, were purified, BP-1 and BP-1A behave as highly asymmetric dimers in aqueous solution according to velocity sedimentation and gel filtration, Both have globular heads with rod-like tails of roughly equal length, 55-60 nm, upon rotary shadowing, BP-1A content of cu-helix, determined by circular dichroism, is similar to 90%, consistent with alpha-helical coiled-coil formation in the rod-like tails, The estimated rod length, 383 +/- 57 amino acids (0.15 nm/amino acid), implies that globular folding in the BPAG1 N-terminal extends to the end of N-terminal homology with DPI and plectin. These findings support the existence of a common domain structure in the N-terminal regions of the BPAG1/DPI/plectin family.	TEXAS A&M UNIV, COLL MED, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, COLL AGR, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								ACKERS GK, 1967, J BIOL CHEM, V242, P3237; AIYER RA, 1983, J BIOL CHEM, V258, P4992; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COMPTON CC, 1989, LAB INVEST, V60, P600; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; ISHIKO A, 1993, J CLIN INVEST, V91, P1608, DOI 10.1172/JCI116368; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KLATTE DH, 1994, J INVEST DERMATOL, V2, P39; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LEACH SJ, 1960, J AM CHEM SOC, V82, P4790, DOI 10.1021/ja01503a008; LI K, 1991, J BIOL CHEM, V266, P24064; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCNALLY E, 1991, METHOD ENZYMOL, V196, P368; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NOZAKI Y, 1976, BIOCHEMISTRY-US, V15, P3884, DOI 10.1021/bi00662a036; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; OWARIBE K, 1990, DIFFERENTIATION, V45, P207, DOI 10.1111/j.1432-0436.1990.tb00475.x; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TANDON S, 1987, J BIOL CHEM, V262, P4486; TANG HY, 1993, THESIS TEXAS A M U; THACHER SM, 1991, EXP CELL RES, V194, P238, DOI 10.1016/0014-4827(91)90360-7; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THACHER SM, 1991, J INVEST DERMATOL, V96, P139, DOI 10.1111/1523-1747.ep12515936; VANHOLDE KE, 1985, PHYSICAL BIOCH; VIRATA MLA, 1992, P NATL ACAD SCI USA, V89, P544, DOI 10.1073/pnas.89.2.544; WHITBY FG, 1992, J MOL BIOL, V227, P441, DOI 10.1016/0022-2836(92)90899-U; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; YANG JT, 1986, METHOD ENZYMOL, V130, P208	55	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9716	9722		10.1074/jbc.271.16.9716	http://dx.doi.org/10.1074/jbc.271.16.9716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621649	hybrid			2022-12-25	WOS:A1996UG04400080
J	Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A				Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A			Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice	ONCOGENE			English	Article						thyroid; oncogene; tyrosine-kinase; mice	RET TYROSINE KINASE; PROTO-ONCOGENE; PROTOONCOGENE; TUMORIGENESIS; MUTATIONS; NEOPLASIA; FUSION; INVIVO; GENE; LINE	Gene rearrangements activating the RET proto-oncogene are frequently associated with human thyroid carcinomas belonging to the papillary subtype, These rearrangements cause the fusion of the tyrosine-kinase domain of RET to the 5-terminal region of different genes creating the RET/PTC chimeric oncogenes. Here we report the generation of transgenic mice lines expressing the RET/PTC1 oncogene under the control of the thyroid-specific rat thyroglobulin promoter. RET/PTC1-transgenic mice developed thyroid tumors displaying the histological aspect of papillary carcinomas. These tumors were slowly progressive and did not cause premature death of the animals. Two additional mice developed areas of thyroid hyperplasia. Immunohistochemical and reverse-transcriptase polymerase chain reaction analyses confirmed the thyroid-specific expression of the transgene. Given the frequency of activating rearrangements of RET in human papillary thyroid carcinomas we conclude that this animal system could be a good model for studying the neoplastic progression of thyroid carcinomas.	FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY.		Salvatore, Domenico/D-4881-2013; Portella, Giuseppe/AFU-6826-2022; Cerrato, Aniello/AAY-1484-2020	Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; SALVATORE, DOMENICO/0000-0002-4556-7620				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BIANCIFIORI C, 1979, 23 IARC, V2, P451; BOND JA, 1994, ONCOGENE, V9, P281; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOGAN B, 1986, MANIPULATING MOUSE E; IWAMOTO T, 1990, ONCOGENE, V5, P535; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LANZI C, 1992, ONCOGENE, V7, P2189; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MONACO C, 1995, INT J CANCER, V63, P757, DOI 10.1002/ijc.2910630525; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; PORTELLA G, 1989, ONCOGENE, V4, P181; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTELLI G, 1993, CANCER RES, V53, P1; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; [No title captured]	39	207	218	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1821	1826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622903				2022-12-25	WOS:A1996UG45800025
J	Abeijon, C; Mandon, EC; Robbins, PW; Hirschberg, CB				Abeijon, C; Mandon, EC; Robbins, PW; Hirschberg, CB			A mutant yeast deficient in golgi transport of uridine diphosphate N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; GUANOSINE DIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; VESICLE MEMBRANES; UDP-GALACTOSE; GLYCOSYLATION; TRANSLOCATION; APPARATUS; TOPOGRAPHY; PROTEIN	Mannan chains of Kluyveromyces lactis mannoproteins are similar to those of Saccharomyces cerevisiae except that they have terminal alpha 1-2-linked N-acetylglucosamine and lack mannose phosphate. In a previous study, Douglas and Ballou (Douglas, R. K., and Ballou, C. E. (1982) Biochemistry 21, 1561-1570) characterized a mutant, mnn2-2, which lacked terminal N-acetylglucosamine in its mannoproteins. The mutant had normal levels of N-acetylglucosaminyltransferase activity, and the partially purified enzyme from wild-type and mutant cells had the same apparent size, heat stability, affinity for substrates, metal requirement, and subcellular location. No qualitative or quantitative differences were found between mutant and wild-type cells in endogenous mannan accepters and pools of UDP-GlcNAc. Chitin was synthesized at similar rates in wild-type and mutant cells, and the latter did not have a soluble inhibitor of the N-acetylglucosaminyltransferase or a hexosaminidase that could remove N-acetylglucosamine from mannoproteins. Together, the above observations led Douglas and Ballou ((1982) Biochemistry 21, 1561-1570) to postulate that the mutant might have a defect in compartmentation of substrates involved in the biosynthesis of mannoproteins. We determined whether the above mutant phenotype is the result of defective transport of UDP-GlcNAc into Golgi vesicles from K. lactis. Golgi vesicles which were sealed and of the same membrane topographical orientation as in vivo were isolated from wild-type and mnn2-2 mutant cells and incubated with UDP-GlcNAc in an assay in vitro. The initial rate of transport of UDP-GlcNAc into Golgi vesicles from wild-type cells was temperature dependent, saturable with an apparent Ii, of 5.5 mu M and a V-max of 8.2 pmol/mg of protein/3 min. No transport of UDP-GlcNAc was detected into Golgi vesicles from mutant cells. However, Golgi vesicles from both cells translocated GDP-mannose at comparable velocities, indicating that the above transport defect is specific. In addition to the above defect in mannoproteins, mutant cells were also deficient in the biosynthesis of glucosamine containing lipids.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT)				Hirschberg, Carlos/0000-0003-2299-7721; Robbins, Phillips/0000-0002-5121-1524	NIGMS NIH HHS [GM45188, GM30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365, R01GM045188] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ABEIJON C, 1988, P NATL ACAD SCI USA, V85, P1010, DOI 10.1073/pnas.85.4.1010; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BERNINSONE P, 1995, J BIOL CHEM, V270, P14564, DOI 10.1074/jbc.270.24.14564; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOUGLAS RH, 1982, BIOCHEMISTRY-US, V21, P1561, DOI 10.1021/bi00536a015; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KROKOW JL, 1986, J BIOL CHEM, V261, P12147; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1985, J BIOL CHEM, V260, P4671; RASCHKE WC, 1972, BIOCHEMISTRY-US, V11, P3807, DOI 10.1021/bi00770a021; SMITH WL, 1975, J BIOL CHEM, V250, P3426; Toma L, 1996, J BIOL CHEM, V271, P3897; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351	21	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8851	8854		10.1074/jbc.271.15.8851	http://dx.doi.org/10.1074/jbc.271.15.8851			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621525	hybrid			2022-12-25	WOS:A1996UE73000056
J	Hu, ZW; Shi, XY; Lin, RZ; Hoffman, BB				Hu, ZW; Shi, XY; Lin, RZ; Hoffman, BB			alpha(1) Adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells - Role in mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SIGNALING PATHWAYS; G-PROTEIN; KINASE; ACCUMULATION; INHIBITION; COMPLEX; INDUCE; BIND	Activation of alpha(1) adrenergic receptors stimulates mitogenesis in human vascular smooth muscle cells (HVSMCs), To examine signaling pathways by which activation of alpha(1) receptors may induce mitogenesis in HVSMCs, we have found that alpha(1) receptor stimulated-DNA synthesis and activation of mitogen-activated protein (MAP) kinase are blocked by wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), To determine directly if activation of alpha(1) receptors stimulated PI 3-kinase, in vitro assays of kinase activity were performed in immunocomplexes precipitated by an antibody against the p85 alpha subunit of PI 3-kinase, Noradrenaline stimulated a time- and concentration-dependent activation of PI 3-kinase in the presence of a beta adrenergic receptor antagonist, Noradrenaline-stimulated PI 3-kinase activation was blocked by antagonists of alpha(1) receptors and by pertussis toxin, suggesting that alpha(1) receptors activate PI 3-kinase via a pertussis toxin-sensitive G protein. Direct activation of protein kinase C by a phorbol ester did not stimulate PI 3-kinase; also, a Ca2+ L-channel blocker did not inhibit noradrenaline-stimulated PI 3-kinase activity, Increased PI S-kinase activity was detected in both anti-Pas and anti-phosphotyrosine immunoprecipitates from noradrenaline-stimulated HVSMCs, Moreover, noradrenaline stimulated formation of active Ras-GTP complexes, Because blockade of PI S-kinase by wortmannin inhibited formation of this complex, this result suggests that Pas might be a target of PI 3-kinase, Noradrenaline stimulated tyrosine phosphorylation of the p85 subunit of PI 3-kinase, and a phosphorylated tyrosine protein could be co-immuno precipitated with anti-p85 of PI 3-kinase, These results demonstrate that stimulation of alpha(1) receptors activates PI 3-kinase in HVSMCs and that alpha(1) receptor-activated PI 3-kinase is associated with an increase in active Ras-GTP and activation of tyrosine protein phosphorylation, These pathways may contribute to alpha(1) receptor-stimulated mitogenic responses including activation of MAP kinase and DNA synthesis in HVSMCs.	STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University	Hu, ZW (corresponding author), VET ADM MED CTR,GRECC 182B,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.		Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; FUKUI Y, 1991, ONCOGENE, V6, P407; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MINNEMAN KP, 1994, ANNU REV PHARMACOL, V34, P117; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	34	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8977	8982		10.1074/jbc.271.15.8977	http://dx.doi.org/10.1074/jbc.271.15.8977			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621543	hybrid			2022-12-25	WOS:A1996UE73000074
J	Erlich, R; Gleeson, PA; Campbell, P; Dietzsch, E; Toh, BH				Erlich, R; Gleeson, PA; Campbell, P; Dietzsch, E; Toh, BH			Molecular characterization of trans-Golgi p230 - A human peripheral membrane protein encoded by a gene on chromosome 6p12-22 contains extensive coiled-coil alpha-helical domains and a granin motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; GLOBULAR PROTEINS; LEUCINE-ZIPPER; PREDICTION; COMPLEX; CONFORMATION; TRANSLATION; EXPRESSION; PATTERNS	Using autoantibodies from a Sjogren's syndrome patient, we have previously identified a 230-kDa peripheral membrane protein associated with the cytosolic face of the trans-Golgi (Kooy, J., Toh, B. H., Pettitt, J. M., Erlich, R. and Gleeson, P. A. (1992) J. Biol. Chem. 267, 20255-20263), Here we report the molecular cloning and sequence analysis of human p230 and the localization of its gene to chromosome 6p12-22, Partial cDNA clones, isolated from a HeLa cell cDNA library using autoantibodies, were used to obtain additional cDNAs, which together span 7695 base pairs (bp), The p230 mRNA is similar to 7.7 kilobases. Two alternatively spliced mRNAs for p230 were detected, These differed by 21- and 63-bp insertions in the 3'-sequence, resulting in differences in amino acid sequence at the carboxyl terminus, The predicted 261-kDa protein is highly hydrophilic with 17-20% homology with many proteins containing coiled-coil domains, Apart from two proline-rich regions (amino acids 1-117 and 239-270), p230 contains a very high frequency of heptad repeats, characteristic of alpha-helices that form dimeric coiled-coil structures, p230 also includes the sequence ESLALEELEL (amino acids 538-546), a motif found in the granin family of acidic proteins present in secretory granules of neuroendocrine cells, This is the first report of a cytosolic Golgi protein containing a granin motif. The structural characteristics of p230 indicate that it may play a role in vesicular transport from the trans-Golgi.	MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,MELBOURNE,VIC 3181,AUSTRALIA; FLINDERS MED CTR,DEPT CLIN IMMUNOL,BEDFORD PK,SA,AUSTRALIA; UNIV CAPE TOWN,SCH MED,DEPT BIOCHEM MED,CAPE TOWN 7925,SOUTH AFRICA	Monash University; Flinders Medical Centre; University of Cape Town				Gleeson, Paul/0000-0002-5336-6503				ALDERUCCIO F, 1993, J EXP MED, V178, P419, DOI 10.1084/jem.178.2.419; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHOMCZYNSKI P, 1992, NUCLEIC ACIDS RES, V20, P3791, DOI 10.1093/nar/20.14.3791; CHOO KH, 1991, PROTOCOLS HUMAN MOL, V7, P233; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDOW SA, 1994, J CELL SCI, V107, P859; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NARULA A, 1995, P NATL ACAD SCI USA, V92, P2874; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WEBBER LM, 1983, PATHOLOGY, V15, P112; WEBBER LM, 1983, CANCER GENET CYTOGEN, V8, P123, DOI 10.1016/0165-4608(83)90044-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012	55	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8328	8337		10.1074/jbc.271.14.8328	http://dx.doi.org/10.1074/jbc.271.14.8328			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626529	hybrid			2022-12-25	WOS:A1996UD60000069
J	Frins, S; Bonigk, W; Muller, F; Kellner, R; Koch, KW				Frins, S; Bonigk, W; Muller, F; Kellner, R; Koch, KW			Functional characterization of a guanylyl cyclase-activating protein from vertebrate rods - Cloning, heterologous expression, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSITIVE ACTIVATOR; OUTER SEGMENTS; PHOTOTRANSDUCTION; PURIFICATION; RECOVERIN	The membrane-bound guanylyl cyclase in vertebrate photoreceptor cells is one of the key enzymes in visual transduction. It is highly sensitive to the free calcium concentration ([Ca2+]). The activation process is cooperative and mediated by a novel calcium-binding protein named GCAP (guanylyl cyclase-activating protein). We isolated GCAP from bovine rod outer segments, determined amino acid sequences of proteolytically obtained peptides, and cloned its gene. The Ca2+-bound form of native GCAP has an apparent molecular mass of 20.5 kDa and the Ca2+-free form of 25 kDa as determined by SDS-polyacrylamide gel electrophoresis. Recombinant GCAP was functionally expressed in Escherichia coli. Activation of guanylyl cyclase in vertebrate photoreceptor cells by native acylated GCAP was half-maximal at 100 nM free [Ca2+] with a Hill coefficient of 2.5. Activation by recombinant nonacylated GCAP showed a lower degree of cooperativity (n = 2.0), and half-maximal activation was shifted to 261 nM free [Ca2+]. Immunocytochemically we localized GCAP only in rod and cone cells of a bovine retina.	FORSCHUNGSZENTRUM JULICH, FORSCHUNGSZENTRUM, INST BIOL INFORMAT VERARBEITUNG, D-52425 JULICH, GERMANY; UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY	Helmholtz Association; Research Center Julich; Johannes Gutenberg University of Mainz			Mueller, Frank/I-7196-2013; Koch, Karl-Wilhelm/C-9551-2015	Mueller, Frank/0000-0001-7264-1227; Koch, Karl-Wilhelm/0000-0003-1501-0044				DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAKKI S, 1990, BIOCHEMISTRY-US, V29, P1088, DOI 10.1021/bi00456a035; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1992, COLLOQ INSE, V221, P391; KOCH KW, 1994, EUR J BIOCHEM, V222, P589, DOI 10.1111/j.1432-1033.1994.tb18901.x; KOCH KW, 1991, J BIOL CHEM, V266, P8634; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LAMBRECHT HG, 1991, FEBS LETT, V294, P207, DOI 10.1016/0014-5793(91)80670-X; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RATTO GM, 1988, J NEUROSCI, V8, P3240; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUBBARAYA I, 1994, J BIOL CHEM, V269, P31080; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024	32	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8022	8027		10.1074/jbc.271.14.8022	http://dx.doi.org/10.1074/jbc.271.14.8022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626484	hybrid			2022-12-25	WOS:A1996UD60000024
J	Kounnas, MZ; Church, FC; Argraves, WS; Strickland, DK				Kounnas, MZ; Church, FC; Argraves, WS; Strickland, DK			Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha(1)-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-1-PROTEINASE INHIBITOR; ANTI-THROMBIN; NEUTROPHIL CHEMOATTRACTANT; PLASMINOGEN-ACTIVATOR; INVIVO CATABOLISM; SERINE PROTEINASE; HUMAN-PLASMA; ELASTASE	The inhibition of proteinase activity by members of the serine proteinase inhibitor (serpin) family is a critical regulatory mechanism for a variety of biological processes. Once formed, the serpin enzyme complexes (SECs) are removed from the circulation by a hepatic receptor. The present study suggests that this receptor is very likely the low density lipoprotein receptor-related protein (LRP), a prominent liver receptor. In vitro binding studies revealed that antithrombin III (ATIII) thrombin, heparin cofactor II (HCII). thrombin, and alpha(1)-antitrypsin (alpha(1)-AT). trypsin bound to purified LRP, and their binding was inhibited by the 39-kDa receptor-associated protein (RAP), an antagonist of LRP-ligand binding activity, In contrast, native or modified forms of the inhibitors were unable to bind to LRP. Mouse embryonic fibroblasts, which express LRP, mediate the cellular internalization leading to degradation of these SECs, while mouse fibroblasts genetically deficient in LRP showed no capacity to internalize and degrade these complexes, SECs were also degraded by HepG2 cells, and this process was inhibited by LRP antibodies, RAP, and chloroquine. The cellular-mediated uptake and degradation was specific for SECs; native or modified forms of the inhibitors were not internalized and degraded. Finally, in vivo clearance studies in rats demonstrated that RAP inhibited the clearance of ATIII I-125-thrombin complexes from the circulation. Together, these results indicate that LRP functions as a liver receptor responsible for the plasma clearance of SECs.	AMER RED CROSS, DEPT BIOCHEM, HOLLAND LAB, ROCKVILLE, MD 20855 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL & MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	American Red Cross; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BAUER PI, 1982, THROMB RES, V28, P595, DOI 10.1016/0049-3848(82)90151-7; BJORK I, 1986, PROTEINASE INHIBITOR, P489; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHURCH FC, 1994, TRENDS CARDIOVAS MED, V4, P140, DOI 10.1016/1050-1738(94)90066-3; CHURCH FC, 1995, MOL BASIS THROMBOSIS, V18, P379; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; FUCHS HE, 1982, BIOCHIM BIOPHYS ACTA, V716, P151, DOI 10.1016/0304-4165(82)90263-X; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOFFMAN M, 1989, BLOOD, V73, P1682; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LANE DA, 1991, THROMB HAEMOSTASIS, V66, P657; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LOLLAR P, 1980, J CLIN INVEST, V66, P1222, DOI 10.1172/JCI109973; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1984, RECEPTORS, P177; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; RAO NV, 1991, J BIOL CHEM, V266, P9540; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SHIFMAN MA, 1982, J BIOL CHEM, V257, P3243; SIE P, 1985, LANCET, V2, P414; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TRAN TH, 1985, LANCET, V2, P413; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	62	136	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6523	6529		10.1074/jbc.271.11.6523	http://dx.doi.org/10.1074/jbc.271.11.6523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626456	hybrid			2022-12-25	WOS:A1996UA36300085
J	Li, ZS; Szczypka, M; Lu, YP; Thiele, DJ; Rea, PA				Li, ZS; Szczypka, M; Lu, YP; Thiele, DJ; Rea, PA			The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; SACCHAROMYCES-CEREVISIAE; EXPORT PUMP; RAT-LIVER; ATP; TRANSPORT; S-(2,4-DINITROPHENYL)GLUTATHIONE; PURIFICATION; SUBUNITS; CELLS	The yeast cadmium factor gene (YCF1) from Saccharomyces cerevisiae, which was isolated according to its ability to confer cadmium resistance, encodes a 1,515-amino acid ATP-binding cassette (ABC) protein with extensive sequence homology to the human multidrug resistance-associated protein (MRP1) (Szczypka, M., Wemmie, J. A., Moye-Rowley, W. S., and Thiele, D. J, (1994) J. Biol. Chem. 269, 22853-22857). Direct comparisons between S. cerevisiae strain DTY167, harboring a deletion of the YCF1 gene, and the isogenic wild type strain, DTY165, demonstrate that YCF1 is required for increased resistance to the toxic effects of the exogenous glutathione S-conjugate precursor, 1-chloro-2,4-di nitrobenzene, as well as cadmium. Whereas membrane vesicles isolated from DTY165 cells contain two major pathways for transport of the model compound S-(2,4-dinitrophenyl)glutathione (DNP-GS), an MgATP-dependent, uncoupler-insensitive pathway and an electrically driven pathway. the corresponding membrane fraction from DTY167 cells is more than 90% impaired for MgATP-dependent, uncoupler-insensitive DNP-GS transport. Of the two DNP-GS transport pathways identified, only the MgATP-dependent, uncoupler-insensitive pathway is subject to inhibition by glutathione disulfide, vanadate, verapamil, and vinblastine. The capacity for MgATP-dependent, uncoupler-insensitive conjugate transport in vitro strictly copurifies with the vacuolar membrane fraction. Intact DTY165 cells, but not DTY167 cells, mediate vacuolar accumulation of the fluorescent glutathione-conjugate, monochlorobimane-GS. Introduction of plasmid borne, epitope-tagged gene encoding functional YCF1 into DTY167 cells alleviates the 1-chloro-2,4-dinitrobenzene hypersensitive phenotype concomitant with restoration of the capacity of vacuolar membrane vesicles isolated from these cells for MgATP-dependent, uncoupler-insensitive DNP-GS transport. On the basis of these findings, the YCF1 gene of S. cerevisiae is inferred to encode an MgATP-energized, uncoupler insensitive vacuolar glutathione S-conjugate transporter. The energy requirements, kinetics, substrate specificity, and inhibitor profile of YCF1-mediated transport demonstrate that the vacuolar glutathione conjugate pump of yeast bears a strong mechanistic resemblance to the MRP1-encoded transporter of mammalian cells and the cognate, but as yet molecularly undefined, function of plant cells.	UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Pennsylvania; University of Michigan System; University of Michigan					NIEHS NIH HHS [1R01 ES06902] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006902] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ELFERINK RO, 1993, HEPATOLOGY, V17, P343; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; ISHIKAWA T, 1995, IN PRESS INT ISSI WO; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KOSOWER EM, 1980, J AM CHEM SOC, V102, P4983, DOI 10.1021/ja00535a028; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KUNST M, 1989, BIOCHIM BIOPHYS ACTA, V983, P123, DOI 10.1016/0005-2736(89)90389-1; LEIER I, 1994, J BIOL CHEM, V269, P27807; LI ZS, 1995, PLANT PHYSIOL, V107, P1257, DOI 10.1104/pp.107.4.1257; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PETERSON GL, 1977, ANAL BIOCHEM, V83, P646; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sherman F., 1983, METHODS YEAST GENETI; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; STPIERRE MV, 1994, P NATL ACAD SCI USA, V91, P9476, DOI 10.1073/pnas.91.20.9476; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	35	357	371	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6509	6517		10.1074/jbc.271.11.6509	http://dx.doi.org/10.1074/jbc.271.11.6509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626454	hybrid			2022-12-25	WOS:A1996UA36300083
J	ShakinEshleman, SH; Spitalnik, SL; Kasturi, L				ShakinEshleman, SH; Spitalnik, SL; Kasturi, L			The amino acid at the X position of an Asn-X-ser sequon is an important determinant of N-linked core-glycosylation efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABIES VIRUS GLYCOPROTEIN; CELL-SURFACE EXPRESSION; THR-CONTAINING PEPTIDES; STRUCTURAL REQUIREMENTS; PLASMINOGEN-ACTIVATOR; TRANSLATION SYSTEM; MESSENGER-RNA; PROTEIN; SITES; SEQUENCE	N-Linked glycosylation is a common form of protein processing that can profoundly affect protein expression, structure, and function. N-Linked glycosylation generally occurs at the sequon Asn-X-Ser/Thr, where X is any amino acid except Pro. To assess the impact of the X amino acid on core glycosylation, rabies virus glycoprotein variants were generated by site-directed mutagenesis with each of the 20 common amino acids substituted at the X position of an Asn-X-Ser sequon. The efficiency of core glycosylation at the sequon in each variant was quantified in a rabbit reticulocyte lysate cell-free translation system supplemented with canine pancreas microsomes. The presence of Pro at the X position completely blocked core glycosylation, whereas Trp, Asp, Glu, and Leu were associated with inefficient core glycosylation. The other variants were more efficiently glycosylated, and several were fully glycosylated. These findings demonstrate that the X amino acid is an important determinant of N-linked core-glycosylation efficiency.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	ShakinEshleman, SH (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, INST PATHOL, 2085 ADELBERT RD, CLEVELAND, OH 44106 USA.			Spitalnik, Steven/0000-0002-8528-4561				ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; AUBERT JP, 1981, ARCH BIOCHEM BIOPHYS, V208, P20, DOI 10.1016/0003-9861(81)90118-1; BAUSE E, 1982, BIOCHEM J, V203, P761, DOI 10.1042/bj2030761; BAUSE E, 1979, FEBS LETT, V108, P341, DOI 10.1016/0014-5793(79)80559-1; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BEELEY JG, 1977, BIOCHEM BIOPH RES CO, V76, P1051, DOI 10.1016/0006-291X(77)90962-7; BERGMAN LW, 1977, BIOCHEMISTRY-US, V16, P4490, DOI 10.1021/bi00639a025; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GLABE CG, 1980, J BIOL CHEM, V255, P9236; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; INOUYE S, 1991, BIOCHEM BIOPH RES CO, V179, P352, DOI 10.1016/0006-291X(91)91377-O; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LIVI GP, 1991, J BIOL CHEM, V266, P15348; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; NAKAI K, 1988, J BIOCHEM-TOKYO, V104, P693, DOI 10.1093/oxfordjournals.jbchem.a122535; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OMURA F, 1992, EUR J BIOCHEM, V210, P591, DOI 10.1111/j.1432-1033.1992.tb17459.x; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; RADEMACHER TW, 1989, CIBA F SYMP, V145, P241; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; Shakin-Eshleman W. H., 1993, TRENDS GLYCOSCI GLYC, V5, P355; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; SHAKINESHLEMAN SH, 1993, BIOCHEMISTRY-US, V32, P9465, DOI 10.1021/bi00087a026; STEVENSON SC, 1993, BIOCHEMISTRY-US, V32, P5121, DOI 10.1021/bi00070a021; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; WUNNER WH, 1988, REV INFECT DIS, V10, pS771	48	241	257	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6363	6366		10.1074/jbc.271.11.6363	http://dx.doi.org/10.1074/jbc.271.11.6363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626433	hybrid			2022-12-25	WOS:A1996UA36300062
J	Chertov, O; Michiel, DF; Xu, LL; Wang, JM; Tani, K; Murphy, WJ; Longo, DL; Taub, DD; Oppenheim, JJ				Chertov, O; Michiel, DF; Xu, LL; Wang, JM; Tani, K; Murphy, WJ; Longo, DL; Taub, DD; Oppenheim, JJ			Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHEMOTACTIC FACTOR; PURIFICATION; RECEPTOR; PEPTIDE; EXPRESSION; CYTOKINES; SEQUENCE; ADHESION; PRODUCE	Reports that interleukin-8 (IL-8) induces the infiltration of neutrophils followed by T-cells into injection sites led us to postulate that by stimulation of neutrophil degranulation IL-8 may cause the release of factors with chemoattractant activity for T-lymphocytes. Extracts of human neutrophil granules were chromatographed to isolate and purify T-lymphocyte chemoattractant factors. Two major peaks of T-cell chemotactic activity were purified by C18 reversed phase high pressure liquid chromatography (HPLC). The first peak was resolved further by C4 reversed phase HPLC and yielded an active fraction shown by NH2-terminal amino acid sequence analysis to contain defensins HNP-1, HNP-2, and HNP-3. Purified defensins HNP-1 and HNP-2 (kindly provided by Dr. R. I. Lehrer, UCLA) were also potent chemoattractants for human T-cells, while HNP-3 was inactive. The second peak of T-cell chemoattractant activity was also further purified to homogeneity by C4 reversed phase HPLC and identified by NH2-terminal sequence analysis as CAP37/azurocidin, a protein with sequence homology to serine proteases, 0.1-100 ng of defensins and 1.0-100 ng/ml CAP37 were able to stimulate in vitro T-cell chemotaxis. Neutrophil activating factors, i.e. IL-8, phorbol 12-myristate 18-acetate/ionomycin, and formylmethionylleucylphenylalanine each induced the release of CAP37 and defensins from neutrophil granules. Subcutaneous administration of defensins or CAP37/azurocidin into BALB/c mice resulted in a moderate neutrophil and mononuclear cell infiltrate by 4 h, which was greater by 24 h at the site of injection. Additionally, subcutaneous injection of defensins into chimeric huPBL-SCID mice resulted in significant infiltration by human CD3+ cells within 4 h. These results identify the antimicrobial proteins, CAP37/azurocidin and defensins HNP-1 and HNP-8, as potent neutrophil-derived chemoattractants for T-cells. These proteins represent primordial antimicrobial peptides which may have evolved into acute inflammatory cell-derived signals that mobilize immunocompetent T-cells and other inflammatory cells.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,NIH,DIV CANC TREATMENT,FREDERICK,MD 21702; SCI APPLICAT INT CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; SCI APPLICAT INT CORP,CLIN SERV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC)			Longo, Dan L./F-6022-2011	Chertov, Oleg/0000-0002-0426-2521	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BRANDT E, 1992, J IMMUNOL, V149, P1356; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; CROUCH SPM, 1992, INFECT IMMUN, V60, P4504, DOI 10.1128/IAI.60.11.4504-4509.1992; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; GALLAGHER S, 1993, CURRENT PROTOCOLS IM, V1; GALLIN JI, 1988, PHAGOCYTIC CELLS DIS, P493; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; GANZ T, 1988, J CLIN INVEST, V82, P552, DOI 10.1172/JCI113631; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MILLARD PJ, 1984, J IMMUNOL, V132, P3197; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURPHY WJ, 1994, EUR J IMMUNOL, V24, P1823, DOI 10.1002/eji.1830240815; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; SAXENA RK, 1982, NATURE, V295, P240, DOI 10.1038/295240a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHAFER WM, 1986, INFECT IMMUN, V53, P651, DOI 10.1128/IAI.53.3.651-655.1986; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; STRIETER RM, 1992, AM J PATHOL, V141, P397; TALALAY P, 1946, J BIOL CHEM, V166, P757; TAUB DD, 1996, IN PRESS J CLIN INVE; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WESTLIN WF, 1992, J LEUKOCYTE BIOL, V52, P43, DOI 10.1002/jlb.52.1.43; WILLEMS J, 1989, IMMUNOLOGY, V67, P540; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	37	458	484	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2935	2940		10.1074/jbc.271.6.2935	http://dx.doi.org/10.1074/jbc.271.6.2935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621683	hybrid			2022-12-25	WOS:A1996TU69100012
J	Johnson, NL; Gardner, AM; Diener, KM; LangeCarter, CA; Gleavy, J; Jarpe, MB; Minden, A; Karin, M; Zon, LI; Johnson, GL				Johnson, NL; Gardner, AM; Diener, KM; LangeCarter, CA; Gleavy, J; Jarpe, MB; Minden, A; Karin, M; Zon, LI; Johnson, GL			Signal transduction pathways regulated by mitogen-activated extracellular response kinase kinase kinase induce cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; ACTIVATION DOMAIN; PROTEIN-KINASE; E1A PROTEINS; APOPTOSIS; PHOSPHORYLATION; BCL-2; CYTOTOXICITY; EXPRESSION	Mitogen-activated/extracellular response kinase kinase (MEK) kinase (MEKK) is a serine-threonine kinase that regulates sequential protein phosphorylation pathways, leading to the activation of mitogen-activated protein kinases (MAPK), including members of the Jun kinase (JNK)/stress-activated protein kinase (SAPK) family. In Swiss 3T3 and REF52 fibroblasts, activated MEKK induces cell death involving cytoplasmic shrinkage, nuclear condensation, and DNA fragmentation characteristic of apoptosis. Expression of activated MEKK enhanced the apoptotic response to ultraviolet irradiation, indicating that MEKK-regulated pathways sensitize cells to apoptotic stimuli. Inducible expression of activated MEKK stimulated the transactivation of c-Myc and Elk-1. Activated Raf, the serine-threonine pro tein kinase that activates the ERK members of the MAPK family, stimulated Elk-1 transactivation but not c-Myc; expression of activated Raf does not induce any of the cellular changes associated with MEKK-mediated cell death, Thus, MEKK selectively regulates signal transduction pathways that contribute to the apoptotic response.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA; HARVARD UNIV, SCH MED,HOWARD HUGHES MED INST,CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California San Diego				Lange, Carol/0000-0003-2751-3976; Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48845, DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ASKEW DS, 1991, ONCOGENE, V6, P1915; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JIMENEZ B, 1995, ONCOGENE, V10, P811; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEDERMAN S, 1994, J IMMUNOL, V152, P2163; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAPP UR, 1991, ONCOGENE, V6, P495; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUMIMOTO SI, 1994, J IMMUNOL, V153, P2488; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAN MH, 1994, NATURE, V372, P798	61	314	321	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3229	3237		10.1074/jbc.271.6.3229	http://dx.doi.org/10.1074/jbc.271.6.3229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621725	hybrid, Green Published			2022-12-25	WOS:A1996TU69100054
J	Sinkins, WG; Vaca, L; Hu, YF; Kunze, DL; Schilling, WP				Sinkins, WG; Vaca, L; Hu, YF; Kunze, DL; Schilling, WP			The COOH-terminal domain of Drosophila TRP channels confers thapsigargin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; TYROSINE KINASE INHIBITORS; ACTIVATED CALCIUM CURRENT; MAST-CELLS; DEPLETION; PROTEIN; TRANSDUCTION; ENTRY; PHOTOTRANSDUCTION; PHOSPHORYLATION	Previous studies have shown that the Drosophila cation channels designated Trp and TrpI can be functionally expressed in Sf9 insect cells using baculovirus expression vectors. The trp gene encodes a Ca2+-permeable channel that is activated by thapsigargin, blocked by low micromolar Gd3+, and is relatively selective for Ca2+ versus Na+ and Ba2+. In contrast, trpl encodes a Ca2+-permeable cation channel that is constitutively active, not affected by thapsigarsn, blocked by high micromolar Gd3+, and non-selective with respect to Ca2+, Na+, and Ba2+. The region of lowest sequence identity between Trp and TrpI occurs in the COOH-terminal domain. To test the hypothesis that this region is responsible for the differential sensitivity of these channels to thapsigargin, chimeric constructs of Trp and TrpI were created in which the COOH terminal tail region of each protein was exchanged. The Trp construct with the TrpI COOH-tail was constitutively active, insensitive to thapsigarsn, but retained selectivity for Ca2+ over Na+ and Ba2+. In contrast, the TrpI construct with the Trp COOH-tail was not constitutively active, could be activated by thapsigargin, but remained nonselective with respect to Ca2+, Ba2+, and Na+. These results suggest that the COOH-terminal domain of TrpI plays an important role in determining constitutive activity, whereas the COOH-terminal region of Trp contains the structural features necessary for activation by thapsigargin.	CASE WESTERN RESERVE UNIV,RAMMELKAMP CTR EDUC & RES,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System				Vaca, Luis/0000-0003-2266-4847	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045880, R01HL047876, R29HL044119] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47876, HL45880, HL44119] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KM, 1993, J BIOL CHEM, V268, P9945; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Sambrook J, 1989, MOL CLONING LABORATO; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; SINKINS WG, 1995, BIOPHYS J, V68, P263; TGLIALATELA M, 1994, SCIENCE, V264, P844; VACA L, 1993, AM J PHYSIOL, V264, pH1319, DOI 10.1152/ajpheart.1993.264.4.H1319; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WINER BJ, 1962, STATISTICAL PRINCIPL; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	38	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2955	2960		10.1074/jbc.271.6.2955	http://dx.doi.org/10.1074/jbc.271.6.2955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621686	hybrid			2022-12-25	WOS:A1996TU69100015
J	Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y			The ntpJ gene in the Enterococcus hirae ntp operon encodes a component of KtrII potassium transport system functionally independent of vacuolar Na+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; ION-TRANSPORT; ALKALINE PH; BACTERIA; CLONING; SUBUNIT; AMPLIFICATION; ANTIPORTER	The ntpJ gene, the tail end in the vacuolar type Na+-ATPase (ntp) operon of Enterococcus hirae, encodes a putative 49-kDa hydrophobic protein resembling K+ transporter protein in Saccharomyces cerevisiae (Takase, K., Kakinuma, S., Yamato, I., Konishi, K., Igarashi, K., and Kakinuma, Y. (1994) J. Biol. Chem. 269, 11037-11044). Northern blotting experiment revealed that the ntpJ gene was transcribed as a cistron in the ntp operon. We constructed an Enterococcus strain in which the ntpJ gene was disrupted by cassette mutagenesis with erythromycin resistance gene. The growth of this mutant was normal at low pH. However, the mutant did not grow at high pH in K+-limited medium (less than 1 mM), while the wild type strain grew well; the internal K+ concentration of this mutant was as low as 7% of that of the wild type strain, suggesting that the K+ accumulation at high pH was inactivated by disruption of the ntpJ gene. Potassium uptake activity via the KtrII system, which had been proposed as the proton potential-independent, Na+-ATPase-coupled system working at high pH (Kakinuma, Y., and Harold, F. M. (1985) J. Biol. Chem. 260, 2086-2091), was missing in this mutant strain. However this mutant retained as high activities of Na+-ATPase and Na+ pumping as the wild type strain. From these results, we conclude that the NtpJ is a membraneous component of the KtrII K+ uptake system but not a functional subunit of vacuolar Na+-ATPase complex; the interplay between the KtrII system and the Na+-ATPase was discussed.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Chiba University; Tokyo University of Science			Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAKKER EP, 1980, J BIOL CHEM, V255, P433; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1992, ANN NY ACAD SCI, V671, P310, DOI 10.1111/j.1749-6632.1992.tb43805.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HAROLD FM, 1985, ANN NY ACAD SCI, V456, P375, DOI 10.1111/j.1749-6632.1985.tb14888.x; HEEFNER DL, 1982, MOL CELL BIOCHEM, V44, P81; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; KAKINUMA Y, 1991, FEBS LETT, V292, P64, DOI 10.1016/0014-5793(91)80835-Q; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1995, FEBS LETT, V359, P255, DOI 10.1016/0014-5793(95)00056-F; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KAKINUMA Y, 1988, J BIOL CHEM, V263, P14166; KAKINUMA Y, 1993, ALKALI CATION TRANSP, P277; KOBAYASHI H, 1982, J BACTERIOL, V150, P506, DOI 10.1128/JB.150.2.506-511.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACRINA FL, 1982, GENE, V19, P345, DOI 10.1016/0378-1119(82)90025-7; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1993, ALKALI CATION TRANSP, P3; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P293; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; TOKUDA H, 1985, MICROBIOL SCI, V2, P65; WASER M, 1992, J BIOL CHEM, V267, P5396; Yamato I., 1993, ALKALI CATION TRANSP, P53	43	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10042	10047		10.1074/jbc.271.17.10042	http://dx.doi.org/10.1074/jbc.271.17.10042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626559	hybrid			2022-12-25	WOS:A1996UG25700031
J	Corpuz, LM; Funderburgh, JL; Funderburgh, ML; Bottomley, GS; Prakash, S; Conrad, GW				Corpuz, LM; Funderburgh, JL; Funderburgh, ML; Bottomley, GS; Prakash, S; Conrad, GW			Molecular cloning and tissue distribution of keratocan - Bovine corneal keratan sulfate proteoglycan 37A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; SEQUENCE; LUMICAN; FIBROMODULIN; ISOFORMS; UNIQUE; GENE	Previous studies showed that the keratan sulfate-containing proteoglycans of bovine corneal stroma contain three unique core proteins designated 37A, 37B, and 25 (Funderburgh, J, L,, Funderburgh, M. L., Mann, M, M,, and Conrad, G, W, (1991) J, Biol, Chem, 266, 14226-14231), Degenerate oligonucleotides designed from amino acid sequences of the 37A protein were used to screen a cDNA expression library from cultured bovine keratocytes, A cDNA clone coding for keratocan, a 37A protein, was isolated and sequenced. The deduced keratocan amino acid sequence is unique but related to two other keratan sulfate-containing proteins, lumican (the 37B core protein) and fibromodulin, These three proteins share approximately 35% amino acid identity and a number of conserved structural features.;Northern hybridization and immunoblotting of tissue extracts found keratocan distribution to be more limited than that of lumican or fibromodulin, Keratocan is abundant in cornea and sclera and detected in much lesser amounts in skin, ligament, cartilage, artery, and striated muscles, Only in cornea was keratocan found to contain large, sulfated keratan sulfate chains. Keratocan, like lumican, is a core protein of a major corneal proteoglycan but is present in non-corneal tissues primarily as a nonsulfated glycoprotein.	KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506	Kansas State University					NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER; NEI NIH HHS [EY09368, EY00952] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD GW, 1982, J BIOL CHEM, V257, P464; FISHER LW, 1993, DERMATAN SULPHATE PR, P103; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; HEDBYS BO, 1961, EXP EYE RES, V1, P81, DOI 10.1016/S0014-4835(61)80012-2; JOST CJ, 1991, J BIOL CHEM, V266, P13336; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Nei M., 1987, MOL EVOLUT GENET, P293; OBEN M, 1987, BIOCHEM J, V248, P85; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; Suzuki M., 1939, J BIOCHEM, V30, P185, DOI [10.1093/oxfordjournals.jbchem.a125896, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A125896]; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	23	184	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9759	9763		10.1074/jbc.271.16.9759	http://dx.doi.org/10.1074/jbc.271.16.9759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621655	hybrid			2022-12-25	WOS:A1996UG04400086
J	Kast, C; Canfield, V; Levenson, R; Gros, P				Kast, C; Canfield, V; Levenson, R; Gros, P			Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANT CELLS; MDR GENE FAMILY; CLASS-II REGION; FUNCTIONAL CONSEQUENCES; BINDING; ANTIBODIES; MUTATIONS; SEQUENCES; HOMOLOGY	P-glycoprotein (P-gp) is an integral membrane protein that causes multidrug resistance when overexpressed in tumor cells. Efforts to identify the position and polarity of its 12 putative transmembrane (TM) domains have so far failed to yield a consistent topological model. Recently, we have described a method for topology mapping based on the insertion of a small antigenic peptide epitope (YPYDVPDYA) in predicted intra- or extracellular loops of the protein. The tagged proteins are then functionally expressed in Chinese hamster ovary cells, and the polarity of the inserted tag with respect to plasma membrane is deduced by immunofluorescence in intact or permeabilized cells. We previously localized segments between TM1 and TM2, and TM5 and TM6 as extracellular and segments between TM2 and TM3 and downstream of TM6 as intracellular (Kast, C., Canfield, V., Levenson, R., and Gros, P. (1995) Biochemistry 34, 4402-4411). We have now inserted single epitope tags at positions 207, 235, 276, 741, 782, 797, 815, 849, 887, 961, and 1024; double epitope tags at positions 736, 849, and 961; and a triple epitope tag at position 849. Insertions of epitopes at positions 235, 736, 741, 849, 887, 961, and 1024 resulted in functional proteins, whereas insertions at positions 207, 276, 782, 797, and 815 abrogated the capacity of P-gp to confer multidrug resistance. The epitope tags inserted at positions 736, 849, and 961 were localized extracellularly, whereas tags at positions 235, 887, and 1024 mapped intracellularly. These results indicate that the intervening segments separated by TM4-TM5, TM10-TM11, and downstream of TM12 are cytoplasmic; segments delineated by TM7-TM8, TM9-TM10, and TM11-TM12 are extracellular. Our combined analysis of the amino- and carboxyl-terminal halves of P-gp supports a 12-TM domain topology with intracellular amino and carboxyl termini and ATP binding sites and an extracellular glycosylated loop (TM1-TM2) in agreement with hydropathy prediction. These results are clearly distinct from those obtained by the analysis of truncated P-gps in vitro and in heterologous expression systems.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; PENN STATE COLL MED,MILTON S HERSHEY MED CTR,DEPT PHARMACOL,HERSHEY,PA 17033	McGill University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Levenson, Robert/0000-0002-0936-8421				BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BEJA O, 1995, J BIOL CHEM, V270, P12351; BIBI E, 1994, J BIOL CHEM, V269, P19910; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CIANFRIGLIA M, 1994, INT J CANCER, V56, P153; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1991, J BIOL CHEM, V266, P2074; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOOF T, 1994, J BIOL CHEM, V269, P20575; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1993, J BIOL CHEM, V268, P19965; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; RAO US, 1995, J BIOL CHEM, V270, P6686; REUTZ S, 1994, J BIOL CHEM, V269, P12277; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAFA AR, 1990, BIOCHEM BIOPH RES CO, V166, P259; SAFA AR, 1993, CANCER INVEST, V11, P46, DOI 10.3109/07357909309020260; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHURR E, 1989, CANCER RES, V49, P2729; SHUSTIK C, 1995, MOL ASPECTS MED, V16, P1, DOI 10.1016/0098-2997(94)00040-A; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101; ZHANG JT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P191, DOI 10.1016/0005-2736(93)90405-O; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	59	123	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9240	9248		10.1074/jbc.271.16.9240	http://dx.doi.org/10.1074/jbc.271.16.9240			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621583	hybrid			2022-12-25	WOS:A1996UG04400014
J	Neuburger, M; Rebeille, F; Jourdain, A; Nakamura, S; Douce, R				Neuburger, M; Rebeille, F; Jourdain, A; Nakamura, S; Douce, R			Mitochondria are a major site for folate and thymidylate synthesis in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA LEAF MITOCHONDRIA; GAMMA-GLUTAMATE SYNTHETASE; ONE-CARBON METABOLISM; FOLIC ACID COMPOUNDS; DIHYDROFOLATE-REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHETASE; SERINE HYDROXYMETHYLTRANSFERASE; STREPTOCOCCUS-PNEUMONIAE; DIHYDROPTEROATE SYNTHASE; BIFUNCTIONAL POLYPEPTIDE	The subcellular distributions of folate and folate-synthesizing enzymes were investigated in pea leaves. It was observed that the mitochondrial folate pool (similar to 400 mu M) represented similar to 50% of the total pool. Furthermore, all the enzymes involved in tetrahydrofolate polyglutamate synthesis were present in the mitochondria. In marked contrast, we failed to detect any significant activity of these enzymes in chloroplasts, cytosol, and nuclei. The presence of the tetrahydrofolate synthesis pathway in mitochondria is apparently a general feature in plants since potato tuber mitochondria also contained a high folate concentration (similar to 200 mu M) and all the enzymes required for tetrahydrofolate polyglutamate synthesis. The specific activities of tetrahydrofolate-synthesizing enzymes were rather low (1.5-15 nmol h(-1) mg(-1) matrix protein), except for dihydrofolate reductase (180-500 nmol h(-1) mg(-1) matrix protein). Dihydrofolate reductase was purified to homogeneity. The enzyme had a native molecular mass of similar to 140 kDa and was constituted of two identical 62-kDa subunits. Interestingly, this mitochondrial protein appeared to be a bifunctional enzyme, also supporting thymidylate synthesis. The cell distribution of thymidylate synthase was also investigated. No significant activity was observed in cell fractions other than mitochondria, indicating that plant cell mitochondria are also a major site for thymidylate synthesis.	CEA,DEPT BIOL MOLEC & STRUCT,CNRS URA 576,F-38054 GRENOBLE 09,FRANCE	CEA								ALBANI D, 1985, PLANT MOL BIOL, V5, P363, DOI 10.1007/BF00037557; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; [Anonymous], METHODS CHLOROPLAST; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V2, P275; BESSON V, 1995, PLANT PHYSIOL BIOCH, V33, P665; BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; BROWN SS, 1965, BIOCHEM J, V97, pC34, DOI 10.1042/bj0970034C; CELLA R, 1988, PLANT MOL BIOL, V10, P331, DOI 10.1007/BF00029883; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; CLARKE AK, 1992, PLANT PHYSIOL, V100, P2081, DOI 10.1104/pp.100.4.2081; COSSINS EA, 1984, PHYTOCHEMISTRY, V23, P965, DOI 10.1016/S0031-9422(00)82593-5; COSSINS EA, 1984, FOLATES PTERINS, V1, P2; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; DUNHAM VL, 1983, ISOLATION MEMBRANES, P237; FERONE R, 1980, P NATL ACAD SCI-BIOL, V77, P5802, DOI 10.1073/pnas.77.10.5802; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; IKEDA M, 1975, J NUTR SCI VITAMINOL, V21, P1; IMESON HC, 1991, J PLANT PHYSIOL, V138, P476, DOI 10.1016/S0176-1617(11)80526-2; IVANETICH KM, 1990, FASEB J, V4, P1591, DOI 10.1096/fasebj.4.6.2180768; IWAI K, 1975, J NUTR SCI VITAMINOL, V21, P7; KAGAWA T, 1982, METHODS CHLOROPLAST, P695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR G, 1993, PLANT J, V3, P657, DOI 10.1111/j.1365-313X.1993.00657.x; LIN BF, 1993, J BIOL CHEM, V268, P21674; LOMAX MIS, 1967, J BIOL CHEM, V242, P109; LOPEZ P, 1987, J BACTERIOL, V169, P4320, DOI 10.1128/jb.169.9.4320-4326.1987; LOPEZ P, 1990, J BACTERIOL, V172, P4766, DOI 10.1128/jb.172.9.4766-4774.1990; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MOURIOUX G, 1979, BIOCHIMIE, V61, P1283; NEUBURGER M, 1986, FEBS LETT, V207, P18, DOI 10.1016/0014-5793(86)80005-9; OKINAKA O, 1970, J VITAMINOL, V16, P201, DOI 10.5925/jnsv1954.16.201; OKINAKA O, 1970, J VITAMINOL, V16, P196, DOI 10.5925/jnsv1954.16.196; PENNER MH, 1985, J BIOL CHEM, V260, P5366; PRIEST DG, 1981, ANAL BIOCHEM, V115, P163, DOI 10.1016/0003-2697(81)90540-6; REBEILLE F, 1994, BIOCHEM J, V302, P223, DOI 10.1042/bj3020223; REDDY VA, 1976, ARCH BIOCHEM BIOPHYS, V174, P675, DOI 10.1016/0003-9861(76)90398-2; ROOS DS, 1993, J BIOL CHEM, V268, P6269; Scrimgeour K G, 1980, Methods Enzymol, V66, P517; SHANE B, 1986, METHOD ENZYMOL, V122, P323; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; TOBIN A, 1980, PLANT PHYSIOL, V66, P225, DOI 10.1104/pp.66.2.225; TOTH I, 1987, EMBO J, V6, P1853, DOI 10.1002/j.1460-2075.1987.tb02443.x; TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149; Waxman S, 1980, Methods Enzymol, V66, P468	52	114	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9466	9472		10.1074/jbc.271.16.9466	http://dx.doi.org/10.1074/jbc.271.16.9466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621617	hybrid			2022-12-25	WOS:A1996UG04400048
J	Shibata, N; Akagi, R; Hosoya, T; Kawahara, K; Suzuki, A; Ikuta, K; Kobayashi, H; Hisamichi, K; Okawa, Y; Suzuki, S				Shibata, N; Akagi, R; Hosoya, T; Kawahara, K; Suzuki, A; Ikuta, K; Kobayashi, H; Hisamichi, K; Okawa, Y; Suzuki, S			Existence of novel branched side chains containing beta-1,2 and alpha-1,6 linkages corresponding to antigenic factor 9 in the mannan of Candida guilliermondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALBICANS SEROTYPE-A; NIH B-792 STRAIN; CELL-WALL; SACCHAROMYCES-CEREVISIAE; OLIGOMANNOSYL RESIDUES; NIH-B-792 STRAIN; FORM CELLS; YEAST; PHOSPHOMANNAN; OLIGOSACCHARIDES	Isolation of beta-linkage-containing side chain oligosaccharides from the mannan of Candida gilliermondii IFO 10279 strain has been conducted by acetolysis under mild conditions, A structural study of these oligosaccharides by one- and two-dimensional NMR and methylation analyses indicated the presence of extended oligosaccharide side chains with two consecutive beta-1,2-linked mannose units at the nonreducing terminal of alpha-linked oligosaccharides, The linkage sequence present in this mannan, Man beta 1-->2Man alpha 1-->3Man alpha-->, has also been found in the mannan of Saccharomyces kluyveri but not in the mannan of Candida species, Furthermore, these oligosaccharides are branched at position 6 of the 3-O-substituted mannose units as follows. [GRAPHICS] The H-1 signals of the mannose units substituted by a 3,6-di-O-substituted unit showed a significant upfield shift (Delta delta = 0.04-0.08 ppm) due to a steric effect, The inhibition of an enzyme linked immunosorbent assay between the mannan of C. guilliermondii and factor 9 serum with oligosaccharides obtained from several mannans indicated that only the oligosaccharides with the above structure were active, suggesting that these correspond to the epitope of antigenic factor 9.	TOHOKU COLL PHARMACEUT SCI, DEPT MED CHEM 1, SENDAI, MIYAGI 981, JAPAN	Tohoku Medical & Pharmaceutical University	Shibata, N (corresponding author), TOHOKU COLL PHARMACEUT SCI, DEPT HYG CHEM 2, AOBA KU, 4-4-1 KOMATSUSHIMA, SENDAI, MIYAGI 981, JAPAN.							AMES BN, 1960, J BIOL CHEM, V235, P769; ATAOGLU H, 1993, INFECT IMMUN, V61, P3313, DOI 10.1128/IAI.61.8.3313-3317.1993; BALLOU CE, 1973, J BIOL CHEM, V248, P4667; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAILLE C, 1991, BIOCHEM BIOPH RES CO, V181, P1251, DOI 10.1016/0006-291X(91)92073-S; FAILLE C, 1990, INFECT IMMUN, V58, P3537, DOI 10.1128/IAI.58.11.3537-3544.1990; FUKAZAWA K, 1980, J IMMUNOL, P127; FUKAZAWA Y, 1980, MED MYCOL, P127; FUNAYAMA M, 1983, CARBOHYD RES, V117, P229, DOI 10.1016/0008-6215(83)88089-6; GARNER RE, 1994, J LEUKOCYTE BIOL, V55, P161, DOI 10.1002/jlb.55.2.161; HEARN VM, 1993, STRUCTURE ANTIGENS, P211; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; JOUAULT T, 1995, INFECT IMMUN, V63, P2378, DOI 10.1128/IAI.63.6.2378-2381.1995; KAGAYA K, 1989, J IMMUNOL, V143, P3353; KANBE T, 1994, INFECT IMMUN, V62, P1662, DOI 10.1128/IAI.62.5.1662-1668.1994; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; KOBAYASHI H, 1994, INFECT IMMUN, V62, P615, DOI 10.1128/IAI.62.2.615-622.1994; KOBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V272, P364, DOI 10.1016/0003-9861(89)90230-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; KOGAN G, 1988, CARBOHYD RES, V172, P243, DOI 10.1016/S0008-6215(00)90858-9; LI RK, 1993, J BIOL CHEM, V268, P18293; MENCACCI A, 1994, INFECT IMMUN, V62, P5353, DOI 10.1128/IAI.62.12.5353-5360.1994; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; NELSON RD, 1991, CLIN MICROBIOL REV, V4, P1; OKAWA Y, 1996, IN PRESS CLIN DIAGNO, V3; OKUBO Y, 1980, J BACTERIOL, V144, P92, DOI 10.1128/JB.144.1.92-96.1980; PANG D, 1981, J BIOL CHEM, V256, P80; PODZORSKI RP, 1990, J IMMUNOL, V144, P707; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1993, ARCH BIOCHEM BIOPHYS, V302, P113, DOI 10.1006/abbi.1993.1188; SHIBATA N, 1992, BIOCHEMISTRY-US, V31, P5680, DOI 10.1021/bi00139a036; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1993, EUR J BIOCHEM, V217, P1, DOI 10.1111/j.1432-1033.1993.tb18211.x; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SHIBATA N, 1991, ARCH BIOCHEM BIOPHYS, V290, P535, DOI 10.1016/0003-9861(91)90578-7; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; SUZUKI A, 1995, FEBS LETT, V373, P275, DOI 10.1016/0014-5793(95)01061-I; SUZUKI M, 1982, MICROBIOL IMMUNOL, V26, P387, DOI 10.1111/j.1348-0421.1982.tb00189.x; SUZUKI S, 1991, FUNGAL CELL WALL IMM, P111; THIEME TR, 1971, BIOCHEMISTRY-US, V10, P4121, DOI 10.1021/bi00798a017; TSUCHIYA T, 1974, MYCOPATH MYCOL APPL, V53, P77, DOI 10.1007/BF02127199; TSUCHIYA T, 1984, METHOD MICROBIOL, P75; VECCHIARELLI A, 1991, CELL IMMUNOL, V134, P65, DOI 10.1016/0008-8749(91)90331-5; ZHANG W, 1981, J BIOL CHEM, V256, P73	49	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9259	9266		10.1074/jbc.271.16.9259	http://dx.doi.org/10.1074/jbc.271.16.9259			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621586	hybrid			2022-12-25	WOS:A1996UG04400017
J	Guzder, SN; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Sung, P; Prakash, L; Prakash, S			Nucleotide excision repair in yeast is mediated by sequential assembly of repair factors and not by a pre-assembled repairosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; STRANDED-DNA ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; RAD3 PROTEIN; RECOMBINATION; GENE; TRANSCRIPTION; ENCODES; HELICASE; ATPASE	In yeast and humans, nucleotide excision repair (NER) of ultraviolet (UV)-damaged DNA requires a large number of highly conserved protein factors, which include the multisubunit RNA polymerase II transcription factor TFIIH, Here, we examine whether NER occurs by sequential assembly of different repair factors at the site of DNA damage or by the placement there of a ''preformed'' repairosome containing TFIIH and all the other essential NER factors, Contrary to the recent report (Svejstrup, J. Q., Wang, Z., Feaver, W. J., Wu, X., Bushnell, D. A, Donahue, T. F., Friedberg, E. C., and Kornberg, R. D. (1995) Cell 80, 21-28), our results provide no evidence for a pre-assembled repairosome; instead, they support the sequential assembly model, By several independent criteria, including co-purification, immunoprecipitation, and gel filtration of homogeneous proteins, me show that the damage recognition factor Rad14 exists in a ternary complex with the Rad1-Rad10 nuclease, We also find that Rad14 interacts directly with Rad1, but only slightly with Rad10, and that it interacts with the Rad1-Rad10 complex much more efficiently than with Rad1 alone, In the reconstituted NER system, a higher level of incision of UV-damaged DNA is achieved with the Rad1-Rad10-Rad14 complex, which we designate as nucleotide excision repair factor-1, NEF-1.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA41261, CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035035, R37CA035035, R37CA041261, R01CA041261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	34	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8903	8910		10.1074/jbc.271.15.8903	http://dx.doi.org/10.1074/jbc.271.15.8903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621533	hybrid			2022-12-25	WOS:A1996UE73000064
J	Hashim, MF; Marnett, LJ				Hashim, MF; Marnett, LJ			Sequence-dependent induction of base pair substitutions and frameshifts by propanodeoxyguanosine during in vitro DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; POLYMERASE INSERTION FIDELITY; KINETICS; MUTAGENESIS; LESIONS; BYPASS; SITES; OLIGODEOXYNUCLEOTIDES; OLIGONUCLEOTIDE; SPECIFICITY	Template primers containing propanodeoxyguanosine (PdG) in two different sequence contexts (C-PdG-C and T-PdG-T) were replicated by the klenow fragment of DNA polymerase I. The presence of PdG in the template strand reduced the extent of in vitro DNA synthesis 10(3)-10(4)-fold compared with unmodified template primers. Partial blockade was observed 1 base 3' to the adduct and opposite the adduct. Purines were preferentially incorporated opposite the adduct; the V-max/K-m values for incorporation of dGMP were similar in both sequence contexts, whereas the V-max/K-m for dAMP incorporation increased 4.7-fold when the base pair 3' to PdG was changed from C:G to T:A. Oligonucleotides containing 1- and S-base deletions were major products of replication in both sequence contexts. Full-length products were observed with templates containing T-PdG-T but not C-PdG-C. The major full-length product resulted from incorporation of dAMP residues opposite PdG. Kinetic analysis revealed that the major factor contributing to the selective incorporation of dAMP in full-length products seas preferential extension of template primers containing PdG:dA termini rather than preferential incorporation of dAMP opposite PdG. The observation of PdG --> T mutations in the T-PdG-T context but not the C-PdG-C context during in vitro DNA replication parallels findings of in vivo experiments that base pair substitutions are induced by PdG in the former sequence context but not the latter.	VANDERBILT UNIV,SCH MED,AB HANCOCK JR MEM LAB CANC RES,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NCI NIH HHS [CA47479] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BENAMIRA M, 1995, CARCINOGENESIS, V16, P93, DOI 10.1093/carcin/16.1.93; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6747; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; CAI H, 1993, J BIOL CHEM, V268, P23567; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; Fink SP, 1996, CHEM RES TOXICOL, V9, P277, DOI 10.1021/tx950060w; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GROLLMAN A P, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P682; JOHNSON KA, 1995, THESIS VANDERBILT U; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; LEHMAN IR, 1964, J BIOL CHEM, V239, P233; Maniatis T, 1989, DECONTAMINATION DILU; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGH US, 1993, CHEM RES TOXICOL, V6, P825, DOI 10.1021/tx00036a012; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WEISS SJ, 1992, J BIOL CHEM, V267, P18520	37	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9160	9165		10.1074/jbc.271.15.9160	http://dx.doi.org/10.1074/jbc.271.15.9160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621568	hybrid			2022-12-25	WOS:A1996UE73000099
J	Kogan, G; Uhrin, D; Brisson, JR; Paoletti, LC; Blodgett, AE; Kasper, DL; Jennings, HJ				Kogan, G; Uhrin, D; Brisson, JR; Paoletti, LC; Blodgett, AE; Kasper, DL; Jennings, HJ			Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXOID CONJUGATE VACCINE; PROTECTIVE ANTIBODIES; NMR-SPECTROSCOPY; ACID; ANTIGEN; CONFORMATION; EPITOPE; IV	The type VIII capsular polysaccharide has been isolated and purified from a newly described strain of group B Streptococcus which is a leading cause of sepsis and neonatal meningitis in Japan. The polysaccharide contains D-glucose, D-galactose, L-rhamnose, and sialic acid in the molar ratio 1:1:1:1. By means of high resolution H-1 nuclear magnetic resonance (H-1 NMR), C-13 NMR, and homo- and heterocorrelated NMR, the repeating unit structure of the type VIII polysaccharide was delineated as the following, [GRAPHICS] Enzymatic studies established this polysaccharide as the first from which sialic acid, linked to a branched beta-D-galactopyranosyl residue, is known to be removed by bacterial neuraminidase.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA, ON K1A 0R6, CANADA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA 02115 USA; SLOVAK ACAD SCI, INST CHEM, BRATISLAVA 84238, SLOVAKIA	National Research Council Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Slovak Academy of Sciences			Kogan, Grigorij/J-9913-2014	Kogan, Grigorij/0000-0002-6657-298X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023339, R37AI023339, N01AI025152] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-25152, AI-23339] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER CJ, 1988, ANN NY ACAD SCI, V549, P193, DOI 10.1111/j.1749-6632.1988.tb23972.x; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P4007, DOI 10.1021/bi00066a022; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; BROWN DW, 1981, J MAGN RESON, V45, P302, DOI 10.1016/0022-2364(81)90127-X; Corfield A.P., 1982, Cell Biology Monographs, V10, P5; Corfield A. P., 1982, CELL BIOL MONOGR, V10, P195; DIFABIO JL, 1989, CAN J CHEM, V67, P877; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDWARDS MS, 1980, J EXP MED, V151, P1275, DOI 10.1084/jem.151.5.1275; FERRIERI P, 1990, REV INFECT DIS, V12, pS394; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; JELINKOVA J, 1985, J CLIN MICROBIOL, V21, P361; JENNINGS HJ, 1990, CURR TOP MICROBIOL, V150, P97; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1983, J BIOL CHEM, V258, P1793; JENNINGS HJ, 1981, BIOCHEMISTRY-US, V20, P4511, DOI 10.1021/bi00519a001; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; KOGAN G, 1994, J CARBOHYD CHEM, V13, P1071, DOI 10.1080/07328309408011849; KOGAN G, 1995, CARBOHYD RES, V277, P1, DOI 10.1016/0008-6215(95)00195-Y; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MICHON F, 1988, BIOCHEMISTRY-US, V27, P5341, DOI 10.1021/bi00414a059; MURAI T, 1992, ZBL BAKT S, V22, P467; PAOLETTI LC, 1992, INFECT IMMUN, V60, P4009, DOI 10.1128/IAI.60.10.4009-4014.1992; SKOZA L, 1976, BIOCHEM J, V159, P457, DOI 10.1042/bj1590457; VANHEYNI.WE, 1974, NATURE, V249, P415, DOI 10.1038/249415a0; VONHUNOLSTEIN C, 1993, INFECT IMMUN, V61, P1272, DOI 10.1128/IAI.61.4.1272-1280.1993; WARREN L, 1959, J BIOL CHEM, V234, P1971; WESSELS MR, 1987, P NATL ACAD SCI USA, V84, P9170, DOI 10.1073/pnas.84.24.9170; WESSELS MR, 1989, P NATL ACAD SCI USA, V86, P8983, DOI 10.1073/pnas.86.22.8983; WESSELS MR, 1991, J BIOL CHEM, V266, P6714; WESSELS MR, 1993, INFECT IMMUN, V61, P4760, DOI 10.1128/IAI.61.11.4760-4766.1993; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; WESSELS MR, 1987, J BIOL CHEM, V262, P8262	37	61	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8786	8790		10.1074/jbc.271.15.8786	http://dx.doi.org/10.1074/jbc.271.15.8786			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621515	hybrid			2022-12-25	WOS:A1996UE73000046
J	Wang, N; Tabas, I; Winchester, R; Ravalli, S; Rabbani, LE; Tall, A				Wang, N; Tabas, I; Winchester, R; Ravalli, S; Rabbani, LE; Tall, A			Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SMOOTH-MUSCLE CELLS; HUMAN ATHEROSCLEROTIC PLAQUE; GENE-EXPRESSION; MESSENGER-RNA; LYMPHOCYTES-T; RICH AREAS; LINE THP-1; DEGRADATION	in order to identify novel genes expressed in macrophage-derived foam cells, we used a multigene assay to examine the expression of genes in control versus cholesterol-loaded macrophages. We compared THP-1 macrophages incubated with or without acetylated LDL (acLDL) +/- acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor (compound 58035) for 20 h and assessed changes in mRNA of chemokines, growth factors, interleukins, and adhesion molecules, Among 49 genes examined, an increase in mRNA was observed only for interleukin 8 (IL-8) in THP-1 macrophages. Northern analysis confirmed a 3 to 4-fold increase of IL-8 mRNA and an enzyme-linked immunosorbent assay (ELISA) revealed a corresponding increase in IL-8 in conditioned medium, Oxidized LDL (oxLDL) also induced IL.8 mRNA but native LDL had no effect, 58035 had a moderate effect on IL-8 induction by acLDL, AcLDL-induced IL-8 expression was concentration- and time-dependent, The time course of IL-8 induction paralleled that of cholesterol loading, MCP-1, a chemokine implicated in recruiting monocytes in atherogenesis, was also induced by acLDL, The induction of MCP-1, however, peaked at 1 h after addition of acLDL and returned to basal level by 20 h while IL-8 induction peaked at 8 h and was still a-fold higher than basal level at 20 h, IL-8 induction was also observed in fresh human monocyte-derived macrophage cells treated with acLDL, Finally, immunohistochemistry and in situ hybridization studies using specimens of human coronary atheromas showed expression of IL-8 mRNA in a macrophage-rich area, We conclude that IL-8 is induced in macrophage foam cells as a response to cholesterol loading, The chemoattractant and/or mitogenic effects of IL-8 on neutrophils, T cells, smooth muscle, or vascular endothelial cells may contribute to the progression and complications of atherosclerosis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV CARDIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Tall, Alan/AAT-8528-2021					BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BANKA CL, 1991, J LIPID RES, V32, P35; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BOTTALICO LA, 1993, ARTERIOSCLER THROMB, V13, P264, DOI 10.1161/01.ATV.13.2.264; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COLOTTA F, 1992, J IMMUNOL, V148, P760; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; HANSSON GK, 1994, BASIC RES CARDIOL, V89, P41; HANSSON GK, 1989, AM J PATHOL, V135, P169; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAHLON R, 1992, CAN J CARDIOL, V8, P60; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; KLURFELD DM, 1985, ARCH PATHOL LAB MED, V109, P445; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1993, AM J PATHOL, V142, P1423; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LESNIK P, 1992, P NATL ACAD SCI USA, V89, P10370, DOI 10.1073/pnas.89.21.10370; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1994, CURR OPIN LIPIDOL, V5, P157; MCCLOSKEY HM, 1987, BIOCHIM BIOPHYS ACTA, V921, P320, DOI 10.1016/0005-2760(87)90033-6; MUNRO JM, 1987, HUM PATHOL, V18, P375; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; OBRIEN ER, 1994, AM J PATHOL, V145, P883; RAVALLI S, 1995, ARTERIOSCL THROM VAS, V15, P340, DOI 10.1161/01.ATV.15.3.340; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; TABAS I, 1989, J CLIN INVEST, V84, P1713, DOI 10.1172/JCI114354; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VIA DP, 1989, J LIPID RES, V30, P1515; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WILSON L, 1993, FEBS LETT, V325, P295, DOI 10.1016/0014-5793(93)81092-E; WINCHESTER R, 1993, CLIN EXP RHEUMATOL, V11, pS87; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; YUE TL, 1993, EUR J PHARMACOL, V240, P81	54	193	204	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8837	8842		10.1074/jbc.271.15.8837	http://dx.doi.org/10.1074/jbc.271.15.8837			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621523	hybrid			2022-12-25	WOS:A1996UE73000054
J	Xia, ZN; Ghildyal, N; Austen, KF; Stevens, RL				Xia, ZN; Ghildyal, N; Austen, KF; Stevens, RL			Post-transcriptional regulation of chymase expression in mast cells - A cytokine-dependent mechanism for controlling the expression of granule neutral proteases of hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOLECULAR-CLONING; SERINE PROTEASES; TRICHINELLA-SPIRALIS; MOUSE CHROMOSOME-14; GROWTH-FACTOR; HALF-LIFE; P-CELL; GENE; DIFFERENTIATION	Although all mouse mast cells are derived from a common progenitor, these effector cells exhibit tissue-specific differences in their expression of the chymase family of serine proteases whose genes reside on chromosome 14, Immature bone marrow-derived mast cells (mBMMC), developed in vitro with interleukin (IL) 3-enriched medium, were cultured in the presence or absence of IL-10 to determine at the molecular level how the expression of the individual chymases is differentially regulated, As assessed by RNA blot analysis, mBMMC contain high steady-state levels of the transcript that encodes mouse mast cell protease (mMCP) 5, but not the homologous chymase transcripts that encode mMCP-1, mMCP-2, or mMCP-4. Nevertheless, nuclear run-on analysis revealed that these cells transcribe all four mast cell chymase genes. IL-10 elicited high steady-state levels of the mMCP-2 transcript, and pulse-chase experiments revealed that the half-life of the mMCP-2 transcript in mBMMC maintained in the presence of IL-10 is similar to 4-fold longer than that in replicate cells subsequently cultured in medium without IL-10. Reverse transcription-polymerase chain reaction/ nucleotide sequence analysis demonstrated that mBMMC cultured in the absence or presence of IL-10 correctly process mMCP-2 pre-mRNA. Experiments with cycloheximide and actinomycin D indicated that IL-10 induces expression of a trans-acting factor(s) that stabilizes the mMCP-2 transcript or facilitates its processing. The discovery that the expression of certain chymases in mBMMC is regulated primarily at the post-transcriptional level provides a basis for understanding the mechanism by which specific cytokines dictate expression of the chromosome 14 family of serine proteases in cells that participate in inflammatory processes.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI022531, R37AI022531, R01AI023483, U19AI031599] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31599, AI-22531, AI-23483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DEUSTACHIO P, 1988, J IMMUNOL, V141, P3067; EKLUND KK, 1993, J IMMUNOL, V151, P4266; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HEUSEL JW, 1993, BLOOD, V81, P1614; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUNT JE, 1995, FASEB J, V9, pA802; IHLE JN, 1983, J IMMUNOL, V131, P282; JARBOE DL, 1989, J IMMUNOL, V142, P2405; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; LOUAHED J, 1995, J IMMUNOL, V154, P5061; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; NAKAHATA T, 1982, BLOOD, V60, P352; NEWLANDS GFJ, 1987, IMMUNOLOGY, V62, P629; OLSEN BR, 1988, EUR J BIOCHEM, V179, P71; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WILSON SD, 1990, J EXP MED, V171, P1301, DOI 10.1084/jem.171.4.1301; YUNG YP, 1983, J IMMUNOL, V130, P2843	45	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8747	8753		10.1074/jbc.271.15.8747	http://dx.doi.org/10.1074/jbc.271.15.8747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621509	hybrid			2022-12-25	WOS:A1996UE73000040
J	Kuhlman, PA; Hughes, CA; Bennett, V; Fowler, VM				Kuhlman, PA; Hughes, CA; Bennett, V; Fowler, VM			A new function for adducin - Calicium calmodulin-regulated capping of the barbed ends of actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; SKELETAL-MUSCLE; ALPHA-ACTININ; BINDING-SITES; BETA-ADDUCIN; PROTEIN; SPECTRIN; PURIFICATION; POLYMERIZATION; COMPLEX	Adducin is a membrane skeleton protein originally described in human erythrocytes that promotes the binding of spectrin to actin and also binds directly to actin and bundles actin filaments, Adducin is associated with regions of cell cell contact in nonerythroid cells, where it is believed to play a role in regulating the assembly of the spectrin-actin membrane skeleton. In this study we demonstrate a novel function for adducin; it completely blocks elongation and depolymerization at the barbed (fast growing) ends of actin filaments, thus functioning as a barbed end capping protein (K-cap similar to 100 nM). This barbed end capping activity requires the in tact adducin molecule and is not provided by the NH2-terminal globular head domains alone nor by the COOH-terminal extended tail domains, which were previously shown to contain the spectrin-actin binding, calmodulin binding, and phosphorylation sites. A novel difference between adducin and other previously described capping proteins is that it is down-regulated by calmodulin in the presence of calcium. The association of stoichio- metric amounts of adducin with the short erythrocyte actin filaments in the membrane skeleton indicates that adducin could be the functional barbed end capper in erythrocytes and play a role in restricting actin filament length, Our experiments also suggest novel possibilities for calcium regulation of actin filament assembly by adducin in erythrocytes and at cell-cell contact sites in nonerythroid cells.	Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Scripps Research Institute; Duke University; Duke University; Duke University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029808, R01DK029808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29808] Funding Source: Medline; NIGMS NIH HHS [GM34225] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JP, 1987, J BIOL CHEM, V262, P6365; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Huxley H. E., 1960, CELL, V4, P365; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBART MC, 1993, J BIOL CHEM, V268, P5642; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; LIN DC, 1979, P NATL ACAD SCI USA, V76, P2345, DOI 10.1073/pnas.76.5.2345; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; OOSAWA F, 1995, THERMODYNAMICS POLYM, P1; PAGE SG, 1963, J CELL BIOL, V19, P369, DOI 10.1083/jcb.19.2.369; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PINDER JC, 1984, FEBS LETT, V169, P161, DOI 10.1016/0014-5793(84)80310-5; PINDER JC, 1986, J MOL BIOL, V191, P461, DOI 10.1016/0022-2836(86)90141-5; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SCHAFER DA, 1995, J CELL BIOL, V128, P61, DOI 10.1083/jcb.128.1.61; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SINARD JH, 1994, MOL BIOL CELL, V5, P421; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TAYLOR KA, 1994, BIOPHYS J, V67, P1976, DOI 10.1016/S0006-3495(94)80680-0; TSUKITA S, 1984, J CELL BIOL, V98, P1102, DOI 10.1083/jcb.98.3.1102; URSITTI JA, 1994, J CELL SCI, V107, P1633; WEBER A, 1987, BIOCHEMISTRY-US, V26, P2528, DOI 10.1021/bi00383a019; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2	53	160	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7986	7991		10.1074/jbc.271.14.7986	http://dx.doi.org/10.1074/jbc.271.14.7986			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626479	hybrid			2022-12-25	WOS:A1996UD60000019
J	Lee, RJ; Huang, L				Lee, RJ; Huang, L			Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; MAMMALIAN-CELLS; OVARIAN-CANCER; DELIVERY; ENDOCYTOSIS; EXPRESSION; EFFICIENT	We have developed a lipidic gene transfer vector, LP-DII, where DNA was first complexed to polylysine at a ratio of 1:0.75 (w/w) and then entrapped into folate-targeted pH-sensitive anionic liposomes composed of dioleoyl phosphatidylethanolamine (DOPE)/cholesteryl hemisuccinate/folate-polyethlene glycol-DOPE (6:4:0.01 mol/mol) via charge interaction. LPDII transfection of KB cells, a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA ratio and the lipid composition. At low lipid to DNA ratios (e.g. 4 and 6), LPDII particles were positively charged; transfection and cellular uptake levels were independent of the folate receptor and did not require a pH-sensitive lipid composition. Meanwhile, transfection and uptake of negatively charged LPDII particles, Le. those with high lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive lipid composition. The transfection activity of LPDII was lost when the inverted cone-shaped DOPE was replaced by dioleoyl phosphatidylcholine. LPDII particles with lipid to DNA ratios of 4, 6, 10, and 12 were similar to 20-30 times more active than DNA . 3-beta-[N-(N',N'-dimethylethane)carbamoyl]cholesterol cationic liposome complexes in KB cells and were much less cytotoxic. On the sucrose gradient, LPDII particles had a migration rate in between those of the free DNA and the DNA polylysine complex. An electron micrograph of LPDII showed a structure of spherical particles with a positively stained core enclosed in a lipidic envelope with a mean diameter of 74 +/- 14 nm. This novel gene transfer vector may potentially be useful in gene therapy for tumor-specific delivery.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,LAB DRUG TARGETING,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [P01CA059327] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044935] Funding Source: NIH RePORTER; NCI NIH HHS [CA59327] Funding Source: Medline; NHLBI NIH HHS [HL50256] Funding Source: Medline; NIDDK NIH HHS [DK44935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMPBELL IG, 1991, CANCER RES, V51, P5329; CONEY LR, 1991, CANCER RES, V51, P6125; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GARINCHESA P, 1993, AM J PATHOL, V142, P557; GOTTSCHALK S, 1994, GENE THER, V1, P185; KANE MA, 1986, J BIOL CHEM, V261, P5625; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEE RJ, 1994, J BIOL CHEM, V269, P3198; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; MATHIAS CJ, 1996, IN PRESS J NUCL MED; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Prensky W, 1976, Methods Cell Biol, V13, P121, DOI 10.1016/S0091-679X(08)61800-2; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; Sambrook J., 2002, MOL CLONING LAB MANU; WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851; WANG S, 1995, P NATL ACAD SCI USA, V92, P3318, DOI 10.1073/pnas.92.8.3318; WU GY, 1987, J BIOL CHEM, V262, P4429; Zhou X, 1992, J LIPOSOME RES, V2, P125	27	354	399	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8481	8487		10.1074/jbc.271.14.8481	http://dx.doi.org/10.1074/jbc.271.14.8481			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626549	hybrid			2022-12-25	WOS:A1996UD60000089
J	Lepley, RA; Muskardin, DT; Fitzpatrick, FA				Lepley, RA; Muskardin, DT; Fitzpatrick, FA			Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE SYNTHESIS; PROTEIN-KINASE; HUMAN-LEUKOCYTES; MEMBRANE TRANSLOCATION; LAVENDUSTIN-A; HERBIMYCIN-A; INHIBITION; PHOSPHORYLATION; CELLS; MACROPHAGE	Tyrosine kinase activity, a determinant of Src homology domain interactions, has a prominent effect on cellular localization and catalysis by 5-lipoxygenase. Six separate inhibitors of tyrosine kinase each inhibited 5(S)-hydroxyeicosatetraenoic acid formation by HL-60 cells stimulated with calcium ionophore, in the presence or absence of exogenous arachidonic acid substrate, indicating that they modulated cellular 5-lipoxygenase activity. The tyrosine kinase inhibitors also blocked the translocation of 5-lipoxygenase from cytosol to membranes during cellular activation, consistent with their effects on its catalytic activity. These results fit a model which postulates that Src homology domain interactions are a molecular determinant of the processes which coordinate the subcellular localization and functions of 5-lipoxygenase. In addition, we demonstrate that activated leukocytes contain two molecularly distinct forms of 5-lipoxygenase: a phosphorylated form and a nonphosphorylated form. In activated HL-60 cells the pool of phosphorylated 5-lipoxygenase accumulates in the nuclear fraction, not with the membrane or cytosolic fractions. The amount of phosphorylated 5-lipoxygenase is a small fraction of the total. Overall, equilibrium reactions involving the nuclear localizing sequence, the proline-rich SH3 binding motif, and the phosphorylation state of 5-lipoxygenase may each influence its partnership with other cellular proteins and any novel functions derived from such partnerships.			Lepley, RA (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL C236, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI26730-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CHARLESON S, 1992, MOL PHARMACOL, V41, P873; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FALGUEYRET JP, 1993, BIOCHEM PHARMACOL, V45, P978, DOI 10.1016/0006-2952(93)90185-Y; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GULBINS E, 1994, J IMMUNOL, V152, P2123; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; LEPLEY RA, 1994, J BIOL CHEM, V269, P2627; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROLLET E, 1994, J IMMUNOL, V153, P353; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TSUJISHITA Y, 1994, P NATL ACAD SCI USA, V91, P6274, DOI 10.1073/pnas.91.14.6274; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YOUNG SK, 1990, AM J RESP CELL MOL, V2, P523, DOI 10.1165/ajrcmb/2.6.523	46	117	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6179	6184		10.1074/jbc.271.11.6179	http://dx.doi.org/10.1074/jbc.271.11.6179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626407	hybrid			2022-12-25	WOS:A1996UA36300036
J	Smith, TK; Cottaz, S; Brimacombe, JS; Ferguson, MAJ				Smith, TK; Cottaz, S; Brimacombe, JS; Ferguson, MAJ			Substrate specificity of the dolichol phosphate mannose: Glucosaminyl phosphatidylinositol alpha 1-4-mannosyltransferase of the glycosylphosphatidylinositol biosynthetic pathway of African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; NOCTURNAL HEMOGLOBINURIA CELLS; ANCHOR BIOSYNTHESIS; MEMBRANE ANCHORS; GLYCOPHOSPHATIDYLINOSITOL ANCHORS; STRUCTURAL CHARACTERIZATION; TOXOPLASMA-GONDII; MAMMALIAN-CELLS; PRECURSORS; BRUCEI	The biosynthesis of glycosylphosphatidylinositol (GPI) precursors in Trypanosoma brucei involves the D-mannosylation of D-GlcN alpha 1-6-D-myo-inositol-1-PO4-sn-1,2-diacylglycerol (GlcN-PI). An assay for the first mannosyltransferase of the pathway, Dol-P-Man:GlcN-PI alpha 1-4-mannosyltransferase, is described. Analysis of the acceptor specificity revealed (a) that the enzyme requires the myo-inositol residue of the GlcN-PI substrate have the D configuration; (b) that the enzyme requires the presence of the NH2 group of the D-GlcN residue; (c) that GlcNAc-PI is more efficiently presented to the enzyme than GlcN-PI, suggesting a degree of substrate channelling via the preceding GlcNAc-PI de-N-acetylase enzyme; (d) that the fatty acid and phosphoglycerol components of the phosphatidyl moiety are important for enhancing substrate presentation and substrate recognition, respectively; and (e) that D-GlcN alpha 1-6-D-myo-inositol is the minimum structure that can support detectable acceptor activity. Analysis of the donor specificity revealed that short chain (C-5 and C-15) analogues of dolichol phosphate can act as substrates for the trypanosomal dolichol-phosphomannose synthetase, whereas the corresponding mannopyranosides cannot act as donors for the Dol-P-Man:GlcN-PI alpha 1-4-mannosyltransferase.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT CHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714; cottaz, sylvain/0000-0001-8674-0162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; COTTAZ S, 1993, J CHEM SOC PERK T 1, P2945, DOI 10.1039/p19930002945; COTTAZ S, 1995, CARBOHYD RES, V270, P85, DOI 10.1016/0008-6215(95)00012-I; COTTAZ S, 1995, J CHEM SOC PERK T 1, P1673, DOI 10.1039/p19950001673; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DELUCA AW, 1994, GLYCOBIOLOGY, V4, P909, DOI 10.1093/glycob/4.6.909; DOERING TL, 1989, J BIOL CHEM, V264, P11168; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; GEROLD P, 1994, J BIOL CHEM, V269, P2597; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; GUTHER MLS, 1986, J BIOL CHEM, V261, P13813; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KATRITZKY AR, 1990, ORG PREP PROCED INT, V22, P209, DOI 10.1080/00304949009458197; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; MANKOWSKI T, 1976, BIOCHEMISTRY-US, V15, P2125, DOI 10.1021/bi00655a015; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILNE KG, 1994, J BIOL CHEM, V269, P16403; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; NEUGEBAUER J, 1992, GUIDE PROPERTIES USE, P25; PRADOFIGUEROA M, 1994, MOL BIOCHEM PARASIT, V63, P255, DOI 10.1016/0166-6851(94)90061-2; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1991, J BIOL CHEM, V266, P21051; PUOTI A, 1992, J BIOL CHEM, V267, P22673; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STEVENS VL, 1993, J BIOL CHEM, V268, P9718; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TOMAVO S, 1992, J BIOL CHEM, V267, P11721; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023	48	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6476	6482		10.1074/jbc.271.11.6476	http://dx.doi.org/10.1074/jbc.271.11.6476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626449	hybrid			2022-12-25	WOS:A1996UA36300078
J	Ali, H; Tomhave, D; Richardson, RM; Haribabu, B; Snyderman, R				Ali, H; Tomhave, D; Richardson, RM; Haribabu, B; Snyderman, R			Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GLYCOPROTEIN-V HYDROLYSIS; BETA-GAMMA-SUBUNITS; ALPHA-THROMBIN; CATALYTIC ACTIVITY; HUMAN NEUTROPHILS; PHOSPHOLIPASE-C; HUMAN-PLATELETS; BINDING-SITES; CELLS	To define the molecular basis of human chemoattractant receptor regulation, rat basophilic leukemia RBL-2H3 cells, which are thrombin-responsive, were transfected to stably express epitope-tagged receptors for C5a, interleukin-8 (IL-8), formylpeptides (e.g. N-formylmethionyl-leucyl phenylalanine (fMLP)), and platelet-activating factor (PAF), Here we demonstrate that both thrombin and a synthetic peptide ligand for the thrombin receptor (sequence SFLLRN) caused phosphorylation and heterologous desensitization of the receptors for C5a, IL-8, and PAF but not that for formylpeptides as measured by agonist stimulated [S-35]guanosine 5'-3-O-(thio)triphosphate binding to membranes, Consistent with the PAF receptor phosphorylation, both thrombin and thrombin receptor peptide inhibited phosphoinositide hydrolysis, Ca2(+) mobilization, and degranulation stimulated by PAF, Unexpectedly, despite heterologous desensitization at the level of receptor/G protein activation, there was enhancement (''priming'') by thrombin of subsequent activities stimulated by C5a and IL-8 as well as fMLP, The priming effect of thrombin was blocked by its inhibitor, hirudin, However, two other activators of the thrombin receptor, the peptide SFLLRN and trypsin, stimulated Ca2+ mobilization in RBL-2H3 cells but did not cause priming, In addition, SFLLRN and the thrombin receptor antagonist peptide FLLRN both inhibited thrombin-induced Ca2+ mobilization but not priming, Furthermore, the proteolytically active gamma-thrombin, which does not stimulate the tethered ligand thrombin receptor and caused little or no Ca2+ mobilization in RBL-2H3 cells, effectively primed the response to fMLP. These data demonstrate that heterologous receptor phosphorylation and attenuation of G protein activation are not, by themselves, sufficient for the inhibition of biological responses mediated by C5a and IL-8, Moreover, thrombin appears to utilize mechanism(s) independent of its tethered ligand receptor to selectively prime phospholipase C-mediated biological responses of the C5a, IL-8, and formylpeptide receptors but not PAF, Because C5a, IL-8, and formylpeptide activate phospholipase C beta(2) whereas PAF stimulates a different phospholipase C, the striking selectivity of thrombin's priming may be mediated via its ability to enhance receptor-mediated activation of phospholipase C beta(2).	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University	Ali, H (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3680,DURHAM,NC 27710, USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-29589] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BAUER PI, 1983, BLOOD, V61, P368; BIENZ D, 1986, BLOOD, V68, P720; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; BLANK JL, 1993, J BIOL CHEM, V268, P25184; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARNEY DH, 1984, J CELL BIOCHEM, V26, P181, DOI 10.1002/jcb.240260306; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DHAR A, 1994, J BIOL CHEM, V269, P9123; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; HOFFMAN M, 1993, J LEUKOCYTE BIOL, V54, P145, DOI 10.1002/jlb.54.2.145; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; JANDROTPERRUS M, 1987, THROMB HAEMOSTASIS, V58, P915; JONES CLA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P271; JOSEPH S, 1993, BIOCHEM J, V290, P571, DOI 10.1042/bj2900571; KUDAHL K, 1991, EXP CELL RES, V193, P45, DOI 10.1016/0014-4827(91)90536-4; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LO TN, 1987, J BIOL CHEM, V262, P4141; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; MACPHEE CH, 1992, BIOCHEM J, V286, P535, DOI 10.1042/bj2860535; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MCGOWAN EB, 1983, J BIOL CHEM, V258, P1243; NACCACHE PH, 1991, CELL SIGNAL, V3, P635, DOI 10.1016/0898-6568(91)90040-2; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PHILIPS MR, 1995, P NATL ACAD SCI USA, V92, P2283, DOI 10.1073/pnas.92.6.2283; PIKE MC, 1982, CELL, V28, P107, DOI 10.1016/0092-8674(82)90380-4; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; SIMOES AP, 1993, FEBS LETT, V331, P248, DOI 10.1016/0014-5793(93)80346-V; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; VANOBBERGHENSCHILLING E, 1985, BIOCHIM BIOPHYS ACTA, V847, P335, DOI 10.1016/0167-4889(85)90039-4; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	47	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3200	3206		10.1074/jbc.271.6.3200	http://dx.doi.org/10.1074/jbc.271.6.3200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621721	Green Published, hybrid			2022-12-25	WOS:A1996TU69100050
J	Borgnia, MJ; Eytan, GD; Assaraf, YG				Borgnia, MJ; Eytan, GD; Assaraf, YG			Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; ENTAMOEBA-HISTOLYTICA; MEMBRANE-VESICLES; PLASMA-MEMBRANE; CELL-LINES; PURIFICATION; BINDING; MDR1; RECONSTITUTION	The aim of the present study was to demonstrate that the modulation of P-glycoprotein (Pgp) ATPase activity by peptides, drugs, and chemosensitizers takes place on a common drug pharmacophore. To this end, a highly emetine-resistant Chinese hamster ovary cell line was established, in which Pgp constituted 18% of plasma membrane protein, Reconstituted proteoliposomes, the Pgp content of which was up to 40%, displayed a basal activity of 2.6 +/- 0.45 mu mol of P-i/min/mg of protein, suggesting the presence of an endogenous Pgp substrate. This basal ATPase activity was stimulated (up to 5.2 mu mol of P-i/min/mg of protein) by valinomycin and various Pgp substrates, whereas, to our surprise, gramicidin D, an established Pgp substrate, was inhibitory, Taking advantage of this novel inhibition of Pgp ATPase activity by gramicidin D, a drug competition assay was devised in which gramicidin D-inhibited Pgp ATPase was coincubated with increasing concentrations of various substrates that stimulate its ATPase activity, Gramicidin D inhibition of Pgp ATPase was reversed by Pgp substrates, including various cytotoxic agents and chemosensitizers. The inhibition of the basal ATPase activity and the reversal of gramicidin D inhibition of Pgp ATPase by its various substrates conformed to classical Michaelis-Menten competition. This competition involved an endogenous substrate, the inhibitory drug gramicidin D, and a stimulatory substrate. We conclude that the various MDR type substrates and chemosensitizers compete on a common drug binding site present in Pgp.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology								ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Andersen O.S., 1992, BIOMEMBRANE STRUCTUR, P227; ASSARAF YG, 1993, ANTI-CANCER DRUG, V4, P395, DOI 10.1097/00001813-199306000-00018; ASSARAF YG, 1994, EUR J BIOCHEM, V222, P813, DOI 10.1111/j.1432-1033.1994.tb18928.x; ASSARAF YG, 1989, J BIOL CHEM, V264, P18326; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P201, DOI 10.1016/0166-6851(92)90112-W; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DRORI S, 1995, EUR J BIOCHEM, V228, P1020, DOI 10.1111/j.1432-1033.1995.1020m.x; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ESEN A, 1978, ANAL BIOCHEM, V89, P264, DOI 10.1016/0003-2697(78)90749-2; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; EYTAN GD, 1994, J BIOL CHEM, V269, P26058; FREI E, 1985, CANCER RES, V45, P6523; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARRIES J, 1982, J ROY SOC MED, V75, P190; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KESSEL D, 1968, CANCER RES, V28, P938; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; LINCKE CR, 1990, CANCER RES, V50, P1779; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; LOE DW, 1994, BBA-BIOMEMBRANES, V1190, P72, DOI 10.1016/0005-2736(94)90035-3; NAITO M, 1989, CANCER RES, V49, P1452; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; SAMUELSON J, 1990, MOL BIOCHEM PARASIT, V38, P281, DOI 10.1016/0166-6851(90)90031-G; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; SLOVAK ML, 1988, CANCER RES, V48, P2793; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TOPPMEYER DL, 1994, BIOCHEM PHARMACOL, V48, P609, DOI 10.1016/0006-2952(94)90292-5; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WOOLFE G, 1965, PROGRESS DRUG RESEAR, V8, P11	58	140	145	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3163	3171		10.1074/jbc.271.6.3163	http://dx.doi.org/10.1074/jbc.271.6.3163			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621716	hybrid			2022-12-25	WOS:A1996TU69100045
J	Wilkins, JA; Li, AL; Ni, HY; Stupack, DG; Shen, CX				Wilkins, JA; Li, AL; Ni, HY; Stupack, DG; Shen, CX			Control of beta(1) integrin function - Localization of stimulatory epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIIA; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; CELL-ADHESION; T-CELLS; EXPRESSION; ACTIVATION; BINDING; VITRONECTIN	The beta(1) integrins can be expressed on the surface of cells in a latent form, which is activated by a variety of stimuli, As an approach to examining the transition to an active receptor, a panel of stimulatory antibodies to beta(1) were produced and characterized, These antibodies induced adherence of the T-leukemic cell line Jurkat to collagen and fibronectin, Competitive antibody binding assays indicated the existence of at least three distinct epitope clusters A (B3B11, JB1B, 21C8), B (B44, 13B9), and C (N29) defined by the indicated antibodies, Two antibodies to the A site, JB1B and B3B11, were shown to localize to positions 671-703 and 657-670, respectively, of the beta(1). This region is located in an area encompassing a predicted disulfide bond between linearly distant cysteines in beta(1) (Cys(415)-Cys(671)). The homologous region of the beta(3) integrin (490-690 and 602-690) has been shown to be one of the sites recognized by stimulatory antibodies to ligand-induced binding sites. The present results indicate the existence of multiple stimulatory regions and suggest considerable homology between the locations of beta(1) and beta(3) regulatory sites.	UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG,MB R3A 1M4,CANADA; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3A 1M4,CANADA	University of Manitoba; University of Manitoba	Wilkins, JA (corresponding author), UNIV MANITOBA,DEPT INTERNAL MED,RES LAB,RHEUMAT DIS UNIT,RR014,800 SHERBROOK ST,WINNIPEG,MB R3A 1M4,CANADA.			Ni, Heyu/0000-0002-7621-2945				ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARRAYO AG, 1992, J CELL BIOL, V117, P659; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHAN BMC, 1991, J IMMUNOL, V147, P398; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DU XP, 1993, J BIOL CHEM, V268, P23087; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAO JX, 1995, CELL IMMUNOL, V163, P178, DOI 10.1006/cimm.1995.1114; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1994, BIOESSAYS, V16, P663, DOI 10.1002/bies.950160912; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KOUNS WC, 1991, BLOOD, V78, P3215; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH SS, 1993, BLOOD, V81, P2827; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; STUPACK DG, 1994, CELL IMMUNOL, V155, P237, DOI 10.1006/cimm.1994.1116; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239	37	78	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3046	3051		10.1074/jbc.271.6.3046	http://dx.doi.org/10.1074/jbc.271.6.3046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621699	hybrid			2022-12-25	WOS:A1996TU69100028
J	Gamby, C; Waage, MC; Allen, RG; Baizer, L				Gamby, C; Waage, MC; Allen, RG; Baizer, L			Growth-associated protein-43 (GAP-43) facilitates peptide hormone secretion in mouse anterior pituitary AtT-20 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; KINASE-C SUBSTRATE; AXONALLY TRANSPORTED PROTEINS; RETINAL GANGLION-CELLS; B-50 GAP-43; NORADRENALINE RELEASE; NEUROTRANSMITTER RELEASE; SUBCELLULAR FRACTION; PHOSPHORYLATION-SITE; SYNAPTIC PLASTICITY	The neuronal growth-associated protein (GAP)-43 (neuromodulin, B-50, F1), which is concentrated in the growth cones of elongating axons during neuronal development and in nerve terminals in restricted regions of the adult nervous system, has been implicated in the release of neurotransmitter. To study the role of GAP-43 in evoked secretion, we transfected mouse anterior pituitary AtT-20 cells with the rat GAP-43 cDNA and derived stably transfected cell lines. Depolarization-mediated beta-endorphin secretion was greatly enhanced in the GAP-43-expressing AtT-20 cells without a significant change in Ca2+ influx; in contrast, expression of GAP-43 did not alter corticotropin releasing factor-evoked hormone secretion. The transfected cells also displayed a flattened morphology and extended processes when plated on laminin-coated substrates. These results suggest that AtT-20 cells are a useful model system for further investigations on the precise biological function(s) of GAP-43.	GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, DEPT DEV & CELL BIOL, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, CTR RES OCCUPAT & ENVIRONM TOXICOL, PORTLAND, OR 97209 USA	Oregon Health & Science University; Oregon Health & Science University					NINDS NIH HHS [NS26806] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026806] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ALOYO VJ, 1983, J NEUROCHEM, V41, P649, DOI 10.1111/j.1471-4159.1983.tb04790.x; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; Baetge E E, 1992, Perspect Dev Neurobiol, V1, P21; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BENOWITZ LI, 1983, J NEUROSCI, V3, P2153; BENOWITZ LI, 1987, J NEUROCHEM, V48, P1640, DOI 10.1111/j.1471-4159.1987.tb05713.x; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUONASSISI V, 1962, P NATL ACAD SCI USA, V48, P1184, DOI 10.1073/pnas.48.7.1184; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMLER BM, 1985, J BIOL CHEM, V260, P784; CIMLER BM, 1987, J BIOL CHEM, V262, P12158; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1991, J NEUROCHEM, V56, P1146, DOI 10.1111/j.1471-4159.1991.tb11404.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; EIPPER BA, 1978, J BIOL CHEM, V253, P5732; FITZGERALD M, 1991, NEUROSCIENCE, V41, P187, DOI 10.1016/0306-4522(91)90209-7; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; GORDONWEEKS PR, 1989, TRENDS NEUROSCI, V12, P363, DOI 10.1016/0166-2236(89)90073-8; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILD S, 1987, J PHARMACOL EXP THER, V241, P126; HATFIELD JM, 1988, DEV BIOL, V126, P164, DOI 10.1016/0012-1606(88)90250-3; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HENS JJH, 1993, J NEUROCHEM, V60, P1264, DOI 10.1111/j.1471-4159.1993.tb03286.x; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KRISTJANSSON GI, 1982, J NEUROCHEM, V39, P371, DOI 10.1111/j.1471-4159.1982.tb03958.x; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LIU YC, 1994, J NEUROSCI, V14, P5807; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; NELSON RB, 1985, EXP NEUROL, V89, P213, DOI 10.1016/0014-4886(85)90277-8; NEVE RL, 1988, P NATL ACAD SCI USA, V85, P3638, DOI 10.1073/pnas.85.10.3638; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; PADEN CM, 1994, ENDOCRINOLOGY, V134, P503, DOI 10.1210/en.134.1.503; PERRONEBIZZOZERO NI, 1987, J NEUROCHEM, V48, P644, DOI 10.1111/j.1471-4159.1987.tb04141.x; ROSENTHAL A, 1987, EMBO J, V6, P3641, DOI 10.1002/j.1460-2075.1987.tb02696.x; SABOL SL, 1980, ARCH BIOCHEM BIOPHYS, V203, P37, DOI 10.1016/0003-9861(80)90151-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEA TB, 1991, J NEUROSCI, V11, P1685; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J NEUROSCI, V1, P419; SKENE JHP, 1981, J CELL BIOL, V89, P86, DOI 10.1083/jcb.89.1.86; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; VANDERNEUT R, 1990, NEUROSCI LETT, V109, P36, DOI 10.1016/0304-3940(90)90534-G; VANDERZEE CEEM, 1989, J NEUROSCI, V9, P3505; VITALE N, 1994, J BIOL CHEM, V269, P30293; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	84	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10023	10028		10.1074/jbc.271.17.10023	http://dx.doi.org/10.1074/jbc.271.17.10023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626556	hybrid			2022-12-25	WOS:A1996UG25700028
J	Pinkoski, MJ; Winkler, U; Hudig, D; Bleackley, RC				Pinkoski, MJ; Winkler, U; Hudig, D; Bleackley, RC			Binding of granzyme B in the nucleus of target cells - Recognition of an 80-kilodalton protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; DNA FRAGMENTATION; SERINE PROTEASES; NUCLEOLUS; SPECIFICITY; CYTOLYSIS; APOPTOSIS; KINETICS; GENES; C23	Granzyme B (cytotoxic cell proteinase 1) is a serine proteinase that has been implicated in cytotoxic T lymphocyte-induced apoptosis, In order to understand how granzyme B is involved in mechanisms of target cell destruction, characterization and identification of substrates are required. We have developed an in situ binding assay using permeabilized cells and recombinant granzyme B that allows us to visualize potential substrates after immunostaining with anti granzyme B antiserum. Confocal laser scanning microscopy and immunoelectron microscopic analyses demonstrate that granzyme B recognizes a nuclear substrate. The labeling pattern observed corresponds with regions of positive staining with uranyl acetate which binds to heterochromatin in the nucleus. Positive labeling of target cells with granzyme B is dependent on the presence of a catalytically active proteinase, since an inactive proenzyme form of granzyme B fails to give rise to any binding in the target cells. Far-Western blotting and immunoprecipitation of subcellular fractions of target cells have shown that the putative substrate of catalytically active granzyme B is an 80-kDa nuclear protein. Minor cytosolic bands of 50 and 94 kDa are also observed. A cytoplasmic band of 69 kDa is detected by both active and zymogen forms of granzyme B.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV NEVADA,DEPT MICROBIOL,RENO,NV 89557; UNIV NEVADA,CELL & MOL BIOL GRAD PROGRAM,RENO,NV 89557	University of Alberta; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno								BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BIGGIOGERA M, 1990, DEVELOPMENT, V110, P1263; BIGGIOGERA M, 1989, J HISTOCHEM CYTOCHEM, V37, P1371, DOI 10.1177/37.9.2768807; Bollag D.M., 1991, PROTEIN METHODS; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FAKAN S, 1986, BIOL CELL, V56, P189, DOI 10.1111/j.1768-322X.1986.tb00452.x; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEREZ P, 1985, J IMMUNOL, V134, P478; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POE M, 1991, J BIOL CHEM, V266, P98; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDELAER M, 1993, EXP CELL RES, V205, P430, DOI 10.1006/excr.1993.1110; WEIMER R, 1992, HUM GENET, V88, P673, DOI 10.1007/BF02265296; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	27	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10225	10229		10.1074/jbc.271.17.10225	http://dx.doi.org/10.1074/jbc.271.17.10225			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626587	hybrid			2022-12-25	WOS:A1996UG25700059
J	Jockers, R; DaSilva, A; Strosberg, AD; Bouvier, M; Marullo, S				Jockers, R; DaSilva, A; Strosberg, AD; Bouvier, M; Marullo, S			New molecular and structural determinants involved in beta(2)-adrenergic receptor desensitization and sequestration - Delineation using chimeric beta(3)/beta(2)-adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; AGONIST-PROMOTED DESENSITIZATION; HUMAN BETA-3-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; BETA-2-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; PROTEIN-KINASE; IDENTIFICATION; PATHWAYS; BINDING	As the beta(3)-adrenergic receptor (beta(3)AR) is resistant to short term agonist-promoted desensitization and sequestration, chimeric beta(3)/beta(2) receptors were generated to identify the molecular determinants responsible for these regulatory processes in the beta(2)AR. By exchanging single or multiple intracellular domains of the beta(3)AR for the corresponding regions of the beta(2)AR, we show that specific domains can be identified as additive determinants for desensitization, while sequestration is more dependent on global structural conformation, The carboxyl-terminal tail, the third and the second intracellular loops of the beta(2)AR provided additive contributions to the desensitization observed upon short term agonist stimulation, The second intracellular loop plays a role which is as important as that of third cytoplasmic loop and carboxyl-terminal tail which had previously been identified as the major determinants of agonist-promoted desensitization. Additive contributions of the cytoplasmic domains of the beta(2)AR were also observed for agonist-promoted sequestration, The substitution of the first and second intracellular loops and the carboxyl tail were associated with a beta(2)-like sequestration phenotype. However, in contrast to what is observed for desensitization the co-substitution of the third cytoplasmic loop with any of the other domains completely suppressed sequestration, These results suggest that sequestration depends not only on appropriate interactions of multiple molecular determinants within the cytoplasmic region of the beta(2)AR but also on conformational determinants that may influence their orientation.	UNIV MONTREAL,GRP RECH SYST NERVEUX AUTONOME,MONTREAL,PQ H3C 3J7,CANADA; CNRS UPR 0415,F-75014 PARIS,FRANCE; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE	Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jockers, R (corresponding author), UNIV MONTREAL,DEPT BIOCHIM,2900 EDOUARD MONTPETIT,CASE POSTALE 6128,SUCCURSA,MONTREAL,PQ H3C 3J7,CANADA.		Jockers, Ralf/P-2272-2017; Bouvier, Michel/H-2758-2014; Jockers, Ralf/Q-2100-2019; Marullo, Stefano/C-6142-2008	Jockers, Ralf/0000-0002-4354-1750; Bouvier, Michel/0000-0003-1128-0100; Jockers, Ralf/0000-0002-4354-1750; Marullo, Stefano/0000-0001-9604-9973				BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHRY A, 1994, J PHARMACOL EXP THER, V271, P1253; CLARK RB, 1989, MOL PHARMACOL, V36, P343; DOLAN JA, 1994, J PHARMACOL EXP THER, V269, P1000; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FEVE B, 1991, J BIOL CHEM, V266, P20329; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1992, MOL PHARMACOL, V42, P634; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, N-S ARCH PHARMACOL, V345, P444; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MORO O, 1993, J BIOL CHEM, V268, P22273; NANTEL F, 1993, MOL PHARMACOL, V43, P548; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SLICE LW, 1994, J BIOL CHEM, V269, P21755; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; YU SS, 1993, J BIOL CHEM, V268, P337	35	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9355	9362		10.1074/jbc.271.16.9355	http://dx.doi.org/10.1074/jbc.271.16.9355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621600				2022-12-25	WOS:A1996UG04400031
J	Kannan, R; Yi, JR; Tang, D; Li, Y; Zlokovic, BV; Kaplowitz, N				Kannan, R; Yi, JR; Tang, D; Li, Y; Zlokovic, BV; Kaplowitz, N			Evidence for the existence of a sodium-dependent glutathione (GSH) transporter - Expression of bovine brain capillary mRNA and size fractions in Xenopus laevis oocytes and dissociation from gamma-glutamyltranspeptidase and facilitative gsh transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED GLUTATHIONE; RAT; BARRIER; INHIBITION; SYSTEM	Our laboratory previously has shown apparent carrier-mediated glutathione (GSH) uptake across the blood-brain barrier (BBB) in two animal models, In the present study, when Xenopus oocytes were injected with bovine brain capillary mRNA expression of intact GSH, uptake was observed after 3 days, When total mRNA was converted to cDNA and subfractionated with subsequent cRNA injection into oocytes, three distinct fractions (5, 7-8, and 11-12) expressed carrier-mediated intact GSH transport, Northern blot analysis established the presence of RcGshT, the previously cloned sodium-independent hepatic canalicular transporter, only in fraction 5, GSH transport activity in fraction 7 was significantly inhibited by replacement of NaCl with choline chloride and by sulfobromophthalein-GSH, neither of which affects RcGshT, The Na+-dependent GSH uptake kinetics exhibited high affinity (similar to 400 mu M) and low affinity (similar to 10 mM) components. Fraction 11 expressed Na+-independent transport of intact GSH and also contained the GGT transcript, In conclusion, we have identified three distinct sized transcripts from bovine brain capillary mRNA which express GSH transport: one fraction expresses a novel Na+-dependent GSH uptake which can be dissociated unequivocally from both GGT and RcGshT for the first time and which may account for uptake of GSH against its electrochemical gradient at the BBB.	UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT NEUROL SURG,LOS ANGELES,CA 90033; VET ADM OUTPATIENT CLIN,LOS ANGELES,CA 90033	University of Southern California; University of Southern California	Kannan, R (corresponding author), UNIV SO CALIF,SCH MED,DIV GI & LIVER DIS,CTR LIVER DIS,2011 ZONAL AVE,HMR 803A,LOS ANGELES,CA 90033, USA.			Kannan, Ram/0000-0002-1583-3414	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R01DK030312, R37DK030312] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522, DK30312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FARRIS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1993, J BIOL CHEM, V268, P2324; FOLBERGROVA J, 1979, J NEUROCHEM, V32, P1621, DOI 10.1111/j.1471-4159.1979.tb02271.x; GUO N, 1992, NEUROSCIENCE, V51, P835, DOI 10.1016/0306-4522(92)90524-6; HAGEN RM, 1987, AM J PHYSIOL, V252, pG687; HAGEN TM, 1989, BIOCHEM PHARMACOL, V75, P4537; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; KANNAN R, 1992, J PHARMACOL EXP THER, V263, P964; KANNAN R, 1990, J CLIN INVEST, V85, P2009, DOI 10.1172/JCI114666; LASH LH, 1984, J BIOL CHEM, V259, P4508; LESLIE SW, 1992, MOL PHARMACOL, V41, P308; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MEISTER A, 1989, METABOLIC BASIS INHE, P855; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; YI JR, 1995, P NATL ACAD SCI USA, V92, P1495, DOI 10.1073/pnas.92.5.1495; YI JR, 1994, J CLIN INVEST, V93, P1841, DOI 10.1172/JCI117170; YUDKOFF M, 1990, J NEUROCHEM, V55, P137, DOI 10.1111/j.1471-4159.1990.tb08831.x; ZLOKOVIC BV, 1994, BIOCHEM BIOPH RES CO, V201, P402, DOI 10.1006/bbrc.1994.1715	19	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9754	9758		10.1074/jbc.271.16.9754	http://dx.doi.org/10.1074/jbc.271.16.9754			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621654	hybrid			2022-12-25	WOS:A1996UG04400085
J	Kato, R; Yamamoto, N; Kito, K; Kuramitsu, S				Kato, R; Yamamoto, N; Kito, K; Kuramitsu, S			ATPase activity of uvrB protein from Thermus thermophilus HB8 and its interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI UVRB; AMINO-ACID-SEQUENCE; 3-ISOPROPYLMALATE DEHYDROGENASE; EXTREME THERMOPHILE; (A)BC EXCINUCLEASE; MICROCOCCUS-LUTEUS; RNA HELICASE; GENE; CLONING	Many living organisms remove wide range of DNA lesions from their genomes by the nucleotide excision repair system. The uvrB gene, which plays an essential role in the prokaryotic excision repair, was cloned from an extremely thermophilic bacterium, Thermus thermophilus HB8. Its nucleotide sequence was determined, and the deduced amino acid sequence showed it possessed a helicase motif, including a nucleotide-binding consensus sequence (Walker's A-type motif), which was also conserved in other UvrB proteins. The prokaryotic UvrB proteins and eukaryotic DNA repair helicases (Rad3 and XP-D) were classified into different groups by molecular phylogenetic analysis. The T. thermophilus uvrB gene product was overproduced in Escherichia coli and purified to apparent homogeneity. The purified T. thermophilus UvrB protein was stable up to 80 degrees C at neutral pH, T. thermophilus UvrB protein showed ATPase activity at its physiological temperature, whereas the E. coli UvrB protein alone has not been shown to exhibit detectable ATPase activity, The values of K-m and k(cat) for the ATPase activity were 4.2 mM and 0.32 s(-1) without DNA, and 4.0 mM and 0.46 s(-1) with single-stranded DNA, respectively. This suggests that T. thermophilus UvrB protein could interact with single-stranded DNA in the absence of UvrA protein.	OSAKA UNIV, FAC SCI, DEPT BIOL, TOYONAKA, OSAKA 560, JAPAN	Osaka University				Kato, Ryuichi/0000-0003-2087-2896				Ambler R P, 1972, Methods Enzymol, V25, P262, DOI 10.1016/S0076-6879(72)25023-6; ARGOS P, 1979, BIOCHEMISTRY-US, V18, P5698, DOI 10.1021/bi00592a028; ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BLACK CG, 1995, J BACTERIOL, V177, P1952, DOI 10.1128/jb.177.8.1952-1958.1995; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P9641, DOI 10.1093/nar/16.20.9641; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1995, DNA REPAIR; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; KATO R, 1993, J BIOCHEM-TOKYO, V114, P926, DOI 10.1093/oxfordjournals.jbchem.a124278; KIRINO H, 1991, J BIOCHEM-TOKYO, V109, P852, DOI 10.1093/oxfordjournals.jbchem.a123470; KOYAMA Y, 1990, J BACTERIOL, V172, P3490, DOI 10.1128/jb.172.6.3490-3495.1990; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LIN JJ, 1992, J BIOL CHEM, V267, P17688; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; NOJIMA H, 1979, J BIOCHEM, V85, P1509, DOI 10.1093/oxfordjournals.jbchem.a132480; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; REYNOLDS P, 1985, NUCLEIC ACIDS RES, V13, P2357, DOI 10.1093/nar/13.7.2357; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; Shi Q., 1990, GEL ELECTROPHORESIS; SHIOTA S, 1988, MOL GEN GENET, V213, P21, DOI 10.1007/BF00333393; SICARD N, 1992, J BACTERIOL, V174, P2412, DOI 10.1128/JB.174.7.2412-2415.1992; STALLINGS WC, 1985, J BIOL CHEM, V260, P6424; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TAGUCHI H, 1983, J BIOCHEM, V93, P7, DOI 10.1093/oxfordjournals.jbchem.a134179; TSO PO, 1966, BIOCHEMISTRY-US, V5, P4153, DOI 10.1021/bi00876a052; VANHOUTEN B, 1988, J BIOL CHEM, V263, P16553; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE K, 1994, EUR J BIOCHEM, V226, P277, DOI 10.1111/j.1432-1033.1994.tb20051.x; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8856; YEH MF, 1976, J BIOL CHEM, V251, P3134; ZUCKERKANDL EMILE, 1965, P97	54	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9612	9618		10.1074/jbc.271.16.9612	http://dx.doi.org/10.1074/jbc.271.16.9612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621636	hybrid			2022-12-25	WOS:A1996UG04400067
J	Loe, DW; Almquist, KC; Deeley, RG; Cole, SPC				Loe, DW; Almquist, KC; Deeley, RG; Cole, SPC			Multidrug resistance protein (MRP)-mediated transport of leukotriene C-4 and chemotherapeutic agents in membrane vesicles - Demonstration of glutathione-dependent vincristine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; P-GLYCOPROTEIN; RAT-HEART; GENE; EXPRESSION; ADRIAMYCIN; BINDING; CARRIER; EXPORT; SYSTEM	The 190-kDa multidrug resistance protein (MRP) has recently been associated with the transport of cysteinyl leukotrienes and several glutathione (GSH) S-conjugates. In the present study, we have examined the transport of leukotriene C-4 (LTC(4)) in membrane vesicles from MRP-transfected HeLa cells (T14), as well as drug-selected H69AR lung cancer cells which express high levels of MRP. V-max and K-m values for LTC(4) transport by membrane vesicles from T14 cells were 529 +/- 176 pmol mg(-1) min(-1) and 105 +/- 31 nM, respectively, At 50 nM LTC(4), the K-m (ATP) was 70 mu M. Transport in T14 vesicles was osmotically-sensitive and was supported by various nucleoside triphosphates but not by non- or slowly-hydrolyzable ATP analogs, LTC, transport rates in membrane vesicles derived from H69AR cells and their parental and revertant variants were consistent with their relative levels of MRP expression. A 190-kDa protein in T14 membrane vesicles was photolabeled by [H-3]LTC(4) and immunoprecipitation with MRP-specific monoclonal antibodies (mAbs) confirmed that this protein was MRP, LTC, transport was inhibited by an MRP-specific mAb (QCRL-3) directed against an intracellular conformational epitope of MRP, but not by a mAb (QCRL-1) which recognizes a linear epitope, Photolabeling with [H-3]LTC(4) was also inhibitable by mAb QCRL-3 but not mAb &CRL-I, GSH did not inhibit LTC, transport, However, the ability of alkylated GSH derivatives to inhibit transport increased markedly with the length of the alkyl group, S-Decylglutathione was a potent competitive inhibitor of [H-3]LTC(4) transport (K-i(app) 116 nM), suggesting that the two compounds bind to the same, or closely related, site(s) on MRP. Chemotherapeutic agents including colchicine, doxorubicin, and daunoru bicin were poor inhibitors of [H-3]LTC, transport, Taxol, VP-16, vincristine, and vinblastine were also poor inhibitors of LTC, transport but inhibition by these compounds was enhanced by GSH. Uptake of[H-3]vincristine into T14 membrane vesicles in the absence of GSB was low and not dependent on ATP, However, in the presence of GSH, ATP-dependent vincristine transport was observed, Levels of transport increased with concentrations of GSH up to 5 mM. The identification of an MRP-specific mAb that inhibits LTC, transport and prevents photolabeling of MRP by LTC(4), provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes, Our studies also demonstrate that MRP is capable of mediating ATP-dependent transport of vincristine and that transport is GSH-dependent.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada			Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; 				ALMQUIST KC, 1995, CANCER RES, V55, P102; BALLATORI N, 1995, J BIOL CHEM, V270, P3594, DOI 10.1074/jbc.270.8.3594; BARRAND MA, 1993, EUR J CANCER, V29A, P408, DOI 10.1016/0959-8049(93)90397-X; BLUMRICH M, 1990, BIOCHIM BIOPHYS ACTA, V1029, P1, DOI 10.1016/0005-2736(90)90430-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, CAN J PHYSIOL PHARM, V70, P313, DOI 10.1139/y92-040; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; DALTON WS, 1986, CANCER RES, V46, P5125; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Georges E, 1990, Adv Pharmacol, V21, P185, DOI 10.1016/S1054-3589(08)60343-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; HIPFNER DR, 1994, CANCER RES, V54, P5788; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; LOE DW, 1996, IN PRESS EUR J CANC; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; OGITA K, 1995, J NEUROCHEM, V64, P1088; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; SAFA AR, 1992, CANCER INVEST, V10, P295, DOI 10.3109/07357909209032754; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SCHLEMMER SR, 1995, ANAL BIOCHEM, V228, P226, DOI 10.1006/abio.1995.1343; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; TEW KD, 1994, CANCER RES, V54, P4313; TWENTYMAN PR, 1986, BRIT J CANCER, V53, P529, DOI 10.1038/bjc.1986.83; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	44	531	536	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9675	9682		10.1074/jbc.271.16.9675	http://dx.doi.org/10.1074/jbc.271.16.9675			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621643	hybrid			2022-12-25	WOS:A1996UG04400074
J	Miao, CH; Ho, WT; Greenberg, DL; Davie, EW				Miao, CH; Ho, WT; Greenberg, DL; Davie, EW			Transcriptional regulation of the gene coding for human protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; HEMOPHILIA-B LEYDEN; BETA-HYDROXYASPARTIC ACID; LIVER-SPECIFIC EXPRESSION; K-DEPENDENT PROTEIN; NUCLEAR FACTOR-III; HUMAN FACTOR-X; BOVINE PLASMA; FACTOR-IX; NUCLEOTIDE-SEQUENCE	The promoter for the gene coding for human protein C has been characterized as to nucleotide sequences that regulate the synthesis of mRNA. The major transcription start site was found 65 nucleotides upstream from the first intron/exon boundary along with two minor sites, Functional characterization of 1528 base pairs at the 8'-end of the gene was then carried out by chloramphenicol acetyltransferase reporter assays, protection from DNase I digestion, and electrophoretic mobility shift assays employing HepG2 and HeLa cells. One of the upstream regions (nucleotides -25 to +9) contained binding sites for at least two different transcription factors, including a hepatic nuclear factor 1-binding site (-10 to +9) and two overlapping and oppositely oriented hepatic nuclear factor 3-binding sites (-25 to -11). A second major region (PCE1) (+12 to +30) appeared to be a unique, liver-specific regulatory sequence, An Sp1-binding site in exon I (+58 to +65) was also recognized by cotransfection experiments with an Spl expression plasmid. Specific mutations in these promoter elements reduced transcriptional activity and abolished the binding of hepatic nuclear proteins. Finally, a strong silencer element (PCS1) (between -162 and -82) and two possible liver-specific enhancer regions (PCE2 and PCE3), which interact coordinately with the promoter elements, were also found (between -1462 and -162).	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANCROFT JD, 1990, GENE, V95, P253, DOI 10.1016/0378-1119(90)90368-2; BERG LP, 1994, HUM MOL GENET, V3, P2147, DOI 10.1093/hmg/3.12.2147; BRENNER B, 1995, THROMB HAEMOSTASIS, V73, P942; BRIET E, 1985, ANN INTERN MED, V103, P225, DOI 10.7326/0003-4819-103-2-225; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GRIFFIN JH, 1982, BLOOD, V60, P261; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUANG MN, 1992, J BIOL CHEM, V267, P15440; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Jackson R C, 1980, Ann N Y Acad Sci, V343, P391, DOI 10.1111/j.1749-6632.1980.tb47268.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MACGILLIVRAY RTA, 1991, THROMB HAEMOSTASIS, V65, P612; MANDEL H, 1995, THROMB HAEMOSTASIS, V73, P1361; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MIAO CH, 1992, J BIOL CHEM, V267, P7395; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REITSMA PH, 1993, THROMB HAEMOSTASIS, V69, P77; ROYLE NJ, 1987, SOMAT CELL MOLEC GEN, V13, P285, DOI 10.1007/BF01535211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPEK CA, 1995, ARTERIOSCL THROM VAS, V15, P214, DOI 10.1161/01.ATV.15.2.214; SPEK CA, 1995, J BIOL CHEM, V270, P24216, DOI 10.1074/jbc.270.41.24216; STENFLO J, 1976, J BIOL CHEM, V251, P355; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; TSAY W, 1993, BLOOD COAGUL FIBRIN, V4, P791, DOI 10.1097/00001721-199304050-00017; VANAMSTEL HKP, 1990, BIOCHEMISTRY-US, V29, P7853, DOI 10.1021/bi00486a011; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	55	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9587	9594		10.1074/jbc.271.16.9587	http://dx.doi.org/10.1074/jbc.271.16.9587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621633	hybrid			2022-12-25	WOS:A1996UG04400064
J	Hansen, H; Svensson, U; Zhu, JW; Laviola, L; Giorgino, F; Wolf, G; Smith, RJ; Riedel, H				Hansen, H; Svensson, U; Zhu, JW; Laviola, L; Giorgino, F; Wolf, G; Smith, RJ; Riedel, H			Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH FACTOR-I; PROTEIN; PHOSPHORYLATION; BINDING; SUBSTRATE-1; SPECIFICITY; EXPRESSION; TRUNCATION; SUBUNIT	Grb10 is a member of a recently identified family of adapter proteins that are thought to play a role in receptor tyrosine kinase-mediated signal transduction. We identified and isolated the Grb10 SH2 domain based on its interaction with the intracellular domain of the insulin receptor beta-subunit using the yeast two-hybrid system, The interaction was specific for the insulin receptor and the insulin-like growth factor-1 receptor, and it required a catalytically active receptor kinase domain and an intact Grb10 SH2 domain. Glutathione S-transferase fusion proteins containing the Grb10 SH2 domain associated in an insulin-dependent manner with insulin receptors from cell lysates and with purified insulin receptors. Go-precipitation experiments revealed the association of cellular Grb10 with hormone-stimulated insulin receptors in cell extracts. The Grb10 SH2 domain did not bind to an insulin receptor lacking 43 amino acids at the carboxyl terminus, and it exhibited highest affinity for a phosphopeptide containing Tyr(P)-1322. Unlike p85 and Syp, which also bind to Tyr(P)-1322, Grb10 was not found to associate with insulin receptor substrate-1, These results suggest that Grb10 is a novel insulin receptor interactive protein and provide direct evidence for an insulin receptor substrate-1-independent function of the insulin receptor carboxyl terminus in protein binding.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,MOLEC BIOL SECT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,METAB SECT,BOSTON,MA 02215; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,SECT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02215	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Giorgino, Francesco/K-7262-2016	Giorgino, Francesco/0000-0001-7372-2678; Laviola, Luigi/0000-0001-8860-5845	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43038, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, J BIOL CHEM, V267, P1367; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GOREN HJ, 1987, BIOCHEMISTRY-US, V26, P2374, DOI 10.1021/bi00382a044; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MYERS MG, 1991, J BIOL CHEM, V266, P10616; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; REUSCH JEB, 1995, ENDOCRINOLOGY, V136, P2464, DOI 10.1210/en.136.6.2464; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Siddle Kenneth, 1992, Progress in Growth Factor Research, V4, P301, DOI 10.1016/0955-2235(92)90013-8; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	43	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8882	8886		10.1074/jbc.271.15.8882	http://dx.doi.org/10.1074/jbc.271.15.8882			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621530	hybrid			2022-12-25	WOS:A1996UE73000061
J	Nikolakaki, E; Simos, G; Spyros, D; Georgatos, SD; Giannakouros, T				Nikolakaki, E; Simos, G; Spyros, D; Georgatos, SD; Giannakouros, T			A nuclear envelope-associated kinase phosphorylates arginine-serine motifs and modulates interactions between the lamin B receptor and other nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; SENSITIVE METHOD; GENE ENCODES; DOMAINS; BINDING; CLONING; SITE	Previous studies have identified a subassembly of nuclear envelope proteins, termed ''the LBR complex'' This complex includes the lamin B receptor protein (LBR or p58), a kinase which phosphorylates LBR in a constitutive fashion (LBR kinase), the nuclear lamins A and B, an 18-kDa polypeptide (p18), and a 34-kDa protein (p34/p32). The latter polypeptide has been shown to interact with the HIV-1 proteins Rev and Tat and with the splicing factor 2 (SF2). Using recombinant proteins produced in bacteria and synthetic peptides representing different regions of LBR, we now show that the LBR kinase modifies specifically arginine-serine (RS) dipeptide motifs located at the nucleoplasmic, NH2-terminal domain of LBR and in members of the SR family of splicing factors. Furthermore, we show that the NH2-terminal domain of LBR binds to p34/p32, whereas a mutated domain lacking the RS region does not. Phosphorylation of LBR by the RS kinase completely abolishes binding of p34/p32, suggesting that this enzyme regulates interactions among the components of the LBR complex.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69117 HEIDELBERG, GERMANY; ARISTOTELIAN UNIV THESSALONIKI, BIOCHEM LAB, FAC CHEM, GR-54006 THESSALONIKI, GREECE; UNIV CRETE, FAC MED, DEPT BASIC SCI, GR-71110 IRAKLION, CRETE, GREECE	European Molecular Biology Laboratory (EMBL); Aristotle University of Thessaloniki; University of Crete			GIANNAKOUROS, THOMAS/R-3204-2019; Simos, George/AAH-2596-2021	Georgatos, Spyros/0000-0002-2078-7467; Simos, George/0000-0001-5453-3185				ANTONIOU M, 1993, J CELL BIOL, V123, P1055, DOI 10.1083/jcb.123.5.1055; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MAISON C, 1995, EMBO J, V14, P3311, DOI 10.1002/j.1460-2075.1995.tb07338.x; MEIER J, 1994, EMBO J, V13, P1888, DOI 10.1002/j.1460-2075.1994.tb06458.x; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH S, 1994, P NATL ACAD SCI USA, V91, P10124, DOI 10.1073/pnas.91.21.10124; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YE Q, 1994, J BIOL CHEM, V269, P11306; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	42	88	90	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8365	8372		10.1074/jbc.271.14.8365	http://dx.doi.org/10.1074/jbc.271.14.8365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626534	hybrid			2022-12-25	WOS:A1996UD60000074
J	George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J				George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J			Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma	ONCOGENE			English	Article						N-myc; gene amplification; neuroblastoma; DDX1; pG21	HUMAN NEURO-BLASTOMA; DEPENDENT RNA HELICASE; CELL-LINES; DNA; EXPRESSION; ONCOGENE; FAMILY; TUMOR; COAMPLIFICATION; ASSOCIATION	Although N-myc amplification is strongly associated with a poor prognosis, not all patients with neuroblastomas having N-myc amplification fare badly. To investigate whether genes other than N-myc are responsible for contributing to the prognosis, we examined seven cell lines and 87 primary tumours for co-amplification of candidate genes known to be present near the normal N-myc locus: ornithine decarboxylase (ODC), ribonucleotide reductase (RRM2), syndecan-1 and a DEAD box protein gene, DDX1. Sequence analysis of the pG21 cDNA clone previously reported to represent an expressed gene frequently co-amplified with N-myc, showed this to be from the DDX1 gene. No coamplification with the first three genes was found in any of the cell lines or tumour samples. DDX1, however was found to be amplified along with N-myc in 4/6 (67%) cell lines and 6/16 (38%) of the N-myc amplified tumours. Co-amplification of DDX1 and N-myc was found more frequently in stage 4 or 4S tumours than lower stage (1-3) tumours. With the exclusion of a single 4S case, there was a highly significant reduction in the mean disease-free interval from 24.4 +/- 4.7 (SE, n = 10) months for cases with co-amplification of N-myc and DDX1 compared with 9.2 +/- 1.8 (SE, n = 5) months for those cases showing amplification of N-myc alone (P = 0.0056, Welch's unpaired t-test). No amplification of DDX1, ODC, RRM2, or syndecan-1 was found in the absence of N-myc amplification. These observations indicate that the N-myc amplicon is of varied size and/or position relative to the N-myc gene, with DDX1 representing at least one other gene frequently coamplified with N-myc. Further studies are required to confirm the biological and prognostic significance of DDX1 co-amplification and to elucidate the role that DDX1 plays in tumour genesis and progression.	UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; AMLER LC, 1995, IN PRESS GENES CHROM; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARACHI R, 1987, BRIT J CANCER, V55, P407, DOI 10.1038/bjc.1987.80; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GRADYLEOPARDI EF, 1986, CANCER RES, V44, P5444; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIEMSTRA JL, 1994, ADV NEUROBLASTOMA RE, V4, P51; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LONGO L, 1988, J CANCER RES CLIN, V114, P636, DOI 10.1007/BF00398190; MALI M, 1990, J BIOL CHEM, V265, P6884; MOSHIER JA, 1990, J BIOL CHEM, V265, P4884; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHILOH Y, 1986, CANCER RES, V46, P5297; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH K, 1993, ONCOGENE, V8, P933; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE JA, 1995, ONCOGENE, V10, P1417; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WHELDON TE, 1985, BRIT J RADIOL, V58, P661, DOI 10.1259/0007-1285-58-691-661	42	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1583	1587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622876				2022-12-25	WOS:A1996UF07600024
J	Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y				Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y			Activation of the erythropoietin gene in the majority of F-MuLV-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; advanced tumorigenicity	MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; WILD-TYPE P53; TRANSGENIC MICE; INSERTIONAL ACTIVATION; RECEPTOR GENE; CELL-GROWTH; EXPRESSION; ONCOGENE; FLI-1	Retroviral insertional activation of I;li-l is the first detectable genetic alteration associated with F-MuLV-induced primary erythroleukemias, while mutations within p53 are only observed in Epo-dependent (ED) cell lines derived from syngeneic mice serially transplanted with F-MuLV-induced primary erythroleukemias. In this study we have determined the mechanism of growth factor independence in several Epo-independent (EI) cell lines established from adult mice previously injected with ED-erythroleukemia cell lines or serially transplanted primary tumor cells. Here we have shown constitutive expression of the Epa gene in 12 of 15 (80%) EI-erythroleukemia cell Lines. Among these 12 cell lines, eight were shown to possess clonal rearrangement of the Epo gene which could be detected in the tumors used to establish the majority of these EI-cell lines. Analysis of the pattern of proviral integration revealed that the activation of the Epo gene in these cell lines is independent of retroviral insertional mutagenesis, but apparently the result of genomic rearrangements. Furthermore, the acquisition of growth factor independence by these leukemic cells confers a selective growth advantage in vivo and is associated with enhanced tumorigenicity. Together these observations suggest that the activation of the Epo gene in the large majority of these F-MuLV-induced erythroleukemic cell lines establishes an autocrine loop resulting in the constitutive of the Epo receptor transduction pathway, thereby conferring advantage in vivo and in vitro.	SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL RES, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5S 1A1, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto			Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432; Hawley, Robert/0000-0003-3512-5818				BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BERU N, 1989, ANN NY ACAD SCI, V554, P29, DOI 10.1111/j.1749-6632.1989.tb22406.x; BONDURANT M, 1993, ERYTHROPOIETIN, P241; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HOWARD JC, 1993, ONCOGENE, V8, P2721; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; OLIFF A, 1981, BLOOD, V58, P244; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RENCRICCA N J, 1970, Blood, V36, P764; SCHUSTER SJ, 1987, BLOOD, V70, P316; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	42	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1405	1415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622856				2022-12-25	WOS:A1996UF07600004
J	Bennett, DL; Cheek, TR; Berridge, MJ; DeSmedt, H; Parys, JB; Missiaen, L; Bootman, MD				Bennett, DL; Cheek, TR; Berridge, MJ; DeSmedt, H; Parys, JB; Missiaen, L; Bootman, MD			Expression and function of ryanodine receptors in nonexcitable cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CA-2+ RELEASE CHANNEL; CA2+-INDUCED CA2+ RELEASE; SKELETAL-MUSCLE; MOLECULAR-CLONING; BINDING-SITES; RABBIT BRAIN; HELA-CELLS; RAT-LIVER; CAFFEINE	We have used reverse transcriptase-polymerase chain reaction to investigate the expression of ryanodine receptors in several excitable and nonexcitable cell types. Consistent with previous reports, we detected ryanodine receptor expression in brain, heart, and skeletal muscle. In addition, we detected ryanodine receptor expression in various other excitable cells including PC12 and A7r5 cells, Several muscle cell lines (BC(3)H1, C2C12, L6, and Sol8) weakly expressed ryanodine receptor when undifferentiated but strongly expressed type 1 and type 3 ryanodine receptor isoforms when differentiated into a muscle phenotype. Only 2 (HeLa and LLC-PK1 cells) out of 11 nonexcitable cell types examined expressed ryanodine receptors. Expression of ryanodine receptors at the protein level in these cells was confirmed using [H-3]ryanodine binding. We also investigated the function of ryanodine receptors in Ca2+ signaling in HeLa cells using single-cell Fura-2 imaging, Neither caffeine nor ryanodine caused a detectable elevation of cytoplasmic Ca2+ in single HeLa cells, However, ryanodine caused a significant decrease in the amplitude of Ca2+ signals evoked by repetitive stimulation with ATP. These studies show that ryanodine receptors are expressed in some nonexcitable cell types and furthermore suggest that the ryanodine receptors may be involved in a subtle regulation of intracellular Ca2+ responses.	KATHOLIEKE UNIV LEUVEN,FYSIOL LAB,B-3000 LOUVAIN,BELGIUM	KU Leuven	Bennett, DL (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,BABRAHAM INST,MOLEC SIGNALLING LAB,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451; Parys, Jan/0000-0002-3591-4967				AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; BARRY VA, 1994, BIOCHEM J, V300, P589, DOI 10.1042/bj3000589; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1996, RYANODINE RECEPTORS, P119; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DIARRA A, 1992, PFLUG ARCH EUR J PHY, V422, P40, DOI 10.1007/BF00381511; FENG L, 1992, CELL CALCIUM, V13, P79, DOI 10.1016/0143-4160(92)90001-9; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FLORINI JR, 1989, AM J PHYSIOL, V256, pC701, DOI 10.1152/ajpcell.1989.256.4.C701; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MASUO M, 1991, CIRC RES, V69, P1327, DOI 10.1161/01.RES.69.5.1327; MCNULTY TJ, 1993, BIOCHEM J, V291, P799, DOI 10.1042/bj2910799; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; NATHANSON MH, 1994, GASTROENTEROLOGY, V106, P1349, DOI 10.1016/0016-5085(94)90030-2; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; OTSU K, 1990, J BIOL CHEM, V265, P13472; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; PARYS JB, 1990, J CELL PHYSIOL, V144, P365, DOI 10.1002/jcp.1041440302; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SHOSHANBARMATZ V, 1991, BIOCHEM J, V276, P41, DOI 10.1042/bj2760041; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x	43	139	143	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6356	6362		10.1074/jbc.271.11.6356	http://dx.doi.org/10.1074/jbc.271.11.6356			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626432	hybrid			2022-12-25	WOS:A1996UA36300061
J	Chung, KY; Agarwal, A; Uitto, J; Mauviel, A				Chung, KY; Agarwal, A; Uitto, J; Mauviel, A			An AP-1 binding sequence is essential for regulation of the human alpha 2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; MAMMALIAN-CELLS; DNA-SEQUENCES; TRANSCRIPTION; ACTIVATION; EXPRESSION; DIFFERS; GENES	Previous studies have shown that transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) modulate type I collagen gene expression in fibroblasts. To fine-map the corresponding response elements in the human alpha 2(I) collagen (COL1A2) promoter, we have generated a series of 5' deletion promoter/ chloramphenicol acetyltransferase (CAT) reporter gene constructs, Transient cell transfection assays using human dermal fibroblasts and stable transfection experiments using NIH 3T3 fibroblasts identified the region located between residues -265 and -241, as critical for TGF-beta response, Specifically, we demonstrate that this 25-base pair region mediates the up-regulatory effect of TGF-beta on COL1A2 promoter activity and allows antagonistic activity of TNF-alpha on the TGF-beta effect. Gel mobility shift assays indicate that nuclear factor binding to this 25-base pair region of COL1A2 promoter is competed by AP-1, but not NF-1 or NF-kappa B, oligonucleotides. Transient cell transfection experiments with plasmid constructs in which the potential AP-1-binding site located within this short region of promoter was modified by site-directed mutagenesis indicated that this element plays a significant role in the basal activity of the promoter. Furthermore, this sequence is essential for TGF-beta response and does not require the presence of the three Sp-1-binding sites located further upstream, between nucleotides -273 and -304. In addition, overexpression of c-jun in co-transfection experiments with COL1A2 promoter/CAT constructs blocks the TGF-beta response, further implicating AP-1 in the regulation of COL1A2 gene expression. Our results clarify the molecular mechanisms involved in the regulation of type I collagen gene expression and further emphasize the importance of AP-1 in mediating some of the TGF-beta effects on gene transcription.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University			MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R01-AR41439, T32-AR07651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOAST S, 1990, J BIOL CHEM, V265, P13351; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	19	279	302	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3272	3278		10.1074/jbc.271.6.3272	http://dx.doi.org/10.1074/jbc.271.6.3272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621730	hybrid			2022-12-25	WOS:A1996TU69100059
J	LustiNarasimhan, M; Chollet, A; Power, CA; Allet, B; Proudfoot, AEI; Wells, TNC				LustiNarasimhan, M; Chollet, A; Power, CA; Allet, B; Proudfoot, AEI; Wells, TNC			A molecular switch of chemokine receptor selectivity - Chemical modification of the interleukin-8 Leu(25)->Cys mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PROTEINS; CLONING; BINDING; ASSAY	Interleukin-8 (IL-8), a member of the CXC chemokine family, is a key activator of neutrophils. We have previously shown that two novel CC chemokine-like properties, namely monocyte chemoattraction and binding to CC CKR-1, are introduced into IL-8 by mutating Leu(25) to the conserved tyrosine present in CC chemokines. To further investigate the role of this position in receptor selectivity, we have mutated Leu(25) to cysteine. The protein folds correctly with two disulfide bonds and a free thiol group at Cys(25). This mutant behaves overall like wild-type IL-8, with little change in neutrophil chemotaxis and IL-8 receptor binding, and has no effect on CC CKR-1. These data are consistent with cysteine being approximately isosteric with the natural amino acid leucine, However, modification of the cysteine by addition of a fluorescent N-methyl-N-(2-N-methyl, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminoethyl)acetamido (NBD) group lowers potency in neutrophil chemotaxis and affinity in IL-8 receptor binding assays by 2 orders of magnitude. This Leu(25) --> Cys-NBD mutant introduces monocyte chemoattractant activity and the ability to displace I-125-labeled macrophage inflammatory protein-1 alpha from the recombinant CC CKR-1 receptor. Additionally, we show a specific interaction between the fluorescent mutant and the N-terminal 34-amino acid peptide from CC CKR-1. This confirms the importance of this region in IL-8 in receptor binding and in conferring specificity between CXC and CC chemokines. Circular dichroism spectra of the IL-8 mutants having CC chemokine-like activity show a consistent drop in alpha-helical content compared with the spectra for wild-type IL-8. This suggests that distortion of the C-terminal helix may play a role in chemokine receptor-ligand selectivity.	GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND	GlaxoSmithKline				Wells, Timothy/0000-0001-9796-847X; Narasimhan, Manjulaa/0000-0003-0598-6887				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9304; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; LEATHERBARROW RJ, 1993, GRAFIT VERSION 301; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MEYRS SJ, 1995, J BIOL CHEM, V270, P5786; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POWER CA, 1994, EUR J BIOCHEM, V221, P713, DOI 10.1111/j.1432-1033.1994.tb18784.x; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROUDFOOT AEI, 1996, IN PRESS J BIOL CHEM, V271; SHI YF, 1993, J IMMUNOL METHODS, V164, P149, DOI 10.1016/0022-1759(93)90307-S; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; VOGEL H, 1987, BIOCHEMISTRY-US, V26, P4562, DOI 10.1021/bi00388a060; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	28	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3148	3153		10.1074/jbc.271.6.3148	http://dx.doi.org/10.1074/jbc.271.6.3148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621714	hybrid			2022-12-25	WOS:A1996TU69100043
J	Chestukhin, A; Litovchick, L; Schourov, D; Cox, S; Taylor, SS; Shaltiel, S				Chestukhin, A; Litovchick, L; Schourov, D; Cox, S; Taylor, SS; Shaltiel, S			Functional malleability of the carboxyl-terminal tail in protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLITTING MEMBRANAL PROTEINASE; CIRCULAR DICHROIC EVIDENCE; CATALYTIC SUBUNIT; INHIBITOR PROTEIN; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; MAGNETIC-RESONANCE; ESCHERICHIA-COLI; BASIC RESIDUES	The catalytic (C) subunit of protein kinase A (PKA) is regarded as a framework for the protein kinase family. Its sequence is composed of a conserved core (residues 40-300) between two segments at the amino and carboxyl termini of the protein. Since the various protein kinases differ in their specificity, it seems reasonable to assume that these nonhomologous segments may be involved in endowing each kinase with its individual specificity. Here we present data to show that the cluster of acidic amino acids ((328)DDYEEEE(334)) at the carboxyl-terminal ''tail'' of the C subunit, specifically Tyr(330), contributes to its substrate recognition. This is based on three complementary lines of evidence: (i) on a conformation-sensitive cleavage of the C subunit by a kinase-splitting membranal proteinase that specifically recognizes this cluster, to demonstrate the occurrence in solution of ''open'' (cleavable) and ''closed'' (noncleavable) conformations of the C subunit; (ii) on analysis of the three-dimensional structures of the open and closed conformations of the C subunit, showing an similar to 7-Angstrom movement of the phenolic hydroxyl of Tyr(330) to reach (in the closed conformation) an similar to 3-Angstrom distance from the nitrogen atoms of the Arg residue at position p-3 of the PKA consensus sequence; and (iii) on single-site mutations of the C subunit (e.g. Y330A) that show a significant contribution of Tyr(330) to the K-m of PKA for its substrates/inhibitors and to its catalytic efficacy (V-max/K-m).	WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL; UNIV CALIF SAN DIEGO, DEPT CHEM, SAN DIEGO, CA 92093 USA	Weizmann Institute of Science; University of California System; University of California San Diego				Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; Cleland W. W, 1970, ENZYMES, V2, P1; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; EGAN JJ, 1988, ANAL BIOCHEM, V175, P552, DOI 10.1016/0003-2697(88)90583-0; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRANOT J, 1980, BIOCHEMISTRY-US, V19, P3537, DOI 10.1021/bi00556a019; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; JIMENEZ JS, 1981, FEBS LETT, V130, P127, DOI 10.1016/0014-5793(81)80680-1; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; JOHNSON EM, 1975, BIOCHEMISTRY-US, V14, P3873, DOI 10.1021/bi00688a022; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINZEL V, 1987, ARCH BIOCHEM BIOPHYS, V253, P341, DOI 10.1016/0003-9861(87)90187-1; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KUPFER A, 1980, BIOCHEM BIOPH RES CO, V96, P77, DOI 10.1016/0006-291X(80)91183-3; KUPFER A, 1982, BIOCHEMISTRY-US, V21, P1631, DOI 10.1021/bi00536a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; POMERANTZ AH, 1977, P NATL ACAD SCI USA, V74, P4261, DOI 10.1073/pnas.74.10.4261; REED J, 1984, BIOCHEMISTRY-US, V23, P968, DOI 10.1021/bi00300a026; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SEGER R, 1989, EMBO J, V8, P435, DOI 10.1002/j.1460-2075.1989.tb03395.x; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEGER R, 1993, INNOVATION PROTEASES, P231; SHALTIEL S, 1988, ROOTS OF MODERN BIOCHEMISTRY, P781; SHALTIEL S, 1989, INTRACELLULAR PROTEO, P188; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	60	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10175	10182		10.1074/jbc.271.17.10175	http://dx.doi.org/10.1074/jbc.271.17.10175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626579	hybrid			2022-12-25	WOS:A1996UG25700051
J	Merli, A; Brodersen, DE; Morini, B; Chen, ZW; Durley, RCE; Mathews, FS; Davidson, VL; Rossi, GL				Merli, A; Brodersen, DE; Morini, B; Chen, ZW; Durley, RCE; Mathews, FS; Davidson, VL; Rossi, GL			Enzymatic and electron transfer activities in crystalline protein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN METHYLAMINE DEHYDROGENASE; BLUE COPPER PROTEIN; C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; AMICYANIN; PURIFICATION; COFACTOR	Enzymatic and electron transfer activities have been studied by polarized absorption spectroscopy in single crystals of both binary and ternary complexes of methylamine dehydrogenase (MADH) with its redox partners, Within the crystals, MADH oxidizes methylamine, and the electrons are passed from the reduced tryptophan tryptophylquinone (TTQ) cofactor to the copper of amicyanin and to the heme of cytochrome c(551i) via amicyanin, The equilibrium distribution of electrons among the cofactors, and the rate of heme reduction after reaction with substrate, are both dependent on pH, The presence of copper in the ternary complex is not absolutely required for electron transfer from TTQ to heme, but its presence greatly enhances the rate of electron flow to the heme.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	Washington University (WUSTL); University of Parma; University of Mississippi; University of Mississippi Medical Center			Brodersen, Ditlev E./AAQ-5241-2020	Davidson, Victor/0000-0002-1966-7302; Brodersen, Ditlev/0000-0002-5413-4667	NIGMS NIH HHS [GM41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP GR, 1995, BIOCHEMISTRY-US, V34, P12082, DOI 10.1021/bi00037a052; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; BROOKS HB, 1993, BIOCHEM J, V294, P211, DOI 10.1042/bj2940211; CANTERS CW, 1992, CURR OPIN STRUC BIOL, V2, P859; CHEN L, 1988, J MOL BIOL, V203, P1137, DOI 10.1016/0022-2836(88)90134-9; CHEN LY, 1993, PROTEIN SCI, V2, P147; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; DAVIDSON VL, 1995, J BIOL CHEM, V270, P23941, DOI 10.1074/jbc.270.41.23941; DAVIDSON VL, 1990, BIOCHEMISTRY-US, V29, P10786, DOI 10.1021/bi00500a010; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; DAVIDSON VL, 1990, ANAL CHIM ACTA, V249, P235; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GRAY KA, 1988, J BIOL CHEM, V263, P13987; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; HUSAIN M, 1986, BIOCHEMISTRY-US, V25, P2431, DOI 10.1021/bi00357a020; KUMAR MA, 1990, BIOCHEMISTRY-US, V29, P5299, DOI 10.1021/bi00474a012; KUUSK V, 1994, J BIOL CHEM, V269, P26136; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; ROBERTS VA, 1991, J BIOL CHEM, V266, P13431; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; SALEMME FR, 1976, J MOL BIOL, V102, P563, DOI 10.1016/0022-2836(76)90334-X; TEGONI M, 1983, J BIOL CHEM, V258, P5424; WEBER PC, 1985, J BIOL CHEM, V260, P5568	32	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9177	9180		10.1074/jbc.271.16.9177	http://dx.doi.org/10.1074/jbc.271.16.9177			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621571	hybrid			2022-12-25	WOS:A1996UG04400002
J	Tsai, J; Douglas, MG				Tsai, J; Douglas, MG			A conserved HPD sequence of the J-domain is necessary for YDJ1 stimulation of Hsp70 ATPase activity at a site distinct from substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI-DNAJ; LAMBDA-P-PROTEIN; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ENDOPLASMIC-RETICULUM; EUKARYOTIC HOMOLOGS; GRPE; CHAPERONE; REPLICATION	The 46-kDa protein YDJ1 is one of several known yeast homologues of the Escherichia coli DnaJ protein. Like all J homologues, it shares homology with the highly conserved NH2-terminal ''J-domain'' of DnaJ. A component of the DnaK (Hsp70) chaperone machinery that mediates protein folding, DnaJ is necessary for survival at elevated temperatures. It stimulates ATP hydrolysis by DnaK and effects the release of DnaK-bound polypeptides. Previous genetic and biochemical studies indicate that the J-domain is necessary for these functions. Using peptides corresponding to J-domain sequence, we show that a peptide containing the highly conserved His-Pro-Asp sequence at positions 34-36 in the J-domain competes off YDJ1 stimulation of Hsp70 ATPase activity. Inhibitory concentrations of peptide do not prevent binding of folding substrates, therefore YDJ1 must interact with Hsp70 at a site distinct from that for substrate binding. This interaction is critical for Hsp70 activity, since a mutant YDJ1 protein harboring a H34Q change (ydj1Q34) stimulates neither Hsp70 ATPase nor substrate release. The importance of the proper function of this region of the protein is supported by the poor growth and temperature-sensitive phenotype of yeast expressing ydj1Q34.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE ON AGING [R01AG011527] Funding Source: NIH RePORTER; NIA NIH HHS [5-RO1-AG11527-01-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEHRENS S, 1993, FEMS MICROBIOL LETT, V114, P53, DOI 10.1016/0378-1097(93)90141-N; BESSOULE JJ, 1993, FEBS LETT, V323, P21; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P2798; DESHAIES R, 1992, NATURE, V332, P800; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH S, 1994, J BIOL CHEM, V269, P1000; Guthrie C, 1991, GUIDE YEAST GENETICS; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HIGUCHI R, 1992, PCR PROTOCOLS GUIDE, P177; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HUPP TR, 1993, J BIOL CHEM, V268, P13143; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MUKAI H, 1994, GENE, V145, P125; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OHKI M, 1986, J BIOL CHEM, V261, P1778; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHRODER H, 1993, EMBO J, V12, P4317; SCHWARZ E, 1994, GENE, V145, P121, DOI 10.1016/0378-1119(94)90333-6; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SIKORSKI R S, 1991, P302; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; VOLGEL JP, 1990, J CELL BIOL, V110, P1885; WALL D, 1994, J BIOL CHEM, V269, P5446; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZHANG S, 1992, EMBO J, V11, P1787; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	62	210	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9347	9354		10.1074/jbc.271.16.9347	http://dx.doi.org/10.1074/jbc.271.16.9347			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621599	hybrid, Green Published			2022-12-25	WOS:A1996UG04400030
J	Zhang, DX; Sun, M; Samols, D; Kushner, I				Zhang, DX; Sun, M; Samols, D; Kushner, I			STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-1-ACID GLYCOPROTEIN GENE; ACUTE-PHASE RESPONSE; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; NUCLEAR FACTOR; ELEMENTS; PROMOTER; EXPRESSION; SEQUENCES	Interlenkin-6 (IL-6) is the major cytokine inducing transcription of human C-reactive protein (CRP) during the acute phase response. STAT (signal transducers and activators of transcription) family members, recently shown to be important mediators of the effects of many cytokines including IL-6, generally induce their effects by binding to palindromic sequences with TT(N)(5)AA motifs. We report an IL-6 responsive element in the proximal region of the human CRP 5'-flanking region that bears a TT(N)(4)AA motif, which we have termed CRP acute phase response element (CRP-APRE). In Hep3B cells, IL-6 but not interferon-gamma was capable of activating CAT constructs driven by the CRP promoter containing CRP-APRE. Overexpressed STAT3 was able to transactivate CRP-chloramphenicol acetyltransferase constructs through the CRP-APRE and was able to enhance endogenous CRP mRNA accumulation in response to IL-6. STAT3 (or an antigenically related molecule) bound to the CRP-APRE in response to IL-6. Overexpression of STAT3 in the presence of IL-6 was capable of inducing expression of a construct consisting of the CRP-APRE and a minimal thymidine kinase promoter lacking a C/EBP site. Taken together, these findings indicate that STAT3 participates in the transcriptional activation of CRP in response to IL-6.	CASE WESTERN RESERVE UNIV,METROHLTH MED CTR,DEPT MED,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System; Case Western Reserve University			Kwiatkowska, Katarzyna/ABE-9713-2021	Kwiatkowska, Katarzyna/0000-0002-0550-8394	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002467] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-40765] Funding Source: Medline; NIA NIH HHS [AG-02467] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; HALL CV, 1983, J MOL APPL GENET, V2, P11; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KEL OV, 1995, NUCLEIC ACIDS RES, V23, P4097, DOI 10.1093/nar/23.20.4097; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; KUSHNER I, 1993, ACUTE PHASE PROTEINS, P3; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LI SP, 1990, J BIOL CHEM, V265, P4136; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MURPHY C, 1995, J BIOL CHEM, V270, P704, DOI 10.1074/jbc.270.2.704; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1994, LIVER GENE EXPRESSIO, P131; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAZ R, 1994, J BIOL CHEM, V269, P24391; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG D, 1995, BIOCHEM J, V310, P145; ZHANG DX, 1995, BIOTECHNIQUES, V18, P750; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	49	218	227	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9503	9509		10.1074/jbc.271.16.9503	http://dx.doi.org/10.1074/jbc.271.16.9503			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621622	hybrid			2022-12-25	WOS:A1996UG04400053
J	Knippschild, U; Oren, M; Deppert, W				Knippschild, U; Oren, M; Deppert, W			Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion	ONCOGENE			English	Article						nuclear-cytoplasmic transport; tumor suppressor p53	TUMOR SUPPRESSOR GENE; AUTOREGULATORY FEEDBACK LOOP; LARGE-T-ANTIGEN; CELL-CYCLE; MDM2 GENE; PROTEIN; TRANSPORT; MUTANT; EXPRESSION; CANCER	We used clone 6 cells (rat embryo fibroblasts transformed by the temperature sensitive mutant p53(val135) and an activated H-ras-gene (Michalovitz et al., 1990)), growth arrested at 32 degrees C, as a model to analyse whether and how transformed cells, growth-arrested by an overexpressed wild-type p53, might overcome p53-mediated growth inhibition, When clone 6 cells were kept at 32 degrees C for about 2 weeks, foci of cells appeared which grew temperature-independent. Analysis of individual clones of such cell demonstrated that the ectopically expressed tsp53-gene had not been altered by an additional mutation, but that the tsp53 in these cells at 32 degrees C had lost its ability to upregulate expression of the p53 target genes waf1 and mdm2. This loss of p53-specific transactivation correlated with nuclear exclusion of the tsp53 at 32 degrees C, which was most likely mediated by cytoplasmic retention of the tsp53 protein via short-lived anchor proteins, Cytoplasmic retention of the tsp53 at 32 degrees C was also observed in PC12 pheochromocytoma cells ectopically expressing tsp53(val135), there occurring without specific selection, Also in these exclusion of the tsp53 correlated with mediated growth inhibition, Nuclear exclusion of p53 thus might serve as an epigenetic mechanism to eliminate the growth-inhibitory function of p53.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Heinrich Pette Institute; University of Hamburg; Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; Deppert W., 1993, MOL CELL BIOL METHOD, P27; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALTHOFF H, 1993, ONCOGENE, V8, P289; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; LADANYI M, 1993, CANCER RES, V53, P16; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LANE DP, 1992, NATURE, V359, P486, DOI 10.1038/359486b0; LANFORD RE, 1982, VIROLOGY, V119, P169, DOI 10.1016/0042-6822(82)90074-5; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1985, VIROLOGY, V147, P72, DOI 10.1016/0042-6822(85)90228-4; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OTTO A, 1993, ONCOGENE, V8, P2591; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI K, 1994, ONCOGENE, V9, P183; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, J BIOL CHEM, V269, P10923; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	49	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622896				2022-12-25	WOS:A1996UG45800018
J	Chan, DW; LeesMiller, SP				Chan, DW; LeesMiller, SP			The DNA-dependent protein kinase is inactivated by autophosphorylation of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; HUMAN KU-AUTOANTIGEN; CELL-NUCLEI; PHOSPHORYLATION; ANTIGEN; COMPONENT; CDNA; P53; JUN	The DNA-dependent protein kinase (DNA-PK) requires for activity free ends or other discontinuities in the structure of double strand DNA In vitro, DNA-PK phosphorylates several transcription factors and other DNA-binding proteins and is thought to function in DNA damage recognition or repair and/or transcription. Here we show that in vitro DNA-PK undergoes autophosphorylation of all three protein subunits (DNA-PKcs, Ku p70 and Ku p80) and that phosphorylation correlates with inactivation of the serine/threonine kinase activity of DNA-PK Significantly, activity is restored by the addition of purified native DNA-PKcs but not Ku, suggesting that inactivation is due to autophosphorylation of DNA-PKcs. Our data also suggest that autophosphorylation results in dissociation of DNA-PKcs from the Ku-DNA complex. We suggest that autophosphorylation is an important mechanism for the regulation of DNA-PK activity.	UNIV CALGARY,DEPT BIOL SCI,CALGARY,AB T2N 1N4,CANADA	University of Calgary				Lees-Miller, Susan/0000-0001-5809-2516				ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ANDERSON CW, 1995, METHODS PROTEIN STRU, P895; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P101; CAO QP, 1994, BIOCHEMISTRY-US, V33, P6354; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN DW, 1995, IN PRESS BIOCH CELL; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; LIU SH, 1993, J BIOL CHEM, V268, P21147; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SIPLEY JD, 1995, P NATL ACAD SCI USA, V92, P7515, DOI 10.1073/pnas.92.16.7515; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x	46	232	233	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8936	8941		10.1074/jbc.271.15.8936	http://dx.doi.org/10.1074/jbc.271.15.8936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621537	hybrid			2022-12-25	WOS:A1996UE73000068
J	Gao, P; Malbon, CC				Gao, P; Malbon, CC			Morphogen-induced decline in G(i alpha 2) triggers F9 teratocarcinoma stem cell progression via phospholipase C and mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; SYNTHETIC PEPTIDE; DIFFERENTIATION; FIBROBLASTS; INHIBITOR; ENDODERM; POTENT; TRANSFORMATION; EXPRESSION; HYDROLYSIS	The linkage between G(i alpha 2) and morphogen-induced promotion of F9 embryonic teratocarcinoma stem (F9 stem) cells to primitive endoderm was explored using probes of the mitogen-activated protein (MAP) kinase network. The morphogen-induced decline in G(i alpha 2) is shown to trigger activation of phospholipase C, thereby activating protein kinase C, MAP kinase, and cell progression to primitive endoderm. In the absence of retinoic acid, reduction-of-function mutants (G(i alpha 2)-deficient) display the effects of morphogen, i.e. activation of phospholipase C, protein kinase C, MAP kinase, and progression to primitive endoderm. Gain-of-function mutants (expressing the Q205L activating-mutation of G(i alpha 2) displayed no activation of phospholipase C, protein kinase C, MAP kinase and no progression to primitive endoderm, even in the presence of retinoic acid. Selective inhibitors of protein kinase C, like the gain-of-function mutations, effectively block morphogen-induced progression to primitive endoderm. Morphogen triggers F9 stem cell progression by triggering G(i alpha 2) loss and thereby activation of downstream elements, including protein kinase C and MAP kinase.	SUNY STONY BROOK, HLTH SCI CTR,MED CTR, DIABET & METAB DIS RES PROGRAM, DEPT MOLEC PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; Bell R M, 1986, Methods Enzymol, V124, P353; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	44	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9002	9008		10.1074/jbc.271.15.9002	http://dx.doi.org/10.1074/jbc.271.15.9002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621547	hybrid			2022-12-25	WOS:A1996UE73000078
J	Meyer, CF; Wang, XP; Chang, C; Templeton, D; Tan, TH				Meyer, CF; Wang, XP; Chang, C; Templeton, D; Tan, TH			Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappa B enhancer activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The Rel family of transcription factors are important mediators of various cytokine stimuli such as interleukin (IL)-1, tumor necrosis factor (TNF)-alpha, and CD28 costimulation in T cell effector responses, These stimuli induce Rel family DNA-binding activity to the kappa B enhancer and CD28 response elements of many cytokine gene promoters leading to cytokine production, Consistent with the importance of Rel family induction during immune responses, c-Rel knockout mice exhibit profound defects in T cell functions including IL-2 secretion and T cell proliferative responses to CD28 plus T cell receptor costimulation. The novel protein kinases, c-Jun NH2-terminal kinases (JNKs)/stress-activated protein kinases, are also activated by TNF-alpha, IL-1, and CD28 costimulation. Because of the common regulation of c-Rel and JNK1 by these agents in T cells, we investigated the role of JNK1 in c-Rel activation, We found that MAP kinase kinase kinase (MEKK) 1, a JNK1 activator, induced transcription from the human immunodeficiency virus-1 long terminal repeat and IL-2R alpha promoters in a kappa B-dependent manner, Coexpression of I kappa B alpha, a c-Rel inhibitor, inhibited the MEKK1-induced transcriptional activity, JNK1 synergized with MEKK1 in activating transcription from a kappa B-driven heterologous promoter. Furthermore, JNK1 associated with c-Rel in vivo in Jurkat T cells by coimmunoprecipitation assays and bound directly to c-Rel in a yeast two-hybrid assay, c-Rel also competed with c-Jun in in vitro kinase assays. However, JNK1 did not phosphorylate c-Rel, NF-kappa B, and I kappa B alpha in vitro, indicating that c-Rel may serve as a docking molecule to allow JNK1 phosphorylation of certain Rel-associated proteins. Transactivation of the IL-2R alpha and HIV-kappa B-driven promoters by c-Rel was augmented by coexpression of MEKK1, These results demonstrate the first significant role for the MEKK1 kinase cascade module in c-Rel-mediated transcription.	BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Baylor College of Medicine; Case Western Reserve University			Templeton, Dennis J/F-7695-2011; Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, T32AI007483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07483, R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P189; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSEN CA, 1985, CELL, V41, P613; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; VLACH J, 1992, J VIROL, V66, P3616, DOI 10.1128/JVI.66.6.3616-3623.1992; VONDAM H, 1995, EMBO J, V14, P1798; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798	34	158	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8971	8976		10.1074/jbc.271.15.8971	http://dx.doi.org/10.1074/jbc.271.15.8971			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621542	hybrid			2022-12-25	WOS:A1996UE73000073
J	Stancato, LF; Silverstein, AM; Gitler, C; Groner, B; Pratt, WB				Stancato, LF; Silverstein, AM; Gitler, C; Groner, B; Pratt, WB			Use of the thiol-specific derivatizing agent N-iodoacetyl-3[I-125]iodotyrosine to demonstrate conformational differences between the unbound and hsp90-bound glucocorticoid receptor hormone binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-BINDING; DNA-BINDING; FUNCTIONAL DOMAINS; WILD-TYPE; RECONSTITUTION; FRAGMENT; ARSENITE; STATE; LOCALIZATION	The hormone binding domain (HBD) of the glucocorticoid receptor (GR) contains five cysteine residues, with three of them being spaced close to one another in the steroid binding pocket, The HBD also contains the contact region for the chaperone protein hsp90, which must be bound to the GR for it to have a steroid binding conformation, Binding of hsp90 to the receptor through its HBD inactivates the DNA binding domain (DBD), The DBD contains a number of cysteines essential to its DNA binding activity, Here, we assess the effects of hsp90 binding on the accessibility of cysteine residues in both the HBD and DBD to derivatization by a thiol-specific reagent, We report that N-iodoacetyltyrosine (IAT) inactivates steroid binding activity of the immunopurified, untransformed GR hsp90 complex in a manner that is prevented by the sulfhydryl reagents cysteine and dithiothreitol but is not reversed by them, The I-125-labeled IAT derivative N-iodoacetyl-3-[I-125]iodotyrosine ([I-125]IAIT) covalently labels the immunopurified, hsp90-bound receptor in a thiol-specific manner, Dissociation of hsp90 leads to an similar to 2-fold increase in [I-125]IAIT labeling of the full-length, 100-kDa GR. The increase in thiol labeling is related to the presence of hsp90 because it is blocked by molybdate, which prevents hsp90 dissociation, Cleavage of the [I-125]IAIT-labeled receptor with trypsin yields a 15-kDa labeled fragment containing the DBD and a 30-kDa labeled fragment containing all of the cysteines in the HBD and the contact region for hsp90, Dissociation of hsp90 from the GR results in a 2.3-fold increase in [I-125]IAIT labeling of the 15-kDa fragment and a 50% decrease in labeling of the 30-kDa fragment, These data are consistent with the proposal that dissociation of hsp90 from the GR produces a conformational change in the HBD such that some of the thiols that are exposed in the GR hsp90 complex become buried and are no longer accessible to the [I-125]IAIT probe, In contrast, binding of the GR to hsp90 restricts access of cysteines in the DBD to this small thiol-derivatizing agent, a restriction that is relieved as a result of unmasking or conformational change accompanying hsp90 dissociation.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; INST EXPTL CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY	University of Michigan System; University of Michigan; Weizmann Institute of Science					NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; GITLER C, 1994, METHOD ENZYMOL, V233, P403; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOECK W, 1989, J BIOL CHEM, V264, P14396; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MILLER NR, 1988, J BIOL CHEM, V263, P15217; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1988, J BIOL CHEM, V263, P267; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; STANCATO LF, 1993, BIOCHEMISTRY-US, V32, P3729, DOI 10.1021/bi00065a027	34	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8831	8836		10.1074/jbc.271.15.8831	http://dx.doi.org/10.1074/jbc.271.15.8831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621522	hybrid			2022-12-25	WOS:A1996UE73000053
J	Meigs, TE; Roseman, DS; Simoni, RD				Meigs, TE; Roseman, DS; Simoni, RD			Regulation of 3-hydroxy-3-methylglularyl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; MEMBRANE DOMAIN; STEROL; CELLS; PROTEIN; ENZYME; GLYCOPROTEIN; PRODUCT	We have previously reported that degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in the isoprenoid pathway leading to cholesterol production, can be accelerated in cultured cells by the addition of farnesyl compounds, which are thought to mimic a natural, nonsterol mevalonate metabolite(s). In this paper we report accelerated reductase degradation by the addition of farnesol, a natural product of mevalonate metabolism, to intact cells. We demonstrate that this regulation is physiologically meaningful, shown by its blockage by several inhibitory conditions that are known to block the degradation induced by mevalonate addition. We further show that intracellular farnesol levels increase significantly after mevalonate addition. Based on these results, we conclude that farnesol is a nonsterol, mevalonate-derived product that plays a role in accelerated reductase degradation. Our conclusion is in agreement with a previous report (Correll, C. C., Ng, L., and Edwards, P. A. (1994) J. Biol. Chem, 269, 17390-17393), in which an in vitro system was used to study the effect of farnesol on reductase degradation. However, the apparent stimulation of degradation in vitro appears to be due to non-physiological processes. Our findings demonstrate that in vitro, farnesol causes reductase to become detergent insoluble and thus lost from immunoprecipitation experiments, yielding apparent degradation. We further show that another resident endoplasmic reticulum protein, calnexin, similarly gives the appearance of protein degradation after farnesol addition in vitro. However, after the addition of farnesol to cells in vivo, calnexin remains stable, whereas reductase is degraded, providing further evidence that the in vivo effects of farnesol are physiologically meaningful and specific for reductase, whereas the in vitro effects are not.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL VS, 1994, ARCH BIOCHEM BIOPHYS, V315, P393, DOI 10.1006/abbi.1994.1516; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; BRADFUTE DL, 1992, J BIOL CHEM, V267, P18308; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHOI JW, 1995, BIOCHEM J, V307, P233, DOI 10.1042/bj3070233; CHRISTOPHE J, 1961, J LIPID RES, V2, P244; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; DAVID V, 1993, J BIOL CHEM, V268, P9585; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; INOUE S, 1991, J BIOL CHEM, V266, P13311; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STRAKA MS, 1995, ARCH BIOCHEM BIOPHYS, V317, P235, DOI 10.1006/abbi.1995.1158; TSAI SC, 1966, J BIOL CHEM, V241, P4043	31	116	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7916	7922		10.1074/jbc.271.14.7916	http://dx.doi.org/10.1074/jbc.271.14.7916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626470	hybrid			2022-12-25	WOS:A1996UD60000010
J	Stevens, WK; Cote, HCF; MacGillivray, RTA; Nesheim, ME				Stevens, WK; Cote, HCF; MacGillivray, RTA; Nesheim, ME			Calcium ion modulation of meizothrombin autolysis at Arg(55)-Asp(56) and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; PROTHROMBIN FRAGMENT-1; FACTOR-VA; BOVINE PROTHROMBIN; SELF-ASSOCIATION; METAL-IONS; BINDING; ACTIVATION; THROMBIN; TRANSITIONS	When a recombinant variant of prothrombin with the cleavage site mutations R155A, R271A, and R284A (rMZ) is exposed to either prothrombinase or ecarin, a form of meizothrombin (rMZa) is generated that is stable for weeks in the presence of Ca2+ (Cote, H. C, F., Stevens, W. K., Bajzar, L., Banfield, D. K., Nesheim, M. E., and MacGillivray, R. T. A. (1994) J. Biol. Chem. 269, 11374-11380). In the absence of Ca2+ however, rMZa is rapidly cleaved within a disulfide bonded loop in the Fl domain at Arg(55) in the sequence RTPR down arrow DKL, yielding a molecule with 3 chains joined by two disulfide bonds (rMZa*). Cleavage kinetics are first order regardless of the rMZa concentration, indicating an intramolecular cleavage. This cleavage does not occur at Ca2+ concentrations in excess of 1.0 mM. To assess the role of the F1 domain in rMZa activity, another variant lacking the R155A mutation (rMZdesF1) was expressed, which when activated yields meizothrombin lacking the F1 domain (rMZdesF1a). Rates of hydrolysis of the tripeptide substrate S2238 by rMZa or rMZa* increase from 60% to 90% that of recombinant thrombin as Ca2+, Mg2+, or Mn2+ concentrations are varied from 0 to 10 mM. K-m and k(cat) values for rMZa in the absence and presence of 5 mM Ca2+ are 1.9 and 2.2 mu M and 65 and 105 s(-1), TAME esterase activity of rMZa also increases with 5 mM Ca2+, No such metal ion-dependent effects are obtained with either thrombin or rMZdesF1a. Fibrinogen clotting activities, relative to that of thrombin, increase in a manner analogous to those obtained with small substrates, for rMZa and rMZa* but not rMZdesF1a, Complexes of the active site probe dansylarginine N-(3-ethyl-1,5-pentanediyl)amide with rMZa and rMZa*, but not thrombin or rMZdesF1a exhibit large cation-dependent decreases in fluorescence intensity, suggesting that metal ion binding in the F1 domain alters the environment of the probe at the active site. These results indicate that in the absence of divalent cations, the activity of rMZa is inhibited, perhaps by obstruction of the active site by the F1 domain, and that Ca2+ binding to the F1 domain modulates the properties of not only the F1 domain but also the protease domain.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA	Queens University - Canada; Queens University - Canada; University of British Columbia			Cote, Helene/K-7896-2012					ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BISHOP ML, 1992, CLIN CHEM PRINCIPLES; BLOOM JW, 1978, BIOCHEMISTRY-US, V17, P4430, DOI 10.1021/bi00614a012; BOARD PG, 1983, BRIT J HAEMATOL, V54, P245, DOI 10.1111/j.1365-2141.1983.tb02092.x; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; CHURCH FC, 1985, ARCH BIOCHEM BIOPHYS, V240, P607, DOI 10.1016/0003-9861(85)90067-0; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; FURIE B, 1991, HEMATOLOGY BASIC PRI, P1213; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NI F, 1993, J BIOL CHEM, V268, P16899; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; SESHADRI TP, 1991, J MOL BIOL, V220, P481, DOI 10.1016/0022-2836(91)90025-2; SILVERBERG SA, 1979, J BIOL CHEM, V254, P88; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1973, BIOCHEM BIOPH RES CO, V50, P98, DOI 10.1016/0006-291X(73)91069-3; TANS G, 1994, J BIOL CHEM, V269, P15969; TARVERS RC, 1982, J BIOL CHEM, V257, P708; UHTEG LC, 1977, BIOCHIM BIOPHYS ACTA, V491, P551, DOI 10.1016/0005-2795(77)90300-2; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; WU A, 1994, J BIOL CHEM, V269, P3725	31	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8062	8067		10.1074/jbc.271.14.8062	http://dx.doi.org/10.1074/jbc.271.14.8062			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626490	hybrid			2022-12-25	WOS:A1996UD60000030
J	Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M				Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M			p300 gene alterations in colorectal and gastric carcinomas	ONCOGENE			English	Article						p300 gene; NF2 gene; colorectal carcinoma; gastric carcinoma; somatic mutation	FAMILIAL ADENOMATOUS POLYPOSIS; CHROMOSOME-22	Colorectal tumors frequently have loss of heterozygosity on chromosome 22q, suggesting that inactivation of tumor suppressor gene(s) on 22q participates in the tumor development. Neurofibromatosis 2 (NF2) gene and E1A binding protein p300 gene, recently identified on 22q, are thought to be candidates for tumor suppressor genes. In this study, mutation of the NF2 gene in 59 colorectal carcinomas, and mutation of the p300 gene in 27 colorectal and two gastric carcinomas, were analysed using PCR-SSCP, RT-PCR-SSCP and direct sequencing methods. Missense mutations of p300 gene were detected in a colorectal carcinoma, and in a gastric carcinoma, though no mutation of NF2 gene was detected. Both p300 mutations were somatic and coupled to deletion of the second allele of the gene, which suggests inactivation of the p300 gene in these carcinomas. The mutations are located within the Cys/His-rich regions, which are assumed to play important roles in the function of p300. These are the first cases in which p300 gene has been found to be altered in both alleles, suggesting that inactivation of the p300 gene may be involved in the development of carcinomas, and that this gene may be the target of loss of 22q in carcinomas of the digestive tract.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT NEUROSURG,TOKYO,JAPAN; TOKYO MED & DENT UNIV,DEPT SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Medical & Dental University (TMDU)								ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GREENBLATT MS, 1994, CANCER RES, V54, P4855; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SEKIDO Y, 1995, CANCER RES, V55, P1227; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207	26	264	276	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1565	1569						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622873				2022-12-25	WOS:A1996UF07600021
J	Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P				Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P			Microsatellite instability analysis of primary human brain tumors	ONCOGENE			English	Article						brain neoplasms; polymerase chain reaction; microsatellite markers; loss of heterozygosity; replication errors; microsatellite instability	COLORECTAL-CANCER; GENETIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; REPEAT; COLON; LOCUS; DNA	Microsatellite instability, as shown by the presence of additional alleles or shifts of electrophoretic mobility at simple sequence tandem repeat loci, has been demonstrated in hereditary and sporadic colorectal tumors and many other tumor types. To study microsatellite instability in human brain tumors, we examined a total of 144 sporadic neoplasms. These included 33 astrocytic tumors, 23 oligodendrogliomas, six gangliogliomas, 41 meningiomas, 10 vestibular schwannomas and 31 pituitary adenomas. Di-, tri- and tetranucleotide repeat microsatellite markers localized on chromosome 4 and 9, X, 13 and 22, respectively, were used to assess whether instability was a significant aspect of their abnormal chromosomal pattern. Instability of microsatellite markers was detected in four oligodendrogliomas (17.4%), one pituitary adenoma (3.2%), one meningioma (2.4%), one astrocytic tumor (3.0%) and not at all in gangliogliomas and schwannomas. Therefore, our results suggest that the microsatellite instability which occurs in colorectal cancers with defective mismatch repair is infrequent in many types of human brain tumors and that the lower level of instability observed in brain tumors may be reflective of other mechanisms of genetic instability.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,NEUROSURG LABS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,BRAIN TUMOR CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT NEUROSURG,BOSTON,MA 02111	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University				Beggs, Alan/0000-0001-8818-0568				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BURKS RT, 1994, ONCOGENE, V9, P1163; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; ICHIMURA K, 1994, CANCER RES, V54, P3127; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; MERIO A, 1994, CANCER RES, V54, P2098; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Petrukhin Konstantin E., 1992, Human Molecular Genetics, V1, P349, DOI 10.1093/hmg/1.5.349; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SHAPIRO S, 1989, J NEUROSURG, V71, P77, DOI 10.3171/jns.1989.71.1.0077; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN Y, 1992, BIOTECHNIQUES, V12, P639; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VENTER DJ, 1991, ONCOGENE, V6, P445; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Wu J K, 1992, Neurol Res, V14, P39; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YEE CJ, 1994, CANCER RES, V54, P1641; ZHU JG, 1994, J CLIN ENDOCR METAB, V78, P922, DOI 10.1210/jc.78.4.922	43	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1417	1423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622857				2022-12-25	WOS:A1996UF07600005
J	Richards, JD; Gold, MR; Hourihane, SL; DeFranco, AL; Matsuuchi, L				Richards, JD; Gold, MR; Hourihane, SL; DeFranco, AL; Matsuuchi, L			Reconstitution of B cell antigen receptor-induced signaling events in a nonlymphoid cell line by expressing the Syk protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; PHOSPHOLIPASE-C; LYMPHOCYTES-B; MAP KINASE; PHOSPHORYLATION; ACTIVATION; TRANSDUCTION; STIMULATION; ASSOCIATION	B cell antigen receptor (BCR) cross-linking activates both Src family and Syk tyrosine kinases, resulting in increased cellular protein-tyrosine phosphorylation and activation of several downstream signaling enzymes. To define the role of Syk in these events, we expressed the BCR in the AtT20 mouse pituitary cell line. These nonlymphoid cells endogenously expressed the Src family kinase Fyn but not Syk. Anti-IgM stimulation of these cells failed to induce most of the signaling events that occur in B cells. BCR-expressing AtT20 transfectants were generated that also expressed Syk. Syk expression reconstituted several signaling events upon anti-IgM stimulation, including Syk phosphorylation and association with the BCR, tyrosine phosphorylation of numerous proteins including Shc, and activation of mitogen-activated protein kinase. In contrast, Syk expression did not reconstitute anti-IgM-induced inositol phosphate production. A catalytically inactive Syk mutant could associate with the BCR and become tyrosine phosphorylated but could not reconstitute downstream signaling events. Expression of the Src family kinase Lck instead of Syk also did not reconstitute signaling. Thus, wild type Syk was required to reconstitute several BCR-induced signaling events but was not sufficient to couple the BCR to the phosphoinositide signaling pathway.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER,BC V6T 1Z4,CANADA; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z4,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia; University of California System; University of California San Francisco; University of British Columbia; University of British Columbia			Gold, Michael/AAF-2081-2021	Gold, Michael/0000-0003-1222-3191	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020038, T32AI007334] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07334-07, R01 AI20038] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Bothwell A., 1990, METHODS CLONING ANAL; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DEFRANCO AL, 1992, EUR J BIOCHEM, V210, P381, DOI 10.1111/j.1432-1033.1992.tb17432.x; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1994, J IMMUNOL, V153, P2369; GOLD MR, 1992, BIOCHEM J, V287, P269, DOI 10.1042/bj2870269; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SMIT L, 1994, J BIOL CHEM, V269, P20209; SZOLLOSI J, 1991, CYTOMETRY, V12, P707, DOI 10.1002/cyto.990120804; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x	51	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6458	6466		10.1074/jbc.271.11.6458	http://dx.doi.org/10.1074/jbc.271.11.6458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626447	hybrid			2022-12-25	WOS:A1996UA36300076
J	Scott, DK; Mitchell, JA; Granner, DK				Scott, DK; Mitchell, JA; Granner, DK			Identification and characterization of a second retinoic acid response element in the phosphoenolpyruvate carboxykinase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; REGULATORY ELEMENTS; NUCLEAR RECEPTORS; VITAMIN-A; GTP GENE; TRANSCRIPTION; INDUCTION; BINDING; RAR; HETERODIMERS	A previously characterized retinoic acid response element (RARE1) in the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter confers approximately 50% of the response of this gene to retinoic acid (RA). Transient transfection experiments were performed using constructs containing progressive 5' deletions of the PEPCK promoter to locate other elements that contribute to the RA response. A second RARE (RARE2) was located between -402 and -306. Methylation interference and mobility gel shift assays indicated that RAR/RXR bound specifically to a segment of DNA located between -337 and -321. This region contains consensus and degenerate half-sites for receptor binding separated by 5 bp. Mutations in either half-site selectively decreased the RA response and diminished RAR/RXR binding in mobility gel shift assays. When both RARE1 and RARE2 were mutated, 80% of the RA response was lost. Finally, RARE2 conferred a RA response in a heterologous promoter context. We conclude that RAR/RXR binds to RARE2, and that this DRS-type element is a major contributor to the response of the PEPCK gene to RA.	VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University					NIDDK NIH HHS [DK07061, DK35107, DK20593] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, P30DK020593, T32DK007061, P60DK020593, R01DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARIK S, 1993, PCR PROTOCOLS CURREN, P277; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRANNER DK, 1986, RECENT PROG HORM RES, V42, P111; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MADER S, 1993, J BIOL CHEM, V268, P591; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PAN CJ, 1990, BIOCHEMISTRY-US, V29, P10883, DOI 10.1021/bi00501a004; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RICHARD S, 1991, J BIOL CHEM, V266, P21428; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCOTT DK, 1995, BIOCHEM J, V310, P483, DOI 10.1042/bj3100483; SHIN DJ, 1995, BIOCHEM BIOPH RES CO, V213, P706, DOI 10.1006/bbrc.1995.2188; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WOLF G, 1957, J BIOL CHEM, V225, P995; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	49	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6260	6264		10.1074/jbc.271.11.6260	http://dx.doi.org/10.1074/jbc.271.11.6260			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626419	hybrid			2022-12-25	WOS:A1996UA36300048
J	Shaul, PW; Smart, EJ; Robinson, LJ; German, Z; Yuhanna, IS; Ying, YS; Anderson, RGW; Michel, T				Shaul, PW; Smart, EJ; Robinson, LJ; German, Z; Yuhanna, IS; Ying, YS; Anderson, RGW; Michel, T			Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CELLS	Endothelial nitric-oxide synthase (eNOS) generates the key signaling molecule nitric oxide in response to intralumenal hormonal and mechanical stimuli. We designed studies to determine whether eNOS is localized to plasmalemmal microdomains implicated in signal transduction called caveolae. Using immunoblot analysis, eNOS protein was detected in caveolar membrane fractions isolated from endothelial cell plasma membranes by a newly developed detergent-free method; eNOS protein was not found in noncaveolar plasma membrane. Similarly, NOS enzymatic activity was 9.4-fold enriched in caveolar membrane versus whole plasma membrane, whereas it was undetectable in noncaveolar plasma membrane, 51-86% of total NOS activity in postnuclear supernatant was recovered in plasma membrane, and 57-100% of activity in plasma membrane was recovered in caveolae. Immunoelectron microscopy showed that eNOS heavily decorated endothelial caveolae, whereas coated pits and smooth plasma membrane were devoid of gold particles. Furthermore, eNOS was targeted to caveolae in COS-7 cells transfected with wild-type eNOS cDNA. Studies with eNOS mutants revealed that both myristoylation and palmitoylation are required to target the enzyme to caveolae and that each acylation process enhances targeting by 10-fold. Thus, acylation targets eNOS to plasmalemmal caveolae, Localization to this microdomain is likely to optimize eNOS activation and the extracellular release of nitric oxide.	UNIV TEXAS,SW MED CTR,DEPT NEUROSCI & CELL BIOL,DALLAS,TX 75235; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,BOSTON,MA 02115	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Shaul, PW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030276] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NICHD NIH HHS [HD30276] Funding Source: Medline; NIGMS NIH HHS [GM15631] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORIN AM, 1993, J NEUROSCI RES, V36, P272, DOI 10.1002/jnr.490360305; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OBRIEN AJ, 1995, HISTOCHEM CELL BIOL, V103, P221, DOI 10.1007/BF01454027; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHAUL PW, 1994, AM J RESP CELL MOL, V11, P432, DOI 10.1165/ajrcmb.11.4.7522486; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; SHAUL PW, 1995, ADV PEDIATR, P367; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705	28	599	615	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6518	6522		10.1074/jbc.271.11.6518	http://dx.doi.org/10.1074/jbc.271.11.6518			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626455	hybrid			2022-12-25	WOS:A1996UA36300084
J	Radominska, A; Drake, RR; Zhu, XY; Veronese, ME; Little, JM; Nowell, S; McManus, ME; Lester, R; Falany, CN				Radominska, A; Drake, RR; Zhu, XY; Veronese, ME; Little, JM; Nowell, S; McManus, ME; Lester, R; Falany, CN			Photoaffinity labeling of human recombinant sulfotransferases with 2-azidoadenosine 3',5'-[5'-P-32]bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER; PHENOL SULFOTRANSFERASE; DEHYDROEPIANDROSTERONE SULFOTRANSFERASE; UDP-GLUCURONOSYLTRANSFERASE; HUMAN-BRAIN; PURIFICATION; BINDING; PROTEINS; IDENTIFICATION; PROBES	Photoaffinity labeling with 2-azidoadenosine 3',5'-[5'-P-32]bisphosphate was used to identify and characterize adenosine 3',5'-bisphosphate-binding proteins in human liver cytosol and recombinant sulfotransferase proteins, The sulfotransferases investigated in these studies were the human phenol sulfotransferases, HAST1, -3, and -4, dehydroepiandrosterone sulfotransferase, and estrogen sulfotransferase. The cDNAs for these enzymes have been previously cloned and expressed in COS-7 cells or Escherichia coli, Photoaffinity labeling of all proteins was highly dependent on UV irradiation, was protected by co-incubation with unlabeled adenosine 3',5'-bisphosphate and phosphoadenosine phosphosulfate, and reached saturation at concentrations above 10 mu M. To verify that the 31-35-kDa photolabeled proteins were indeed sulfotransferases, specific antibodies known to recognize human sulfotransferases were used for Western blot analyses of photolabeled proteins, It was shown unequivocally that the proteins in the 31-35-kDa region recognized by the antibodies also photoincorporated 2-azidoadenosine 3',5'-[5'-P-32]bisphosphate. This is the first application of photoaffinity labeling with 2-azidoadenosine 3',5'-[5'-P-32]bisphosphate for the characterization of recombinant human sulfotransferases. Photoaffinity labeling will be also useful in the purification and functional identification of other adenosine 3',5'-bisphosphate-binding proteins and to determine amino acid sequences at or near their active sites.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; FLINDERS UNIV S AUSTRALIA,DEPT CLIN PHARMACOL,BEDFORD PK,SA 5042,AUSTRALIA; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,ST LUCIA,QLD 4067,AUSTRALIA; UNIV ALABAMA,DEPT PHARMACOL & TOXICOL,BIRMINGHAM,AL 35294	University of Arkansas System; University of Arkansas Medical Sciences; Flinders University South Australia; University of Queensland; University of Alabama System; University of Alabama Birmingham	Radominska, A (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038678, R01DK045123] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45123, DK-38678] Funding Source: Medline; NIGMS NIH HHS [GM-38952] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL NRC, 1987, BIOCHEM PHARMACOL, V36, P1435, DOI 10.1016/0006-2952(87)90108-0; COMER KA, 1992, MOL PHARMACOL, V41, P645; CUSACK NJ, 1976, PROC R SOC SER B-BIO, V193, P307, DOI 10.1098/rspb.1976.0048; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; FALANY CN, 1990, ARCH BIOCHEM BIOPHYS, V278, P312, DOI 10.1016/0003-9861(90)90265-Z; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; FALANY CN, 1994, CHEM-BIOL INTERACT, V92, P57, DOI 10.1016/0009-2797(94)90053-1; HALEY BE, 1983, FED PROC, V42, P2831; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HEROUX JA, 1989, MOL PHARMACOL, V36, P29; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; LEE RWH, 1984, J BIOL CHEM, V259, P1153; MACKENZIE PI, 1987, J BIOL CHEM, V262, P9744; OTTERNESS DM, 1990, MOL PHARMACOL, V39, P34; RADOMINSKA A, 1988, J LIPID RES, V29, P501; REIN G, 1982, BIOCHEM PHARMACOL, V31, P1893, DOI 10.1016/0006-2952(82)90493-2; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STEINMAUS H, 1971, J ORG CHEM, V36, P3594; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERONESE ME, 1994, BIOCHEM J, V302, P497, DOI 10.1042/bj3020497; WEINSHILBOUM RM, 1986, FASEB J, V45, P2220; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; YU PH, 1983, BIOCHIM BIOPHYS ACTA, V742, P517, DOI 10.1016/0167-4838(83)90269-8; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V192, P671, DOI 10.1006/bbrc.1993.1467; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018	30	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3195	3199		10.1074/jbc.271.6.3195	http://dx.doi.org/10.1074/jbc.271.6.3195			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621720	hybrid			2022-12-25	WOS:A1996TU69100049
J	Andersson, M; Holmgren, A; Spyrou, G				Andersson, M; Holmgren, A; Spyrou, G			NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase - Implication for a protective mechanism against NK-lysin cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ANTIMICROBIAL PEPTIDE; ANTIBIOTIC PEPTIDES; GROWTH-FACTOR; PANETH CELLS; HOST DEFENSE; FACTOR ADF; RECEPTOR; IMMUNITY; INVITRO	The cytotoxic and antibacterial polypeptide NK-lysin has a molecular mass of approximately 9 kDa and contains three disulfide bonds. The activity was highly dependent on intact disulfides, because the bactericidal effect on Escherichia coli and the cytolytic effect on human 3B6 lymphocytes was inhibited when NK-lysin was treated with dithiothreitol prior to incubation with the cells. NK-lysin was a direct substrate for human or calf thymus thioredoxin reductase and preincubation of the peptide with mammalian thioredoxin reductase, and NADPH abolished its antibacterial and cytolytic activities. The addition of human thioredoxin further enhanced the inhibitory effect of thioredoxin reductase and NADPH. In contrast, E. coli thioredoxin reductase showed no direct disulfide reductase activity with NK-lysin in agreement with previous data showing large differences in structure and substrate specificity between the mammalian and E. coli enzymes. NK-lysin is the first identified macromolecular disulfide substrate for human thioredoxin reductase apart from human thioredoxin. When 3B6 cells were incubated with NADPH, thioredoxin, and thioredoxin reductase prior to addition of NK-lysin, cytotoxicity was markedly reduced. These data suggest that thioredoxin reductase inactivates NK-lysin and provides a mechanism by which the cytotoxic activity of NK-lysin is regulated.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Karolinska Institutet	Andersson, M (corresponding author), KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, MED NOBEL INST, S-17177 STOCKHOLM, SWEDEN.		Andersson, Mats/A-2903-2008; Andersson, Mats L/M-9124-2014	Andersson, Mats L/0000-0001-7582-8791				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; ANDERSSON M, 1995, FEBS LETT, V362, P328, DOI 10.1016/0014-5793(95)00268-E; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1994, CIBA F S, V186; CORFT LR, 1980, HDB PROTEIN SEQUENCE, P422; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1981, TRENDS BIOCHEM SCI, V6, P26, DOI 10.1016/0968-0004(81)90010-4; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KUDRYASHOV BA, 1990, B EXP BIOL MED+, V109, P513, DOI 10.1007/BF00840056; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LOZANO RM, 1994, ARCH BIOCHEM BIOPHYS, V309, P356, DOI 10.1006/abbi.1994.1124; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NAKABAYASHI H, 1990, FEBS LETT, V267, P135, DOI 10.1016/0014-5793(90)80307-5; RADERMACHER SW, 1993, J NEUROSCI RES, V36, P657, DOI 10.1002/jnr.490360606; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROSEN A, 1995, INT IMMUNOL, V7, P625, DOI 10.1093/intimm/7.4.625; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHALLREUTER KU, 1991, INT J CANCER, V48, P15; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TTRAPANI GD, 1991, HUM REPROD, V6, P450; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAKASUGI H, 1987, P NATL ACAD SCI USA, V84, P804, DOI 10.1073/pnas.84.3.804; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; WIEGAND M, 1989, J STEROID BIOCHEM, V32, P53, DOI 10.1016/0022-4731(89)90013-7; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; YAMASHITA T, 1995, BBA-GEN SUBJECTS, V1243, P295, DOI 10.1016/0304-4165(94)00139-O; YAMAUCHI A, 1992, MOL IMMUNOL, V29, P263; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	59	95	97	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10116	10120		10.1074/jbc.271.17.10116	http://dx.doi.org/10.1074/jbc.271.17.10116			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626570	hybrid			2022-12-25	WOS:A1996UG25700042
J	Ostlund, RE; Seemayer, R; Gupta, S; Kimmel, R; Ostlund, EL; Sherman, WR				Ostlund, RE; Seemayer, R; Gupta, S; Kimmel, R; Ostlund, EL; Sherman, WR			A stereospecific myo-inositol D-chiro-inositol transporter in HepG2 liver cells - Identification with D-chiro-[3-H-3]inositol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL UPTAKE; LIQUID-CHROMATOGRAPHY; DIABETES-MELLITUS; HEPATOCYTES; METABOLISM; PROTEIN	D-chiro-Inositol is an epimer of myo-inositol that is found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity. In order to generate a probe for metabolic studies, D-chiro-[3-H-3]inositol was synthesized by selective reduction of D-chiro-3-inosose at pH 6.5 with sodium borotritide. D-chiro-[3-H-3]Inositol was taken up by HepG2 human liver cells through a saturable and stereospecific pathway in which D-chiro-inositol and myo-inositol competed equally but L-chiro-inositol was not recognized. D-Glucose, but not L-glucose, competed for D-chiro-[3-H-3]inositol uptake over glucose concentrations of 4-28 mM. Maximum transport capacity was 717 pmol/mg cell protein/3 h with a K-m value of 348 mu M. Uptake was reduced by 76% when sodium was eliminated from the medium and by 94% when the experiment was performed at 0 degrees C. The new myo/D-chiro-inositol transporter is distinct from the sodium-myo-inositol co-transporter found in many tissues and accounts for all of the saturable D-chiro-inositol uptake and for a portion of the saturable low affinity myo-inositol uptake in HepG2 cells. It may allow D-chiro-inositol to be used by cells in the presence of a relatively large amount of competing myo-inositol.	WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT PSYCHIAT,ST LOUIS,MO 63110; GENENCOR INT INC,S SAN FRANCISCO,CA 94080; AMER RADIOLABELED CHEM INC,ST LOUIS,MO 63146	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00954] Funding Source: Medline; NIDDK NIH HHS [DK 20579] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CP, 1979, J PHARM SCI, V68, P1022, DOI 10.1002/jps.2600680827; GHIASUDDIN M, 1981, J CHROMATOGR, V211, P295, DOI 10.1016/S0021-9673(00)88050-4; GREENE DA, 1982, J CLIN INVEST, V70, P1009, DOI 10.1172/JCI110688; KENNINGTON AS, 1990, NEW ENGL J MED, V323, P373, DOI 10.1056/NEJM199008093230603; KWON HM, 1992, J BIOL CHEM, V267, P6297; LARNER J, 1988, BIOCHEM BIOPH RES CO, V151, P1416, DOI 10.1016/S0006-291X(88)80520-5; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; MANDEL M, 1993, J ORG CHEM, V58, P2331, DOI 10.1021/jo00060a061; MATO JM, 1987, BIOCHEM BIOPH RES CO, V146, P764, DOI 10.1016/0006-291X(87)90595-X; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; OLGEMOLLER B, 1990, BIOCHIM BIOPHYS ACTA, V1052, P47, DOI 10.1016/0167-4889(90)90056-J; OSTLUND RE, 1993, P NATL ACAD SCI USA, V90, P9988, DOI 10.1073/pnas.90.21.9988; OSTLUND RE, 1995, DIABETES CARE, V18, P1074, DOI 10.2337/diacare.18.7.1074b; PHILLIPS DV, 1982, J AGR FOOD CHEM, V30, P456, DOI 10.1021/jf00111a011; PRPIC V, 1982, J BIOL CHEM, V257, P1315; SASAKI K, 1988, CARBOHYD RES, V183, P1, DOI 10.1016/0008-6215(88)80040-5; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; WAKISAKA M, 1995, DIABETOLOGIA, V38, P291; WALTER EI, 1990, J IMMUNOL, V144, P1030; WANG WT, 1990, ANAL BIOCHEM, V188, P432, DOI 10.1016/0003-2697(90)90632-J; YOREK MA, 1986, ARCH BIOCHEM BIOPHYS, V246, P801, DOI 10.1016/0003-9861(86)90336-X	22	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10073	10078		10.1074/jbc.271.17.10073	http://dx.doi.org/10.1074/jbc.271.17.10073			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626564	hybrid			2022-12-25	WOS:A1996UG25700036
J	Tange, TO; Jensen, TH; Kjems, J				Tange, TO; Jensen, TH; Kjems, J			In vitro interaction between human immunodeficiency virus type 1 rev protein and splicing factor ASF/SF2-associated protein, p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL MESSENGER-RNA; HIV-1 REV; BINDING SITE; EXPRESSION; REGION; OLIGOMERIZATION; PURIFICATION; SEQUENCE; PEPTIDE; ELEMENT	Continuous replication of human immunodeficiency virus type 1 requires the expression of the regulatory protein Rev, which binds to the Rev response element (RRE) and up-regulates the cytoplasmic appearance of singly spliced and unspliced mRNA species. It has been demonstrated that the murine protein YL2 interacts with Rev in vivo and modulates the activity of Rev (Luo, Y., Yu, H., and Peterlin, B. M. (1994) J. Virol. 68, 3850-3856). Here we show that the YL2 human homologue, the p32 protein, which co-purifies with alternative splicing factor ASF/SF2, interacts directly with the basic domain of Rev in vitro and that the Rev-p32 complex is resistant to high concentrations of salt or nonionic detergent. Protein footprinting data suggest that Rev interacts specifically with amino acids within the 196-208 region of p32. An analysis of the ternary complex, formed among p32, Rev, and RRE RNA, shows that Rev can bridge the association of p32 and RRE. Furthermore, we demonstrate that exogenously added p32 specifically relieves the inhibition of splicing in vitro exerted by the basic domain of Rev. Our data are consistent with a model in which p32 functions as a link between Rev and the cellular splicing apparatus.	AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS C,DENMARK	Aarhus University			Jensen, Torben H/G-2954-2017; Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317				BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COLE JL, 1993, BIOCHEMISTRY-US, V32, P11769, DOI 10.1021/bi00095a004; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1994, J VIROL, V68, P951; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; Jeang K T, 1991, AIDS, V5 Suppl 2, pS3, DOI 10.1097/00002030-199101001-00002; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; JENSEN TH, 1995, J BIOL CHEM, V270, P13777, DOI 10.1074/jbc.270.23.13777; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NALIN CM, 1990, P NATL ACAD SCI USA, V87, P7593, DOI 10.1073/pnas.87.19.7593; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SZILVAY AM, 1995, J VIROL, V69, P3315, DOI 10.1128/JVI.69.6.3315-3323.1995; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VENKATESAN S, 1992, J VIROL, V66, P7469, DOI 10.1128/JVI.66.12.7469-7480.1992; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	46	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10066	10072		10.1074/jbc.271.17.10066	http://dx.doi.org/10.1074/jbc.271.17.10066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626563	hybrid			2022-12-25	WOS:A1996UG25700035
J	Carlier, MF; Didry, D; Erk, I; Lepault, J; VanTroys, ML; Vandekerchkove, J; Perelroizen, I; Yin, H; Doi, YK; Pantaloni, D				Carlier, MF; Didry, D; Erk, I; Lepault, J; VanTroys, ML; Vandekerchkove, J; Perelroizen, I; Yin, H; Doi, YK; Pantaloni, D			T beta(4) is not a simple G-actin sequestering protein and interacts with F-actin at high concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMOSIN BETA-4; DEPOLYMERIZING FACTOR; POLYMERIZATION; FILAMENTS; BINDING; MUSCLE; ATP; MODULATION; PLATELETS; GELSOLIN	Thymosin beta(4) is acknowledged as a major G-actin binding protein maintaining a pool of unassembled actin in motile vertebrate cells. We have examined the function of T beta(4) in actin assembly in the high range of concentrations (up to 300 mu M) at which T beta(4) is found ire highly motile blood cells. T beta(4) behaves as a simple G-actin sequestering protein only in a range of low concentrations (<20 mu M). As the concentration of T beta(4) increases, its ability to depolymerize F-actin decreases, due to its interaction with F-actin. The T beta(4)-actin can be incorporated, in low molar ratios, into F-actin, and can be cross-linked in F-actin using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. As a result of the copolymerization of actin and T beta(4)-actin complex, the critical concentration is the sum of free G-actin and T beta(4)-G-actin concentrations at steady state, and the partial critical concentration of G-actin is decreased by T beta(4)-G-actin complex. The incorporation of T beta(4)-actin in F-actin is associated to a structural change of the filaments and eventually leads to their twisting around each other. In conclusion, T beta(4) is not a simple passive actin-sequestering agent, and at high concentrations the ability of T beta(4)-actin to copolymerize with actin reduces the sequestering activity of G-actin-binding proteins. These results question the evaluation of the unassembled actin in motile cells. They account for observations made on living fibroblasts overexpressing beta-thymosins.	CNRS, CTR MOLEC GENET, F-91198 GIF SUR YVETTE, FRANCE; STATE UNIV GHENT, PHYSIOL CHEM LAB, GHENT, BELGIUM; KYOTO WOMENS UNIV, KYOTO 605, JAPAN; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Ghent University; Kyoto Womens University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Carlier, MF (corresponding author), CNRS, ENZYMOL LAB, F-91198 GIF SUR YVETTE, FRANCE.		Lepault, Jean/AAN-8859-2020	Van Troys, Marleen/0000-0003-4283-8103				AEBI U, 1986, ANN NY ACAD SCI, V483, P100, DOI 10.1111/j.1749-6632.1986.tb34502.x; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1986, J BIOL CHEM, V261, P2041; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; DOI Y, 1990, BIOCHEMISTRY-US, V29, P1392, DOI 10.1021/bi00458a008; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HEINTZ D, 1993, FEBS LETT, V329, P9, DOI 10.1016/0014-5793(93)80181-S; HEPTINSTALL S, 1992, THROMB HAEMOSTASIS, V68, P727; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAULT J, 1981, J MOL BIOL, V149, P275, DOI 10.1016/0022-2836(81)90302-8; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; SAFER D, 1991, J BIOL CHEM, V266, P4029; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269; YU FX, 1993, J BIOL CHEM, V268, P502	33	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9231	9239		10.1074/jbc.271.16.9231	http://dx.doi.org/10.1074/jbc.271.16.9231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621582	hybrid			2022-12-25	WOS:A1996UG04400013
J	Catipovic, B; Schneck, JP; Brummet, ME; Marsh, DG; Rafnar, T				Catipovic, B; Schneck, JP; Brummet, ME; Marsh, DG; Rafnar, T			Csk is constitutively associated with a 60-kDa tyrosine-phosphorylated protein in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; MOLECULAR-CLONING; ANTIGEN RECEPTOR; FAMILY KINASES; SH3 DOMAINS; ZETA-CHAIN; PP60C-SRC; BINDING; TRANSFORMATION; EXPRESSION	The protein-tyrosine kinase Csk is one of the main down-regulators of the Src family of kinases, Csk may be involved in the down-regulation of T cell receptor (TCR) signaling by C-terminal tyrosine phosphorylation of Lck and Fyn; however, it is not known how Csk activity is regulated or how it targets these Src family members, We used Jurkat T cells and normal human T cells to examine proteins that bind to the SH2 domain of Csk. In both Jurkat and normal T cells, the Src homology 2 (SH2) domain of Csk bound constitutively to a tyrosine-phosphorylated protein of 60 kDa (p60), The 60-kDa protein was detected in Csk immunoprecipitates from both unstimulated and CD3-stimulated cells, In addition to p60, a protein of 190 kDa coprecipitated with Csk, and both proteins were phosphorylated on tyrosine residues by the immunocomplex. Small amounts of GTPase-activating protein (GAP) were detected in anti-Csk immunoprecipitates, suggesting that p60 may be a GAP-associated protein, Our data demonstrate that the SH2 domain of Csk specifically associates with at least two tyrosine-phosphorylated proteins in normal human T cells, that this association is independent of TCR/CD3 activation, and that Csk may be a part of a multiprotein complex containing GAP.	JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ASTHMA & ALLERGY CTR, DIV CLIN IMMUNOL, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI019727, R01AI019727, R01AI029575] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19727, AI29575] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLEN JB, 1993, ONCOGENE, V8, P2025; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1992, NATURE, V355, P78; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OETKEN C, 1994, ONCOGENE, V9, P1625; OGAWA W, 1994, J BIOL CHEM, V269, P29602; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Rafnar T, 1995, ANN NY ACAD SCI, V766, P206, DOI 10.1111/j.1749-6632.1995.tb26665.x; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDOL M, 1993, ONCOGENE, V8, P823; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	45	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9698	9703		10.1074/jbc.271.16.9698	http://dx.doi.org/10.1074/jbc.271.16.9698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621646	hybrid			2022-12-25	WOS:A1996UG04400077
J	Chen, G; Guy, CT; Chen, HW; Hu, NP; Lee, EYHP; Lee, WH				Chen, G; Guy, CT; Chen, HW; Hu, NP; Lee, EYHP; Lee, WH			Molecular cloning and developmental expression of mouse p130, a member of the retinoblastoma gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN	With sequence homology to the SV40 T antigen-binding domain of the retinoblastoma protein (Rb), p107 and p130 constitute two additional members of che Rb family, To explore the potential function of p130 in mouse development, we cloned the full-length mouse cDNA for p130 and characterized p130 mRNA expression in mice. The deduced mouse p130 protein sequence shares a higher degree of similarity with mouse p107 than with mouse Rb, In adult mice, p130 mRNA is found in all tissues examined, Levels of p130 mRNA vary among different adult tissues, with the highest level in testis. Within testis, p130 mRNA is found predominantly in Leydig cells, Additionally, p130 expression in testis correlates with sexual maturation, suggesting p130 is important for the development of testis and, in particular, Leydig cells, In situ hybridization shows that in post coitus day 12.5 and 14.5 mouse embryos, distribution of p130 mRNA is quite uniform with the exception of a few tissues. Little differences in mRNA levels of either p130 or p107 were found between normal and Rb-deficient embryos, suggesting that p130 and p107 are expressed independently of Rb. Our data are consistent with the hypothesis that p130 and p107 do not compensate for the loss of Rb and support the view that p130 is related to, yet distinct from, the RB gene.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA49649, CA58318] Funding Source: Medline; NICHD NIH HHS [HD30625] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD030625] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA049649, R37CA049649, R01CA049649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P139; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067	26	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9567	9572		10.1074/jbc.271.16.9567	http://dx.doi.org/10.1074/jbc.271.16.9567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621630	hybrid			2022-12-25	WOS:A1996UG04400061
J	PerezVilar, J; Eckhardt, AE; Hill, RL				PerezVilar, J; Eckhardt, AE; Hill, RL			Porcine submaxillary mucin forms disulfide-bonded dimers between its carboxyl-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; VONWILLEBRAND-FACTOR; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; PROTEINS; OLIGOMERIZATION; DIMERIZATION; PURIFICATION; CLEAVAGE; FAMILY	COS-7 cells transfected with three different expression vectors encoding the 240-amino acid residue, disulfide-rich domain at the carboxyl terminus of porcine submaxillary mucin have been used to determine the possible function of the domain in forming higher oligomers of the mucin polypeptide chain, The domain is expressed as a disulfide-bonded dimer, as shown by SDS-gel electrophoretic analysis of the immunoprecipitated domain in the presence and absence of reducing agent and the cross-linking agent bis(sulfosuccinimidyl) suberate. Molecular weight determination by gel filtration on agarose columns in 6 M guanidine HCl confirmed dimer formation, However, the domain expressed is heterogeneous as the result of different extents of glycosylation, Pulse-chase studies with the S-35-labeled domain show that dimer formation and secretion from cells occur very rapidly. Moreover, dimer formation is not dependent on the N-linked oligosaccharides on the do main, Evidence is presented that dimer formation most likely occurs in the endoplasmic reticulum before complex-type oligosaccharide synthesis is completed. Neither brefeldin A nor tunicamycin interferes with the rate of dimer formation, These studies suggest that the disulfide-rich domain acts to form dimers of the polypeptide chain of mucin, This role of the domain is consistent with its amino acid sequence similarity to the disulfide-rich domain of human prepro-von Willebrand factor, which also serves to form dimers of this blood coagulation factor.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025766, R01GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DORNER AJ, 1990, METHOD ENZYMOL, V185, P557; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLOMP LWJ, 1994, BIOCHEM J, V304, P737, DOI 10.1042/bj3040737; KLOMP LWJ, 1994, BIOCHEM J, V304, P693, DOI 10.1042/bj3040693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MOHRI H, 1989, J BIOL CHEM, V264, P17361; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; XU GQ, 1992, J BIOL CHEM, V267, P5401	27	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9845	9850		10.1074/jbc.271.16.9845	http://dx.doi.org/10.1074/jbc.271.16.9845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621668	hybrid			2022-12-25	WOS:A1996UG04400099
J	Wildung, MR; Croteau, R				Wildung, MR; Croteau, R			A cDNA clone for taxadiene synthase, the diterpene cyclase that catalyzes the committed step of taxol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SESQUITERPENE CYCLASE; 4S-LIMONENE SYNTHASE; BACTERIAL EXPRESSION; CONSERVED ASPARTATE; GENE; PROTEINS; RESIDUES; AGENTS	The committed step of taxol (paclitaxel) biosynthesis is catalyzed by taxa-4(5),11(12)-diene synthase, a diterpene cyclase responsible for transforming the ubiquitous isoprenoid intermediate geranylgeranyl diphosphate to the parent olefin with a taxane skeleton, To obtain the corresponding cDNA clone, a set of degenerate primers was constructed based on consensus sequences of related monoterpene, sesquiterpene, and diterpene cyclases, Two of these primers amplified a 83-base pair fragment that was cyclase-like in sequence and that was employed as a hybridization probe to screen a cDNA library constructed from poly(A)(+) RNA extracted from Pacific yew (Taxus brevifolia) stems, Twelve independent clones with insert size in excess of 2 kilobase pairs were isolated and partially sequenced. One of these cDNA isolates was functionally expressed in Escherichia coli, yielding a protein that was catalytically active in converting geranylgeranyl diphosphate to a diterpene olefin that was confirmed to be taxa-4(5),11(12)-diene by combined capillary gas chromatography-mass spectrometry, The sequence specifies an open reading frame of 2586 nucleotides, and the complete deduced polypeptide, including a long presumptive plastidial targeting peptide, contains 862 amino acid residues and has a molecular weight of 98,303, compared with about 79,000 previously determined for the mature native enzyme, Sequence comparisons with monoterpene, sesquiterpene, and diterpene cyclases of plant origin indicate a significant degree of similarity between these enzymes; the taxadiene synthase most closely resembles (46% identity, 67% similarity) abietadiene synthase, a diterpene cyclase from grand fir.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University					NATIONAL CANCER INSTITUTE [R01CA055254, R37CA055254] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE I, 1994, J BIOL CHEM, V269, P802; ARBUCK SG, 1995, TAXOL SCI APPL, P379; ATTUCCI S, 1995, ARCH BIOCHEM BIOPHYS, V321, P493, DOI 10.1006/abbi.1995.1422; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BORMAN S, 1994, CHEM ENG NEWS, V72, P32, DOI 10.1021/cen-v072n008.p032; BRITTEN RJ, 1983, NUCL ACID HYBRIDISAT, P3; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; CHEN AJ, 1994, PROTEIN SCI, V3, P600; COLBY SM, 1993, J BIOL CHEM, V268, P23016; CRAGG GM, 1993, J NAT PROD, V56, P1657, DOI 10.1021/np50100a001; CROTEAU R, 1995, TAXANE ANTICANCER AG, P72; CROTEAU RB, 1990, J CHROMATOGR, V500, P349, DOI 10.1016/S0021-9673(00)96076-X; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; FENG DF, 1990, METHOD ENZYMOL, V183, P375; Floss HG, 1995, TAXOL SCI APPL, P191; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HAN KH, 1994, PLANT SCI, V95, P187, DOI 10.1016/0168-9452(94)90092-2; HEZARI M, 1995, ARCH BIOCHEM BIOPHYS, V322, P437, DOI 10.1006/abbi.1995.1486; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOLMES FA, 1995, ACS SYM SER, V583, P31; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JOLY A, 1993, J BIOL CHEM, V268, P26983; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; KOEPP AE, 1995, J BIOL CHEM, V270, P8686, DOI 10.1074/jbc.270.15.8686; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MCGARVEY DJ, 1995, PLANT CELL, V7, P1015, DOI 10.1105/tpc.7.7.1015; OLD RW, 1989, PRINCIPLES GENE MANI, P34; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; RUBENSTEIN SM, 1995, J ORG CHEM, V60, P7215, DOI 10.1021/jo00127a029; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOLNIK PA, 1994, PLANT PHYSIOL, V104, P1469, DOI 10.1104/pp.104.4.1469; Suffness M., 1995, TAXOL SCI APPL, P3; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TABOR S, 1991, CURRENT PROTOCOLS MO; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; West C. A., 1981, BIOSYNTHESIS ISOPREN, V1, P375; WEST CA, 1979, RECENT ADV PHYTOCHEM, V13, P163	51	214	274	2	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9201	9204		10.1074/jbc.271.16.9201	http://dx.doi.org/10.1074/jbc.271.16.9201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621577	hybrid			2022-12-25	WOS:A1996UG04400008
J	Bacsi, SG; Hankinson, O				Bacsi, SG; Hankinson, O			Functional characterization of DNA-binding domains of the subunits of the heterodimeric aryl hydrocarbon receptor complex imputing novel and canonical basic helix-loop-helix protein-DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATOR PROTEIN; DIOXIN-RESPONSIVE ENHANCER; HEAT-SHOCK PROTEIN; AH-RECEPTOR; MOLECULAR CHARACTERIZATION; DROSOPHILA-HAIRY; TRANSCRIPTION; CLONING; CYTOCHROME-P1-450; ASSOCIATION	The aryl hydrocarbon receptor (AHR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) belong to a novel subclass of basic helix-loop helix transcription factors, The AHR ARNT heterodimer binds to the xenobiotic responsive element (XRE). Substitution of each of four amino acids in the basic region of ARNT with alanine severely diminishes or abolishes XRE binding, intimating that these amino acids contact DNA bases. Three of these amino acids are conserved among basic helix-loop-helix proteins, and the corresponding amino acids of Max and USF are known to contact DNA bases. Alanine scanning mutagenesis of the basic domain of AHR and substitution with conservative amino acids at particular positions in this domain and in a more amino-proximal AHR segment previously shown to be required for XRE binding (Fukunaga, B. N., and Hankinson, O. (1996) J. Biol. Chem 271, 3743-3749) demonstrate that the most carboxyl-proximal amino acid position of the basic domain and a position within the amino-proximal segment are intolerant to amino acid substitution with regard to XRE binding, suggesting that these two amino acids make base contacts. Amino acid positions in these AHR regions and in the ARNT basic region less adversely affected by substitution are also identified, The amino acids at these positions may contact the phosphodiester backbone. The apparent bipartite nature of the DNA binding region of AHR and the identity of those of its amino acids that apparently make DNA contacts impute a novel protein-DNA binding behavior for AHR.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,SCH MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,SCH MED,LOS ANGELES,CA 90095	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA28868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BACSI SG, 1995, MOL PHARMACOL, V47, P432; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN HS, 1994, J BIOL CHEM, V269, P27554; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; JORDAN KL, 1994, ONCOGENE, V9, P1177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1994, J BIOL CHEM, V269, P28098; LITTLEWOOD TD, 1994, TRANSCRIPTION FACTOR; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MAHON MJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P166, DOI 10.1006/abbi.1995.1217; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NEVINS JR, 1992, SCIENCE, V258, P424; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	44	54	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8843	8850		10.1074/jbc.271.15.8843	http://dx.doi.org/10.1074/jbc.271.15.8843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621524	hybrid			2022-12-25	WOS:A1996UE73000055
J	Antle, VD; Liu, DS; McKellar, BR; Caperelli, CA; Hua, M; Vince, R				Antle, VD; Liu, DS; McKellar, BR; Caperelli, CA; Hua, M; Vince, R			Substrate specificity of glycinamide ribonucleotide synthetase from chicken liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PURINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; TRANSFORMYLASE; CLONING	Several analogs of glycinamide ribonucleotide and phosphoribosylamine have been prepared and evaluated as substrates for glycinamide ribonucleotide synthetase purified from chicken liver. Glycinamide ribonucleotide analogs include side chain modifications wherein the glycine side chain (R = CH2NH2) has been replaced by R = CH2NHCH3 and R = CH2CH2NH2, ribose ring replacement by chiral cyclopentane and cyclopentene derivatives, and phosphate replacement by phosphonates. All of these, with the exception of the O-phosphonate, served as substrates for the reverse enzymatic reaction, with V-max values comparable to that obtained with glycinamide ribonucleotide, although the K-m values ranged from 21 to 118 times the K-m for glycinamide ribonucleotide. Analogs of phosphoribosylamine examined as substrates for the forward reaction consist of chiral derivatives of cyclopentane and cyclopentene and a chiral carbocyclic phosphonate. These also served as substrates, with K-m values ranging from 5 to 23 times the K-m for phosphoribosylamine and with diminished V-max values. These studies have begun to define the structural features of the nucleotide substrate necessary to support enzymatic activity. Sarcosine (N-methylglycine) and beta-alanine were also accepted as substrates, albeit with reduced affinity compared with glycine.	UNIV CINCINNATI,MED CTR,COLL PHARM,DIV PHARMACEUT SCI,CINCINNATI,OH 45267; UNIV MINNESOTA,COLL PHARM,DEPT MED CHEM,MINNEAPOLIS,MN 55455	University System of Ohio; University of Cincinnati; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA023263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046243, R15GM042024] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA23263] Funding Source: Medline; NIGMS NIH HHS [R01 GM46243, GM42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIMI J, 1990, NUCLEIC ACIDS RES, V18, P6665, DOI 10.1093/nar/18.22.6665; AMES BN, 1960, J BIOL CHEM, V235, P769; Antle VD, 1996, J BIOL CHEM, V271, P6045, DOI 10.1074/jbc.271.11.6045; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; Bergmann M, 1932, BER DTSCH CHEM GES, V65, P1192, DOI 10.1002/cber.19320650722; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1992, J BIOL CHEM, V267, P9783; CARDINI CE, 1957, METHOD ENZYMOL, V3, P835, DOI 10.1016/S0076-6879(57)03458-8; CHETTUR G, 1977, CARBOHYD RES, V56, P75, DOI 10.1016/S0008-6215(00)84238-X; Cleland W W, 1979, Methods Enzymol, V63, P103; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; INGLESE J, 1989, J MED CHEM, V32, P937, DOI 10.1021/jm00125a002; KAM BL, 1981, J ORG CHEM, V46, P3268, DOI 10.1021/jo00329a026; KAN JLC, 1993, GENE, V137, P195, DOI 10.1016/0378-1119(93)90006-O; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; LIU DH, 1991, J BIOL CHEM, V266, P16699; OLAH GA, 1979, J ORG CHEM, V44, P1247, DOI 10.1021/jo01322a012; RUDOLPH J, 1995, BIOCHEMISTRY-US, V34, P2241, DOI 10.1021/bi00007a019; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; YOUNG M, 1984, BIOCHEMISTRY-US, V23, P3979, DOI 10.1021/bi00312a027	24	9	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8192	8195		10.1074/jbc.271.14.8192	http://dx.doi.org/10.1074/jbc.271.14.8192			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626510	hybrid			2022-12-25	WOS:A1996UD60000050
J	Tanahashi, T; Suzuki, M; Imamura, T; Mitsui, Y				Tanahashi, T; Suzuki, M; Imamura, T; Mitsui, Y			Identification of a 79-kDa heparin-binding fibroblast growth factor (FGF) receptor in rat hepatocytes and its correlation with the different growth responses to FGF-1 between hepatocyte subpopulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LIVER-REGENERATION; AFFINITY BINDING; CELL-SURFACE; EXPRESSION; CLONING; AUTOCRINE; REGULATOR; PROTEINS; GENE	We reported previously that the potency of heparin-binding fibroblast growth factor-1 (FGF-1) as a mitogen for rat hepatocytes in primary culture is as high as that of epidermal growth factor (EGF) and hepatocyte growth factor. To gain insight into the pathophysiological significance of FGF-1 in hepatocyte growth, we analyzed the cooperative mitogenicity of FGF-1 and EGF. Results hom a nuclear labeling assay using [H-3]thymidine suggest that most hepatocytes in primary culture consist of two cell populations that differ in response to FGF-1; one is an FGF-1-responsive cell population, and the other is an EGF-responsive (but not FGF-1-responsive) cell population, On the other hand, autoradiographic analysis of I-125-FGF-1 binding demonstrated that high affinity FGF receptors were homogeneously distributed on the surface of all hepatocytes. Cross-linking I-125-FGF-1 to the nonstimulated hepatocyte surface indicated that the high affinity FGF receptors comprise two FGF receptors that differ in molecular mass (128 and 79 kDa), Furthermore, the 79-kDa receptor was preferentially down-regulated when the hepatocytes were stimulated with EGF or hepatocyte growth factor. These data suggest that the abundant expression of the 79-kDa FGF receptor on some populations of hepatocytes is involved in their lack of response to FGF-1. The 128- and 79-kDa FGF receptors were assigned as FGFR2 using an antibody specific to the ectodomain of FGFR2, whereas the 79-kDa receptor was not reactive to the antibody against the carboxyl terminus of FGFR2. This 79-kDa FGF receptor was not tyrosine-phosphorylated in response to FGF-1 stimulation, while the 128-kDa FGF receptor was recognized by anti-phosphotyrosine antibody under the same conditions, Also, the heterodimer of 79- and 128-kDa FGF receptors was less tyrosine-phosphorylated than the homodimer of 128-kDa FGF receptors. These data suggest that the 79-kDa FGF receptor inhibits the function of the 128-kDa FGF receptor through their heterodimerization. Thus, we surmise that the difference in response to FGF-1 between the cell populations of normal rat hepatocytes was caused by the different levels of the 79-kDa FGF receptor in each cell population.	NATL INST BIOSCI & HUMAN TECHNOL,LAB CHIEF SENIOR RES,TSUKUBA,IBARAKI 305,JAPAN; TABAI ESPEC CORP,DEPT RES & DEV,KITA KU,OSAKA 530,JAPAN	National Institute of Advanced Industrial Science & Technology (AIST)	Tanahashi, T (corresponding author), NATL INST BIOSCI & HUMAN TECHNOL,CELL BIOL LAB,1-1 HIGASHI,TSUKUBA,IBARAKI 305,JAPAN.		Tanahashi, Tadanori/M-4239-2018; Suzuki, Masashi/M-1696-2018	Tanahashi, Tadanori/0000-0002-0331-1862; Suzuki, Masashi/0000-0002-7218-0923				BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER NLR, 1991, J GASTROEN HEPATOL, V6, P615, DOI 10.1111/j.1440-1746.1991.tb00921.x; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FANTL, 1993, ANN REV BIOCH, V62, P453; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GEBHARDT R, 1991, BIOCHEM BIOPH RES CO, V181, P1201, DOI 10.1016/0006-291X(91)92066-S; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUCK KA, 1990, J CELL PHYSIOL, V143, P129, DOI 10.1002/jcp.1041430117; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KOCH KS, 1990, IN VITRO CELL DEV B, V26, P1011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI U, 1991, EUR J CELL BIOL, V55, P158; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TANAHASHI T, 1995, EXP CELL RES, V218, P233, DOI 10.1006/excr.1995.1151; TANAHASHI T, 1994, IN VITRO CELL DEV-AN, V30A, P139; UENO H, 1992, J BIOL CHEM, V267, P1470; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VOLK A, 1995, BIOCHEM BIOPH RES CO, V207, P578, DOI 10.1006/bbrc.1995.1227; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8221	8227		10.1074/jbc.271.14.8221	http://dx.doi.org/10.1074/jbc.271.14.8221			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626515	hybrid			2022-12-25	WOS:A1996UD60000055
J	Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B				Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B			Regulation of nov by WT1: A potential role for nov in nephrogenesis	ONCOGENE			English	Article						novH; nephrogenesis; Wilms' tumor; WT1; IGF-binding-protein	WILMS-TUMOR GENE; GROWTH FACTOR-II; IMMEDIATE-EARLY GENE; ZINC FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER ACTIVITY; BINDING-PROTEIN; RECEPTOR GENE; KIDNEY DEVELOPMENT; SUPPRESSOR WT1	The nov gene encodes a putative Insulin-like-Growth Factor-Binding Protein (IGFBP) of a novel type which is structurally related to a family of growth-factors likely to play a role in the control of cell proliferation. In the kidney, nov is expressed essentially at the embryonic stage and alterations of nov expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. The levels of human nov (novH) and WT1 mRNA in individual Wilms' tumors have been shown to be inversely correlated, suggesting that the expression of novH could be under the negative control of WT1. We have now established the nucleotide sequence of the 5' flanking region,and identified two transcription start sites by RNase protection assays and primer extension. We report that in transient cotransfection experiments the transcription activity of novH promoter constructs was repressed by two isoforms of WT1 proteins (WT1 and WT1 + KTS). Repression of the novH promoter required both intact zinc finger regions and the NH, transcription repression domain of WT1. Inasmuch as the minimal region of novH promoter required to mediate WT1 repression irt vivo failed to bind recombinant WT1 protein in in vitro footprinting assays this repression may be mediated by either (i) low affinity sites cooperative interactions or (ii) indirectly via protein-protein interactions with another factor(s). Furthermore, constitutive expression of wild type WT1 into 293 cells resulted in a decrease of endogenous NOVH protein levels, suggesting that novH may be a physiological target for WT1. The downregulation of novH expression by WT1 might represent a key element in normal and tumoral nephrogenesis.	INST CURIE,LAB ONCOL VIRALE & MOL,F-91405 ORSAY,FRANCE; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PARIS 07,UFR BIOCHIM,F-75221 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; The Wistar Institute; UDICE-French Research Universities; Universite Paris Cite								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DESSEN P, 1990, FRENCH SERVICE ACCES; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MADDEN SL, 1993, ONCOGENE, V8, P405; MAHASWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100; MALOISEL V, 1990, Methods in Molecular and Cellular Biology, V1, P245; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1991, CR ACAD SCI III-VIE, V313, P345; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PATCHNIS V, 1993, DEVELOPMENT, V119, P1005; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Perbal B, 1995, INFECT AGENT DIS, V4, P212; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; PERBAL B, 1994, B CANCER, V81, P957; Perbal B., 1988, PRACTICAL GUIDE MOL; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saxen L., 1987, DEV CELL BIOL SERIES, V19; Scholz G, 1996, MOL CELL BIOL, V16, P481; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WYANG ZY, 1995, ONCOGENE, V10, P415; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	75	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1479	1492						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622864				2022-12-25	WOS:A1996UF07600012
J	Kristal, BS; Park, BK; Yu, BP				Kristal, BS; Park, BK; Yu, BP			4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERT-BUTYL HYDROPEROXIDE; CYCLOSPORINE-A; CULTURED-HEPATOCYTES; LIVER-MITOCHONDRIA; OXIDATIVE STRESS; CA-2+-DEPENDENT PORE; HEART-MITOCHONDRIA; LIPID-PEROXIDATION; MEMBRANE; DAMAGE	Mitochondria undergo at least two types of structural alteration in response to various physiological and pathophysiological stimuli. One type is nonreversible and is associated with mitochondrial lysis. The second is reversible and appears to be associated with calcium-mediated activation of a specific inner mitochondrial membrane channel. The mechanisms underlying the induction of this second alteration, termed a mitochondrial permeability transition (PT), have been the subject of a great deal of recent research. Using rat liver mitochondria, our data demonstrate that calcium-mediated PT induction can be affected by the lipid peroxidation byproducts 4-hydroxynonenal and 4-hydroxyhexenal (HHE). 4-Hydroxynonenal appears inactive at concentrations <1 uM but displays both stimulatory and inhibitory effects as part of a biphasic dose response between approximately 1 and 200 uM. In contrast, HHE consistently enhances calcium mediated induction of the PT, even at femtomolar concentrations. The exquisite specificity and sensitivity of HHE led to further studies to examine the nature of this induction, Studies showing that HHE-mediated induction could be prevented by cyclosporin A confirmed PT involvement. Further studies showed that induction was dependent on both calcium and electron transport chain function. Pretreatment of the HHE with glutathione also prevented PT induction, but simultaneous addition of the thiol reagents dithiothreitol or glutathione, which often prevents PT induction, was ineffective, attesting to the effectiveness of HHE as an inducer. Together, these data provide a possible mechanistic explanation for the previously observed effects of lipid peroxidation on PT induction.	UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284; YALE UNIV,NEW HAVEN,CT 06520	University of Texas System; University of Texas Health San Antonio; Yale University					NIA NIH HHS [AG01188] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; CHEN JJ, 1995, FREE RADICAL BIO MED, V19, P583, DOI 10.1016/0891-5849(95)00066-7; CHEN JJ, 1994, FREE RADICAL BIO MED, V17, P411, DOI 10.1016/0891-5849(94)90167-8; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, BIOCHEM J, V255, P357; DIANZANI MU, 1982, FREE RADICALS LIPID, P129; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; ESTERBAUER H, 1990, MEMBRANE LIPID OXIDA, V1, P239; GRIFFIN D S, 1987, Journal of Biochemical Toxicology, V2, P155, DOI 10.1002/jbt.2570020302; GUUNTER TE, 1994, AM J PHYSIOL, V267, pC313; KRAMER JH, 1994, ANN NY ACAD SCI, V723, P180, DOI 10.1111/j.1749-6632.1994.tb36725.x; KRISTAL BS, 1994, FREE RADICAL BIO MED, V16, P323, DOI 10.1016/0891-5849(94)90033-7; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V270, P672, DOI 10.1016/0003-9861(89)90550-X; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PEREIRA RS, 1992, BIOCHEM PHARMACOL, V44, P1795, DOI 10.1016/0006-2952(92)90074-S; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RICHTER C, 1990, BIOCHEM J, V269, P735, DOI 10.1042/bj2690735; RIGOBELLO MP, 1993, BIOCHEM BIOPH RES CO, V194, P1276, DOI 10.1006/bbrc.1993.1961; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; SAVAGE MK, 1994, ARCH BIOCHEM BIOPHYS, V315, P142, DOI 10.1006/abbi.1994.1483; SEGALL HJ, 1985, SCIENCE, V229, P472, DOI 10.1126/science.4012327; SUKALSKI KA, 1993, FREE RADICAL BIO MED, V14, P57, DOI 10.1016/0891-5849(93)90509-S; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; VANKUIJK FJGM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P116, DOI 10.1016/0005-2760(90)90118-H	38	206	217	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6033	6038		10.1074/jbc.271.11.6033	http://dx.doi.org/10.1074/jbc.271.11.6033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626387				2022-12-25	WOS:A1996UA36300016
J	VeigadaCunha, M; Courtois, S; Michel, A; Gosselain, E; VanSchaftingen, E				VeigadaCunha, M; Courtois, S; Michel, A; Gosselain, E; VanSchaftingen, E			Amino acid conservation in animal glucokinases - Identification of residues implicated in the interaction with the regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; CLONED CDNA; SEQUENCE DETERMINATION; YEAST HEXOKINASE; BRAIN HEXOKINASE; GENE; EXPRESSION; INSULIN; CLONING	To delineate the regions of liver glucokinase that are involved in the binding of its regulatory protein and have therefore been conserved throughout evolution, we have cloned the cDNA of the Xenopus laevis enzyme. It contains an open reading frame of 1374 nucleotides and encodes a protein of 458 amino acids, which displays 78 and 79% overall identity to rat and human liver glucokinases, respectively. The conserved regions are predicted to be present mainly in the small domain and the hinge region of glucokinase, and the nonconserved regions in the large domain of the enzyme. We constructed five mutants of Xenopus glucokinase by replacing sets of 2-5 glucokinase-specific residues with their counterparts in the C-terminal half of rat hexokinase I. The affinity for the regulatory protein was not markedly changed for mutants B, D, and E despite a decreased affinity for glucose in mutants B and D. Two other mutants (A and C) were 9- and 250-fold less sensitive to the rat regulator and 40- and 770-fold less sensitive to the Xenopus regulator, respectively, but presented a normal affinity for glucose. The double mutant (A-C) was completely insensitive to inhibition by the regulatory protein. A control mutant (F), obtained by replacing 3 residues that were not conserved in all glucokinases, had a normal affinity for glucose and for the regulatory protein. The property of glucokinase to be inhibited by palmitoyl-CoA was not affected by the mutations described. It is concluded that His-141 to Leu-144, which are located close to the tip of the small domain, as well as Glu-51 and Glu-52, which are present in the large domain of the enzyme close to the hinge region, or nearby residues participate in the binding of the regulatory protein.	UNIV LOUVAIN, PHYSIOL CHEM LAB, B-1200 BRUSSELS, BELGIUM; INT INST CELLULAR & MOLEC PATHOL, B-1200 BRUSSELS, BELGIUM; UNIV MONS HAINAUT, FAC SCI, DEPT BIOL CHEM, B-7000 MONS, BELGIUM	Universite Catholique Louvain; University of Mons			Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647				ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KORANYI LI, 1992, DIABETES, V41, P807, DOI 10.2337/diabetes.41.7.807; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; LANGE AJ, 1993, J BIOL CHEM, V268, P8078; LIANG Y, 1995, BIOCHEM J, V309, P167, DOI 10.1042/bj3090167; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; STACHELEK C, 1986, NUCLEIC ACIDS RES, V14, P945, DOI 10.1093/nar/14.2.945; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANIZAWA Y, 1991, P NATL ACAD SCI USA, V88, P7294, DOI 10.1073/pnas.88.16.7294; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VEIGADACUNHA M, 1994, EUR J BIOCHEM, V225, P43, DOI 10.1111/j.1432-1033.1994.00043.x; XU LZ, 1995, J BIOL CHEM, V270, P9939, DOI 10.1074/jbc.270.17.9939	34	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6292	6297		10.1074/jbc.271.11.6292	http://dx.doi.org/10.1074/jbc.271.11.6292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626423	hybrid			2022-12-25	WOS:A1996UA36300052
J	Ratajczak, T; Carrello, A				Ratajczak, T; Carrello, A			Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-RECEPTOR COMPLEXES; ESTROGEN-RECEPTOR; ESCHERICHIA-COLI; SNAP HELIX; IMMUNOPHILIN; FK506; EXPRESSION; COMPONENT; CONTAINS	The structurally related immunophilins cyclophilin 40 (CyP-40) and FKBP52 have been identified as components of the unactivated estrogen receptor. Both immunophilins have a similar molecular architecture that includes a C-terminal segment with a tetratricopeptide repeat (TPR) domain predicted to mediate protein interaction. hsp90 is a common cellular target for CyP-40 and FKBP52. Deletion mutants of CyP-40 fused to glutathione S-transferase were immobilized on glutathione-agarose and then used in a rapid hsp90 retention assay to define regions of the CyP-40 C terminus that are important for hsp90 binding. Our evidence suggests that the TPR domain is not sufficient for stable association of CyP-40 with hsp90 and requires the participation of flanking acidic and basic residues clustered at the N- and C-terminal ends, respectively. Both microdomains are characterized by alpha-helical structures with segregated hydrophobic and charged residues. Corresponding regions were identified in FKBP52. By preincubating myometrial cytosol with lysates containing bacterially expressed FKBP52, we have shown that FKBP52 competes with CyP-40 for hsp90 binding. Our results raise the possibility of a mutually exclusive association of CyP-40 and FKBP52 with hsp90. This would lead to separate immunophilin-hsp90-receptor complexes and place the estrogen receptor under the control of distinct immunophilin signaling pathways.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PHARMACOL,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia	Ratajczak, T (corresponding author), SIR CHARLES GAIRDNER HOSP,DEPT ENDOCRINOL & DIABET,NEDLANDS,WA 6009,AUSTRALIA.							BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; CADEPOND F, 1993, P NATL ACAD SCI USA, V90, P10434, DOI 10.1073/pnas.90.22.10434; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; NING YM, 1993, J BIOL CHEM, V268, P6073; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, STEROID HORMONE ACTI, P64; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; TAI PKK, 1994, BIOCHEMISTRY-US, V33, P10666, DOI 10.1021/bi00201a014	34	162	168	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2961	2965		10.1074/jbc.271.6.2961	http://dx.doi.org/10.1074/jbc.271.6.2961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621687	hybrid			2022-12-25	WOS:A1996TU69100016
J	Tang, CL; Capaldi, RA				Tang, CL; Capaldi, RA			Characterization of the interface between gamma and epsilon subunits of Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; CATALYTIC SITES; CRYOELECTRON MICROSCOPY; SECONDARY-STRUCTURE; CROSS-LINKING; F1 ATPASE; F1-ATPASE; MECHANISM; PROTEINS; BINDING	The interaction faces of the gamma and epsilon subunits in the Escherichia coli F-1-ATPase have been explored by a combination of cross-linking and chemical modification experiments using several mutant epsilon subunits as follows: epsilon S10C, epsilon H38C, epsilon T43C, epsilon S65C, epsilon S108C, and epsilon M138C, along with a mutant of the gamma subunit, gamma T106C. The replacement of Ser-10 by a Cys or Met-138 by a Cys reduced the inhibition of ECF(1) by the epsilon subunit, while the mutation S65C increased this inhibitory effect. Modification of the Cys at position 10 with N-ethylmaleimide or fluoroscein maleimide further reduced the binding affinity of, and the maximal inhibition by, the epsilon subunit. Similar chemical modification of the Cys at position 43 of the epsilon subunit (in the mutant epsilon T43C) and a Cys at position 106 of the gamma subunit (gamma T106C) also affected the inhibition of ECF(1) by the epsilon subunit. The various epsilon subunit mutants were reacted with TFPAM3, and the site(s) of cross-linking within the ECF(1) complex was determined. Previous studies have shown cross-linking from the Cys at positions 10 and 38 with the gamma subunit and from a Cys at position 108 to an alpha subunit (Aggeler, R., Chicas-Cruz, K., Cai, S. X., Keana, J. F. W., and Capaldi, R. A. (1992) Biochemistry 31, 2956-2961; Aggeler, R., Weinreich, F., and Capaldi, R. A. (1995) Biochim. Biophys. Acta 1230, 62-68). Here, cross-linking was found from a Cys at position 43 to the gamma subunit and from the Cys at position 138 to a beta subunit. The site of cross-linking from Cys-10 of epsilon to the gamma subunit was localized by peptide mapping to a region of the gamma subunit between residues 222 and 242. Cross-linking from a Cys at position 38 and at position 43 was with the C-terminal part of the gamma subunit, between residues 202 and 286. ECF(1) treated with trypsin at pH 7.0 still binds purified epsilon subunit, while enzyme treated with the protease at pH 8.0 does not. This identifies sites around residue 70 and/or between 202 and 212 of the gamma subunit as involved in epsilon subunit binding.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; KUKI M, 1988, J BIOL CHEM, V263, P17437; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P272, DOI 10.1006/abbi.1993.1210; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; SUSS KH, 1986, FEBS LETT, V201, P63, DOI 10.1016/0014-5793(86)80571-3; TANG CL, 1994, J BIOL CHEM, V269, P4467; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	36	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3018	3024		10.1074/jbc.271.6.3018	http://dx.doi.org/10.1074/jbc.271.6.3018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621695	hybrid			2022-12-25	WOS:A1996TU69100024
J	Wenstrup, RJ; Fowlkes, JL; Witte, DP; Florer, JB				Wenstrup, RJ; Fowlkes, JL; Witte, DP; Florer, JB			Discordant expression of osteoblast markers in MC3T3-E1 cells that synthesize a high turnover matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; BONE SIALOPROTEIN; OSTEOCALCIN GENE; I PROCOLLAGEN; DELETED GENE; COLLAGEN; PHENOTYPE; DIFFERENTIATION; MOUSE; LINE	To examine the autocrine effects that an organizing extracellular matrix has on osteoblast precursors, we created MC3T3-E1 cell lines that stably expressed pro-alpha 1(I) collagen chains with a truncated triple helical domain. Cells that had incorporated the pro-alpha 1(I) expression plasmid (pMG155) expressed shortened pro-alpha 1(I) transcripts at high levels and efficiently secreted the expression gene products into culture media. Those cells lost over 30% of newly deposited collagenous matrix compared with virtually no loss in control cultures, and media from the abnormal cells had qualitative differences in matrix metalloprotinase production. Electron micrographs strongly suggested that type I collagen molecules containing the truncated pro-alpha 1(I) chains dramatically interfered with collagen fibrillogenesis in newly forming osteoblast matrix. Abnormal collagen fibrillogenesis was also associated with altered characteristics of cellular differentiation in that abnormal cells displayed a delayed and attenuated increase in alkaline phosphatase activity. Surprisingly, synthesis of osteocalcin was more than 5-fold higher than control cultures. These findings demonstrate that osteoblasts require a normally structured collagenous matrix for up-regulation of alkaline phosphatase activity. However, in the presence of rapid turnover of osteoblast matrix, osteocalcin gene expression may be up-regulated in response to local signals by an unknown mechanism.	CINCINNATI CHILDRENS HOSP, DIV PATHOL, CINCINNATI, OH 45229 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA	Cincinnati Children's Hospital Medical Center; Duke University	Wenstrup, RJ (corresponding author), CINCINNATI CHILDRENS HOSP, DIV HUMAN GENET, TCHRF ROOM 1033, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002276] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40586] Funding Source: Medline; NIDDK NIH HHS [DK02276] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BARON R, 1983, PEDIATR RES, V17, P204, DOI 10.1203/00006450-198303000-00007; BERG RA, 1982, METHOD ENZYMOL, V82, P372; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BONADIO J, 1985, J BIOL CHEM, V260, P1734; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESBOIS C, 1995, J BONE MINER RES, V10, pS139; DOTY SB, 1971, CLIN ORTHOP RELAT R, P191, DOI 10.1097/00003086-197110000-00027; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FUJISAWA R, 1992, CALCIFIED TISSUE INT, V51, P438; GERSTENFELD LC, 1988, J CELL BIOL, V106, P979, DOI 10.1083/jcb.106.3.979; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GLOWACKI J, 1989, CONNECT TISSUE RES, V20, P121, DOI 10.3109/03008208909023880; GLOWACKI J, 1987, CELL DIFFER DEV, V21, P247, DOI 10.1016/0045-6039(87)90479-9; GRONOWICZ G, 1989, J BONE MINER RES, V4, P313; HELMINEN HJ, 1993, J CLIN INVEST, V92, P582, DOI 10.1172/JCI116625; IKEDA K, 1993, J CELL PHYSIOL, V156, P130, DOI 10.1002/jcp.1041560118; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; OWEN TA, 1993, P NATL ACAD SCI USA, V90, P1503, DOI 10.1073/pnas.90.4.1503; PEREIRA R, 1993, J CLIN INVEST, V91, P709, DOI 10.1172/JCI116252; QUARLES LD, 1992, J BONE MINER RES, V7, P683; QUARLES LD, 1991, ENDOCRINOLOGY, V128, P3144, DOI 10.1210/endo-128-6-3144; ROBEY PG, 1993, J BONE MINER RES, V8, pS483; STEMARIE LG, 1984, J CLIN PATHOL, V37, P1081, DOI 10.1136/jcp.37.10.1081; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKEUCHI Y, 1994, J BONE MINER RES, V9, pS126; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TERMINE JD, 1984, P NATL ACAD SCI-BIOL, V81, P2213, DOI 10.1073/pnas.81.7.2213; UITTO J, 1975, COLLAGEN METABOLISM, P139; VETTER U, 1991, J BONE MINER RES, V6, P501; WU LNY, 1989, J BIOL CHEM, V264, P21346	41	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10271	10276		10.1074/jbc.271.17.10271	http://dx.doi.org/10.1074/jbc.271.17.10271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626594				2022-12-25	WOS:A1996UG25700066
J	Carty, MP; Lawrence, CW; Dixon, K				Carty, MP; Lawrence, CW; Dixon, K			Complete replication of plasmid DNA containing a single UV-induced lesion in human cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; THYMINE CYCLOBUTANE DIMER; ESCHERICHIA-COLI; CIS-SYN; PYRIMIDINE DIMERS; MAMMALIAN-CELLS; DHFR GENE; CHO CELLS; INVITRO; REPAIR	To investigate the effect of the major UV-induced lesions on SV40 origin-dependent DNA replication and mutagenesis in a mammalian cell extract, double-stranded plasmids containing a single cis,syn-cyclobutane dimer or a pyrimidine-pyrimidone (6-4) photoproduct at a unique TT sequence have been constructed. These plasmids have been used as templates in DNA replication-competent extracts from human Beta cells, Plasmids containing a single pyrimidine cyclobutane dimer on the potential lagging strand for DNA replication are replicated with an efficiency approximately equal to that of an unmodified plasmid. A small decrease in replication efficiency of similar to 20% was observed when the lesion was located on the potential leading strand for DNA replication, In both orientations, DpnI-resistant, replicated closed circular plasmid DNA was sensitive to nicking by the pyrimidine dimer-specific enzyme, T4 endonuclease V, indicating that complete replication of the damaged plasmid occurs in vitro. In contrast, a (6-4) photoproduct, within the same site and sequence context on the lagging strand for DNA synthesis, inhibits replication in vitro by an average of similar to 50%, indicating that the mammalian replication complex responds differently to the two major UV-induced lesions during DNA replication in vitro, Analysis of the DpnI-resistant, replicated DNA for mutations targeted to the lesion site indicates that neither of these lesions resulted in significant mutagenesis. UV-induced lesions at TT sites may therefore be poorly mutagenic under these conditions for DNA replication in human cell extracts in vitro.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester	Carty, MP (corresponding author), UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,3223 EDEN AVE,CINCINNATI,OH 45267, USA.			Carty, Michael P/0000-0002-0342-9297	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021858] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES06096, ES05400] Funding Source: Medline; NIGMS NIH HHS [GM21858] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CARTY MP, 1995, ENVIRON MOL MUTAGEN, V29, P139; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DENEKAMP J, 1986, INT J RADIAT BIOL, V49, P357, DOI 10.1080/09553008514552591; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; KRESS S, 1992, CANCER RES, V52, P6400; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LEE SH, 1989, P NATL ACAD SCI USA, V86, P3643; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MENEGHINI R, 1975, BIOCHIM BIOPHYS ACTA, V425, P428; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; ROBERTS DC, 1994, P NATL ACAD SCI USA, V91, P7752; SAGE E, 1993, J PHOTOCH PHOTOBIO B, V20, P211, DOI 10.1016/1011-1344(93)80153-Z; Sambrook S, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SPIVAK G, 1992, BIOCHEMISTRY-US, V31, P6794, DOI 10.1021/bi00144a021; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WHITE JH, 1984, MOL CELL BIOL, V4, P1286, DOI 10.1128/MCB.4.7.1286; 1992, IARC MONOGR EVAL CAR, V55, P43	53	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9637	9647		10.1074/jbc.271.16.9637	http://dx.doi.org/10.1074/jbc.271.16.9637			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621639	hybrid			2022-12-25	WOS:A1996UG04400070
J	Duncalfe, LL; Carpenter, MR; Smillie, LB; Martin, IL; Dunn, SMJ				Duncalfe, LL; Carpenter, MR; Smillie, LB; Martin, IL; Dunn, SMJ			The major site of photoaffinity labeling of the gamma-aminobutyric acid type a receptor by [H-3]flunitrazepam is histidine 102 of the alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE RECEPTOR; GABAA RECEPTOR; BRAIN; PROTEINS; SEQUENCE; BINDING; COMPLEX; RESIDUE; FAMILY	The alpha subunit of the gamma-aminobutyric acid type A (GABA(A)) receptor is known to be photoaffinity labeled by the classical benzodiazepine agonist, [H-3]flunitrazepam, To identify the specific site for [H-3]flunitrazepam photoincorporation in the receptor subunit, we have subjected photoaffinity labeled GABA(A) receptors from bovine cerebral cortex to specific cleavage with cyanogen bromide and purified the resulting photolabeled peptides by immunoprecipitation with an anti-flunitrazepam polyclonal serum, A major photolabeled peptide component from reversed-phase high performance liquid chromatography of the immunopurified peptides was resolved by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate, The radioactivity profile indicated that the [H-3]flunitrazepam photoaffinity label is covalently associated with a 5,4-kDa peptide. This peptide is glycosylated because treatment with the enzyme, peptide-N-4-(N-acetyl-beta-glucosaminyl)asparagine amidase, reduced the molecular mass of the peptide to 3.2 kDa, Direct sequencing of the photolabeled peptide by automated Edman degradation showed that the radioactivity is released in the twelfth cycle, Based on the molecular mass of the peptides that can be generated by cyanogen bromide cleavage of the GABA(A) receptor alpha subunit and the potential sites for asparagine-linked glycosylation, the pattern of release of radioactivity during Edman degradation of the photolabeled peptide was mapped to the known amino acid sequence of the receptor subunit, The major site of photoincorporation by [H-3]flunitrazepam on the GABA(A) receptor is shown to be alpha subunit residue His(102) (numbering based on bovine alpha(1) sequence).	UNIV ALBERTA,DEPT PHARMACOL,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP PROT STRUCT & FUNCT,EDMONTON,AB T6G 2H7,CANADA	University of Alberta; University of Alberta			Jennings, Lori/R-7152-2019					BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; CZAJKOWSKI C, 1986, J NEUROSCI, V6, P2857; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; DUNCALFE LL, 1996, IN PRESS EUR J PHARM; DUNN SMJ, 1994, INT REV NEUROBIOL, V36, P51, DOI 10.1016/S0074-7742(08)60303-7; DUNN SMJ, 1989, BIOCHEMISTRY-US, V28, P2545, DOI 10.1021/bi00432a030; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FUCHS K, 1988, NEUROSCI LETT, V90, P314, DOI 10.1016/0304-3940(88)90208-X; Gros E., 1967, METHOD ENZYMOL, V11, P238; LAMBOLEZ B, 1989, NEUROCHEM INT, V15, P145, DOI 10.1016/0197-0186(89)90093-4; LAMBOLEZ B, 1987, FEBS LETT, V219, P301, DOI 10.1016/0014-5793(87)80240-5; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MIHIC SJ, 1994, J BIOL CHEM, V269, P32768; MOHLER H, 1980, P NATL ACAD SCI-BIOL, V77, P1666, DOI 10.1073/pnas.77.3.1666; OLSEN RW, 1991, NEUROCHEM RES, V16, P317, DOI 10.1007/BF00966095; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZ E, 1989, FEBS LETT, V244, P433, DOI 10.1016/0014-5793(89)80578-2; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1989, BIOCHEM J, V264, P199, DOI 10.1042/bj2640199; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	24	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9209	9214		10.1074/jbc.271.16.9209	http://dx.doi.org/10.1074/jbc.271.16.9209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621579	hybrid			2022-12-25	WOS:A1996UG04400010
J	Loe, DW; Almquist, KC; Cole, SPC; Deeley, RG				Loe, DW; Almquist, KC; Cole, SPC; Deeley, RG			ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP) - Inhibition by cholestatic steroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINE; DUBIN-JOHNSON SYNDROME; MUTANT TR RATS; P-GLYCOPROTEIN; CONJUGATED HYPERBILIRUBINEMIA; HEREDITARY HYPERBILIRUBINEMIA; CANALICULAR TRANSPORT; MEMBRANE-VESICLES; GLUTATHIONE; LIVER	In addition to its ability to confer resistance to a range of natural product type chemotherapeutic agents, multidrug resistance protein (MRP) has been shown to transport the cysteinyl leukotriene, LTC(4), and several other glutathione (GSH) S-conjugates. We now demonstrate that its range of potential physiological substrates also includes cholestatic glucuronidated steroids, ATP dependent, osmotically sensitive transport of the naturally occurring conjugated estrogen, 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G), was readily demonstrable in plasma membrane vesicles from populations of MRP-transfected HeLa cells (V-max 1.4 nmol mg(-1) min(-1), K-m 2.5 mu M). The involvement of MRP was confirmed by demonstrating that transport was completely inhibited by a monoclonal antibody specific for an intracellular conformational epitope of the protein. MRP-mediated transport of LTC, was competitively inhibited by E(2)17 beta G (K-i(app) 22 mu M), despite the lack of structural similarity between these two substrates. Competitive inhibition of [H-3]E(2)17 beta G transport was also observed with a number of other cholestatic conjugated steroids, AU of these compounds prevented photolabeling of MRP with [H-3]LTC(4), demonstrating that the cholestatic steroid and leukotriene conjugates compete either for the same or possibly overlapping sites on the protein, Consistent with the presence of overlapping but non-identical sites, studies using chemotherapeutic drugs to inhibit MRP mediated E(2)17 beta G transport indicated that daunorubicin had the highest relative potency of the drugs tested, whereas it was the least potent inhibitor of LTC, transport, Non-cholestatic steroids glucuronidated at the 3 position of the steroid nucleus, such as 17 beta-estradiol 3-(beta-D-glucuronide), did not compete for transport of E(2)17 beta G by MRP, nor did they inhibit photolabeling of the protein with [H-3]LTC(4). These data identify MRP as a potential transporter of cholestatic conjugated estrogens and demonstrate site-specific requirements for glucuronidation of the steroid nucleus.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada			Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; 				ALMQUIST KC, 1995, CANCER RES, V55, P102; BARRAND MA, 1994, J NATL CANCER I, V86, P110, DOI 10.1093/jnci/86.2.110; BOARD P, 1992, HEPATOLOGY, V15, P722, DOI 10.1002/hep.1840150428; BROCK I, 1995, CANCER RES, V55, P459; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; COLE SPC, 1996, IN PRESS DRUG RESIST; DALTON WS, 1986, CANCER RES, V46, P5125; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; EBNER T, 1993, MOL PHARMACOL, V43, P649; EIJDEMS EWHM, 1995, INT J CANCER, V60, P676, DOI 10.1002/ijc.2910600518; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; ELFERINK RPJO, 1994, PHARMACOL THERAPEUT, V64, P77, DOI 10.1016/0163-7258(94)90034-5; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; GOSLAND M, 1993, CANCER RES, V53, P5382; GRANT CE, 1994, CANCER RES, V54, P357; HANDE K, 1988, CANCER RES, V48, P1829; HASEGAWA S, 1995, BRIT J CANCER, V71, P907, DOI 10.1038/bjc.1995.177; HIPFNER DR, 1994, CANCER RES, V54, P5788; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KITAMURA T, 1992, HEPATOLOGY, V15, P1154, DOI 10.1002/hep.1840150629; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; KRUH GD, 1995, J NATL CANCER I, V87, P1256, DOI 10.1093/jnci/87.16.1256; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LUCIER GW, 1977, J STEROID BIOCHEM, V8, P867, DOI 10.1016/0022-4731(77)90096-6; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; MIRSKI SEL, 1987, CANCER RES, V47, P2594; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; SATHIRAKUL K, 1994, J PHARMACOL EXP THER, V268, P65; SCHNEIDER E, 1995, BLOOD, V85, P186, DOI 10.1182/blood.V85.1.186.bloodjournal851186; SLAPAK CA, 1994, BLOOD, V84, P3113, DOI 10.1182/blood.V84.9.3113.bloodjournal8493113; SLAPAK CA, 1994, CANCER RES, V54, P5607; SLOVAK ML, 1993, CANCER RES, V53, P3221; STEEN H, 1992, BIOCHEM PHARMACOL, V44, P2323, DOI 10.1016/0006-2952(92)90676-A; STRIDE BD, 1996, IN PRESS MOL PHARM; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TEW KD, 1994, CANCER RES, V54, P4313; VORE M, 1985, TRENDS PHARMACOL SCI, V6, P256, DOI 10.1016/0165-6147(85)90118-X; VORE M, 1993, TOXICOL APPL PHARM, V118, P2, DOI 10.1006/taap.1993.1002; VORE M, 1987, GASTROENTEROLOGY, V93, P643, DOI 10.1016/0016-5085(87)90928-0; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1993, CANCER RES, V53, P1747	55	280	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9683	9689		10.1074/jbc.271.16.9683	http://dx.doi.org/10.1074/jbc.271.16.9683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621644				2022-12-25	WOS:A1996UG04400075
J	ODea, MH; Tamura, JK; Gellert, M				ODea, MH; Tamura, JK; Gellert, M			Mutations in the B subunit of Escherichia coli DNA gyrase that affect ATP-dependent reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; NUCLEOTIDE BINDING; TOPOISOMERASE-II; NALIDIXIC-ACID; BASE-PAIRS; PROTEIN; MECHANISM; ENERGY; ENZYME; SITE	We have previously reported specific labeling of Escherichia coli DNA gyrase by the ATP affinity analog pyridoxal 5'-diphospho-5'adenosine (PLP-AMP), which resulted in inhibition of ATP-dependent reactions,The analog was found to be covalently bound at Lys(103) and Lys(110) on the gyrase B subunit (Tamura, J, K,, and Gellert, M, (1990) J, Biol, Chem, 265, 21342-21349), In this study, the importance of these two lysine residues is examined by site-directed mutagenesis. Substitutions of Lys(103) result in the loss of ATP-dependent functions, These mutants are unable to supercoil DNA, to hydrolyze ATP, or to bind a nonhydrolysable ATP analog, 5'-adenylyl-beta, gamma-imidodiphosphate (ADPNP), The ATP-independent functions of gyrase, such as relaxation of negatively supercoiled DNA and oxolinic acid induced cleavage of double-stranded DNA, are unaffected by these mutations, suggesting that the mutant B subunits are assembling correctly with the A subunits, Gyrase with substitutions of Lys(110) retains all activities, However, the affinity of ATP is decreased, The DNA supercoiling activity of gyrase A(2)B(2) tetramers reconstituted with varying ratios of inactive mutant and wild-type gyrase B subunits is consistent with a mechanism of DNA supercoiling that requires the interdependent activity of both B subunits in ATP binding and hydrolysis.	NIDDK, MOLEC BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; BATES AD, 1989, EMBO J, V8, P1861, DOI 10.1002/j.1460-2075.1989.tb03582.x; Bates AD, 1996, BIOCHEMISTRY-US, V35, P1408, DOI 10.1021/bi952433y; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; Huang W M, 1994, Adv Pharmacol, V29A, P201; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; MAXWELL A, 1993, INT S DNA TOP CHEM N, P21; MAXWELL A, 1986, 4TH P CONV BIOM STER, V3, P137; Menzel R, 1994, Adv Pharmacol, V29A, P39; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MORRISON A, 1980, J BIOL CHEM, V255, P2211; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	35	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9723	9729		10.1074/jbc.271.16.9723	http://dx.doi.org/10.1074/jbc.271.16.9723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621650	hybrid			2022-12-25	WOS:A1996UG04400081
J	Sun, HQ; Kwiatkowska, K; Yin, HL				Sun, HQ; Kwiatkowska, K; Yin, HL			beta-thymosins are not simple actin monomer buffering proteins - Insights from overexpression studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPOLYMERIZING FACTOR; F-ACTIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CELL LOCOMOTION; EXPRESSION; PROFILIN; GELSOLIN; MUSCLE; POLYMERIZATION; PURIFICATION	beta-Thymosins are the currently favored candidates for maintaining the large actin monomer (G-actin) pool in living cells, To determine if beta-thymosin behaves like a simple G-actin buffering agent in the complex environment of a cell, we overexpressed thymosin beta 10 (T beta 10) in NIH3T3 cells and determined the effect on the monomer/polymer equilibrium, T beta 10 is the predominant beta-thymosin isoform in the NIH3T3 cell line, and it is present in approximately equal molar ratio to profilin and cofilin/actin depolymerizing factor, two other well characterized actin monomer binding proteins, Clonal cell. lines that overexpressed three times more T beta 10 had 23-33% more polymerized actin than control cells, and the filaments appeared thicker after staining with fluorescent phalloidin. There was no change in total actin, profilin, and cofilin/actin depolymerizing factor content, The overexpressing cells were more motile; they spread faster and had higher chemotactic and wound healing activity, Assuming that there is no compensatory inactivation pf the. other classes of monomer binding proteins, our paradoxical observation can be accounted for quantitatively by a parallel in vitro study (Carlier, M.-F., Didry, D., Erk, I., Lepault, J., Van Troys, L., Vanderkekove, J., Perelroizen, I., Yin, H. L., Doi, Y., and Pantaloni, D., (1996) J. Biol. Chem. 271, 9231-9239), beta-Thymosin at levels comparable with that found in the overexpressing cells binds actin filaments and decreases the critical concentration (C-c) for actin polymerization, This reduces the monomer buffering ability of beta-thymosin, so that above a certain threshold an incremental increase in thymosin does not lead to a corresponding increase in G-actin. Furthermore, the decrease in C-c reduces the buffering capacity of the other actin monomer binding proteins, As a consequence, an increase in beta-thymosin does not necessarily result in a proportionate increase in actin monomer content in a complex environment containing other actin monomer binding proteins, The outcome depends on the level of beta-thymosin expression relative to the composition of the other actin monomer binding protein, Our results suggest that beta-thymosins are not simple actin buffering proteins and that their biphasic action may have physiological significance.	UNIV TEXAS, SW MED CTR DALLAS, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Kwiatkowska, Katarzyna/0000-0002-0550-8394	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031430] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51112] Funding Source: Medline; NINDS NIH HHS [NS31430] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; BABCOCK G, 1993, CELL MOTIL CYTOSKEL, V24, P179, DOI 10.1002/cm.970240305; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLLA R, 1994, MOL BIOL CELL, V4, P383; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LI X, 1996, IN PRESS GENOMICS; LIN SC, 1991, J BIOL CHEM, V266, P23347; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; YIN HL, 1980, J BIOL CHEM, V255, P9490; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1993, J BIOL CHEM, V268, P502; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	47	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9223	9230		10.1074/jbc.271.16.9223	http://dx.doi.org/10.1074/jbc.271.16.9223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621581	hybrid			2022-12-25	WOS:A1996UG04400012
J	Arts, EJ; Ghosh, M; Jacques, PS; Ehresmann, B; LeGrice, SFJ				Arts, EJ; Ghosh, M; Jacques, PS; Ehresmann, B; LeGrice, SFJ			Restoration of tRNA(3)(Lys)-primed (-)-strand DNA synthesis to an HIV-1 reverse transcriptase mutant with extended tRNAs - Implications for retroviral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANGSTROM RESOLUTION; TRANSFER RNA(LYS-3); CRYSTAL-STRUCTURE; INITIATION; PRIMER; RNA; SEQUENCE; LOOP	The mechanism for the initiation of reverse transcription in human immunodeficiency virus type 1 (HIV-1) was studied utilizing a unique reverse transcriptase (RT) mutant altered in its noncatalytic p51 subunit. This mutant (p66/p51 Delta 13) retains full DNA- and RNA-dependent DNA polymerase activity but has reduced affinity for tRNA(3)(Lys), the cognate HIV primer. When the ability to support (-)-strand DNA synthesis on a viral RNA template was evaluated, this mutant initiated from an 18-nucleotide (nt) oligoribo- or oligodeoxyribonucleotide primer complementary to the primer binding site (pbs), However, it failed to do so from natural and synthetic versions of tRNA(3)(Lys). tRNA-primed (-)-strand synthesis could, however, be rescued by substituting the 76-nt tRNA(3)(Lys) with 81- and 107-nt tRNA-DNA chimeras, ie. tRNA(3)(Lys) extended by 5 and 31 deoxyribonucleotides complementary to the viral genome upstream of the pbs, These findings imply that through interactions involving its p51 subunit, RT may be required to disrupt additional tRNA-viral RNA duplexes outside the pbs to proceed into productive (-)-strand DNA synthesis. Alternatively, specific interactions between tRNA(3)(Lys) and HIV-1 RT may be necessary for efficient initiation of (-)-strand DNA synthesis.	CASE WESTERN RESERVE UNIV,SCH MED,CTR AIDS RES,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; CNRS,INST BIOL MOLEC & CELLULAIRE,F-67084 STRASBOURG,FRANCE	Case Western Reserve University; Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Arts, Eric/0000-0002-4880-7968	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147, T32AI007381] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07381, AI31147] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; Arts EJ, 1996, J VIROL, V70, P712, DOI 10.1128/JVI.70.2.712-720.1996; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACQUES PS, 1994, J BIOL CHEM, V269, P26472; JACQUES PS, 1994, J BIOL CHEM, V269, P1388; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; Maxam A M, 1980, Methods Enzymol, V65, P499; MISHIMA V, 1995, EMBO J, V14, P2679; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; VERMA IM, 1971, NATURE-NEW BIOL, V233, P131, DOI 10.1038/newbio233131a0; WILHELM M, 1994, NUCLEIC ACIDS RES, V22, P4530; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; WOHRL BM, 1994, J BIOL CHEM, V269, P8541	26	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9054	9061		10.1074/jbc.271.15.9054	http://dx.doi.org/10.1074/jbc.271.15.9054			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621554	hybrid			2022-12-25	WOS:A1996UE73000085
J	Camadro, JM; Labbe, P				Camadro, JM; Labbe, P			Cloning and characterization of the yeast HEM14 gene coding for protoporphyrinogen oxidase, the molecular target of diphenyl ether-type herbicides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SHUTTLE VECTORS; BRADYRHIZOBIUM-JAPONICUM; ACIFLUORFEN-METHYL; ENZYMIC CONVERSION; LATE STEP; DNA; PURIFICATION; PROTEINS	Protoporphyrinogen oxidase, which catalyzes the oxygen dependent aromatization of protoporphyrinogen IX to protoporphyrin IX, is the molecular target of diphenyl ether type herbicides. The structural gene for the yeast protoporphyrinogen oxidase, HEM14, was isolated by functional complementation of a hem14-1 protoporphyrinogen oxidase-deficient yeast mutant, using a novel one-step colored screening procedure to identify heme-synthesizing cells. The hem14-1 mutation was genetically linked to URA3, a marker on chromosome V, and HEM14 was physically mapped on the right arm of this chromosome, between PRP22 and FAA2. Disruption of the HEM14 gene leads to protoporphyrinogen oxidase deficiency in vivo (heme deficiency and accumulation of heme precursors), and in vitro (lack of immunodetectable protein or enzyme activity). The HEM14 gene encodes a 539-amino acid protein (59,665 De; pi 9.3) containing an ADP-beta alpha beta-binding fold similar to those of several other flavoproteins. Yeast protoporphyrinogen oxidase was somewhat similar to the HemY gene product of Bacillus subtilis and to the human and mouse protoporphyrinogen oxidases. Studies on protoporphyrinogen oxidase overexpressed in yeast and purified as wild-type enzyme showed that (i) the NH2-terminal mitochondrial targeting sequence of protoporphyrinogen oxidase is not cleaved during importation; (ii) the enzyme, as purified, had a typical flavin semiquinone absorption spectrum; and (iii) the enzyme was strongly inhibited by diphenyl ether-type herbicides and readily photolabeled by a diazoketone derivative of tritiated acifluorfen. The mutant allele hem14-1 contains two mutations, L422P and K424E, responsible for the inactive enzyme. Both mutations introduced independently in the wild-type HEM14 gene completely inactivated the protein when analyzed in an Escherichia coli expression system.			Camadro, JM (corresponding author), INST JACQUES MONOD, DEPT MICROBIOL, LAB BIOCHIM PORPHYRINES, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.			Camadro, Jean-Michel/0000-0002-8549-2707				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BERGEN G, 1991, YEAST, V7, P475; CAMADRO JM, 1982, BIOCHEM BIOPH RES CO, V106, P724, DOI 10.1016/0006-291X(82)91771-5; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAMADRO JM, 1994, J BIOL CHEM, V269, P32085; CAMADRO JM, 1995, EUR J BIOCHEM, V229, P669, DOI 10.1111/j.1432-1033.1995.tb20512.x; CAMADRO JM, 1993, TARGET ASSAYS MODERN, P29; CHANG YH, 1990, J BIOL CHEM, V265, P19892; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DAILEY TA, 1994, J BIOL CHEM, V269, P813; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; FALK JE, 1964, PORPHYRINS METALLOPO, V2, P162; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; HAID A, 1983, METHOD ENZYMOL, V96, P192; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HANSSON M, 1994, J BACTERIOL, V176, P5962, DOI 10.1128/jb.176.19.5962-5970.1994; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS NJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P540, DOI 10.1016/0304-4165(78)90328-8; JACOBS NJ, 1976, BIOCHIM BIOPHYS ACTA, V449, P1, DOI 10.1016/0005-2728(76)90002-5; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; JORDAN OPM, 1991, BIOSYNTHESIS TETRAPY, V19, P257; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Labbe P, 1969, Bull Soc Chim Biol (Paris), V51, P1642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HJ, 1994, J AGR FOOD CHEM, V42, P2610, DOI 10.1021/jf00047a044; LEE HJ, 1993, PLANT PHYSIOL, V102, P881, DOI 10.1104/pp.102.3.881; LESUISSE E, 1995, ANAL BIOCHEM, V226, P375, DOI 10.1006/abio.1995.1239; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MATRINGE M, 1988, PLANT PHYSIOL, V86, P619, DOI 10.1104/pp.86.2.619; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NAKAYASHIKI T, 1995, GENE, V153, P67, DOI 10.1016/0378-1119(94)00805-3; NISHIMURA K, 1995, J BIOL CHEM, V270, P8076, DOI 10.1074/jbc.270.14.8076; OBRIAN MR, 1987, J BACTERIOL, V169, P1089, DOI 10.1128/jb.169.3.1089-1094.1987; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POULSON R, 1976, J BIOL CHEM, V251, P3730; POULSON R, 1975, J BIOL CHEM, V250, P1269; POWELL JF, 1989, BIOCHEM J, V259, P407, DOI 10.1042/bj2590407; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; RAMSEIER TM, 1989, ARCH MICROBIOL, V151, P203, DOI 10.1007/BF00413131; SASARMAN A, 1993, CAN J MICROBIOL, V39, P1155, DOI 10.1139/m93-174; SASARMAN A, 1979, J GEN MICROBIOL, V113, P297, DOI 10.1099/00221287-113-2-297; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; SIKORSKI RS, 1989, GENETICS, V122, P19; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKETANI S, 1995, EUR J BIOCHEM, V230, P760, DOI 10.1111/j.1432-1033.1995.0760h.x; TANAKA S, 1992, NUCLEIC ACIDS RES, V20, P3011, DOI 10.1093/nar/20.12.3011; URBANGRIMAL D, 1981, MOL GEN GENET, V183, P85, DOI 10.1007/BF00270144; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WITKOWSKI DA, 1989, PLANT PHYSIOL, V90, P1239, DOI 10.1104/pp.90.4.1239; YAMATO S, 1994, PESTIC BIOCHEM PHYS, V50, P72, DOI 10.1006/pest.1994.1059; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	60	40	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9120	9128		10.1074/jbc.271.15.9120	http://dx.doi.org/10.1074/jbc.271.15.9120			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621563	hybrid			2022-12-25	WOS:A1996UE73000094
J	Cheng, M; Boulton, TG; Cobb, MH				Cheng, M; Boulton, TG; Cobb, MH			ERK3 is a constitutively nuclear protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CONSERVED FEATURES; INSULIN; IDENTIFICATION; PURIFICATION; FAMILY; ANTIBODIES; TYROSINE; PATHWAY	The ERK3 cDNA predicts a protein of 62,000 in size with a C-terminal domain that extends 180 amino acids beyond the conserved core of ERK family protein kinases, Immunoblotting with antibodies raised to recombinant protein and to peptides from the catalytic core and three regions of the C-terminal tail revealed that ERK3 is the expected size and is ubiquitously expressed in a variety of cell lines and tissues, ERK3, unlike the MAP kinases ERK1 and ERK2, is localized in the nucleus in exponentially growing, quiescent, and growth factor-stimulated cells, If the 180 amino acids at its C terminus are deleted, the resulting ERK3 fragment of 45 kDa is still found primarily in the nucleus, indicating that the C terminus is not required for its localization. Recombinant ERK3 expressed in mammalian cells or in bacteria is a protein kinase, as deduced from its capacity to autophosphorylate. Mutation of a conserved residue (Asp(171)) expected to be involved in catalysis eliminated autophosphorylation, Ser(189) of ERK3, which corresponds to Thr(183), of the activating phosphorylation sites of ERK2, is autophosphorylated in vitro and phosphorylated in vivo, Despite marked similarities to ERK1 and ERK2, ERK3 does not phosphorylate typical MAP kinase substrates, indicating that it has distinct functions.			Cheng, M (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	35	80	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8951	8958		10.1074/jbc.271.15.8951	http://dx.doi.org/10.1074/jbc.271.15.8951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621539	hybrid			2022-12-25	WOS:A1996UE73000070
J	Miyata, S; Goto, S; Federici, AB; Ware, J; Ruggeri, ZM				Miyata, S; Goto, S; Federici, AB; Ware, J; Ruggeri, ZM			Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; IIB-IIIA; RNA-POLYMERASE; DISEASE; RISTOCETIN; PROTEIN; IDENTIFICATION; BOTROCETIN; COMPLEX; IX	The interaction between von Willebrand factor (vWF) Al domain and platelet glycoprotein Ib alpha occurs in the presence of high shear stress or when vWF becomes immobilized onto a surface but not appreciably in the normal circulation, To investigate the structural properties regulating Al domain function, we have used recombinant fragments prepared either in cyclic form with oxidized Cys(509)-Cys(695) disulfide bond or reduced and alkylated. Interaction with glycoprotein Ib alpha was assessed by testing inhibition of monoclonal antibody LJ-Ib1 binding to platelets and inhibition of shear-induced platelet aggregation mediated by native vWF. Fragments exposed to pH between 2.5 and 3.5 adopted the molten globule conformation with loosened tertiary structure intermediate between native and completely unordered state, Maximal receptor binding activity was observed when fragments kept at acidic pH, particularly after reduction of the Cys(509)-Cys(695) disulfide bond, were subjected to quick refolding by rapid pH increase, In contrast, slow refolding by incremental pH change over several hours resulted in at least 20-fold lower activity. A specific single point mutation (I546V) resulted in enhanced receptor binding, whereas another mutation (S561G) caused markedly reduced binding, These results provide experimental evidence that conformational transitions can modulate function of the VWF Al domain in solution.	SCRIPPS RES INST, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; Scripps Res Inst, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [R01 HL050545, R01 HL050545-06, HL-42846, HL-48728] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, R01HL050545, P01HL048728, R37HL042846] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1993, J BIOL CHEM, V268, P2821; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; CORASH L, 1990, BLOOD CELLS, V16, P97; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOLMBERG L, 1993, J CLIN INVEST, V91, P2169, DOI 10.1172/JCI116443; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KRONER PA, 1992, BLOOD, V79, P2048; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NICHOLS TC, 1986, CIRC RES, V59, P15, DOI 10.1161/01.RES.59.1.15; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PETERSON DM, 1987, BLOOD, V69, P625; PRIOR CP, 1993, BIO-TECHNOL, V11, P709, DOI 10.1038/nbt0693-709; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; READ MS, 1989, BLOOD, V74, P1031; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; VICENTE V, 1990, J BIOL CHEM, V265, P274; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946	49	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9046	9053		10.1074/jbc.271.15.9046	http://dx.doi.org/10.1074/jbc.271.15.9046			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621553	hybrid			2022-12-25	WOS:A1996UE73000084
J	Kim, DH; Iijima, H; Goto, K; Sakai, J; Ishii, H; Kim, HJ; Suzuki, H; Kondo, H; Saeki, S; Yamamoto, T				Kim, DH; Iijima, H; Goto, K; Sakai, J; Ishii, H; Kim, HJ; Suzuki, H; Kondo, H; Saeki, S; Yamamoto, T			Human apolipoprotein E receptor 2 - A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; MESSENGER-RNA; MEDIATED ENDOCYTOSIS; NERVOUS-SYSTEM; SEQUENCE; PROTEIN; DNA; SURFACE; RABBIT; CELLS	Isolation and characterization of a human cDNA demonstrated a novel lipoprotein receptor designated apolipoprotein E receptor 2 (apoER2). The new receptor consists of five functional domains resembling the low density lipoprotein (LDL) and very low density lipoprotein (VLDL) receptors. LDL receptor deficient Chinese hamster ovary cells expressing human apoER2 bound apoE rich beta-migrating VLDL with high affinity and internalized. LDL was bound with much lower affinity to these cells. The 4.5- and 8.5-kb mRNAs for the receptor were most highly expressed in human brain and placenta. In rabbit tissues, multiple species of the mRNA with 4, 4.5, 5.5, 8.5, and 11 kb were detected most intensely in brain and testis and, to a much lesser extent, in ovary, but were undetectable in other tissues. In rat adrenal pheochromocytoma PC12 cells, the receptor mRNA was induced by treatment of the cells with nerve growth factor. The receptor transcripts were detectable most intensely in the cerebellar cortex, choroid plexus, ependyma, hippocampus, olfactory bulb and, to a much lesser extent, in the cerebral cortex as revealed by in situ hybridization histochemistry. In the cerebellar cortex, the receptor transcripts were densely deposited in Purkinje cell somata.	TOHOKU UNIV,CTR GENE RES,SENDAI,MIYAGI 981,JAPAN; TOHOKU UNIV,SCH MED,DEPT ANAT,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University				Sakai, Juro/0000-0003-4043-1035				BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; Dhopeshwarkar G A, 1973, Adv Lipid Res, V11, P109; DOBBING J, 1963, J NEUROCHEM, V10, P739, DOI 10.1111/j.1471-4159.1963.tb08930.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOFMANN SL, 1987, P NATL ACAD SCI USA, V84, P6312, DOI 10.1073/pnas.84.17.6312; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; Kabara J J, 1973, Prog Brain Res, V40, P363; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; NIMPF J, 1989, J BIOL CHEM, V264, P1393; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SWANSON LW, 1988, P NATL ACAD SCI USA, V85, P9821, DOI 10.1073/pnas.85.24.9821; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	45	346	356	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8373	8380		10.1074/jbc.271.14.8373	http://dx.doi.org/10.1074/jbc.271.14.8373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626535	hybrid			2022-12-25	WOS:A1996UD60000075
J	Nomura, M; Nawata, H; Morohashi, K				Nomura, M; Nawata, H; Morohashi, K			Autoregulatory loop in the regulation of the mammalian ftz-f1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; SPLICE JUNCTION SEQUENCES; AUTO-REGULATION; PIT-1 GENE; DROSOPHILA; TRANSCRIPTION; EXPRESSION; ELEMENTS; PROMOTER; ACTIVATION	The mammalian ftz-f1 (mftz-f1) gene encoding Ad4BP/SF-1 has been demonstrated to be essential for the development of adrenal and gonadal glands. In a previous study, we identified an E box as the transcriptional element in the 5'-upstream region of the rat mftz-f1 gene. In the present study, we found a steroidogenic cell-specific transcriptional element in the first intron of the gene. Gel mobility shift and DNase I footprint analyses clearly revealed that Ad4BP itself binds to the element (Ad4 site). This finding was further supported by the positive effect of an Ad4BP expression vector on the transcription and by the significant decrease in the transcription caused by nucleotide substitutions within the Ad4 site. Similar loss was also caused by substitutions in the E box, indicating that the two elements are essential for the full transcriptional activity of the gene. DNase I hypersensitivity assays revealed that the chromatin structure around the Ad4 site and the E box was ''open up'' in the adrenal glands and Y-1 cells, whereas ''closed down'' in the liver. These observations indicated that the mftz-f1 gene is controlled by the autoregulatory loop in the steroidogenic tissues. The autoregulatory mechanism seems to be necessary to keep the mftz-f1 gene activated and thus maintain the tissues differentiated.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT MOLEC BIOL, HIGASHI KU, FUKUOKA 812, JAPAN; KYUSHU UNIV, SCH MED, DEPT INTERNAL MED 3, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University; Kyushu University								ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COHEN RS, 1992, PROG NEUROBIOL, V38, P423, DOI 10.1016/0301-0082(92)90045-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; HATANO O, 1994, DEVELOPMENT, V120, P2787; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KORB M, 1993, NUCLEIC ACIDS RES, V21, P5901, DOI 10.1093/nar/21.25.5901; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SINCLIR AH, 1993, CELL MOL BIOL TESTIS, P43; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WU C, 1989, METHOD ENZYMOL, V170, P269; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	41	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8243	8249		10.1074/jbc.271.14.8243	http://dx.doi.org/10.1074/jbc.271.14.8243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626518	hybrid			2022-12-25	WOS:A1996UD60000058
J	Baselga, J; Mendelsohn, J; Kim, YM; Pandiella, A				Baselga, J; Mendelsohn, J; Kim, YM; Pandiella, A			Autocrine regulation of membrane transforming growth factor-alpha cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MONOCLONAL-ANTIBODIES; TGF-ALPHA; EGF-RECEPTOR; TRANSGENIC MICE; CELL-SURFACE; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; A431 CELLS; PRECURSOR; INDUCTION	Transforming growth factor alpha (TGF-alpha) is biosynthesized as a membrane bound precursor protein, pro-TGF-alpha that undergoes sequential endoproteolytic cleavages to release a soluble form of the factor, In the present study, we have analyzed the biosynthesis and regulation of TGF-alpha production in human tumor-derived cell lines that endogenously express pro-TGF-alpha and the epidermal growth factor (EGF) receptor, These cells biosynthesized membrane-anchored forms of the TGF-alpha that accumulated on the cell surface, Membrane-bound pro-TGF-alpha interacted with the EGF receptor, and complexes of receptor and pro-TGF-alpha contained tyrosine-phosphorylated receptor. Activation of the EGF receptor by soluble EGF or TGF-alpha had a dual effect on TGF-alpha production: an increase in pro-TGF-alpha mRNA levels and an increase in pro-TGF-alpha cleavage, These effects were largely prevented by preincubation with an anti-EGF receptor monoclonal antibody that blocked ligand binding, Growth factor autoinduction of cleavage could be stimulated by several second messenger pathways that are activated by the EGF receptor, including protein kinase C and intracellular calcium, and by other alternative mechanisms, EGF-stimulated cleavage of pro-TGF-alpha could be partially blocked by inhibition of these second messenger pathways, These results suggest that juxtacrine stimulation takes place in human tumor cells that coexpress both the EGF receptor and membrane-anchored TGF-alpha and that TGF-alpha is able to induce its own endoproteolytic cleavage by activating the EGF receptor.	MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; UNIV SALAMANCA,CSIC,INST MICROBIOL BIOQUIM,E-37007 SALAMANCA,SPAIN	Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Baselga, J (corresponding author), MEM SLOAN KETTERING CANC CTR,RECEPTOR BIOL LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.		Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971	NCI NIH HHS [CA37641, CA 42060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042060, U19CA037641, U01CA037641, R37CA042060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BASELGA J, 1993, ONCOGENE, V8, P3257; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P702; DIMARCO E, 1989, ONCOGENE, V4, P831; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FAN Z, 1994, J BIOL CHEM, V269, P27595; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GILL GN, 1984, J BIOL CHEM, V259, P7755; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LINSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356, DOI 10.1073/pnas.82.2.356; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASUI H, 1984, CANCER RES, V44, P1002; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANDIELLA A, 1989, TRENDS PHARMACOL SCI, V10, P411; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SPORN MB, 1985, NATURE, V313, P747; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	46	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3279	3284		10.1074/jbc.271.6.3279	http://dx.doi.org/10.1074/jbc.271.6.3279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621731	hybrid			2022-12-25	WOS:A1996TU69100060
J	Pritchard, AE; Dallmann, HG; McHenry, CS				Pritchard, AE; Dallmann, HG; McHenry, CS			In vivo assembly of the tau-complex of the DNA polymerase III holoenzyme expressed from a five-gene artificial operon - Cleavage of the tau-complex to form a mixed gamma-tau-complex by the ompT protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBUNIT; PURIFICATION; IDENTIFICATION; OVEREXPRESSION; COMPONENTS	A plasmid was constructed that encodes all five subunits of the Escherichia coli tau-complex on a single artificially constructed operon under the control of an inducible promoter. The proteins tau, delta, delta', chi, and psi overproduced from this artificial operon assemble efficiently in vivo, providing an efficient source of homogeneous tau-complex. The gamma subunit is a truncated form of tau that is produced by a translational frameshift. When protein expression was induced in bacterial strains containing the outer membrane protein T (OmpT) protease, tau was proteolyzed after lysis to a gamma-like protein, gamma(P), and a peptide, C-tau, corresponding to the C terminus of tau. N-terminal sequencing of C-tau revealed a cleavage site between two lysines at positions 429 and 430 of tau. The deduced sequence of gamma(P) is, therefore, only two amino acids shorter than natural gamma. The proteolysis by OmpT was also shown directly by using purified OmpT and tau-complex in an in vitro reaction. A gamma(P)-complex and a mixed tau-gamma(P)-complex were purified from ompT(+) cells. When the tau-complex proteins were overexpressed in ompT(-) bacteria, intact tau-complex lacking gamma(P) could be purified.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WHITE CB, 1995, J BIOL CHEM, V270, P12990, DOI 10.1074/jbc.270.22.12990; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378	28	29	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10291	10298		10.1074/jbc.271.17.10291	http://dx.doi.org/10.1074/jbc.271.17.10291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626597	hybrid			2022-12-25	WOS:A1996UG25700069
J	Schwemmle, M; Kaspers, B; Irion, A; Staeheli, P; Schultz, U				Schwemmle, M; Kaspers, B; Irion, A; Staeheli, P; Schultz, U			Chicken guanylate-binding protein - Conservation of GTPase activity and induction by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON; ESTABLISHMENT; SEQUENCE; GAMMA	To gain further insights into the cytokine network of birds, we used polymerase chain reaction technology to clone a cDNA that codes for a chicken homolog of the interferon-induced guanylate-binding proteins (GBPs). In its N-terminal moiety, the 64-kDa chicken GBP contains two sequence blocks of 100 and 19 amino acids, respectively, that are about 70% identical to mammalian GBPs. The first region includes two motifs of the canonical GTP-binding consensus element. The other parts of chicken GBP are poorly conserved, except for a CAAX motif at the extreme C terminus which might signal isoprenylation. Like mammalian GBPs, recombinant chicken GBP specifically bound to agarose-immobilized guanine nucleotides and hydrolyzed GTP to both GDP and GMP. Regulation by interferons was also conserved: chicken GBP RNA was barely detectable in uninduced chicken cells. Low GBP RNA levels were found in cells treated with type I interferon, whereas very high levels were observed in cells treated with supernatant of a chicken T cell line that secretes a gamma-interferon-like activity. Together with recent phylogenetic studies of interferon genes, these results suggest that in spite of low sequence conservation, the various components of the avian interferon system are functionally well conserved.	UNIV FREIBURG,DEPT VIROL,INST MED MIKROBIOL & HYG,ABT VIROL,D-79008 FREIBURG,GERMANY; UNIV MUNICH,INST TIERPHYSIOL,MUNICH,GERMANY	University of Freiburg; University of Munich								BERNASCONI D, 1995, J INTERF CYTOK RES, V15, P47, DOI 10.1089/jir.1995.15.47; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHENG YSE, 1985, J BIOL CHEM, V260, P5834; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMAYER EM, 1988, INTERFERONS OTHER RE; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DIJKMANS R, 1990, VET IMMUNOL IMMUNOP, V26, P319, DOI 10.1016/0165-2427(90)90116-A; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JUNGWIRTH C, 1995, P NATL ACAD SCI USA, V92, P3105, DOI 10.1073/pnas.92.8.3105; KAADEN OR, 1982, IN VITRO CELL DEV B, V18, P827, DOI 10.1007/BF02796323; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; PANABIERES F, 1984, BIOCHEM BIOPH RES CO, V118, P767, DOI 10.1016/0006-291X(84)91461-X; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; SCHULTZ U, 1995, EUR J IMMUNOL, V25, P847, DOI 10.1002/eji.1830250332; SCHULTZ U, 1995, EUR J BIOCHEM, V229, P73, DOI 10.1111/j.1432-1033.1995.tb20439.x; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; SCHWEMMLE M, 1994, VIROLOGY, V206, P545; SEKELLICK MJ, 1994, J INTERFERON RES, V14, P71, DOI 10.1089/jir.1994.14.71; STAEHELI P, 1984, VIROLOGY, V137, P135, DOI 10.1016/0042-6822(84)90016-3; Staeheli P, 1987, Interferon, V8, P1	24	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10304	10308		10.1074/jbc.271.17.10304	http://dx.doi.org/10.1074/jbc.271.17.10304			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626599	hybrid			2022-12-25	WOS:A1996UG25700071
J	Whitelock, JM; Murdoch, AD; Iozzo, RV; Underwood, PA				Whitelock, JM; Murdoch, AD; Iozzo, RV; Underwood, PA			The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; DENSITY-LIPOPROTEIN RECEPTOR; BIOLOGICAL-ACTIVITIES; SULFATE PROTEOGLYCAN; SUBSTRATE-SPECIFICITY; ADHESION MOLECULES; FACTOR BINDING; HEPARIN; PURIFICATION; DOMAINS	Perlecan is a modular heparan sulfate proteoglycan that is localized to cell surfaces and within basement membranes. Its ability to interact with basic fibroblast growth factor (bFGF) suggests a central role in angiogenesis during development, wound healing, and tumor invasion. In the present study we investigated, using domain specific anti-perlecan monoclonal antibodies, the binding site of bFGF on human endothelial perlecan and its cleavage by proteolytic and glycolytic enzymes. The heparan sulfate was removed from perlecan by heparitinase treatment, and the similar to 450-kDa protein core was digested with various proteases. Plasmin digestion resulted in a large fragment of similar to 300 kDa, whereas stromelysin and rat collagenase cleaved the protein core into smaller fragments. All three proteases removed immunoreactivity toward the anti-domain I antibody. We showed also that perlecan bound bFGF specifically by the heparan sulfate chains located on the amino-terminal domain I. Once bound, the growth factor was released very efficiently by stromelysin, rat collagenase, plasmin, heparitinase I, platelet extract, and heparin. Interestingly, heparinase I, an enzyme with a substrate specificity for regions of heparan sulfate similar to those that bind bFGF, released only small amounts of bFGF. Our findings provide direct evidence that bFGF binds to heparan sulfate sequences attached to domain I and support the hypothesis that perlecan represents a major storage site for this growth factor in the blood vessel wall. Moreover, the concerted action of proteases that degrade the protein core and heparanases that remove the heparan sulfate may modulate the bioavailability of the growth factor.	THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University	Whitelock, JM (corresponding author), CSIRO,DIV BIOMOLEC ENGN,POB 184,SYDNEY,NSW 2114,AUSTRALIA.		Iozzo, Renato/AAS-1980-2020	Whitelock, John/0000-0003-1835-802X; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA-47282, R01 CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, BLOOD, V81, P3324; BENEZRA M, 1992, EXP CELL RES, V201, P208, DOI 10.1016/0014-4827(92)90365-F; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOSPODAROWICZ D, 1981, J CELL PHYSIOL, V109, P69, DOI 10.1002/jcp.1041090109; Graham LD, 1995, BIOCHEM MOL BIOL INT, V37, P239; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LYONS JG, 1989, MATRIX, V9, P7, DOI 10.1016/S0934-8832(89)80012-5; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MENASHI S, 1995, FEBS LETT, V361, P61, DOI 10.1016/0014-5793(95)00125-S; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NADER HB, 1990, J BIOL CHEM, V265, P16807; NETHERY A, 1986, ANAL BIOCHEM, V159, P390, DOI 10.1016/0003-2697(86)90358-1; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; UNDERWOOD PA, 1983, J IMMUNOL METHODS, V60, P33, DOI 10.1016/0022-1759(83)90332-0; UNDERWOOD PA, 1989, J CELL SCI, V93, P641; UNDERWOOD PA, 1992, J CELL SCI, V102, P833; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1993, MOL CELLULAR ASPECTS, P327; WALKER A, 1994, J BIOL CHEM, V269, P931; WEIS JR, 1991, THROMB RES, V61, P171, DOI 10.1016/0049-3848(91)90245-R; [No title captured]	43	483	509	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10079	10086		10.1074/jbc.271.17.10079	http://dx.doi.org/10.1074/jbc.271.17.10079			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626565	hybrid			2022-12-25	WOS:A1996UG25700037
J	David, M; Wong, L; Flavell, R; Thompson, SA; Wells, A; Larner, AC; Johnson, GR				David, M; Wong, L; Flavell, R; Thompson, SA; Wells, A; Larner, AC; Johnson, GR			STAT activation by epidermal growth factor (EGF) and amphiregulin - Requirement for the EGF receptor kinase but not for tyrosine phosphorylation sites or JAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PROMOTER; CELLS	The epidermal growth factor (EGF) receptor activates several signaling cascades in response to the ligands EGF and amphiregulin (AR). One of these signaling events involves the tyrosine phosphorylation of STATs (signal transducers and activators of transcription), a process believed to require the activation of a tyrosine kinase of the JAK family, In this report we demonstrate that EGF- and AR-induced STAT activation requires the intrinsic kinase activity of the receptor but not the presence of Jak1. We show that both wild type (WT) and truncated EGF receptors lacking all autophosphorylation sites activate STAT 1, 3, and 5 in response to either EGF or AR. Furthermore, relative to cells expressing WT receptor, ligand-induced tyrosine phosphorylation of the STATs was enhanced in cells expressing only the truncated receptor, These results provide the first evidence that (i) EGF receptor-mediated STAT activation occurs in a Jak1-independent manner, (ii) the intrinsic tyrosine kinase activity of the receptor is essential for STAT activation, and (iii) tyrosine phosphorylation sites within the EGF receptor are not required for STAT activation.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; BERLEX BIOSCI,DEPT PROT CHEM & BIOPHYS,RICHMOND,CA 94804; UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	Howard Hughes Medical Institute; Yale University; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	David, M (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,RM 2B06,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Wells, Alan/0000-0002-1637-8150				CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; JOHNSON GR, 1995, TRENDS GLYCOSCI GLYC, V7, P261; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	24	147	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9185	9188		10.1074/jbc.271.16.9185	http://dx.doi.org/10.1074/jbc.271.16.9185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621573	hybrid			2022-12-25	WOS:A1996UG04400004
J	Hoffman, RT; Schmidt, ER; Case, ST				Hoffman, RT; Schmidt, ER; Case, ST			A cell-specific glycosylated silk protein from Chironomus thummi salivary glands - Cloning, chromosomal localization, and characterization of cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPE TOMOGRAPHY; AMORPHOUS CODING SEQUENCES; BALBIANI RING GENE; SECRETORY PROTEIN; AMINO-ACID; GEL ELECTROPHORESIS; INTERNAL STRUCTURE; FIBROIN GENE; BOMBYX-MORI; TENTANS	Chironomid salivary glands contain 40 cells dedicated to the synthesis of a relatively small ensemble of silk proteins. Glands in some species contain a special lobe composed of 4 cells distinguishable from the others, We have cloned a special lobe-specific cDNA from Chironomus thummi salivary glands, Northern blots of salivary gland RNA demonstrated that the cDNA hybridizes to a 2.5-kilobase transcript present only in the special lobe. In situ hybridization mapped the gene encoding this cDNA to region A2b on polytene chromosome TV, the locus of the special lobe-specific Balbiani ring a, The deduced amino acid sequence encodes a protein with a calculated molecular mass of 77 kDa and numerous potential glycosylation sites; it appears unrelated to other known chironomid silk proteins, Polyclonal antibody, raised against a cDNA-encoded fusion protein, reacted exclusively with a special lobe-specific 160-kDa silk protein, Lectin binding studies indicate that the immunoreactive 160-kDa protein contains both N- and O-linked glycan moieties. We conclude that glycosylation most likely contributes to the difference between calculated and apparent molecular masses and that this cDNA encodes the special lobe-specific silk protein previously described as ssp160	UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA; UNIV MAINZ, INST MOLEC GENET, D-55099 MAINZ, GERMANY	University of Mississippi; University of Mississippi Medical Center; Johannes Gutenberg University of Mainz								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BAUMLEIN H, 1982, NUCLEIC ACIDS RES, V10, P3893, DOI 10.1093/nar/10.13.3893; BEERMANN W, 1961, CHROMOSOMA, V12, P1, DOI 10.1007/BF00328911; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRUMLEY LL, 1995, COMP BIOCH PHYSL B, V104, P731; Case S.T., 1992, Results and Problems in Cell Differentiation, V19, P187; CASE ST, 1978, J MOL BIOL, V124, P223, DOI 10.1016/0022-2836(78)90157-2; DAVIS MM, 1984, P NATL ACAD SCI-BIOL, V81, P2194, DOI 10.1073/pnas.81.7.2194; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DIGNAM SS, 1989, J BIOL CHEM, V264, P9444; DIGNAM SS, 1990, GENE, V88, P133, DOI 10.1016/0378-1119(90)90024-L; DREESEN TD, 1988, J CELL BIOL, V106, P21, DOI 10.1083/jcb.106.1.21; DREESEN TD, 1987, GENE, V55, P55, DOI 10.1016/0378-1119(87)90248-4; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; FRANCKE C, 1982, EMBO J, V1, P59, DOI 10.1002/j.1460-2075.1982.tb01124.x; GAGE LP, 1980, J BIOL CHEM, V255, P9444; GALLER R, 1984, P NATL ACAD SCI-BIOL, V81, P1448, DOI 10.1073/pnas.81.5.1448; GALLI J, 1993, J BIOL CHEM, V268, P11888; GALLI J, 1994, J MOL EVOL, V38, P482, DOI 10.1007/BF00178848; GARRISON K, 1991, J BIOL CHEM, V266, P22899; Grond C., 1987, Results and Problems in Cell Differentiation, V14, P69; Grossbach U., 1977, Results Probl Cell Differ, V8, P147; GROSSBACH U, 1969, CHROMOSOMA, V28, P136, DOI 10.1007/BF00331528; HAN JH, 1987, NUCLEIC ACIDS RES, V15, P6304, DOI 10.1093/nar/15.15.6304; Harlow E., 1988, ANTIBODIES LAB MANUA; HERTNER T, 1983, CHROMOSOMA, V88, P194, DOI 10.1007/BF00285620; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; KAO WY, 1985, J CELL BIOL, V101, P1044, DOI 10.1083/jcb.101.3.1044; Kaplan D., 1993, SILK POLYM MAT SCI B; KIKNADZE II, 1985, BIOL ZBL, V104, P113; KIKNADZE II, 1990, ANIMAL SPECIES DEV S, V1, P133; KISELEVA EV, 1989, FEBS LETT, V257, P251, DOI 10.1016/0014-5793(89)81545-5; KLOETZEL JA, 1969, J ULTRA MOL STRUCT R, V29, P15, DOI 10.1016/S0022-5320(69)80053-5; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOLESNIKOV NN, 1981, CHROMOSOMA, V83, P661, DOI 10.1007/BF00328525; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MANNING RF, 1980, J BIOL CHEM, V255, P9451; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OHSHIMA Y, 1977, P NATL ACAD SCI USA, V74, P5363, DOI 10.1073/pnas.74.12.5363; OLINS DE, 1983, SCIENCE, V220, P498, DOI 10.1126/science.6836293; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P51, DOI 10.1093/nar/10.1.51; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH SV, 1995, PROTEIN SCI, V4, P945; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; Spiro R G, 1973, Adv Protein Chem, V27, P349, DOI 10.1016/S0065-3233(08)60451-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLMAN SE, 1989, J BIOL CHEM, V264, P10878; WIESLANDER L, 1994, PROG NUCLEIC ACID RE, V48, P275, DOI 10.1016/S0079-6603(08)60858-2; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120	61	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9809	9815		10.1074/jbc.271.16.9809	http://dx.doi.org/10.1074/jbc.271.16.9809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621663	hybrid			2022-12-25	WOS:A1996UG04400094
J	Li, HY; Sadler, PJ; Sun, HZ				Li, HY; Sadler, PJ; Sun, HZ			Unexpectedly strong binding of a large metal ion (Bi3+) to human serum transferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; N-LOBE; X-RAY; RESOLUTION; MECHANISM; OVOTRANSFERRIN; ALUMINUM(3+)	Large metal ions (>0.9 Angstrom ionic radius) have previously been found to bind only weakly to human serum transferrin (hTF, 80 kDa), presumably because the interdomain cleft cannot close around the metal and synergistic anion. Surprisingly, therefore, we report that Bi3+ (ionic radius 1.03 Angstrom), a metal ion widely used in anti-ulcer drugs, binds strongly to both the N- and C-lobes with log K-1* = 19.42 and log K-2* = 18.58 (10 mM Hepes, 5 mM bicarbonate, 310 K). The uptake of Bi3+ by apo hTF from bismuth citrate complexes is very slow (hours), whereas that from bismuth nitrilotriacetate is rapid (minutes), Evidence from absorption and NMR spectroscopy is presented to show that Bi3+ binds to the specific Fe3+ binding sites along with carbonate as the synergistic anion. Under the conditions used, preferential binding of Bi3+ to the C-lobe of hTF is observed. Linear free energy relationships show that there is a strong correlation between the strength of binding of Bi3+ and Fe3+ to a wide variety of ligands which include transferrin. Therefore we conclude that the strength of metal ion binding to transferrin is determined more by the ligand donor set than by the size of the ion.	UNIV LONDON,DEPT CHEM,GORDON HOUSE & CHRISTOPHER INGOLD LABS,BIRKBECK COLL,LONDON WC1H 0PP,ENGLAND	University of London; Birkbeck University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARAMINI JM, 1994, J AM CHEM SOC, V116, P11506, DOI 10.1021/ja00104a034; ARAMINI JM, 1993, J AM CHEM SOC, V115, P245, DOI 10.1021/ja00054a035; ARAMINI JM, 1994, J AM CHEM SOC, V116, P1988, DOI 10.1021/ja00084a044; ARAMINI JM, 1994, BIOCHEMISTRY-US, V33, P3304, DOI 10.1021/bi00177a022; ASATO E, 1995, INORG CHEM, V34, P2447, DOI 10.1021/ic00113a028; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BATES GW, 1971, J BIOL CHEM, V246, P3679; BAXTER GF, 1992, CHEM BRIT, V28, P445; BAXTER GF, 1989, PHARM J, V243, P805; BEATTY EJ, 1995, THESIS U LONDON; BERTINI I, 1986, INORG CHEM, V25, P1782, DOI 10.1021/ic00231a013; BROCK JH, 1985, METALLOPROTEINS 2, P183; CASTELLANO AC, 1994, BIOCHEM BIOPH RES CO, V198, P646, DOI 10.1006/bbrc.1994.1094; CHAHINE JME, 1993, J CHEM SOC DALTON, P3137, DOI 10.1039/dt9930003137; CHASTEEN ND, 1977, BIOCHEMISTRY-US, V16, P363, DOI 10.1021/bi00622a004; CHASTEEN ND, IRON IRON STORAGE, P69; CLITHEROW JW, 1990, Patent No. 2220937; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; HANCOCK RD, 1994, J CHEM SOC DALTON, P2679, DOI 10.1039/dt9940002679; HARRIS AW, 1977, CANCER RES, V37, P3634; Harris D., 1989, IRON CARRIERS IRON P, P239; HARRIS WR, 1983, BIOCHEMISTRY-US, V22, P292, DOI 10.1021/bi00271a010; HARRIS WR, 1994, INORG CHEM, V33, P4991, DOI 10.1021/ic00100a024; HERRMANN WA, 1991, INORG CHEM, V30, P2579, DOI 10.1021/ic00012a001; KOZAK RW, 1986, TRENDS BIOTECHNOL, V4, P259, DOI 10.1016/0167-7799(86)90189-7; KRATZ F, 1994, J BIOL CHEM, V269, P2581; KUBAL G, 1992, BIOCHEM J, V285, P711, DOI 10.1042/bj2850711; KUBAL G, 1994, EUR J BIOCHEM, V220, P781, DOI 10.1111/j.1432-1033.1994.tb18679.x; KUBAL G, 1993, BIOCHEMISTRY-US, V32, P3387, DOI 10.1021/bi00064a024; KUBAL G, 1992, J AM CHEM SOC, V114, P1117, DOI 10.1021/ja00029a066; LEIBMAN A, 1979, BLOOD, V53, P1058; LI H, 1995, J INORG BIOCHEM, V59, P105; LINDLEY PF, 1993, ACTA CRYSTALLOGR D, V49, P292, DOI 10.1107/S0907444992012101; MARTIN RB, 1992, ALUMINUM BIOL MED, P18; PATCH MG, 1981, INORG CHIM A-BIOINOR, V56, pL71, DOI 10.1016/S0020-1693(00)88536-9; PETTIT G, 1993, IUPAC STABILITY CONS; RAYMOND C, 1981, PHYSICAL CHEM APPL B, P247; SADLER PJ, 1995, J CHEM SOC DALTON, P1395, DOI 10.1039/dt9950001395; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SMITH CA, 1994, J AM CHEM SOC, V116, P7889, DOI 10.1021/ja00096a053; SUMMERS SP, 1994, INORG CHEM, V33, P88, DOI 10.1021/ic00079a017; WELCH MJ, 1980, INORGANIC CHEM BIOL, P121; ZUCCOLA HJ, 1993, THESIS GEORGIA I TEC	44	86	92	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9483	9489		10.1074/jbc.271.16.9483	http://dx.doi.org/10.1074/jbc.271.16.9483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621619	hybrid, Green Published			2022-12-25	WOS:A1996UG04400050
J	Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN				Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN			Expression of the D-MEF2 transcription factor in the Drosophila brain suggests a role in neuronal cell differentiation	ONCOGENE			English	Article						D-MEF2 transcription factor; Kenyon cells; muscle; mushroom bodies; neuron differentiation; transcriptional enhancers	TINMAN	D-MEF2 is a MADS domain transcription factor expressed in the cardiac, somatic, and visceral muscle cell lineages in the Drosophila embryo, Genetic studies have demonstrated that D-mef2 gene function is required for the proper differentiation of all three of these muscle types, We show that D-MEF2 is also expressed in a limited number of other cell types during development, including Kenyon cells present in the mushroom bodies of the Drosophila brain, This finding suggests a role for D-mef2 in neuron differentiation, To investigate D-mef2 expression in muscle and Kenyon cells, we assayed 26 kb of D-mef2 5'-flanking and intragenic DNA for regulatory sequences controlling the expression of the gene, Our results show that separable enhancer sequences direct D-mef2 gene expression in the myogenic and neuronal cell lineages. The identification of these regulatory DNAs provides a starting point for the analysis of transcriptional regulators controlling the cell-specific expression of D-mef2 and a means to address the function of D-mef2 in Kenyon cell differentiation.			Schulz, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.							Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BODMER R, 1993, DEVELOPMENT, V118, P719; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TRUMAN JW, 1993, DEV DROSOPHILA MELAN; YANG MY, 1995, NEURON, V15, P45	21	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1827	1831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622904				2022-12-25	WOS:A1996UG45800026
J	Jarvis, WD; Fornari, FA; Traylor, RS; Martin, HA; Kramer, LB; Erukulla, RK; Bittman, R; Grant, S				Jarvis, WD; Fornari, FA; Traylor, RS; Martin, HA; Kramer, LB; Erukulla, RK; Bittman, R; Grant, S			Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; D-ERYTHRO-SPHINGOSINE; D-THREO-SPHINGOSINE; LONG-CHAIN BASES; HL-60 CELLS; PROMYELOCYTIC LEUKEMIA; MONOCYTIC DIFFERENTIATION; L-SERINE; INHIBITION; ACTIVATION	Prior studies demonstrated that ceramide promotes apoptotic cell death in the human myeloid leukemia cell lines HL-60 and U937 (Jarvis, W. D., Kolesnick, R. N., Fornari, F. A. Jr., Traylor, R. S., Gewirtz, D. A., and Grant, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 73-77), and that this lethal process is potently suppressed by diglyceride (Jarvis, W. D., Fornari, F. A., Jr., Browning, J. L., Gewirtz, D. A., Kolesnick, R. N., and Grant, S. (1994) J. Biol. Chem. 269, 31685-31692). The present findings document the intrinsic ability of sphingoid bases to induce apoptosis in HL-60 and U937 cells. Exposure to either sphingosine or sphinganine (0.001-10 mu M) for 6 h promoted apoptotic degradation of genomic DNA as indicated by (a) electrophoretic resolution of 50-kilobase pair DNA loop fragments and 0.2-1.2-kilobase pair DNA fragment ladders on agarose gels, and (b) spectrofluoro-photometric determination of the formation and release of double-stranded fragments and corresponding loss of integrity of bulk DNA. DNA damage correlated directly with reduced cloning efficiency and was associated with the appearance of apoptotic cytoarchitectural traits. At sublethal concentrations (less than or equal to 750 nM), however, sphingoid bases synergistically augmented the apoptotic capacity of ceramide (10 mu M), producing both a leftward shift in the ceramide concentration-response profile and a pronounced increase in the response to maximally effective levels of ceramide. Thus, sphingosine and sphinganine increased both the potency and efficacy of ceramide. The apoptotic capacity of bacterial sphingomyelinase (50 milliunits/ml) was similarly enhanced by either (a) acute co-exposure to highly selective pharmacological inhibitors of protein kinase C such as calphostin C and chelerythrine or (b) chronic pre-exposure to the nontumor-promoting protein kinase C activator bryostatin 1, which completely down-modulated total assayable protein kinase C activity. These findings demonstrate that inhibition of protein kinase C by physiological or pharmacological agents potentiates the lethal actions of ceramide in human leukemia cells, providing further support for the emerging concept of a cytoprotective function of the protein kinase C isoenzyme family in the regulation of leukemic cell survival.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED CHEM,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL TOXICOL,RICHMOND,VA 23298; CUNY QUEENS COLL,DEPT CHEM & BIOCHEM,FLUSHING,NY 11367	Virginia Commonwealth University; Virginia Commonwealth University; City University of New York (CUNY) System; Queens College NY (CUNY)	Jarvis, WD (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MED HEM ONC,DEPT MED,BOX 980230,MCV STN,RICHMOND,VA 23298, USA.				NATIONAL CANCER INSTITUTE [P30CA016059, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63753, CA-16059] Funding Source: Medline; PHS HHS [NL-16660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERTRAND B, 1993, ANC RES, V54, P997; BICKNELL GR, 1994, J CELL SCI, V107, P2483; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; CAMPBELL PI, 1983, CYTOBIOS, V37, P21; CHAO R, 1992, J BIOL CHEM, V267, P23459; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; GALLAGHER R, 1979, BLOOD, V54, P713; GARNER P, 1988, J ORG CHEM, V53, P4395, DOI 10.1021/jo00253a039; GARNER P, 1991, ORG SYNTH, V70, P18; GO M, 1987, BIOCHEM BIOPH RES CO, V144, P598; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRANT S, 1994, ONCOL RES, V6, P87; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; HUANG CX, 1995, CANCER RES, V55, P1655; HUBERMAN E, 1982, CARCINOGENESIS, V3, P111, DOI 10.1093/carcin/3.1.111; HUBERMAN E, 1979, P NATL ACAD SCI USA, V72, P739; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, CANCER RES, V54, P1707; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JARVIS WD, 1994, BIOCHEM PHARMACOL, V47, P838; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; MACFARLANE DE, 1993, LEUKEMIA, V7, P1846; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATSUI T, 1986, CANCER RES, V46, P583; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; NAKAKI T, 1984, CANCER RES, V44, P1908; NOMURA H, 1986, BIOCHEM BIOPH RES CO, V140, P1143, DOI 10.1016/0006-291X(86)90754-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHTA H, 1995, CANCER RES, V55, P691; PORENTEAU H, 1992, NUTR CANC, V17, P235; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; PUSHKAREVA MY, 1993, BIOCHEM J, V294, P699, DOI 10.1042/bj2940699; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P482; STEVENS VL, 1989, CANCER RES, V49, P3229; STONE RM, 1988, BLOOD, V72, P739; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDENBARK GR, 1984, J CLIN INVEST, V73, P448, DOI 10.1172/JCI111231; WANG E, 1991, J BIOL CHEM, V266, P14486	66	129	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8275	8284		10.1074/jbc.271.14.8275	http://dx.doi.org/10.1074/jbc.271.14.8275			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626522	hybrid			2022-12-25	WOS:A1996UD60000062
J	Pande, A; Tremmel, KD; DeMaria, CT; Blaxall, BC; Minobe, WA; Sherman, JA; Bisognano, JD; Bristow, MR; Brewer, G; Port, JD				Pande, A; Tremmel, KD; DeMaria, CT; Blaxall, BC; Minobe, WA; Sherman, JA; Bisognano, JD; Bristow, MR; Brewer, G; Port, JD			Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; FAILING HUMAN HEART; HUMAN VENTRICULAR MYOCARDIUM; 3' UNTRANSLATED REGION; BETA-2-ADRENERGIC RECEPTORS; CROSS-REGULATION; GENE-EXPRESSION; RICH DOMAINS; C-PROTEINS; GM-CSF	In both cell culture based model systems and in the failing human heart, beta-adrenergic receptors (beta-AR) undergo agonist-mediated down-regulation. This decrease correlates closely with down-regulation of its mRNA, an effect regulated in part by changes in mRNA stability. Regulation of mRNA stability has been associated with mRNA-binding proteins that recognize A + U-rich elements within the 3'-untranslated regions of many mRNAs encoding proto-oncogene and cytokine mRNAs. We demonstrate here that the mRNA-binding protein, AUF1, is present in both human heart and in hamster DDT1-MF2 smooth muscle cells and that its abundance is regulated by beta-AR agonist stimulation. In human heart, AUF1 mRNA and protein was significantly increased in individuals with myocardial failure, a condition associated with increases in the beta-adrenergic receptor agonist norepinephrine. In the same hearts, there was a significant decrease (similar to 50%) in the abundance of beta(1)-AR mRNA and protein. In DDT1-MFB cells, where agonist-mediated destabilization of beta(2)-AR mRNA was first described, exposure to beta-AR agonist resulted in a significant increase in AUF1 mRNA and protein (similar to 100%). Conversely, agonist exposure significantly decreased (similar to 40%) beta(2)-adrenergic receptor mRNA abundance. Last, we demonstrate that AUF1 can be immunoprecipitated from polysome-derived proteins following UV cross-linking to the 3'-untranslated region of the human beta(1)-AR mRNA and that purified, recombinant p37(AUF1) protein also binds to beta(1)-AR 3'-untranslated region mRNA.	UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT IMMUNOL & MICROBIOL,WINSTON SALEM,NC 27157	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Wake Forest University; Wake Forest Baptist Medical Center			bristow, michael r/G-7850-2011; Blaxall, Burns/ABD-8289-2021		NHLBI NIH HHS [HL51239, R01 HL051239, HL48013] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048013, R01HL051239, R29HL051239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAHOUTH SW, 1992, MOL PHARMACOL, V42, P971; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRISTOW MR, 1992, J CLIN INVEST, V89, P803, DOI 10.1172/JCI115659; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; BRODDE OE, 1986, J CARDIOVASC PHARM, V8, P1235, DOI 10.1097/00005344-198611000-00021; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; FELDMAN AM, 1991, CIRCULATION, V83, P1866, DOI 10.1161/01.CIR.83.6.1866; FERRY RC, 1994, J BIOL CHEM, V269, P31850; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HENICS T, 1994, J BIOL CHEM, V269, P5377; HUANG LY, 1993, J BIOL CHEM, V268, P25769; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LANGECARTER CA, 1991, J BIOL CHEM, V266, P22529; LEE NH, 1994, J BIOL CHEM, V269, P4291; LOGANZO F, 1993, MOL ENDOCRINOL, V7, P434, DOI 10.1210/me.7.3.434; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RUBIN SA, 1994, CIRCULATION, V90, P145; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; TREMMEL KD, 1996, KEYSTONE S MOL BIOL, P47; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VRIZ S, 1989, FEBS LETT, V251, P201, DOI 10.1016/0014-5793(89)81455-3; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	67	137	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8493	8501		10.1074/jbc.271.14.8493	http://dx.doi.org/10.1074/jbc.271.14.8493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626551	hybrid			2022-12-25	WOS:A1996UD60000091
J	Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L				Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L			Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induces tumors in transgenic mice	ONCOGENE			English	Article						Epstein-Barr virus; EBNA(2); transgenic mice; renal cancer	LYMPHOEPITHELIOMA-LIKE CARCINOMA; FACTOR-II GENE; HODGKINS-DISEASE; LYMPHOMA-CELLS; VIRAL GENOME; WILMS-TUMOR; VIRUS; DNA; PROTEIN; RNA	The effect of EBNA2 in normal cells in vivo has not as yet been explored. The experiments described here were initiated to follow the consequences of the expression of EBNA2 in different tissues in transgenic mice. EBNA2 transgenic strains were generated using a vector containing EBNA2 encoding sequences under the control of the simian virus 40 (SV40) early enhancer/promoter fused to the endogenous EBNA2 Wp promoter. Control mice carrying a transgene with the same sequence but lacking the EBV DNA part remained healthy during observation periods of up to 15 months. The SV-EBNA2 transgenic animals, however, over time developed abdominal masses that on necropsy showed to be due to kidney tumors. Histological examination revealed the presence of tumors with the morphology of kidney adenocarcinoma with a solid growth pattern. At the age of 20 weeks the kidneys of all animals investigated showed disseminated islands of tubular hyperplasia but no true malignant neoplasms. At about 50 weeks of age multiple foci of microscopic tubular adenocarcinomas were found in both kidneys. Eventually, tumors could be diagnosed in about 90% of the SV-EBNA2 transgenic mice. EBNA2-encoding RNA was expressed in both non-malignant kidney tissue and in tumors as shown by cDNA/PCR analysis. Immunoprecipitation and immunoblot analysis showed that the tumor cells contained a polypeptide of the same size as EBNA2 in B95-8 cells that reacted with a monoclonal anti-EBNA2 antibody. Immunohistochemistry demonstrated nuclear expression of EBNA2 in hyperplastic tubules and in tumor tissue.	GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CLIN CHEM & TRANSFUS MED,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CELL BIOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT INTERNAL MED,S-41345 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg					NCI NIH HHS [CA 28380-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BEGIN LR, 1987, J SURG ONCOL, V36, P280, DOI 10.1002/jso.2930360413; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GOSH D, 1990, J VIROL, V64, P1855; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HIRSHFELD H, 1995, P 5 INT C HORM CANC, P140; HOGAN B, 1986, MANIPULATING MOUSE E; HUEN DS, 1993, J GEN VIROL, V74, P1381, DOI 10.1099/0022-1317-74-7-1381; HUFF JE, 1991, IARC SCI PUBL, V115, P229; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; Koike K, 1993, Nihon Rinsho, V51, P536; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; Liebowitz David, 1993, P107; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PITTALUGA S, 1992, MODERN PATHOL, V5, P661; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; RICKSTEN A, 1987, J GEN VIROL, V68, P2407, DOI 10.1099/0022-1317-68-9-2407; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SEARLE PF, 1994, J GEN VIROL, V75, P1125, DOI 10.1099/0022-1317-75-5-1125; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STADLER W, 1993, ANN ONCOL, V4, P451, DOI 10.1093/oxfordjournals.annonc.a058550; SU IJ, 1991, BLOOD, V77, P799; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WEISS LM, 1987, AM J PATHOL, V129, P86; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yamamura K, 1990, Gastroenterol Jpn, V25 Suppl 2, P49; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	47	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622868				2022-12-25	WOS:A1996UF07600016
J	Collette, Y; Dutartre, H; Benziane, A; RamosMorales, F; Benarous, R; Harris, M; Olive, D				Collette, Y; Dutartre, H; Benziane, A; RamosMorales, F; Benarous, R; Harris, M; Olive, D			Physical and functional interaction of Nef with Lck - HIV-1 Nef-induced T-cell signaling defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE P56LCK; SURFACE CD4 EXPRESSION; ANTIGEN RECEPTOR; DOWN-REGULATION; ENVELOPE GLYCOPROTEIN; TRANSGENIC MICE; TYROSINE KINASE; TAT PROTEIN; SH3 DOMAINS	The nef gene is unique to the primate lentiviruses and encodes a cytoplasmic membrane-associated protein that affects T-cell signaling and is essential for both maintenance of a high virus load in vivo and for disease progression. Here we investigated the perturbation of cell signaling by Nef in T-cells and found that Nef interacts with the T-cell restricted Lck tyrosine kinase both in vitro and in vivo. The molecular basis for this interaction was analyzed. We show that cell-derived Nef is precipitated in a synergistic manner by the recombinant Src homology 2 (SH2) and SH3 domains from Lck. A functional proline-rich motif and the tyrosine phosphorylation of Nef were evidenced as likely participants in this interaction, The precipitation of Nef by the Lck recombinant proteins was specific, since neither Fyn, Csk, p85 phosphatidylinositol 3-kinase nor phospholipase C gamma SH2 domains coprecipitated Nef from T-cells, Finally, depressed Lck kinase activity resulted from the presence of Nef, both in vitro and in intact cells, and nef expression resulted in impairment of both proximal and distal Lck-mediated signaling events, These results provide a molecular basis for the Nef-induced T-cell signaling defect and its role in AIDS pathogenesis.	INSERM, U119, F-13009 MARSEILLE, FRANCE; INST COCHIN GENET MOLEC, INSERM, U363, F-75014 PARIS, FRANCE; INST COCHIN GENET MOLEC, INSERM, U332, F-75014 PARIS, FRANCE; UNIV GLASGOW, DEPT VET PATHOL, GLASGOW G61 1QH, LANARK, SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Glasgow			COLLETTE, Yves/F-2270-2013; Ramos-Morales, Francisco/C-5734-2008; Dutartre, Helene/L-7463-2019	COLLETTE, Yves/0000-0001-5359-7099; Ramos-Morales, Francisco/0000-0002-1151-4547; Dutartre, Helene/0000-0002-2682-4302; Harris, Mark/0000-0002-9821-1003				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ANDERSON S, 1993, J VIROL, V67, P4923, DOI 10.1128/JVI.67.8.4923-4931.1993; BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BANDRES JC, 1995, VIROLOGY, V207, P338, DOI 10.1006/viro.1995.1089; BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; BOUGERET C, 1993, ONCOGENE, V8, P1241; BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; COLLETTE Y, 1996, IN PRESS CYTOKINES P; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; DHIVER C, 1989, AIDS, V3, P835, DOI 10.1097/00002030-198912000-00009; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; FUJII Y, 1993, VACCINE, V11, P837, DOI 10.1016/0264-410X(93)90359-6; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HARRIS M, 1995, BIOCHEM SOC T, V23, P557, DOI 10.1042/bst0230557; HARRIS M, 1993, J GEN VIROL, V74, P1581, DOI 10.1099/0022-1317-74-8-1581; HARRIS MPG, 1994, J MOL BIOL, V241, P136; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; LINDEMANN D, 1994, J EXP MED, V179, P797, DOI 10.1084/jem.179.3.797; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MAITRA RK, 1991, VIROLOGY, V182, P522, DOI 10.1016/0042-6822(91)90593-Z; MANCA F, 1990, LANCET, V335, P811, DOI 10.1016/0140-6736(90)90935-X; MEYAARD L, 1992, EUR J IMMUNOL, V22, P2729, DOI 10.1002/eji.1830221038; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEBREDA AR, 1991, VIROLOGY, V183, P151, DOI 10.1016/0042-6822(91)90128-X; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; NUNES J, 1993, BIOCHEM J, V293, P835, DOI 10.1042/bj2930835; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PERI KG, 1993, ONCOGENE, V8, P2765; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TERWILLIGER EF, 1991, P NATL ACAD SCI USA, V88, P10971, DOI 10.1073/pnas.88.23.10971; VEILLETTE A, 1990, EUR J IMMUNOL, V20, P1397, DOI 10.1002/eji.1830200628; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	83	142	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6333	6341		10.1074/jbc.271.11.6333	http://dx.doi.org/10.1074/jbc.271.11.6333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626429	hybrid			2022-12-25	WOS:A1996UA36300058
J	Panneerselvam, K; Freeze, HH				Panneerselvam, K; Freeze, HH			Mannose enters mammalian cells using a specific transporter that is insensitive to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSYLATION; HEXOSE-TRANSPORT; EXPRESSION; FIBROBLASTS; LIVER	The concentration of D-mannose in serum is 20-50 mu M, but its physiological significance for glycoprotein synthesis is unknown. Here, we show that the uptake of D-mannose by different mammalian cell lines involves a mannose-specific transporter(s) with a K-uptake Of about 30-70 mu M and a V-max which is probably sufficient to account for the bulk of mannose needed for glycoprotein synthesis. Mannose uptake appears to be through a facilitated transport process since it is not inhibited by cyanide. Phloretin completely inhibits mannose uptake, but phloridzin inhibits only 25-30%. Both of these inhibitors can block 2-deoxyglucose uptake in fibroblasts which occurs through the typical glucose transporters. None of 9 other sugars tested inhibited mannose transport. Most importantly, 5 mM D-glucose only inhibits mannose uptake by 50% showing that it is not an efficient competitor. These results suggest that this transporter(s) may use serum mannose for glycoprotein synthesis.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	PHS HHS [R01 49096] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKAZAWA S, 1986, J CLIN ENDOCR METAB, V62, P984, DOI 10.1210/jcem-62-5-984; ASANO T, 1991, J BIOL CHEM, V266, P24632; BAILEY WH, 1943, J BIOL CHEM, V152, P135; CACAN R, 1992, GLYCOBIOLOGY, V2, P127, DOI 10.1093/glycob/2.2.127; CHARON JP, 1994, AM J PHYSIOL-LUNG C, V267, pL390, DOI 10.1152/ajplung.1994.267.4.L390; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DAVIS SE, 1975, CARBOHYDRATE S PHYSL, P296; DRINGEN R, 1994, NEUROCHEM RES, V19, P23, DOI 10.1007/BF00966724; GERMINARIO RJ, 1992, J CELL PHYSIOL, V151, P156, DOI 10.1002/jcp.1041510120; GERMINARIO RJ, 1987, CLIN INVEST MED, V10, P295; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRACY RW, 1968, J BIOL CHEM, V243, P3161; HARDING VJ, 1934, J BIOL CHEM, V128, P2036; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERMAN RH, 1971, AM J CLIN NUTR, V24, P488; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE WS, 1994, J BIOL CHEM, V269, P12032; LEFEVRE PG, 1959, J BIOL CHEM, V234, P3022; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MAYOR P, 1992, DIABETES, V41, P274, DOI 10.2337/diabetes.41.3.274; MCNAMARA PD, 1976, AM J PHYSIOL, V231, P9, DOI 10.1152/ajplegacy.1976.231.1.9; MIYAMOTO K, 1993, BIOCHEM J, V295, P211, DOI 10.1042/bj2950211; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; PANNEERSELVAM K, 1995, BIOCHEM BIOPH RES CO, V205, P517; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; RIJCKEN WRP, 1995, BIOCHEM J, V305, P865, DOI 10.1042/bj3050865; RIMOLDI D, 1990, MOL CELL BIOCHEM, V93, P129, DOI 10.1007/BF00226184; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHWARTZ NB, 1992, TXB BIOCH CLIN CORRE, V2, P359; SILVERMAN M, 1970, American Journal of Physiology, V218, P743; SLOVITER HA, 1970, J NEUROCHEM, V17, P1109, DOI 10.1111/j.1471-4159.1970.tb02266.x; SOYAMA K, 1984, CLIN CHEM, V30, P293; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VILLERS C, 1994, BIOCHEM J, V298, P135, DOI 10.1042/bj2980135; WOOD FC, 1963, J CLIN INVEST, V42, P1300, DOI 10.1172/JCI104814; Yurchenco P D, 1978, Methods Enzymol, V50, P175	40	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9417	9421		10.1074/jbc.271.16.9417	http://dx.doi.org/10.1074/jbc.271.16.9417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621609	hybrid			2022-12-25	WOS:A1996UG04400040
J	SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R				SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R			Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells	ONCOGENE			English	Article						signaling; erbB receptors; heregulin	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; CARCINOMA-CELLS; EGF RECEPTOR; TUMOR-CELLS; ACTIVATING FACTOR; ONCOGENE PRODUCT; NEU RECEPTOR; PROTEIN	Heregulins (HRGs) induce tyrosine phosphorylation of several members of the erb-B family of receptors. Although originally isolated as the ligands for p185(c-erbB-2), recent evidence suggests that other receptors of the erb B family, including p180(erbB-3) and p180(erbB-4), are their true cognate receptors. Stimulation of MDA MB-453 cells with HRG beta 2 resulted in the tyrosine phosphorylation of p185(c-erbB-2) and p180(erbB-4) in a time- and dose-dependent fashion, This event was accompanied by the formation of multimeric complexes between the activated receptors and SH2-containing proteins. Ligand caused p120-rasGTPase activating protein (GAP), SHC and the p85 subunit of phosphatidylinositol-3'-kinase (PI3K) to be associated with both p185(c-erbB-2) and p180(erbB-4). In addition, tyrosine phosphorylation of p85-PI3K and SHC, but not of GAP or of its associated p62 and p190 proteins, was also detected, HRG also induced the association of GRB2 with tyrosine phosphorylated p185(c-erbB-2)) p180(crbB-4) and SHC. Activation of mitogen-activated protein kinase (MAPK) (> 30-fold over untreated controls) was observed upon receptor(s) activation, as it was the induction of the immediate early gene c-fos (> 200-fold). These observations suggest that p21(ras) activation plays a role in the HRG pathway. Furthermore, comparative anlaysis of the binding of p85-PI3K to 185(c-crbB-2) and p180(crbB-4), revealed a preferential association with activated p180(erbB-4). These findings might suggest a model of HRG action in which the relative expression of the various erb-B family members and the partitioning of signal transduction molecules between each type of receptor might determine the nature of the signal elicited by the ligand and the biological response attained.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, PROGRAM CELL BIOLOG & GENET, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, DEPT MED, NEW YORK, NY 10021 USA; GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Georgetown University			Rosen, Neal/ABF-2677-2020		NCI NIH HHS [R01 CA 55406-01, R01 CA 58706-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058706, R01CA055406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DECORTE V, 1994, J CELL SCI, V107, P405; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIN YZJ, 1991, ONCOGENE, V6, P639; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; LUPU R, 1991, INT S PRINC TAK CANC, V22, P49; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; TANG C, 1994, P AM ASSOC CANC RES, V35, pA214; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	74	66	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1679	1687						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622888				2022-12-25	WOS:A1996UG45800010
J	Ishii, H; Kizaki, K; Horie, S; Kazama, M				Ishii, H; Kizaki, K; Horie, S; Kazama, M			Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-C ACTIVATION; TISSUE-FACTOR; NATURAL ANTICOAGULANT; HEMOSTATIC PROPERTIES; COFACTOR ACTIVITY; RETINOIC ACID; CYCLIC-AMP; EXPRESSION; SURFACE	Oxidized low density lipoprotein (LDL), a potent atherogenic lipoprotein, has been shown to cause the alteration of various endothelial functions. We have examined the effect of oxidized LDL on the cofactor activity for thrombin-dependent protein C activation and expression of thrombomodulin (TM), a cell surface antithrombotic glycoprotein, on cultured human umbilical vein endothelial cells. Oxidized LDL prepared by irradiation of LDL with 254-nm ultraviolet light did not directly affect the cofactor activity of isolated TM. Exposure of the cells to oxidized LDL (25-200 mu g/ml), but not native LDL and acetylated LDL, reduced TM cofactor activity in parallel with its antigen levels on the cell surface in an oxidation-, concentration- and time dependent manner. TM mRNA levels were reduced prior to decrease in TM antigen levels and were 50% of the control levels at 3.0 h after treatment of the cells with oxidized LDL. The apparent half-life time (t(1/2) = 2.8 h) of TM mRNA in the oxidized LDL-treated cells, however, did not significantly differ from that (t(1/2) = 2.6 h) in the control cells when the cells were coincubated with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, a transcriptional inhibitor. Treatment of the cells with bafilomycin A1, an inhibitor for the proton pump of the lysosomes, inhibited intracellular degradation of the LDL and prevented down-regulations of the mRNA and the cell surface TM antigen levels caused by oxidized LDL. The inhibitor molecule in oxidized LDL was shown to be a lipid; organic solvent extracts (300 mg/ml cholesterol, an equivalent concentration with lipids in 200 mu g/ml oxidized LDL) of oxidized LDL inhibited expression of TM antigen to nearly the same extent as the oxidized LDL, although water extracts did not affect TM expression on the cells. These results suggested that down-regulation of TM on endothelial cells exposed to oxidized LDL resulted from inhibition of its transcription mediated by lysosomal degradation of oxidized LDL and that a lipid component in the LDL could be an active species. A decrease in TM expression on the surface of endothelial cells may contribute to promote thrombosis in atherosclerotic lesions.			Ishii, H (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT CLIN BIOCHEM,1091-1 SUARASHI,SAGAMIKO,KANAGAWA 19901,JAPAN.							ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buege J A, 1978, Methods Enzymol, V52, P302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DERIJKE YB, 1994, BIOCHEM J, V304, P69, DOI 10.1042/bj3040069; DITTMAN WA, 1990, BLOOD, V75, P329; DOUSSET N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P219, DOI 10.1016/0005-2760(90)90123-F; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FEI H, 1993, ARTERIOSCLER THROMB, V138, P601; GARCIAMALDONADO M, 1991, TRANSPLANTATION, V51, P701, DOI 10.1097/00007890-199103000-00030; Gimbrone M., 1986, VASCULAR ENDOTHELIUM, P1; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREENWALT DE, 1992, BLOOD, V80, P1105; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HAYASHI T, 1992, BLOOD, V79, P2930; HIROKAWA K, 1991, J CELL PHYSIOL, V147, P157, DOI 10.1002/jcp.1041470120; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; ISHII H, 1990, THROMB RES, V59, P841, DOI 10.1016/0049-3848(90)90397-U; ISHII H, 1992, BLOOD, V80, P2556; ISHII H, 1990, THROMB HAEMOSTASIS, V63, P157; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KIZAKI K, 1994, THROMB HAEMOSTASIS, V72, P573; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LENTZ SR, 1991, BLOOD, V77, P542; LENTZ SR, 1994, THROMBIN THROMBOMODU, P91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAGANUMA S, 1992, BIOCHIM BIOPHYS ACTA, V1126, P41, DOI 10.1016/0005-2760(92)90214-G; NAITO M, 1991, AM J PATHOL, V139, P1411; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEMERSON Y, 1988, BLOOD, V71, P1; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; SALEM HH, 1984, J BIOL CHEM, V259, P2246; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE JF, 1994, J IMMUNOL, V153, P378; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	57	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8458	8465		10.1074/jbc.271.14.8458	http://dx.doi.org/10.1074/jbc.271.14.8458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626546	hybrid			2022-12-25	WOS:A1996UD60000086
J	Wada, H; Ivester, CT; Carabello, BA; Cooper, G; McDermott, PJ				Wada, H; Ivester, CT; Carabello, BA; Cooper, G; McDermott, PJ			Translational initiation factor eIF-4E - A link between cardiac load and protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC PERFUSION-PRESSURE; ADULT FELINE CARDIOCYTES; HYPERTROPHY; DEFORMATION; DETERMINANT	To define the coupling mechanism between cardiac load and the rate of protein synthesis, changes in the extent of eIF-4E phosphorylation were measured after imposition of a load. Electrically stimulated contraction of adult feline cardiocytes increased eIF-4E phosphorylation to 34% after 4 h, as compared with 8% phosphorylation in quiescent controls. However, eIF-4E phosphorylation did not increase upon electrical stimulation in the presence of 7.5 mM 2,3-butanedione monoxime, an inhibitor of actin-myosin cross-bridge cycling and active tension development. Treatment of adult cardiocytes with either 0.1 mu M insulin or 0.1 mu M phorbol 12-myristate 13-acetate increased eIF-4E phosphorylation to 23 and 64%, respectively, but these increases were not blocked by 2,3-butanedione monoxime. In canine models of acute hemodynamic overload in vivo, eIF-4E phosphorylation increased to 23% in response to left ventricular pressure overload as compared with 7% phosphorylation in controls. Acute volume overload had no effect on eIF-4E phosphorylation. These changes in eIF-4E phosphorylation account for differences in anabolic responses to acute pressure versus acute volume overload. These data suggest that eIF-4E phosphorylation is a mechanism by which increased cardiac load is coupled to accelerated rates of protein synthesis.	VET ADM MED CTR,CARDIOL SECT,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT MED,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT PHYSIOL,CHARLESTON,SC 29401; GAZES CARDIAC RES INST,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29401	US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-48788] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1994, J PHYSIOL-LONDON, V476, P487, DOI 10.1113/jphysiol.1994.sp020149; CLERK A, 1994, J BIOL CHEM, V269, P32848; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HESKETH JE, 1991, BIOCHEM J, V277, P1; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; INGBER DE, 1994, INT REV CYTOL, V150, P173; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KATO S, 1995, AM J PHYSIOL-HEART C, V268, pH2495; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041	28	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8359	8364		10.1074/jbc.271.14.8359	http://dx.doi.org/10.1074/jbc.271.14.8359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626533	hybrid			2022-12-25	WOS:A1996UD60000073
J	Yang, CH; Shi, W; Basu, L; Murti, A; Constantinescu, SN; Blatt, L; Croze, E; Mullersman, JE; Pfeffer, LM				Yang, CH; Shi, W; Basu, L; Murti, A; Constantinescu, SN; Blatt, L; Croze, E; Mullersman, JE; Pfeffer, LM			Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUTATHIONE-S-TRANSFERASE; SH3 DOMAINS; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; TYROSINE KINASE; ALPHA RECEPTOR; CELLS; EXPRESSION	Based on the reports of the activation of the transcription factor known as STAT3 (for signal transducers and activators of transcription) or APRF (for acute phase response factor) by various cytokines, we investigated the possible role of STAT3 in type I interferon (IFN) receptor signaling. We show that STAT3 undergoes IFN alpha-dependent tyrosine phosphorylation and IFN alpha treatment induces protein-DNA complexes that contain STAT3. In addition, STAT3 associates with the IFNAR-1 chain of the type I receptor in a tyrosine phosphorylation-dependent manner upon IFN alpha addition. The binding of STAT3 to the IFNAR-1 chain occurs through a direct interaction between the SH2 domain-containing portion of STAT3 and the tyrosine-phosphorylated IFNAR-1 chain. Furthermore, tyrosine-phosphorylated STAT3 bound to the IFNAR-1 chain also undergoes a secondary modification involving serine phosphorylation. This phosphorylation event is apparently mediated by protein kinase C, since it was blocked by low concentrations of the protein kinase inhibitor H-7. The biological relevance of IFN activation of STAT3 is further illustrated by the finding that STAT3 is not activated by IFN in a cell line resistant to the antiviral and antiproliferative actions of IFN alpha but in which other components of the JAK-STAT pathway are activated by IFN alpha.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PATHOL, MEMPHIS, TN 38163 USA; BERLEX BIOSCI INC, DEPT PROT BIOCHEM & BIOPHYS, RICHMOND, CA 94804 USA; AMGEN INC, INTERFERON PROGRAM, THOUSAND OAKS, CA 91320 USA	University of Tennessee System; University of Tennessee Health Science Center; Amgen			Constantinescu, Stefan N/E-5277-2012	Constantinescu, Stefan N./0000-0002-8599-2699; Pfeffer, Lawrence/0000-0003-2809-1234	NIGMS NIH HHS [GM36716] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036716] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIDAKA H, 1987, TRENDS PHARMACOL SCI, V8, P162, DOI 10.1016/0165-6147(87)90155-6; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLERSMAN JE, 1995, TRENDS BIOCHEM SCI, V20, P55, DOI 10.1016/S0968-0004(00)88956-2; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDENBROECKE C, 1988, J INTERFERON RES, V8, P803; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG C, 1993, P NATL ACAD SCI USA, V90, P6944, DOI 10.1073/pnas.90.15.6944; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	115	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8057	8061		10.1074/jbc.271.14.8057	http://dx.doi.org/10.1074/jbc.271.14.8057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626489	hybrid			2022-12-25	WOS:A1996UD60000029
J	Zarrilli, R; Romano, M; Pignata, S; Casola, S; Bruni, CB; Acquaviva, AM				Zarrilli, R; Romano, M; Pignata, S; Casola, S; Bruni, CB; Acquaviva, AM			Constitutive insulin-like growth Factor-II expression interferes with the enterocyte-like differentiation of CaCo-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; FACTOR RECEPTOR; 2 PROMOTERS; IGF-I; GENE; PROLIFERATION; INHIBITION; LIGAND; OVEREXPRESSION; MYOBLASTS	In this study we have examined the role of insulin-like growth factor-II (IGF-II) in the differentiation of the CaCo-2 human colon carcinoma cell line. We have shown previously that IGF-II is an autocrine growth factor for CaCo-2 cells, IGF-II expression is high in proliferating, undifferentiated CaCo-2 cells and markedly decreases when cells become confluent and start to differentiate, To evaluate whether differentiation of CaCo-2 cells depends on an IGF-II related pathway, we treated cells with a blocking antibody to the IGF-I receptor that mediates most IGF-II biological effects, Treatment of preconfluent CaCo-2 cells with this antibody decreased by 40% autonomous cell proliferation and induced differentiation as shown by an increase in sucrase isomaltase activity and apolipoprotein A-I (apoA-I) mRNA levels. To examine the significance of autocrine IGF-II production in CaCo-2 cell differentiation, we generated stable CaCo-2 cell lines that constitutively express rat IGF-II under the control of a Rous sarcoma virus promoter. Sustained expression of IGF-II resulted in: (a) increased proliferative rate; (b) high IGF I receptor number, even after reaching confluence; (c) increased capability of anchorage-independent growth; (d) inhibition of the expression of apoA-I and SI mRNAs, Analysis of several independent IGF-II-transfected clones showed an inverse correlation between IGF-II mRNA levels and expression of the differentiation markers, the cells expressing the higher levels of the transfected IGF-II being the less differentiated ones. Our data suggest that perturbation of IGF-II-mediated cell proliferation interferes with the enterocyte-like differentiation pathway of CaCo-2 cells.	CATTEDRA GASTROENTEROL,DIPARTIMENTO INTERNIST CLIN & SPERIMENTALE,NAPLES,ITALY; FDN G PASCALE,IST NAZL TUMORI,DIV ONCOL MED B,NAPA,CA		Zarrilli, R (corresponding author), UNIV NAPLES FEDERICO II,CNR,CTR ENDCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY.		Casola, Stefano/AAN-8319-2021; Casola, Stefano/O-3922-2014; Zarrilli, Raffaele/F-5067-2012	Casola, Stefano/0000-0001-5580-0986; Zarrilli, Raffaele/0000-0003-4191-9032; ROMANO, Marco/0000-0002-3271-349X; pignata, sandro/0000-0002-8836-2633; ACQUAVIVA, Angela Maria/0000-0001-9538-2766				BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; BASERGA R, 1995, CANCER RES, V55, P249; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELEON DD, 1994, ENDOCRINOLOGY, V134, P1960, DOI 10.1210/en.134.4.1960; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GLOVER DM, 1985, DNA CLONING PRACTICA, V2, P143; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; Harlow E., 1988, ANTIBODIES LAB MANUA; HOEFLICH A, 1994, MOL CELL ENDOCRINOL, V101, P141, DOI 10.1016/0303-7207(94)90228-3; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINNITI CP, 1995, CELL GROWTH DIFFER, V6, P263; MOHAN S, 1993, J CELL PHYSIOL, V156, P462, DOI 10.1002/jcp.1041560305; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; PINTO M, 1983, BIOL CELL, V47, P323; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; QUINN LS, 1993, EXP CELL RES, V208, P504, DOI 10.1006/excr.1993.1273; QUINN LS, 1993, J CELL PHYSIOL, V156, P453, DOI 10.1002/jcp.1041560304; ROUYERFESSARD C, 1990, GASTROENTEROLOGY, V98, P703, DOI 10.1016/0016-5085(90)90291-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; TANAKA H, 1989, ENDOCRINOLOGY, V124, P870, DOI 10.1210/endo-124-2-870; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; YANG D, 1995, CARCINOGENESIS, V12, P1893; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4	44	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8108	8114		10.1074/jbc.271.14.8108	http://dx.doi.org/10.1074/jbc.271.14.8108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626497	hybrid			2022-12-25	WOS:A1996UD60000037
J	Kiefer, P; Mathieu, M; Mason, I; Dickson, C				Kiefer, P; Mathieu, M; Mason, I; Dickson, C			Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues	ONCOGENE			English	Article						zebrafish FGF3; fibroblast growth factor; mitogenesis; protein chimeras	FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; FACTOR RECEPTORS; FACTOR FAMILY; DEVELOPMENTAL EXPRESSION; CLONING; CELLS; PRODUCT; LAEVIS	Zebrafish (Brachyodanio rerio) Fgf-3 cDNAs expressed in COS-1 cells give rise to a heterogeneous set of secreted proteins with relative molecular masses in the range of 29-30.5 kDa. These proteins associate strongly with the extracellular matrix but are quantitatively released into the culture medium in the presence of heparin (5 mu g/ml). Extracellular zebrafish FGF3 (ZFGF3) also contains a smaller sized component that appears to result from an amino-terminal proteolytic cleavage. These properties are similar to those described for Xenopus FGF3 (XFGF3). Receptor binding experiments indicate that ZFGF3 has a higher affinity for the IIIb rather than the IIIc isoform of FGFR2; properties that are more reminiscent of the mouse than the Xenopus homologue. Consistent with the FGF receptor binding properties, ZFGF3 shows a restricted mitogenic potential and a reduced transforming activity on NIH3T3 cells compared to XFGF3. Hybrid proteins made between Xenopus and zebrafish FGF3 implicate the C-terminal region in determining the differences in receptor binding affinities, mitogenic potency and transforming activity. Thus, ZFGF3 shows the structural and secretory properties of XFGF3, but has biological properties more akin to those of the mouse homologue.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT DEV NEUROBIOL,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; EMORI Y, 1992, FEBS LETT, V314, P176, DOI 10.1016/0014-5793(92)80968-M; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KIEFER P, 1996, CURR TOP DEV BIOL, V25, P77; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MATHIEU M, 1995, IN PRESS J BIOL CHEM; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PETERS G, 1991, SEMIN VIROL, V2, P319; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; SEDDON AP, 1995, BIOCHEMISTRY-US, V34, P731, DOI 10.1021/bi00003a004; SHI DL, 1992, DEVELOPMENT, V116, P261; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRAHLE U, 1992, Current Biology, V2, P135, DOI 10.1016/0960-9822(92)90256-A; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; WILKIE AOM, 1995, CURR BIOL, V5, P500; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622866				2022-12-25	WOS:A1996UF07600014
J	Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G				Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G			Analysis of human c-Abl tyrosine kinase activity and regulation in S-pombe	ONCOGENE			English	Article						protein tyrosine kinase; SH3 domain; SH2 domain; autophosphorylation; Abl	FISSION YEAST; BCR-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; SH2 DOMAIN; PROTEIN; SRC; GENE; AUTOPHOSPHORYLATION; MUTATIONS	c-Abl protein tyrosine kinase activity is tightly regulated in vertebrate cells. Several mutations, including deletions of the SH3 domain, can activate abl and convert it into an oncogene. To study c-Abl activity in a cellular environment likely to lack specific regulators, we have expressed human c-Abl in Schizosaccharomyces pombe in an inducible fashion. c-Abl, but not a kinase inactive form of the molecule, causes growth arrest followed by death of the cells. Concomitant to Abl expression we observed extensive phosphorylation of endogenous proteins on tyrosine. Mutations in the SH2 domain or in the autophosphorylation site dramatically reduce the ability of Abl to confer the growth arrest phenotype and to phosphorylate endogenous proteins, suggesting a fundamental role of these structures in the activity of the enzyme. An SH3 domain deletion mutant of Abl is equally active as wild type c-Abl in yeast, even under conditions allowing detection of subtle differences. These results demonstrate that there is no intrinsic regulation of c-Abl kinase activity via the SH3 domain and suggest that the inhibitory effect of the SH3 domain observed in mammalian cells is mediated by a factor that is absent in fission yeast. Expression of Abl in S.pombe provides a novel quantitative assay for Abl activity and regulation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	European Molecular Biology Laboratory (EMBL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; Koegl M, 1995, ONCOGENE, V11, P2317; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAWYERS CL, 1994, CELL, V77, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1513	1520						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622867				2022-12-25	WOS:A1996UF07600015
J	Brandes, HK; Hartman, FC; Lu, TYS; Larimer, FW				Brandes, HK; Hartman, FC; Lu, TYS; Larimer, FW			Efficient expression of the gene for spinach phosphoribulokinase in Pichia pastoris and utilization of the recombinant enzyme to explore the role of regulatory cysteinyl residues by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAF RIBULOSE-5-PHOSPHATE KINASE; YEAST 3-PHOSPHOGLYCERATE KINASE; ESCHERICHIA-COLI; PHOSPHOGLYCERATE KINASE; CO2 ASSIMILATION; ACTIVE-SITE; SULFATE ION; BINDING; PURIFICATION; SEQUENCE	Phosphoribulokinase (PRK), unique to photosynthetic organisms, is regulated in higher plants by thioredoxin-mediated thiol-disulfide exchange in a light-dependent manner. Prior attempts to overexpress the higher plant PRK gene in Escherichia coli for structure-function studies have been hampered by sensitivity of the recombinant protein to proteolysis as well as toxic effects of the protein on the host. To overcome these impediments, we have spliced the spinach PRK coding sequence immediately downstream from the AOX1 (alcohol oxidase) promoter of Pichia pastoris, displacing the chromosomal AOX1 gene. The PRK gene is now expressed, in response to methanol, at 4-6% of total soluble protein, without significant in vivo degradation of the recombinant enzyme. This recombinant spinach PRK is purified to homogeneity by successive anion-exchange and dye-affinity chromatography and is shown to be electrophoretically and kinetically indistinguishable from the authentic spinach counterpart. Site-specific replacement of all of PRK's cysteinyl residues (both individually and in combination) demonstrates a modest catalytically facilitative role for Cys-55 (one of the regulatory residues) and the lack of any catalytic role for Cys-16 (the other regulatory residue), Cys-244, or Cys-250. Mutants with seryl substitutions at position 55 display non-hyperbolic kinetics relative to the concentration of ribulose 5-phosphate. Sulfate restores hyperbolic kinetics and enhances kinase activity, presumably reflecting conformational differences between the position 55 mutants and wild-type enzyme. Catalytic competence of the C16S-C55S double mutant proves that mere loss of free sulfhydryl groups by oxidative regulation cannot account entirely for the accompanying total inactivation.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								BRANDES HK, 1992, BIOCHEMISTRY-US, V31, P12833, DOI 10.1021/bi00166a018; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; CHARLIER HA, 1994, BIOCHEMISTRY-US, V33, P9343, DOI 10.1021/bi00197a039; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; FAIRBROTHER WJ, 1990, EUR J BIOCHEM, V190, P161, DOI 10.1111/j.1432-1033.1990.tb15560.x; GREGORY JD, 1993, J BIOL CHEM, V268, P3880; GREY M, 1992, CURR GENET, V22, P335, DOI 10.1007/BF00317931; HUDSON GS, 1992, AUST J PLANT PHYSIOL, V19, P213, DOI 10.1071/PP9920213; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KAGAWA T, 1982, METHODS CHLOROPLAST, P695; KRIEGER TJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P362, DOI 10.1016/0003-9861(87)90457-7; KRIEGER TJ, 1986, BIOCHEMISTRY-US, V25, P3496, DOI 10.1021/bi00360a003; KRIEGER TJ, 1987, BIOCHIM BIOPHYS ACTA, V915, P112, DOI 10.1016/0167-4838(87)90130-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; MILANEZ S, 1988, GENE, V66, P55, DOI 10.1016/0378-1119(88)90224-7; MILANEZ S, 1991, J BIOL CHEM, V266, P10694; PONTREMOLI S, 1962, J BIOL CHEM, V237, P643; PORTER MA, 1990, PLANTA, V181, P349, DOI 10.1007/BF00195887; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTER MA, 1986, BIOCHEMISTRY-US, V25, P7314, DOI 10.1021/bi00371a011; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; RACKER E., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P300, DOI 10.1016/0003-9861(57)90496-4; RAO BDN, 1978, J BIOL CHEM, V253, P8056; ROBERTS DL, 1995, PROTEIN SCI, V4, P2442, DOI 10.1002/pro.5560041126; ROESLER KR, 1988, NUCLEIC ACIDS RES, V16, P7192, DOI 10.1093/nar/16.14.7192; ROUSTAN C, 1980, BIOCHEMISTRY-US, V19, P5168, DOI 10.1021/bi00564a003; SANDBAKEN MG, 1992, BIOCHEMISTRY-US, V31, P3715, DOI 10.1021/bi00129a022; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLOSIUK RA, 1993, FASEB J, V7, P622, DOI 10.1096/fasebj.7.8.8500687	35	36	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6490	6496		10.1074/jbc.271.11.6490	http://dx.doi.org/10.1074/jbc.271.11.6490			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626451	hybrid			2022-12-25	WOS:A1996UA36300080
J	Kuroiwa, T; Sakaguchi, M; Omura, T; Mihara, K				Kuroiwa, T; Sakaguchi, M; Omura, T; Mihara, K			Reinitiation of protein translocation across the endoplasmic reticulum membrane for the topogenesis of multispanning membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; STOP-TRANSFER SEQUENCE; STRUCTURAL REQUIREMENTS; MICROSOMAL-MEMBRANES; BOVINE OPSIN; INSERTION; CYTOCHROME-P-450; SEGMENT; ANCHOR; TRANSLATION	The reinitiation of the translocation of the growing nascent chain across the endoplasmic reticulum membrane is essential for the topogenesis of multispanning membrane proteins, We investigated the requirements for the reinitiation process using model proteins in which systematically designed sequences were inserted after two preceding topogenic sequences, namely the N-terminal signal sequence (S) and stop transfer sequence (St), The model proteins were translated in vitro in the presence of rough microsomes, and the final topology of the proteins in the microsomal membrane was examined by proteolytic digestion, The structural requirements for S and the reinitiation sequence (R) overlapped to some extent, but substantial differences were noticed, When St and R were separated by a short cytoplasmic segment (58 amino acids), the efficiency of the reinitiation was not affected by the concentration of the signal recognition particle (SRP) in the translation system, even though the sequence inserted as R was an SRP dependent signal sequence. However, when the cytoplasmic segment was longer (100 amino acids), the reinitiation efficiency was reduced, and the SRP improved the overall efficiency as well as impaired the accessibility of the processing site after the R to the signal peptidase.	KYUSHU UNIV,GRAD SCH MED SCI,DEPT MOLEC BIOL,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University								AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CUTLER DF, 1986, J CELL BIOL, V102, P889, DOI 10.1083/jcb.102.3.889; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HEGNER M, 1992, J BIOL CHEM, V267, P16928; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LILJESTROM P, 1991, J VIROL, V65, P147; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MELANCON P, 1986, EMBO J, V5, P1551, DOI 10.1002/j.1460-2075.1986.tb04396.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAGUCHI M, 1991, J BIOCHEM-TOKYO, V109, P799, DOI 10.1093/oxfordjournals.jbchem.a123460; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SPIESS M, 1989, J BIOL CHEM, V264, P19117; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6423	6428		10.1074/jbc.271.11.6423	http://dx.doi.org/10.1074/jbc.271.11.6423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626442	hybrid			2022-12-25	WOS:A1996UA36300071
J	Nakano, H; Yamazaki, T; Miyatake, S; Nozaki, N; Kikuchi, A; Saito, T				Nakano, H; Yamazaki, T; Miyatake, S; Nozaki, N; Kikuchi, A; Saito, T			Specific interaction of topoisomerase II beta and the CD3 epsilon chain of the T cell receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; CYTOPLASMIC DOMAIN; TYROSINE KINASE; BINDING PROTEIN; ACTIVATION; SEQUENCE; LOCALIZATION; RECOGNITION; CLONING; TAIL	T cell antigen receptor (TCR) CDS complex is composed of six different subunits: TCR alpha and TCR beta and CD3 gamma, CD3 delta, CD3 epsilon, and CD3 zeta. Antigen recognition signals are transduced from TCR to the cytoplasm through the cytoplasmic domain of the CD3 chains. To understand the downstream signal transduction pathways, we cloned genes encoding proteins capable of binding to CD3 epsilon with a probe of glutathione S-transferase fused to the cytoplasmic region of CD3 epsilon. One of these clones was found to encode topoisomerase II beta (topoII beta). The binding region of CD3 epsilon is located within the N-terminal 12 amino acids containing the motif of a basic amino acid cluster. A similar motif was found in the gamma chain of Fc receptors (FcR gamma) but not in the CD3 zeta chain, and indeed, FcR gamma but not CD3 zeta bound to topoII beta. The binding region of topoII beta was determined to be the C terminus, Since this region appears to be the regulatory region of the enzymatic activity, the binding of CD3 epsilon might affect the function of topoII beta. Although topoII beta is localized mainly in the nucleus and CD3 epsilon is a membrane protein, we demonstrated the presence of CD3 epsilon in the nuclear fraction of thymocytes, which increased upon T cell activation. The specific interaction in cells was evidenced by co-immunoprecipitation of topoII beta and CD3 epsilon from the nuclear fraction of T cells. The possible function of this interaction is discussed.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC GENET,CHUO KU,CHIBA 260,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Chiba University			Saito, Takashi/C-9684-2009	Saito, Takashi/0000-0001-9495-3547; Nakano, Hiroyasu/0000-0003-4843-1427				AOE T, 1995, INT IMMUNOL, V6, P1671; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; BURG DL, 1994, J BIOL CHEM, V269, P28136; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; KIM RS, 1994, CANCER RES, V54, P4958; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LOBIE PE, 1994, J BIOL CHEM, V269, P21330; MURANO H, 1989, J IMMUNOL, V1433, P931; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NAKANO H, 1994, MOL CELL BIOL, V14, P1213, DOI 10.1128/MCB.14.2.1213; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PELLICCIARI C, 1993, EUR J HISTOCHEM, V37, P381; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIESBECK K, 1994, J IMMUNOL, V153, P343; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SINGH H, 1989, BIOTECHNIQUES, V7, P252; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEBB CF, 1993, NUCLEIC ACIDS RES, V21, P4363, DOI 10.1093/nar/21.18.4363; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	36	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6483	6489		10.1074/jbc.271.11.6483	http://dx.doi.org/10.1074/jbc.271.11.6483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626450	hybrid			2022-12-25	WOS:A1996UA36300079
J	Cho, SK; Yeh, JC; Cho, MJ; Cummings, RD				Cho, SK; Yeh, JC; Cho, MJ; Cummings, RD			Transcriptional regulation of alpha 1,3-galactosyltransferase in embryonal carcinoma cells by retinoic acid - Masking of Lewis X antigens by alpha-galactosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MOUSE TERATOCARCINOMA CELLS; N-ACETYLGLUCOSAMINYLTRANSFERASE-III; MOLECULAR-WEIGHT GLYCOPROTEINS; ACUTE-PHASE RESPONSE; INDUCED DIFFERENTIATION; MONOCLONAL-ANTIBODY; PARIETAL ENDODERM; STEM-CELLS; CYCLIC-AMP	Treatment of mouse teratocarcinoma F9 cells with all-trans-retinoic acid (RA) causes a 9-fold increase in steady-state levels of mRNA for UDP-Gal:beta-D-Gal alpha 1,3-galactosyltransferase (alpha 1,3GT) beginning at 36 h, Enzyme activity rises in a similar fashion, which also par allels the induction of laminin and type IV collagen, Nuclear run-on assays indicate that this increase in alpha 1,3GT in RA-treated F9 cells, like that of type IV collagen, is transcriptionally regulated, Differentiation also results in increased secretion of soluble alpha 1,3GT activity into the growth media, The major alpha-galactosylated glycoprotein present in the media of RA-treated F9 cells, but not of untreated cells, was identified as laminin, Differentiation of F9 cells is accompanied by an increase in alpha-galactosylation of membrane glycoproteins and a decrease in expression of the stage-specific embryonic antigen, SSEA-1 (also known as the Lewis X antigen or Le(X)), which has the structure Gal beta 1-4(Fuc alpha 1-3)Glc-NAc beta 1-R. However, flow cytometric analyses with specific antibodies and lectins, following treatment of cells with alpha-galactosidase, demonstrate that differentiated cells contain Le(X) antigens that are masked by alpha-galactosylation, Thus, RA induces alpha 1,3GT at the transcriptional level, resulting in major alterations in the surface phenotype of the cells and masking of Le(X) antigens.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center					NCI NIH HHS [CA37626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; AMOS B, 1990, INT J CANCER, V46, P86, DOI 10.1002/ijc.2910460117; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; BERGER EG, 1993, NEWS PHYSIOL SCI, V8, P57; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BOEGGEMAN EE, 1993, PROTEIN ENG, V6, P779, DOI 10.1093/protein/6.7.779; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DE LUCA LM, 1991, FASEB J, V5, P2924; DHARMESH SM, 1993, P NATL ACAD SCI USA, V90, P11127, DOI 10.1073/pnas.90.23.11127; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FEIZI T, 1987, BIOCHEM J, V245, P1; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; FUSHUKU N, 1987, J BIOL CHEM, V262, P10086; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GOLDSTEIN IJ, 1981, J BIOL CHEM, V256, P3890; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GOWDA DC, 1994, J BIOL CHEM, V269, P20031; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; GUDAS LJ, 1990, METHOD ENZYMOL, V190, P131; Gudas Lorraine J., 1994, P443; HAKOMORI S, 1981, BIOCHEM BIOPH RES CO, V100, P1578, DOI 10.1016/0006-291X(81)90699-9; HAKOMORI S, 1984, TRENDS BIOCHEM SCI, V9, P453, DOI 10.1016/0968-0004(84)90156-7; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HEFFERNAN M, 1993, J BIOL CHEM, V268, P1242; HELTON TE, 1994, ENDOCRINOLOGY, V134, P2347, DOI 10.1210/en.134.6.2347; Hesford F. J., 1984, Glycoconjugate Journal, V1, P141, DOI 10.1007/BF01213727; Hogan B. L. M, 1983, CANCER SURV, V2, P115; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUDGIN RL, 1971, CAN J BIOCHEM CELL B, V49, P829, DOI 10.1139/o71-117; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1993, BIOCHEM BIOPH RES CO, V194, P358, DOI 10.1006/bbrc.1993.1828; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KUDO T, 1995, GLYCOBIOLOGY, V5, P397, DOI 10.1093/glycob/5.4.397; KUIJPERS TW, 1993, BLOOD, V81, P873; KURKINEN M, 1983, J BIOL CHEM, V258, P6543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; Linney E., 1994, ADV DEVELOPMENTAL BI, V3, P73; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; LOPEZ LC, 1989, MOL CELL BIOL, V9, P2370, DOI 10.1128/MCB.9.6.2370; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADDOX DE, 1982, P NATL ACAD SCI-BIOL, V79, P166, DOI 10.1073/pnas.79.1.166; MARTICORENA P, 1983, CELL DIFFER DEV, V12, P1, DOI 10.1016/0045-6039(83)90111-2; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MCGUIRE EJ, 1970, BLOOD TISSUE ANTIGEN, P461; MURAMATSU H, 1983, J BIOCHEM-TOKYO, V94, P799, DOI 10.1093/oxfordjournals.jbchem.a134422; MURAMATSU H, 1983, FEBS LETT, V163, P181, DOI 10.1016/0014-5793(83)80814-X; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; MURAMATSU T, 1979, BIOCHIM BIOPHYS ACTA, V587, P392, DOI 10.1016/0304-4165(79)90443-4; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; NAKAO H, 1990, BIOCHEM BIOPH RES CO, V172, P1260, DOI 10.1016/0006-291X(90)91585-G; NARASIMHAN S, 1988, J BIOL CHEM, V263, P1273; NOMOTO S, 1986, EXP CELL RES, V164, P49, DOI 10.1016/0014-4827(86)90453-2; OZAWA M, 1985, J BIOCHEM-TOKYO, V97, P317, DOI 10.1093/oxfordjournals.jbchem.a135056; PAULSON JC, 1987, BIOCHEM SOC T, V15, P618, DOI 10.1042/bst0150618; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PENNINGTON JE, 1985, J EMBRYOL EXP MORPH, V90, P335; RICKLES RJ, 1989, MOL CELL BIOL, V9, P1691, DOI 10.1128/MCB.9.4.1691; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SCHACHTER H, 1971, J BIOL CHEM, V246, P5321; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHARMA RK, 1993, CARCINOGENESIS, V14, P1095, DOI 10.1093/carcin/14.6.1095; SHEARES BT, 1987, J IMMUNOL, V139, P3748; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1979, DEV BIOL, V70, P515, DOI 10.1016/0012-1606(79)90043-5; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURKINGTON RW, 1986, J BIOL CHEM, V243, P3382; UEMURA M, 1992, CANCER RES, V52, P6153; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WANG XC, 1993, J BIOL CHEM, V268, P4355; WANG XC, 1990, J BIOL CHEM, V265, P17849; WANG XC, 1989, J BIOL CHEM, V264, P1854; WOOD L, 1988, FEBS LETT, V227, P5, DOI 10.1016/0014-5793(88)81402-9	104	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3238	3246		10.1074/jbc.271.6.3238	http://dx.doi.org/10.1074/jbc.271.6.3238			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621726	hybrid			2022-12-25	WOS:A1996TU69100055
J	Meikrantz, W; Schlegel, R				Meikrantz, W; Schlegel, R			Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GENE-EXPRESSION; C-MYC; DNA-REPLICATION; DISTINCT ROLES; ACTIVATION; CDC2; INDUCTION; SURVIVAL; LINES	In many cell types, position in the cell cycle appears to play a role in determining susceptibility to apoptosis (programmed cell death), and expression of various cyclins and activation of cyclin-dependent kinases (CDKs) have been shown to correlate with the onset of apoptosis in a number of experimental systems. To assess the role of CDK-mediated cell cycle events in apoptosis, we have expressed CDK dominant negative mutants in human HeLa cells. Dominant negative mutants of CDC2, CDK2, and CDK3 each suppressed apoptosis induced by both staurosporine and tumor necrosis factor alpha, whereas a dominant negative mutant of CDK5 was without effect. Like CDC2 and CDK2, CDK3 was shown to form a complex with cyclin A in vivo. CDK5 did not bind cyclin A to any detectable extent. Overexpression of wild type CDC2, CDK2, CDK3, or cyclin A (but not cyclin B) markedly elevated the incidence of apoptosis in BCL-2(+) cells, which otherwise fail to respond to these agents, These results help identify cell cycle events that are also important for efficient apoptosis.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NCI NIH HHS [CA61626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA061626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANG F, 1993, J CELL SCI, V106, P983; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KULL FC, 1981, CANCER RES, V41, P4885; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MARTI A, 1994, ONCOGENE, V9, P1213; MEIKRANTZ W, 1990, P NATL ACAD SCI USA, V87, P9600, DOI 10.1073/pnas.87.24.9600; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MYERSON M, 1992, EMBO J, V11, P2909; NISHIOKA WK, 1992, J EXP MED, V175, P23, DOI 10.1084/jem.175.1.23; NISHIOKA WK, 1994, J EXP MED, V179, P769, DOI 10.1084/jem.179.2.769; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEINMANN KE, 1994, ONCOGENE, V9, P387; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALLACH D, 1984, J IMMUNOL, V132, P2464; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	53	185	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10205	10209		10.1074/jbc.271.17.10205	http://dx.doi.org/10.1074/jbc.271.17.10205			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626584	hybrid			2022-12-25	WOS:A1996UG25700056
J	Brandl, CJ; Martens, JA; Margaliot, A; Stenning, D; Furlanetto, AM; Saleh, A; Hamilton, KS; Genereaux, J				Brandl, CJ; Martens, JA; Margaliot, A; Stenning, D; Furlanetto, AM; Saleh, A; Hamilton, KS; Genereaux, J			Structure/function properties of the yeast dual regulator protein NGG1 that are required for glucose repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; GAL4 PROTEIN; SATURATION MUTAGENESIS; CATABOLITE REPRESSION; MONOCLONAL-ANTIBODIES; SECONDARY STRUCTURE; NEGATIVE CONTROL; PHOSPHOLIPASE-C	NGG1p/ADA3p is a yeast dual function regulator required for the complete glucose repression of GAL4p-activated genes (Brandl, C. J., Furlanetto, A. M., Martens, J. A., and Hamilton, K. S. (1993) EMBO J. 12, 5255-5265). Evidence for a direct role for NGG1p in regulating activator function is supported by the finding that NGG1p is also required for transcriptional activation by GAL4p-VP16 and LexA-GCN4p (Pina, B., Berger, S. L., Marcus, G. A., Silverman, N., Agapite, J., and Guarente, L. (1993) Mol. Cell. Biol. 13, 5981-5989). By analyzing deletion derivatives of the 702-amino acid protein, we identified a region essential for glucose repression within residues 274-373. Essential sequences were further localized to a segment rich in Phe residues that is predicted to be an amphipathic alpha helix. As well as finding mutations within this region that reduced glucose repression, we identified mutations that made NGG1p a better repressor. In addition, NGG1p probably represses GAL4p activity as part of a complex containing ADA2p because single and double disruptions of ngg1 and ada2 had comparable effects on glucose repression. We also localized a transcriptional activation domain within the amino-terminal amino acids of NGG1p that is proximal or overlapping the region required for glucose repression. Activation by GAL4p-NGG1p(1-373) requires ADA2p; however, activation by GAL4p-NGG1p(1-308) is ADA2p-independent. This suggests that a site required for ADA2p interaction lies between amino acids 308 and 373 and that ADA2p has a regulatory role in activation by GAL4p-NGG1p(1-373).			Brandl, CJ (corresponding author), UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5C1,CANADA.			Saleh, Ayman M/0000-0003-1126-6018				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; AUSUBEL FA, 1990, PROTOCOLS MOL BIOL; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BHAT PJ, 1990, GENETICS, V125, P281; BHAT PJ, 1992, MOL CELL BIOL, V12, P2701, DOI 10.1128/MCB.12.6.2701; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; FLICK JS, 1992, GENETICS, V130, P295; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUISMAN O, 1987, GENETICS, V116, P191; INOSTROZA JA, 1992, CELL, V70, P477; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; JOHNSTON M, 1993, BIOL YEAST SACCHAROM, V2, P193; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STONE G, 1993, EMBO J, V12, P1375, DOI 10.1002/j.1460-2075.1993.tb05782.x; STRUHL K, 1985, NATURE, V317, P822, DOI 10.1038/317822a0; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TORCHIA TE, 1986, GENETICS, V113, P229; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; WEST RW, 1987, GENE DEV, V1, P1118, DOI 10.1101/gad.1.10.1118	73	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9298	9306		10.1074/jbc.271.16.9298	http://dx.doi.org/10.1074/jbc.271.16.9298			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621592	hybrid			2022-12-25	WOS:A1996UG04400023
J	Otto, A; Stoltz, M; Sailer, HP; Brandsch, R				Otto, A; Stoltz, M; Sailer, HP; Brandsch, R			Biogenesis of the covalently flavinylated mitochondrial enzyme dimethylglycine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ASPARTATE-AMINOTRANSFERASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; OXIDASE; PRESEQUENCE; PROTEIN; PRECURSOR; IMPORT; FAD	Rat dimethylglycine dehydrogenase (Me(2)GlyDH) was used as model protein to study the biogenesis of a covalently flavinylated mitochondrial enzyme, Here we show that: 1) enzymatically active holoenzyme correlated with trypsin resistance of the protein; 2) folding of the reticulocyte lysate-translated protein into the trypsin-resistant, holoenzyme form was a slow process that was stimulated by the presence of the flavin cofactor and was more efficient at 15 degrees C than at 30 degrees C; 3) the mitochondrial presequence reduced the extent but did not prevent holoenzyme formation; 4) covalent attach ment of FAD to the Me(2)GlyDH apoenzyme proceeded spontaneously and did not require a mitochondrial protein factor; 5) in vitro only the precursor, but not the mature form, of the protein was imported into isolated rat liver mitochondria; in vivo, in stably transfected HepG2 cells, both the precursor and the mature form were imported into the organelle; 6) holoenzyme formation in the cytoplasm did not prevent the translocation of the proteins into the mitochondria in vivo; and 7) lack of vitamin B-2 in the tissue culture medium resulted in a reduced recovery of the precursor and the mature form of Me(2)GlyDH from cell mitochondria, suggesting a decreased efficiency of mitochondrial protein import.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg								Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994; BARILE M, 1993, ARCH BIOCHEM BIOPHYS, V305, P442, DOI 10.1006/abbi.1993.1444; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; CHLUMSKY LJ, 1995, J BIOL CHEM, V270, P18252, DOI 10.1074/jbc.270.31.18252; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; COOK RJ, 1986, METHOD ENZYMOL, V106, P255; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DECKER K, 1991, BIOFACTORS, V3, P69; DECKER K, 1992, CHEM BIOCH FLAVOENZY, P344; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; GIANNATTASIO S, 1992, ARCH BIOCHEM BIOPHYS, V298, P532, DOI 10.1016/0003-9861(92)90446-4; GIANNATTASIO S, 1991, ARCH BIOCHEM BIOPHYS, V290, P528, DOI 10.1016/0003-9861(91)90577-6; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JANSKI AM, 1980, BIOCHEM J, V186, P423, DOI 10.1042/bj1860423; Kim J, 1995, J BIOL CHEM, V270, P31202, DOI 10.1074/jbc.270.52.31202; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUTCHAN TM, 1995, J BIOL CHEM, V270, P24475, DOI 10.1074/jbc.270.41.24475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; LANG H, 1991, EUR J BIOCHEM, V198, P793, DOI 10.1111/j.1432-1033.1991.tb16083.x; MARAS B, 1994, J BIOL CHEM, V269, P18429; MIHALIK SJ, 1991, J BIOL CHEM, V266, P4822; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P207, DOI 10.1093/oxfordjournals.jbchem.a123182; NAGAO M, 1992, J BIOL CHEM, V267, P17925; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; REYES AM, 1993, J BIOL CHEM, V268, P22281; Sambrook J., 2002, MOL CLONING LAB MANU; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SINGER TP, 1955, ARCH BIOCHEM BIOPHYS, V60, P255; STOLTZ M, 1995, J BIOL CHEM, V270, P8016, DOI 10.1074/jbc.270.14.8016; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029	44	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9823	9829		10.1074/jbc.271.16.9823	http://dx.doi.org/10.1074/jbc.271.16.9823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621665	hybrid			2022-12-25	WOS:A1996UG04400096
J	Schmidt, VA; Vitale, E; Bahou, WF				Schmidt, VA; Vitale, E; Bahou, WF			Genomic cloning and characterization of the human thrombin receptor gene - Structural similarity to the proteinase activated receptor-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; MOLECULAR-CLONING; AGONIST PEPTIDES; GROWTH-FACTOR; CDNA CLONING; EXPRESSION; MECHANISM; CHROMOSOME-5; SEQUENCES; ENHANCER	The seven-transmembrane segment thrombin receptor (TR) represents the prototype of a putative family of proteolytically cleaved receptors that may include the proteinase activated receptor-2, A panel of somatic cell hybrids retaining distinct portions of human chromosome 5 were used to establish that the human TR gene is present as a single-copy locus within the region 5q11.2-->q13.3, confirming our previous localization using fluorescent in situ hybridization analysis, To further characterize the TR gene, overlapping clones from a human genomic library were isolated, Genomic analysis confirmed that the TR gene is of limited complexity, spanning similar to 27 kilobases and containing two exons separated by a large similar to 22-kilobase intron, The larger second exon contains the majority of the coding sequence and the thrombin cleavage site, remarkably similar to the organization of the proteinase activated receptor-2 gene in which the putative cleavage site is also contained within the large second exon, Primer extension analysis using two 30-mer oligonucleotide primers known to be contained within the first exon identified the predominant transcription initiation site 351 base pairs upstream from the initiator methionine in both human umbilical vein endothelial and human erythroleukemia cells, Sequence analysis of the 5'-flanking region revealed the TR promoter to be TATA-less, although nucleic acid motifs potentially involved in transcriptional gene regulation were evident and include a GATA motif, octamer enhancer sequences, AP-2-like sites, and Sp1 sites. These data provide evidence for remarkable similarity at the gene level between both proteolytically cleaved receptors described to date.	SUNY STONY BROOK,DIV HEMATOL,HLTH SCI CTR T15040,DEPT MED,STONY BROOK,NY 11794; COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Columbia University; Columbia University			vitale, emilia/A-5282-2011	Vitale, Emilia/0000-0003-4651-3875	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BAHOU WF, 1992, J BIOL CHEM, V267, P13986; BAHOU WF, 1994, BLOOD, V84, P4195, DOI 10.1182/blood.V84.12.4195.bloodjournal84124195; BAHOU WF, 1993, BLOOD, V82, P1532, DOI 10.1182/blood.V82.5.1532.bloodjournal8251532; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; DANA S, 1982, MOL CELL BIOL, V2, P1220, DOI 10.1128/MCB.2.10.1220; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOLIGORSKY M, 1990, J BIOL CHEM, V264, P16771; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P6549; Jamieson G A, 1988, Prog Clin Biol Res, V283, P137; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Maniatis T., 1982, MOL CLONING; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUSTELL J, 1986, NUCLEIC ACIDS RES, V14, P479, DOI 10.1093/nar/14.1.479; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	36	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9307	9312		10.1074/jbc.271.16.9307	http://dx.doi.org/10.1074/jbc.271.16.9307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621593	hybrid			2022-12-25	WOS:A1996UG04400024
J	Turner, PR; Bambino, T; Nissenson, RA				Turner, PR; Bambino, T; Nissenson, RA			A putative selectivity filter in the G-protein-coupled receptors for parathyroid hormone and secretin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ADENYLATE-CYCLASE; CHANNEL; EXPRESSION; ACTIVATION; BINDING; CELLS	The seven transmembrane segments (TMs) of many G-protein-coupled receptors (GPCRs) are thought to form a cavity into which cognate ligands insert, leading to receptor activation, Residues lining the cavity are often essential for optimal ligand binding and/or signal transduction. The present studies evaluated whether residues lining the cavity also contribute to specificity, using GPCRs for the polypeptides parathyroid hormone (PTH) and secretin as models, These ligands display no sequence homology with one another, and neither ligand cross-reacts with the other's receptor, However, mutation of a single amino acid in the second TRI of the secretin receptor to the corresponding residue in the PTH receptor (N192I) resulted in a receptor that binds and signals in response to PTH. The reciprocal mutation in the PTH receptor (I234N) likewise unmasked responsiveness to secretin. Neither mutation significantly altered the response of the receptors to their own ligands, The results suggest a model of specificity wherein TM residues near the extracellular surface of the receptor function as a selectivity filter that restricts access of inappropriate ligands to an activation site in the transmembrane cavity.	VET AFFAIRS MED CTR,ENDOCRINE UNIT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIDDK NIH HHS [DK07418, DK35323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007418, R01DK035323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGER A, 1994, J MOL BIOL, V237, P479, DOI 10.1006/jmbi.1994.1249; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; FATHI Z, 1993, J BIOL CHEM, V268, P14622; Hille B., 1992, IONIC CHANNELS EXCIT; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HUCHO F, 1989, FEBS LETT, V257, P17, DOI 10.1016/0014-5793(89)81775-2; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NISSENSON RA, 1985, CANCER RES, V45, P5358; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024	28	37	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9205	9208		10.1074/jbc.271.16.9205	http://dx.doi.org/10.1074/jbc.271.16.9205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621578	hybrid			2022-12-25	WOS:A1996UG04400009
J	Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP				Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP			Evidence for genomic instability in human colonic aberrant crypt foci	ONCOGENE			English	Article						colon cancer precursors; premalignant lesions; genomic instability; aberrant crypt foci	QUANTIFICATION; MUTATIONS; CANCER	Aberrant crypt foci (ACF) are morphologically abnormal structures that can be identified in whole mounts of colonic tissue from rodents treated with colon carcinogens and from patients at risk for development of colon tumors, ACF are heterogeneous and exhibit properties, such as altered patterns of cell proliferation, the presence of dysplasia, and mutations in protooncogenes and tumor suppressor genes, consistent with the hypothesis that a subset of these structures are precursors to tumor formation, In this study, we have investigated the presence of genomic instability in DNA isolated from human ACF from patients with colon cancer, Altered allele length detected by electrophoretic separation of PCR amplified oligo A or microsatellite loci was used to identify candidate samples which were then more rigorously investigated by sequence analysis for instability, Of 20 patients examined, two exhibited alterations at two loci, and this instability could be confirmed by sequence analysis, An additional seven of the 20 patients had evidence for instability at a single locus, Quantitative sequence analysis of the DNA from an ACF of one of these seven patients was consistent with alteration of allele length in this patient, but the alteration was not sufficiently different from normal to reach statistical significance, Thus, genomic instability, manifest as altered length of microsatellite and oligo A sequences, is present in some ACF, and therefore can be a very early event in the development of some human colon cancers.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	Augenlicht, LH (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R21CA066642, R01CA048032, R01CA057694] Funding Source: NIH RePORTER; NCI NIH HHS [CA57694, CA66642, CA48032] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AUGENLICHT L, 1994, GASTROENTEROLOGY, V107, P1894, DOI 10.1016/0016-5085(94)90840-0; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; CHEN JS, 1995, CANCER RES, V55, P174; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, CANCER RES, V54, P5523; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1994, CANCER RES, V54, P5059; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRETLOW TP, 1991, CANCER RES, V51, P1564; PRETLOW TP, 1994, GASTROENTEROLOGY, V107, P1719, DOI 10.1016/0016-5085(94)90812-5; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; PRETLOW TP, 1994, INT J CANCER, V56, P599, DOI 10.1002/ijc.2910560422; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; RONCUCCI L, 1993, CANCER RES, V53, P3726; SMITH AJ, 1994, CANCER RES, V54, P5527; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	23	63	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1767	1772						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622897				2022-12-25	WOS:A1996UG45800019
J	Foster, SA; Galloway, DA				Foster, SA; Galloway, DA			Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells	ONCOGENE			English	Article						HPV; E7; epithelial cells; cell cycle	RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; CELLULAR-RESPONSE; P53 PROTEIN; DNA DAMAGE; CYCLIN-A; PHOSPHORYLATION; EXPRESSION; E6; IMMORTALIZATION	Human mammary epithelial cells (HMEC) isolated from reduction mammoplasty tissue are proliferative for several passages but then enter a period termed 'selection' or M0 during which the majority of the cells become larger, flattened, and less proliferative. Early passage HMEC (prior to M0) were transduced with human papillomavirus type-16 E6, E7, or E6/E7 by using recombinant retroviral vectors. E7 alone or E6/E7, but not E6 alone, alleviated the M0 proliferation block, suggesting a possible role for Rb or Rb-related proteins, but not p53, in M0. In addition, cells in M0 did not have increased levels of p53 or p21 proteins, further indicating that induction of these proteins is not required for the M0 proliferation block. Early passage cells contained Rb which was primarily hyperphosphorylated while cells in M0 contained Rb protein which was predominantly underphosphorylated. Cells in M0 accumulated in G(1) or G(0) and expressed reduced levels of cyclin A and CDKZ proteins.			Foster, SA (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, C1-015, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [R01CA064795, F32CA062584] Funding Source: NIH RePORTER; NCI NIH HHS [CA64795, CA62584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, ONCOGENE, V8, P1407; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Werness B A, 1991, Important Adv Oncol, P3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	75	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622898				2022-12-25	WOS:A1996UG45800020
J	Pratico, D; FitzGerald, GA				Pratico, D; FitzGerald, GA			Generation of 8-epiprostaglandin F-2 alpha by human monocytes - Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; INDUCIBLE CYCLOOXYGENASE; ALVEOLAR MACROPHAGES; EXPRESSION; LIPOPOLYSACCHARIDE; ATHEROSCLEROSIS; RECEPTORS; INDUCTION	F-2-isoprostanes are free radical-catalyzed products of arachidonic acid. One of these compounds, 8-epiprostaglandin F-2 alpha (8-epi-PGF(2 alpha)), is a mitogen and vasoconstrictor. We have shown that 8-epi-PGF(2 alpha), unlike other F-2-isoprostanes, is a minor product of the prostaglandin endoperoxide synthase-1 (PG G/H S-1) expressed in human platelets (Pratico, D., Lawson, J. A., and FitzGerald, G. A. (1995) J. Biol. Chem. 270, 9800-9808). Human monocytes express PG G/H S-1 constitutively and exhibit regulated expression of PG G/H S-2. Induction of PO G/H S-2 by concanavalin A, the phorbol ester, phorbol 12-myristate 13-acetate, and bacterial lipopolysaccharide was confirmed with a specific antibody in monocytes pretreated with aspirin to inhibit PC: G/H S-1. Induction of PO G/H S-2 by all three stimuli coincided with increased formation of prostaglandin E(2) (PGE(2)), thromboxane B-2 (TxB(2)), and 8-epi-PGF(2 alpha), but not of other F-2-isoprostanes. Confirmation of PG G/H S-2 as the source of 8-epi-PGF(2 alpha) formation was obtained by down-regulating the enzyme with dexamethasone; preventing protein synthesis with cycloheximide; and preventing synthesis of PGE(2), TxB(2), and 8-epi-PGF(2 alpha) with the specific PG G/H S-2 inhibitor, L 745,337. Monocytes also exhibit the facility to generate 8-epi-PGF(2 alpha) in a free radical-dependent manner. Thus, stimulation with opsonized zymosan or coincubation with low density lipoprotein was unassociated with product formation. However, coincubation of low density lipoprotein with zymosan-stimulated human monocytes resulted in marked formation of 8-epi-PGF(2 alpha), but not of PGE(2) or TxB(2). Production of 8-epi-PGF(2 alpha) coincided with that of thiobarbituric acid-reactive substances and lipid hydroperoxides, but was unaccompanied by PG G/H S-2 induction. Pretreatment of monocytes with the antioxidant, butylated hydroxytoluene or with superoxide dismutase, but not with L 745,337, suppressed formation of 8-epi-PGF(2 alpha), thiobarbituric acid-reactive substances, and lipid hydroperoxides. In conclusion, human monocytes may form bioactive 8-epi-PGF(2 alpha) either via free radical- or enzyme-catalyzed pathways. 8-Epi-PGF(2 alpha) is a more abundant product of monocyte PG G/H S-2 than of platelet PG G/H S-1. Formation by inducible PG G/H S-2 must be considered as a source of this compound in vivo.	UNIV PENN, CTR EXPTL THERAPEUT, STELLAR CHANCE LABS 901, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010					BOYUM A, 1968, SCAND J CLIN LAB INV, V21, P97; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1988, IN VITRO CELL DEV B, V24, P1001; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; DAVIES MJ, 1993, BRIT HEART J, V69, P377; DELANTY N, 1996, IN PRESS BR J CLIN P; DELANTY N, 1996, IN PRESS CIRCULATION; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FU JY, 1990, J BIOL CHEM, V265, P16737; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GERRITY RG, 1981, AM J PATHOL, V103, P181; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JOHNSTON RB, 1981, METHODS STUDYING MON, P489; JONES DA, 1993, J BIOL CHEM, V268, P9049; KNAPP HR, 1988, THROMB RES, V50, P377, DOI 10.1016/0049-3848(88)90267-8; KOSKI IR, 1976, IN VITRO METHODS CEL, P359; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEE SH, 1992, J BIOL CHEM, V267, P25934; LULIANO L, 1992, LIPIDS, V27, P349, DOI 10.1007/BF02536149; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; NAVAB M, 1988, J CLIN INVEST, V82, P1853, DOI 10.1172/JCI113802; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1993, BIOCHEM BIOPH RES CO, V191, P1294, DOI 10.1006/bbrc.1993.1358; PICKETT WC, 1981, ANAL BIOCHEM, V111, P115, DOI 10.1016/0003-2697(81)90237-2; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; REILLY M, 1996, IN PRESS CIRCULATION; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEEGER W, 1989, J CLIN INVEST, V84, P220, DOI 10.1172/JCI114144; SESSA WC, 1990, CIRC RES, V66, P383, DOI 10.1161/01.RES.66.2.383; SINZINGER H, 1993, J CARDIOVASC PHARM, V21, P503, DOI 10.1097/00005344-199303000-00023; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826	49	169	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8919	8924		10.1074/jbc.271.15.8919	http://dx.doi.org/10.1074/jbc.271.15.8919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621535	hybrid			2022-12-25	WOS:A1996UE73000066
J	Farrance, IKG; Ordahl, CP				Farrance, IKG; Ordahl, CP			The role of transcription enhancer factor-1 (TEF-1) related proteins in the formation of M-CAT binding complexes in muscle and non-muscle tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-T-GENE; CHAIN-BETA-GENE; MYOGENIC CELL-LINE; SV40 ENHANCER; LATE PROMOTER; FACTOR-I; EXPRESSION; SKELETAL; ELEMENT; ANTIGEN	M-CAT sites are required for the activity of many promoters in cardiac and skeletal muscle. M-CAT binding activity is muscle-enriched, but is found in many tissues and is immunologically related to the HeLa transcription enhancer factor-1 (TEF-1). TEF-1-related cDNAs (RTEF-1) have been cloned from chick heart. RTEF-1 mRNA is muscle-enriched, consistent with a role for RTEF-1 in the regulation of muscle-specific gene expression. Here, we have examined the tissue distribution of TEF-1-related proteins and of M-CAT binding activity by Western analysis and mobility shift polyacrylamide gel electrophoresis. TEF-1-related proteins of 57, 54 and 52 kDa were found in most tissues with the highest levels in muscle tissues. All of these TEF-1-related proteins bound M-CAT DNA and the 57- and 54-kDa TEF-1-related polypeptides were phosphorylated. Proteolytic digestion mapping showed that the 54-kDa TEF-1-related polypeptide is encoded by a different gene than the 52- and 57-kDa TEF-1-related polypeptides. A comparison of the migration and proteolytic digestion of the 54-kDa TEF-1-related polypeptide with proteins encoded by the cloned RTEF-1 cDNAs showed that the 54-kDa TEF-1-related polypeptide is encoded by RTEF-1A. High resolution mobility shift polyacrylamide gel electrophoresis showed multiple M-CAT binding activities in tissues. All of these activities contained TEF-1-related proteins. One protein-M-CAT DNA complex was muscle-enriched and was up-regulated upon differentiation of a skeletal muscle cell line. This complex contained the 54-kDa TEF-1-related polypeptide, Therefore, RTEF1-A protein is a component of a muscle-enriched transcription complex that forms on M-CAT sites and may play a key role in the regulation of transcription in muscle.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL035561] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43821, HL-35561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; ANTIN PB, 1991, DEV BIOL, V143, P122, DOI 10.1016/0012-1606(91)90059-C; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Azakie A, 1996, J BIOL CHEM, V271, P8260, DOI 10.1074/jbc.271.14.8260; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CASAZ P, 1991, J VIROL, V65, P6535, DOI 10.1128/JVI.65.12.6535-6543.1991; CHAUDHARY S, 1995, J BIOL CHEM, V270, P3631, DOI 10.1074/jbc.270.8.3631; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; Harlow E., 1988, ANTIBODIES LAB MANUA; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SCIELLER P, 1991, VIROLOGY, V181, P783, DOI 10.1016/0042-6822(91)90918-2; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1992, MOL CELL BIOL, V12, P619, DOI 10.1128/MCB.12.2.619; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649	56	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8266	8274		10.1074/jbc.271.14.8266	http://dx.doi.org/10.1074/jbc.271.14.8266			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626521	hybrid			2022-12-25	WOS:A1996UD60000061
J	PerezMartin, J; deLorenzo, V				PerezMartin, J; deLorenzo, V			Identification of the repressor subdomain within the signal reception module of the prokaryotic enhancer-binding protein XylR of Pseudomonas putida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOL PLASMID; NUCLEOTIDE-SEQUENCE; PROMOTER; FAMILY	In the presence of m-xylene, the protein XylR encoded by the TOL plasmid of Pseudomonas putida, activates the sigma(54)-dependent promoter Pu. Early activation stages involve the release of the intramolecular repression caused by the signal reception N-terminal (A domain) of XylR on the central module of the protein. A genetic approach has been followed to locate the specific segment within A domain of XylR that is directly responsible for its down-regulation in the absence of inducer, as compared to that involved in effector (m-xylene) binding. For this, a reporter Escherichia coli strain carrying a monocopy transcriptional fusion of Pu to lacZ was transformed with a collection of plasmids encoding equivalent truncated varieties of XylR, consisting of nested and internal deletions throughout the entire A domain. Examination of the resulting phenotypes allowed the assignment of the A domain region near the central activation domain, as the portion of the protein responsible for the specific repression of XylR activity in the absence of m-xylene.	CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1991, J BIOL CHEM, V266, P15832; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BURKHARD R, 1993, J MOL BIOL, V232, P584; DELGADO A, 1995, J BIOL CHEM, V270, P5144, DOI 10.1074/jbc.270.10.5144; DELGADO A, 1994, J BIOL CHEM, V269, P8059; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; INOUYE S, 1988, GENE, V66, P301; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; Miller J.H., 1972, EXPT MOL GENETICS; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAKAZAWA T, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P133; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PEREZMARTIN J, 1996, IN PRESS J MOL BIOL; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993	21	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7899	7902		10.1074/jbc.271.14.7899	http://dx.doi.org/10.1074/jbc.271.14.7899			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626467	hybrid, Green Published			2022-12-25	WOS:A1996UD60000007
J	Tzameli, I; Zannis, VI				Tzameli, I; Zannis, VI			Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; 9-CIS RETINOIC ACID; HORMONE RESPONSE ELEMENT; THYROID-HORMONE; PLASMA-LEVELS; GENE; TRANSCRIPTION; EXPRESSION; RXR; SUPERFAMILY	Three proximal regulatory elements, AIB, AIC, and AID, of the apoA-I gene are necessary and sufficient for its hepatic expression in vivo and in vitro. DNA binding and competition assays showed that elements AIB and AID contain hormone response elements composed of imperfect direct repeats that support the binding of the hepatic nuclear factor-4, other nuclear orphan receptors, and the ligand-dependent nuclear receptors retinoic X receptor (RXR alpha), RXR alpha/RAR alpha, and RXR alpha/T(3)R beta. Substitution mutations on repeats 1 and 2 in the hormone response sites of elements AIB and AID, respectively, abolished the binding of all nuclear receptors and reduced promoter activity to background levels, indicating the importance of both hormone response elements for the hepatic expression of the apoA-I gene. Cotransfection experiments in HepG2 cells with normal and mutated promoter constructs and plasmids expressing nuclear hormone receptors showed that RXR alpha homodimers transactivated the wild type promoter 150% of control, in the presence of 9-cis-retinoic acid (RA), whereas RXR alpha/T(3)R beta heterodimers repressed transcription to 60% of control, in the presence of T-3. RXR alpha/RAR alpha and hepatic nuclear factor-4 did not affect the transcription, driven by the proximal apoA-I promoter. Potassium permanganate and dimethyl sulfate interference experiments showed that RXR alpha homodimers, RXR alpha/RAR alpha, and RXR alpha/T(3)R beta heterodimers participate in protein-DNA interactions with 12, 13, and 11 out of the 14 nucleotides, respectively, that span repeats 1 and 2 and the spacer region separating them on the hormone response element of element AID. The binding of RXR alpha homodimers and RXR alpha/T(3)R beta heterodimers is associated with ligand-dependent activation by 9-cis-RA or repression by T-3. Upon deletion or mutation of repeat 1, homodimeric binding of RXR alpha is lost whereas heterodimeric binding is retained. This heterodimeric binding to the mutated element AID is mediated solely by interactions with repeat 2 and one adjacent nucleotide and is confined to a heptameric core recognition motif. The interactions of the RXR alpha heterodimers with repeat 2 are associated with low levels of ligand independent transcriptional activity. The findings suggest that the specific types of homo- and heterodimers of nuclear hormone receptors occupying the hormone response elements of apoA-I and the availability of the ligand may play an important role in the transcriptional regulation of the human apoA-I gene.	BOSTON UNIV,MOLEC GENET SECT,CTR ADV BIOMED RES,CARDIOVASC INST,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048739, R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33952, HL-48739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GILLER T, 1995, J LIPID RES, V36, P1021; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LENG XH, 1994, J BIOL CHEM, V269, P31436; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAKRIDES SC, 1988, EUR J BIOCHEM, V173, P465, DOI 10.1111/j.1432-1033.1988.tb14022.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM, V8, P319; MEITUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WALSH A, 1989, J BIOL CHEM, V264, P6488; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	46	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8402	8415		10.1074/jbc.271.14.8402	http://dx.doi.org/10.1074/jbc.271.14.8402			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626539				2022-12-25	WOS:A1996UD60000079
J	Chen, RH; Juo, PCH; Curran, T; Blenis, J				Chen, RH; Juo, PCH; Curran, T; Blenis, J			Phosphorylation of c-Fos at the C-terminus enhances its transforming activity	ONCOGENE			English	Article						c-Fos; MAP kinase; pp90(RSK)	SERUM RESPONSE ELEMENT; ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; DNA-BINDING ACTIVITY; GROWTH-FACTOR; MAP KINASES; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; COMPLEX-FORMATION	c-Fos is phosphorylated by MAP kinase and the 90 kDa-ribosomal S6 kinase (RSK) in vitro at serines 362 and 374 (rat) which we demonstrate are major in vivo phosphorylation sites in early G1. We have constructed c-Fos mutants with these serines changed to aspartic acid residues (FosD) to mimic phosphorylation or to alanine residues (FosA) to prevent phosphorylation. Cells expressing FosD exhibited a more extensive transformed phenotype than those expressing either FosA or wild type c-Fos (FosWT). We also observed that FosA has a reduced half-life in comparison with FosD in G1. Furthermore, we observed enhanced AP-1 transactivation activity in cells expressing FosD. These results indicate that phosphorylation of c-Fos at its extreme carboxy-terminus, possibly by MAP kinase and RSK, supports the proliferative response by increasing c-Fos stability and/or by increasing its transactivation activity. Under conditions in which the MAP kinase pathway is constitutively activated, c-Fos phosphorylation probably contributes to cellular transformation. The highly conserved nature of these phosphorylation sites in other c-fos family members suggest that these may also be targets of MAP kinase and RSK.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital			Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUDA MC, 1994, ONCOGENE, V9, P2537; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONIG H, 1991, MOL CELL BIOL, V11, P2451; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Sambrook J, 1989, MOL CLONING; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	48	142	143	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1493	1502						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622865				2022-12-25	WOS:A1996UF07600013
J	Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J				Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J			Involvement of p27(KIP1) in G(1) arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; mAb; p27(KIP1); cyclins; CDKs; cell cycle arrest	PROTEIN-KINASE; BREAST-CANCER; FACTOR-ALPHA; CELLS; CARCINOMA; CYCLIN	Activation of the cyclin dependent kinases (CDK4/CDK6 and CDK2) is required for G(1) phase progression and entry into S-phase. The activation of these kinases is regulated by checkpoints that monitor environmental and intracellular conditions. Progression into S-phase is controlled, in part, by the availability of growth factors, and we have investigated the relationship between growth factor availability and the activation of the CDK kinases. Blocking activation of epidermal growth factor (EGF) receptor tyrosine kinase with anti-EGF receptor monoclonal antibody (mAb) 225 induces G(1) phase cell cycle arrest in DiFi human colon adenocarcinoma cells. When DiFi cells are treated with mAb 225 for 24 h, eve observe marked decreases in the activities of CDK2 kinase and cyclin E-associated CDK kinase which are not accompanied by reduced levels of cyclin E and CDK2 proteins. However, the amount of cyclin/CDK kinase inhibitor p27(KIP1) increases in the mAb-treated cells and p27(KIP1) is bound to CDK2 in increasing amounts. Immunodepletion of p27(KIP1) removes an inhibitory activity from lysates of mAb-treated cells: the immuno-depleted and heated lysates lose the capacity to inhibit cyclin E/CDK2 activity in an in vitro assay. The results suggest that G(1) arrest in the cell cycle induced by EGF receptor blockade involves p27(KIP1).	MEM SLOAN KETTERING CANC CTR,LAB RECEPTOR BIOL,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University				Rubin, Mark/0000-0002-8321-9950	NCI NIH HHS [CA42060, CA 37641] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042060, U01CA037641, U19CA037641, R37CA042060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; FAN Z, 1995, FJ CELL BIOL, V131, P235; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRANA X, 1995, ONCOGENE, V11, P211; GROSS ME, 1991, CANCER RES, V51, P1452; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARRIS AL, 1989, CANCER CEL, V7, P353; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1995, PROGR CELL CYCLE RES, P141; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; NEAL DE, 1985, LANCET, V1, P366; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; Sato J D, 1983, Mol Biol Med, V1, P511; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	37	212	225	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1397	1403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622855				2022-12-25	WOS:A1996UF07600003
J	ElBenna, J; Faust, LP; Johnson, JL; Babior, BM				ElBenna, J; Faust, LP; Johnson, JL; Babior, BM			Phosphorylation of the respiratory burst oxidase subunit p47(phox) as determined by two-dimensional phosphopeptide mapping - Phosphorylation by protein kinase C, protein kinase A, and a mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; HUMAN-NEUTROPHILS; 47-KDA PROTEIN; LYMPHOCYTES-B; COMPONENTS; EXPRESSION; COMPLEX; DEFECTS	The respiratory burst oxidase is responsible for superoxide (O-2(radical anion)) production by phagocytes and B lymphocytes. This multicomponent enzyme is dormant in resting cells but is activated on exposure of the cells to an appropriate stimulus. Upon activation, several serine residues on the cytosolic oxidase subunit p47(phox) become phosphorylated, Using two-dimensional tryptic phosphopeptide mapping, we studied the phosphorylation of p47(phox) in P-32(i)-loaded Epstein-Barr virus-transformed B lymphoblasts expressing wild type p47(phox) or any of several p47(phox) Ser --> Ala mutants. We were able to identify the labeled peptides from wild type p47(phox) as those containing Ser(303/304), Ser(315), Ser(320), Ser(328) and/or Ser(359/370), and Ser(345/348); no P-32-labeled Ser(310)-containing peptide was found. When purified p47(phox) was phosphorylated in vitro by various protein kinases, varying phosphopeptide patterns were observed, Protein kinase C phosphorylated all the peptides except the one containing Ser(345/348); protein kinase A phosphorylated the peptide containing Ser(320) and one or both of the peptides containing Ser(328) and Ser(359/370); while mitogen activated protein kinase phophorylated only the peptide containing Ser(345/348). These findings suggest that these three kinases play distinct roles in the activation of the respiratory burst oxidase, each of them catalyzing the phosphorylation of a different group of serines in p47(phox).	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; CHU XAVIER BICHAT, INSERM, U294, F-75018 PARIS, FRANCE	Scripps Research Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite					NCRR NIH HHS [RR-OO833] Funding Source: Medline; NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024227, R37AI024227, R01AI028479] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHANOCK SJ, 1992, P NATL ACAD SCI USA, V89, P10174, DOI 10.1073/pnas.89.21.10174; COMBADIERE C, 1993, BLOOD, V82, P2890; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; KRAMER IM, 1988, BIOCHIM BIOPHYS ACTA, V971, P189; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAX KJ, 1989, BLOOD REV, V3, P94, DOI 10.1016/0268-960X(89)90004-0; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MALY FE, 1989, J IMMUNOL, V142, P1260; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGAL AW, 1988, HEMATOL ONCOL CLIN N, V2, P213, DOI 10.1016/S0889-8588(18)30616-6; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; WOLFSON M, 1985, J IMMUNOL, V135, P2057	25	208	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6374	6378						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626435				2022-12-25	WOS:A1996UA36300064
J	Jezek, P; Hanus, J; Semrad, C; Garlid, KD				Jezek, P; Hanus, J; Semrad, C; Garlid, KD			Photoactivated azido fatty acid irreversibly inhibits anion and proton transport through the mitochondrial uncoupling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; BOVINE SERUM-ALBUMIN; BINDING-SITES; RECONSTITUTION; MECHANISMS; ACTIVATION; UNIPORT	The protonophoretic function of uncoupling protein (UCP) is activated by fatty acids. According to the ''docking site'' hypothesis (Jezek, P., and Garlid, K. D., J. Biol. Chem. 265, 19303-19311, 1990), the fatty acid binding site is identical with the anion channel of UCP. Skulachev (Skulachev, V. P. (1991) FEBS Left. 294, 158-162) extended this hypothesis by suggesting that fatty acid anions are transported by UCP and that H+ are delivered by back-diffusion of the protonated fatty acid through the lipid bilayer. In this model, UCP does not transport H+ at all but rather enables fatty acids to act as cycling protonophores. New evidence supports this mechanism (Garlid, K. D., Orosz, D. E., Modriansky, M., Vassanelli, S., and Jezek, P. (1996) J. Biol. Chem. 271, 2615-2620). To help elucidate these hypotheses, we synthesized a photoreactive analog of dodecanoic acid, 12-(4-azido-2-nitrophenylamino)dodecanoic acid (AzDA), and studied its effect on transport in mitochondria and proteoliposomes. AzDA behaved in every respect like a typical fatty acid. In micromolar doses, AzDA activated H+ translocation and inhibited Cl- and hexanesulfonate uniport through UCP. After UV light exposure, however, activation of H+ transport was inhibited, whereas inhibition of anion transport was preserved. These effects were irreversible. Photolabeling of mitochondria with [H-3]AzDA resulted in a prominent 32 kDa band of UCP, and few other proteins were labeled. The results indicate that AzDA can be ligated to the protein at or near the docking site, causing irreversible inhibition of both H+ and anion transport, The finding that fatty acid-induced H+ transport disappears along with anion transport supports the fatty acid-protonophore mechanism of H+ transport by UCP.	ACAD SCI CZECH REPUBL,INST EXPTL BOT,CR-14220 PRAGUE,CZECH REPUBLIC; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291	Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences	Jezek, P (corresponding author), ACAD SCI CZECH REPUBL,INST PHYSIOL,DEPT MEMBRANE TRANSPORT BIOPHYS 375,VIDENSKA 1083,CR-14220 PRAGUE,CZECH REPUBLIC.		Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; FIC NIH HHS [TW00120] Funding Source: Medline; NIGMS NIH HHS [GM31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BISSON R, 1981, BIOCHEM J, V193, P757, DOI 10.1042/bj1930757; CISTOLA DP, 1987, J BIOL CHEM, V262, P10980; CISTOLA DP, 1987, J BIOL CHEM, V262, P10971; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; FLEET GWJ, 1972, BIOCHEM J, V128, P499, DOI 10.1042/bj1280499; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1996, J BIOL CHEM, V270, P2615; HARP KN, 1975, J ORG CHEM, V40, P3423; JAZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1990, J BIOL CHEM, V265, P10522; JEZEK P, 1990, J BIOL CHEM, V265, P19296; JEZEK P, 1995, FEBS LETT, V361, P303, DOI 10.1016/0014-5793(95)00201-J; JEZEK P, 1994, FEBS LETT, V343, P22, DOI 10.1016/0014-5793(94)80599-7; JEZEK P, 1996, IN PRESS B MAGN RESO; JEZEK P, 1989, J LIPID MEDIATORS, V2, P85; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1976, EUR J BIOCHEM, V67, P511; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; RUZICKA M, 1994, EBEC SHORT REPORTS, V8, P92; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WINKLER E, 1994, J BIOL CHEM, V269, P2508; ZHAO J, 1994, AM J PHYSIOL-CELL PH, V267, pC969, DOI 10.1152/ajpcell.1994.267.4.C969	34	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6199	6205		10.1074/jbc.271.11.6199	http://dx.doi.org/10.1074/jbc.271.11.6199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626410	hybrid			2022-12-25	WOS:A1996UA36300039
J	Premont, RT; Macrae, AD; Stoffel, RH; Chung, NJ; Pitcher, JA; Ambrose, C; Inglese, J; MacDonald, ME; Lefkowitz, RJ				Premont, RT; Macrae, AD; Stoffel, RH; Chung, NJ; Pitcher, JA; Ambrose, C; Inglese, J; MacDonald, ME; Lefkowitz, RJ			Characterization of the G protein-coupled receptor kinase GRK4 - Identification of four splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE GENE; BETA-GAMMA-SUBUNITS; RHODOPSIN KINASE; FAMILY; REGION; ISOPRENYLATION; MEMBER	A novel human G protein-coupled receptor kinase was recently identified by positional cloning in the search for the Huntington's disease locus (Ambrose, C., James, M., Barnes, G., Lin, C., Bates, G., Altherr, M., Duyao, M., Groot, N., Church, D., Wasmuth, J. J., Lehrach, H., Housman, D., Buckler, A., Gusella, J. F., and MacDonald, M. E. (1993) Hum. Mel. Genet. 1, 697-703). Comparison off the deduced amino acid sequence of GRK4 with those of the closely related GRK5 and GRK6 suggested the apparent loss of 32 codons in the amino-terminal domain and 46 codons in the carboxyl terminal domain of GRK4. These two regions undergo alternative splicing in the GRK4 mRNA, resulting from the presence or absence of exons filling one or both of these apparent gaps. Each inserted sequence maintains the open reading frame, and the deduced amino acid sequences are similar to corresponding regions of GRK5 and GRK6. Thus, the GRK4 mRNA and the GRK4 protein can exist as four distinct variant forms. The human GRK4 gene is composed of 16 exons extending over 75 kilobase pairs of DNA. The two alternatively spliced exons correspond to exons II and XV. The genomic organization of the GRK4 gene is completely distinct from that of the human GRK2 gene, highlighting the evolutionary distance since the divergence of these two genes. Human GRK4 mRNA is expressed highly only in testis, and both alternative exons are abundant in testis mRNA. The four GRK4 proteins have been expressed, and all incorporate [H-3]palmitate. GRK4 is capable of augmenting the desensitization of the rat luteinizing hormone/chorionic gonadotropin receptor upon coexpression in HEK293 cells and of phosphorylating the agonist-occupied, purified beta(3)-adrenergic receptor, indicating that GRK4 is a functional protein kinase.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NHGRI NIH HHS [HG00169] Funding Source: Medline; NHLBI NIH HHS [HL16037] Funding Source: Medline; NINDS NIH HHS [NS16367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016367, P01NS016367] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLITTO BA, 1991, GENOMICS, V9, P104, DOI 10.1016/0888-7543(91)90226-5; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; LIN CS, 1991, SOMAT CELL MOLEC GEN, V17, P481, DOI 10.1007/BF01233172; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PENN RB, 1994, J BIOL CHEM, V269, P14924; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; Watson S., 1994, G PROTEIN LINKED REC; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; 1993, CELL, V72, P971	39	162	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6403	6410		10.1074/jbc.271.11.6403	http://dx.doi.org/10.1074/jbc.271.11.6403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626439	hybrid			2022-12-25	WOS:A1996UA36300068
J	Uckun, FM; TuelAhlgren, L; Waddick, KG; Jun, X; Jin, JH; Myers, DE; Rowley, RB; Burkhardt, AL; Bolen, JB				Uckun, FM; TuelAhlgren, L; Waddick, KG; Jun, X; Jin, JH; Myers, DE; Rowley, RB; Burkhardt, AL; Bolen, JB			Physical and functional interactions between Lyn and p34(cdc2) kinases in irradiated human B-cell precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PRIMARY CLONOGENIC BLASTS; INTRINSIC RADIATION-RESISTANCE; CHRONIC GRANULOMATOUS-DISEASE; BONE-MARROW TRANSPLANTATION; CDC2 PROTEIN-KINASE; CANCER-STUDY-GROUP; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PRESENTING FEATURES	Exposure of human B-cell precursors (BCP) to ionizing radiation results in cell cycle arrest at the G(2)-M checkpoint as a result of inhibitory tyrosine phosphorylation of p34(cdc2). Here, we show that ionizing radiation promotes physical interactions between p34(cdc2) and the Src family protein-tyrosine kinase Lyn in the cytoplasm of human BCP leading to tyrosime phosphorylation of p34(cdc2). Lyn kinase immunoprecipitated from lysates of irradiated BCP as well as a full-length glutathione S-transferase (GST)-Lyn fusion protein-phosphorylated recombinant human p34(cdc2) on tyrosine 15. Furthermore, Lyn kinase physically associated with and tyrosine-phosphorylated p34(cdc2) kinase in vivo when coexpressed in COS-7 cells, Binding experiments with truncated GST-Lyn fusion proteins suggested a functional role for the SH3 rather than the SH2 domain of Lyn in Lyn-p34(cdc2) interactions in BCP. The first 27 residues of the unique amino-terminal domain of Lyn were also essential for the ability of GST-Lyn fusion proteins to bind to p34(cdc2) from BCP lysates. Ionizing radiation failed to cause tyrosine phosphorylation of p34(cdc2) or G(2) arrest in Lyn kinase-deficient BCP, supporting am important role of Lyn kinase in radiation-induced G(2) phase-specific cell cycle arrest. Our findings implicate Lyn as an important cytoplasmic suppressor of p34(cdc2) function.	UNIV MINNESOTA,HLTH SCI CTR,DEPT THERAPEUT RADIOL,BIOTHERAPY PROGRAM,MOLEC SIGNAL TRANSDUCT LAB,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,DEPT RADIAT ONCOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,HLTH SCI CTR,DEPT PEDIAT,MINNEAPOLIS,MN 55455; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,SIGNAL TRANSDUCT LAB,PRINCETON,NJ 08543	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb				Uckun, Fatih M./0000-0001-9334-183X	NATIONAL CANCER INSTITUTE [R01CA042111, R01CA042633] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA42633, R01-CA-42111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BLEYER WA, 1986, MED PEDIATR ONCOL, V14, P271, DOI 10.1002/mpo.2950140506; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CHAMPLIN R, 1989, BLOOD, V73, P2051; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; CRIST W, 1989, BLOOD, V74, P1252; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GAYNON PS, 1988, LANCET, V2, P921; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; HANCOCK JT, 1989, BIOCHEM J, V262, P373, DOI 10.1042/bj2620373; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; JUN X, 1996, IN PRESS LEUKEMIA LY; KERSEY JH, 1987, NEW ENGL J MED, V317, P461, DOI 10.1056/NEJM198708203170801; KHARBANDA S, 1994, CANCER RES, V54, P1412; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM SH, 1992, INT J RADIAT ONCOL, V25, P61; KIMLER BF, 1981, RADIAT RES, V74, P430; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI S, 1990, BLOOD, V75, P458; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEE MS, 1994, J BIOL CHEM, V269, P30530; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1994, CANCER RES, V54, P4933; MALY FE, 1988, J IMMUNOL, V140, P2334; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAGATA A, 1991, NEW BIOL, V3, P959; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STEWART DJ, 1989, CANCER TREAT REV, V16, P1, DOI 10.1016/0305-7372(89)90002-9; STRONCEK DF, 1990, BLOOD, V75, P744; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TUELAHLGREN L, 1996, IN PRESS LEUKEMIA LY; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, J CLIN INVEST, V91, P1044, DOI 10.1172/JCI116261; UCKUN FM, 1993, INT J RADIAT ONCOL, V27, P899, DOI 10.1016/0360-3016(93)90466-9; UCKUN FM, 1993, CANCER RES, V53, P1431; UCKUN FM, 1993, BLOOD, V81, P1323; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; UCKUN FM, 1988, CANCER RES, V48, P5788; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; WHITACRE CM, 1992, CELL IMMUNOL, V144, P287, DOI 10.1016/0008-8749(92)90245-K; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	60	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6389	6397		10.1074/jbc.271.11.6389	http://dx.doi.org/10.1074/jbc.271.11.6389			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626437	hybrid			2022-12-25	WOS:A1996UA36300066
J	Zhang, J; Zhang, J; Shattil, SJ; Cunningham, MC; Rittenhouse, SE				Zhang, J; Zhang, J; Shattil, SJ; Cunningham, MC; Rittenhouse, SE			Phosphoinositide 3-kinase gamma and p85/phosphoinositide 3-kinase in platelets - Relative activation by thrombin receptor or beta-phorbol myristate acetate and roles in promoting the ligand-binding function of alpha(IIb)beta(3) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IIB-IIIA COMPLEX; PHOSPHORYLATION; FIBRINOGEN; ACCUMULATION; EPINEPHRINE; INHIBITION; WORTMANNIN; ANTIBODIES; ACID	Platelets exposed to thrombin or thrombin receptor agonist peptide (SFLLRN) activate phospholipase C and protein kinase C (PKC), and accumulate 3-phosphorylated phosphoinositides (S-PPI) as a function of the activation and relocalization of two cytoskeletally-associated phosphoinositide 3-kinases (PI 3-K): p85/PI 3-K and PI 3-K gamma. We now report that exposure of platelets to PKC-activating beta-phorbol myristate acetate (beta PMA) does not stimulate PI 3-K gamma, but rather stimulates p85/PI 3-K, which associates with the cytoskeleton. Wortmannin is an inhibitor of both PI 3-Ks, known to act with more potency on p85/PI 3-K, beta PMA-stimulated 3-PPI accumulation is more sensitive to wortmannin (IC50 = 1.3 nM) than is SFLLRN- or thrombin-stimulatad 3-PPI accumulation (IC50 = 10 nM). The activity of p85/PI 3-K in immunoprecipitates or in cytoskeletal fractions is inhibited more potently by exposure of platelets to wortmannin than is the activity of PI 3-K gamma. beta PMA or SFLLRN promotes the conversion of platelet integrin alpha(IIb)beta(3) into a fibrinogen-binding form required for platelet aggregation. Activation of alpha(IIb)beta(3) in response to beta PMA or SFLLRN is inhibited by wortmannin with an IC50 of 1 nM in each case. Wortmannin inhibits neither activation of alpha(IIb)beta(3) by ligand-induced binding site antibody (anti-LIBS6 Fab) nor anti-LIBS6 Fab-induced platelet aggregation in the presence of fibrinogen, indicating that this type of ''outside-in'' signaling by alpha(IIb)beta(3) is largely PI 3-K-independent. We conclude that p85/PI 3-K, in preference to PI 3-K gamma, contributes to activation of alpha(IIb)beta(3) when the thrombin receptor or PKC is stimulated.	JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; CARDEZA FDN, PHILADELPHIA, PA 19107 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA	Jefferson University; Jefferson University; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL038622] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL38622] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHOI EJ, 1988, J BIOL CHEM, V263, P17167; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUINEBAULT C, 1993, BIOCHEM J, V292, P851, DOI 10.1042/bj2920851; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LLOYD JV, 1973, BRIT J HAEMATOL, V25, P77, DOI 10.1111/j.1365-2141.1973.tb01718.x; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RITTENHOUSE SE, 1995, SEMIN HEMATOL, V32, P120; RITTENHOUSE SE, 1996, ADV MOL CELL BIOL PL; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TAKAI Y, 1985, J CELL BIOCHEM, V29, P143, DOI 10.1002/jcb.240290209; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YANO H, 1993, J BIOL CHEM, V268, P25846; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	42	123	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6265	6272		10.1074/jbc.271.11.6265	http://dx.doi.org/10.1074/jbc.271.11.6265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626420	hybrid			2022-12-25	WOS:A1996UA36300049
J	Hori, H; Tsubaki, M; Mogi, T; Anraku, Y				Hori, H; Tsubaki, M; Mogi, T; Anraku, Y			EPR study of NO complex of bd-type ubiquinol oxidase from Escherichia coli - The proximal axial ligand of heme d is a nitrogenous amino acid residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; AEROBIC RESPIRATORY-CHAIN; CYTOCHROME-D COMPLEX; RESONANCE RAMAN-SPECTROSCOPY; AZOTOBACTER-VINELANDII; PROSTHETIC GROUP; BINUCLEAR CENTER; CLONING; IDENTIFICATION; PURIFICATION	The heme axial ligands of bd-type ubiquinol oxidase of Escherichia coli were studied by EPR and optical spectroscopies using nitric oxide (NO) as a monitoring probe. We found that NO bound to ferrous heme d of the air-oxidized and fully reduced enzymes with very high affinity and to ferrous heme b(595) of the fully reduced enzyme with low affinity. EPR spectrum of the (NO)-N-14 complex of the reduced enzyme exhibited an axially symmetric signal with g-values at g(perpendicular to) = 2.041 and g(parallel to) = 1.993 and a clear triplet of triplet (or a triplet of doublet for the (NO)-N-15 complex) superhyperfine structure originating from a nitrogenous proximal ligand trans to NO was observed. This EPR species was assigned to the ferrous heme d-NO complex. This suggests that the proximal axial ligand of heme d is a histidine residue in an anomalous condition or other nitrogenous amino acid residue. Furthermore, the EPR line shape of the ferrous heme d-NO was slightly influenced by the oxidation state of the heme b(595). This indicates that heme d exists in close proximity to heme b(595) forming a binuclear center. Another axially symmetric EPR signal with g-values at g(parallel to) = 2.108 and g(perpendicular to) = 2.020 appeared after prolonged incubation of the reduced enzyme with NO and was attributed to the ferrous heme b(595)-NO complex.	HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Hyogo; University of Tokyo	Hori, H (corresponding author), OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN.							ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BARRETT J, 1956, BIOCHEM J, V64, P626, DOI 10.1042/bj0640626; DMELLO R, 1994, FEMS MICROBIOL LETT, V121, P115, DOI 10.1111/j.1574-6968.1994.tb07084.x; FANG H, 1989, J BIOL CHEM, V264, P8026; GREEN GN, 1984, J BIOL CHEM, V259, P7994; GREEN GN, 1984, GENE, V32, P99, DOI 10.1016/0378-1119(84)90037-4; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; JIANG FS, 1993, J AM CHEM SOC, V115, P10293, DOI 10.1021/ja00075a052; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KELLY MJS, 1990, J BACTERIOL, V172, P6010, DOI 10.1128/jb.172.10.6010-6019.1990; KITA K, 1984, J BIOL CHEM, V259, P3375; MEINHARDT SW, 1989, BIOCHIM BIOPHYS ACTA, V975, P175, DOI 10.1016/S0005-2728(89)80216-6; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; MOSHIRI F, 1991, J BACTERIOL, V173, P6230, DOI 10.1128/jb.173.19.6230-6241.1991; ROTHERY RA, 1989, BIOCHEM J, V261, P437, DOI 10.1042/bj2610437; ROTHERY RA, 1987, J GEN MICROBIOL, V133, P3247; SOTIRIOU C, 1988, J AM CHEM SOC, V110, P2264, DOI 10.1021/ja00215a042; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; TIMKOVICH R, 1985, J AM CHEM SOC, V107, P6069, DOI 10.1021/ja00307a041; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1993, FEBS LETT, V335, P13, DOI 10.1016/0014-5793(93)80430-3; VAVRA MR, 1986, ARCH BIOCHEM BIOPHYS, V250, P461, DOI 10.1016/0003-9861(86)90750-2	28	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9254	9258		10.1074/jbc.271.16.9254	http://dx.doi.org/10.1074/jbc.271.16.9254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621585	hybrid			2022-12-25	WOS:A1996UG04400016
J	Ollagnier, S; Mulliez, E; Gaillard, J; Eliasson, R; Fontecave, M; Reichard, P				Ollagnier, S; Mulliez, E; Gaillard, J; Eliasson, R; Fontecave, M; Reichard, P			The anaerobic Escherichia coli ribonucleotide reductase - Subunit structure and iron sulfur center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; QUANTITATION; ACTIVATION; PROTEIN; GENE	During anaerobic growth Escherichia coli uses a specific ribonucleoside triphosphate reductase for the production of deoxyribonucleoside triphosphates. The active species of this enzyme was previously found to be a large homodimer of 160 kDa (alpha(2)) with a stable, oxygen-sensitive radical located at Gly-681 of the 80-kDa polypeptide chain. The radical is formed in an enzymatic reaction involving S-adenosylmethionine, NADPH, a reducing flavodoxin system and an additional 17.5-kDa polypeptide, previously called activase. Here, we demonstrate by EPR spectroscopy that this small protein contains a 4Fe-4S cluster that joins two peptides in a 35-kDa small homodimer (beta(2)). A degraded form of this cluster may have been responsible for an EPR signal observed earlier in preparations of the large 160-kDa subunit that suggested the presence of a 3Fe-4S cluster in the reductase. These preparations were contaminated with a small amount of the small protein, The large and the small proteins form a tight complex. From sucrose gradient centrifugation, we determined a 1:1 stoichiometry of the two proteins in the complex. The anaerobic reductase thus has an alpha(2) beta(2) structure, We speculate that the small protein interacts with S-adenosylmethionine and forms a transient radical involved in the generation of the stable glycyl radical in the large protein that participates in the catalytic process.	KAROLINSKA INST, MBB, MED NOBEL INST, DEPT BIOCHEM 1, S-17177 STOCKHOLM, SWEDEN; UNIV GRENOBLE 1, CNRS URA 332, ETUD DYNAM & STRUCT SELECT LAB, F-38041 GRENOBLE 09, FRANCE; SCPM, SESAM, DEPT RECH FONDAMENTALE MAT CONDENSEE, CEA, F-38054 GRENOBLE 09, FRANCE; KAROLINSKA INST, MBB, MED NOBEL INST, DEPT BIOCHEM 1, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Karolinska Institutet				Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FREY M, 1994, J BIOL CHEM, V269, P12432; GEORGIADIS MM, 1992, SCIENCE, V92, P2499; HARDER J, 1992, J BIOL CHEM, V267, P25548; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005	22	88	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9410	9416		10.1074/jbc.271.16.9410	http://dx.doi.org/10.1074/jbc.271.16.9410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621608	hybrid			2022-12-25	WOS:A1996UG04400039
J	Rousseau, P; Betermier, M; Chandler, M; Alazard, R				Rousseau, P; Betermier, M; Chandler, M; Alazard, R			Interactions between the repressor and the early operator region of bacteriophage Mu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; EARLY PROMOTER; FACTOR BINDS; DNA; PROTEIN; ENDS; SITE; TRANSPOSITION; SEQUENCE; IS1	The repressor of bacteriophage Mu, c, binds to three operator sites, O1, O2, and O3, overlapping two divergent promoters, which regulate the lytic and lysogenic pathways, Its binding to this operator region generates several complexes, which were analyzed by DNase I protection experiments. We demonstrate that c first binds to two Ii-base pair partially repeated sequences in O2 that could represent ''core'' binding sites for the repressor. This initial interaction serves as an organizer of a more complex nucleoprotein structure in which O2, O1, and O3 become successively occupied. The quaternary structure of the repressor was also investigated, Size exclusion chromatography and protein-protein crosslinking experiments with chemicals that possess linking arms of various lengths indicate that the repressor oligomerizes in solution. A model is proposed describing the successive interactions of c with the operator sites O2, O1, and O3 leading to the elaboration of a higher order structure in which the early lytic functions are repressed.	CNRS,LAB MICROBIOL & GENET MIL,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)				Chandler, Michael/0000-0002-0292-6662; Betermier, Mireille/0000-0002-5407-6292				ALAZARD R, 1992, MOL MICROBIOL, V6, P1707, DOI 10.1111/j.1365-2958.1992.tb00895.x; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; BETERMIER M, 1995, J MOL BIOL, V249, P332, DOI 10.1006/jmbi.1995.0300; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; GAMA MJ, 1992, MOL MICROBIOL, V6, P1715, DOI 10.1111/j.1365-2958.1992.tb00896.x; GAMAS P, 1987, J MOL BIOL, V195, P261, DOI 10.1016/0022-2836(87)90648-6; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; GOOSEN N, 1984, GENE, V32, P419, DOI 10.1016/0378-1119(84)90017-9; GRIFFITH IP, 1972, BIOCHEM J, V126, P553, DOI 10.1042/bj1260553; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; KRAUSE HM, 1983, NUCLEIC ACIDS RES, V11, P5483, DOI 10.1093/nar/11.16.5483; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUKOLJ G, 1992, J BIOL CHEM, V267, P17827; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; RAO RN, 1984, GENE, V31, P247, DOI 10.1016/0378-1119(84)90216-6; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; Sambrook J., 2002, MOL CLONING LAB MANU; SPAENYDEKKING L, 1995, J BACTERIOL, V177, P222, DOI 10.1128/jb.177.1.222-228.1995; STAROS JV, 1987, METHOD ENZYMOL, V150, P503; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANRIJN PA, 1991, NUCLEIC ACIDS RES, V19, P2825, DOI 10.1093/nar/19.11.2825; VOGEL JL, 1991, J BACTERIOL, V173, P6568, DOI 10.1128/jb.173.20.6568-6577.1991; ZERBIB D, 1987, EMBO J, V6, P3163, DOI 10.1002/j.1460-2075.1987.tb02627.x	33	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9739	9745		10.1074/jbc.271.16.9739	http://dx.doi.org/10.1074/jbc.271.16.9739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621652				2022-12-25	WOS:A1996UG04400083
J	Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J				Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J			Expression of cyclin D1 and EMS1 in bladder tumours; Relationship with chromosome 11q13 amplification	ONCOGENE			English	Article						contactin; cyclin D1; EMS1; amplification; bladder tumor	HUMAN CARCINOMAS; GENES; IDENTIFICATION; SUBSTRATE; OVEREXPRESSION; CANCER; ONCOGENE; TUMORS; INT-2; HST	11q13 amplifications have been found in several cancers, including bladder tumours,However, the biological significance of this genetic alteration is not yet fully understood, To get more insight into the role of 11q13 amplification in bladder tumour development, we have studied the level of amplification and expression of 4 (protoonco)genes lying within the amplicon: cyclin D1, FGF3, FGF4 and EMS1 DNA amplification was found in 5/46 tumours, There was no correlation between amplification and clinico-pathological data. No expression of FGF3 and FGF4 was detected whereas both cyclin D1 and EMS1 were expressed at higher level in tumours with amplifications, Thus cyclin D1 and EMS1, but not FGF3 and FGF4, are likely to play a pathogenic role in the 11q13 amplification in bladder cancer, However, amplification is not the unique way of activation of these genes, Indeed, in situ hybridisation and Northern blot analysis have shown that most bladder tumours have a fair to high expression of cyclin D1 and EMS1 in contrast to normal urothelium with a moderate expression, Interestingly, a trend towards higher expression occurs in superficial versus invasive tumours (8.8+/-2.0 versus 1.9+/-0.4; P approximate to 13% for cyclin D1 and 4.5 +/- 1.4 versus 2.0 +/- 0.4; P approximate to 8% for EMS1), Moreover, the 9 tumours with low expression are all highly malignant, leading to the hypothesis that the tumours developing through a cyclin D1/EMS1 independent pathway are more aggressive.	UNIV LEIDEN HOSP, DEPT PATHOL, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Bringuier, PP (corresponding author), UNIV NIJMEGEN HOSP, UROL RES LAB, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Schalken, Jack A/B-1277-2014	Schalken, Jack A/0000-0001-8274-7797				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; GILLETT C, 1994, CANCER RES, V54, P1812; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; KNOWLES MA, 1994, CANCER RES, V54, P531; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mostofi FK, 1973, INT HISTOLOGICAL CLA; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA N, 1994, CANCER RES, V54, P3107; PETERS G, 1994, J CELL SCI, P89; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAMIMI Y, 1993, CANCER RES, V53, P5512; THEILLET C, 1989, ONCOGENE, V4, P915; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; *UICC, 1992, TNM CLASS INT UN CAN; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	36	126	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1747	1753						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622895				2022-12-25	WOS:A1996UG45800017
J	Garlid, KD; Paucek, P; YarovYarovoy, V; Sun, XC; Schindler, PA				Garlid, KD; Paucek, P; YarovYarovoy, V; Sun, XC; Schindler, PA			The mitochondrial K-ATP channel as a receptor for potassium channel openers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-SCATTERING; CARDIAC MYOCYTES; MATRIX VOLUME; RAT-LIVER; GLIBENCLAMIDE; CROMAKALIM; DIAZOXIDE; CONTRACTION; TOLBUTAMIDE; ISCHEMIA	The biochemical properties of the mitochondrial K-ATP channel are very similar to those of plasma membrane K-ATP channels, including inhibition by low concentrations of ATP and glyburide (Paucek, P,, Mironova, G., Mahdi, F., Beavis, A, D,, Woldegiorgis, G,, and Garlid, K. D, (1992) J, Biol, Chem. 267, 26062-26069), Plasma membrane K-ATP channels are highly sensitive to the family of drugs known as K+ channel openers, raising the question whether mitochondrial K-ATP channels are similarly sensitive to these agents, Ne addressed this question by measuring K+ flux in intact rat liver mitochondria and in liposomes containing K-ATP channels purified from rat liver and beef heart mitochondria, K+ channel openers completely reversed ATP inhibition of K+ flux in both systems, In Liposomes, ATP-inhibited K+ flux was restored by diazoxide (K-1/2 = 0.4 mu M), cromakalim (K-1/2 = 1 mu M), and two developmental cromakalim analogues, EMD60480 and EMD57970 (K-1/2 = 6 nM), Similar K-1/2 values were observed in intact mitochondria, These potencies are well within the range observed with plasma membrane K-ATP channels, We also compared the potencies of these K+ channel openers on the plasma membrane K-ATP channel purified from beef heart myocytes, The K-ATP channel from cardiac mitochondria is 2000-fold more sensitive to diazoxide than the channel from cardiac sarcolemma, indicating that two distinct receptor subtypes coexist within the myocyte. Ne suggest that the mitochondrial K-ATP channel is an important intracellular receptor that should be taken into account in considering the pharmacology of K+ channel openers.			Garlid, KD (corresponding author), OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,POB 91000,PORTLAND,OR 97291, USA.		Yarov-Yarovoy, Vladimir/ABE-5454-2020	Yarov-Yarovoy, Vladimir/0000-0002-2325-4834; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL336573] Funding Source: Medline; NIGMS NIH HHS [GM31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BELYAEVA EA, 1993, BIOCHEM MOL BIOL INT, V31, P493; COLE WC, 1993, CARDIOVASC DRUG THER, V7, P527, DOI 10.1007/BF00877618; Cook NS, 1990, POTASSIUM CHANNELS S, P181; ESCANDE D, 1993, EUR HEART J, V14, P2, DOI 10.1093/eurheartj/14.suppl_B.2; ESCANDE D, 1988, BIOCHEM BIOPH RES CO, V154, P620, DOI 10.1016/0006-291X(88)90184-2; FAIVRE JF, 1989, BIOCHIM BIOPHYS ACTA, V984, P1, DOI 10.1016/0005-2736(89)90334-9; FLATT PR, 1994, DIABETES METAB, V20, P157; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1988, INTEGRATION MITOCHON; GROSS GJ, 1992, CARDIOVASC RES, V26, P1011, DOI 10.1093/cvr/26.11.1011; GROVER GJ, 1989, J PHARMACOL EXP THER, V251, P98; GROVER GJ, 1994, J CARDIOVASC PHARM, V24, pS18, DOI 10.1097/00005344-199424014-00004; GUY HR, 1994, SOC GEN PHY, V49, P197; HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P522, DOI 10.1042/bst0220522; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; JONES NGB, 1984, ETHOL SOCIOBIOL, V5, P1; LAZDUNSKI M, 1994, J CARDIOVASC PHARM, V24, pS1; MCPHERSON GA, 1993, GEN PHARMACOL, V24, P275, DOI 10.1016/0306-3623(93)90303-F; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Paucek P., 1995, Biophysical Journal, V68, pA145; PAUCEK P, 1993, BIOPHYS J, V64, pA311; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; PAUCEK P, 1996, BIOPHYS J, V70, pA1688; PERIYASAMY SM, 1990, J BIOL CHEM, V265, P6035; QUAST U, 1989, J PHARMACOL EXP THER, V250, P261; SZEWCZYK A, 1995, BIOCHEM BIOPH RES CO, V207, P126, DOI 10.1006/bbrc.1995.1162; THURINGER D, 1989, MOL PHARMACOL, V36, P897; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506	32	370	387	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8796	8799		10.1074/jbc.271.15.8796	http://dx.doi.org/10.1074/jbc.271.15.8796			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621517	hybrid			2022-12-25	WOS:A1996UE73000048
J	Abeysinghe, RD; Roberts, PJ; Cooper, CE; MacLean, KH; Hider, RC; Porter, JB				Abeysinghe, RD; Roberts, PJ; Cooper, CE; MacLean, KH; Hider, RC; Porter, JB			The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE SYNTHESIS; HUMAN 5-LIPOXYGENASE; SUPEROXIDE PRODUCTION; ARACHIDONIC-ACID; INHIBITORS; BIOSYNTHESIS; RESIDUES; PROTEIN; MUTAGENESIS	The mechanisms of lipoxygenase inhibition by iron chelators have been investigated in human neutrophils and in isolated soybean lipoxygenase. Their Fe(III)-containing active sites have been targeted by synthesizing novel bidentate chelators from the hydroxypyridinone family sufficiently small to gain access through the hydrophobic channels of lipoxygenase. In stimulated human neutrophils, release of [H-3]arachidonate-labeled eicosanoids is dependent on the lipid solubility of hydroxypyridinones, but larger hexadentate chelators have no effect on this or on total cellular leukotriene B-4 production, Lipophilic hydroxypyridinones inhibit 5-lipoxygenase at equivalent concentrations to the established inhibitor, piriprost, and show additional but minor anti-phospholipase A(2) activity. Soybean 15-lipoxygenase inhibition is also dependent on the lipid solubility and coordination structure of chelators. Inhibition is associated with the formation of chelate-iron complexes, which are removed by dialysis without restoration of enzyme activity. Only after adding back iron is activity restored. Electron paramagnetic resonance studies show the removal of the iron center signal (g = 6) is concomitant with formation of Fe(III)-chelator complexes, identical in spectral shape and g value to 3:1 hydroxypyridinone Fe(III) complexes. Removal of iron is not the only mechanism by which hydroxypyridinones can inhibit lipoxygenase in intact cells, however, as a lipophilic non-iron-binding hydroxypyridinone, which shows no inhibition of the soybean lipoxygenase activity, partially inhibits 5-lipoxygenase in intact neutrophils without inhibiting neutrophil phospholipase A(2).	UCL, SCH MED, DEPT CLIN HEMATOL, LONDON WC1E 6HX, ENGLAND; UCL, SCH MED, DEPT PAEDIAT, LONDON WC1E 6JJ, ENGLAND; UNIV LONDON KINGS COLL, DEPT PHARM, LONDON SW3, ENGLAND	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School			Cooper, Chris/AAK-9729-2020	Cooper, Chris/0000-0003-0381-3990; Porter, John/0000-0003-3000-9359	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042800] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-42800-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BARRADAS MA, 1989, FEBS LETT, V245, P105, DOI 10.1016/0014-5793(89)80201-7; BATT DG, 1990, J MED CHEM, V33, P360, DOI 10.1021/jm00163a058; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADY MC, 1988, J INORG BIOCHEM, V32, P9; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CONNOLLY S, 1993, CURR OPIN THER PAT, V8, P1141; COUTTS SM, 1985, PROSTAGLANDINS LEUKO, P627; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOBBIN PS, 1993, J MED CHEM, V36, P2448, DOI 10.1021/jm00069a002; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Hall, 1991, PERSPECTIVES BIOINOR, V1, P209; HAMMOND ML, 1989, J MED CHEM, V32, P1006, DOI 10.1021/jm00125a014; HARRISON PM, 1980, IRON BIOCH MED, V2, P131; ISHII S, 1992, BIOCHEM BIOPH RES CO, V182, P1482, DOI 10.1016/0006-291X(92)91901-2; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; MULLER K, 1994, ARCH PHARM, V327, P3; NAITO Y, 1991, CHEM PHARM BULL, V39, P1736; NELSON MJ, 1991, J BIOL CHEM, V266, P8225; NGUYEN T, 1991, J BIOL CHEM, V266, P22057; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; PETERSSON L, 1987, BIOCHIM BIOPHYS ACTA, V913, P228, DOI 10.1016/0167-4838(87)90334-7; POWELL WS, 1987, PROSTAGLANDINS RELAT; PRASIT P, 1993, J LIPID MEDIATOR, V6, P239; ROBERTS PJ, 1990, J LEUKOCYTE BIOL, V48, P247, DOI 10.1002/jlb.48.3.247; ROBERTS PJ, 1993, MEDIAT INFLAMM, V2, P211, DOI 10.1155/S0962935193000286; ROBERTS PJ, 1996, BRIT J HAEMATOL, V92, P802; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SLAPPENDEL S, 1982, BIOCHEM BIOPH RES CO, V108, P673, DOI 10.1016/0006-291X(82)90882-8; SMITH RJ, 1982, BIOCHEM BIOPH RES CO, V109, P943, DOI 10.1016/0006-291X(82)92031-9; STREATER M, 1990, J MED CHEM, V33, P1749, DOI 10.1021/jm00168a033; SUMMERS JB, 1987, J MED CHEM, V30, P2121, DOI 10.1021/jm00394a032; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; TAYLOR PD, 1988, TALANTA, V35, P507, DOI 10.1016/0039-9140(88)80123-1; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; ZHANG YY, 1993, J BIOL CHEM, V268, P2535	41	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7965	7972		10.1074/jbc.271.14.7965	http://dx.doi.org/10.1074/jbc.271.14.7965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626476	hybrid			2022-12-25	WOS:A1996UD60000016
J	Nashed, EM; Glaudemans, CPJ				Nashed, EM; Glaudemans, CPJ			Observations on the binding of four anti-carbohydrate monoclonal antibodies to their homologous ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOMA PROTEINS; CHEMICAL SYNTHESIS; O-ANTIGEN; OLIGOSACCHARIDES; GLYCOSIDES; SUBSITES; DEXTRAN; THERMODYNAMICS; SPECIFICITY; SALMONELLA	The binding of four monoclonal immunoglobulins, two with specificity for beta(1-->6)-linked D-galactopyranans (IgA X24 and IgA J539) and two with specificity for the chain terminus of alpha(1-->6)-linked D-glucopyranans (IgA W3129 and IgA 16.4.12E), was measured with a number of their homologous oligosaccharide ligands at different temperatures. The results show a linear relationship between lnk(alpha) and 1/T, where K-alpha is the affinity constant and T is the absolute temperature. The unitary free energy of binding, Delta G(u), is virtually independent of T, and the Delta S-u is small when compared with Delta G(u). The enthalpy changes derived from van't Hoff plots are large and negative, indicating an exothermic binding effect, whereas the entropy changes are small and negative, indicating minor overall hydrophobic contributions. Measurements of the free energies of binding, in low and high salt buffers, of methyl beta-D-galactopyranoside and the methyl glycoside of beta(1-->6)-D-galactopyranotetraose with anti-galactan IgA X24 indicate that the monosaccharide has no hydrophobic interaction with the highest affinity subsite of IgA, whereas the tetraoside might have a modest hydrophobic interaction with the three other hapten-binding subsites of IgA. The standard entropy change of binding of the two groups (galactosyl and glucosyl) of oligosaccharides to the two respective sets (anti-galactan and anti-dextran) of antibodies shows a distinct, differing correlation with the hapten chain length within each set. This correlation agrees with the type of association previously established between the antibodies and either the interior determinants of the antigen (in the case of the anti-galactans) or the chain terminus (in the case of the anti-dextrans).			Nashed, EM (corresponding author), NIDDK, NIH, BETHESDA, MD 20892 USA.							Ben- Naim A., 1980, HYDROPHOBIC INTERACT; BENNETT LG, 1979, BIOCHEMISTRY-US, V18, P3337, DOI 10.1021/bi00582a021; BENNETT LG, 1979, CARBOHYD RES, V72, P315, DOI 10.1016/S0008-6215(00)83958-0; BRESLOW R, 1991, ACCOUNTS CHEM RES, V24, P159, DOI 10.1021/ar00006a001; CISAR J, 1974, J EXP MED, V139, P159, DOI 10.1084/jem.139.1.159; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; GLAUDEMANS CPJ, 1993, ACS SYM SER, V519, P72; GLAUDEMANS CPJ, 1988, ACS SYM SER, V374, P78; GLAUDEMANS CPJ, 1987, MOL IMMUNOL, V24, P371, DOI 10.1016/0161-5890(87)90179-9; GLAUDEMANS CPJ, 1984, BIOCHEMISTRY-US, V23, P6732, DOI 10.1021/bi00321a069; GLAUDEMANS CPJ, 1994, METHOD ENZYMOL, V247, P305; GLAUDEMANS CPJ, 1989, CARBOHYD RES, V190, P267, DOI 10.1016/0008-6215(89)84130-8; GLAUDEMANS CPJ, 1994, ACS SYM SER, V560, P157; GLAUDEMANS CPJ, 1991, CHEM REV, V91, P25, DOI 10.1021/cr00001a002; GURNEY RW, 1953, IONIC PROCESSES SOLU, P89; HARTMAN AB, 1984, EMBO J, V3, P3023, DOI 10.1002/j.1460-2075.1984.tb02249.x; JOLLEY ME, 1973, BIOCHEMISTRY-US, V12, P3039, DOI 10.1021/bi00740a015; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KOVAC P, 1986, CARBOHYD RES, V153, P237, DOI 10.1016/S0008-6215(00)90266-0; KOVAC P, 1988, CARBOHYD RES, V184, P87, DOI 10.1016/0008-6215(88)80008-9; MANJULA BN, 1982, MOL IMMUNOL, V19, P913, DOI 10.1016/0161-5890(82)90358-3; NASHED EM, 1990, J BIOL CHEM, V265, P20699; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; PAVLIAK V, 1993, J BIOL CHEM, V268, P25797; POTTER M, 1977, ADV IMMUNOL, V25, P141; POTTER M, 1972, METHOD ENZYMOL, V28, P388; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; TANAKA T, 1986, ELECTROPHORESIS, V7, P204, DOI 10.1002/elps.1150070503; TROPEA JE, 1992, BIOORG CHEM, V20, P67, DOI 10.1016/0045-2068(92)90027-Z; WEIGERT M, 1974, J EXP MED, V139, P137, DOI 10.1084/jem.139.1.137; ZIEGLER T, 1992, CARBOHYD RES, V229, P271, DOI 10.1016/S0008-6215(00)90575-5	33	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8209	8214		10.1074/jbc.271.14.8209	http://dx.doi.org/10.1074/jbc.271.14.8209			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626513	hybrid			2022-12-25	WOS:A1996UD60000053
J	Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB				Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB			Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein	ONCOGENE			English	Article						osteopontin; src-deficient; epidermal growth factor (EGF); homozygous; osteopetrosis	TYROSINE KINASE; GROWTH-FACTOR; PHOSPHOPROTEIN; BONE; OSTEOCLASTS; EXPRESSION; ACTIVATION; INDUCTION; PATHWAYS	Mice carrying homozygous disruption of the c-src protooncogene (Src-/-) develop osteopetrosis due to an impaired ability of osteoclasts to adhere to the bone surface and/or to form bone-resorbing ruffled border. It has also been reported that osteopontin (OPN), a secreted phosphoprotein, mediates osteoclast adherence to the bone matrix. We report here that cells from Src-/- mice, both in vitro and in vivo, express OPN mRNA and protein at a significantly reduced level as compared to cells from Src+/- and +/+ animals, suggesting a potential role for the proto-oncogene c-src in the regulation of OPN gene expression. Our data also show that OPN gene expression can be induced by treatment of Src -/- cells with epidermal growth factor (EGF) and 12-O-tetradecanoyl phorbol-13-acetate (TPA). Results obtained from studies using inhibitors of receptor tyrosine kinases (RTKs) and protein kinase C (PKC) suggest that PKC and RTK are positioned in a pathway with PKC as the downstream effector for the EGF-induced OPN gene expression in Src-/- cells, and that pp60(c-src) and EGF may regulate OPN gene expression through a common signalling pathway. Furthermore, contrary to published reports, our study shows that EGF-mediated cell signalling does not require functional interaction between the EGF-receptor and pp60(c-src).	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; NICHHD, SECT DEV GENET, HERITABLE DISORDERS BRANCH, NIH, BETHESDA, MD 20892 USA; UNIV MONTREAL, FAC DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA; RUTGERS STATE UNIV, WAKSMAN INST, DEPT MICROBIOL, PISCATAWAY, NJ 08855 USA	McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montreal; Rutgers State University New Brunswick			McKee, Marc D/E-2187-2011; Lin, Pei-Hui/I-3011-2015	McKee, Marc D/0000-0001-8349-965X; Lin, Pei-Hui/0000-0002-3894-5099				BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BENDAYAN M, 1989, COLLOIDAL GOLD PRINC, V1, P33; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; Dveksler G S, 1992, PCR Methods Appl, V1, P283; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOPEZ CA, 1995, ANN NY ACAD SCI, V760, P324, DOI 10.1111/j.1749-6632.1995.tb44648.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARKS S C JR, 1987, Applied Pathology, V5, P172; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749-6632.1995.tb44629.x; MCKEE MD, 1993, ANAT REC, V3, P219; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; QURESHI SA, 1991, ONCOGENE, V6, P995; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	42	44	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1457	1467						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622862				2022-12-25	WOS:A1996UF07600010
J	Chapline, C; Mousseau, B; Ramsay, K; Duddy, S; Li, Y; Kiley, SC; Jaken, S				Chapline, C; Mousseau, B; Ramsay, K; Duddy, S; Li, Y; Kiley, SC; Jaken, S			Identification of a major protein kinase C-binding protein and substrate in rat embryo fibroblasts - Decreased expression in transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CONTACTS; PURIFICATION; ISOZYMES; FAMILY; ACID	We have used an interaction cloning strategy to isolate cDNAs for sequences that interact with protein kinase C (Chapline, C., Ramsay, K., Klauck, T., and Jaken, S. (1993) J. Biol. Chem. 268, 6858-6861). In this paper, we report a novel sequence, clone 72, isolated according to this method. Clone 72 has a 4.8-kilobase pair open reading frame; antibodies to clone 72 recognize a >200-kDa protein in cell and tissue extracts. Clone 72 message and protein are detected in a variety of tissues. Immunoprecipitation studies demonstrate that clone 72 is the major >200-kDa binding protein described previously in REF52 fibroblasts (Hyatt, S. L., Liao, L., Aderem, A., Nairn, A., and Jaken, S. (1994) Cell Growth & Differ. 5, 495-502). Expression of clone 72 message and protein are decreased in progressively transformed REF52 cells. Since clone 72 is both a protein kinase C (PKC)-binding protein and substrate, decreased levels of clone 72 may influence both the subcellular location of endogenous PKCs as well as signaling events associated with clone 72 phosphorylation. Our results emphasize that the role of PKCs in carcinogenesis may involve several factors, including the quantity and location of the PKCs isozymes and their downstream targets.	W ALTON JONES CELL SCI CTR INC,LAKE PLACID,NY 12946						NATIONAL CANCER INSTITUTE [R01CA053841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050152] Funding Source: NIH RePORTER; NCI NIH HHS [CA53841] Funding Source: Medline; NIGMS NIH HHS [GM50152] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BURNS DJ, 1992, ADENINE NUCLEOTIDES, P207; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; HA KS, 1993, J BIOL CHEM, V268, P10534; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KILEY SC, 1995, J CELL SCI, V108, P1003; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIN S, 1995, MOL CELL BIOL, V15, P2754; MCCLURE DB, 1984, CANCER CELL, V1, P17; MCCLURE DB, 1982, GROWTH CELLS HORMONA, P345; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIZUKA Y, 1995, FASEB J, V9, P464; PEARS C, 1992, ADENINE NUCLEOTIDES, P231	25	73	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6417	6422		10.1074/jbc.271.11.6417	http://dx.doi.org/10.1074/jbc.271.11.6417			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626441	hybrid			2022-12-25	WOS:A1996UA36300070
J	SawkaVerhelle, D; TartareDeckert, S; White, MF; vanObberghen, E				SawkaVerhelle, D; TartareDeckert, S; White, MF; vanObberghen, E			Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRS-1; PROTEIN; CELLS	We compared the interaction between the insulin receptor (IR) and the IR substrate (IRS) proteins (IRS-1 and IRS-2) using the yeast two hybrid system. Both IRS proteins interact specifically with the cytoplasmic portion of the IR and the related insulin-like growth factor-I receptor, and these interactions require receptor tyrosine kinase activity. Alignment of IRS-1 and IRS-2 revealed two conserved domains at the NH2 terminus, called IH1(PH) and IH2(PTB), which resemble a pleckstrin homology (PH) domain and a phosphotyrosine binding (PTB) domain, respectively. The IH2(PTB) binds to the phosphorylated NPXY motif (Tyr-960) in the activated insulin receptor, providing a specific mechanism for the interaction between the receptor and IRS-1. Although the IH2(PTB) of IRS-2 also interacts with the NPEY motif of the insulin receptor, it is not essential for the inter action between the insulin receptor and IRS-2 in the yeast two-hybrid system. IRS-2 contains another interaction domain between residues 591 and 786, which is absent in IRS-1. This IRS-2-specific domain is independent of the IH2(PTB) and does not require the NPEY motif; however, it requires a functional insulin receptor kinase and the presence of three tyrosine phosphorylation sites in the regulatory loop (Tyr-1146, Tyr-1150, and Tyr-1151). Importantly, this novel domain mediates the association between IRS-2 and insulin receptor lacking the NPXY motif and may provide a mechanism by which the stoichiometry of regulatory loop autophosphorylation enhances IRS-2 phosphorylation.	FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720	NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038712, R01DK043808, R01DK038712, R55DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HARPER JW, 1993, CELL, V75, P805; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Miller J.H., 1972, EXPT MOL GENETICS; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PONS S, 1995, MOL CELL BIOL, V15, P4453; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TARTAREDECKERT S, 1996, IN PRESS ENDOCRINOLO, V137; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	30	155	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5980	5983		10.1074/jbc.271.11.5980	http://dx.doi.org/10.1074/jbc.271.11.5980			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626379	hybrid			2022-12-25	WOS:A1996UA36300008
J	Scita, G; Darwiche, N; Greenwald, E; Rosenberg, M; Politi, K; De Luca, LM				Scita, G; Darwiche, N; Greenwald, E; Rosenberg, M; Politi, K; De Luca, LM			Retinoic acid down-regulation of fibronectin and retinoic acid receptor alpha proteins in NIH-3T3 cells - Block of this response by ras transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKEMIA CELLS; MESSENGER-RNA; TERATOCARCINOMA CELLS; CYCLIC-AMP; VITAMIN-A; EXPRESSION; GENE; DIFFERENTIATION; GAMMA; IMMUNODETECTION	All trans-retinoic acid (RA) markedly reduced the level of intracellular fibronectin (FN) in a time- and concentration-dependent fashion in NIH-3T3 cells, but not in NIH-3T3 cells transformed by an activated Ha-ras oncogene. Pulse/chase experiments indicated that RA affects FN biosynthesis rather than its turnover rate. Steady state levels of FN transcripts did not change after treatment of the cells with RA for various times or concentrations, suggesting that RA acts at the translational level. Similar effects were observed in other fibroblasts. In NIH-3T3 cells, RA had distinct effects on different receptors; it down-modulated retinoic acid receptor (RAR) alpha protein and transcript levels, it up-regulated RAR beta transcripts, and it had no effect on RAR gamma. Transformation of NIH-3T3 cells with an activated Ha-ras oncogene down-modulated RAR expression and abolished responsiveness to RA. We identified the retinoid signal transduction pathways responsible for the effects of RA on FN and RAR alpha proteins by the use of the retinoid X receptor-selective compound, SR11237, by stable overexpression of a truncated form of the RAR alpha gene, RAR alpha 403, with strong RAR dominant negative activity, and by overexpression of RAR alpha. We conclude that: 1) RA-dependent FN down-modulation is mediated by RARs, 2) retinoid X receptors mediate the observed reduction of RAR alpha by RA, and 3) the block of RA responsiveness in Ha-ras cells cannot be overcome by overexpression of RAR alpha. These studies have defined fibronectin and RAR alpha as targets of RA in fibroblast cells and have shown that oncogenic transformation renders the cells resistant to RA action.	NCI, LAB CELLULAR CARCINOGENESIS & TUMOR PROMOT, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Scita, Giorgio/J-9670-2012	Scita, Giorgio/0000-0001-7984-1889; Rosenberg, Miriam/0000-0001-5348-8247; Darwiche, Nadine/0000-0002-1862-5426				ALI M, 1992, BIOCHEM BIOPH RES CO, V182, P1032, DOI 10.1016/0006-291X(92)91835-E; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHANDLER LA, 1991, CELL GROWTH DIFFER, V2, P379; CHANDLER LA, 1994, MOL CELL BIOL, V14, P3085, DOI 10.1128/MCB.14.5.3085; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; COOPER AR, 1983, DEV BIOL, V99, P510, DOI 10.1016/0012-1606(83)90300-7; COX LR, 1991, J CANCER RES CLIN, V117, P102, DOI 10.1007/BF01613132; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DE LUCA LM, 1991, FASEB J, V5, P2924; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GALLAGHER RE, 1989, LEUKEMIA, V3, P789; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GOPAS J, 1992, INT J CANCER, V52, P329, DOI 10.1002/ijc.2910520229; GUDAS LJ, 1990, METHOD ENZYMOL, V190, P131; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Hynes RO, 1990, FIBRONECTIN; KAMEI Y, 1992, BIOCHEM INT, V26, P923; KIM HY, 1987, J BIOL CHEM, V262, P365; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOSA K, 1993, BIOCHEM BIOPH RES CO, V196, P1025, DOI 10.1006/bbrc.1993.2354; KREIDER BL, 1992, ONCOGENE, V7, P135; LARGMAN C, 1989, BLOOD, V74, P99; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; PEMRICK SM, 1994, LEUKEMIA, V8, pS1; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SCITA G, 1994, CARCINOGENESIS, V15, P1043, DOI 10.1093/carcin/15.5.1043; SCITA G, 1994, BBA-MOL CELL RES, V1223, P29, DOI 10.1016/0167-4889(94)90070-1; SMARDA J, 1995, MOL CELL BIOL, V15, P2474; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TALMAGE DA, 1994, ONCOGENE, V9, P3557; TALMAGE DA, 1992, ONCOGENE, V7, P1837; THE HD, 1995, EMBO J, V8, P429; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSOU HC, 1994, EXP CELL RES, V211, P74, DOI 10.1006/excr.1994.1061; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; WANG C, 1989, LEUKEMIA, V3, P699; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1994, CANCER RES, V54, P5663	54	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6502	6508		10.1074/jbc.271.11.6502	http://dx.doi.org/10.1074/jbc.271.11.6502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626453	hybrid			2022-12-25	WOS:A1996UA36300082
J	Chakrabarti, G; Sengupta, S; Bhattacharyya, B				Chakrabarti, G; Sengupta, S; Bhattacharyya, B			Thermodynamics of colchicinoid-tubulin interactions - Role of B-ring and C-7 substituent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; ANALOGS; FLUORESCENCE; KINETICS; DISSOCIATION; PROTEIN; DIMER; THIOCOLCHICINE; POLYMERIZATION; MICROTUBULES	The quenching of tryptophan fluorescence has been used to determine the kinetic and thermodynamic parameters of binding of B-ring analogs of colchicine to tubulin. The on rate, activation energy, off rate, and thermodynamics of binding reaction have been found to be controlled at different points of analog structure. The on-rate and off-rate of deacetamidocolchicine (DAAC) binding with tubulin is 17 times slower than that of 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone-tubulin (AC-tubulin) interaction, although both reactions have very similar activation energies. The presence of B-ring alone does not significantly affect the thermodynamics of the binding reactions either, since both AC-tubulin and DAAC-tubulin interactions are enthalpy driven. Introduction of a NH2 group at C-7 position of the B-ring, as in deacetylcolchicine (NH2-DAAC) lowers the on-rate further with a significant rise in the value of the activation energy. However, bulkier substitutions at the same position, as in demecolcine (NHMe-DAAC) and N-methyl-demecolcine (NMe(2)-DAAC) have no significant additional effect either on the on-rate or on the value of activation energy. Introduction of NH2 group in the C-7 position of B-ring also increases the positive entropy of the binding reaction to a significant extent, and it is maximum when NMe(2) is substituted instead of NH2 group. Thus, interaction of NH2-DAAC, NHMe-DAAC, and NMe(2)-DAAC with tubulin are entropy driven. Our results suggest that the B-ring side chain of aminocolchicinoids makes contact(s) with dimeric tubulin molecules.	BOSE INST,DEPT BIOCHEM,CALCUTTA 700054,W BENGAL,INDIA	Department of Science & Technology (India); Bose Institute				Sengupta, Suparna/0000-0003-3639-4630				ANDREU JM, 1991, BIOCHEMISTRY-US, V30, P3777, DOI 10.1021/bi00229a027; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; ANDREU JM, 1984, BIOCHEMISTRY-US, V23, P1742, DOI 10.1021/bi00303a025; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1994, J BIOL CHEM, V269, P10324; BARROW GM, 1973, PHYSICAL CHEM, P473; Beck A, 1932, N-S ARCH EX PATH PH, V165, P208, DOI 10.1007/BF01929818; BELLEAU B, 1988, CAN J BIOCHEM, V46, P1397; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BHATTACHARYYA B, 1986, P NATL ACAD SCI USA, V83, P2052, DOI 10.1073/pnas.83.7.2052; BROSSI A, 1988, MED RES REV, V8, P77, DOI 10.1002/med.2610080105; BRYAN J, 1971, EXP CELL RES, V66, P129, DOI 10.1016/S0014-4827(71)80020-4; BRYAN J, 1972, BIOCHEMISTRY-US, V11, P2611, DOI 10.1021/bi00764a010; Capraro H.G., 1984, ALKALOIDS, V23, P1; DETRICH HW, 1982, BIOCHEMISTRY-US, V21, P2392, DOI 10.1021/bi00539a018; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; FITZGERALD TJ, 1976, BIOCHEM PHARMACOL, V25, P1383; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; HAMEL E, 1981, ARCH BIOCHEM BIOPHYS, V209, P29, DOI 10.1016/0003-9861(81)90253-8; HASTIE SB, 1989, BIOCHEMISTRY-US, V28, P7753, DOI 10.1021/bi00445a035; KANG GJ, 1990, J BIOL CHEM, V265, P10255; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; LINCOLN P, 1991, BIOCHEMISTRY-US, V30, P1179, DOI 10.1021/bi00219a003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUMRY R, 1970, BIOPOLYMERS, V9, P2890; MEDRANO FJ, 1989, BIOCHEMISTRY-US, V28, P5589, DOI 10.1021/bi00439a038; MENENDEZ M, 1989, J BIOL CHEM, V264, P16367; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; PYLES EA, 1993, BIOCHEMISTRY-US, V32, P2329, DOI 10.1021/bi00060a026; PYLES EA, 1993, J ORG CHEM, V58, P2751, DOI 10.1021/jo00062a016; RAY K, 1981, J BIOL CHEM, V256, P6241; RAY K, 1984, EUR J BIOCHEM, V142, P577, DOI 10.1111/j.1432-1033.1984.tb08325.x; ROSNER M, 1981, J MED CHEM, V24, P257; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SACKETT DL, 1991, BIOCHEMISTRY-US, V30, P3511, DOI 10.1021/bi00228a023; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; STARETZ ME, 1993, J MED CHEM, V36, P758, DOI 10.1021/jm00058a013; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; WILSON L, 1970, BIOCHEMISTRY-US, V9, P4999, DOI 10.1021/bi00827a026; WOLFF J, 1995, J BIOL CHEM, V270, P16809, DOI 10.1074/jbc.270.28.16809; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803	42	49	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2897	2901		10.1074/jbc.271.6.2897	http://dx.doi.org/10.1074/jbc.271.6.2897			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621677	hybrid			2022-12-25	WOS:A1996TU69100006
J	Glick, J; Santoyo, G; Casey, PJ				Glick, J; Santoyo, G; Casey, PJ			Arachidonate and related unsaturated fatty acids selectively inactivate the guanine nucleotide-binding regulatory protein, G(z)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; KINASE-C; CATECHOLAMINE SECRETION; ESCHERICHIA-COLI; CHROMAFFIN CELLS; ALPHA; INHIBITION; GZ	G(z) is a member of the family of trimeric guanine nucleotide-binding regulatory proteins (G proteins) which plays a crucial role in signaling across cell membranes. The expression of G(z) is predominately confined to neuronal cells and platelets, suggesting an involvement in a neuroendocrine process. Although the signaling pathway in which G(z) participates is not yet known, it has been linked to inhibition of adenylyl cyclase. We have found that arachidonate and related unsaturated fatty acids suppress guanine nucleotide binding to the alpha subunit of G(z). This inhibition of nucleotide binding by cis-unsaturated fatty acids is specific for G(z alpha); other G protein alpha subunits are relatively insensitive to these lipids. The IC50 for inhibition by the lipids closely corresponds to their critical micellar concentrations, suggesting that the interaction of the lipid micelle with G(z alpha) is the primary event leading to inhibition. The presence of the acidic group of the fatty acid is critical for inhibition, as no effect is observed with the corresponding fatty alcohol. While arachidonic acid produces near-complete inhibition of both GDP and guanosine 5'-(3-O-thio)triphosphate binding by G(z alpha), release of GDP from the protein was unaffected. Furthermore, the rate of inactivation of G(z alpha) by arachidonate is essentially identical to the rate of GDP release from the protein, indicating that GDP release is required for inactivation. These observations indicate that the mechanism of inactivation of G(z alpha) by unsaturated fatty acids is through an interaction of an acidic lipid micelle with the nucleotide-free form of the protein. Although the physiologic significance of this finding is unclear, similar effects of unsaturated fatty acids on other proteins involved in cell signaling indicate potential roles for these lipids in signal modulation. Additionally, the ability of arachidonate to inactivate this adenylyl cyclase-inhibitory G protein provides a molecular mechanism for previous findings that treatment of platelets with arachidonate results in elevated cAMP levels.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	Glick, J (corresponding author), DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA.			Casey, Patrick/0000-0002-7366-9309				CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FRYE RA, 1985, J NEUROCHEM, V44, P265, DOI 10.1111/j.1471-4159.1985.tb07140.x; FRYE RA, 1984, J NEUROCHEM, V43, P146, DOI 10.1111/j.1471-4159.1984.tb06690.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALL A, 1986, J BIOL CHEM, V261, P963; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HASLAM RJ, 1987, THROMB DIATH HAEMO, P147; HILDEBRANDT E, 1991, BIOCHEMISTRY-US, V30, P464, DOI 10.1021/bi00216a023; HINTON DR, 1990, J NEUROSCI, V10, P2763; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KOWALSKA MA, 1988, BIOCHEM J, V253, P255, DOI 10.1042/bj2530255; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER BL, 1982, BLOOD, V60, P436; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; SAMUELSSON B, 1991, ANN NY ACAD SCI, V629, P89; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	35	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2949	2954		10.1074/jbc.271.6.2949	http://dx.doi.org/10.1074/jbc.271.6.2949			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621685	hybrid			2022-12-25	WOS:A1996TU69100014
J	August, A; Dupont, B				August, A; Dupont, B			Association between mitogen-activated protein kinase and the zeta chain of the T cell receptor (TcR) with the SH2,3 domain of p56(lck) - Differential regulation by TcR cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; COMPLEX; PHOSPHORYLATION; STIMULATION; P56LCK; RAF-1; CD4	A number of protein-tyrosine kinases have been shown to be important in T cell activation. One such kinase, Lck, has been demonstrated genetically to be essential for T cell receptor (TcR) signaling, and the SH2 and SH3 (src homology 2 and 3) domains of Lck have been shown to be indispensable for T cell activation. We have sought substrates with which the SH2,3 domain mould interact following T cell activation using fusion proteins containing the Lck SH2 and SH3 domains linked to glutathione S-transferase. We demonstrate that the SH2,3 region interacts specifically and directly with numerous tyrosine-phosphorylated molecules following TcR cross-linking, including constitutively with mitogen-activated protein kinase (MAPK)/extracellular-regulated kinase and inducibly with the zeta chain of the TcR. The interaction with MAPK/extracellular-regulated kinase was via the SH3 domain. The interaction with the tyrosine-phosphorylated zeta chain, while phosphotyrosine-dependent, required both the SH3 and SH2 domains. These interactions were specific as molecules known to be tyrosine-phosphorylated following TcR cross-linking, phospholipase C-gamma 1 and Fyn, were not bound. Thus, we suggest that during TcR signaling, Lck interacts with numerous molecules, including MAPK and TcR-zeta, via its SH2,3 domain. The interaction with MAPK mould place Lck in a position to be involved in the complex resulting in the activation of MAPK. In addition, the binding of Lck to the tyrosine-phosphorylated zeta chain of the TcR would serve to strengthen the interaction of the associated CD4 and the TcR complex, leading to increased avidity for the antigen-major histocompatibility protein complex.	SLOAN KETTERING INST CANC RES,PROGRAM IMMUNOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [P01CA022507, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA22507, CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; GOLD MR, 1994, J IMMUNOL, V153, P2369; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERI KG, 1993, ONCOGENE, V8, P2765; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WENG ZG, 1993, J BIOL CHEM, V268, P14956; XU H, 1993, CELL, V74, P638	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10054	10059						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626561				2022-12-25	WOS:A1996UG25700033
J	Gattoni, M; Boffi, A; Sarti, P; Chiancone, E				Gattoni, M; Boffi, A; Sarti, P; Chiancone, E			Stability of the heme-globin linkage in alpha beta dimers and isolated chains of human hemoglobin - A study of the heme transfer reaction from the immobilized proteins to albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATING PROTEINS; MUTANT	The stability of the heme-globin linkage in alpha beta dimers and in the isolated chains of human hemoglobin has been probed by studying the transfer of heme from the proteins immobilized onto CNBr-activated Sepharose 4B to human albumin. The kinetic and equilibrium features of the reaction have been measured spectrophotometrically given the stability of the heme donors and the ease with which heme donor and acceptor can be separated. Isolated alpha and beta chains transfer heme to albumin at similar rates (1-6 x 10(-2) s(-1) at pH 9.0 and 20 degrees C) in the ferrous CO-bound and in the ferric state. In alpha beta dimers the heme-globin linkage is strengthened considerably, albeit to a different extent in the ferrous CO-bound and ferric met-aquo derivatives. Only in the latter heme is lost at a measurable rate, 0.065 +/- 0.011 x 10(-2) s(-1) for alpha heme and 2.8 +/- 0.6 x 10(-2) s(-1) for beta heme at pH 9.0 and 20 degrees C, which is very close to the rate measured with soluble met-aquo-hemoglobin at micromolar concentrations. These results indicate that in human hemoglobin the heme-globin linkage in the alpha chains is stabilized by interactions between unlike chains at the alpha(1) beta(2) interface, whereas heme binding to the beta chains is stabilized by interactions at the alpha(1) beta(2) interface. These long range factors have to be taken into account in addition to the local factors at the heme pocket when evaluating the effect of point mutation and chemical modification.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI A ROSSI FANELLI, CNR, CTR MOLEC BIOL, I-00185 ROME, ITALY; UNIV CAGLIARI, INST BIOL CHEM, I-09100 CAGLIARI, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Cagliari			Sarti, Paolo/D-2946-2009	Sarti, Paolo/0000-0002-8219-4827				ANTONINI E, 1977, ANNU REV BIOPHYS BIO, V6, P239, DOI 10.1146/annurev.bb.06.060177.001323; ANTONINI E, 1975, PROTEIN LIGAND INTER, P45; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P127; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BERGER RL, 1973, ANAL LETT, V6, P125; BROWN SB, 1970, BIOCHEM J, V117, P733, DOI 10.1042/bj1170733; BUNN HF, 1968, J BIOL CHEM, V243, P465; CHIANCONE E, 1986, ANAL BIOCHEM, V158, P211, DOI 10.1016/0003-2697(86)90611-1; CHIANCONE E, 1968, J BIOL CHEM, V243, P1212; CHIANCONE E, 1987, METHOD ENZYMOL, V135, P484; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DILORIO EE, 1991, BIOPHYS J, V59, P742, DOI 10.1016/S0006-3495(91)82287-1; FANELLI MRR, 1978, EUROPEAN J BIOCH, V92, P253; GERACI G, 1969, J BIOL CHEM, V244, P4664; Gilbert L M, 1973, Methods Enzymol, V27, P273; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IDE GJ, 1976, J AM CHEM SOC, V98, P1595, DOI 10.1021/ja00422a060; ROSENFELD M, 1950, J BIOL CHEM, V183, P663; SMITH ML, 1984, FEBS LETT, V169, P147, DOI 10.1016/0014-5793(84)80307-5; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303	22	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10130	10136		10.1074/jbc.271.17.10130	http://dx.doi.org/10.1074/jbc.271.17.10130			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626572	hybrid			2022-12-25	WOS:A1996UG25700044
J	Liu, PS; Ying, YS; Ko, YG; Anderson, RGW				Liu, PS; Ying, YS; Ko, YG; Anderson, RGW			Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; RECEPTOR; INTERNALIZATION; MOLECULES; PDGF	Previously we showed that interleukin 1 beta stimulates the conversion of sphingomyelin to ceramide in the caveolae fraction of normal human fibroblasts. The ceramide, in turn, blocked platelet-derived growth factor (PDGF) stimulated DNA synthesis. We now present evidence that the PDGF receptor initiates signal transduction from caveolae. Cell fractionation and immunocytochemistry show caveolae to be the principal location of PDGF receptors at the cell surface. Multiple caveolae proteins acquire phosphotyrosine when PDGF binds to its receptor, but the hormone appears to have little effect on the tyrosine phosphorylation of non-caveolae membrane proteins. Five proteins known to interact with the phosphorylated receptor were found to be highly enriched in caveolae membrane. PDGF caused the concentration of three of these proteins to significantly increase in the caveolae fraction. Finally, PDGF stimulated the association of a 190-kDa phosphoprotein with the caveolae marker protein, caveolin. Therefore, ceramide may modulate PDGF receptor function directly in caveolae.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Liu, Pingsheng/B-7124-2012		NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SMART EJ, 1995, IN PRESS COLD SPRING; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	27	335	339	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10299	10303		10.1074/jbc.271.17.10299	http://dx.doi.org/10.1074/jbc.271.17.10299			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626598				2022-12-25	WOS:A1996UG25700070
J	Robinson, AS; Bockhaus, JA; Voegler, AC; Wittrup, KD				Robinson, AS; Bockhaus, JA; Voegler, AC; Wittrup, KD			Reduction of BiP levels decreases heterologous protein secretion in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; IMMUNOGLOBULIN HEAVY-CHAIN; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; GRP78-BIP GENE; CHAPERONE BIP; YEAST; TRANSLOCATION; EXPRESSION	Increased levels of the endoplasmic reticulum-resident protein folding chaperone BiP would be expected to either increase protein secretory capacity by improved solubilization of folding precursors or decrease secretory capacity by binding and retaining misfolded proteins. To address this question, the relationship between BiP levels and heterologous secretion in yeast was determined. A yeast strain was constructed in which BiP expression is tunable from 5 to 250% of wild-type levels, and this strain was used to explore the effect of varying BiP level on overall secretion of three heterologous proteins: human granulocyte colony-stimulating factor, Schizosaccharomyces pombe acid phosphatase, and bovine pancreatic trypsin inhibitor. For all three proteins examined, reduction in BiP expression below wild-type level diminished overall secretion, whereas 5-fold BiP overexpression from a constitutive glycolytic promoter did not substantially increase or decrease secretion titers. These results are consistent with a positive role for BiP in promoting membrane translocation and solubilization of folding precursors but are inconsistent with a negative role in proofreading and improper retention of heterologous secreted proteins.	UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign			Robinson, Anne Skaja/H-7894-2012	Robinson, Anne Skaja/0000-0001-7235-1481				BITTER GA, 1987, METHOD ENZYMOL, V153, P516; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CHON Q, 1992, NUCLEIC ACIDS RES, V20, P1717; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HODGSON J, 1993, BIO-TECHNOL, V11, P887, DOI 10.1038/nbt0893-887; HSU TA, 1994, PROTEIN EXPRES PURIF, V5, P595, DOI 10.1006/prep.1994.1082; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; ROBINSON AS, 1993, ACS SYM SER, V526, P121; ROBINSON AS, 1995, BIOTECHNOL PROGR, V11, P171, DOI 10.1021/bp00032a009; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Shuster J R, 1991, Curr Opin Biotechnol, V2, P685, DOI 10.1016/0958-1669(91)90035-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; TOKUNAGA M, 1992, J BIOL CHEM, V267, P17553; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; WITTRUP KD, 1994, BIOTECHNOL TECH, V8, P161, DOI 10.1007/BF00161582; WITTRUP KD, 1995, ANN NY ACAD SCI, V745, P321	55	74	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10017	10022		10.1074/jbc.271.17.10017	http://dx.doi.org/10.1074/jbc.271.17.10017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626555	hybrid			2022-12-25	WOS:A1996UG25700027
J	Tazi, A; LeBras, S; Lamghitnia, HO; Vincent, JD; Czernichow, P; Scharfmann, R				Tazi, A; LeBras, S; Lamghitnia, HO; Vincent, JD; Czernichow, P; Scharfmann, R			Neurotrophin-3 increases intracellular calcium in a rat insulin-secreting cell line through its action on a functional TrkC receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ENDOCRINE-CELLS; KINASE; EXPRESSION; NEURONS; BDNF; IDENTIFICATION; ESTABLISHMENT; FAMILY; CA-2+	Pancreatic beta cells and neuronal cells show a large number of similarities. For example, functional receptors for nerve growth factor are present in beta cells. Here we investigate whether TrkC, a neuronal high affinity receptor for neurotrophin-3, is expressed in the insulin-secreting cell line INS-1. We demonstrate the expression in INS-1 cells of mRNAs coding for TrkC identical in size to those found in the brain. As in neuronal cells, different alternatively spliced forms of TrkC mRNA differing by the insertion of an alternative exon in their kinase domain, were expressed in INS-1 cells. TrkC protein is also expressed in INS-1 cells and is functional. Indeed, when INS-1 cells were treated with neurotrophin-3, TrkC became phosphorylated on tyrosine residues, and the expression of early response genes was induced. This activation of the receptor was paralleled by a rapid and transient increase in cytosolic free calcium due to an influx of extracellular calcium. Functional receptors for NT-3 are thus expressed in INS-1 cells. This cell line provides a new model for the study of NT-3 signal transduction and should be useful in the understanding of the role of neurotrophins in insulin-secreting cells.	HOP ROBERT DEBRE,INSERM,CJF 9313,F-75019 PARIS,FRANCE; CNRS,INST ALFRED FESSARD,F-91198 GIF SUR YVETTE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X; Tazi, Abdelali/0000-0002-0258-3794				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DURBEEJ M, 1993, DEVELOPMENT, V119, P977; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P761, DOI 10.1210/en.136.2.761; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; PHILIPSON LH, 1993, DIABETES, V42, P1372, DOI 10.2337/diabetes.42.9.1372; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SCHARFMANN R, 1993, DIABETES, V42, P1829, DOI 10.2337/diabetes.42.12.1829; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; TAPLEY P, 1992, ONCOGENE, V7, P371; TAZI A, 1995, J NEUROENDOCRINOL, V7, P29, DOI 10.1111/j.1365-2826.1995.tb00664.x; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496	44	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10154	10160		10.1074/jbc.271.17.10154	http://dx.doi.org/10.1074/jbc.271.17.10154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626576	hybrid			2022-12-25	WOS:A1996UG25700048
J	Cataldi, M; Taglialatela, M; Guerriero, S; Amoroso, S; Lombardi, G; diRenzo, G; Annunziato, L				Cataldi, M; Taglialatela, M; Guerriero, S; Amoroso, S; Lombardi, G; diRenzo, G; Annunziato, L			Protein-tyrosine kinases activate while protein-tyrosine phosphatases inhibit L-type calcium channel activity in pituitary GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN SECRETION; ACTION-POTENTIALS; BAY K-8644; GH3 CELLS; PHOSPHORYLATION; RECEPTOR; GENISTEIN; INFLUX; ENTRY; SELECTIVITY	The aim of this study was to evaluate the effect of protein-tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP) inhibitors on Ca2+ channels in GH(3) cells, The activity of Ca2+ channels was monitored either by single-cell microfluorometry or by the whole cell configuration of the patch-clamp technique, Genistein (20-200 mu M) and herbimycin A (1-15 mu M) inhibited [Ca2+](i) rise induced either by 55 mM K+ or 10 mu M Bay K 8644, In addition, genistein and lavendustin A inhibited whole-cell Ba2+ currents, By contrast, daidzein, a genistein analogue devoid of PTK inhibitory properties, did not modify Ca2+ channel activity. The inhibitory action of genistein on the [Ca2+](i) increase was completely counteracted by the PTP inhibitor vanadate (100 mu M). Furthermore, vanadate alone potentiated [Ca2+](i) response to both 55 mM K+ and 10 mu M Bay K 8644. The possibility that genistein could decrease the [Ca2+](i) elevation by enhancing Ca2+ removal from the cytosol seems unlikely since genistein also reduced the increase in fura-2 fluorescence ratio induced by Ba2+, a cation that enters into the cells through Ca2+ channels but cannot be pumped out by Ca2+ extrusion mechanisms, Finally, in unstimulated GH(3) cells, genistein caused a decline of [Ca2+](i) and the disappearance of [Ca2+](i) oscillations, whereas vanadate induced an increase of [Ca2+](i) and the appearance of [Ca2+](i) oscillations in otherwise non-oscillating cells. The present results suggest that in GH(3) cells PTK activation causes an increase of L-type Ca2+ channel function, whereas PTPs exert an inhibitory role.	UNIV NAPLES 2, DEPT NEUROSCI, PHARMACOL SECT, I-80131 NAPLES, ITALY; UNIV CATANZARO, SCH PHARM, I-88021 CATANZARO, ITALY	Universita della Campania Vanvitelli; Magna Graecia University of Catanzaro			Taglialatela, Maurizio/A-2062-2019; Cataldi, Mauro/AAB-3642-2019; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/ABH-4262-2020; Di Renzo, Gian C./P-3819-2017	Cataldi, Mauro/0000-0001-7787-3406; Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; Di Renzo, Gian C./0000-0003-4467-240X; ANNUNZIATO, LUCIO/0000-0002-8534-8270				AANESTAD M, 1993, ACTA ENDOCRINOL-COP, V128, P361, DOI 10.1530/acta.0.1280361; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; ENYEART JJ, 1990, MOL ENDOCRINOL, V4, P727, DOI 10.1210/mend-4-5-727; FATATIS A, 1994, J BIOL CHEM, V269, P18021; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; KIDOKORO Y, 1975, NATURE, V258, P741, DOI 10.1038/258741a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEE KM, 1993, J BIOL CHEM, V268, P9945; MACEWAN DJ, 1991, FEBS LETT, V291, P79, DOI 10.1016/0014-5793(91)81108-K; MARCHETTI C, 1988, AM J PHYSIOL, V254, pC206, DOI 10.1152/ajpcell.1988.254.1.C206; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NASTAINCZYK W, 1987, EUR J BIOCHEM, V169, P137, DOI 10.1111/j.1432-1033.1987.tb13590.x; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; NOWYCKY MC, 1985, P NATL ACAD SCI USA, V82, P2178, DOI 10.1073/pnas.82.7.2178; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WHITE BA, 1981, J BIOL CHEM, V256, P5942; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	37	86	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9441	9446		10.1074/jbc.271.16.9441	http://dx.doi.org/10.1074/jbc.271.16.9441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621613	hybrid			2022-12-25	WOS:A1996UG04400044
J	Collins, S; Surwit, RS				Collins, S; Surwit, RS			Pharmacologic manipulation of ob expression in a dietary model of obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C57BL/6J MICE; RECEPTORS	Mutation of the obese (ob) gene results in severe hereditary obesity and diabetes in the C57BL/6J and related strains of mice. In this study we examined the expression of the ob gene in a dietary model in which moderate obesity develops in response to fat (58% of calories from fat) without mutation of the ob gene, and in four genetic models of obesity in mice: ob/ob, db/db, tubby, and fat, Several white and brown adipose depots were examined (epididymal, subcutaneous, perirenal, and interscapular), Northern blot analysis shows that levels of ob mRNA are increased in all adipose depots examined in every model of obesity, The average fold increases were 12.0 +/- 2.1 (ob/ob), 4.8 +/- 1.5 (db/db), 2.8 +/- 0.1 (tubby), 2.4 +/- 0.3 (fat), and 2.1 +/- 0.2 (high fat diet-induced A/J), Moreover, we found that the expression of the ob gene could be manipulated by pharmacologically blocking the development of diet-induced obesity. Supplementation of a high fat diet with a beta(3)-adrenergic receptor agonist (CL316,243) prevented obesity, but not hyperphagia associated with high fat feeding (body weights of high fat-fed A/J mice = 34.0 +/- 1.0 g; high fat plus CL316,243-fed mice = 26.8 +/- 0.5 g; n = 10), CL316,243-treated, high fat-fed animals contained levels of ob mRNA in all adipose depots that were equal to or less than levels in low fat-fed mice (average levels in high fat plus CL316,243-fed mice relative to low fat-fed mice: 0.93 +/- 0.09), Inasmuch as fat cell size, but not number, was increased in a previous study in diet-induced obese A/J mice, these results indicate that expression of the ob gene serves as a sensor of fat cell hypertrophy, independent of any effects on food intake.	DUKE UNIV, MED CTR, SARAH W STEDMAN CTR NUTRIT STUDIES, DURHAM, NC 27710 USA	Duke University	Collins, S (corresponding author), DUKE UNIV, MED CTR, DEPT PSYCHIAT & BEHAV SCI, BOX 3557, DURHAM, NC 27710 USA.				NIDDK NIH HHS [DK43106, DK49066, DK46793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043106, R01DK049066, R29DK046793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; ASTRUP A, 1994, AM J CLIN NUTR, V59, P350, DOI 10.1093/ajcn/59.2.350; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1982, DIABETES, V31, P1; COLLINS S, 1988, J BIOL CHEM, V263, P9067; CONSIDINE RV, 1995, J CLIN INVEST, V96, P2720; EZZELL C, 1995, J NIH RES, V7, P39; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; LARGIS EE, 1994, DRUG DEVELOP RES, V32, P69, DOI 10.1002/ddr.430320203; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MEIER MK, 1984, INT J OBESITY, V8, P215; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RINK TJ, 1994, NATURE, V372, P406, DOI 10.1038/372406a0; SIMS EAH, 1989, MED CLIN N AM, V73, P97, DOI 10.1016/S0025-7125(16)30694-0; SURWIT RS, 1991, DIABETES, V40, P82, DOI 10.2337/diabetes.40.1.82; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9437	9440		10.1074/jbc.271.16.9437	http://dx.doi.org/10.1074/jbc.271.16.9437			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621612	hybrid			2022-12-25	WOS:A1996UG04400043
J	Medvedev, AE; Espevik, T; Ranges, G; Sundan, A				Medvedev, AE; Espevik, T; Ranges, G; Sundan, A			Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; SOLUBLE RECEPTORS; FACTOR-BETA; HUMAN-MONOCYTES; CELL-SURFACE; BINDING; CYTOTOXICITY; RESOLUTION; ACTIVATION; RELEASE	The role for the two tumor necrosis factor (TNF) receptors in discriminating TNF and lymphotoxin alpha (LT alpha) effects has been studied, TNF and LT alpha were equally mitogenic in Fs4 fibroblasts, which express a high amount of the p55 compared to the p75 TNF receptors (TNFRs). In contrast, TNF was more potent than LT alpha in mediating gene regulation and cytotoxicity in SW480-beta Gal cells and KYM-1 cells, which have a high p75/p55 TNFR ratio, Both TNF and LT alpha showed comparable affinities for the two TNFRs, However, in contrast to LT alpha, TNF dissociated rapidly from the p75 TNFR, whereas both cytokines dissociated slowly from the p55 TNFR, Soluble p55 TNFR was much more potent than soluble p75 TNFR in inhibiting TNF cytotoxicity, whereas both soluble receptors moderately decreased LT alpha-mediated cytotoxicity with comparable efficacy, Antagonistic monoclonal antibodies against either TNFR types markedly inhibited TNF effects, However, only the p55 TNFR antagonistic antibody significantly decreased LT alpha-mediated cytotoxicity and cytomegalovirus promoter activation, whereas blocking of the p75 TNFR enhanced the LT alpha effects, These data suggest that whereas the p75 TNFR can both directly propagate TNF signals and ''pass'' TNF to the p55 TNFR, it attenuates LT alpha and may serve as a decoy receptor for this cytokine.	UNIV TRONDHEIM, MED CTR, INST CANC RES & MOL BIOL, N-7005 TRONDHEIM, NORWAY; MILES INC, INST INFLAMMAT & EXPT MED, West Haven, CT 06516 USA									ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BEUTLER B, 1990, PEPTIDE GROWTH FACTO, V2, P39; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DESCH CE, 1990, BLOOD, V75, P2030; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Espevik Terje, 1994, P165; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IWAMOTO S, 1994, BIOCHEM BIOPH RES CO, V199, P70, DOI 10.1006/bbrc.1994.1195; Kircheis R, 1992, Eur Cytokine Netw, V3, P381; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LIEU E, 1995, EUR J IMMUNOL, V25, P2714, DOI 10.1002/eji.1830250948; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; OSTER W, 1987, BLOOD, V70, P1700; PALEOLOG EM, 1994, BLOOD, V84, P2578; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORTER A G, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P193, DOI 10.1016/0378-1097(90)90609-T; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SCHUCHMANN M, 1995, EUR J IMMUNOL, V25, P2183, DOI 10.1002/eji.1830250810; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SPINAS GA, 1992, J CLIN INVEST, V90, P533, DOI 10.1172/JCI115891; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845	46	91	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9778	9784		10.1074/jbc.271.16.9778	http://dx.doi.org/10.1074/jbc.271.16.9778			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621658	hybrid			2022-12-25	WOS:A1996UG04400089
J	Sala, A; Casella, I; Bellon, T; Calabretta, B; Watson, RJ; Peschle, C				Sala, A; Casella, I; Bellon, T; Calabretta, B; Watson, RJ; Peschle, C			B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; C-MYB; RETINOBLASTOMA PROTEIN; G1 PHASE; A-MYB; EXPRESSION; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION	The retinoblastoma protein family has been implicated in growth control and modulation of the activity of genes involved in cell proliferation, such as B-myb. Recent evidence indicates that the product of the B-myb gene is necessary for the growth and survival of several human and murine cell. lines. Upon overexpression, B-myb induces deregulated cell growth of certain cell lines. Here we show that B-myb overexpression is able to induce DNA synthesis in p107 growth-arrested human osteosarcoma cells (SAOS2). p107 might exert its growth-suppressive activity by regulating B-myb gene transcription. Indeed, p107 down-modulated B-myb promoter activity and drastically decreased E2F-mediated transactivation. Finally, B-myb was able to stimulate DNA synthesis of both stably and transiently transfected human glioblastoma cells (T98G). Altogether, these data provide definitive evidence that the human B-myb protein is involved in growth control of human cells, and that p107 has a significant role in regulating B-myb gene activity.	JEFFERSON CANC INST,PHILADELPHIA,PA 19107; IST SUPER SANITA,DEPT HEMATOL & ONCOL,I-00161 ROME,ITALY; ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Jefferson University; Istituto Superiore di Sanita (ISS); Imperial College London; Ludwig Institute for Cancer Research	Sala, A (corresponding author), THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Bellón, Teresa/ABF-4916-2020; sala, arturo/C-4959-2008	Bellón, Teresa/0000-0002-0138-6879; Sala, Arturo/0000-0002-2841-7866; Casella, Ida/0000-0002-3358-4976	NCI NIH HHS [CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CLAUDIO PP, 1994, CANCER RES, V54, P5556; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOLAY J, 1991, BLOOD, V77, P149; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NEVINS JR, 1992, SCIENCE, V258, P424; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SALA A, 1994, CANCER RES, V54, P1402; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; TASHIRO S, 1995, ONCOGENE, V10, P1699; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	38	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9363	9367		10.1074/jbc.271.16.9363	http://dx.doi.org/10.1074/jbc.271.16.9363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621601	hybrid			2022-12-25	WOS:A1996UG04400032
J	Hammond, MEW; Shyamala, V; Siani, MA; Gallegos, CA; Feucht, PH; Abbott, J; Lapointe, GR; Moghadam, M; Khoja, H; Zakel, J; TekampOlson, P				Hammond, MEW; Shyamala, V; Siani, MA; Gallegos, CA; Feucht, PH; Abbott, J; Lapointe, GR; Moghadam, M; Khoja, H; Zakel, J; TekampOlson, P			Receptor recognition and specificity of interleukin-8 is determined by residues that cluster near a surface-accessible hydrophobic pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULCERATIVE-COLITIS; AMINO TERMINUS; BINDING; IL-8; MUTAGENESIS; ANTIBODY; PROTEINS; CLONING; FAMILY; YEAST	To determine the regions of interleukin-8 (IL-8) that allow high affinity and interleukin-8 receptor type 1 (IL8R1)-specific binding of chemokines, we produced chimeric proteins containing structural domains from IL-8, which binds to both IL8R1 and interleukin-8 receptor type 2 (IL8R2) with high affinity, and from GRO gamma, which does not bind to IL8R1 and binds to IL8R2 with reduced affinity, Receptor binding activity was tested by competition of I-125-IL-8 binding to recombinant IL8R1 and IL8R2 cell lines, Substitution into IL-8 of the GRO gamma sequences corresponding to either the amino-terminal loop (amino acids 1-18) or the first beta-sheet (amino acids 18-32) reduced binding to both IL8R1 and IL8R2, The third beta-sheet of IL-8 (amino acids 46-53) was required for binding to IL8R1 but not IL8R2, Exchanges of the second beta-sheet (amino acids 32-46) or the carboxyl-terminal alpha-helix (amino acids 53-72) had no significant effect, When IL-8 sequences were substituted into GRO gamma, a single domain containing the second beta-sheet of IL-8 (amino acids 18-32) was sufficient to confer high affinity binding for both IL8R1 and IL8R2, The amino-terminal loop (amino acids 1-18) and the third beta-sheet (amino acids 46-53) of IL-8 had little effect when substituted individually but showed increased binding to both receptors when substituted in combination. Individual amino acid substitutions were made at positions where IL-8 and GRO gamma sequences differ within the regions of residues 11-21 and 46-53, IL-8 mutations L49A or L49F selectively inhibited binding to IL8R1, Mutations Y13L and F21N enhanced binding to IL8R1 with little effect on IL8R2, A combined mutation Y13L/S14Q selectively decreased binding to IL8R2, Residues Tyr(13), Ser(14), Phe(21), and Lys(49) are clustered in and around a surface-accessible hydrophobic pocket on IL-8 that is physically distant from the previously identified ELR binding sequence, A homology model of GRO gamma, constructed from the known structure of IL-8 by refinement calculations, indicated that access to the hydrophobic pocket was effectively abolished in GRO gamma, These studies suggest that the surface hydrophobic pocket and/or adjacent residues participate in IL-8 receptor recognition for both IL8R1 and IL8R2 and that the hydrophobic pocket itself may be essential for IL8R1 binding, Thus this region contains a second site for IL-8 receptor recognition that, in combination with the Glu(4)-Leu(5)-Arg(6) region, can modulate receptor binding affinity and IL8R1 specificity.			Hammond, MEW (corresponding author), CHIRON CORP,4560 HORTON ST,EMERYVILLE,CA 94608, USA.							BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BRAKE AJ, 1990, METHOD ENZYMOL, V185, P408; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; ENDO H, 1991, LYMPHOKINE CYTOK RES, V10, P245; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEINRICH JN, 1994, MOL CELL BIOL, V14, P2849, DOI 10.1128/MCB.14.5.2849; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IZZO RS, 1992, AM J GASTROENTEROL, V87, P1447; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEATHERBARROW RJ, 1991, GRAFIT; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; MAHIDA YR, 1992, CLIN SCI, V82, P273, DOI 10.1042/cs0820273; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MILLER EJ, 1995, PROTEIN EXPRES PURIF, V6, P357, DOI 10.1006/prep.1995.1047; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHYAMALA V, 1991, GENE, V97, P1, DOI 10.1016/0378-1119(91)90002-S; Shyamala V, 1993, Methods Mol Biol, V15, P339, DOI 10.1385/0-89603-244-2:339; SHYAMALA V, 1994, CELL MOL BIOL RES, V40, P285; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	42	63	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8228	8235		10.1074/jbc.271.14.8228	http://dx.doi.org/10.1074/jbc.271.14.8228			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626516	hybrid			2022-12-25	WOS:A1996UD60000056
J	Henseler, M; Klein, A; Glombitza, GJ; Suzuki, K; Sandhoff, K				Henseler, M; Klein, A; Glombitza, GJ; Suzuki, K; Sandhoff, K			Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSIDE SULFATE ACTIVATOR; METACHROMATIC LEUKODYSTROPHY; BETA-GLUCOSIDASE; MESSENGER-RNA; SAPOSIN-A; DEFICIENCY; PROSAPOSIN; DISEASE; ACID; GENE	Sphingolipid activator proteins (SAPs) are non-enzymatic glycoproteins required for lysosomal degradation of various sphingolipids with short oligosaccharide chains by their respective exohydrolases. Four of these (SAP-A to SAP-D or saposins A to D) are derived from a common precursor by proteolytic processing. Alternative splicing of the SAP-precursor gene results in insertion of additional 6 or 9 bases of exon 8' or 8, respectively, into the SAP-B coding region of the transcribed mRNAs. To examine the features of the three different SAP-precursor proteins (prosaposins), the respective cDNAs were stably expressed in baby hamster kidney cells. Pulse-chase experiments with transfected cells and endocytosis studies on human fibroblasts showed that synthesis, transport, and maturation of all SAP-precursor led to formation of the four mature SAPs (SAP-A to SAP-D). In order to determine the biological function of the three different SAP-B isoforms, SAP-precursor-deficient human fibroblasts were loaded with recombinant SAP-precursor proteins with or without 2- and 3-amino acid insertions, respectively, purified from the medium of the baby hamster kidney cells. They were found to stimulate at nanomolar concentrations the turnover of biosynthetically labeled ceramide, glucosylceramide, and lactosylceramide. Since the physiological function of SAP-B is to stimulate the degradation of sulfatide by arylsulfatase A (EC 3.1.6.1) and globotriaosylceramide by beta-galactosidase (EC 3.2.1.23) loading studies with the respective exogenously labeled lipids on SAP precursor-deficient fibroblasts were performed. Addition of different purified SAP-precursors to the medium of the lipid-loaded fibroblasts showed positive stimulation of the lipid degradation by all three SAP-B isoforms derived from the SAP-precursors. These findings establish that all three forms of the SAP-B can function as sulfatide/ globotriaosylceramide activator.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV N CAROLINA,SCH MED,BRAIN & DEV RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT NEUROL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PSYCHIAT,CHAPEL HILL,NC 27599	University of Bonn; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NICHD NIH HHS [P30-HD03110] Funding Source: Medline; NINDS NIH HHS [NS24289] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; FLUHARTY AL, 1995, TRENDS GLYCOSCI GLYC, V7, P167, DOI 10.4052/tigg.7.167; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; Henseler M, 1996, AM J HUM GENET, V58, P65; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; HOLTSCHMIDT H, 1991, FEBS LETT, V280, P267, DOI 10.1016/0014-5793(91)80308-P; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; ITO K, 1993, EUR J BIOCHEM, V215, P171, DOI 10.1111/j.1432-1033.1993.tb18020.x; KAO FT, 1987, SOMAT CELL MOLEC GEN, V13, P685, DOI 10.1007/BF01534489; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KUDOH T, 1982, J CLIN INVEST, V70, P89, DOI 10.1172/JCI110607; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; KYRKLUND T, 1987, LIPIDS, V22, P274, DOI 10.1007/BF02533991; LAMONTAGNE S, 1994, J BIOL CHEM, V269, P20528; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; PATON BC, 1992, BIOCHEM J, V285, P481, DOI 10.1042/bj2850481; POTIER M, 1988, BIOCHEM BIOPH RES CO, V155, P32, DOI 10.1016/S0006-291X(88)81045-3; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS RL, 1993, BIOCHEMISTRY-US, V32, P4051, DOI 10.1021/bi00066a028; SUZUKI Y, 1972, J LIPID RES, V13, P680; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; TAYAMA M, 1993, BIOCHEM J, V290, P401, DOI 10.1042/bj2900401; TSUDA M, 1992, BIOCHEM BIOPH RES CO, V184, P1266, DOI 10.1016/S0006-291X(05)80019-1; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WEITZ G, 1983, HOPPESEYLERS Z PHYSL, V364, P862; WIRTH M, 1988, GENE, V73, P419, DOI 10.1016/0378-1119(88)90506-9; YAMASHITA K, 1990, BIOCHEMISTRY-US, V29, P3030, DOI 10.1021/bi00464a020; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	51	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8416	8423		10.1074/jbc.271.14.8416	http://dx.doi.org/10.1074/jbc.271.14.8416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626540	hybrid, Green Published			2022-12-25	WOS:A1996UD60000080
J	Holt, KH; Waters, SB; Okada, S; Yamauchi, K; Decker, SJ; Saltiel, AR; Motto, DG; Koretzky, GA; Pessin, JE				Holt, KH; Waters, SB; Okada, S; Yamauchi, K; Decker, SJ; Saltiel, AR; Motto, DG; Koretzky, GA; Pessin, JE			Epidermal growth factor receptor targeting prevents uncoupling of the Grb2-SOS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; INSULIN-RECEPTOR; SH3 DOMAIN; RAS; RAF-1; PHOSPHORYLATION; INTERACTS	Insulin stimulates the Ras/Raf/MEK/ERK pathway leading to feedback phosphorylation of the Ras guanylnucleotide exchange protein SOS and dissociation of Grb2 from SOS. Even though epidermal growth factor (EGF) also stimulates ERK activity and phosphorylation of SOS similar to insulin, EGF induces a dissociation of the Grb2 SOS complex from She. To determine the molecular basis for this difference, we examined the signaling properties of a mutant EGF receptor lacking the five major autophosphorylation sites, Although EGF stimulation of the mutant EGF receptor activates ERK and phosphorylation of both She and SOS, it fails to directly associate with either She or Grb2. However, under these conditions EGF induces a dissociation of the Grb2-SOS complex suggesting a role for receptor and/or plasma membrane targeting in the stabilization of Grb2-SOS interaction, Consistent with this hypothesis, expression of an SHc domain Grb2 mutant which is unable to mediate plasma membrane targeting of the Grb2-SOS complex results in both insulin- and EGF-stimulated uncoupling of Grb2 from SOS. Furthermore, a plasma membrane bound Grb2 fusion protein remains constitutively associated with SOS. Together, these data demonstrate that EGF stimulation prevents the feedback uncoupling of Grb2 from SOS by inducing a persistent plasma membrane receptor targeting of the Grb2-SOS complex.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Iowa; University of Iowa; Pfizer			Saltiel, Alan/L-3632-2019; Koretzky, Gary/AAU-5381-2021	Saltiel, Alan/0000-0002-9726-9828				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	53	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8300	8306		10.1074/jbc.271.14.8300	http://dx.doi.org/10.1074/jbc.271.14.8300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626525	hybrid			2022-12-25	WOS:A1996UD60000065
J	McDonnell, JM; Jones, GE; White, TK; Tanzer, ML				McDonnell, JM; Jones, GE; White, TK; Tanzer, ML			Calreticulin binding affinity for glycosylated laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CHAINS	Several lines of evidence indicate that calreticulin has lectin-like properties. As a molecular chaperone, calreticulin binds preferentially to nascent glycoproteins via their immature carbohydrates; this property closely resembles that seen for calnexin, a chaperone with extensive molecular identity to calreticulin. A cell surface form of calreticulin also exhibits lectin-like properties, binding specific oligomannosides including those covalently linked to laminin. In the present study we examined the interaction between calreticulin and laminin by means of surface plasmon resonance. The results show that calreticulin specifically binds to glycosylated laminin but fails to specifically bind tunicamycin-derived unglycosylated laminin or bovine serum albumin. Calreticulin binding to glycosylated laminin requires calcium and is abolished in the presence of EDTA. Scatchard analysis of binding yields an apparent association constant, K-a, of 2.1 +/- 0.9 x 10(6) M(-1) while kinetic analysis yields an estimate of the association on rate, (K-assoc), as 2 x 10(5) M(-1) s(-1). The composite results support calreticulin's lectin-like properties as well as its proposed role in laminin recognition, both in the cell interior and on the cell. surface.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; UNIV LONDON KINGS COLL,RANDALL INST,LONDON WC2B 5RL,ENGLAND	University of Connecticut; University of London; King's College London			Jones, Gareth E/H-2282-2012	Jones, Gareth E/0000-0001-5879-3048; McDonnell, James/0000-0001-9037-2980	NIAMS NIH HHS [AR-17720] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3367; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3356; COPEMAN MC, 1988, J CELL SCI, V91, P281; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEAN JW, 1990, J BIOL CHEM, V265, P12553; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ROWLING PJE, 1994, PROTEIN EXPRES PURIF, V5, P331, DOI 10.1006/prep.1994.1049; SHINOHARA Y, 1994, EUR J BIOCHEM, V223, P189, DOI 10.1111/j.1432-1033.1994.tb18982.x; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; YAMAMOTO K, 1994, BIOCHEMISTRY-US, V33, P8159, DOI 10.1021/bi00192a021	25	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7891	7894		10.1074/jbc.271.14.7891	http://dx.doi.org/10.1074/jbc.271.14.7891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626465				2022-12-25	WOS:A1996UD60000005
J	McLaughlin, MM; Kumar, S; McDonnell, PC; VanHorn, S; Lee, JC; Livi, GP; Young, PR				McLaughlin, MM; Kumar, S; McDonnell, PC; VanHorn, S; Lee, JC; Livi, GP; Young, PR			Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYBRID SYSTEM; MUTATIONS; YEAST; P53	CSBP p38 is a mitogen-activated protein kinase that is activated in response to stress, endotoxin, interleukin 1, and tumor necrosis factor. Using a catalytically inactive mutant (D168A) of human CSBP2 as the bait in a yeast two-hybrid screen, we have identified and cloned a novel kinase which shares similar to 70% amino acid identity to mitogen-activated protein kinase-activated protein kinase (MAPKAP kinase)-2, and thus was designated MAPKAP kinase-3. The binding of CSBP to MAPKAP kinase-3 was confirmed in vitro by the precipitation of epitope-tagged CSBP1, CSBP2, and CSBP2(D168A) and endogenous CSBP from mammalian cells by a bacterially expressed GST-MAPKAP kinase-3 fusion protein and in vivo by co-precipitation of the epitope-tagged proteins co expressed in HeLa cells. MAPKAP kinase-3 was phosphorylated by both CSBP1 and CSBP2 and was then able to phosphorylate HSP27 in vitro. Treatment of HeLa cells with sorbitol or TNF resulted in activation of CSBP and MAPKAP kinase-3 and activation of MAPKAP kinase-3 could be blocked by preincubation of cells with SB203580, a specific inhibitor of CSBP kinase activity. These data suggest that MAPKAP kinase-3 is activated by stress and cytokines and is a novel substrate of CSBP both in vitro and in vivo.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL UE0548,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT GENE EXPRESS SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO VN, 1994, ONCOGENE, V9, P1855; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	35	306	321	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8488	8492		10.1074/jbc.271.14.8488	http://dx.doi.org/10.1074/jbc.271.14.8488			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626550	hybrid			2022-12-25	WOS:A1996UD60000090
J	Stefansson, S; Lawrence, DA; Argraves, WS				Stefansson, S; Lawrence, DA; Argraves, WS			Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; ANTITHROMBIN-III; ENDOTHELIAL-CELLS; ALPHA-THROMBIN; HEPARIN-ANTITHROMBIN; BLOOD-COAGULATION; INVIVO CATABOLISM; GROWTH-FACTOR; S-PROTEIN; BINDING	Thrombin is a multifunctional protein that has both proteinase and growth factor-like activities. Its regulation is largely mediated by interaction with a host of inhibitors including antithrombin III (ATIII), heparin cofactor II (HCII), alpha(2)-macroglobulin (alpha(2)-M), protease nexin I, and plasminogen activator inhibitor-1 (PAI-1). ATIII, HCII, and alpha(2)-M are all abundant in blood and can inactivate blood-borne thrombin leading to rapid hepatic clearance of the thrombin-inhibitor complex. PAI-1 alone, a poor solution phase inhibitor of thrombin, can efficiently inhibit thrombin in the presence of native vitronectin (VN), In this study, active thrombin was found to be efficiently endocytosed and degraded by cultured pre-type II pneumocyte cells, and both processes could be blocked by polyclonal antibodies to PAI-1. When the relative efficiency of cellular endocytosis of thrombin in complex with a number of inhibitors was examined, I-125-thrombin-PAI-1 complexes were most efficiently cleared compared to I-125-thrombin in complex with the serpins ATIII, HCII, alpha(1)-proteinase inhibitor, or D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone. Low density lipoprotein receptor-related proteins 1 (LRP) and 2 (gp330/megalin) mediate the endocytosis of thrombin-PAI-l, since antagonists of receptor function such as LRP-1 and LRP-2 antibodies and the 39-kDa receptor-associated protein blocked I-125-thrombin-PAI-1 endocytosis and degradation. The LRP-mediated clearance of exogenously added I-125-thrombin by cultured cells was found to be enhanced 5-fold by inclusion of wild-type PAI-1 but by only 2-fold when a mutant form of PAI-1 that is unable to bind VN was included. This wild-type PAI-1 enhancement of I-125-thrombin clearance was found to occur only in the presence of native VN and not with its conformationally altered form. The results highlight a novel mechanism for cellular clearance of thrombin involving native VN promoting the interaction of thrombin and PAI-1 and the subsequent endocytosis of the complex by LRP-1 or LRP-2. This pathway is potentially important for the regulation of the potent biological activities of thrombin, particularly at sites of vascular injury.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross				Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [HL55374] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARSHAVIT R, 1984, BIOCHEMISTRY-US, V23, P397, DOI 10.1021/bi00298a001; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; CARLSON TH, 1986, MOL CELL BIOCHEM, V71, P97, DOI 10.1007/BF00214768; CARNEY DH, 1992, SEMIN THROMB HEMOST, V18, P91, DOI 10.1055/s-2007-1002414; CARNEY DH, 1978, CELL, V14, P811, DOI 10.1016/0092-8674(78)90337-9; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; DAWES KE, 1993, EUR J CELL BIOL, V61, P126; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FUCHS HE, 1982, BIOCHIM BIOPHYS ACTA, V716, P151, DOI 10.1016/0304-4165(82)90263-X; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GOSPODAROWICZ D, 1978, J CELL BIOL, V77, P774, DOI 10.1083/jcb.77.3.774; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; ILL CR, 1985, J BIOL CHEM, V260, P5610; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LIU CY, 1979, J BIOL CHEM, V254, P421; MALIK AB, 1986, SEMIN THROMB HEMOST, V12, P184, DOI 10.1055/s-2007-1003549; MALLAMPALLI RK, 1992, IN VITRO CELL DEV-AN, V28A, P181; MIMURO J, 1989, J BIOL CHEM, V264, P936; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; PREISSNER KT, 1989, BLOOD, V74, P989; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; SAEGUSA Y, 1988, J IMMUNOL, V141, P4140; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; STEFANSSON S, 1995, J CELL SCI, V108, P2361; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9038; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793; ZETTER BR, 1979, J SUPRAMOL STR CELL, V11, P361, DOI 10.1002/jss.400110311; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	60	63	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8215	8220		10.1074/jbc.271.14.8215	http://dx.doi.org/10.1074/jbc.271.14.8215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626514	hybrid			2022-12-25	WOS:A1996UD60000054
J	Chen, B; Kubelik, AR; Mohr, S; Breitenberger, CA				Chen, B; Kubelik, AR; Mohr, S; Breitenberger, CA			Cloning and characterization of the neurospora crassa cyt-5 Gene - A nuclear-coded mitochondrial, RNA polymerase with a polyglutamine repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION INITIATION; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; BACTERIOPHAGE T3; PROTEIN; IDENTIFICATION; MUTANT; DNA	The Neurospora crassa mutants, cyt-5-1 and cyt-5-4, have a cytochrome b- and aa(3)-deficient phenotype, suggesting that they result from a deficiency in a nuclear-coded component of the mitochondrial gene expression apparatus (Bertrand, H., Nargang, F. E., Collins, R. A., and Zagozeski, C. A. (1977) Mol. Gen, Genet. 153, 247-257). The complementing wild-type gene has been cloned and sequenced, and shown to encode a protein with significant sequence similarity to Saccharomyces cerevisiae mitochondrial RNA polymerase and bacteriophage RNA polymerases. There are remarkable differences between the N. crassa protein and its yeast homologue, including a region of very little homology near the N termini of the two gene products. The cyt-5 gene encodes a stretch of polyglutamine in this region of unique sequence. In addition, an acidic insertion (86 amino acids, of which 24 are Asp or Glu and 10 are Arg or Lys) is present near the C terminus of the cyt-5 gene product. Transcript levels of the cytochrome b and cytochrome oxidase subunit III genes are severely reduced in cyt-5 mutants, suggesting a likely mechanism for the cytochrome-deficient phenotype. In contrast, mitochondrial rRNAs accumulate to nearly normal levels in cyt-5 mutants. However, mitochondrial rRNA levels are not indicative of the rate of transcription of the corresponding genes, since crude lysates of mitochondria from cyt-5 mutants exhibit greatly reduced transcriptional activity with a 19 S rRNA promoter. The cyt-5 gene is flanked by at least one gene whose product also may be involved in mitochondrial function.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	Ohio State University; Ohio State University; Ohio State University			Breitenberger, Caroline/O-6176-2014	Breitenberger, Caroline/0000-0001-6001-156X	NIGMS NIH HHS [GM39498, GM37949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949, R29GM039498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; AKINS RA, 1984, P NATL ACAD SCI-BIOL, V81, P3791, DOI 10.1073/pnas.81.12.3791; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; BARATH Z, 1972, NATURE-NEW BIOL, V240, P195, DOI 10.1038/newbio240195a0; BERTRAND H, 1982, CELL, V29, P517, DOI 10.1016/0092-8674(82)90168-4; BERTRAND H, 1977, MOL GEN GENET, V153, P247, DOI 10.1007/BF00431590; BERTRAND H, 1973, CAN J GENET CYTOL, V15, P654; BERTRAND H, 1969, GENETICS, V61, P643; BOGENHAGEN DF, 1988, MOL CELL BIOL, V8, P2910, DOI 10.1128/MCB.8.7.2910; BREITENBERGER CA, 1985, EMBO J, V4, P185, DOI 10.1002/j.1460-2075.1985.tb02335.x; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOBINSON KF, 1989, GENETICS, V123, P97; DUNN JJ, 1988, GENE, V68, P259, DOI 10.1016/0378-1119(88)90028-5; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GUO QB, 1991, J BIOL CHEM, V266, P1809; HANCOCK JM, 1993, NUCLEIC ACIDS RES, V21, P2823, DOI 10.1093/nar/21.12.2823; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOGE JHC, 1982, EXP MYCOL, V6, P225, DOI 10.1016/0147-5975(82)90114-1; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; JOHO KE, 1990, J MOL BIOL, V215, P31, DOI 10.1016/S0022-2836(05)80092-0; KELLY JL, 1986, J BIOL CHEM, V261, P348; KENNELL JC, 1989, MOL CELL BIOL, V9, P3603, DOI 10.1128/MCB.9.9.3603; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; KUBELIK AR, 1990, J BIOL CHEM, V265, P4515; KUBELIK AR, 1991, MOL CELL BIOL, V11, P4022, DOI 10.1128/MCB.11.8.4022; KUIPER MTR, 1988, J BIOL CHEM, V263, P2840; KUNTZEL H, 1971, NATURE-NEW BIOL, V231, P265, DOI 10.1038/newbio231265a0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; LISOWSKY T, 1990, MOL GEN GENET, V220, P186; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCGRAW NJ, 1985, NUCLEIC ACIDS RES, V13, P6753, DOI 10.1093/nar/13.18.6753; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; RAMBOSEK J, 1987, CRIT REV BIOTECHNOL, V6, P357, DOI 10.3109/07388558709089387; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINKEL AH, 1989, TRENDS GENET, V5, P149, DOI 10.1016/0168-9525(89)90056-5; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; YUAN GF, 1991, MOL CELL BIOL, V11, P5735, DOI 10.1128/MCB.11.11.5735	54	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6537	6544		10.1074/jbc.271.11.6537	http://dx.doi.org/10.1074/jbc.271.11.6537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626458	hybrid			2022-12-25	WOS:A1996UA36300087
J	Tang, W; Bunting, M; Zimmerman, GA; McIntyre, TM; Prescott, SM				Tang, W; Bunting, M; Zimmerman, GA; McIntyre, TM; Prescott, SM			Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; GROWTH-FACTOR; ZINC-FINGER; ACID; EXPRESSION; METABOLISM; SEQUENCE; MOTIFS	Diacylglycerol (DAG) is a second messenger that activates protein kinase C and also occupies a central role in phospholipid biosynthesis. Conversion of DAG to phosphatidic acid by DAG kinase regulates the amount of DAG and the route it takes. We used degenerate primers to amplify polymerase chain reaction products from cDNA derived from human endothelial cells. A product with a novel sequence was identified and used to clone a 2,6-kilobase cDNA from an endothelial cell library. When transfected with a truncated version of this cDNA, COS-7 cells had a marked increase in DAG kinase activity, which demonstrated clear selectivity for arachidonoyl-containing species of diacylglycerol. The open reading frame of this clone has 567 residues with a predicted protein of 64 kDa. This enzyme, which we designated DGK epsilon, has two distinctive zinc finger-like structures in its N-terminal region, but does not contain the E-F hand motifs found in several other mammalian DGKs. The catalytic domain of DGK epsilon, which is related to other DGKs, contains two ATP-binding motifs. Northern blotting demonstrated that DGK epsilon is expressed predominantly in testis. This unique diacylglycerol kinase may terminate signals transmitted through arachidonoyl-DAG or may contribute to the synthesis of phospholipids with defined fatty acid composition.	UNIV UTAH, PROGRAM HUMAN MOL BIOL & GENET, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING IN, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [R01CA059548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER; NCI NIH HHS [CA59548] Funding Source: Medline; NHLBI NIH HHS [HL50153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Holub B J, 1978, Adv Lipid Res, V16, P1; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO M, 1987, J BIOL CHEM, V262, P5696; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SEVERSON DL, 1986, BIOCHEM CELL BIOL, V64, P976, DOI 10.1139/o86-130; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	25	147	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10237	10241		10.1074/jbc.271.17.10237	http://dx.doi.org/10.1074/jbc.271.17.10237			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626589	hybrid			2022-12-25	WOS:A1996UG25700061
J	Masamune, A; Igarashi, Y; Hakomori, S				Masamune, A; Igarashi, Y; Hakomori, S			Regulatory role of ceramide in interleukin (IL)-1 beta-induced E-selectin expression in human umbilical vein endothelial cells - Ceramide enhances IL-1 beta action, but is not sufficient for E-selectin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LEUKOCYTE ADHESION MOLECULE-1; PROTEIN-KINASE-C; ELAM-1 GENE-TRANSCRIPTION; NECROSIS-FACTOR-ALPHA; LEUKEMIA HL-60 CELLS; SIGNAL-TRANSDUCTION; CYTOKINE INDUCTION; SPHINGOMYELIN; ACTIVATION	Recent studies indicate that sphingolipids mediate several cellular processes, We assessed roles of sphingolipids in the regulation of E-selectin expression in human umbilical vein endothelial cells, All exogenously-added sphingolipids (sphingosine, C-2-ceramide, sphingosine 1-phosphate, and N,N-dimethylsphingosine) failed to induce E-selectin expression by themselves. C-2-ceramide at 5 mu M enhanced interleukin-1 beta (IL-1 beta)-induced E-selectin expression 2.7-fold, whereas other sphingolipids tested had no effects on this process, Sphingomyelinase, but not phospholipases A(2), C, or D, mimicked the enhancing effect of C-2-ceramide, Northern blot analyses revealed that C-2-ceramide and sphingomyelinase increased interleukin-1 beta-induced E-selectin gene transcription levels, C-2-ceramide and sphingomyelinase induced NF-kappa B activation by themselves and enhanced activation by IL-1 beta, which is essential for E-selectin expression, Immunological analyses with anti-NF-kappa B antibodies showed that subunit composition of NF-kappa B activated by IL-1 beta differs from that activated by C-2-ceramide, suggesting that signaling pathways utilized by these stimuli may be different. Treatment with C-2-ceramide or sphingomyelinase did not alter NF-ELAM1 specific binding activity, IL-1 beta induced sphingomyelin hydrolysis to ceramide; intracellular ceramide level increased to 182% of control value at 30 min. Taken together, these findings suggest that (i) sphingomyelin hydrolysis to ceramide does not trigger, but rather enhances cytokine-induced E-selectin expression, ill part through NF-kappa B; (ii) sphingomyelin hydrolysis to ceramide does not mediate all the effects of IL-1 beta, although it may play important roles in IL-1 beta signal transduction in human umbilical vein endothelial cells.	BIOMEMBRANE INST,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCI NIH HHS [CA-42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P2048; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GRABER N, 1990, J IMMUNOL, V145, P819; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAKOMORI S, 1990, J BIOL CHEM, V256, P18713; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MASAMUNE A, 1995, FEBS LETT, V367, P205, DOI 10.1016/0014-5793(95)00566-R; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MENON SD, 1993, J BIOL CHEM, V268, P26805; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHTA H, 1995, CANCER RES, V55, P691; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2326; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VANVELDHOVEN PP, 1989, J LIPID RES, V30, P611; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLCHOK JD, 1993, J LEUKOCYTE BIOL, V55, P7; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YOUNES A, 1992, J BIOL CHEM, V267, P842; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	60	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9368	9375		10.1074/jbc.271.16.9368	http://dx.doi.org/10.1074/jbc.271.16.9368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621602	hybrid			2022-12-25	WOS:A1996UG04400033
J	Pirskanen, A; Kaimio, AM; Myllyla, R; Kivirikko, KI				Pirskanen, A; Kaimio, AM; Myllyla, R; Kivirikko, KI			Site-directed mutagenesis of human lysyl hydroxylase expressed in insect cells - Identification of histidine residues and an aspartic acid residue critical for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS SYNDROME; PROLYL 4-HYDROXYLASE; 2 SIBLINGS; GENE; DECARBOXYLATION; 2-OXOGLUTARATE; INHIBITORS; COLLAGEN; CLONING; VECTORS	Lysyl hydroxylase (EC 1.14.11.4), an alpha(2) homodimer, catalyzes the formation of hydroxylysine in collagens. We expressed here human lysyl hydroxylase in insect cells by baculovirus vectors, About 90% of the enzyme produced was soluble 32 h after infection, whereas only 10% was soluble at 72 h, Twelve histidines, five aspartates, and all four asparagines that may act as N-glycosylation sites were converted individually to serine, alanine, or glutamine, respectively, and the mutant enzymes were expressed in insect cells, Three histidine mutations and one aspartate mutation appeared to inactivate the enzyme completely, These and other data suggest that histidines 656 and 708 and aspartate 658 provide the three ligands required for the binding of Fe2+ to a catalytic site, whereas the role of the third critical histidine (residue 706) remains to be established, Three additional histidine mutations also had a major effect, although they did not inactivate the enzyme completely, whereas six further histidine mutations and four out of five aspartate mutations had a much more minor effect. Data on the four asparagine mutations suggested that only two of the potential N-glycosylation sites may be fully glycosylated in insect cells and that one of these carbohydrate units may be needed for full enzyme activity.	UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND; UNIV OULU,COLLAGEN RES UNIT,BIOCTR,SF-90220 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND; UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu								GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HA VT, 1994, J CLIN INVEST, V93, P1716, DOI 10.1172/JCI117155; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HAUTALA T, 1993, GENOMICS, V15, P399, DOI 10.1006/geno.1993.1074; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5952, DOI 10.1021/bi00342a040; KELLOKUMPU S, 1994, J BIOL CHEM, V269, P30524; KIDD IM, 1993, APPL BIOCHEM BIOTECH, V42, P137, DOI 10.1007/BF02788049; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1972, BIOCHEMISTRY-US, V11, P122, DOI 10.1021/bi00751a021; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAJAMAA K, 1985, BIOCHEM J, V229, P127, DOI 10.1042/bj2290127; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; MYLLYLA R, 1991, J BIOL CHEM, V266, P2805; POUSI B, 1994, AM J HUM GENET, V55, P899; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P40, DOI 10.1016/0005-2744(80)90040-6; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Steinmann Beat, 1993, P351; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; TURPEENNIEMIHUJANEN TM, 1981, COLLAGEN REL RES, V1, P355; YEOWELL HN, 1992, J INVEST DERMATOL, V99, P864, DOI 10.1111/1523-1747.ep12614840	31	57	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9398	9402		10.1074/jbc.271.16.9398	http://dx.doi.org/10.1074/jbc.271.16.9398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621606	hybrid			2022-12-25	WOS:A1996UG04400037
J	Takahashi, K; Stamenkovic, I; Cutler, M; Dasgupta, A; Tanabe, KK				Takahashi, K; Stamenkovic, I; Cutler, M; Dasgupta, A; Tanabe, KK			Keratan sulfate modification of CD44 modulates adhesion to hyaluronate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA CELL MOTILITY; MONOCLONAL-ANTIBODIES; COLORIMETRIC ASSAY; COLON CARCINOMAS; ACID BINDING; I COLLAGEN; RECEPTOR; IDENTIFICATION; PROTEOGLYCAN; MOLECULE	CD44 alternative splicing has been implicated in the regulation of CD44 function, CD44 undergoes significant posttranslational modification in all cells, but the functional consequences of these modifications are poorly understood, In the current study, we have demonstrated that keratan sulfate modification of CD44 significantly modulates its ability to bind to hyaluronate. We observed naturally occurring differences in CD44 keratan sulfate substitution between two clonal variants of the KM12 human colon carcinoma cell line. CD44 on the highly metastatic KM12L4 clone is more heavily substituted with keratan sulfate than CD44 on the poorly metastatic KM12C6 clone, Moreover, CD44H on KM112L4 bound to hyaluronate poorly compared to CD44H on KM12C6, Removal of keratan sulfate from CD44 greatly enhanced CD44-mediated cell adhesion to hyaluronate. Removal of keratan sulfate from CD44H-immunoglobulin fusion proteins also enhanced their adhesion to hyaluronate, The influence of glycosaminoglycan substitution on CD44 function was specific to keratan sulfate substitution; treatment to remove chondroitin sulfate, heparan sulfate, or hyaluronate did not affect CD44-mediated cell adhesion to hyaluronate, Use of site-directed CD44H cDNA mutants with arginine changed to alanine at position 41 indicated that keratan sulfate modification of CD44 modulates hyaluronate adhesion through its B loop domain. These findings suggest that keratan sulfate modification of CD44 may play an important regulatory role in the broad spectrum of biological processes attributed to CD44, including normal development, tumor progression, and lymphocyte function.	MASSACHUSETTS GEN HOSP,DIV SURG ONCOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,DIV MED ONCOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA055735, R29CA064454] Funding Source: NIH RePORTER; NCI NIH HHS [CA64454, CA55735] Funding Source: Medline; NIDDK NIH HHS [DK433351] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSTEE DJ, 1991, IMMUNOLOGY, V74, P197; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BIRCH M, 1991, CANCER RES, V51, P6660; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; FAASSEN AE, 1993, J CELL SCI, V105, P501; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FOX SB, 1994, CANCER RES, V54, P4539; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; KIKUCHI Y, 1987, J BIOCHEM-TOKYO, V102, P1519, DOI 10.1093/oxfordjournals.jbchem.a122199; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MORIKAWA K, 1988, CANCER RES, V48, P1943; MURAKAMI S, 1994, J IMMUNOL, V152, P467; NAGASAKA S, 1995, J NEUROSURG, V82, P858, DOI 10.3171/jns.1995.82.5.0858; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; Takahashi K, 1995, ONCOGENE, V11, P2223; TANABE KK, 1995, ANN SURG, V222, P493; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; YANG BH, 1993, J BIOL CHEM, V268, P8617	43	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9490	9496		10.1074/jbc.271.16.9490	http://dx.doi.org/10.1074/jbc.271.16.9490			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621620	hybrid			2022-12-25	WOS:A1996UG04400051
J	vanWijk, KJ; Andersson, B; Aro, EM				vanWijk, KJ; Andersson, B; Aro, EM			Kinetic resolution of the incorporation of the D1 protein into photosystem II and localization of assembly intermediates in thylakoid membranes of spinach chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; PHOTOINHIBITION; TURNOVER; DAMAGE; POLYPEPTIDES; TRANSLATION; TRANSPORT; COMPLEXES; REPAIR	The chloroplast-encoded D1 protein of photosystem II (PSII) has a much higher turnover rate than the other subunits of the PSII complex as a consequence of photodamage and subsequent repair of its reaction center. The replacement of the D1 protein in existing PSII complexes was followed in two in vitro translation systems consisting of isolated chloroplasts or isolated thylakoid membranes with attached ribosomes. By application of pulse-chase translation experiments, we followed translation elongation, release of proteins from the ribosomes, and subsequent incorporation of newly synthesized products into PSII (sub)complexes. The time course of incorporation of newly synthesized proteins into the different PSII (sub)complexes was analyzed by sucrose density gradient centrifugation. Immediately after termination of translation, the D1 protein was found both unassembled in the membrane as well as already incorporated into PSII reaction center complexes, possibly due to a cotranslational association of the D1 protein with other PSII reaction center components, Later steps in the reassembly of PSII were clearly post-translational and sequential. Different rate-limiting steps in the assembly process were found to be related to the depletion of nuclear encoded and stromal components as well as the lateral migration of subcomplexes within the heterogeneous thylakoid membrane. The slow processing of precursor D1 in the thylakoid translation system revealed that processing was not required for the assembly of the D1 protein into a PSII (sub)complex and that processing of the unassembled precursor could take place, The limited incorporation into PSII subcomplexes of three other PSII core proteins (D2 protein, CP43, and CP47) was clearly post-translational in both translation systems. Radiolabeled assembly intermediates smaller than the PSII core complex were found to be located in the stroma-exposed thylakoid membranes, the site of protein synthesis. Larger PSII assembly intermediates were almost exclusively located in the appressed regions of the membranes.	UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; UNIV TURKU,DEPT BIOL,SF-20014 TURKU,FINLAND	Stockholm University; University of Turku			Andersson, Bertil/C-9328-2009; Aro, Eva-Mari/Q-8664-2017	Aro, Eva-Mari/0000-0002-2922-1435				ADIR N, 1990, J BIOL CHEM, V265, P12563; ADIR N, 1988, J BIOL CHEM, V263, P283; ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ANDERSSON B, 1994, ADV MOL CEL, V10, P1; ANDERSSON B, 1992, MOL MECHANISMS BIOEN, P121; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; BOSCHETTI A, 1990, PLANT SCI, V68, P131, DOI 10.1016/0168-9452(90)90219-E; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; COHEN Y, 1995, BBA-REV BIOMEMBRANES, V1241, P1, DOI 10.1016/0304-4157(94)00012-3; DEVITRY C, 1989, J CELL BIOL, V109, P999; ERICKSON JM, 1992, TOPICS PHOTOSYNTHESI, V11, P101; FOTINOU C, 1993, PHOTOSYNTH RES, V37, P41, DOI 10.1007/BF02185437; GHIRARDI ML, 1989, CURRENT RES PHOTOSYN, V2, P733; HERRIN D, 1985, FEBS LETT, V184, P90, DOI 10.1016/0014-5793(85)80660-8; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V2, P175; IRRGANG KD, 1995, J BIOL CHEM, V270, P17588, DOI 10.1074/jbc.270.29.17588; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KIM J, 1994, PLANT PHYSIOL, V104, P907, DOI 10.1104/pp.104.3.907; KIM J, 1994, J BIOL CHEM, V269, P17918; KIM JH, 1993, PLANT PHYSIOL, V103, P181, DOI 10.1104/pp.103.1.181; KLEIN RR, 1988, J CELL BIOL, V106, P289, DOI 10.1083/jcb.106.2.289; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; LETO KJ, 1985, EMBO J, V4, P1645, DOI 10.1002/j.1460-2075.1985.tb03832.x; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MANT A, 1994, J BIOL CHEM, V269, P27303; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MISHRA RK, 1994, PHOTOSYNTH RES, V42, P37, DOI 10.1007/BF00019056; MOSKALENKO AA, 1992, FEBS LETT, V314, P271, DOI 10.1016/0014-5793(92)81487-7; MULLET JE, 1986, EUR J BIOCHEM, V155, P331, DOI 10.1111/j.1432-1033.1986.tb09495.x; NEALE PJ, 1990, PLANT PHYSIOL, V92, P1196, DOI 10.1104/pp.92.4.1196; SANTINI C, 1994, EUR J BIOCHEM, V221, P307, DOI 10.1111/j.1432-1033.1994.tb18742.x; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; TOMO T, 1993, FEBS LETT, V323, P15, DOI 10.1016/0014-5793(93)81438-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANWIJK KJ, 1994, J BIOL CHEM, V269, P28382; VANWIJK KJ, 1995, FEBS LETT, V368, P263, DOI 10.1016/0014-5793(95)00668-Y; VANWIJK KJ, 1995, J BIOL CHEM, V270, P25685, DOI 10.1074/jbc.270.43.25685; VANWIJK KJ, 1992, THESIS U GRONINGEN N; [No title captured]	47	52	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9627	9636		10.1074/jbc.271.16.9627	http://dx.doi.org/10.1074/jbc.271.16.9627			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621638	hybrid			2022-12-25	WOS:A1996UG04400069
J	Williams, G; Borkakoti, N; Bottomley, GA; Cowan, I; Fallowfield, AG; Jones, PS; Kirtland, SJ; Price, GJ; Price, L				Williams, G; Borkakoti, N; Bottomley, GA; Cowan, I; Fallowfield, AG; Jones, PS; Kirtland, SJ; Price, GJ; Price, L			Mutagenesis studies of interleukin-8 - Identification of a second epitope involved in receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HUMAN NEUTROPHILS; SPECTROSCOPY; ANTIBODY; RESIDUES; PROTEINS; IL-8; NMR	Interleukin-8 (IL-8) is a dimeric, C-X-C chemokine, produced by a variety of cells and which elicits proinflammatory responses from the neutrophil. As a prelude to drug design, we have investigated the interactions between IL-8 and its receptor by preparing a number of single site mutants of IL-8 and determining their activity in receptor-binding and functional assays, In order to define the binding surface as precisely as possible, we have used chemical shifts obtained from nuclear magnetic resonance spectroscopy to screen mutant proteins for structural changes which affect regions of the IL-8 surface remote from the site of mutation, In addition to a previously recognized sequence, Glu(4)-Leu(5)-Arg(6) in the N-terminal peptide, we have identified a second epitope comprising a contiguous group of non-sequential, solvent-exposed, hydrophobic residues, Phe(17), Phe(21), Ile(22), and Leu(43). These two receptor-binding regions are separated by over 20 Angstrom in the IL.8 structure and are important both for receptor binding and function. In addition, we have shown through the production of a covalently linked IL-8 dimer, that subunit dissociation is not necessary for biological activity.			Williams, G (corresponding author), ROCHE RES CTR,WELWYN GARDEN CIT AL7 3AY,HERTS,ENGLAND.			Borkakoti, Nivedita/0000-0002-5878-1490				BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BARTIK K, 1993, EUR J BIOCHEM, V215, P255, DOI 10.1111/j.1432-1033.1993.tb18030.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLORE GM, 1989, J BIOL CHEM, V264, P18907; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FERSHT A, 1985, ENZYME STRUCTURE MEC, P299; GAO Y, 1989, EUR J BIOCHEM, V182, P57, DOI 10.1111/j.1432-1033.1989.tb14800.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOCH JC, 1983, THESIS HARVARD U; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KIM KS, 1994, J BIOL CHEM, V269, P32909; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MOSER B, 1993, J BIOL CHEM, V268, P7125; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; SCHNITZEL W, 1994, J LEUKOCYTE BIOL, V55, P763, DOI 10.1002/jlb.55.6.763; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STUBER D, 1984, EMBO J, V3, P3143; WESTLIN WF, 1991, FASEB J, V5, pA1624; WILLIAMS DH, 1991, J AM CHEM SOC, V113, P7020, DOI 10.1021/ja00018a047; WILLIAMSON MP, 1995, J MOL BIOL, V247, P541, DOI 10.1006/jmbi.1995.0160; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025	46	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9579	9586		10.1074/jbc.271.16.9579	http://dx.doi.org/10.1074/jbc.271.16.9579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621632	hybrid			2022-12-25	WOS:A1996UG04400063
J	Post, GR; Goldstein, D; Thuerauf, DJ; Glembotski, CC; Brown, JH				Post, GR; Goldstein, D; Thuerauf, DJ; Glembotski, CC; Brown, JH			Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; MYOCARDIAL-CELL HYPERTROPHY; ATRIAL-NATRIURETIC-FACTOR; CARDIAC GENE-EXPRESSION; ADRENERGIC-STIMULATION; SIGNAL-TRANSDUCTION; GROWTH-FACTORS; MAP KINASE; PARACRINE MECHANISM; PATHWAYS	In response to hormones and mechanical stretch, neonatal rat ventricular myocytes exhibit a hypertrophic response that is characterized by induction of cardiac-specific genes and increased myocardial cell size. Hypertrophic stimuli also activate mitogen-activated protein kinase (MAPK), an enzyme thought to play a central role in the regulation of cell growth and differentiation. To determine if MAPK activation is sufficient for acquisition of the molecular and morphological features of cardiac hypertrophy we compared four agonists that stimulate G protein-coupled receptors. Whereas phenylephrine and endothelin transactivate cardiac-specific promoter/luciferase reporter genes, increase atrial natriuretic factor (ANF) expression, and promote myofilament organization, neither carbachol nor ATP induces these responses. Interestingly, all four agonists activate both the p42 and the p44 isoforms of MAPK. Furthermore, the kinetics of MAPK activation are not different for the hypertrophic agonist phenylephrine and the nonhypertrophic agonist carbachol. Transient transfection of myocytes with dominant-interfering mutants of p42 and p44 MAPK failed to block phenylephrine-induced ANF expression, although Ras-induced gene expression was inhibited by expression of the mutant MAPK constructs. Moreover, PD 098059, an inhibitor of MAPK kinase, blocked phenylephrine-stimulated MAPK activity but not ANF reporter gene expression. Thus, MAPK activation is not sufficient for G protein receptor-mediated induction of cardiac cell growth and gene expression and is apparently not required for transcriptional activation of the ANF gene.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA	University of California System; University of California San Diego; California State University System; San Diego State University; California State University System; San Diego State University					NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline; NINDS NIH HHS [NS 25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMESHITA I, 1989, LIFE SCI, V52, P521; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE HR, 1988, J BIOL CHEM, V263, P7352; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCDONOUGH PM, 1993, AM J PHYSIOL, V264, pH625, DOI 10.1152/ajpheart.1993.264.2.H625; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	42	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8452	8457		10.1074/jbc.271.14.8452	http://dx.doi.org/10.1074/jbc.271.14.8452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626545	hybrid			2022-12-25	WOS:A1996UD60000085
J	Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ				Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ			Cis trans-activation of the interleukin-9 receptor gene in an HTLV-I-transformed human lymphocytic cell	ONCOGENE			English	Article						interleukin-9; receptor; T-lymphocyte; long terminal repeat; HTLV-I; HIV-1	VIRUS TYPE-I; NF-KAPPA-B; LEUKEMIA-ASSOCIATED ANTIGEN; STIMULATING FACTOR GENE; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX; MOLECULAR-CLONING; T-CELLS; EXPRESSION; PROTEIN	The MT-2 cell-line, which had been established through in vitro cell to cell transmission of human T-cell leukemia virus type T (HTLV-I) among human primary lymphocytes, was shown to possess multiple copies of integrated proviruses, including defective proviral genomes. By analysing a genomic clone, we identified the integration site of a single HTLV-I long terminal repeat (LTR) in the interleukin-9 (IL-9) receptor (IL-9R) gene. The integrated HTLV-I-LTR was shown to be functional as a promoter and the integration site was located in an intron upstream of the first coding exon of the IL-9R gene. Upon analysis of total cellular RNA, specific expression of HTLV-I-LTR IL-9R chimeric mRNAs in MT-2 cells was demonstrated. Cloning and characterization of these cDNAs have identified HTLV-I-IL-9R chimeric splicing, using either intact or alternative splice sites within the IL-9R gene. The potential roles of multiple interactions between IL-9, IL-9R and HTLV-I in the monoclonal expansion and transformation of MT-2 cells are explored.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,SECT MOL RETROVIROL,PHILADELPHIA,PA 19107; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Jefferson University; Kyoto University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED YF, 1991, CELL, V64, P727, DOI 10.1016/0092-8674(91)90502-P; CHANG MS, 1994, BLOOD, V83, P3199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffin J. M., 1990, VIROLOGY, P1437; DEROSSI A, 1985, VIROLOGY, V143, P640, DOI 10.1016/0042-6822(85)90405-2; Derse David, 1994, AIDS Research and Human Retroviruses, V10, pS120; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAERTLE T, 1985, J BIOL CHEM, V229, P563; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; KELLEHER K, 1991, BLOOD, V77, P1436; KOBAYASHI N, 1984, EMBO J, V3, P1399; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MERZ H, 1991, BLOOD, V78, P1311; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; MORI N, 1994, BLOOD, V84, P1688; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMASHITA I, 1994, BLOOD, V84, P1573	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1441	1447						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622860				2022-12-25	WOS:A1996UF07600008
J	Karoui, H; Hogg, N; Frejaville, C; Tordo, P; Kalyanaraman, B				Karoui, H; Hogg, N; Frejaville, C; Tordo, P; Kalyanaraman, B			Characterization of sulfur-centered radical intermediates formed during the oxidation of thiols and sulfite by peroxynitrite - ESR-SPIN trapping and oxygen uptake studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; ONE-ELECTRON; SUPEROXIDE; THIYL; GLUTATHIONE; (BI)SULFITE; CYSTEINE	Using a novel phosphorylated spin trap, 5-diethoxy-phosphoryl-5- methyl-1-pyrroline N-oxide (DEPMPO), an analog of the commonly used trap 5,5'-dimethyl-1-pyrroline N-oxide (DMPO), we have investigated the reactions of sulfur-centered radicals produced from the oxidation of thiols and sulfite by peroxynitrite. The predominant species trapped in all cases are the corresponding sulfur-centered radicals, i.e. glutathionyl radical (GS(.)) from glutathione (GSH), N-acetyl-DL-penicillamine thiyl radical (S-.-NAP) from N-acetyl-DL-penicillamine (NAP) and sulfite anion radical (SO3radical anion) from sulfite. These radicals consume molecular oxygen forming either peroxyl or superoxide anion radicals. GS(.), S-.-NAP, and SO3radical anion-derived radicals react with ammonium formate to form the carbon dioxide anion radical (CO2radical anion). Further support of spin adduct assignments and radical reactions are obtained from photolysis of S-nitrosoglutathione and S-nitroso-Nacetyl-DL-penicillamine. We conclude that the direct reaction of peroxynitrite with thiols and sulfite forms thiyl and sulfite anion radicals, respectively, by a hydroxyl radical-independent mechanism. Pathological implications of thiyl radical formation and subsequent oxyradical-mediated chain reactions are discussed. Oxygen activation by thiyl radicals formed during peroxynitrite-mediated oxidation of glutathione may limit the effectiveness of GSH against peroxynitrite-mediated toxicity in cellular systems.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226; UNIV AIX MARSEILLE 1,LAB STRUCT & REACT ESPECES PARAMAGNET,CNRS,URA 1412,F-13331 MARSEILLE,FRANCE	Medical College of Wisconsin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			KAROUI, HAKIM/ABE-3416-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045058, R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250, HL45058] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS GE, 1969, T FARADAY SOC, V65, P2981, DOI 10.1039/tf9696502981; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FORNI LG, 1986, BIOCHEM J, V240, P897, DOI 10.1042/bj2400897; FREJAVILLE C, 1994, J CHEM SOC CHEM COMM, P1793, DOI 10.1039/c39940001793; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; FRIDOVICH I, 1961, J BIOL CHEM, V236, P1836; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; GRIERSON L, 1992, INT J RADIAT BIOL, V62, P265, DOI 10.1080/09553009214552111; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; HARVEY SB, 1995, BBA-MOL CELL RES, V1267, P41, DOI 10.1016/0167-4889(95)00059-2; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KAROUI H, 1994, THESIS U SAINT JEROM; KING PA, 1993, NUCLEIC ACIDS RES, V21, P2473, DOI 10.1093/nar/21.10.2473; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEMERCIER JN, 1995, ARCH BIOCHEM BIOPHYS, V321, P31, DOI 10.1006/abbi.1995.1364; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; MOTTLEY C, 1988, ARCH BIOCHEM BIOPHYS, V267, P681, DOI 10.1016/0003-9861(88)90077-X; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; REED GA, 1986, P NATL ACAD SCI USA, V83, P7499, DOI 10.1073/pnas.83.19.7499; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; Royall J A, 1995, New Horiz, V3, P113; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; SI X, 1994, BIOCHEM BIOPH RES CO, V203, P1515; TUCCIO B, 1995, J CHEM SOC PERK T 2, P295, DOI 10.1039/p29950000295; WALKER MW, 1995, PEDIATR RES, V37, P41, DOI 10.1203/00006450-199501000-00010; WINTERBOURN CC, 1994, ARCH BIOCHEM BIOPHYS, V314, P284, DOI 10.1006/abbi.1994.1444; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; WU M, 1994, AM J PHYSIOL, V35, pH2108; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZHAO R, 1994, J AM CHEM SOC, V116, P12010, DOI 10.1021/ja00105a048	45	198	202	3	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6000	6009		10.1074/jbc.271.11.6000	http://dx.doi.org/10.1074/jbc.271.11.6000			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626383	hybrid			2022-12-25	WOS:A1996UA36300012
J	Minn, AJ; Boise, LH; Thompson, CB				Minn, AJ; Boise, LH; Thompson, CB			Bcl-x(S) antagonizes the protective effects of Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CELL-DEATH; BCL-2; MICE	Bcl-x, a member of the Bcl-2 family, has two alternatively spliced forms, Bcl-x(L) and Bcl-x(S). Bcl-x(L), like Bcl-2, is able to protect cells from a wide variety of apoptotic stimuli, Bcl-x(S), as a result of alternative splicing, lacks 63 amino acids that comprise the region of greatest amino acid identity between Bcl-x(L) and Bcl-2. These amino acids contain the highly conserved BH1 and BH2 regions, which have been used to define the Bcl-2 family. We show that both Bcl-x(L) and Bcl-x(S) are able to regulate cell survival in a dose-dependent fashion, Bcl-x(L) is able to increase the cellular apoptotic threshold and is able to form stable complexes with Bax both in vitro and in vivo. In contrast, Bcl-x(S) can effectively inhibit the protective effects of Bcl-x(L) following growth factor withdrawal and chemotherapeutic drug treatment. However, compared with Bax, Bcl-x(S) binds to Bcl-x(L) weakly when assessed by in vitro binding assays, Coimmunoprecipitation from mammalian cells demonstrates that Bcl-x(S) does not show an observable ability to form heterodimers with other Bcl-2 family members. In addition, overexpression of Bcl-x(S) does not alter the ability of Bax to heterodimerize with Bcl-x(L) in vitro. Thus, Bcl-x(S) does not appear to function by competitively disrupting the formation of dimers composed of other Bcl-2 family members. This suggests that Bcl-x(S) can enhance cellular sensitivity to apoptosis via a mechanism of action distinct from other Bcl-2 family members that promote apoptosis.	UNIV CHICAGO, COMM IMMUNOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Minn, AJ (corresponding author), UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, 924 E 57TH ST, RM R413A, CHICAGO, IL 60637 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035294] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35294] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DOLE M, 1994, CANCER RES, V54, P3253; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FISHER TC, 1993, CANCER RES, V53, P3321; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	28	180	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6306	6312		10.1074/jbc.271.11.6306	http://dx.doi.org/10.1074/jbc.271.11.6306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626425	hybrid			2022-12-25	WOS:A1996UA36300054
J	Ruat, M; Snowman, AM; Hester, LD; Snyder, SH				Ruat, M; Snowman, AM; Hester, LD; Snyder, SH			Cloned and expressed rat Ca2+-sensing receptor - Differential cooperative responses to calcium and magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; PHOSPHOLIPASE-A2; INHIBITION; RELEASE	We have stably expressed cDNA for the rat brain Ca2+-sensing receptor in Chinese hamster ovary cells. Stimulation of phosphatidylinositol hydrolysis and arachidonic acid (AA) release displayed markedly cooperative responses to Ca2+ with Hill coefficients of 4-5. Both phosphatidylinositol and AA responses were not detected below a threshold of 1.5 mM Ca2+. Mg2+ behaved as a partial agonist with only half the maximal inositol phosphate and AA responses displayed by Ca2+ and with a more shallow concentration-response slope. The potency of Mg2+ in augmenting inositol phosphate and AA responses, in the presence of 1.5 mM Ca2+, implies that serum Mg2+ concentrations attained in clinical conditions will influence the Ca2+-sensing receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1995, EUR J ENDOCRINOL, V132, P523, DOI 10.1530/eje.0.1320523; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; JANICIC N, 1995, AM J HUM GENET, V56, P880; LEURS R, 1994, J NEUROCHEM, V62, P519; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; TRAIFFORT E, 1992, P NATL ACAD SCI USA, V89, P2649, DOI 10.1073/pnas.89.7.2649; ZALOGA GP, 1994, PHARM APPROACH CRITI, P777	18	111	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5972	5975		10.1074/jbc.271.11.5972	http://dx.doi.org/10.1074/jbc.271.11.5972			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626377	hybrid			2022-12-25	WOS:A1996UA36300006
J	Sadhukhan, R; Sen, I				Sadhukhan, R; Sen, I			Different glycosylation requirements for the synthesis of enzymatically active angiotensin-converting enzyme in mammalian cells and yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; DIPEPTIDYL CARBOXYPEPTIDASE; CATALYTIC PROPERTIES; EXPRESSION; SOLUBILIZATION; TRANSCRIPTION; SITES; GENE	For facilitating crystallization and structural studies of the testicular isozyme of angiotensin-converting enzyme (ACE(T)), we attempted the production of enzymatically active ACE(T) proteins which are unglycosylated or underglycosylated. Expression in Escherichia coli of the rabbit ACE(T) cDNA resulted in the synthesis of an unglycosylated but inactive protein. Similarly, unglycosylated ACE(T) synthesized in HeLa cells, by using a cDNA in which all five potential N-glycosylation sites had been mutated, was inactive and rapidly degraded. Several ACE(T) variants carrying mutations in one or more of the potential N-glycosylation sites were used to examine the role of glycosylation at specific sites on ACE(T) synthesis, transport to the cell surface, cleavage processing, and enzyme activity. These experiments demonstrated that allowing glycosylation only at the first or the second site, as counted from the NH2 terminus, was sufficient for normal synthesis and processing of active ACE(T). In contrast, ACE(T)g3, which had only the third glycosylation site available, was unglycosylated, enzymatically inactive and rapidly degraded. N-Glycosylated ACE(T) could also be produced in yeast. Surprisingly, the mutant ACE(T)g3 was synthesized, N-glycosylated, and properly transported in yeast. Wild type and mutant ACE proteins were cleavage-secreted from yeast and enzymatically active.	CLEVELAND CLIN FDN, RES INST, DEPT MOLEC CARDIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NHLBI NIH HHS [HL-48258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; CONROY JM, 1978, BIOCHIM BIOPHYS ACTA, V524, P403, DOI 10.1016/0005-2744(78)90177-8; CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479; CUSHMAN DW, 1980, PROG MED CHEM, V17, P42; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1992, BIOCHEM BIOPH RES CO, V183, P199, DOI 10.1016/0006-291X(92)91628-4; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ERDOS E. G., 1967, LIFE SCI, V6, P569, DOI 10.1016/0024-3205(67)90090-2; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUBERT C, 1991, J BIOL CHEM, V266, P15377; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RAMCHANDRAN R, 1996, IN PRESS AM J PHYSL; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; WEI L, 1991, J BIOL CHEM, V266, P5540	28	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6429	6434		10.1074/jbc.271.11.6429	http://dx.doi.org/10.1074/jbc.271.11.6429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626443	hybrid			2022-12-25	WOS:A1996UA36300072
J	Staab, JF; Ferrer, CA; Sundstrom, P				Staab, JF; Ferrer, CA; Sundstrom, P			Developmental expression of a tandemly repeated, proline and glutamine-rich amino acid motif on hyphal surfaces of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM TUBE FORMATION; SACCHAROMYCES-CEREVISIAE; CELL-WALL; POLYACRYLAMIDE GELS; SEQUENCE-ANALYSIS; ALPHA-AGGLUTININ; STRUCTURAL GENE; MYCELIAL FORMS; PROTEIN; YEAST	cDNA sequences encoding a cell wall protein have been isolated from the opportunistic pathogen, Candida albicans, an organism that can cause serious disease in immunocompromised patients such as those with AIDS. The cDNA encodes a peptide that is largely composed of an acidic, repeated motif 10 amino acids in length that is rich in proline and glutamine residues. The cDNA gene product was found to be present on hyphal surfaces by immunofluorescence assays using monospecific antisera raised to the recombinant protein produced in Pichia pastoris. The hyphae-specific surface location was also seen on organisms colonizing the gastrointestinal mucosa of mice, indicating that the antigen is produced and developmentally regulated during growth in host tissues. The cDNA clone hybridized to an abundant messenger RNA 2.3 kilobases in size that was present in hyphal but not yeast forms, These studies demonstrate that the bud-hypha transition is accompanied by the de novo synthesis of proteins that are targeted to hyphal surfaces. The primary sequence of the unique amino acid motif shares features with surface proteins of other lower eukaryotic microorganisms and with host acidic salivary proline-rich proteins.	OHIO STATE UNIV, COLL MED, DEPT MED MICROBIOL & IMMUNOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011375, R01DE010144] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE10144, DE11375] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAEI S, 1993, INFECT IMMUN, V61, P1395, DOI 10.1128/IAI.61.4.1395-1399.1993; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENNICK A, 1975, BIOCHEM J, V145, P557, DOI 10.1042/bj1450557; BINNS M, 1990, J GEN VIROL, V71, P2883, DOI 10.1099/0022-1317-71-12-2883; BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; BLASI E, 1995, INFECT IMMUN, V63, P1806, DOI 10.1128/IAI.63.5.1806-1809.1995; BLASI E, 1992, INFECT IMMUN, V60, P832, DOI 10.1128/IAI.60.3.832-837.1992; BOUALI A, 1987, J GEN MICROBIOL, V133, P545; BOUCHARA JP, 1990, INFECT IMMUN, V58, P48, DOI 10.1128/IAI.58.1.48-54.1990; BRADWAY SD, 1992, BIOCHEM J, V284, P557, DOI 10.1042/bj2840557; BRADWAY SD, 1993, CRIT REV ORAL BIOL M, V4, P293, DOI 10.1177/10454411930040030601; BRUMMEL M, 1982, DEV BIOL, V89, P211, DOI 10.1016/0012-1606(82)90308-6; CALDERONE R, 1993, J MICROBIOL METH, V18, P197, DOI 10.1016/0167-7012(93)90036-H; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CARLSON DM, 1993, CRIT REV ORAL BIOL M, V4, P495, DOI 10.1177/10454411930040033401; CASANOVA M, 1989, INFECT IMMUN, V57, P262, DOI 10.1128/IAI.57.1.262-271.1989; CHATTAWAY FW, 1974, J GEN MICROBIOL, V83, P423, DOI 10.1099/00221287-83-2-423; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND RD, 1978, J CLIN INVEST, V61, P349, DOI 10.1172/JCI108945; DIAMOND RD, 1978, J CLIN INVEST, V61, P360, DOI 10.1172/JCI108946; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FREVERT J, 1985, BIOCHEMISTRY-US, V24, P753, DOI 10.1021/bi00324a033; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; GLEE PM, 1995, INFECT IMMUN, V63, P1373, DOI 10.1128/IAI.63.4.1373-1379.1995; GREEN MR, 1975, ANAL BIOCHEM, V65, P66, DOI 10.1016/0003-2697(75)90491-1; Harlow E, 1988, ANTIBODIES LAB MANUA, P104; HAZEN BW, 1988, INFECT IMMUN, V56, P2521, DOI 10.1128/IAI.56.9.2521-2525.1988; HAZEN KC, 1992, INFECT IMMUN, V60, P1499, DOI 10.1128/IAI.60.4.1499-1508.1992; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOLMES AR, 1992, ORAL MICROBIOL IMMUN, V7, P32, DOI 10.1111/j.1399-302X.1992.tb00017.x; HOYER LL, 1995, MOL MICROBIOL, V15, P39, DOI 10.1111/j.1365-2958.1995.tb02219.x; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIMURA LH, 1980, INFECT IMMUN, V28, P464; KLEIN BS, 1993, J CLIN INVEST, V92, P330, DOI 10.1172/JCI116571; KURTZ MB, 1986, MOL CELL BIOL, V6, P142, DOI 10.1128/MCB.6.1.142; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin B., 1994, GENES-BASEL; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MAROTLEBLOND A, 1993, FEMS IMMUNOL MED MIC, V7, P175, DOI 10.1111/j.1574-695X.1993.tb00397.x; MERSONDAVIES LA, 1991, J MED MICROBIOL, V35, P321, DOI 10.1099/00222615-35-6-321; MILLER AD, 1984, SCIENCE, V225, P630, DOI 10.1126/science.6377498; MOLINARI A, 1993, EUR J CELL BIOL, V60, P146; NICHOLSON RL, 1986, PHYTOPATHOLOGY, V76, P1315, DOI 10.1094/Phyto-76-1315; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLLERT MW, 1990, INFECT IMMUN, V58, P625, DOI 10.1128/IAI.58.3.625-631.1990; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; PAGE S, 1988, J GEN MICROBIOL, V134, P2693; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; PONTON J, 1986, INFECT IMMUN, V53, P565, DOI 10.1128/IAI.53.3.565-572.1986; POSTLETHWAIT P, 1995, J BACTERIOL, V177, P1772, DOI 10.1128/jb.177.7.1772-1779.1995; PROFT T, 1995, J BACTERIOL, V177, P3370, DOI 10.1128/jb.177.12.3370-3378.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SELKIRK ME, 1991, J BIOL CHEM, V266, P11002; SHERWOOD J, 1992, J MED VET MYCOL, V30, P461; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SIMON M, 1988, J BIOL CHEM, V263, P18093; SMAIL EH, 1984, INFECT IMMUN, V45, P74, DOI 10.1128/IAI.45.1.74-81.1984; SRIKANTHA T, 1995, MOL CELL BIOL, V15, P1797; SUNDSTROM P, 1992, J BACTERIOL, V174, P6789, DOI 10.1128/JB.174.21.6789-6799.1992; SUNDSTROM P, 1990, J BACTERIOL, V172, P2036, DOI 10.1128/jb.172.4.2036-2045.1990; SUNDSTROM P, 1994, J INFECT DIS, V169, P452, DOI 10.1093/infdis/169.2.452; SUNDSTROM PM, 1984, INFECT IMMUN, V43, P850, DOI 10.1128/IAI.43.3.850-855.1984; SUNDSTROM PM, 1985, INFECT IMMUN, V49, P609, DOI 10.1128/IAI.49.3.609-614.1985; SUNDSTROM PM, 1987, INFECT IMMUN, V55, P616, DOI 10.1128/IAI.55.3.616-620.1987; TOROSANTUCCI A, 1990, J GEN MICROBIOL, V136, P1421, DOI 10.1099/00221287-136-7-1421; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRONCHIN G, 1989, EUR J CELL BIOL, V50, P285; TRONCHIN G, 1991, EUR J EPIDEMIOL, V7, P23, DOI 10.1007/BF00221338; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947; [No title captured]	80	145	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6298	6305		10.1074/jbc.271.11.6298	http://dx.doi.org/10.1074/jbc.271.11.6298			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626424	hybrid			2022-12-25	WOS:A1996UA36300053
J	Monfardini, C; KieberEmmons, T; Voet, D; Godillot, AP; Weiner, DB; Williams, WV				Monfardini, C; KieberEmmons, T; Voet, D; Godillot, AP; Weiner, DB; Williams, WV			Rational design of granulocyte-macrophage colony-stimulating factor antagonist peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; CELL-SURFACE RECEPTOR; GM-CSF RECEPTOR; HUMAN INTERLEUKIN-4; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; AFFINITY BINDING; IDENTIFICATION; PROTEIN	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a member of the four helix bundle family of cytokines/growth factors which exhibit several activities. It is a hematopoietic growth factor, a cytokine involved in inflammatory and immune processes, an adjunct for cancer therapy, and an anti-tumor immunomodulator. Studies of interactions between GM-CSF and its receptor and identification of small peptides presenting binding capacity to the receptor are important goals for the development of GM-CSF analogs. Here we describe the study of two cyclic peptides, 1785 and 1786, developed based on structural analysis of the GM-CSF region mimicked by anti-anti-GM-CSF recombinant antibody 23.2. These peptides were designed to structurally mimic the positions of specific residues on the B and C helices of human GM-CSF implicated in receptor binding and bioactivity. Both 1785 and 1786 were specifically recognized by polyclonal anti-GM-CSF antibody (stronger for 1786 than 1785). 1786 also competitively inhibited binding of GM-CSF to the GM-CSF receptor on HL-60 cells and demonstrated antagonist bioactivity, as shown by its reversal of GM-CSF's ability to inhibit apoptosis of the GM-CSF-dependent cell line M07E. These studies support the role of residues on the GM-CSF B and C helices in receptor binding and bioactivity and suggest strategies for mimicking binding sites on four-helix bundle proteins with cyclic peptides.	UNIV PENN,SCH MED,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST BIOTECHNOL & ADV MOLEC MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Weiner, David B/H-8579-2014	Williams, William/0000-0003-3611-9284				ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; ANTMAN KH, 1993, EUR J CANCER, V3, pS2; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BROWN CB, 1990, J IMMUNOL, V144, P2184; BROWN CB, 1994, EUR J BIOCHEM, V225, P873, DOI 10.1111/j.1432-1033.1994.0873b.x; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIBA S, 1990, LEUKEMIA, V4, P29; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; GARRETT DS, 1992, BIOCHEMISTRY-US, V31, P4347, DOI 10.1021/bi00132a027; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOUGH NM, 1987, EUR J BIOCHEM, V169, P353, DOI 10.1111/j.1432-1033.1987.tb13619.x; GREENFIELD RS, 1993, J IMMUNOL, V150, P5241; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; HORIE M, 1995, EXP HEMATOL, V23, P168; KANAKURA Y, 1991, BLOOD, V77, P1033; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; LALONDE JM, 1989, J MOL BIOL, V205, P783, DOI 10.1016/0022-2836(89)90323-9; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MONFARDINI C, 1995, J BIOL CHEM, V270, P6628, DOI 10.1074/jbc.270.12.6628; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PARK LS, 1986, J BIOL CHEM, V261, P4177; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; REDFIELD C, 1992, BIOCHEMISTRY-US, V31, P10431, DOI 10.1021/bi00158a003; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SEELIG G, 1990, J CELL BIOCHEM, V14, P246; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VONFELDT JM, 1994, IMMUNOL RES, V13, P96, DOI 10.1007/BF02918271; VONFELDT JM, 1995, PEPTIDE RES, V8, P20; WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5; WEISBART RH, 1989, HEMATOL ONCOL CLIN N, V3, P401, DOI 10.1016/S0889-8588(18)30537-9; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; YOKOTA T, 1993, LEUKEMIA, V7, pS102	52	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2966	2971		10.1074/jbc.271.6.2966	http://dx.doi.org/10.1074/jbc.271.6.2966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621688	hybrid			2022-12-25	WOS:A1996TU69100017
J	Diggle, C; Quirk, PG; Bizouarn, T; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB				Diggle, C; Quirk, PG; Bizouarn, T; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB			Mutation of Tyr(235) in the NAD(H)-binding subunit of the proton-translocating nicotinamide nucleotide transhydrogenase of Rhodospirillum rubrum affects the conformational dynamics of a mobile loop and lowers the catalytic activity of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-CAPSULATUS; H+-TRANSHYDROGENASE; ESCHERICHIA-COLI; BINDING SITES	The Tyr residue in the mobile loop region of the soluble, domain I polypeptide (called Th-s) of the proton-translocating transhydrogenase from Rhodospirillum rubrum has been substituted by Asn and by Phe. The recombinant proteins were expressed at high levels in Escherichia coli and purified to homogeneity. The two well defined resonances at 6.82 and 7.12ppm, observed in the one-dimensional proton NMR spectrum of wild-type protein, and previously attributed to the Tyr residue, were absent in both mutants. In the Tyr(235) --> Phe mutant Th-s, they were replaced by two new resonances at 7.26 and 7.33 ppm, characteristic of a Phe residue. In both mutants, narrow resonances attributable to Met residues (and in the Tyr(235) --> Phe mutant, resonances attributable to Ala residues) were shifted relative to the wild type, but other features in the NMR spectra were unaffected. The conformational dynamics of the mobile loop closure in response to nucleotide binding by the protein were altered in the two mutants. The fluorescence emission from Trp(72) was unaffected by both Tyr substitutions, and the fluorescence was still quenched by NADH. The mutant Th-s proteins bound to chromatophore membranes depleted of their native Th-s with undiminished affinity. In these reconstituted systems, the K-m values for thio-NADP(+) and NADH, during light-driven transhydrogenation, were similar to those of wild-type, but the k(cat) values were decreased about 2-fold. In reverse transhydrogenation, the K-m values for NADPH were slightly decreased in the mutants relative to wild-type, but those for acetyl pyridine adenine dinucleotide were increased about 10- and 13-fold, respectively, and the k(cat) values were decreased about 2- and 5-fold, respectively, in the Tyr(235) --> Phe and Tyr(235) --> Asn mutants. It is concluded that Tyr(235) may contribute to the process of nucleotide binding and that substitution of this residue prevents proper functioning of the mobile loop in catalysis.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Thomas, Christopher M/J-8258-2017; bizouarn, tania/W-6782-2019	Thomas, Christopher M/0000-0002-2810-0455; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 1996, J BIOL CHEM, V271, P10103, DOI 10.1074/jbc.271.17.10103; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; CLAYTON RK, 1963, BIOCHIM BIOPHYS ACTA, V75, P312, DOI 10.1016/0006-3002(63)90618-8; COTTON NPJ, 1989, EUR J BIOCHEM, V182, P593, DOI 10.1111/j.1432-1033.1989.tb14868.x; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1101, P345, DOI 10.1016/0167-4838(92)90562-R; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; FISHER RR, 1969, FEBS LETT, V3, P27, DOI 10.1016/0014-5793(69)80087-6; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GLAVAS NA, 1995, BBA-BIOENERGETICS, V1231, P297, DOI 10.1016/0005-2728(95)00089-2; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; OLAUSSON T, 1993, BIOCHEMISTRY-US, V32, P13237, DOI 10.1021/bi00211a036; PALMER T, 1992, BIOCHIM BIOPHYS ACTA, V1099, P157, DOI 10.1016/0304-4173(92)90022-7; Sambrook J., 2002, MOL CLONING LAB MANU; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784	22	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10109	10115		10.1074/jbc.271.17.10109	http://dx.doi.org/10.1074/jbc.271.17.10109			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626569	hybrid			2022-12-25	WOS:A1996UG25700041
J	Hu, CA; Lin, WW; Valle, D				Hu, CA; Lin, WW; Valle, D			Cloning, characterization, and expression of cDNAs encoding human Delta(1)-pyrroline-5-carboxylate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DELTA-AMINOTRANSFERASE; GAMMA-SEMIALDEHYDE DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL MATRIX; GYRATE ATROPHY; SEQUENCE; YEAST; LIVER; HYPERPROLINEMIA; COMPLEMENTATION	Delta(1)-Pyrroline-5-carboxylate dehydrogenase (P5CDh; EC 1.5.1.12), a mitochondrial matrix NAD(+)-dependent dehydrogenase, catalyzes the second step of the proline degradation pathway, Deficiency of this enzyme is associated with type II hyperprolinemia (HPII), an autosomal recessive disorder characterized by accumulation of Delta(1)-pyrroline-5-carboxylate (P5C) and proline. As an initial step in understanding the biochemistry of human P5CDh and molecular basis of HPII, we utilized published peptide sequence data and degenerate primer polymerase chain reaction to clone two full-length human P5CDh cDNAs, differing in length by 1 kilobase pair (kb), Both cDNAs have the identical 1689-base pair open reading frame encoding a protein of 563 residues with a predicted molecular mass of 62 kDa. The long cDNA contains an additional 1-kb insert in the 3'-untranslated region that appears to be an alternatively spliced intron, The conceptual translation of human P5CDh has 89% sequence identity with the published human P5CDh peptide sequences and 42 and 26% identity with Saccharomyces cerevisiae and Escherichia coli P5CDhs, respectively, as well as homology to several other aldehyde dehydrogenases, Both P5CDh cDNA clones detect a single 3.2-kb transcript on Northern blots of multiple human tissues, indicating the long cDNA containing the S'-untranslated intron represents the predominant transcript, The P5CDh structural gene appears to be single copy with a size of about 20 kb localized to chromosome 1, To confirm the identity of the putative P5CDh cDNAs, we expressed them in a P5CDh-deficient strain of S, cerevisiae, Both conferred measurable P5CDh activity and the ability to grow on proline as a sole nitrogen source.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, PREDOCTORAL TRAINING PROGRAM HUMAN GENET & MOL BI, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University					NEI NIH HHS [EY02948] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGARWAL DP, 1993, ENZYMOLOGY MOL BIOL, V4, P191; ALLEN SW, 1993, NUCLEIC ACIDS RES, V21, P1676, DOI 10.1093/nar/21.7.1676; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BRANDRISS MC, 1986, MOL CELL BIOL, V6, P3502, DOI 10.1128/MCB.6.10.3502; BRANDRISS MC, 1983, MOL CELL BIOL, V3, P1846, DOI 10.1128/MCB.3.10.1846; Cooper DN, 1995, METABOLIC MOL BASES, P259; DOUGHERTY KM, 1993, HUM MOL GENET, V2, P1835, DOI 10.1093/hmg/2.11.1835; DOUGHERTY KM, 1992, J BIOL CHEM, V267, P871; FLYNN MP, 1989, ARCH DIS CHILD, V64, P1699, DOI 10.1136/adc.64.12.1699; FORTEMCROBBIE CM, 1986, J BIOL CHEM, V261, P2154; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HEMPEL J, 1992, COMP BIOCHEM PHYS B, V102, P791, DOI 10.1016/0305-0491(92)90081-2; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; KRAUS JP, 1993, HUM MOL GENET, V2, P1633, DOI 10.1093/hmg/2.10.1633; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; KRYZWICKI KA, 1984, MOL CELL BIOL, V4, P2837; LING MF, 1994, J MOL BIOL, V243, P950, DOI 10.1006/jmbi.1994.1696; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMALL WC, 1990, J BIOL CHEM, V265, P18668; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; Valle, 1995, METABOLIC MOL BASES, P1125; VALLE D, 1976, J CLIN INVEST, V58, P598, DOI 10.1172/JCI108506; VALLE DL, 1974, SCIENCE, V185, P1053, DOI 10.1126/science.185.4156.1053; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	37	53	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9795	9800		10.1074/jbc.271.16.9795	http://dx.doi.org/10.1074/jbc.271.16.9795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621661	hybrid			2022-12-25	WOS:A1996UG04400092
J	Pages, F; Ragueneau, M; Klasen, S; Battifora, M; Couez, D; Sweet, R; Truneh, A; Ward, SG; Olive, D				Pages, F; Ragueneau, M; Klasen, S; Battifora, M; Couez, D; Sweet, R; Truneh, A; Ward, SG; Olive, D			Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ACTIVATION; RECEPTOR; DOMAIN; EXPRESSION; BINDING; IDENTIFICATION; COSTIMULATION; LYMPHOCYTES; LIGATION	Through the interaction with its ligands, CD80/B7-1 and CD86/B7-2 or B70, the human CD28 molecule plays a major functional role as a costimulator of T cells along with the CD3-TcR complex, We and others have previously reported that phosphatidylinositol 3-kinase inducibly associates with CD28. This association is mediated by the SH2 domains of the p85 adaptor subunit interacting with a cytoplasmic YMNM consensus motif present in CD28 at position 173-176. Disruption of this binding site by site-directed mutagenesis abolishes CD28-induced activation events in a murine T-cell hybridoma transfected with human CD28 gene. Here we show that the last 10 residues of the intracytoplasmic domain of CD28 (residues 193-202) are required for its costimulatory function, These residues are involved in interleukin-2 secretion, p85 binding, and CD28-associated phosphatidylinositol 3-kinase activity. In contrast, the CD28/CD80 interaction is unaffected by this deletion, as is the induction of other second messengers such as the rise in intracellular calcium and tyrosine phosphorylation of CD28-specific substrates, Furthermore, we also demonstrate that, within these residues, the tyrosine at position 200 is involved in p85 binding, probably together with the short proline-rich motif present between residues 190 and 194 (PYAPP).	INSERM U119, F-13009 MARSEILLE, FRANCE; SMITHKLINE BEECHAM PHARMACEUT, KING OF PRUSSIA, PA 19406 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); GlaxoSmithKline			Ward, Stephen/AAE-4341-2020; Truneh, Alem/ABB-7891-2020	Ward, Stephen G./0000-0002-6795-6002; COUEZ, Dominique/0000-0002-3102-3489				ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CLARK GJ, 1992, IMMUNOGENETICS, V35, P54; COUEZ D, 1994, MOL IMMUNOL, V31, P47, DOI 10.1016/0161-5890(94)90137-6; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; GROSS JA, 1990, J IMMUNOL, V144, P3201; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LU YL, 1992, J IMMUNOL, V149, P24; NUNES J, 1993, BIOCHEM J, V293, P835, DOI 10.1042/bj2930835; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TRUITT KE, 1995, J IMMUNOL, V155, P4702; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YOUNG JR, 1994, J IMMUNOL, V152, P3848; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9403	9409		10.1074/jbc.271.16.9403	http://dx.doi.org/10.1074/jbc.271.16.9403			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621607	hybrid			2022-12-25	WOS:A1996UG04400038
J	Zhang, B; Graziano, MP; Doebber, TW; Leibowitz, MD; WhiteCarrington, S; Szalkowski, DM; Hey, PJ; Wu, M; Cullinan, CA; Bailey, P; Lollmann, B; Frederich, R; Flier, JS; Strader, CD; Smith, RG				Zhang, B; Graziano, MP; Doebber, TW; Leibowitz, MD; WhiteCarrington, S; Szalkowski, DM; Hey, PJ; Wu, M; Cullinan, CA; Bailey, P; Lollmann, B; Frederich, R; Flier, JS; Strader, CD; Smith, RG			Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES ADIPOCYTE DIFFERENTIATION; INSULIN-SENSITIZING AGENT; GLUCOSE; PIOGLITAZONE; CIGLITAZONE; PARABIOSIS; INVIVO; CELLS	Obese (ob) is a recently identified gene involved in the regulation of energy balance in the mouse, We report here that AD-5075, a potent thiazolidinedione which lowered plasma glucose and triglyceride in Zucker diabetic fatty (ZDF) rats and db/db mice, decreased the expression of the ob gene in these animal models of obesity and non-insulin-dependent diabetes mellitus, The level of adipose ob mRNA in ZDF rats was 3-fold greater than that detected in the Zucker lean littermates, Chronic treatment with AD-5075 elicited a 67 and 70% reduction of ob mRNA in ZDF and control lean rats, respectively, Furthermore, the amount of adipose ob mRNA in db/db mice was 7 times higher than that detected in lean littermates, Treatment of db/db mice with AD-5075 resulted in a 78% reduction of the level of ob mRNA with parallel changes in circulating level of the ob gene product, leptin, The reduction of the ob mRNA in the Zucker lean rats was accompanied by significantly greater food intake and weight gain, However, in ZDF rats and db/db mice, there was profound increase in body weight without hyperphagia, The results demonstrate that the expression of the ob gene is up-regulated in these two rodent models of diabetes compared to their lean counterparts and that such overexpression is attenuated by treatment with an agent that improves insulin sensitivity and glucose homeostasis in vivo.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC ENDOCRINOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT ENDOCRINE PHARMACOL,RAHWAY,NJ 07065; BETH ISRAEL HOSP,DEPT ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Merck & Company; Merck & Company; Merck & Company; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Flier, jeffrey/AAG-6223-2019		NHLBI NIH HHS [K08HL02564] Funding Source: Medline; NIDDK NIH HHS [R37DK28082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKMORE PF, 1993, METABOLISM, V42, P1583, DOI 10.1016/0026-0495(93)90154-G; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHANG AY, 1983, DIABETOLOGIA, V25, P514; COLEMAN DL, 1969, AM J PHYSIOL, V217, P1298; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FUJITA T, 1983, DIABETES, V32, P804, DOI 10.2337/diabetes.32.9.804; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON BS, 1995, NAT MED, V1, P953, DOI 10.1038/nm0995-953; HARRIS RBS, 1987, INT J OBESITY, V11, P275; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KLETZIEN RF, 1992, MOL PHARMACOL, V42, P558; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEITER EH, 1993, CRIT REV FOOD SCI, V33, P333, DOI 10.1080/10408399309527629; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Sambrook J., 2002, MOL CLONING LAB MANU; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; SUGIYAMA Y, 1990, ARZNEIMITTEL-FORSCH, V40-1, P263; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	175	190	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9455	9459		10.1074/jbc.271.16.9455	http://dx.doi.org/10.1074/jbc.271.16.9455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621615	hybrid			2022-12-25	WOS:A1996UG04400046
J	Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM				Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM			Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas	ONCOGENE			English	Article						rhabdomyosarcoma; hepatocyte growth factor; proto-oncogenes; tyrosine kinase receptors	HEPATOCYTE GROWTH-FACTOR; TUMOR ALVEOLAR RHABDOMYOSARCOMA; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; N-MYC ONCOGENE; C-MET; EPITHELIAL-CELLS; MOLECULAR-CLONING; METASTATIC ABILITY; SEQUENCE-ANALYSIS	The MET oncogene encodes the receptor for HGF/Scatter Factor, known to control cell motility and invasion in epithelial cells, We report that the Met/HGF receptor, absent in differentiated adult skeletal muscles, is aberrantly expressed in clinical samples and in established cell lines of human rhabdomyosarcomas. In both the embryonal and alveolar histotypes the oncogene is overexpressed and, in some cases, amplified, The Met receptor is exposed at the cell surface and is functionally active in response to HGF/Scatter Factor, Accordingly, rhabdomyosarcoma cells exhibit an invasive phenotype in vitro in response to exogenous HGF/Scatter factor, As the factor is known to be produced by connective tissues, a paracrine stimulation of rhabdomyosarcoma invasiveness in vivo is hypothesized, Two alveolar rhabdomyosarcomas were found to co-express the 'two-kringle' alternatively-spliced HGF/Scatter Factor variant, which has been previously shown to stimulate cell motility and matrix invasion in vitro, These cells displayed the invasive phenotype in the absence of exogenous HGF/Scatter Factor, suggesting an autocrine mechanism in vivo, These data indicate that aberrant expression of the MET proto-oncogene provides rhabdomyosarcoma cells with the same property as embryonal myoblasts to migrate into the surrounding connective tissues.	UNIV TURIN,SCH MED,INST CANC RES,TURIN,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,INST CANC RES,BOLOGNA,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,ONCOL LAB,BOLOGNA,ITALY	University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Ferracini, R (corresponding author), SAVIGLIANO GEN HOSP,ORTHOPAED DIV,VIA OSPEDALI 14,I-121028 SAVIGLIANO,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; Ferracini, Riccardo/AAL-4622-2020; De Giovanni, Carla/B-1312-2009; olivero, martina/J-4811-2018; Scotlandi, Katia/J-9009-2016; Lollini, Pier Luigi/A-7644-2008	DI RENZO, Maria Flavia/0000-0002-5093-3373; olivero, martina/0000-0002-6815-3498; Scotlandi, Katia/0000-0001-6114-9499; Lollini, Pier Luigi/0000-0003-1702-4108; Comoglio, Paolo/0000-0002-7056-5328; BASSO, GIUSEPPE/0000-0002-2634-9302; Nanni, Patrizia/0000-0001-5319-0803				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ASMAR L, 1994, CANCER, V74, P2579, DOI 10.1002/1097-0142(19941101)74:9<2579::AID-CNCR2820740928>3.0.CO;2-A; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V254, P1382; Braun AC, 1975, CANCER COMPREHENSIVE, V3, P3; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAM AML, 1991, SCIENCE, V254, P1382; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DEGIOVANNI C, 1989, ANTICANCER RES, V9, P1943; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EBERT M, 1994, CANCER RES, V54, P5775; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GARSON JA, 1986, LANCET, V1, P1496; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOSCIELNIAK E, 1992, MED PEDIATR ONCOL, V20, P209, DOI 10.1002/mpo.2950200305; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOLLINI PL, 1991, INVAS METAST, V11, P116; LONGATI P, 1994, ONCOGENE, V9, P49; MCCUSKER RH, 1989, J BIOL CHEM, V264, P7795; MEDICO E, 1996, MOL BIOL CELL, V7; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1985, CELL, V42, P460; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NANNI P, 1989, INVAS METAST, P231; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARHAM DM, 1994, SEMIN DIAGN PATHOL, V11, P39; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1990, INVAS METAST, V10, P49; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUBLETT JE, 1995, ONCOGENE, V11, P545; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; Uriel J., 1975, CANCER COMPREHENSIVE, V3, P21; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1990, J CELL BIOL, V111, P2907	88	112	114	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1697	1705						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622890				2022-12-25	WOS:A1996UG45800012
J	Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U				Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U			A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice	ONCOGENE			English	Article						herpes virus; transgenic mice; T-cell lymphoma; tumor induction; oncogene	DELETION MUTANTS; U RNAS; REGION; VIRUS; GENE; TRANSFORMATION; CLASSIFICATION; MARMOSETS; SEQUENCES; STRAINS	Herpesvirus saimiri is an oncogenic virus causing rapid T-cell lymphomas in New World primates and rabbits, Deletion analysis of one strain of H saimiri has indicated an open reading frame, StpA, necessary for oncogenicity in monkeys, We have investigated the function of StpA in tumor induction by the generation of transgenic mice, Expression of two different constructs caused the development of peripheral lymphomas, The infiltrating cells were of T-cell origin, expressing mainly the CD4 phenotype and restricted sets of V beta chains, Thus, StpA is not only necessary for the oncogenicity of Herpesvirus saimiri, but is also sufficient for the induction of peripheral pleomorphic T-cell lymphomas.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; UNIV ERLANGEN NURNBERG,INST PATHOL,D-91054 ERLANGEN,GERMANY; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,D-91054 ERLANGEN,GERMANY	Hannover Medical School; University of Erlangen Nuremberg; European Molecular Biology Laboratory (EMBL); University of Erlangen Nuremberg			Beckers, Johannes/K-7237-2012; Murphy, Carol/ABE-4282-2021; Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Beckers, Johannes/0000-0001-7874-3822; Murphy, Carol/0000-0003-1353-8558; Fickenscher, Helmut/0000-0003-0043-1153				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BIEINGER B, 1995, J BIOL CHEM, V270, P4729; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLE GA, 1994, INT IMMUNOL, V6, P1767, DOI 10.1093/intimm/6.11.1767; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1982, J VIROL, V43, P352, DOI 10.1128/JVI.43.1.352-356.1982; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FALINI B, 1990, BLOOD, V75, P434; FLECKENSTEIN B, 1979, BIOCHIM BIOPHYS ACTA, V560, P301, DOI 10.1016/0304-419X(79)90007-6; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HARRIS NL, 1994, BLOOD, V84, P1361; HODGES E, 1994, LEUKEMIA, V8, P295; HOGAN B, 1986, MANIPULATING MOUSE E, P230; HUEGIN AW, 1991, SCIENCE, V252, P424; HUNT RD, 1970, J NATL CANCER I, V44, P447; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LEE SI, 1988, CELL, V54, P599, DOI 10.1016/S0092-8674(88)80004-7; LEE SI, 1990, J VIROL, V64, P3905, DOI 10.1128/JVI.64.8.3905-3915.1990; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MURPHY C, 1994, ONCOGENE, V9, P221; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SCHAFFER PA, 1975, J NATL CANCER I, V55, P1243, DOI 10.1093/jnci/55.5.1243; STANSFELD AG, 1988, LANCET, V1, P292; STANSFELD AG, 1988, LANCET, V1, P603; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; THOMSON BJ, 1991, NATURE, V351, P530, DOI 10.1038/351530a0; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YAO M, 1994, BRIT J HAEMATOL, V87, P535, DOI 10.1111/j.1365-2141.1994.tb08309.x; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x	47	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1609	1616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622880				2022-12-25	WOS:A1996UG45800002
J	Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G				Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G			Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1	ONCOGENE			English	Article						Bcl-2 family; EBV-BHRF1; apoptosis; oncogenesis; p53; E1A; R-ras	PROGRAMMED CELL-DEATH; B-CELLS; BCL-2 GENE; C-MYC; VIRUS; P53; EXPRESSION; E1A; ONCOGENES; HOMOLOG	The BHRF1 protein of Epstein-Barr virus (EBV) is a structural and functional homolog of the Bcl-2 protein, Both BHRF1 and Bcl-2 proteins promote the survival of cells exposed to various apoptotic stimuli. This promotion of cell survival is associated with a block in proliferation, It is believed that the Bcl-2 family of anti-apoptosis proteins contribute to oncogenesis merely by promoting cell survival. We have discovered that mutations within a regulatory domain of the BHRF1 protein not only suppress apoptosis induced by the tumor suppressor protein p53, but also permit efficient proliferation of cells that would otherwise undergo total apoptosis, These gain-of-function mutants of BHRF1 cooperate more efficiently with the E1a oncogene in transformation of primary rat kidney cells where E1A expression results in apoptosis. Our results suggest that such mutational inactivation of a proliferation-restraining activity in the BHRF1 gene may play a direct role in oncogenesis.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NCI NIH HHS [CA-33616, R01 CA033616, CA-31719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COX AD, 1994, ONCOGENE, V9, P3281; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAEZ R, 1994, ONCOGENE, V9, P2877; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG HG, 1994, ONCOGENE, V9, P2751; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	44	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1707	1713						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622891				2022-12-25	WOS:A1996UG45800013
J	Bikle, DD; Munson, S; Komuves, L				Bikle, DD; Munson, S; Komuves, L			Zipper protein, a B-G protein with the ability to regulate actin/myosin 1 interactions in the intestinal brush border	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MYOSIN-I; CHICKEN; BINDING; ACTIN; MICROVILLI; REGION	We recently identified a 28-kDa protein in the intestinal brush border that resembled tropomyosin in terms of size, homology, and alpha helical content, This protein contained 27 heptad repeats, nearly all of which began with leucine, leading to its name zipper protein, Subsequent analysis, however, indicated that both a 49-kDa and a 28-kDa immunoreactive protein existed in intestinal brush-border extracts, Using 5'-rapid amplification of cDNA ends analysis, we extended the N-terminal sequence of zipper protein to the apparent translation start site, This additional sequence contained a putative transmembrane domain and two potential tryptic cleavage sites C-terminal to the transmembrane domain which would release a 28-kDa cytoplasmic protein if utilized, The additional sequence was highly homologous to members of the B-G protein family, a family with no known function. Immunoelectron microscopy showed that zipper protein was confined to the membrane of the microvillus where it was in close association with brush-border myosin 1 (BBM1), Recombinant zipper protein (28-kDa cytoplasmic portion) blocked the binding of actin to BBM1 and inhibited actin-stimulated BBM1 ATPase activity, In contrast, zipper protein had no effect on endogenous or K/EDTA-stimulated BBM1 ATPase activity, Furthermore, zipper protein displaced tropomyosin from binding to actin, suggesting that these homologous proteins bind to the same sites on the actin molecule, We conclude that zipper protein is a transmembrane protein of the B-G family localized to the intestinal epithelial cell microvillus, The extended cytoplasmic tail either in the intact molecule or after tryptic cleavage may participate in regulating the binding and, thus, activation of BBM1 by actin in a manner similar to tropomyosin.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT DERMATOL, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bikle, DD (corresponding author), VET ADM MED CTR, ENDOCRINE UNIT 111N, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028116] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK28116] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P11767; BIKLE DD, 1993, J BIOL CHEM, V268, P620; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; FATH KR, 1994, CURR OPIN CELL BIOL, V6, P131, DOI 10.1016/0955-0674(94)90126-0; GLENNEY JR, 1982, EXP CELL RES, V138, P199, DOI 10.1016/0014-4827(82)90106-9; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HOCKFIELD S, 1990, SELECTED METHODS ANT, P120; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; KAUFMAN J, 1990, P NATL ACAD SCI USA, V87, P8277, DOI 10.1073/pnas.87.21.8277; KAUFMAN J, 1989, IMMUNOGENETICS, V30, P440, DOI 10.1007/BF02421176; KORN ED, 1982, METHOD ENZYMOL, V85, P357; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P657, DOI 10.1083/jcb.92.3.657; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MILLER MM, 1991, P NATL ACAD SCI USA, V88, P4377, DOI 10.1073/pnas.88.10.4377; MILLER MM, 1990, IMMUNOGENETICS, V32, P45, DOI 10.1007/BF01787328; MOOSEKER MS, 1989, J CELL BIOL, V109, P1153, DOI 10.1083/jcb.109.3.1153; MOOSEKER MS, 1989, J CELL BIOL, V108, P2395, DOI 10.1083/jcb.108.6.2395; PINK JRL, 1977, IMMUNOGENETICS, V5, P203, DOI 10.1007/BF01570477; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; SALOMONSENJ, 1991, P NATL ACAD SCI USA, V88, P1359, DOI 10.1073/pnas.88.4.1359; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; ZOT HG, 1995, CELL MOTIL CYTOSKEL, V30, P26, DOI 10.1002/cm.970300105	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9075	9083		10.1074/jbc.271.15.9075	http://dx.doi.org/10.1074/jbc.271.15.9075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621557	hybrid			2022-12-25	WOS:A1996UE73000088
J	Liu, YQ; Uyeda, K				Liu, YQ; Uyeda, K			A mechanism for fatty acid inhibition of glucose utilization in liver - Role of xylulose 5-P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 2,6-BISPHOSPHATE; RAT-LIVER; PHOSPHORYLATION STATES; ISOLATED HEPATOCYTES; AD-LIBITUM; CYCLE; GLYCOLYSIS; INSULIN	The glucose-stimulated rise in Fru-2,6-P-2 in liver results from xylulose 5-P activation of a specific protein phosphatase 2A which dephosphorylates Fru-6-P,2-kinase:Fru-2,6-bisphosphatase (Nishimura, M., and Uyeda, K. (1994) J. Biol Chem. 269, 26100-26106). In order to determine the role of xylulose 5-P in regulating Fru-2,6-P, in liver, the effect of fatty acids, various hexoses, and hormones was examined in perfused rat liver and in intact rats. When 24-h starved rat Livers were perfused with acetate, butyrate, or propionate, Fru-2,6-P-2 and xylulose 5-P decreased to the same extent and at similar rates. The activity ratios of the kinase and the phosphatase changed in a reciprocal manner, indicating that the phosphorylated form of the enzyme was increased by the fatty acids perfusion. The fatty acids caused the similar changes in the metabolites and the phosphorylation state of the bifunctional enzyme in livers of fed animals. Fructose, galactose, or mannose perfusion in starved rat liver increased both Fru-2,6-P-2 and xylulose 5-P and converted the bifunctional enzyme to the dephospho form. form. Both the Fru-2,6-P-2 and xylulose 5-P levels in rats fed a high fat diet decreased over 50% compared to that in control rats, These results indicated a close correlation between Fru-2,6-P-2 and xylulose 5-P levels and the phosphorylation state of fructose 6-P,2-kinase:fructose 2,6-bisphosphatase. Fatty acid inhibition of glucose metabolism can be explained by a decrease in xylulose 5-P, which lowers xylulose 5-P-activated protein phosphatase 2A activity, resulting in more phosphorylated form of the bifunctional enzyme and consequently lower Fru-2,6-P-2.	DEPT VET AFFAIRS MED CTR,RES SERV,DALLAS,TX 75216; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75216	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BERRY MN, 1993, FEBS LETT, V319, P26, DOI 10.1016/0014-5793(93)80030-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; Dagley S., 1974, METHOD ENZYMAT AN, P1562; FEDOROV S, 1992, J BIOL CHEM, V267, P20826; FRANCONE O, 1992, AM J PHYSIOL, V236, pE615; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; HOLNESS MJ, 1988, BIOCHEM J, V252, P357, DOI 10.1042/bj2520357; HUE L, 1981, J BIOL CHEM, V256, P8900; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1984, BIOCHEM J, V224, P779, DOI 10.1042/bj2240779; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; KUWAJIMA M, 1986, J BIOL CHEM, V261, P2632; LOWRY OH, 1982, FLEXIBLE SYSTEM ENZY, P146; MICHAL G, 1974, METHOD ENZYMAT AN, P1314; NEELY P, 1981, DIABETES, V30, P1062, DOI 10.2337/diabetes.30.12.1062; NISHI T, 1989, JPN J SURG, V19, P351, DOI 10.1007/BF02471412; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; PILKIS SJ, 1983, ADV ENZYME REGUL, V21, P147, DOI 10.1016/0065-2571(83)90013-4; Randle P J, 1966, Recent Prog Horm Res, V22, P1; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; RICHARDS CS, 1982, BIOCHEM BIOPH RES CO, V109, P394, DOI 10.1016/0006-291X(82)91734-X; RICHARDS CS, 1980, BIOCHEM BIOPH RES CO, V109, P394; ROSS BD, 1967, BIOCHEM J, V102, P942, DOI 10.1042/bj1020942; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; STRUCK E, 1965, BIOCHEM Z, V343, P107; TOMINAGA N, 1993, J BIOL CHEM, V268, P15951; UYEDA K, 1982, MOL CELL BIOCHEM, V48, P97; UYEDA K, 1981, J BIOL CHEM, V256, P8394; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P887, DOI 10.1042/bj1920887; VEECH RL, 1972, BIOCHEM J, V127, P387, DOI 10.1042/bj1270387; VEECH RL, 1986, MYOCARDIAL SKELETAL, P617; WILLIAMSON J, 1961, BIOCHEM J, V80, P540, DOI 10.1042/bj0800540; WOODS HG, 1970, BIOCHEM J, V119, P501, DOI 10.1042/bj1190501	37	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8824	8830		10.1074/jbc.271.15.8824	http://dx.doi.org/10.1074/jbc.271.15.8824			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621521	hybrid			2022-12-25	WOS:A1996UE73000052
J	Naver, H; Scott, MP; Golbeck, JH; Moller, BL; Scheller, HV				Naver, H; Scott, MP; Golbeck, JH; Moller, BL; Scheller, HV			Reconstitution of barley photosystem I with modified PSI-C allows identification of domains interacting with PSI-D and PSI-A/B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERREDOXIN-NADP+ OXIDOREDUCTASE; CENTER-B; CENTER-A; 9-KDA POLYPEPTIDE; CORE PROTEIN; SUBUNIT; SEQUENCE; PSAC; PURIFICATION; RESOLUTION	The PSI-C subunit of photosystem I shows similarity to soluble 2[4Fe-4S] ferredoxins. Alignment analysis clearly shows that PSI-C contains an 8-residue internal loop and a 15-residue C-terminal extension that are absent in the ferredoxins. The remaining residues in PSI-C are likely to be folded in a way similar to the soluble 2[4Fe-4S] ferredoxins. Two modified PSI-C subunits lacking either the 8-residue loop or 10 residues of the C terminus were expressed in Escherichia coli and used to reconstitute a barley P700-F-x core prepared to specifically lack PSI-C, PSI-D, and PSI-E, As shown by EPR spectroscopy, the modified proteins carry two [4Fe-4S] clusters with characteristics similar to those of native PSI-C, Western blot analysis of the reconstituted photosystem I complexes showed that the modified PSI-C proteins bind 60 the P700-F-x core. Flash photolysis revealed that in photosystem I complexes reconstituted in the presence of PSI-D with the C-terminally deleted PSI-C, the F-A/F-B back-reaction was less efficiently restored than with wild-type PSI-C, The loop-deleted PSI-C was even less efficient. We attribute these differences 60 altered binding properties of the modified proteins. Comparison of reconstitutions performed in the presence and absence of PSI-D shows that the loop-deleted PSI-C is unable to bind without PSI-D, whereas the C-terminally deleted PSI-C binds only weakly with PSI-D. These results imply that the internal loop of PSI-C interacts with the PSI-A/B heterodimer and that the C terminus of PSI-C interacts with PSI-D.	UNIV NEBRASKA,CTR BIOL CHEM,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln	Naver, H (corresponding author), ROYAL VET & AGR UNIV,DEPT PLANT BIOL,PLANT BIOCHEM LAB,40 THORVALDSENSVEJ,DK-1871 FREDERIKSBERG C,DENMARK.		Møller, Birger Lindberg/GQI-1792-2022; Scheller, Henrik/AAH-4770-2020; Scheller, Henrik V/A-8106-2008; Møller, Birger Lindberg/H-2657-2014	Møller, Birger Lindberg/0000-0002-3252-3119; Scheller, Henrik/0000-0002-6702-3560; Scheller, Henrik V/0000-0002-6702-3560; Møller, Birger Lindberg/0000-0002-3252-3119; Naver, Helle/0000-0002-7364-3862				ANDERSEN B, 1992, FEBS LETT, V311, P169, DOI 10.1016/0014-5793(92)81391-X; ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BRYANT DA, 1992, CURRENT TOPICS PHOTO, V11, P501; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; ELLEFSON WL, 1980, METHOD ENZYMOL, V69, P223; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GOLBECK JH, 1993, CURR OPIN STRUC BIOL, V3, P508, DOI 10.1016/0959-440X(93)90076-W; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; HE WZ, 1994, PHOTOSYNTH RES, V41, P381, DOI 10.1007/BF02183040; HERMAN PL, 1994, PLANT PHYSIOL, V104, P1459, DOI 10.1104/pp.104.4.1459; HOJ PB, 1987, J BIOL CHEM, V262, P12676; HOJ PB, 1986, J BIOL CHEM, V261, P14292; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; KAMLOWSKI A, 1995, PHOTOSYNTHESIS LIGHT, V2, P29; Kjaer B, 1996, PHOTOSYNTH RES, V47, P33, DOI 10.1007/BF00017751; KJAERULFF S, 1993, PLANT PHYSIOL, V101, P335; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; NAVER H, 1995, PHOTOSYNTHESIS LIGHT, V2, P155; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; RODDAY SM, 1994, PHOTOSYNTH RES, V42, P185, DOI 10.1007/BF00018261; RODDAY SM, 1993, PHOTOSYNTH RES, V36, P1, DOI 10.1007/BF00018069; SAKURAI H, 1991, PHOTOSYNTH RES, V27, P65, DOI 10.1007/BF00029977; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLER HV, 1989, CARLSBERG RES COMMUN, V54, P11, DOI 10.1007/BF02910468; SCOTT MP, 1992, RES PHOTOSYNTHESIS, V1, P593; SERRANO A, 1982, ANAL BIOCHEM, V126, P109, DOI 10.1016/0003-2697(82)90115-4; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	37	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8996	9001		10.1074/jbc.271.15.8996	http://dx.doi.org/10.1074/jbc.271.15.8996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621546	hybrid			2022-12-25	WOS:A1996UE73000077
J	Rau, M; Ohlmann, T; Morley, SJ; Pain, VM				Rau, M; Ohlmann, T; Morley, SJ; Pain, VM			A reevaluation of the cap-binding protein, eIF4E, as a rate-limiting factor for initiation of translation in reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; GLOBIN MESSENGER-RNA; COMPLEX; PHOSPHORYLATION; LOCALIZATION; INVITRO; CLONING; VIRUS	The cap-binding eukaryotic initiation factor, eIF4E, is a key target for the regulation of translation in mammalian cells and is widely thought to be present at very low molar concentrations, Here we present observations with the reticulocyte lysate that challenge this view, When reticulocyte ribosomes are harvested by centrifugation, most (similar to 75%) of the eIF4E remains in the postribosomal supernatant (PRS), In a reconstituted translation system we find that the ribosome-associated eIF4E alone can sustain much of the overall activity, suggesting that much of the factor in the PRS is functionally redundant, Consistent with this, our estimates of eIF4E in the reticulocyte lysate reveal much higher concentrations than previously reported, The association of a small proportion of eIF4E with the ribosome fraction appears to be functional and dependent on interaction with the factor eIF4G, This fraction of eIF4E is, as expected, more highly phosphorylated than that in the PRS; however, at least half the total phosphorylated eIF4E in reticulocyte lysate translation systems resides in the PRS fraction, suggesting that, while phosphorylation may enhance activity, it is not in itself sufficient to promote utilization of the factor. We also show that the eIF4E-binding factor, eIF4E-BP1 or PHAS-I, which regulates eIF4E activity in insulin-responsive cells, is present in the reticulocyte PRS at an approximately 1:1 molar ratio relative to eIF4E and demonstrate by coimmunoprecipitation studies that the binding of PHAS-I and eIF4G to eIF4E is mutually exclusive, These data are consistent with a potential regulatory role for PHAS-I in the reticulocyte lysate.	UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex			ohlmann, Theophile/M-4463-2014; Ohlmann, Theophile/H-6522-2016	ohlmann, Theophile/0000-0002-2001-8916; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMSON RD, 1988, J BIOL CHEM, V263, P3826; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BU X, 1993, J BIOL CHEM, V268, P4975; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1987, J BIOL CHEM, V262, P380; ETCHISON D, 1984, J VIROL, V51, P832, DOI 10.1128/JVI.51.3.832-837.1984; ETCHISON D, 1990, J BIOL CHEM, V265, P7492; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HANSEN JL, 1982, MOL CELL BIOL, V2, P1639, DOI 10.1128/MCB.2.12.1639; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERNANDEZ G, 1995, BBA-GENE STRUCT EXPR, V1261, P427, DOI 10.1016/0167-4781(95)00039-J; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JAGUS R, 1993, DEV GENET, V14, P412, DOI 10.1002/dvg.1020140603; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; METHOT N, 1996, IN PRESS RNA; METZ AM, 1992, NUCLEIC ACIDS RES, V15, P4096; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MORLEY SJ, 1990, BIOCHIMIE, V72, P259, DOI 10.1016/0300-9084(90)90081-Q; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; MORLEY SJ, 1996, IN PRESS PROTEIN PHO; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; OHLMANN T, 1996, IN PRESS EMBO J; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; WEBB NR, 1994, BIOCHEMISTRY-US, V23, P177; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	65	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8983	8990		10.1074/jbc.271.15.8983	http://dx.doi.org/10.1074/jbc.271.15.8983			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621544	hybrid			2022-12-25	WOS:A1996UE73000075
J	Xu, XH; Vo, L; Macher, BA				Xu, XH; Vo, L; Macher, BA			Structure-function analysis of human alpha 1,3-fucosyltransferase - Amino acids involved in acceptor substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWIS-NEGATIVE INDIVIDUALS; GENE; TRANSFERASES; BINDING	A series of molecular biology experiments were carried out to identify the catalytic domain of two human alpha 1,3/4-fucosyltransferases (fucosyltransferases (FucTs) III and V), and to identify amino acids that function in acceptor substrate binding, Sixty-one and 75 amino acids could be eliminated from the N terminus of FucTs III and V, respectively, without a significant loss of enzyme activity. In contrast, the truncation of one or more amino acids from the C terminus of FucT V resulted in a dramatic or total loss of enzyme activity. Results from the truncation experiments demonstrate that FucT III62-361 (containing amino acids 62-361) and FucT V76-374 (containing amino acids 76-374) are active, whereas shorter forms of the enzymes were inactive. The shortest, active forms of the enzymes are more than 93% identical at the predicted amino acid level, but have distinct acceptor substrate specificities, Thus, FucT III is an alpha 1,4-fucosyltransferase, whereas FucT V is an alpha 1,3-fucosyltransferase with disaccharide substrates. All but one of the amino acid sequence differences between the two proteins occur near their N terminus. Results obtained from domain swapping experiments demonstrated that the single amino acid sequence difference near the C terminus of these enzymes did not alter the enzyme's substrate specificity. However, swapping a region near the N terminus of the truncated form of FucT III into an homologous region in FucT V produced a protein with both alpha 1,3- and alpha 1,4-fucosyltransferase activity. This region contains 8 of the amino acid sequence differences that occur between the two proteins.	SAN FRANCISCO STATE UNIV,DEPT CHEM & BIOCHEM,SAN FRANCISCO,CA 94132	California State University System; San Francisco State University								AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; ELMGREN A, 1993, BIOCHEM BIOPH RES CO, V196, P515, DOI 10.1006/bbrc.1993.2280; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P217; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; KODA Y, 1993, BLOOD, V82, P2915; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YADAV S, 1990, J BIOL CHEM, V265, P14163; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257	28	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8818	8823		10.1074/jbc.271.15.8818	http://dx.doi.org/10.1074/jbc.271.15.8818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621520	hybrid			2022-12-25	WOS:A1996UE73000051
J	Zhang, HL; Malpure, S; Li, ZY; Hiasa, H; DiGate, RJ				Zhang, HL; Malpure, S; Li, ZY; Hiasa, H; DiGate, RJ			The role of the carboxyl-terminal amino acid residues in Escherichia coli DNA topoisomerase III-mediated catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLEX DNA; PROTEIN; CATENATION; ENZYME; MECHANISM; SEQUENCE; BINDING	The role that the carboxyl-terminal amino acids of Escherichia coli DNA topoisomerase I (Topo I) and III (Topo III) play in catalysis was examined by comparing the properties of Topo III with those of a truncated enzyme lacking the generalized DNA binding domain of Topo III, Topo I, and a hybrid topoisomerase polypeptide containing the amino-terminal 605 amino acids of Topo III and the putative generalized DNA binding domain of Topo I, The deletion of the carboxyl-terminal 49 amino acids of Topo III decreases the affinity of the enzyme for its substrate, single-stranded DNA, by approximately 2 orders of magnitude and reduces Topo III-catalyzed relaxation of supercoiled DNA and Topo III-catalyzed resolution of DNA replication intermediates to a similar extent, Fusion of the carboxyl-terminal 312 amino acid residues of Topo I onto the truncated molecule stimulates topoisomerase-catalyzed relaxation 15-20-fold, to a level comparable with that of full-length Topo III. However, topoisomerase-catalyzed resolution of DNA replication intermediates was only stimulated 2-3-fold. Therefore, the carboxyl-terminal amino acids of these topoisomerases constitute a distinct and separable domain, and this domain is intimately involved in determining the catalytic properties of these polypeptides.	UNIV MARYLAND, CELL & MOLEC BIOL PROGRAM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH PHARM, DEPT PHARMACEUT SCI, BALTIMORE, MD 21201 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048445, R01GM048445] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48445] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; DEAN FB, 1985, J BIOL CHEM, V260, P4984; DEAN FB, 1982, COLD SPRING HARB SYM, V47, P4984; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIU LF, 1979, J BIOL CHEM, V254, P1082; PASTORIC M, 1982, THESIS U CHICAGO; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSE YC, 1980, J BIOL CHEM, V255, P5560; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YU LP, 1995, BIOCHEMISTRY-US, V34, P7622, DOI 10.1021/bi00023a008; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700	27	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9039	9045		10.1074/jbc.271.15.9039	http://dx.doi.org/10.1074/jbc.271.15.9039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621552	hybrid			2022-12-25	WOS:A1996UE73000083
J	Fukuda, M; Kojima, T; Mikoshiba, K				Fukuda, M; Kojima, T; Mikoshiba, K			Phospholipid composition dependence of Ca2+-dependent phospholipid binding to the C2A domain of synaptotagmin IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; EXOCYTOSIS; DROSOPHILA; MUTANTS; P65	Synaptotagmins I and II are Ca2+- and phospholipid-binding proteins of synaptic vesicles that may function as Ca2+ receptors for neurotransmitter release via their first C2 domains. Herein, we describe the phospholipid binding properties of C2A domains of multiple synaptotagmins (II-VI). We demonstrate that all synaptotagmins can bind negatively charged phospholipids (phosphatidylserine (PS) and phosphatidylinositol (PI)) in a Ca2+-dependent manner, although it was previously reported that synaptotagmins IV and VI do not bind phos pholipids. The Ca2+-dependent interaction of the C2A domain of synaptotagmin IV with PS was found to have two components with EC(50) values of approximately 5 and 120 mu M free Ca2+ and exhibited positive cooperativity (Hill coefficient of approximately 2 for both components). This value is lower than that of the C2A domain of synaptotagmin II (Hill coefficient of approximately 3). All other isoforms bound PS with high affinity (EC(50) of 0.3-1 mu M free Ca2+ Hill coefficient of 3-3.5). In addition, the C2A domain df synaptotagmin IV cannot bind liposomes consisting of PS (or PI) and phosphatidylcholine, PC (or phosphatidylethanolamine, PE) (1:1, w/w), indicating that the binding to negatively charged phospholipids is inhibited by the presence of PC or PE. In contrast, other isoforms bound all of the liposomes, which include either PS or PI, in a Ca2+-dependent manner. Mutational analysis indicated that this phospholipid composition-dependent Ca2+ binding of synaptotagmin IV results in the substitution of Asp for Ser at position 244. The cytoplasmic domain of synaptotagmin IV also shows this unique phospholipid binding. However, it binds PS with a positive cooperativity and an affinity similar to those of the C2A domains of other isoforms. Our results suggest that synaptotagmin IV is also a potential Ca2+ sensor for neurotransmitter release.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; EXPLORATORY RES ADV TECHNOL,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo	Fukuda, M (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CRAXTON M, 1995, FEBS LETT, V361, P196, DOI 10.1016/0014-5793(95)00176-A; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MOCHIDA S, 1995, SAT S 15 ISN M JUN 2, P124; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OHARAIMAIZUMI M, 1995, SAT S 15 ISN M JUN 2, P125; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	28	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8430	8434		10.1074/jbc.271.14.8430	http://dx.doi.org/10.1074/jbc.271.14.8430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626542	hybrid			2022-12-25	WOS:A1996UD60000082
J	Takezawa, D; Ramachandiran, S; Paranjape, V; Poovaiah, BW				Takezawa, D; Ramachandiran, S; Paranjape, V; Poovaiah, BW			Dual regulation of a chimeric plant serine threonine kinase by calcium and calcium calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BINDING PROTEIN; EXPRESSION; AUTOPHOSPHORYLATION; CDNA; PHOSPHORYLATION; SEQUENCE; VISININ; CLONING; SYSTEM	A chimeric Ca2+/calmodulin dependent protein kinase (CCaMK) gene characterized by a catalytic domain, a calmodulin-binding domain, and a neural visinin-like Ca2+-binding domain was recently cloned from plants (Patil, S., Takezawa, D., and Poovaiah, B. W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4797-4801), The Escherichia coli-expressed CCaMK phosphorylates various protein and peptide substrates in a Ca2+/calmodulin-dependent manner, The calmodulin-binding region of CCaMK has similarity to the calmodulin-binding region of the alpha-subunit of multifunctional Ca2+/calmodulin-dependent protein kinase (CaMKII). CCaMK exhibits basal autophosphorylation at the threonine residue(s) (0.098 mol of P-32/mol) that is stimulated 3.4-fold by Ca2+ (0.339 mol of P-32/mol), while calmodulin inhibits Ca2+-stimulated autophosphorylation to the basal level, A deletion mutant lacking the visinin-like domain did not show Ca2+-stimulated autophosphorylation activity but retained Ca2+/calmodulin dependent protein kinase activity at a reduced level, Ca2+-dependent mobility shift assays using E. coli-expressed protein from residues 358-520 revealed that Ca2+ binds to the visinin-like domain, Studies with site-directed mutants of the visinin-like domain indicated that EF-hands II and III are crucial for Ca2+-induced conformational changes in the visinin-like do main, Autophosphorylation of CCaMK increases Ca2+/calmodulin-dependent protein kinase activity by about B-fold, whereas it did not affect its Ca2+-independent activity, This report provides evidence for the existence of a protein kinase in plants that is modulated by Ca2+ and Ca2+/calmodulin, The presence of a visinin-like Ca2+-binding domain in CCaMK adds an additional Ca2+-sensing mechanism not previously known to exist in the Ca2+/calmodulin-mediated signaling cascade in plants.	WASHINGTON STATE UNIV, DEPT HORT, LAB PLANT MOL BIOL & PHYSIOL, PULLMAN, WA 99164 USA	Washington State University			大輔, 竹澤/H-9175-2012					AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BLOWERS DP, 1987, BIOCHEM BIOPH RES CO, V143, P691, DOI 10.1016/0006-291X(87)91409-4; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BUSH DS, 1993, PLANT PHYSIOL, V103, P7, DOI 10.1104/pp.103.1.7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FONG YL, 1989, J BIOL CHEM, V264, P16759; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GILROY S, 1993, J CELL SCI, V106, P453; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; PERERA IY, 1992, PLANT PHYSIOL, V100, P812, DOI 10.1104/pp.100.2.812; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; RENNER M, 1993, P NATL ACAD SCI USA, V90, P6493, DOI 10.1073/pnas.90.14.6493; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STONE JM, 1995, PLANT PHYSIOL, V108, P451, DOI 10.1104/pp.108.2.451; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; VELUTHAMBI K, 1984, SCIENCE, V223, P167, DOI 10.1126/science.223.4632.167; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O	48	100	110	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8126	8132		10.1074/jbc.271.14.8126	http://dx.doi.org/10.1074/jbc.271.14.8126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626500	Green Published, hybrid			2022-12-25	WOS:A1996UD60000040
J	Cai, K; Schirch, V				Cai, K; Schirch, V			Structural studies on folding intermediates of serine hydroxymethyltransferase using single tryptophan mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRP APOREPRESSOR; PROTEINS; EQUILIBRIUM; RESOLUTION; UREA	Previous studies showed that during the in vitro folding of Escherichia coli serine hydroxymethyltransferase at 4 degrees C, both monomer and dimer intermediates accumulated and were stable for periods of minutes to hours (Cai, K., Schirch, D., and Schirch, V., (1995) J. Biol. Chem. 270, 19294-19299). To obtain structural information on these intermediates, two of the three Trp residues in the protein were changed to Phe to generate a set of three single Trp mutant enzymes. These mutant enzymes were purified and characterized and shown to retain essentially all of the properties of the wild-type enzyme. The fluorescence and circular dichroism measurements of each mutant enzyme were studied under unfolding-refolding equilibrium conditions and during refolding. In addition, the sensitivity of the protein to digestion by subtilisin during refolding was investigated. The results of these studies show that the unfolded enzyme has two domains that rapidly fold to form a monomer in which the first 55 amino acids and a segment between residues 225 and 276 remain in a largely disordered form. This partially folded enzyme can form dimers and slowly undergoes a rate determining conformational change in which the unstructured segments assume their native state.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NIGMS NIH HHS [GM 28143] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; CUPO JF, 1983, BIOCHEMISTRY-US, V22, P2654, DOI 10.1021/bi00280a010; DELLEFRATTE S, 1994, FEBS LETT, V225, P395; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; IRACE G, 1981, BIOCHEMISTRY-US, V20, P792, DOI 10.1021/bi00507a022; MANN CJ, 1993, PROTEIN SCI, V2, P1853, DOI 10.1002/pro.5560021107; MARTENSSON LG, 1995, BIOCHEMISTRY-US, V34, P1011, DOI 10.1021/bi00003a036; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PACE CN, 1975, CRIT REV BIOCH, V3, P11; Parker C. A., 1968, PHOTOLUMINESCENCE SO, P220; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; Price N. C., 1994, MECH PROTEIN FOLDING, P160; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SCHIRCH V, 1985, J BACTERIOL, V163, P1; ZETINA CR, 1982, J MOL BIOL, V157, P133, DOI 10.1016/0022-2836(82)90516-2	21	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2987	2994		10.1074/jbc.271.6.2987	http://dx.doi.org/10.1074/jbc.271.6.2987			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621691	hybrid			2022-12-25	WOS:A1996TU69100020
J	Haske, TN; DeBlasi, A; LeVine, H				Haske, TN; DeBlasi, A; LeVine, H			An intact n terminus of the gamma subunit is required for the G beta gamma stimulation of rhodopsin phosphorylation by human beta-adrenergic receptor kinase-1 but not for kinase binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; HETEROTRIMERIC G-PROTEINS; DEPENDENT PHOSPHORYLATION; LIMITED PROTEOLYSIS; SIGNALING PROTEINS; MECHANISM; DOMAIN; PRENYLATION; EXPRESSION; TRANSDUCIN	Cleavage after lysine 32 in the G gamma(2) subtype and after lysine 36 in the G gamma(3) subtype of purified mixed brain G beta gamma by endoproteinase Lys-C blocks G beta gamma-mediated stimulation of phosphorylation of rhodopsin in urea-extracted rod outer segments by recombinant human beta-adrenergic receptor kinase (h beta ARK1) holoenzyme while h beta ARK1 binding to rod outer segments is partially affected. This treatment does not attenuate the binding of the treated G beta gamma to C-terminal fragments of h beta ARK1 containing the pleckstrin homology domain. Lys-C proteolysis also does not alter the association of the G beta gamma with phospholipids, its ability to support pertussis toxin-catalyzed G alpha(0)/G alpha(i) ADP-ribosylation, or its ability to inhibit forskolin stimulated platelet adenylate cyclase. The G beta subunit remains noncovalently associated with the cleaved G gamma fragments. Thus, in addition to recruiting h beta ARK1 to its receptor substrate, G gamma contributes secondary and/or tertiary structural features to activate the kinase.	CONSORZIO MARIO NEGRI SUD,CTR RIC FARMACOL & BIOMED,I-66030 CHIETI,ITALY	Consorzio Mario Negri Sud	Haske, TN (corresponding author), WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,ANN ARBOR,MI 48105, USA.							BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BUBUS J, 1990, J BIOL CHEM, V265, P12995; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HUFF RM, 1986, J BIOL CHEM, V261, P1105; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KIM CM, 1993, J BIOL CHEM, V268, P15412; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LEVINE H, 1988, BRAIN RES, V439, P47, DOI 10.1016/0006-8993(88)91460-6; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1984, J BIOL CHEM, V259, P4222; PARISH CA, 1994, BIOCHEMISTRY-US, V33, P9986, DOI 10.1021/bi00199a023; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SALLESE M, 1995, J RECEPT SIGNAL TR R, V15, P81, DOI 10.3109/10799899509045209; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201; 1993, GUIDE PROPERTIES USE	51	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2941	2948		10.1074/jbc.271.6.2941	http://dx.doi.org/10.1074/jbc.271.6.2941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621684	hybrid			2022-12-25	WOS:A1996TU69100013
J	Panchamoorthy, G; Fukazawa, T; Miyake, S; Soltoff, S; Reedquist, K; Druker, B; Shoelson, S; Cantley, L; Band, H				Panchamoorthy, G; Fukazawa, T; Miyake, S; Soltoff, S; Reedquist, K; Druker, B; Shoelson, S; Cantley, L; Band, H			p120(cbl) is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL T-CELLS; V-CBL; PROTEIN-KINASE; LYMPHOCYTES-B; MICE LACKING; SRC FAMILY; ZETA-CHAIN; ASSOCIATION; TRUNCATION; ACTIVATION	We and others have demonstrated that the c-cbl protooncogene product is one of the earliest targets of tyrosine phosphorylation upon T cell receptor stimulation. Given the similarities in the B and T lymphocyte antigen receptors, and the induction of pre-B leukemias in mice by the v-cbl oncogene, we examined the potential involvement of Cbl in B cell receptor signaling. We demonstrate prominent and early tyrosine phosphorylation of Cbl upon stimulation of human B cell lines through surface IgM. Cbl was associated in vivo with Fyn and, to a lesser extent, other Src family kinases. B cell activation also induced a prominent association of Cbl with Syk tyrosine kinase. A substantial fraction of Cbl was constitutively associated with Grb2 and this interaction was mediated by Grb2 SH3 domains. Tyrosine-phosphorylated Shc, which prominently associated with Grb2, was detected in association with Cbl in activated B cells. Thus, Grb2 and Shc adaptors, which associate with immunoreceptor tyrosine based activation motifs, may link Cbl to the B cell receptor. B cell activation also induced a prominent association between Cbl and the p85 subunit of phosphatidylinositol (PI) 3-kinase resulting in the association of a substantial fraction of PI 3-kinase activity with Cbl. Thus, Cbl is likely to play an important role to couple the B cell receptor to the PI 3-kinase pathway. Our results strongly suggest a role for p120(cbl) in signaling downstream of the B cell receptor and support the idea that Cbl participates in a general signal transduction function downstream of the immune cell surface receptors.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,JOSLIN DIABET CTR,RES DIV,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115; OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,PORTLAND,OR 97201	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Oregon Health & Science University			Fukazawa, Takuya/GLR-7099-2022; Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Druker, Brian/0000-0001-8331-8206	NIAMS NIH HHS [AR36308] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM36624] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM036624] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FLASWINKEL H, 1994, ADV EXP MED BIOL, V365, P1; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOLD MR, 1994, J IMMUNOL, V152, P42; GOLD MR, 1992, J IMMUNOL, V148, P2012; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOLINA TJ, 1993, J IMMUNOL, V151, P699; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REEDQUIST KA, 1996, IN PRESS J BIOL CHEM; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMIT L, 1994, J BIOL CHEM, V269, P20209; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANAKA S, 1995, J BIOL CHEM, V270, P1447; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	56	176	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3187	3194		10.1074/jbc.271.6.3187	http://dx.doi.org/10.1074/jbc.271.6.3187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621719	hybrid			2022-12-25	WOS:A1996TU69100048
J	Bunting, M; Tang, W; Zimmerman, GA; McIntyre, TM; Prescott, SM				Bunting, M; Tang, W; Zimmerman, GA; McIntyre, TM; Prescott, SM			Molecular cloning and characterization of a novel human diacylglycerol kinase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE CONTROL PROTEINS; CELL-CELL-INTERACTIONS; RETINAL DEGENERATION; SIGNAL TRANSDUCTION; TRANSFORMED FIBROBLASTS; ACTIVATING PROTEIN; ENDOTHELIAL-CELLS; BINDING-PROTEIN; PHOSPHOLIPASE-C; NERVOUS-SYSTEM	Diacylglycerol (DAG) occupies a central position in the synthesis of complex Lipids and also has important signaling roles. For example, DAG is an allosteric regulator of protein kinase C, and the cellular levels of DAG may influence a variety of processes including growth and differentiation. We previously demonstrated that human endothelial cells derived from umbilical vein express growth-dependent changes in their basal levels of diacylglycerol and diacylglycerol kinase activity (Whatley, R. E., Stroud, E. D., Bunting, M., Zimmerman, G. A., McIntyre, T. M., and Prescott, S. M. (1993) J. Biol. Chem. 268, 16130-16138). To further explore the role of diacylglycerol metabolism in endothelial responses, we used a degenerate reverse transcription-polymerase chain reaction method to identify diacylglycerol kinase isozymes expressed by human endothelial cells. We report the isolation of a 3.5-kilobase cDNA encoding a novel diacylglycerol kinase (hDGK zeta) with a predicted molecular mass of 103.9 kDa. Human DGK zeta contains two zinc fingers, an ATP binding site, and four ankyrin repeats near the carboxyl terminus, A unique feature, as compared with other diacylglycerol kinases, is the presence of a sequence homologous to the MARCKS phosphorylation site domain. From Northern blot analysis of multiple tissues, we observed that hDGK zeta mRNA is expressed at highest levels in brain, COS-7 cells transfected with the hDGK zeta cDNA express 117-kDa and 114-kDa proteins that react specifically with an antibody to a peptide derived from a unique sequence in hDGK zeta. The transfected cells also express increased diacylglycerol kinase activity, which is not altered in the presence of R59949, an inhibitor of human platelet DGK activity. The hDGK zeta displays stereoselectivity for 1,2-diacylglycerol species in comparison to 1,3-diacylglycerol, but does not exhibit any specificity for molecular species of long chain diacylglycerols.	UNIV UTAH, ECCLES PROGRAM HUMAN MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL CANCER INSTITUTE [R01CA059548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER; NCI NIH HHS [CA59548] Funding Source: Medline; NHLBI NIH HHS [HL50153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDEN N, 1993, BIOCHEM J, V289, P439, DOI 10.1042/bj2890439; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; INOUE H, 1989, J BIOL CHEM, V264, P5996; ISHIKAWA F, 1986, JPN J CANCER RES, V77, P1183; JOHNSON MA, 1982, J INSECT PHYSIOL, V28, P233, DOI 10.1016/0022-1910(82)90082-8; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KATO M, 1987, J BIOL CHEM, V262, P5696; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHMIDT SY, 1983, J NEUROCHEM, V40, P1630, DOI 10.1111/j.1471-4159.1983.tb08136.x; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520	57	150	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10230	10236		10.1074/jbc.271.17.10230	http://dx.doi.org/10.1074/jbc.271.17.10230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626588	hybrid			2022-12-25	WOS:A1996UG25700060
J	Xia, Y; Khatchikian, G; Zweier, JL				Xia, Y; Khatchikian, G; Zweier, JL			Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL REPERFUSION INJURY; XANTHINE-OXIDASE INHIBITOR; INFARCT SIZE; PERFUSED HEART; ISCHEMIA; ALLOPURINOL; GENERATION; PROTECTION; DOGS; METABOLISM	In the presence of its substrates hypoxanthine and xanthine, xanthine oxidase generates oxygen free radicals that cause postischemic injury. Recently, it has been demonstrated that the burst of xanthine oxidase-mediated free radical generation in the reperfused heart is triggered by a large increase in substrate formation, which occurs secondary to the degradation of adenine nucleotides during ischemia. It is not known, however, whether blocking this substrate formation is sufficient to prevent radical generation and functional injury. Therefore, studies were performed in isolated rat hearts in which xanthine oxidase substrate formation was blocked with the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), and measurements of contractile function and free radical generation were performed. Chromatographic measurements of the intracellular adenine nucleotide pool showed that preischemic administration of EHNA blocked postischemic hypoxanthine, xanthine, and inosine formation. Electron paramagnetic resonance spin trapping measurements of free radical generation showed that inhibition of adenosine deaminase with EHNA blocked free radical generation and that it also increased the recovery of contractile function by more than 2-fold. Exogenous infusion of hypoxanthine and xanthine totally reversed the protective effects of EHNA. These results demonstrate that blockade of xanthine oxidase substrate formation by adenosine deaminase inhibition can prevent free radical generation and contractile dysfunction in the postischemic heart.	JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21224 USA; JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, ELECTRON PARAMAGNET RESONANCE CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELFATTAH AS, 1988, CIRCULATION, V78, P224; ABDELFATTAH AS, 1990, CIRCULATION, V82, P341; AKIZUKI S, 1985, CARDIOVASC RES, V19, P686, DOI 10.1093/cvr/19.11.686; ARROYO CM, 1987, FEBS LETT, V221, P101, DOI 10.1016/0014-5793(87)80360-5; BAK MI, 1994, J CLIN INVEST, V93, P40, DOI 10.1172/JCI116974; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; BOLLING SF, 1992, J THORAC CARDIOV SUR, V103, P73; CERUTTI PA, 1988, OXYRADICALS MOL BIOL, P1; CHAMBERS DE, 1985, J MOL CELL CARDIOL, V17, P145, DOI 10.1016/S0022-2828(85)80017-1; CHAMBERS DJ, 1987, ANN THORAC SURG, V44, P291, DOI 10.1016/S0003-4975(10)62076-0; EDDY LJ, 1987, AM J PHYSIOL, V253, pH709, DOI 10.1152/ajpheart.1987.253.3.H709; GRUM CM, 1989, J MOL CELL CARDIOL, V21, P263, DOI 10.1016/0022-2828(89)90741-4; HULLRYDE EA, 1986, J CHROMATOGR, V377, P165, DOI 10.1016/S0378-4347(00)80771-9; JENNINGS RB, 1985, ANNU REV PHYSIOL, V47, P727, DOI 10.1146/annurev.ph.47.030185.003455; KRAUSE SM, 1992, J BIOL CHEM, V267, P2480; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; KUPPUSAMY P, 1989, J BIOL CHEM, V264, P9880; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING AS, 1984, CIRC RES, V55, P545, DOI 10.1161/01.RES.55.4.545; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; PORTER DJT, 1992, BIOCHEMISTRY-US, V31, P8216, DOI 10.1021/bi00150a014; PUETT DW, 1987, CIRCULATION, V76, P678, DOI 10.1161/01.CIR.76.3.678; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; RICHARD VJ, 1988, CIRCULATION, V78, P473, DOI 10.1161/01.CIR.78.2.473; Roy R.S., 1983, CELLULAR MED ASPECTS, VII, P145; SIMPSON PJ, 1987, J LAB CLIN MED, V110, P13; SWAIN JL, 1986, HEART CARDIOVASCULAR, P911; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VARGEESE C, 1994, J MED CHEM, V37, P3844, DOI 10.1021/jm00048a020; WERNS SW, 1986, CIRCULATION, V73, P518, DOI 10.1161/01.CIR.73.3.518; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, AM J PHYSIOL, V266, pC700, DOI 10.1152/ajpcell.1994.266.3.C700; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	42	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10096	10102		10.1074/jbc.271.17.10096	http://dx.doi.org/10.1074/jbc.271.17.10096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626567	hybrid			2022-12-25	WOS:A1996UG25700039
J	Kudo, T; Iwasaki, H; Nishihara, S; Shinya, N; Ando, T; Narimatsu, I; Narimatsu, H				Kudo, T; Iwasaki, H; Nishihara, S; Shinya, N; Ando, T; Narimatsu, I; Narimatsu, H			Molecular genetic analysis of the human Lewis histo-blood group system .2. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCT-III GENE; EXPRESSION; ANTIGEN; CDNA; SERUM; ABO	The Lewis histo-blood group system comprises two major antigens, Lewis a and Lewis b. The Lewis b antigen is a product of two fucosyltransferases, the alpha(1,3/ 1,4)fucosyltransferase (Lewis enzyme; Fuc-TIII) encoded by the Lewis gene and an alpha(1,2)fucosyltransferase which is not required for synthesis of Lewis a antigen. An enzyme responsible for secreting ABH antigens into body secretions (secretor enzyme) is also one of alpha(1,2)fucosyltransferases. A candidate gene encoding secretor enzyme Sec2 gene was recently cloned by Rouquier, S., Lowe, J. B., Kelly, R. J., Fertitta, A. L., Lennon, G. G., and Giorgi, D. ((1995) J. Biol. Chem. 270, 4632-4639) and Kelly, R. J., Rouquier, S., Giorgi, D., Lennon, G. G., and Lowe, J. B. ((1995) J. BioL. Chem. 270, 4640-4649) who demonstrated a G428A nonsense mutation (Trp(143) to terminal codon) in Sec2 of nonsecretors. However, the G428A nonsense mutation discovered in the Sec2 gene of nonsecretors in an ethnic group other than Japanese was not found in any of 45 Japanese nonsecretors, whereas one Filipino who had been erroneously registered as a Japanese possessed the G428A mutation heterozygously. In order to explore the Sec2 gene of a Japanese population, we performed a molecular genetic analysis of the Sec2 gene on 226 Japanese individuals, 21 in a family study and 205 in a random sampling study. We discovered two novel mutations in the Sec2 gene, an A385T missense mutation (Ile(129) to Phe) that results in inactivation of Sec2-encoded alpha(1,2)fucosyltransferase and a C357T silent mutation which is irrelevant to amino acid substitution, in Japanese nonsecretors. The analysis of Japanese individuals using the polymerase chain reaction-restriction fragment length polymorphism method found three alleles in the Sec2 gene, the first having no mutation, the second having a C357T mutation, and the third having both C357T and A385T mutations, which we designated as Se1, Se2, and sej, respectively. Among 226 Japanese individuals, 40 having a Le(a+b-) phenotype and 5 having a Le(a-b-) nonsecretor phenotype were homozygous for sej/sej, whereas 149 having a Le(a-b+) phenotype and 32 having a Le(a-b-)-secretor phenotype possessed at least one Se1 or Se2. The frequencies of occurrence of Se1, Se2, and sej among 410 alleles examined in a random sample of 205 Japanese individuals were 15, 46, and 39%, respectively, indicating a rather wide distribution of the sej allele in the Japanese population. The results show that the Sec2 gene really encodes the secretor enzyme alpha(1,2)fucosyltransferase and indicate that a ethnic group-specific nonsense or missense point mutation in the Sec2 gene determines nonsecretor status. The phylogenic aspect and biological significance of the Se and Le genes are discussed.	SOKA UNIV,INST LIFE SCI,DIV CELL BIOL,HACHIOJI,TOKYO 192,JAPAN; BML INC,BASIC RES DIV,KAWAGOE,SAITAMA 35011,JAPAN; KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN; SAITAMA CENT HOSP,DEPT MED,MIYOSHI,SAITAMA 354,JAPAN	Soka University; BML, Inc.; Keio University				Nishihara, Shoko/0000-0002-1668-2603				BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; HAMMAR L, 1981, VOX SANG, V40, P27, DOI 10.1111/j.1423-0410.1981.tb00665.x; HENRY SM, 1993, VOX SANG, V65, P62, DOI 10.1111/j.1423-0410.1993.tb04527.x; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; IZUMI Y, 1995, EXP CELL RES, V216, P215, DOI 10.1006/excr.1995.1027; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; MARCUS DM, 1969, SCIENCE, V164, P553, DOI 10.1126/science.164.3879.553; MATSUSHITA Y, 1990, LAB INVEST, V63, P780; MCCURLEY RS, 1995, GENOMICS, V2, P142; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; NAKAYAMA T, 1995, CANCER, V75, P2051, DOI 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V196, P624, DOI 10.1006/bbrc.1993.2295; ORIOL R, 1986, VOX SANG, V51, P161, DOI 10.1111/j.1423-0410.1986.tb01946.x; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIDMANN FK, 1981, TECHNICAL MANUAL AM; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAGO K, 1993, CANCER RES, V53, P5559; YAZAWA S, 1995, CANCER RES, V55, P1473	27	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9830	9837		10.1074/jbc.271.16.9830	http://dx.doi.org/10.1074/jbc.271.16.9830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621666	hybrid			2022-12-25	WOS:A1996UG04400097
J	Lester, LB; Coghlan, VM; Nauert, B; Scott, JD				Lester, LB; Coghlan, VM; Nauert, B; Scott, JD			Cloning and characterization of a novel A-kinase anchoring protein - AKAP 220, association with testicular peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; REGULATORY SUBUNIT RII; LOCALIZATION; EXPRESSION; BRAIN; IDENTIFICATION; BETA; MUSCLE; DOMAIN; IMPORT	Compartmentalization of the type II cyclic AMP-dependent kinase (PKA) is achieved through association of the regulatory subunit (RII) with A-kinase anchoring proteins (AKAPs), Using an interaction cloning strategy with RII alpha as a probe, we have isolated cDNAs encoding a novel 1129-amino acid protein that contains both a PKA binding region and a peroxisome targeting motif. Northern analysis detected mRNAs of 9.7 and 7.3 kb in several rat tissues with the highest levels present in the brain and testis, Western analysis and RII overlay experiments showed that the protein is approximately 220 kDa and was, therefore, named AKAP 220. Immunoprecipitation of AKAP 220 from rat testis extracts resulted in co-purification of the type II PKA holoenzyme, The specific activity of PKA increased 458-fold from 7.2 pmol/min/mg in the cell lysate to 3.3 nmol/min/mg in the immunoprecipitate. Immunohistochemical analysis of rat testicular TM4 cells showed that AKAP 220 and a proportion of RII were co-localized in microbodies that appear to be a subset of peroxisomes. Collectively, these results suggest that AKAP 220 may play a role in targeting type II PKA for cAMP-responsive peroxisomal events.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DIV ENDOCRINOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University					NIDDK NIH HHS [DK 44239, DK 09059, DK 02353] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009059, K11DK002353, P01DK044239] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSCH H, 1992, ANNU REV BIOCHEM, V61, P157; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; COGHLAN V, 1995, ADV PROTEIN PHOSPHAT, V9, P51; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, J BIOL CHEM, V264, P21435; Corbin J D, 1974, Methods Enzymol, V38, P287; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KLUCIS E, 1991, BIOCHIM BIOPHYS ACTA, V1074, P294, DOI 10.1016/0304-4165(91)90167-F; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; MENDISHANDAGAMA SMLC, 1988, AM J ANAT, V181, P12, DOI 10.1002/aja.1001810103; MENDISHANDAGAMA SMLC, 1992, ENDOCRINOLOGY, V131, P2839, DOI 10.1210/en.131.6.2839; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; REDDY J, 1972, J HISTOCHEM CYTOCHEM, V20, P140, DOI 10.1177/20.2.140; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SALVATORI S, 1990, BIOCHEM J, V267, P679, DOI 10.1042/bj2670679; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1994, MOL ENDOCRINOL, V13, P5; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; WALSH DA, 1968, J BIOL CHEM, V243, P3763	47	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9460	9465		10.1074/jbc.271.16.9460	http://dx.doi.org/10.1074/jbc.271.16.9460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621616	Green Published, hybrid			2022-12-25	WOS:A1996UG04400047
J	Machiels, BM; Zorenc, AHG; Endert, JM; Kuijpers, HJH; vanEys, GJJM; Ramaekers, FCS; Broers, JLV				Machiels, BM; Zorenc, AHG; Endert, JM; Kuijpers, HJH; vanEys, GJJM; Ramaekers, FCS; Broers, JLV			An alternative splicing product of the lamin A/C gene lacks exon 10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; INTERMEDIATE FILAMENT PROTEINS; NUCLEAR-ENVELOPE; SOMATIC-CELLS; EXPRESSION; LINES; GROWTH; DIFFERENTIATION; ELECTROPHORESIS; IDENTIFICATION	Expression of the A-type lamins was studied in the lung adenocarcinoma cell line GLC-A1. A-type lamins, consisting of lamin A and C, are two products arising from the same gene by alternative splicing. Northern blotting showed in GLC-A1 a relatively low expression level of lamin C and an even lower expression level of lamin A as compared to other adenocarcinoma cell lines, Immunofluorescence studies revealed highly irregular nuclear inclusions of lamin A, suggesting protein or gene expression abnormalities, Reverse transcriptase-polymerase chain reaction-based cDNA analysis followed by sequencing indicated the presence of an as yet unidentified alternative splicing product of the lamin A/C gene. This product differs from lamin A by the absence of the 5' part of exon 10 (90 nucleotides). Therefore we propose to designate this product lamin A Delta 10. Deletion of the 30 amino acids encoded by exon 10 was predicted to result in a shift in pi of the protein from 7.4 to approximately 8.6, which was confirmed by two-dimensional immunoblotting. mRNA analysis in a variety of cell lines, normal colon tissue as well as carcinomas demonstrated the presence of lamin A Delta 10 in all samples examined, suggesting its presence in a variety of cell types.	UNIV LIMBURG,DEPT MOLEC GENET & CELL BIOL,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University								BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRIDGER JM, 1993, J CELL SCI, V104, P297; BROERS JLV, 1993, AM J PATHOL, V143, P211; BROERS JLV, 1988, J CELL SCI, V91, P91; BROWER M, 1986, CANCER RES, V46, P798; CANCE WG, 1992, J EXP CLIN CANC RES, V11, P233; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DELEIJ L, 1985, CANCER RES, V45, P6024; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FURUKAWA K, 1993, EMBO J, V12, P97, DOI 10.1002/j.1460-2075.1993.tb05635.x; GAZDAR AF, 1985, SCIENCE, V229, P679, DOI 10.1126/science.2992083; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HEITLINGER E, 1992, J STRUCT BIOL, V108, P74, DOI 10.1016/1047-8477(92)90009-Y; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HOZAK P, 1995, J CELL SCI, V108, P635; KAMAT AK, 1993, SOMAT CELL MOLEC GEN, V19, P203, DOI 10.1007/BF01233534; KROHNE G, 1986, EXP CELL RES, V162, P1, DOI 10.1016/0014-4827(86)90421-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN F, 1993, J BIOL CHEM, V268, P16321; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LUSTER W, 1983, ACTA ENDOCR-COP    S, V253, P24; MACHIELS BM, 1995, EUR J CELL BIOL, V67, P328; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; ROBER RA, 1990, J CELL SCI, V95, P587; ROBER RA, 1989, DEVELOPMENT, V105, P365; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; WORMAN HJ, 1988, J BIOL CHEM, V263, P12135	42	143	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9249	9253		10.1074/jbc.271.16.9249	http://dx.doi.org/10.1074/jbc.271.16.9249			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621584	hybrid			2022-12-25	WOS:A1996UG04400015
J	Rosenfeld, SS; Rener, B; Correia, JJ; Mayo, MS; Cheung, HC				Rosenfeld, SS; Rener, B; Correia, JJ; Mayo, MS; Cheung, HC			Equilibrium studies of kinesin-nucleotide intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERYLLIUM FLUORIDE; INORGANIC-PHOSPHATE; CYTOPLASMIC MICROTUBULES; STRUCTURAL ANALOGS; ATP HYDROLYSIS; MYOSIN ATPASE; SMOOTH-MUSCLE; HEAVY-CHAIN; F-ACTIN; VANADATE	We have examined the energetics of the interactions of two kinesin constructs with nucleotide and microtubules to develop a structural model of kinesin-dependent motility. Dimerization of the constructs was found to reduce the maximum rate of the microtubule-activated kinesin ATPase 5-fold. Beryllium fluoride and aluminum fluoride also reduce this rate, and they increase the affinity of kinesin for microtubules. By contrast, inorganic phosphate reduces the affinity of a dimeric kinesin construct for microtubules, These findings are consistent with a model in which the kinesin head can assume one of two conformations, ''strong'' or ''weak'' binding, determined by the nature of the nucleotide that occupies the active site, Data for dimeric kinesin are consistent with a model in which kinesin . ATP binds to the microtubule in a strong state with positive cooperativity; hydrolysis of ATP to ADP+P-i leads to dissociation of one of the attached heads and converts the second, attached head to a weak state; and dissociation of phosphate allows the second head to reattach, These results also argue that a large free energy change is associated with formation of kinesin . ADP . P-i and that this step is the major pathway for dissociation of kinesin from the microtubule.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,UAB COMPREHENS CANC CTR,DIV BIOSTAT,BIRMINGHAM,AL 35294; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Mississippi; University of Mississippi Medical Center	Rosenfeld, SS (corresponding author), UNIV ALABAMA,DEPT NEUROL,UAB STN,510 MED EDUC BLDG,BIRMINGHAM,AL 35294, USA.		Mayo, Matthew S/E-3774-2015		NIAMS NIH HHS [AR31239] Funding Source: Medline; NINDS NIH HHS [NS01500, NS31096] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031096] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAPLOW M, 1989, BIOCHEMISTRY-US, V28, P8136, DOI 10.1021/bi00446a026; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; IWAMOTO H, 1995, BIOPHYS J, V68, P243, DOI 10.1016/S0006-3495(95)80180-3; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MARUTA S, 1993, J BIOL CHEM, V268, P7093; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PHAN B, 1992, BIOCHEMISTRY-US, V31, P4787, DOI 10.1021/bi00135a007; PHAN BC, 1993, BIOCHEMISTRY-US, V32, P7712, DOI 10.1021/bi00081a016; RICKARD JE, 1988, J MOL BIOL, V201, P675, DOI 10.1016/0022-2836(88)90466-4; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; SADHU A, 1992, J BIOL CHEM, V267, P11352; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLISTRA MJ, 1991, BIOCHEM J, V277, P839; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TANFORD C, 1961, PHYSICAL CHEM MACROM, P532; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WARSHAW DM, 1991, J BIOL CHEM, V266, P24339; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; YAMAKAWA M, 1991, J GEN PHYSIOL, V98, P657, DOI 10.1085/jgp.98.4.657; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	51	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9473	9482		10.1074/jbc.271.16.9473	http://dx.doi.org/10.1074/jbc.271.16.9473			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621618				2022-12-25	WOS:A1996UG04400049
J	Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H				Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H			Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity	ONCOGENE			English	Article						p53; human papillomavirus; oral squamous cell carcinoma; prognosis	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; CERVICAL CARCINOMAS; NECK-CANCER; LUNG-CANCER; FREQUENT; HEAD; DNA; ASSOCIATION; EXPRESSION	The p53 gene has been indicated to be a tumor is found in mutated form in common human cancers, Human papillomavirus (HPV) has oncogenic activity in cervical and oral squamous cell carcinomas (SCCs), The E6 protein of HPV is known to bind with p53 protein and inactivate the tumor suppressor activity by promoting p53 degradation, Because of this background, we examined 38 primary, resected specimens of oral SCCs for detection of p53 mutations and HPV DNAs, Exons 5 through 8 of the p53 gene were examined using the PCR-SSCP method, p53 Mutations were observed in nine cases (24%), HPV-DNA detection and typing were performed using PCR with 'high risk group' HPV-specific primers, HPV DNA sequences were detected in eight cases (21%), The AvaII digestion pattern of PCR-amplified HPV DNA showed that HPV-16 was present in all eight cases, Seven cases were p53 mutation-positive/HPV-negative, six cases were p53 mutation-negative/HPV-positive, and two intraosseus SCC cases were p53 mutation-positive/HPV-positive. Thus, 15/38 (40%) cases had inactivation of the p53 protein. Interestingly, p53 mutation-negative/HPV-negative cases had a poorer prognosis than p53 mutation positive or HPV-positive cases (P<0.01), We conclude that (1) mutation in the p53 gene and/or HPV infection are frequent (40%) in oral SCC; (2) inactivation of p53 function by mutation and HPV infection are important genetic events in the development of 40% similar to of oral SCCs; (3) p53 mutation and HPV infection are not mutually exclusive events and (4) other oncogenes or tumor suppresor genes may be crucial in the development of oral SCC if the prognosis is poor.	HOKKAIDO UNIV, SCH DENT, DEPT ORAL PATHOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH DENT, DEPT DENT RADIOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH ENGN, DEPT INFORMAT SCI, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Hokkaido University; Hokkaido University; Sapporo Medical University	Chiba, I (corresponding author), HOKKAIDO UNIV, SCH DENT,DEPT ORAL SURG 1,KITA KU,KITA-13, NISHI 7, SAPPORO, HOKKAIDO 060, JAPAN.		Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALARAM P, 1995, INT J CANCER, V61, P450, DOI 10.1002/ijc.2910610403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRANDWEIN M, 1994, MODERN PATHOL, V7, P720; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CAAMANO J, 1993, AM J PATHOL, V142, P1131; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; CHANG F, 1994, BRIT J CANCER, V70, P346, DOI 10.1038/bjc.1994.305; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FUJITA M, 1992, CANCER RES, V52, P5323; Gonzalez-Moles M A, 1994, Bull Group Int Rech Sci Stomatol Odontol, V37, P79; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; HERMANEK P, 1987, TNM CLASSIFICATION M, P1; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; LAZARUS P, 1995, INT J CANCER, V60, P458, DOI 10.1002/ijc.2910600406; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIWA K, 1995, BRIT J CANCER, V71, P219, DOI 10.1038/bjc.1995.47; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARK DJ, 1994, ONCOGENE, V9, P205; RIOU G, 1990, LANCET, V335, P1171; SAKAI E, 1992, ONCOGENE, V7, P927; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SAUTER ER, 1992, AM J SURG, V164, P651, DOI 10.1016/S0002-9610(05)80727-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIN DM, 1994, CANCER RES, V54, P321; SOMERS KD, 1992, CANCER RES, V52, P5997; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TASE T, 1988, CANCER RES, V48, P993; VOGELSTEIN B, 1989, RECESSIVE ONCOGENES; WAHI PN, 1971, INT HISTOLOGICAL CLA, P15; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	43	81	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1663	1668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622886				2022-12-25	WOS:A1996UG45800008
J	Catasti, P; Bradbury, EM; Gupta, G				Catasti, P; Bradbury, EM; Gupta, G			Structure and polymorphism of HIV-1 third variable loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRINCIPAL NEUTRALIZING DETERMINANT; ENVELOPE V3 LOOP; CELL TROPISM; ANTIBODIES; SEQUENCE; GLYCOPROTEIN; CONFORMATION; EPITOPE; PROTEIN; DOMAIN	The third variable (V3) loop of HIV-1 surface glycoprotein, gp120, has been the target of neutralizing antibodies, However, sequence variation inside the V3 loop diminishes its effectiveness as a potential vaccine against HIV-1, The elusive nature of the V3 loop structure prompted us to carry out a systematic study on different isolates in an attempt to identify a common structural motif in the V3 loop regardless of the amino acid sequence variability, We have previously determined the structural features of two V3 loops: V3 Thailand and V3 RIN, In this paper, we present the structure of two other variants: V3 Haiti and V3 RF. Our results show that similar secondary structures are observed in all the four V3 loops: a GPG(R/K/Q) crest in the center of the neutralizing domain, two extended regions flanking the central crest, and a helical region in the C-terminal domain, For the Haitian V3 loop, we also show how the conserved structural features are masked through a conformational switch encoded in the amino acid sequences on the C-terminal side of the GPGK crest.	LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Davis					NIAID NIH HHS [R01 AI32891-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032891] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUHABIB DC, 1994, J VIROL, V68, P6006, DOI 10.1128/JVI.68.9.6006-6013.1994; CATASTI P, 1995, J BIOL CHEM, V270, P2224, DOI 10.1074/jbc.270.5.2224; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; EBENBICHLER C, 1993, AIDS, V7, P639, DOI 10.1097/00002030-199305000-00005; FONTENOT JD, 1995, P NATL ACAD SCI USA, V92, P315, DOI 10.1073/pnas.92.1.315; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUPTA G, 1993, J BIOMOL STRUCT DYN, V11, P345, DOI 10.1080/07391102.1993.10508731; GUPTA G, 1990, 5 C CENT GARD PAR, P99; GYER H, 1988, J BIOL CHEM, V263, P11760; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MATHEWS TJ, 1986, P NATL ACAD SCI USA, V83, P9709; MILICH L, 1993, J VIROL, V67, P5623, DOI 10.1128/JVI.67.9.5623-5634.1993; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; ROTERMAN IK, 1989, J BIOMOL STRUCT DYN, V7, P1; STEIMER KS, 1991, SCIENCE, V254, P105, DOI 10.1126/science.1718036; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015; 1994, MOL SURFACE PACKAGE	28	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8236	8242		10.1074/jbc.271.14.8236	http://dx.doi.org/10.1074/jbc.271.14.8236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626517	hybrid			2022-12-25	WOS:A1996UD60000057
J	Savvides, SN; Karplus, PA				Savvides, SN; Karplus, PA			Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION; ERYTHROCYTES; BINDING; ENZYME; MUTAGENESIS; CATALYSIS; MECHANISM; ANALOGS; DRUGS; CDNA	We have determined the crystal structure of a complex between the noncompetitive inhibitor (K-is = 27 mu M, K-ii = 48 mu M with respect to oxidized glutathione (GSSG) and K-is = 144 mu M, K-ii = 176 mu M with respect to NADPH) 6-hydroxy-3-oxo-3H-xanthene-9-propionic acid (XAN) and human glutathione reductase (hGR). The structure, refined to an R-factor of 0.158 at 2.0 Angstrom resolution, reveals XAN bound in the large cavity present at the hGR dimer interface where it does not overlap the glutathione binding site. The inhibitor binding causes extensive local structural changes that primarily involve amino acid residues from a 30-residue alpha-helix that lines the cavity and contributes to the active site of hGR. Despite the lack of physical overlap of XAN with the GSSG binding site, no GSSG binding is seen in soaks carried out with high XAN and GSSG concentrations, suggesting that some subtle interaction between the sites exists. An earlier crystallographic analysis on the complex between hGR and 3,7-diamino-2,8-dimethyl-5-phenyl-phenazinium chloride (safranin) showed that safranin bound at this same site. We have found that safranin also inhibits hGR in a noncompetitive fashion, but it binds about 16 times less tightly (K-is = 453 mu M, K-ii = 586 mu M with respect to GSSG) than XAN and does not preclude the binding of GSSG in the crystal. Although in structure-based drug design competitive inhibitors are usually targetted, XAN's binding to a well defined site that is unique to glutathione reductase suggests that noncompetitive inhibitors could also serve as lead compounds for structure-based drug design, in particular as components of chimeric inhibitors.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University			Savvides, Savvas/E-1938-2011	Savvides, Savvas/0000-0003-3420-5947; Karplus, Paul/0000-0001-8725-6292	NIGMS NIH HHS [1P01GM48874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER K, 1990, BIOCHEM PHARMACOL, V39, P59, DOI 10.1016/0006-2952(90)90648-5; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BUCHELER US, 1992, NUCLEIC ACIDS RES, V20, P3127, DOI 10.1093/nar/20.12.3127; CATTANI J, 1993, 11 WHO; Cleland W W, 1979, Methods Enzymol, V63, P103; CODY V, 1987, ACTA CRYSTALLOGR C, V43, P705, DOI 10.1107/S0108270187094435; DOCAMPO R, 1984, REV INFECT DIS, V6, P223; DUBOST JP, 1981, CR ACAD SCI II, V292, P965; ELLIOTT AJ, 1992, BIOCHEM PHARMACOL, V44, P1603, DOI 10.1016/0006-2952(92)90478-2; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HUNT NH, 1990, BLOOD CELLS, V16, P499; JANES W, 1990, BIOCHEMISTRY-US, V29, P4022, DOI 10.1021/bi00468a033; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; KAUVAR LM, 1995, CHEM BIOL, V2, P107, DOI 10.1016/1074-5521(95)90283-X; KIRSCH P, 1994, LIEBIGS ANN, P1275; KROHNEEHRICH G, 1977, EUR J BIOCHEM, V80, P65, DOI 10.1111/j.1432-1033.1977.tb11856.x; MULLER JG, 1993, CELL MOL BIOL, V39, P389; NORDHOFF A, 1993, BIOCHEMISTRY-US, V32, P4060, DOI 10.1021/bi00066a029; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAI EF, 1983, J BIOL CHEM, V258, P1752; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; RACKER E, 1955, METHOD ENZYMOL, V2, P722, DOI 10.1016/S0076-6879(55)02291-X; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Schirmer R H, 1987, Free Radic Res Commun, V3, P3, DOI 10.3109/10715768709069763; Schirmer R. H., 1989, GLUTATHIONE CHEM B A, P553; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; WORTHINGTON DJ, 1974, EUR J BIOCHEM, V48, P167, DOI 10.1111/j.1432-1033.1974.tb03754.x	36	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8101	8107		10.1074/jbc.271.14.8101	http://dx.doi.org/10.1074/jbc.271.14.8101			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626496	hybrid			2022-12-25	WOS:A1996UD60000036
J	Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF				Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF			UVB radiation induces p21(Cip1/WAF1) and mediates G1 and S phase checkpoints	ONCOGENE			English	Review						cell cycle; checkpoint; p21(Cip1/WAF1); cyclin G; UVB irradiation	CELL-CYCLE CHECKPOINT; NORMAL HUMAN-SKIN; WILD-TYPE P53; PYRIMIDINE DIMERS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; RAT KERATINOCYTES; DEPENDENT KINASE; DNA-REPLICATION; CDK2 ACTIVITY	In a search for effecters and targets of UVB signaling in mammalian cells, we screened a keratinocyte cDNA library with differentially subtracted UVB-enriched cDNA probes. One of the UVB induced cDNA clones proved to be the rat p21(Cip1/WAF1) homologue. UVB irradiation caused a rise in p53 protein levels, in association with induction of p21(Cip1/WAF1) and cyclin G expression. The effects of UVB irradiation induced p21(Cip1/WAF1) on the cell cycle were examined. In contrast to gamma irradiation, which caused G2 arrest, UVB treatment of asynchronous neonatal rat keratinocytes (NK) led to a marked inhibition of replicative DNA synthesis and prolonged G1 and S phase arrests, persisting to 18-24 h, with recovery of cycling by 36 h post-UVB. G1 arrest was accompanied by inhibition of cyclin D-, E- and A-associated kinases. Kinase inhibition was not due to reduction in cyclin or cdk proteins. While the association of cyclin E with Cdk2 was moderately reduced, cyclin D1/Cdk4 and cyclin A/Cdk2 complexes were not disrupted. The activating threonine 160 phosphorylation of Cdk2 in cyclin complexes was not inhibited. An incremental binding of p21 with Cdk4 paralleled the inhibition of cyclin D1/Cdk4 kinase and a similar rise in Cdk2 binding to p21 was associated with inhibition of cyclin E and cyclin A dependent kinases. Furthermore, a rise in measurable p21(Cip1/WAF1)-Cdk2 inhibitory activity paralleled the loss of G1 cyclin-dependent kinase activity, supporting a role for p21(Cip1/WAF1) in the UVB-induced checkpoints.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED & CLIN BIOCHEM, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1B2, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto			Drucker, Daniel J/A-4092-2010					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; CANMAN CE, 1994, CANCER RES, V54, P5054; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMON M, 1968, RADIAT RES, V35, P350, DOI 10.2307/3572382; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLISON MJ, 1981, PHOTOCHEM PHOTOBIOL, V34, P465, DOI 10.1111/j.1751-1097.1981.tb09026.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREEMAN SE, 1988, J INVEST DERMATOL, V90, P814, DOI 10.1111/1523-1747.ep12462039; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1993, ONCOGENE, V8, P203; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romerdahl C A, 1989, Cancer Commun, V1, P209; ROSEN CF, 1990, CANCER RES, V50, P2631; ROSEN CF, 1992, AM J PHYSIOL, V263, pC1103, DOI 10.1152/ajpcell.1992.263.5.C1103; ROSEN CF, 1995, AM J PHYSIOL-CELL PH, V268, pC846, DOI 10.1152/ajpcell.1995.268.4.C846; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SMITH ML, 1995, ONCOGENE, V10, P1053; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TAMURA K, 1993, ONCOGENE, V8, P2113; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZOLZER F, 1984, PHOTOCHEM PHOTOBIOL, V40, P49, DOI 10.1111/j.1751-1097.1984.tb04552.x	112	82	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1387	1396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622854				2022-12-25	WOS:A1996UF07600002
J	Locati, M; Lamorte, G; Luini, W; Introna, M; Bernasconi, S; Mantovani, A; Sozzani, S				Locati, M; Lamorte, G; Luini, W; Introna, M; Bernasconi, S; Mantovani, A; Sozzani, S			Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONATE-MOBILIZING PHOSPHOLIPASE-A2; ACTIVATING FACTOR MCAF; CELL-LINE; PHOSPHORYLATION; EXPRESSION; ACID; PURIFICATION; MACROPHAGES; NEUTROPHILS	Monocyte chemotactic protein (MCP)-1, a member of the C-C (or beta) branch of the chemokine superfamily, at chemotactic concentrations, induced a rapid release of [H-3]arachidonic acid but not of [C-14]oleic acid from prelabeled human monocytes. This effect was associated with an increase in the intensity of the immunoreactive band corresponding to the phosphorylated form of cytosolic phospholipase A(2) (cPLA(2)). To address the role of cPLA(2) in the induction of monocyte chemotaxis, cells were treated with a specific antisense oligonucleotide. Monocytes cultured in the presence of 10 mu M antisense oligonucleotide for 48 h showed a marked decrease (57 +/- 5%; n = 4) of cPLA(2) expression, as evaluated by Western blot analysis and a nearly complete inhibition (81.8 +/- 4.2%; n = 3) of [H-3]arachidonic acid release in MCP-1-stimulated cells. Monocyte chemotaxis in response to MCP-1 also was inhibited in a concentration-dependent manner by cPLA(2) antisense oligonucleotide (IC50 = 1.9 +/- 1.1 mu M; n = 3), with complete inhibition observed between 3 and 10 mu M. No inhibition of chemotactic response was observed in monocytes treated with a control oligonucleotide. Monocyte migration in response to MCP-3, RANTES (regulated on activation normal T cells expressed and secreted), and MIP-1 alpha/LD78 also was inhibited (>70%) in antisense oligonucleotide-treated cells. On the contrary, the chemotactic response elicited by formyl-methionyl-leucyl-phenylalanine and C5a, two ''classical'' chemotactic agonists, was minimally affected (<20%) by antisense oligonucleotide treatment. These data show that cPLA(2) plays a major role in [H-3]arachidonic acid release by MCP-1 in human monocytes and provide direct evidence for the involvement of cPLA(2) in C-C chemokine-induced monocyte chemotaxis.	IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY; UNIV BRESCIA,DEPT BIOTECHNOL,SECT PATHOL & IMMUNOL,I-25123 BRESCIA,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Brescia			Mantovani, Alberto/HCI-7449-2022; Locati, Massimo/ABF-6807-2021; Sozzani, Silvano/C-1447-2009; Introna, Martino/AAA-5823-2019; Locati, Massimo/H-8404-2015	Mantovani, Alberto/0000-0001-5578-236X; Sozzani, Silvano/0000-0002-3144-8743; Introna, Martino/0000-0001-6216-0892; Locati, Massimo/0000-0003-3077-590X; Lamorte, Giuseppe/0000-0001-9377-7537				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ARSURA M, 1992, BLOOD, V79, P2708; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P99; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BOLOGNESE B, 1995, BBA-LIPID LIPID MET, V1256, P201, DOI 10.1016/0005-2760(95)00023-6; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FRANCI C, 1995, J IMMUNOL, V154, P6511; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P2640, DOI 10.1073/pnas.76.6.2640; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LEFKOWITH JB, 1992, J IMMUNOL, V149, P1729; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCPHAIL LC, 1993, NATURAL IMMUNE SYSTE, P63; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NACCACHE PH, 1985, J BIOL CHEM, V260, P2125; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PERI G, 1994, J IMMUNOL METHODS, V174, P249, DOI 10.1016/0022-1759(94)90029-9; QIU ZH, 1993, J BIOL CHEM, V268, P24506; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SA G, 1994, J BIOL CHEM, V269, P3219; SCHALL TJ, 1994, CYTOKINE HDB, P419; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; SOZZANI S, 1994, BIOCHEM BIOPH RES CO, V199, P761, DOI 10.1006/bbrc.1994.1294; SOZZANI S, 1995, J IMMUNOL, V155, P3292; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WAITE M, 1987, PHOSPHOLIPASES, P111; WANG JM, 1993, CYTOKINE, V5, P264, DOI 10.1016/1043-4666(93)90014-V; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; XU XX, 1994, J BIOL CHEM, V269, P31693; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	62	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6010	6016		10.1074/jbc.271.11.6010	http://dx.doi.org/10.1074/jbc.271.11.6010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626384	hybrid			2022-12-25	WOS:A1996UA36300013
J	Buchko, GW; Treleaven, WD; Dunne, SJ; Tracey, AS; Cushley, RJ				Buchko, GW; Treleaven, WD; Dunne, SJ; Tracey, AS; Cushley, RJ			Structural studies of a peptide activator of human lecithin-cholesterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; APOLIPOPROTEIN-A-I; AMPHIPATHIC HELIX; CIRCULAR-DICHROISM; MEMBRANE-PROTEINS; NMR-SPECTROSCOPY; ION-PAIRS; ANALOGS; ASSOCIATION; SPECTRA	The synthetic lipid-associating peptide, LAP-20 (VSSLLSSLKEYWSSLKESFS), activates lecithin-cholesterol acyltransferase (LCAT) despite its lack of sequence homology to apolipoprotein A-I, the primary in vivo activator of LCAT. Using SDS and dodecylphosphocholine (DPC) to model the lipoprotein environment, the structural features responsible for LAP-20's ability to activate LCAT were studied by optical and two-dimensional H-1 NMR spectroscopy. A large blue shift in the intrinsic fluorescence of LAP-20 with the addition of detergent suggested that the peptide formed a complex with the micelles, Analysis of the CD data shows that LAP-20 lacks well defined structure in aqueous solution but adopts helical, ordered conformations upon the addition of SDS or DPC. The helical nature of the peptides in the presence of both lipids was confirmed by upfield H-alpha NMR secondary shifts relative to random coil values. Average structures for both peptides in aqueous solutions containing SDS and DPC were generated using distance geometry methods from 329 (SDS) and 309 (DPC) nuclear Overhauser effect-based distance restraints. The backbone (N, C-alpha, C=O) RMSD from the average structure of an ensemble of 17 out of 20 calculated structures was 0.41 +/- 0.15 Angstrom for LAP-20 in SDS and 0.41 +/- 0.12 Angstrom for an ensemble of 20 out of 20 calculated structures for LAP-20 in DPC. In the presence of SDS, the distance geometry and simulated annealing calculations show that LAP-20 adopts a well defined class A amphipathic helix with distinct hydrophobic and hydrophilic faces. A similar structure was obtained for LAP-20 in the presence of DPC, suggesting that both detergents may be used interchangeably to model the lipoprotein environment. Conformational features of the calculated structures for LAP-20 are discussed relative to models for apolipoprotein A-I activation of LCAT.	SIMON FRASER UNIV,INST BIOCHEM & MOLEC BIOL,BURNABY,BC V5A 1S6,CANADA; SIMON FRASER UNIV,DEPT CHEM,BURNABY,BC V5A 1S6,CANADA	Simon Fraser University; Simon Fraser University			Buchko, Garry/G-6173-2015	Buchko, Garry/0000-0002-3639-1061				ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BAIRAKTARI E, 1990, BIOCHEMISTRY-US, V29, P10090, DOI 10.1021/bi00495a011; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUCH MD, 1991, PROTEINS, V10, P130, DOI 10.1002/prot.340100206; BUCHKO GW, 1995, PEPTIDE RES, V8, P86; CHUNG BH, 1985, J BIOL CHEM, V260, P256; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; EPAND RM, 1987, J BIOL CHEM, V262, P9389; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FITTON JE, 1981, FEBS LETT, V130, P257, DOI 10.1016/0014-5793(81)81133-7; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; HARA H, 1991, J BIOL CHEM, V266, P3080; HENNESSEY JP, 1982, ANAL BIOCHEM, V125, P177, DOI 10.1016/0003-2697(82)90400-6; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONAS A, 1986, J LIPID RES, V27, P689; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KANELLIS P, 1980, J BIOL CHEM, V255, P1464; KARSLAKE C, 1990, BIOCHEMISTRY-US, V29, P9872, DOI 10.1021/bi00494a017; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; MCDONNELL PA, 1993, J MAGN RESON SER B, V102, P120, DOI 10.1006/jmrb.1993.1073; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MILLER GJ, 1975, LANCET, V1, P16; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PONSIN G, 1986, J BIOL CHEM, V261, P9202; POWNALL HJ, 1984, BIOCHIM BIOPHYS ACTA, V793, P149, DOI 10.1016/0005-2760(84)90316-3; POWNALL HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3154, DOI 10.1073/pnas.77.6.3154; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROZEK A, 1995, BIOCHEMISTRY-US, V34, P7401, DOI 10.1021/bi00022a013; SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1977, CHEM PHYS LIPIDS, V18, P1; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SPARROW JT, 1982, CRC CR REV BIOCH MOL, V13, P87, DOI 10.3109/10409238209108710; SUBBARAO NK, 1988, PROTEINS, V3, P187, DOI 10.1002/prot.340030307; WILSON JC, 1994, BIOCHEMISTRY-US, V33, P6802, DOI 10.1021/bi00188a008; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; WU CSC, 1978, BIOCHEM BIOPH RES CO, V82, P85, DOI 10.1016/0006-291X(78)90580-6; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZHONG Q, 1994, PEPTIDE RES, V7, P99	59	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3039	3045		10.1074/jbc.271.6.3039	http://dx.doi.org/10.1074/jbc.271.6.3039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621698	hybrid			2022-12-25	WOS:A1996TU69100027
J	Bizouarn, T; Diggle, C; Quirk, PG; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB				Bizouarn, T; Diggle, C; Quirk, PG; Grimley, RL; Cotton, NPJ; Thomas, CM; Jackson, JB			Interaction of nucleotides with the NAD(H)-binding domain of the proton-translocating transhydrogenase of Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NICOTINAMIDE; MITOCHONDRIA; KINETICS; ENZYME	Transhydrogenase catalyzes the reduction of NADP(+) by NADH coupled to the translocation of protons across a membrane. The polypeptide composition of the enzyme in Rhodospirillum rubrum is unique in that the NAD(H)-binding domain (called Th-s) exists as a separate polypeptide. Th-s was expressed in Escherichia coli and purified. The binding of nucleotide substrates and analogues to Th-s was examined by one dimensional proton nuclear magnetic resonance (NMR) spectroscopy and by measuring the quenching of fluorescence of its lone Trp residue. NADH and reduced acetylpyridine adenine dinucleotide bound tightly to Th-s, whereas NAD(+), oxidized acetylpyridine adenine dinucleotide, deamino-NADH, 5'-AMP and adenosine bound less tightly. Reduced nicotinamide mononucleotide, NADPH and 2'-AMP bound only very weakly to Th-s. The difference in the binding affinity between NADH and NAD(+) indicates that there may be an energy requirement for the transfer of reducing equivalents into this site in the complete enzyme under physiological conditions. Earlier results had revealed a mobile loop at the surface of Th-s (Diggle, C., Cotton, N. P. J., Grimley, R. L., Quirk, P. G., Thomas, C. M., and Jackson, J. B. (1995) Eur. J. Biochem. 232, 315-326); the loop loses mobility when Th-s binds nucleotide; the reaction involves two steps. This was more clearly evident, even for tight-binding nucleotides, when experiments were carried out at higher temperatures (37 degrees C), where the resonances of the mobile loop were substantially narrower. The binding of adenosine was sufficient to initiate loop closure; the presence of a reduced nicotinamide moiety in the dinucleotide apparently serves to tighten the binding. Two-dimensional 1(H) NMR spectroscopy of the Th-s-5'-AMP complex revealed nuclear Overhauser effect interactions between protons of amino acid residues in the mobile loop (including those in a Tyr residue) and the nucleotide. This suggests that, in the complex, the loop has closed down to within 0.5 nm of the nucleotide.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH BIOL SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Thomas, Christopher M/J-8258-2017; bizouarn, tania/W-6782-2019	Thomas, Christopher M/0000-0002-2810-0455; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; BIZOUARN T, 1996, IN PRESS BIOCH BIOPH; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, J BIOL CHEM, V271, P10109, DOI 10.1074/jbc.271.17.10109; ENANDER K, 1982, J BIOL CHEM, V257, P4760; FISHER RR, 1971, J BIOL CHEM, V246, P4679; FJELLSTROM O, 1995, PROTEINS, V21, P91, DOI 10.1002/prot.340210203; GALANTE YM, 1980, J BIOL CHEM, V255, P9641; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HANSON RL, 1979, J BIOL CHEM, V254, P888; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOMYK M, 1979, BIOCHIM BIOPHYS ACTA, V571, P201, DOI 10.1016/0005-2744(79)90091-3; HU X, 1995, BBA-BIOENERGETICS, V1229, P64, DOI 10.1016/0005-2728(94)00187-A; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; JACKSON JB, 1991, J BIOENERG BIOMEMBR, V23, P715, DOI 10.1007/BF00785998; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; OLAUSSON T, 1995, BBA-BIOENERGETICS, V1231, P1, DOI 10.1016/0005-2728(95)00058-Q; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SAZANOV LA, 1995, BBA-BIOENERGETICS, V1231, P304; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784	28	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10103	10108		10.1074/jbc.271.17.10103	http://dx.doi.org/10.1074/jbc.271.17.10103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626568	hybrid			2022-12-25	WOS:A1996UG25700040
J	Teichmann, U; vanDyck, L; Guiard, B; Fischer, H; Glockshuber, R; Neupert, W; Langer, T				Teichmann, U; vanDyck, L; Guiard, B; Fischer, H; Glockshuber, R; Neupert, W; Langer, T			Substitution of PIM1 protease in mitochondria by Escherichia coli Lon protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; PRECURSOR PROTEIN; LA; BACTERIAL; IMPORT; PROTEOLYSIS; HYDROLYSIS; GENE; DEGRADATION; PRODUCT	PIM1 protease in mitochondria belongs to a conserved family of ATP-dependent proteases, which includes the Escherichia coli Lon protease. Yeast cells lacking PIM1 are largely defective in degrading misfolded proteins in the mitochondrial matrix, are respiratory deficient, and lose integrity of mitochondrial DNA. In order to analyze whether E. coli Lon protease is functionally equivalent to mitochondrial PIM1 protease, yeast cells lacking the PIM1 gene were transformed with a construct consisting of a mitochondrial targeting sequence fused onto the Lon protease. In these cells, the fusion protein was expressed and imported into mitochondria, and the targeting sequence was removed. In the absence of PIM1 protease, the E. coli Lon protease mediated the degradation of misfolded proteins in the matrix space in cooperation with the mitochondrial hsp70 system. These cells maintained the integrity of the mitochondrial genome and the respiratory function at 30 degrees C but not at 37 degrees C. Stabilization of mitochondrial DNA in Delta pim1 cells depended on protein degradation by the E. coli Lon protease, as a proteolytically inactive Lon variant was not capable of substituting for a loss of PIM1 protease. These results demonstrate functional conservation of Lon-like proteases from prokaryotes to eukaryotes and shed new light on the role of Lon-like proteases in mitochondrial biogenesis.	UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY; UNIV PARIS 06, CTR GENET MOLEC, CNRS, F-91190 GIF SUR YVETTE, FRANCE; ETH HONGGERBERG, INST MOLEK BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Swiss Federal Institutes of Technology Domain; ETH Zurich				Langer, Thomas/0000-0003-1250-1462				AMERIK AY, 1994, FEBS LETT, V340, P25, DOI 10.1016/0014-5793(94)80166-5; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; FISCHER H, 1993, J BIOL CHEM, V268, P22502; FISCHER H, 1994, FEBS LETT, V356, P101, DOI 10.1016/0014-5793(94)01244-X; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERRMANN JM, 1994, CELL BIOL LAB HDB; KOL H, 1991, THESIS U MUNCHEN; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; ROSE MD, 1993, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1993, METHODS, V5, P78; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; WATABE S, 1985, J BIOL CHEM, V260, P4498; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	36	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10137	10142		10.1074/jbc.271.17.10137	http://dx.doi.org/10.1074/jbc.271.17.10137			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626573	hybrid			2022-12-25	WOS:A1996UG25700045
J	Kim, S; Burgess, BK				Kim, S; Burgess, BK			Evidence for the direct interaction of the nifW gene product with the MoFe protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; AZORHIZOBIUM-CAULINODANS ORS571; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; NITROGEN-FIXATION; CRYSTALLOGRAPHIC STRUCTURE; NUCLEOTIDE-SEQUENCE; FIXABC REGION; IDENTIFICATION; COMPLEX	The Azotobacter vinelandii nifW gene, under control of the nifH promoter, was subcloned into the broad host range multicopy plasmid pKT230 for overexpression in both wild-type and Delta nifW strains of A. vinelandii, Unlike the parent Delta nifW strain, which grows slowly relative 60 wild-type under N-2-fixing conditions, both overproduction strains grow at the same rate, showing that the overexpressed nifW product is functional in vivo. The similar to 40-fold overexpressed protein was purified, and sequence analysis confirmed its identity, During purification it was observed that NifW in crude extracts ran above the predicted molecular weight on denaturing gels and that as the purification proceeded lower molecular weight forms appeared, Mass spectrometry and studies with protease inhibitors revealed that this abnormal behavior was due to proteolysis, Native molecular weight determinations demonstrate that NifW is a homomultimer, most likely a trimer, Native gel electrophoresis analysis shows that the behavior of wild-type and overexpressed NifW are identical and that when extracts are prepared anaerobically only the homomultimeric forms of NifW are observed. When extracts are exposed to oxygen, however, NifW becomes part of a very high molecular weight complex, Immunoprecipitation with NifW antibodies demonstrate that under those conditions NifW specifically associates with the MoFe protein, These data are consistent with a model whereby NifW is not involved in the initial assembly of an active MoFe protein but rather is part of a system design to protect the MoFe protein from O-2 damage.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [R01-GM43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; BURGESS BK, 1993, ACS SYM SER, V535, P144; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GALLON JR, 1992, NEW PHYTOL, V122, P571; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GOLIGAN JE, 1994, CURRENT PROTOCOLS IM; GOVEZENSKY D, 1991, J BACTERIOL, V173, P6339, DOI 10.1128/jb.173.20.6339-6346.1991; HAAKER H, 1977, EUR J BIOCHEM, V77, P1, DOI 10.1111/j.1432-1033.1977.tb11634.x; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HOOVER T R, 1988, Biofactors, V1, P199; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; KAVANAGH EP, 1993, J GEN MICROBIOL, V139, P1307, DOI 10.1099/00221287-139-6-1307; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KIM S, 1994, J BIOL CHEM, V269, P4215; KIM SY, 1995, THESIS U CALIFORNIA; LIANG JH, 1990, BIOCHEMISTRY-US, V29, P8577, DOI 10.1021/bi00489a011; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MILCAMPS A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P237, DOI 10.1016/0167-4781(93)90188-J; MOSHIRI F, 1994, MOL MICROBIOL, V14, P101, DOI 10.1111/j.1365-2958.1994.tb01270.x; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAUL W, 1989, EUR J BIOCHEM, V178, P675, DOI 10.1111/j.1432-1033.1989.tb14497.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBSON RL, 1979, BIOCHEM J, V181, P569, DOI 10.1042/bj1810569; SCHERINGS G, 1983, EUR J BIOCHEM, V135, P591, DOI 10.1111/j.1432-1033.1983.tb07693.x; SHAH VK, 1983, J BIOL CHEM, V258, P2064; THORNELEY RNF, 1992, BIOCHEMISTRY-US, V31, P1216, DOI 10.1021/bi00119a035; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; WANG ZC, 1985, BIOCHEMISTRY-US, V24, P214, DOI 10.1021/bi00322a031; Yates M. G., 1992, BIOL NITROGEN FIXATI, P685; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	40	17	19	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9764	9770		10.1074/jbc.271.16.9764	http://dx.doi.org/10.1074/jbc.271.16.9764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621656	hybrid			2022-12-25	WOS:A1996UG04400087
J	Mukai, H; Toshimori, M; Shibata, H; Kitagawa, M; Shimakawa, M; Miyahara, M; Sunakawa, H; Ono, Y				Mukai, H; Toshimori, M; Shibata, H; Kitagawa, M; Shimakawa, M; Miyahara, M; Sunakawa, H; Ono, Y			PKN associates and phosphorylates the head-rod domain of neurofilament protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT NETWORKS; GTP-BINDING-PROTEIN; KINASE-C; NF-M; REGULATORY DOMAIN; VIMENTIN SUBUNITS; ADP-RIBOSYLATION; SPINAL-CORD; RHO; EXPRESSION	PKN is a fatty acid-activated serine/threonine kinase that has a catalytic domain highly homologous to that of protein kinase C in the carboxyl terminus and a unique regulatory region in the amino terminus. Recently, we reported that the small GTP-binding protein Rho binds to the amino-terminal region of PKN and activates PKN in a GTP-dependent manner, and we suggested that PKN is located on the downstream of Rho in the signal transduction pathway (Amano, M., Mukai, H., Ono, Y., Chihara, K., Matsui, T., Hamajima, Y., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 271, 648-650; Watanabe, G., Saito, Y., Madaule, P., Ishizaki, T., Fujisawa, K., Morii, N., Mukai, H., Ono, Y. Kakizuka, A., and Narumiya, S. (1996) Science 271, 645-648). To identify other components of the PKN pathway such as substrates and regulatory proteins of PKN, the yeast two-hybrid strategy was employed. By this screening, a clone encoding the neurofilament L protein, a subunit of neuron-specific intermediate filament, was isolated. The amino-terminal regulatory region of PKN was shown to associate with the head-rod domains of other subunits of neurofilament (neurofilament proteins M and H) as well as neurofilament L protein in yeast cells. The direct binding between PKN and each subunit of neurofilament was confirmed by using the in vitro translated amino-terminal region of PKN and glutathione S-transferase fusion protein containing the head-rod domain of each subunit of neurofilament. PKN purified from rat testis phosphorylated each subunit of the native neurofilament purified from bovine spinal cord and the bacterially synthesized head-rod domain of each subunit of neurofilament. Polymerization of neurofilament L protein in vitro was inhibited by phosphorylation of neurofilament L protein by PKN. The identification and characterization of the novel interaction with PKN may contribute toward the elucidation of mechanisms regulating the function of neurofilament.	KOBE UNIV,FAC SCI,DEPT BIOL,NADA KU,KOBE 657,JAPAN	Kobe University			Kitagawa, Michinori/B-1792-2013	Kitagawa, Michinori/0000-0003-1660-6421; Toshimori, Masanao/0000-0003-3869-7790; Mukai, Hideyuki/0000-0002-0167-8695				ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DOSEMECI A, 1992, BIOCHEM J, V282, P477, DOI 10.1042/bj2820477; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HOLLANDER BA, 1992, BRAIN RES, V599, P237, DOI 10.1016/0006-8993(92)90397-R; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JULIEN JP, 1981, J NEUROCHEM, V37, P1579, DOI 10.1111/j.1471-4159.1981.tb06330.x; KAUFMANN E, 1984, FEBS LETT, V170, P81, DOI 10.1016/0014-5793(84)81373-3; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; MILLER RK, 1991, J CELL BIOL, V113, P843, DOI 10.1083/jcb.113.4.843; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORII N, 1992, J BIOL CHEM, V267, P20921; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUNGE MS, 1981, BIOCHEMISTRY-US, V20, P175, DOI 10.1021/bi00504a029; SCOTT D, 1985, J BIOL CHEM, V260, P736; SHECKET G, 1982, J BIOL CHEM, V257, P4788; SIHAG RK, 1989, J BIOL CHEM, V264, P457; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TORUDELBAUFFE D, 1986, BIOCHEM J, V235, P283, DOI 10.1042/bj2350283; TORUDELBAUFFE D, 1983, FEBS LETT, V162, P230, DOI 10.1016/0014-5793(83)80761-3; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WAYS K, 1991, J BIOL CHEM, V266, P1258; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XIAO JS, 1994, J NEUROSCI, V14, P1820, DOI 10.1523/JNEUROSCI.14-03-01820.1994; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	67	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9816	9822		10.1074/jbc.271.16.9816	http://dx.doi.org/10.1074/jbc.271.16.9816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621664	hybrid			2022-12-25	WOS:A1996UG04400095
J	Wollert, KC; Taga, T; Saito, M; Narazaki, M; Kishimoto, T; Glembotski, CC; Vernallis, AB; Heath, JK; Pennica, D; Wood, WI; Chien, KR				Wollert, KC; Taga, T; Saito, M; Narazaki, M; Kishimoto, T; Glembotski, CC; Vernallis, AB; Heath, JK; Pennica, D; Wood, WI; Chien, KR			Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy - Assembly of sarcomeric units in series via gp130 leukemia inhibitory factor receptor-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MYOSIN LIGHT CHAIN-2; IL-6 SIGNAL TRANSDUCER; RAT MYOCARDIAL-CELLS; SERUM GROWTH-FACTORS; GENE-EXPRESSION; CNTF RECEPTOR; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; ALPHA COMPONENT	Cardiotrophin-1 (CT-1) was recently isolated by expression cloning based on its ability to induce an increase in cell size in neonatal rat ventricular cardiomyocytes. Sequence similarity data suggested that CT-1 is a novel member of a family of structurally related cytokines sharing the receptor component gp130. The present study documents that gp130 is required for CT-1 signaling in cardiomyocytes, by demonstrating that a monoclonal anti-gp130 antibody completely inhibits c-fos induction by CT-1, Similarly, a leukemia inhibitory factor receptor subunit beta (LLFR beta) antagonist effectively blocks the CT-1 induction of c-fos, indicating a requirement for LIFR beta in the hypertrophic response, as well, Upon stimulation with CT-1, both gp130 and the LIFR beta are tyrosine-phosphorylated, providing further evidence that CT-1 signals through the gp130/LIFR beta heterodimer in cardiomyocytes, CT-1 induces a hypertrophic response in cardiomyocytes that is distinct from the phenotype seen after alpha-adrenergic stimulation, both with regard to cell morphology and gene expression pattern, Stimulation with CT-1 results in an increase in cardiac cell size that is characterized by an increase in cell length but no significant change in cell width. Confocal laser microscopy of CT-1 stimulated cells reveals the assembly of sarcomeric units in series rather than in parallel, as seen after alpha-adrenergic stimulation. CT-1 induces a distinct pattern of immediate early genes, and up-regulates the atrial natriuretic factor (ANF) gene, but does not affect skeletal alpha-actin or myosin light chain-av expression, As evidenced by nuclear run-on transcription assays, both CT-1 and alpha-adrenerse stimulation lead to an increase in ANF gene transcription, Transient transfection analyses document that, in contrast to alpha-adrenergic stimulation, the CT-1 responsive cis-regulatory elements are located outside of the proximal 3 kilobase pairs of the ANF 5'-flanking region. These studies indicate that CT-I can activate a distinct form of myocardial cell hypertrophy, characterized by the promotion of sarcomere assembly in series, via gp130/LIFR beta-dependent signaling pathways.	UNIV CALIF SAN DIEGO,DEPT MED,CTR GENET MOLEC,SCH MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,AMER HEART ASSOC,BUGHER FDN CTR MOLEC BIOL,LA JOLLA,CA 92093; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,OSAKA,JAPAN; SAN DIEGO STATE UNIV,DEPT MOLEC BIOL,SAN DIEGO,CA 92182; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; GENENTECH INC,DEPT BIOL MOLEC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Diego; University of California System; University of California San Diego; Osaka University; Osaka University; California State University System; San Diego State University; University of Oxford; Roche Holding; Genentech			Kishimoto, Tadamitsu/C-8470-2009	narazaki, masashi/0000-0002-5613-4409	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051549, P01HL046345, P50HL053773] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL46345, 1 RO1 HL51549, HL53773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ANVERSA P, 1983, CIRC RES, V52, P57, DOI 10.1161/01.RES.52.1.57; ANVERSA P, 1986, J AM COLL CARDIOL, V7, P1140, DOI 10.1016/S0735-1097(86)80236-4; BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GERDES AM, 1988, LAB INVEST, V59, P857; GLEMBOTSKI CC, 1987, ENDOCRINOLOGY, V121, P843, DOI 10.1210/endo-121-3-843; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; HARGROVE JL, 1993, FASEB J, V7, P1163, DOI 10.1096/fasebj.7.12.8375615; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRATA Y, 1989, J IMMUNOL, V143, P2900; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; LEE HR, 1988, J BIOL CHEM, V263, P7352; LIM RW, 1987, ONCOGENE, V1, P263; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MORKIN E, 1970, SCIENCE, V167, P1499, DOI 10.1126/science.167.3924.1499; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; ROBERTSON M, 1993, DEV GENET, V14, P165, DOI 10.1002/dvg.1020140303; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SEIDMAN CE, 1984, SCIENCE, V225, P324, DOI 10.1126/science.6234658; SEIDMAN CE, 1991, CAN J PHYSIOL PHARM, V69, P1486, DOI 10.1139/y91-223; SHANI M, 1981, NUCLEIC ACIDS RES, V9, P579, DOI 10.1093/nar/9.3.579; Sheng ZL, 1996, DEVELOPMENT, V122, P419; SHIELDS PP, 1988, J BIOL CHEM, V263, P8091; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555	69	312	328	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9535	9545		10.1074/jbc.271.16.9535	http://dx.doi.org/10.1074/jbc.271.16.9535			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621626	hybrid, Green Accepted			2022-12-25	WOS:A1996UG04400057
J	Murshudov, GN; Grebenko, AI; Barynin, V; Dauter, Z; Wilson, KS; Vainshtein, BK; MelikAdamyan, W; Bravo, J; Ferran, JM; Ferrer, JC; Switala, J; Loewen, PC; Fita, I				Murshudov, GN; Grebenko, AI; Barynin, V; Dauter, Z; Wilson, KS; Vainshtein, BK; MelikAdamyan, W; Bravo, J; Ferran, JM; Ferrer, JC; Switala, J; Loewen, PC; Fita, I			Structure of the heme d of Penicillium vitale and Escherichia coli catalases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTHETIC GROUP; 3-DIMENSIONAL STRUCTURE; LIVER CATALASE; RESOLUTION; HPII	A heme d prosthetic group with the configuration of a cis-hydroxychlorin gamma-spirolactone has been found in the crystal structures of Penicillium vitale catalase and Escherichia coli catalase hydroperoxidase II (HPII), The absolute stereochemistry of the two heme d chiral carbon atoms has been shown to be identical, For both catalases the heme d is rotated 180 degrees about the axis defined by the alpha-gamma-meso carbon atoms, with respect to the orientation found for heme b in beef liver catalase, Only six residues in the heme pocket, preserved in P. vitale and HPII, differ from those found in the bovine catalase, In the crystal structure of the inactive N201H variant of HPII catalase the prosthetic group remains as heme b, although its orientation is the same as in the wild type enzyme, These structural results confirm the observation that heme d is formed from protoheme in the interior of the catalase molecule through a self-catalyzed reaction.	RUSSIAN ACAD SCI, INST CRYSTALLOG, MOSCOW 117333, RUSSIA; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND; DESY, EUROPEAN MOLEC BIOL LAB, D-22603 HAMBURG, GERMANY; UNIV POLITECN CATALUNYA, DEPT ENGN QUIM, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, FAC QUIM, DEPT BIOQUIM & BIOL MOLEC, E-08028 BARCELONA, SPAIN; UNIV MANITOBA, DEPT MICROBIOL, WINNIPEG, MB R3T 2N2, CANADA	Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of York - UK; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Universitat Politecnica de Catalunya; University of Barcelona; University of Manitoba			Bravo, Jeronimo/K-9103-2014; Fita, Ignasi/R-4515-2019; Ferrer, Joan C./AAP-2145-2021	Bravo, Jeronimo/0000-0001-6695-2846; Fita, Ignasi/0000-0002-7521-2679; Ferrer, Joan C./0000-0003-1212-5161; Wilson, Keith/0000-0002-3581-2194				ANDERSSON LA, 1987, J AM CHEM SOC, V109, P258, DOI 10.1021/ja00235a039; BARKIGIA KM, 1991, J AM CHEM SOC, V113, P7445, DOI 10.1021/ja00019a065; BRAVO J, 1995, STRUCTURE, V3, P491, DOI 10.1016/S0969-2126(01)00182-4; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHAGA GS, 1992, J CHROMATOGR, V604, P177, DOI 10.1016/0021-9673(92)85542-2; CHANG JY, 1972, ARCH BIOCHEM BIOPHYS, V148, P505, DOI 10.1016/0003-9861(72)90169-5; CHIU JT, 1989, J AM CHEM SOC, V111, P7046, DOI 10.1021/ja00200a023; CROSSLEY MJ, 1986, J AM CHEM SOC, V108, P3608, DOI 10.1021/ja00273a010; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GOUET P, 1995, J MOL BIOL, V249, P933, DOI 10.1006/jmbi.1995.0350; GULYI MF, 1975, DOKL AKAD NAUK SSSR+, V225, P211; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; JACOB GS, 1979, BIOCHEMISTRY-US, V18, P2975, DOI 10.1021/bi00581a010; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LESLIE AGW, NEWSLETTER PROTEIN C; LLOYD E, 1994, BIOCHEMISTRY-US, V33, P11432, DOI 10.1021/bi00204a005; LOEWEN PC, 1993, BIOCHEMISTRY-US, V32, P10159, DOI 10.1021/bi00089a035; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; MYRONENKO NI, 1978, UKR BIOKHIM ZH+, V50, P234; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; ROUSEL A, 1994, TURBO MANUAL SILICON; SOTIRIOU C, 1988, J AM CHEM SOC, V110, P2264, DOI 10.1021/ja00215a042; Timkovich R., 1990, ADV BIOPHYS CHEM, V1, P203; VAINSHTEIN BK, 1986, J MOL BIOL, V188, P49, DOI 10.1016/0022-2836(86)90479-1; VAVRA MR, 1986, ARCH BIOCHEM BIOPHYS, V250, P461, DOI 10.1016/0003-9861(86)90750-2; 1979, COLLABORATIVE COMPUT	30	54	55	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8863	8868		10.1074/jbc.271.15.8863	http://dx.doi.org/10.1074/jbc.271.15.8863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621527	hybrid			2022-12-25	WOS:A1996UE73000058
J	Nakamura, P; Sakakibara, J; Izumi, T; Shibata, A; Ono, T				Nakamura, P; Sakakibara, J; Izumi, T; Shibata, A; Ono, T			Transcriptional regulation of squalene epoxidase by sterols and inhibitors in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HEPG2 CELLS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; MESSENGER-RNA; LDL RECEPTOR; CHOLESTEROL; SYNTHASE; PATHWAY; ENZYMES; PROTEIN	Regulation of squalene epoxidase (SE) gene expression was studied in comparison with those of 5-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and low density lipoprotein (LDL) receptor. An increased expression of SE mRNA and protein content in mouse L929 cells grown in 10% lipoprotein-deficient fetal bovine serum (LPDS) for 48 h was found by performing immunoblot and Northern blot analyses when compared with the culture in the presence of fetal bovine serum (FBS). The same results in mRNA levels were seen using human cell lines HepG2, HeLa, and Chang liver cells. The increase of SE mRNA in HeLa cells grown in LPDS was preventable in a dose-dependent manner by feeding cells with 25-hydroxycholesterol or cholesterol. When an SE inhibitor, NB-598, was fed to HeLa cells grown in LPDS, it caused further increases in mRNA levels of SE, HMG-CoA reductase, and LDL receptor. In contrast, NB-598 had no effect on the message levels of these genes when fed to HeLa cells grown in FBS. These results suggest that sterol produced endogenously can also regulate SE expression at the level of transcription.	NIIGATA UNIV,SCH MED,DEPT BIOCHEM,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT INTERNAL MED,NIIGATA 951,JAPAN	Niigata University; Niigata University								BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1993, TRENDS BIOCH SOC, V4, P230; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONZALEZ R, 1979, ARCH BIOCHEM BIOPHYS, V196, P574, DOI 10.1016/0003-9861(79)90310-2; HIDAKA Y, 1990, J LIPID RES, V31, P2087; HORIE M, 1990, J BIOL CHEM, V265, P18075; JIANG GJ, 1993, J BIOL CHEM, V268, P12818; KOSUGA K, 1995, BBA-GENE STRUCT EXPR, V1260, P345, DOI 10.1016/0167-4781(94)00245-X; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; NAGUMO A, 1995, J LIPID RES, V36, P1489; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; Rudney Harry, 1993, Current Opinion in Lipidology, V4, P230, DOI 10.1097/00041433-199306000-00009; RYDER NS, 1985, BIOCHEM J, V230, P765, DOI 10.1042/bj2300765; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; SATOH T, 1990, J LIPID RES, V31, P2095; SPENCER TA, 1994, ACCOUNTS CHEM RES, V27, P83, DOI 10.1021/ar00039a004; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	23	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8053	8056		10.1074/jbc.271.14.8053	http://dx.doi.org/10.1074/jbc.271.14.8053			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626488	hybrid			2022-12-25	WOS:A1996UD60000028
J	DeBernardi, MA; Rabin, SJ; Colangelo, AM; Brooker, G; Mocchetti, I				DeBernardi, MA; Rabin, SJ; Colangelo, AM; Brooker, G; Mocchetti, I			trkA mediates the nerve growth factor-induced intracellular calcium accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AFFINITY NGF RECEPTOR; PC12 CELLS; PROTOONCOGENE PRODUCT; TYROSINE PHOSPHORYLATION; NEUROTROPHIN RECEPTORS; MOLECULAR-CLONING; GENE-TRANSFER; CYCLIC-AMP; BINDING	Regulation of the cytosolic free Ca2+ concentration by nerve growth factor was investigated in C6-2B glioma cells newly expressing the high affinity nerve growth factor receptor trkA, using Fura-a fluorescence ratio imaging. In these cells, nerve growth factor (50 ng/ml) evoked a novel similar to 3-fold increase in cytosolic free Ca2+ concentration, while no measurable Ca2+ response was observed in wild type or mock-transfected cells lacking a functional trkA receptor. K-252a, a tyrosine kinase inhibitor which prevents nerve growth factor-mediated responses in C6-2B cells expressing trkA, also blocked the rise in cytosolic free Ca2+ concentration by nerve growth factor. Moreover, basic fibroblast growth factor, which in these cells elicits biochemical changes similar to nerve growth factor, failed to affect cytosolic free Ca2+ concentration, further supporting the specificity of nerve growth factor/trkA receptor in mediating a Ca2+ response. While insensitive to chelation of extracellular Ca2+, the response was abolished following depletion of Ca2+ stores or blockade of intracellular Ca2+ release, providing strong evidence that intracellular Ca2+ is the main source for nerve growth factor-evoked cytosolic free Ca2+ concentration increase. Nerve growth factor increased the cytosolic free Ca2+ concentration also in NIH3T3 cells overexpressing trkA but devoid of p75 nerve growth factor receptor. Our data suggest that trkA but not p75 is required for nerve growth factor-evoked Ca2+ signaling.	GEORGETOWN UNIV,SCH MED,DEPT CELL BIOL,DIV NEUROBIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,DIV NEUROBIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DIV NEUROBIOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University; Georgetown University			Colangelo, Anna Maria AM/Q-3597-2017	Colangelo, Anna Maria AM/0000-0002-7971-4289	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001675, R01NS029664] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HD07459] Funding Source: Medline; NINDS NIH HHS [NS29664, NS01675] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO MT, 1991, BIOCHEM J, V280, P483; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BUSH AB, 1991, J NEUROCHEM, V57, P562, DOI 10.1111/j.1471-4159.1991.tb03787.x; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; COLANGELO AM, 1994, GLIA, V12, P117, DOI 10.1002/glia.440120205; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DEGEORGE JJ, 1988, J NEUROSCI RES, V2, P323; DEVELLIS J, 1973, TISSUE CULTURE NERVO, P231; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; GREEN SH, 1986, J BIOL CHEM, V261, P5316; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAASBERG T, 1988, FEBS LETT, V239, P367, DOI 10.1016/0014-5793(88)80953-0; LANDRETH G, 1980, NATURE, V283, P202, DOI 10.1038/283202a0; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; NIKODIJEVIC B, 1975, P NATL ACAD SCI USA, V72, P4769, DOI 10.1073/pnas.72.12.4769; NIKODIJEVIC B, 1992, J NEUROSCI RES, V31, P591, DOI 10.1002/jnr.490310402; NIKODIJEVIC B, 1991, J NEUROSCI RES, V28, P192, DOI 10.1002/jnr.490280206; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; RABIN SJ, 1995, J NEUROCHEM, V65, P347; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P4055, DOI 10.1073/pnas.74.9.4055; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; TAPLEY P, 1992, ONCOGENE, V7, P371; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSAO H, 1990, J BIOL CHEM, V265, P15471; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAKOVLEV AG, 1990, NEUROSCI LETT, V116, P216, DOI 10.1016/0304-3940(90)90413-4	60	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6092	6098		10.1074/jbc.271.11.6092	http://dx.doi.org/10.1074/jbc.271.11.6092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626395				2022-12-25	WOS:A1996UA36300024
J	Kubota, T; Watanabe, N; Kanai, YY; Stollar, BD				Kubota, T; Watanabe, N; Kanai, YY; Stollar, BD			Enhancement of oxidative cleavage of DNA by the binding sites of two anti-double-stranded DNA antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; VASOACTIVE-INTESTINAL-PEPTIDE; HELICAL OLIGONUCLEOTIDES; AUTOANTIBODIES; RESOLUTION; COMPLEX; PROTEIN; HYDROLYSIS; MECHANISM; CONTACTS	Nucleic acid specificity was tested for two monoclonal anti-double-stranded DNA autoantibodies, 2C10 and H241, derived from two lupus-prone MRL/Mp-lpr/lpr mice. Antibody 2C10 bound double-stranded oligonucleotides with a preference for dA-dT over dG-dC base pairs and did not bind single-stranded oligonucleotides. Distamycin A, an antibiotic that binds to the minor groove, inhibited 2C10 binding of double-stranded DNA, suggesting that this antibody interacts with dA-dT base pairs in the minor groove. Antibody H241 binding was previously shown to have a dG-dC preference and to involve both major and minor grooves. In attempted footprinting assays, both 2C10 and H241 markedly enhanced rather than protected against cleavage of DNA by hydroxyl radical-generating systems. With 2C10, this enhancement effect was observed only when hydroxyl radical generation was associated with oxidation of Fe(II). In contrast, H241 enhancement occurred in the presence of H2O2 and ascorbate or UV light irradiation and did not depend on added metal ion. The enhancement sites were related to the antibody binding specificities, The oligonucleotide 5'-AAAATATATATTT-3' was a much more effective inhibitor of the 2C10 enhancement than of the H241 effect, whereas the oligonucleotide 5'-GGGGCGCGCGCCC-3' was a much more effective inhibitor of the H241 enhancement. In addition, the enhanced cleavage occurred preferentially at dA-dT-rich regions with 2C10 and at dG-dC-rich regions with H241. These findings raise the possibility that anti-DNA autoantibodies could enhance DNA damage in inflammatory lesions in which hydroxyl radicals are generated.	TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, TOKYO 108, JAPAN; TOKYO MED & DENT UNIV, FAC MED, SCH ALLIED HLTH SCI, TOKYO 113, JAPAN	Tufts University; University of Tokyo; Tokyo Medical & Dental University (TMDU)				Kubota, Tetsuo/0000-0003-1021-7898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032375] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32375] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARA J, 1992, IMMUNOL LETT, V34, P195, DOI 10.1016/0165-2478(92)90213-8; Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BLOUNT S, 1990, CLIN EXP IMMUNOL, V81, P384; BRAUN RP, 1987, J IMMUNOL, V139, P175; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; CYGLER M, 1987, J BIOL CHEM, V262, P643; EMERIT I, 1981, P NATL ACAD SCI-BIOL, V78, P2537, DOI 10.1073/pnas.78.4.2537; EMERIT I, 1980, ACTA PHYSIOL SCAND, P59; FEINSTEIN E, 1993, BIOCHEMISTRY-US, V32, P13156, DOI 10.1021/bi00211a026; GAO QS, 1994, J BIOL CHEM, V269, P32389; GOLAN TD, 1994, LUPUS, V3, P103; GOLOLOBOV GV, 1995, P NATL ACAD SCI USA, V92, P254, DOI 10.1073/pnas.92.1.254; GROEN H, 1993, CLIN EXP IMMUNOL, V94, P127; HAKOSHIMA T, 1993, J MOL BIOL, V229, P566, DOI 10.1006/jmbi.1993.1059; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; HARDY JA, 1995, CARCINOGENESIS, V16, P319, DOI 10.1093/carcin/16.2.319; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JANG YJ, 1990, J IMMUNOL, V145, P3353; KANAI Y, 1989, IMMUNOL LETT, V22, P293, DOI 10.1016/0165-2478(89)90168-5; KOFFLER D, 1967, J EXP MED, V126, P607, DOI 10.1084/jem.126.4.607; KOFFLER D, 1974, ANNU REV MED, V25, P149, DOI 10.1146/annurev.me.25.020174.001053; KOREN E, 1995, J IMMUNOL, V154, P4857; KUBOTA T, 1986, IMMUNOL LETT, V14, P53, DOI 10.1016/0165-2478(86)90020-9; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; MEI S, 1991, J BIOL CHEM, V266, P15571; MELLO AC, 1991, MUTAT RES, V251, P109, DOI 10.1016/0027-5107(91)90220-I; OKUDAIRA K, 1987, ARTHRITIS RHEUM, V30, P669, DOI 10.1002/art.1780300610; OLEINICK NL, 1994, INT J RADIAT BIOL, V66, P523, DOI 10.1080/09553009414551561; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; RAZ E, 1989, J IMMUNOL, V142, P3076; RAZ E, 1993, EUR J IMMUNOL, V23, P383, DOI 10.1002/eji.1830230213; REICHLIN M, 1994, J CLIN INVEST, V93, P443, DOI 10.1172/JCI116980; ROBERTS VA, 1995, FASEB J, V9, P94, DOI 10.1096/fasebj.9.1.7821766; RUNKEL L, 1986, J MOL BIOL, V189, P487, DOI 10.1016/0022-2836(86)90319-0; SAKURAI K, 1995, BIOL PHARM BULL, V18, P262; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; STOLLAR BD, 1986, P NATL ACAD SCI USA, V83, P4469, DOI 10.1073/pnas.83.12.4469; STOLLAR BD, 1986, CRC CR REV BIOCH MOL, V20, P1, DOI 10.3109/10409238609115899; STOLLAR BD, 1973, ANTIGENS, P1; SUN M, 1994, J IMMUNOL, V153, P5121; SWAAK T, 1985, ANN RHEUM DIS, V44, P245, DOI 10.1136/ard.44.4.245; SWANSON PC, 1994, J IMMUNOL, V152, P2601; TERMAAT RM, 1992, KIDNEY INT, V42, P1363, DOI 10.1038/ki.1992.428; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UDENFRIEND S, 1954, J BIOL CHEM, V208, P731; YANASE K, 1994, LAB INVEST, V71, P52; ZHAO XY, 1994, ADV EXP MED BIOL, V357, P271; ZOUALI M, 1986, J IMMUNOL METHODS, V90, P105, DOI 10.1016/0022-1759(86)90390-X	56	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6555	6561		10.1074/jbc.271.11.6555	http://dx.doi.org/10.1074/jbc.271.11.6555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626460	hybrid			2022-12-25	WOS:A1996UA36300089
J	Ruegsegger, U; Beyer, K; Keller, W				Ruegsegger, U; Beyer, K; Keller, W			Purification and characterization of human cleavage factor I-m, involved in the 3' end processing of messenger RNA precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATION FACTOR; POLY(A) SITE; SPECIFICITY FACTOR; PROTEIN; AAUAAA; COMPLEX; BINDING; POLYMERASE; REQUIRES	Six different protein factors are required for the specific cleavage and polyadenylation of pre-mRNA in mammals. Whereas four of them have been purified and most of their components cloned, cleavage factor I-m (CF I-m) and cleavage factor IIm (CF IIm) remained poorly characterized. We report here the separation of CF I-m from CF IIm and the purification of CF I-m to near homogeneity. Three polypeptides of 68, 59, and 25 kDa copurify with CF I-m activity. All three polypeptides can be UV cross-linked to a cleavage and polyadenylation substrate in the presence of a large excess of unspecific competitor RNA, but not to a splicing-only substrate. No additional protein factor is required for the binding of CF I-m to pre-mRNA. Gel retardation experiments confirmed the results obtained by UV cross-linking. In addition, we could show that CF I-m stabilizes the binding of the cleavage and polyadenylation specificity factor (CPSF) to pre-mRNA and that CPSF and CF I-m together form a slower migrating complex with pre-mRNA than the single protein factors. Cleavage stimulation factor (CstF) and poly(A) polymerase (PAP) had no detectable effect on the binding of CF I-m to pre-mRNA. Furthermore, the CstF . CPSF . RNA as well as the CstF . CPSF . PAP . RNA complex are supershifted and stabilized upon the addition of CF I-m.	UNIV BASEL,DEPT CELL BIOL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel								BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GUNDERSON SI, 1994, CELL, V76, P561; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAMER A, 1985, EMBO J, V4, P3571, DOI 10.1002/j.1460-2075.1985.tb04119.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MCDONALD CC, 1994, MOL CELL BIOL, V14, P6647; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; Sambrook J, 1989, MOL CLONING LABORATO; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1994, RNA PROCESSING PRACT, P1; WAHLE E, 1992, ANN REV BIOCH, V61, P4189; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244	36	140	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6107	6113						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626397				2022-12-25	WOS:A1996UA36300026
J	Grinstein, E; Weinert, I; Droese, B; Pagano, M; Royer, HD				Grinstein, E; Weinert, I; Droese, B; Pagano, M; Royer, HD			Cell cycle regulation of nuclear factor p92 DNA-binding activity by novel phase-specific inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; THYMIDYLATE SYNTHASE; TRANS-ACTIVATION; PROTEIN; SYNCHRONIZATION; APHIDICOLIN; POLYMERASE; ENHANCER; TUMOR	The nuclear factor p92, originally discovered by its interaction with the human papillomavirus type 18 enhancer, is a cellular protein whose activity is restricted to S phase in human primary fibroblasts, The human papillomavirus type 18 p92 binding sequence confers enhancer activity on a heterologous promoter, suggesting that p92 acts as a transcription factor, We have identified a class of nuclear inhibitory proteins, I-92s, which noncovalently associate with p92 but not with other transcription factors such as AP1, E2F, or NF-KB. Different I-92s occur in G(1), G(2), and G(0), while no I-92 is detectable in S phase. Phase-specific inhibitors, therefore, are responsible for the cell cycle dependence of p92 activity and provide a novel mechanism linking transcription factor regulation with the cell cycle.	MAX DELBRUCK CTR MOLEC MED, DEPT MED GENET, D-13122 BERLIN, GERMANY; MITOTIX INC, CAMBRIDGE, MA 02139 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Royer, Hans-dieter/AAH-6293-2019					AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; GRINSTEIN E, 1995, DNA CELL BIOL, V14, P493, DOI 10.1089/dna.1995.14.493; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; JACKMAN AL, 1991, CANCER RES, V51, P5579; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ F, 1994, EXP CELL RES, V210, P145, DOI 10.1006/excr.1994.1022; MATHERLY LH, 1989, ANAL BIOCHEM, V182, P338, DOI 10.1016/0003-2697(89)90605-2; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; WEITZ J, 1991, NUCLEIC ACIDS RES, V19, P5725, DOI 10.1093/nar/19.20.5725	31	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9215	9222		10.1074/jbc.271.16.9215	http://dx.doi.org/10.1074/jbc.271.16.9215			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621580	hybrid			2022-12-25	WOS:A1996UG04400011
J	Mulvey, MR; Kuhn, LC; Scraba, DG				Mulvey, MR; Kuhn, LC; Scraba, DG			Induction of ferritin synthesis in cells infected with mengo virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA TRANSLATION; BINDING-PROTEIN; GENE-EXPRESSION; UNTRANSLATED REGION; TISSUE ISOFERRITINS; MOLECULAR-CLONING; SULFUR CLUSTER; MUSCLE-CELLS	We have recently identified ferritin as a cellular protein particle whose synthesis is stimulated in mouse or human cells infected by the picornavirus Mengo (1), Immunoprecipitation of the particle from infected murine L929 cells showed a 4- and 6-fold increase in the intracellular concentrations of H and L apoferritin subunits, respectively, This differential expression altered the H/L subunit ratio from 3.0 in uninfected cells to 2.2 in Mengo virus-infected cells, The induction is not due to an increase in transcription of the apoferritin L and H genes, nor is it due to an increase in stability of the apoferritin mRNAs, At the level of translation, the iron regulatory protein (IRP) remained intact, with similar amounts being detected in uninfected and infected cells, The Mengo virus RNA genome does not compete with the iron regulatory element (IRE) for the binding of IRP, and sequence analysis confirmed that there are no IREs in the virus RNA, The IRE binding activity of IRP in infected cells decreased approximately 30% compared with uninfected cells, The decrease in binding activity could be overcome by the addition of Desferal (deferoxamine mesylate; CIBA) an intracellular iron chelator, which suggests that virus infection causes an increase in intracellular free iron, Electron paramagnetic resonance (EPR) studies have confirmed the increase in free iron in Mengo virus infected cells, The permeability of cells for iron does not change in virus infected cells, suggesting that the induction of ferritin by Mengo virus is due to a change in the form of intracellular iron from a bound to a free state.	SWISS INST EXPTL CANC RES, CH-1006 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research	Mulvey, MR (corresponding author), UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA.							ABREU SL, 1976, J VIROL, V18, P182, DOI 10.1128/JVI.18.1.182-194.1976; AMEGLIO F, 1993, AIDS RES HUM RETROV, V9, P795, DOI 10.1089/aid.1993.9.795; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BOEGE U, 1987, VIROLOGY, V159, P358, DOI 10.1016/0042-6822(87)90474-0; BOMFORD A, 1981, J BIOL CHEM, V256, P948; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COULSON RMR, 1993, P NATL ACAD SCI USA, V90, P7613, DOI 10.1073/pnas.90.16.7613; COX F, 1988, J BIOL CHEM, V263, P7060; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DESTEFANO J, 1990, J VIROL, V64, P4445, DOI 10.1128/JVI.64.9.4445-4453.1990; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; FAHMY M, 1993, BIOCHEM J, V296, P175, DOI 10.1042/bj2960175; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HURTA RAR, 1991, BIOCHEM CELL BIOL, V69, P635, DOI 10.1139/o91-094; HUSAIN S, 1965, FED PROC, V24, P158; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT DM, 1973, LAB INVEST, V29, P737; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIAU G, 1991, J BIOL CHEM, V266, P18819; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTBADER ED, 1983, SCIENCE, V220, P423, DOI 10.1126/science.6301008; MATTIA E, 1989, P NATL ACAD SCI USA, V86, P1801, DOI 10.1073/pnas.86.6.1801; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MORIKAWA K, 1994, BLOOD, V83, P737; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULVEY MR, 1994, VIROLOGY, V198, P81, DOI 10.1006/viro.1994.1010; MULVEY MR, 1994, ARCH VIROL, P299; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PANTOPOULOS K, 1995, RNA, V1, P155; RIERA A, 1994, HAEMATOLOGICA, V79, P165; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TIENSIWAKUL P, 1979, J EXP PATHOL, V60, P161; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q	64	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9851	9857		10.1074/jbc.271.16.9851	http://dx.doi.org/10.1074/jbc.271.16.9851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621669	hybrid			2022-12-25	WOS:A1996UG04400100
J	Nauseef, WM; Cogley, M; McCormick, S				Nauseef, WM; Cogley, M; McCormick, S			Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; HUMAN RECOMBINANT MYELOPEROXIDASE; MYELOID LYSOSOMAL-ENZYME; ERYTHROLEUKEMIA-CELLS; OVERLAP EXTENSION; HEME-BIOSYNTHESIS; MESSENGER-RNA; DEFICIENCY; EXPRESSION; HEREDITARY	Human neutrophil microbicidal activity is largely mediated by reactive species generated by the oxygen-dependent myeloperoxidase (MPO) system. Peroxidase-negative neutrophils from many patients with hereditary MPO deficiency possess a 90-kDa MPO-related protein. We recently identified a missense mutation, R569W, in the MPO gene of many subjects with MPO deficiency. In these studies we examined the consequences of R569W on MPO biosynthesis and processing, using stably transfected K562 cells expressing normal MPO or the R569W mutation, K562 cells expressing normal MPO mimicked faithfully many features of MPO biosynthesis in myeloid cells, 1) apopro-MPO was synthesized; 2) a functional heme group was inserted into apopro-MPO, and enzymatically active pro-MPO was thereby generated; 3) pro-MPO underwent proteolytic processing to mature MPO; and 4) hemin augmented the processing of pro-MPO, pREP-R569W cells synthesized apopro-MPO, but heme was not inserted, Neither enzymatically active pro-MPO nor mature MPO was synthesized by transfectants expressing mutated cDNA, confirming our hypothesis that the R569W mutation results in a form of apopro-MPO which does not undergo posttranslational processing to enzymatically active MPO species. In addition, these data support previous suggestions that heme insertion into apopro-MPO is necessary for its subsequent proteolytic processing into mature MPO subunits.	UNIV IOWA,COLL MED,IOWA CITY,IA 52242	University of Iowa	Nauseef, WM (corresponding author), VET ADM MED CTR,DEPT MED,IOWA CITY,IA 52242, USA.			Nauseef, William/0000-0003-4032-757X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028412] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28412] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); BLRD VA		AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1986, J BIOL CHEM, V261, P8370; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BOS AJ, 1982, J LAB CLIN MED, V99, P589; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CULLY J, 1989, EXP CELL RES, V180, P440, DOI 10.1016/0014-4827(89)90070-0; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HURST JK, 1991, PEROXIDASES CHEM BIO, P37; JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y; JACQUET A, 1992, FEBS LETT, V302, P189, DOI 10.1016/0014-5793(92)80437-L; Johnson K. R., 1991, PEROXIDASES CHEM BIO, P63; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KITAHARA M, 1981, BLOOD, V57, P888; KIZAKI M, 1994, BLOOD, V83, P1935; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; KOEFFLER HP, 1985, BLOOD, V65, P484; LEHRER RI, 1969, J CLIN INVEST, V48, P1478, DOI 10.1172/JCI106114; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LUBBERT M, 1991, BLOOD, V77, P909; MARIE JP, 1981, BLOOD, V58, P708; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; NAUSEEF W M, 1990, Hematologic Pathology, V4, P165; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1986, BLOOD, V68, P442; NAUSEEF WM, 1994, J BIOL CHEM, V269, P1212; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; SELSTED ME, 1993, BLOOD, V82, P1317; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TAYLOR KL, 1992, BIOCHEM BIOPH RES CO, V187, P1572, DOI 10.1016/0006-291X(92)90482-Z; TOBLER A, 1989, BLOOD, V73, P1980; ULRICH MJ, 1990, BLOOD, V75, P990; YAMADA M, 1984, J BIOL CHEM, V259, P3021	46	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9546	9549		10.1074/jbc.271.16.9546	http://dx.doi.org/10.1074/jbc.271.16.9546			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621627	hybrid			2022-12-25	WOS:A1996UG04400058
J	vanLeeuwen, JEM; Kearse, KP				vanLeeuwen, JEM; Kearse, KP			Calnexin associates exclusively with individual CD3 delta and T cell antigen receptor (TCR) alpha proteins containing incompletely trimmed glycans that are not assembled into multisubunit TCR complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; DELTA-CHAIN; IDENTIFICATION; CHAPERONE; IP90	Most T lymphocytes express on their surfaces an oligomeric protein complex consisting of clonotypic alpha beta polypeptides associated with invariant CD3-gamma delta epsilon and zeta chains, designated the T cell antigen receptor (TCR) complex. Assembly and intracellular transport of nascent TCR proteins is believed to be assisted by their interaction with the molecular chaperone calnexin, which for certain molecules functions as a lectin for monoglucosylated glycans. However, as most of our knowledge about calnexin-TCR protein associations has been obtained under conditions of limited TCR assembly, the role of calnexin in the formation of nascent TCR complexes is unclear, Here, we studied the role of glucose (Glc) trimming and calnexin association in the oligomerization of TCR alpha and CD3 delta glycoproteins in murine splenic T lymphocytes, a model cell type for efficient assembly of complete TCR complexes. We show that removal of Glc residues from both CD3 delta proteins and TCR alpha proteins occurred prior to their association with any other TCR components and that calnexin specifically interacted with unassembled TCR alpha and CD3 delta proteins containing incompletely trimmed oligosaccharides, Interestingly, we found that removal of Glc residues from glycan chains was necessary for efficient association of calnexin with TCR alpha glycoproteins but not with CD3 delta glycoproteins. These studies define Glc trimming and calnexin association as initial molecular events in the translation of CD3 delta and TCR alpha proteins, occurring coincident with or immediately after their translocation into the endoplasmic reticulum and preceding the ordered pairing of TCR chains, In addition, these data document that calnexin assembly with CD36 and TCR alpha glycoproteins involves both glycan-dependent and glycan-independent mechanisms.	NCI,EXPTL IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			van Leeuwen, Jeroen/G-3555-2010					ALARCON B, 1988, J BIOL CHEM, V263, P2953; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KEARSE KP, 1995, IMMUNITY, V2, P391; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LENTER M, 1994, J BIOL CHEM, V269, P12263; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOO TW, 1994, J BIOL CHEM, V269, P28683; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WIEST DL, 1994, J EXP MED, V180, P1375, DOI 10.1084/jem.180.4.1375; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	33	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9660	9665		10.1074/jbc.271.16.9660	http://dx.doi.org/10.1074/jbc.271.16.9660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621641	hybrid			2022-12-25	WOS:A1996UG04400072
J	Yoshihisa, T; Ito, K				Yoshihisa, T; Ito, K			Pro-OmpA derivatives with a His(6) tag in their N-terminal ''translocation initiation domains'' are arrested by Ni2+ at an early post-targeting stage of translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; SIGNAL SEQUENCE; SUPPRESSOR MUTATIONS; CYTOPLASMIC MEMBRANE; EXPORT; SECY; PREPROTEIN; SECRETION	We examined in vitro translocation of pro-OmpA derivatives with a His(6) tag at various positions in their mature proteins and with a c-Myc tag at their C termini across inverted membrane vesicles of Escherchia coil, Those with a His(6) tag in the N-terminal region of the mature domain, which corresponds to the ''translocation initiation domain'' proposed previously (Andersson, H., and von Heijne, G. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 9751-9754), could not be translocated in the presence of 100 mu M Ni2+, while OmpA derivatives with a His, tag in the middle of or at the C terminus did not show such Ni2+ sensitivity. The inhibitory action of Ni2+ on pro-3His-OmpA' (with a His(6) tag after the third amino acid of the mature OmpA-c-Myc region) translocation was exerted only during early events, after which it became ineffective, The inhibition point of Ni2+ was suggested to lie between membrane targeting and exposure of the signal cleavage site to the periplasm since the unprocessed and membrane-bound form of pro-3His-OmpA' was accumulated by the addition of Ni2+, The Ni2+-''trapped'' precursor was released from its translocation block by 30 mM histidine, which should compete with the His, tag on the precursor protein for formation of a Ni2+ chelating complex, We propose that Ni2+ confers a reversible positive charge effect on the His(6)-tagged initiation domain of the pro-OmpA derivatives and inhibits an early event(s) of protein translocation, such as presentation of the precursor to the membranous part of the translocase, This system will be useful in dissecting early events of the protein translocation pathway.	KYOTO UNIV, INST VIRUS RES, DEPT CELL BIOL, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University			Yoshihisa, Tomoki/AFA-7466-2022					AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BUSH GL, 1991, J BIOL CHEM, V266, P13811; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1992, MOL MICROBIOL, V6, P2423; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KATO M, 1993, J BIOL CHEM, V268, P3586; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; SAKO T, 1988, J BACTERIOL, V170, P5389, DOI 10.1128/jb.170.11.5389-5391.1988; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHIMOIKE T, 1992, MOL MICROBIOL, V6, P1205, DOI 10.1111/j.1365-2958.1992.tb01559.x; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; TANI K, 1990, J BIOL CHEM, V265, P17341; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TOKUDA H, 1994, FEBS LETT, V346, P65, DOI 10.1016/0014-5793(94)00317-3; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774	43	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9429	9436		10.1074/jbc.271.16.9429	http://dx.doi.org/10.1074/jbc.271.16.9429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621611	hybrid			2022-12-25	WOS:A1996UG04400042
J	Sambasivarao, D; Paetkau, V				Sambasivarao, D; Paetkau, V			Interactions of a transcriptional activator in the env gene of the mouse mammary tumor virus with activation-dependent, T cell-specific transacting factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; OPEN READING FRAME; NF-KAPPA-B; INTERLEUKIN-2 GENE; RESTRICTED ACTIVITY; ANTIGEN RECEPTOR; NUCLEAR PROTEINS; ENHANCER ELEMENT; SIMIAN VIRUS-40; DNA-SEQUENCES	The mouse mammary tumor virus env gene contains a transcriptional activator (META) that can control transcription of the adjacent long terminal repeat region. Transcriptional control by META parallels that of several lymphokine genes, being specific to T cells, dependent on their activation, and inhibited by the immunosuppressive drug cyclosporine (CsA). DNase I footprinting indicated that nuclear factors from activated T lymphocytes bound a promoter-proximal site, META(P), and a promoter-distal site, META(D+), within the 400-base pair META region. Nuclear factors from unstimulated, but not from activated cells, bound a site, META(D-), adjacent to META(D+), META(D+) directed transcription of a Linked luciferase gene, and gel shift analysis revealed binding of inducible, CsA-sensitive T cell factors, in parallel with transfection results. Authentic NFAT and NF-KB targets did not compete for the META(D+) binding factor(s). The SV40 core sequence competed for META(D+) binding factors, but META(D+) failed to compete for the complexes obtained with the SV40 probe, Our results, taken together, indicate that META(D+) is a novel transcriptional enhancer element that is similar in its cell-type specificity, activation dependence, and CsA sensitivity to the NFAT element. It may be relevant to the role of MMTV in expression of Mls antigens or the induction of T cell lymphomas.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIEGEL K, 1991, NUCLEIC ACIDS RES, V19, P5929, DOI 10.1093/nar/19.21.5929; BRUNVAND MW, 1993, NUCLEIC ACIDS RES, V21, P4824, DOI 10.1093/nar/21.20.4824; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; ELLIOTT JF, 1988, J VIROL, V62, P1373, DOI 10.1128/JVI.62.4.1373-1380.1988; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; ESPEL E, 1990, EMBO J, V9, P929, DOI 10.1002/j.1460-2075.1990.tb08191.x; ESSER U, 1992, NATURE, V359, P19, DOI 10.1038/359019a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; HOOTON JWL, 1985, J IMMUNOL, V135, P2464; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KWON BS, 1984, J VIROL, V52, P1000, DOI 10.1128/JVI.52.3.1000-1004.1984; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LOBE CG, 1989, NUCLEIC ACIDS RES, V17, P5765, DOI 10.1093/nar/17.14.5765; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MILLER CL, 1992, MOL CELL BIOL, V12, P3262, DOI 10.1128/MCB.12.7.3262; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; MORGAN AR, 1979, NUCLEIC ACIDS RES, V7, P571, DOI 10.1093/nar/7.3.571; MOSTHAF L, 1985, NATURE, V315, P597, DOI 10.1038/315597a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Sambrook J., 2002, MOL CLONING LAB MANU; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735-0651(89)90016-2	48	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8942	8950		10.1074/jbc.271.15.8942	http://dx.doi.org/10.1074/jbc.271.15.8942			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621538	hybrid			2022-12-25	WOS:A1996UE73000069
J	Biddlecome, GH; Berstein, G; Ross, EM				Biddlecome, GH; Berstein, G; Ross, EM			Regulation of phospholipase C-beta 1 by G(q) and m1 muscarinic cholinergic receptor - Steady-state balance of receptor-mediated activation and GTPase-activating protein-promoted deactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; GUANINE-NUCLEOTIDE-BINDING; ADENYLATE-CYCLASE; SUBUNITS; RECONSTITUTION; SPECIFICITY; ANTISERA; VESICLES; COMPLEX; ENZYME	The phospholipase C-beta 1 (PLC-beta 1) signaling pathway was reconstituted by addition of purified PLC to phospholipid vesicles that contained purified recombinant mi muscarinic cholinergic receptor, G(q), and 2-4 mol % [H-3]phosphatidylinositol 4,5-bisphosphate. In this system, the muscarinic agonist carbachol stimulated steady-state PLC activity up to 90-fold in the presence of GTP. Both GTP and agonist were required for PLC activation, which was observed at physiological levels of Ca2+ (10-100 nM). PLC-beta 1 is also a GTPase-activating protein for G(q). It accelerated steady-state GTPase activity up to 60-fold in the presence of carbachol, which alone stimulated activity 6-10-fold, and increased the rate of hydrolysis of G(q)-bound GTP by at least 100-fold. Despite this rapid hydrolysis of G(q)-bound GTP, the receptor maintained >10% of the total G(q) in the active GTP-bound form by catalyzing GTP binding at a rate of at least 20-25 min(-1), similar to 10-fold faster than previously described. These and other kinetic data indicate that the receptor and PLC-beta 1 coordinately regulate the amplitude of the PLC signal and the rates of signal initiation and termination. They also suggest a mechanism in which the receptor, G(q), and PLC form a three-protein complex in the presence of agonist and GTP (stable over multiple GTPase cycles) that is responsible for PLC signaling.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM30355, GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM030355, R37GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAGA K, 1983, J BIOL CHEM, V258, P3575; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1981, CRC CR REV BIOCH MOL, V10, P81, DOI 10.3109/10409238109114550; MARTELL AE, 1952, CHEM METAL CHELATE C; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MAY DC, 1985, J BIOL CHEM, V260, P5829; MCCORMICK F, 1993, HDB EXP PHARM, V108, P345; MICHELL RH, 1970, BIOCHIM BIOPHYS ACTA, V210, P86, DOI 10.1016/0005-2760(70)90064-0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PAGES F, 1992, J BIOL CHEM, V267, P22018; PARKER EM, 1991, J BIOL CHEM, V266, P519; Ross E M, 1978, Methods Enzymol, V53, P222; ROSS EM, 1994, INT CONGR SER, V1051, P211; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I.H., 1975, ENZYME KINETICS; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WONG SKF, 1994, J BIOL CHEM, V269, P18968	50	203	206	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7999	8007		10.1074/jbc.271.14.7999	http://dx.doi.org/10.1074/jbc.271.14.7999			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626481	hybrid			2022-12-25	WOS:A1996UD60000021
J	Ma, WJ; Cheng, S; Campbell, C; Wright, A; Furneaux, H				Ma, WJ; Cheng, S; Campbell, C; Wright, A; Furneaux, H			Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEIN; MYC MESSENGER-RNA; 3' UNTRANSLATED REGION; RICH SEQUENCES; DEGRADATION; DOMAINS; PURIFICATION; LYMPHOKINE; POLY(A); INVITRO	The neuronal-specific Elav-like proteins (HuD, Hel-N, and HuC) contain three RNP-type concensus motifs and bind to AU-rich elements. We have identified and cloned a fourth member of this family (HuR) that is expressed in a wide variety of cell types. The purified recombinant protein binds avidly to the AU-rich element in c-fos and interleukin-3 mRNAs, In the case of the c-fos AU-rich element, HuR binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Mutational analysis has shown that all three AU motifs are required for maximal binding.	MEM SLOAN KETTERING CANC CTR, MOLEC NEUROONCOL LAB, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, CLEVELAND, OH 44195 USA	Memorial Sloan Kettering Cancer Center; Cleveland Clinic Foundation				furneaux, henry/0000-0003-2212-1017	NCI NIH HHS [P30-CA08748] Funding Source: Medline; NINDS NIH HHS [NS29682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1995, NEUROSCIENTIST, DOI DOI 10.1177/107385849500100203; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHUNG S, 1995, UNPUB JBC; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KING PH, 1994, J NEUROSCI, V14, P1943; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; SZABO A, 1993, CLONING CHARACTERIZA; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	36	556	573	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8144	8151		10.1074/jbc.271.14.8144	http://dx.doi.org/10.1074/jbc.271.14.8144			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626503	hybrid			2022-12-25	WOS:A1996UD60000043
J	Schwenger, P; Skolnik, EY; Vilcek, J				Schwenger, P; Skolnik, EY; Vilcek, J			Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION PATHWAY; ASPIRIN-LIKE DRUGS; MAP KINASE; PHOSPHOLIPASE-C; GENE-EXPRESSION; 55-KDA RECEPTOR; L929 CELLS; TNF; PHOSPHORYLATION	Tumor necrosis factor (TNF) activates both p42 and p44 mitogen-activated protein kinases (MAPK) in human FS-4 fibroblasts, cells for which TNF is mitogenic. We now show that TNF activates p42 MAPK in two cell lines whose growth is inhibited by TNF. A mutant TNF that binds only to the p55 TNF receptor (TNFR) produced a similar degree of activation as wild-type TNF in FS-4 fibroblasts, indicating that the p55 TNFR is sufficient to mediate p42/p44 MAPK activation. The upstream intracellular signals that couple the TNFR to MAPK activation are still poorly defined. We now show that neither phorbol ester-sensitive protein kinase C nor G(i alpha) link TNF to p42/p44 MAPK activation, because pretreatment of FS-4 cells with phorbol ester to downregulate protein kinase C or pretreatment with pertussis toxin to block G(i alpha) does not inhibit p42/p44 MAPK activation by TNF. To further analyze MAPK activation in FS-4 cells, we compared p42/p44 MAPK activation by TNF and epidermal growth factor (EGF). While tyrosine phosphorylation of p42/p44 MAPK was detected almost immediately (30 s) after stimulating cells with EGF, TNF-induced tyrosine phosphorylation was detected only after a more prolonged time interval (initially detected at 5 min and peaking at 15-30 min). in addition, the anti-inflammatory drug sodium salicylate, previously demonstrated to inhibit NF-kappa B activation by TNF, blocked the activation of p42/p44 MAPK in response to TNF but not in response to EGF. These findings demonstrate that the TNF and EGF receptors utilize distinct signaling molecules to couple to MAPK activation. Elucidation of the mechanism whereby sodium salicylate blocks TNF-induced p42/p44 MAPK activation may help to clarify TNF-activated signaling pathways.	NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University					NATIONAL CANCER INSTITUTE [R35CA049731, T32CA009161] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09161, R35CA49731] Funding Source: Medline; PHS HHS [49207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BIRD TA, 1992, CYTOKINE, V4, P429, DOI 10.1016/1043-4666(92)90003-A; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BOMALASKI JS, 1986, BIOCHEM BIOPH RES CO, V139, P115, DOI 10.1016/S0006-291X(86)80087-0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FEINMAN R, 1987, J IMMUNOL, V138, P635; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAO GN, 1994, J BIOL CHEM, V269, P32586; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPRIGGS DR, 1990, CANCER RES, V50, P7101; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VANOSTADE X, 1993, NATURE, V361, P266; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WINSTON BW, 1995, J IMMUNOL, V155, P1525; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WONG GHW, 1992, J IMMUNOL, V149, P3350; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	71	77	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8089	8094		10.1074/jbc.271.14.8089	http://dx.doi.org/10.1074/jbc.271.14.8089			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626494	hybrid			2022-12-25	WOS:A1996UD60000034
J	Wood, MW; VanDongen, HMA; VanDongen, AMJ				Wood, MW; VanDongen, HMA; VanDongen, AMJ			The 5'-untranslated region of the N-methyl-D-aspartate receptor NR2A subunit controls efficiency of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR; MOLECULAR-CLONING; RNA; EXPRESSION; SYNAPSE; CHANNEL	The N-methyl-D-aspartate (NMDA) receptor plays a central role in such phenomena as long term potentiation and excitotoxicity. This importance in defining both function and viability suggests that neurons must carefully control their expression of NMDA receptors, Whereas the NR1 subunit of the NMDA receptor is ubiquitously transcribed throughout the brain, transcription of NR2 subunits is spatially and temporally controlled, Since heteromeric assembly of both subunits is required for efficient functional expression, post-transcriptional modification of either subunit would affect NMDA receptor activity. Here it is demonstrated that the 5'-untranslated region (5'-UTR) of the NR2A subunit severely restricts its protein translation in both Xenopus oocytes and in an in vitro translation system. Mutational analysis of the 5'-UTR implicates secondary structure as the major translational impediment, while the five alternate start codons play minor roles, An important biological role for the 5'-UTR of NR2A is further suggested by the unusually high level of sequence conservation between species. In contrast, the 5'-UTR of NR1 does not inhibit translation and is not conserved. Taken together, these findings suggest a mechanism for modulation of NMDA receptor activity through the control of translational efficiency of a single subunit.	DUKE UNIV,DEPT PHARMACOL,DURHAM,NC 27710	Duke University				VanDongen, Antonius/0000-0002-9923-3407	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031557] Funding Source: NIH RePORTER; NIMH NIH HHS [MH11278] Funding Source: Medline; NINDS NIH HHS [NS31557] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; Harris K. M., 1995, Society for Neuroscience Abstracts, V21, P594; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; KARP SJ, 1993, J BIOL CHEM, V268, P3728; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1991, J CELL BIOL, V115, P857; KRAUS JE, 1994, J NEUROSCI, V14, P4196; LEBOURDELLES B, 1994, J NEUROCHEM, V62, P2091; LI Y, 1994, J BIOL CHEM, V269, P27589; MARTONE ME, 1993, J NEUROSCI, V13, P4636; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sonenberg Nahum, 1993, Gene Expression, V3, P317; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; THEIL EC, 1993, BIOFACTORS, V4, P87; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHONG J, 1994, MOL PHARMACOL, V45, P846	35	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8115	8120		10.1074/jbc.271.14.8115	http://dx.doi.org/10.1074/jbc.271.14.8115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626498				2022-12-25	WOS:A1996UD60000038
J	Bianchi, L; Roy, ML; Taglialatela, M; Lundgren, DW; Brown, AM; Ficker, E				Bianchi, L; Roy, ML; Taglialatela, M; Lundgren, DW; Brown, AM; Ficker, E			Regulation by spermine of native inward rectifier K+ channels in RBL-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; LEUKEMIA-CELLS; PATCH-CLAMP; DECARBOXYLASE; EXPRESSION; 5'-(<(Z)-4-AMINO-2-BUTENYL>METHYLAMINO)-5'-DEOXYADENOSINE; POLYAMINES	Polyamines have been shown to participate in the rectification of cloned inwardly rectifying potassium channels, a class of potassium channel proteins that conducts inward current more readily than outward current. Here, basophil leukemia cells were used to determine the effects of polyamines on a native, inwardly rectifying potassium current. Rat basophil leukemia cells were cultured in the presence of two different polyamine biosynthesis inhibitors, and both the electrophysiological properties and the polyamine levels were monitored. Treatment with alpha-difluoromethylornithine, a specific ornithine decarboxylase inhibitor, resulted in no significant change of electrophysiological properties. In contrast, treatment with 5'-{[(Z)-4-amino-2-butenyl]methyl-amino}-5'-deoxyadenosine (MDL73811), an inhibitor of S-adenosylmethionine decarboxylase, resulted in increased outward currents through inwardly rectifying potassium channels while intracellular putrescine was markedly increased and spermidine and spermine levels were decreased. Fluctuations of intracellular polyamine concentrations as imposed by MDL73811 were directly translated in an altered cell excitability. Based on these results we conclude that the rectification properties of native inwardly rectifying potassium channels are largely controlled by intracellular spermine.	CASE WESTERN RESERVE UNIV,SCH MED,RAMMELKAMP CTR EDUC & RES,CLEVELAND,OH 44109; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT NEUROSCI,PHARMACOL SECT,I-80131 NAPLES,ITALY; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT & BIOCHEM,CLEVELAND,OH 44109; UNIV FLORENCE,DEPT PHYSIOL,FLORENCE,ITALY	Case Western Reserve University; MetroHealth System; University of Naples Federico II; Case Western Reserve University; University of Florence			Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/AAB-8621-2022	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36930, NS23877] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUDRY M, 1986, J NEUROSCI, V6, P3430; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; DANZIN C, 1990, BIOCHEM PHARMACOL, V40, P1499, DOI 10.1016/0006-2952(90)90446-R; DROUIN H, EUROPEAN J NEUROSCI, V6, P41294; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P298; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOORE JJ, 1988, J BIOL CHEM, V263, P12765; PAJUNEN AE, 1978, J NEUROCHEM, V30, P331; PEGG AE, 1988, CANCER RES, V48, P759; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WEIGER T, 1994, J MEMBRANE BIOL, V140, P133; WIBLE BA, 1995, CIRC RES, V76, P343, DOI 10.1161/01.RES.76.3.343; WISCHMEYER E, 1995, PFLUG ARCH EUR J PHY, V429, P809, DOI 10.1007/BF00374805; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7	31	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6114	6121		10.1074/jbc.271.11.6114	http://dx.doi.org/10.1074/jbc.271.11.6114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626398	hybrid			2022-12-25	WOS:A1996UA36300027
J	Feres, EJ; Menassa, GB; Trackman, PC				Feres, EJ; Menassa, GB; Trackman, PC			Regulation of lysyl oxidase by basic fibroblast growth factor in osteoblastic MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN MESSENGER-RNA; EXTRACELLULAR-MATRIX; COPPER DEFICIENCY; GENE-EXPRESSION; CROSS-LINKING; BONE-CELLS; CHICK; DNA; HEPARIN; INVITRO	Lysyl oxidase catalyzes the final known enzymatic step required for collagen and elastin cross-linking, A cross-linked collagenous extracellular matrix is required for bone formation, This study investigated whether lysyl oxidase, like its type I collagen substrate, is down-regulated by basic fibroblast growth factor (bFGF) in osteoblastic MC3T3-E1 cells and determined the degree of post-transcriptional control. Steady-state lysyl oxidase mRNA levels decreased to 30% of control after 24 h of treatment with 1 and 10 nM bFGF. This regulation was time-dependent. COL1A1 mRNA levels declined to less than 10% of control after 24 h of bFGF treatment. Media lysyl oxidase activity decreased consistent with steady-state mRNA changes in cultures that were refed after 24 h of growth factor treatment. Interestingly, treatment of MC3T3-E1 cells with 0.01-0.1 nM bFGF for 24 h and treatment with 1 nM bFGF for up to 12 h resulted in a modest stimulation of lysyl oxidase gene expression and enzyme activity. At least 50% of the down-regulation of lysyl oxidase was shown to be posttranscriptional. New protein synthesis was not required for the down-regulation by bFGF, but cycloheximide did increase constitutive lysyl oxidase mRNA levels 2.5-fold, We conclude that lysyl oxidase and COL1A1 are regulated similarly by bFGF in these osteoblastic cells, consistent with the in vivo effects of this growth factor on bone collagen metabolism.	BOSTON UNIV,MED CTR,GOLDMAN SCH GRAD DENT,DEPT PERIODONTOL & ORAL BIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University			Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Feres-Filho, Eduardo Jorge/0000-0001-5795-8058	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE011004, R01DE011004] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 11004] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAILEY AJ, 1993, CONNECT TISSUE RES, V29, P119, DOI 10.3109/03008209309014239; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BOYD CD, 1995, MOL BIOL REP, V21, P95, DOI 10.1007/BF00986499; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERESFILHO EJ, 1996, J BIOL CHEM, V270, P30797; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRENKEL SR, 1992, ACTA ANAT, V145, P265; FRENKEL SR, 1990, BIOMATERIALS, V11, P38; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GERSTENFELD LC, 1993, J BONE MINER RES, V8, P1031; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HUERRE C, 1982, P NATL ACAD SCI-BIOL, V79, P6627, DOI 10.1073/pnas.79.21.6627; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; HURLEY MM, 1992, ENDOCRINOLOGY, V130, P2675, DOI 10.1210/en.130.5.2675; JONAS J, 1993, ANN NUTR METAB, V37, P245, DOI 10.1159/000177774; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; MAATTA A, 1993, BIOCHEM J, V295, P691; MAATTA A, 1994, FEBS LETT, V340, P71, DOI 10.1016/0014-5793(94)80175-4; MARTIN GR, 1961, BIOCHIM BIOPHYS ACTA, V53, P599, DOI 10.1016/0006-3002(61)90227-X; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; MEYERSIEGLER K, 1992, CARCINOGENESIS, V13, P2127, DOI 10.1093/carcin/13.11.2127; OPSAHL W, 1982, J NUTR, V112, P708, DOI 10.1093/jn/112.4.708; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PIERCE RA, 1992, J BIOL CHEM, V267, P11593; QUARLES LD, 1992, J BONE MINER RES, V7, P683; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; RUCKER RB, 1975, J NUTR, V105, P1062, DOI 10.1093/jn/105.8.1062; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SELYE H., 1957, REV CANADIENNE BIOL, V16, P1; TANG SS, 1983, J BIOL CHEM, V258, P4331; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; TRACKMAN PC, 1995, BBA-GENE STRUCT EXPR, V1260, P355, DOI 10.1016/0167-4781(94)00239-Y; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WU Y, 1992, J BIOL CHEM, V267, P24199	52	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6411	6416		10.1074/jbc.271.11.6411	http://dx.doi.org/10.1074/jbc.271.11.6411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626440	hybrid			2022-12-25	WOS:A1996UA36300069
J	Florio, T; Scorziello, A; Fattore, M; DAlto, V; Salzano, S; Rossi, G; Berlingieri, MT; Fusco, A; Schettini, G				Florio, T; Scorziello, A; Fattore, M; DAlto, V; Salzano, S; Rossi, G; Berlingieri, MT; Fusco, A; Schettini, G			Somatostatin inhibits PC C13 thyroid cell proliferation through the modulation of phosphotyrosine phosphatase activity - Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASE; THYROTROPIN RECEPTOR; PANCREATIC-CANCER; GROWTH-FACTOR; TUMOR-CELLS; ANALOGS; DEPHOSPHORYLATION; STIMULATION; BINDING; HORMONE	In this study, we report the effects of somatostatin on the proliferation of PC Cl3 thyroid cell line and the intracellular mechanisms involved. We also evaluated the possible alterations, induced by E1A oncogene transformation on the intracellular pathways mediating somatostatin inhibition of cell proliferation. We showed that somatostatin was able to powerfully inhibit insulin- and insulin + TSH-dependent cell proliferation by in ducing a block in the G(1)/S progression in the cell cycle. These cytostatic effects were completely reverted by vanadate, suggesting that somatostatin may induce antiproliferative effects through the modulation of phosphotyrosine phosphatases. In the E1A-transformed cell line, somatostatin was completely ineffective. The lack of somatostatin inhibitory effects on cell proliferation were not due to alterations in the expression of somatostatin receptors, which were regularly expressed and coupled to adenylyl cyclase activity, but were dependent on an alteration in their coupling with the phosphotyrosine phosphatase. In fact, although in PC Cl3 cells somatostatin increased by 100% phosphotyrosine phosphatase activity, it was completely ineffective in E1A-expressing cells. In conclusion we demonstrated that somatostatin activates phosphotyrosine phosphatases in PC Cl3 thyroid cells to inhibit cell proliferation and that the stable expression of E1A oncogene in these cells completely abolishes this antiproliferative effect.	UNIV GENOA, ADV BIOTECHNOL CTR,NATL INST CANC RES,SCH MED, DEPT CLIN & EXPTL ONCOL,CHAIR PHARMACOL, I-16132 GENOA, ITALY; UNIV NAPLES FEDERICO II, DEPT NEUROSCI & INTERHUMAN COMMUN, PHARMACOL SECT, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, DEPT CELLULAR & MOLEC BIOL & PATHOL L CALIFANO, I-80131 NAPLES, ITALY; CNR, CTR ENDOCRINOL & EXPTL ONCOL, I-80125 NAPLES, ITALY; UNIV REGGIO CALABRIA, DEPT CLIN & EXPTL MED, I-88100 CATANZARO, ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Universita Mediterranea di Reggio Calabria			FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; Scorziello, Antonella/K-6131-2018	Florio, Tullio/0000-0002-2394-996X; Fusco, Alfredo/0000-0003-3332-5197				BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVINI TAL, 1993, 75 END M LAS VEG; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEUNG NW, 1995, 77 ANN M END SOC WAS, pP3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eggo MC, 1990, GROWTH FACTORS, V2, P99, DOI 10.3109/08977199009071497; FLORIO T, 1992, J BIOL CHEM, V267, P24169; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; HUYNH H, 1994, BIOCHEM BIOPH RES CO, V203, P253, DOI 10.1006/bbrc.1994.2175; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LEE MT, 1991, P NATL ACAD SCI USA, V88, P1656, DOI 10.1073/pnas.88.5.1656; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; MEUCCI O, 1994, ENDOCRINOLOGY, V134, P424, DOI 10.1210/en.134.1.424; MEUCCI O, 1995, BIOCHEM BIOPH RES CO, V209, P630, DOI 10.1006/bbrc.1995.1546; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; QUN Y, 1991, INT J CANCER, V47, P765; REICHLIN S, 1987, NEW ENGL J MED, V30, P1494; SCHALLY AV, 1988, CANCER RES, V48, P6977; SCHETTINI G, 1989, BRAIN RES, V492, P65, DOI 10.1016/0006-8993(89)90889-5; SETYONOHAN B, 1987, CANCER RES, V47, P1566; SHENK T, 1991, ADV CANCER RES, V57, P47; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TSUZAKI S, 1990, ENDOCRINOLOGY, V126, P3131, DOI 10.1210/endo-126-6-3131; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; YAMADA Y, 1993, BIOCHEM BIOPH RES CO, V195, P844, DOI 10.1006/bbrc.1993.2122	35	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6129	6136		10.1074/jbc.271.11.6129	http://dx.doi.org/10.1074/jbc.271.11.6129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626400	hybrid			2022-12-25	WOS:A1996UA36300029
J	JaramilloBabb, VL; Sugarman, JL; Scavetta, R; Wang, SJ; Berndt, N; Born, TL; Glass, CK; Schonthal, AH				JaramilloBabb, VL; Sugarman, JL; Scavetta, R; Wang, SJ; Berndt, N; Born, TL; Glass, CK; Schonthal, AH			Positive regulation of cdc2 gene activity by protein phosphatase type 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR OKADAIC ACID; CELL-CYCLE REGULATION; MOUSE FIBROBLASTS; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; EXPRESSION; PROLIFERATION; GROWTH; PHOSPHORYLATION; MITOSIS	Several lines of evidence indicate that serine/threonine protein phosphatases may act as negative regulators of cellular growth. For example, treatment of cells with the tumor-promoter okadaic acid, an inhibitor of certain types of these phosphatases, resulted in the increased expression of several proto-oncogenes, indicating a negative role of the respective phosphatases in gene regulation. However, it was puzzling to find that okadaic acid-treated cells, even in the presence of highly expressed proto-oncogenes, did not proliferate, but were arrested at certain points of the cell cycle. To further analyze this discrepancy, we investigated the involvement of protein phosphatases in the control of other cell cycle regulatory genes, such as cdc2, which encodes an essential cell cycle regulatory kinase. We found that cdc2 gene expression was blocked by okadaic acid, but stimulated by protein phosphatase 2A. Protein phosphatase 2A is shown to be a positive regulator of cdc2 gene activity and to be required for cdc2 expression. Thus, our findings identify protein phosphatase 2A as a positive regulator of a major cell cycle regulatory gene and therefore suggest a stimulatory role of this enzyme in this aspect of cellular growth control.	UNIV SO CALIF, DEPT MOLEC MICROBIOL & IMMUNOL, LOS ANGELES, CA 90033 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, CHILDRENS HOSP, LOS ANGELES, CA 90033 USA	University of Southern California; University of California System; University of California San Diego; University of Southern California; Children's Hospital Los Angeles; University of Southern California			Glass, Christopher/AAI-3933-2021; Schonthal, Axel/ABH-3846-2020	Glass, Christopher/0000-0003-4344-3592; Schonthal, Axel/0000-0003-0662-5653				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERNDT N, 1987, FEBS LETT, V223, P340, DOI 10.1016/0014-5793(87)80316-2; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEAN NM, 1991, CARCINOGENESIS, V12, P665, DOI 10.1093/carcin/12.4.665; HU VW, 1994, CELL CYCLE REGULATOR; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KIM TA, 1993, P NATL ACAD SCI USA, V90, P5460, DOI 10.1073/pnas.90.12.5460; KONKANEN RE, 1991, J BIOL CHEM, V266, P6614; KU DH, 1993, J BIOL CHEM, V268, P2255; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKAMURA K, 1992, BIOCHEM BIOPH RES CO, V187, P507, DOI 10.1016/S0006-291X(05)81523-2; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHEAY W, 1993, BIOTECHNIQUES, V15, P856; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Sugarman Jeffrey L., 1995, Molecular and Cellular Differentiation, V3, P51; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; VANDRE DD, 1992, J CELL SCI, V101, P79; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	35	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5988	5992		10.1074/jbc.271.11.5988	http://dx.doi.org/10.1074/jbc.271.11.5988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626381	hybrid			2022-12-25	WOS:A1996UA36300010
J	Leventhal, PS; Feldman, EL				Leventhal, PS; Feldman, EL			Tyrosine phosphorylation and enhanced expression of paxillin during neuronal differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA-CELLS; GROWTH	Tyrosine phosphorylation has been implicated as a means by which neurite outgrowth is regulated. Because paxillin is a tyrosine-phosphorylated protein that may play a role in regulating cell morphology, we examined its expression in neuronal cells and how its tyrosine phosphorylation is related to neurite outgrowth. Paxillin was identified in several neuronal cell lines with an increased level upon differentiation. In SH-SY5Y cells, paxillin was localized along with actin filaments where processes extended from the cell body and in neuritic growth cones. Furthermore, paxillin was tyrosine-phosphorylated in SH-SY5Y cells upon adhesion to laminin. Paxillin tyrosine phosphorylation paralleled that of focal adhesion kinase and occurred as cell spreading, and neurite formation was initiated. Colchicine blocked neurite outgrowth but had no effect on cell spreading or on paxillin or focal adhesion kinase tyrosine phosphorylation. In contrast, cytochalasin D eliminated neurite outgrowth, cell spreading, and the tyrosine phosphorylation of paxillin and focal adhesion kinase. These results show that paxillin is tyrosine phosphorylated upon integrin ligand binding in neuronal cells. Our findings suggest that paxillin tyrosine phosphorylation is linked to a remodeling of the actin cytoskeleton that leads to cell spreading and neurite formation and thus a differentiated neuronal phenotype.	UNIV MICHIGAN, DEPT NEUROL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan				Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009912, R29NS032843] Funding Source: NIH RePORTER; NINDS NIH HHS [R29 NS32843, 1F32NS09912-01, T5T32NS722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREGUI CO, 1994, J NEUROSCI, V14, P6967; BIXBY JL, 1992, J NEUROBIOL, V23, P468, DOI 10.1002/neu.480230503; BIXBY JL, 1993, J NEUROSCI, V13, P3421; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOZZO C, 1994, EXP CELL RES, V214, P313, DOI 10.1006/excr.1994.1263; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHAKRABORTY M, 1993, BRAIN RES, V625, P197, DOI 10.1016/0006-8993(93)91059-2; CHENG N, 1990, J BIOL CHEM, V265, P2417; CHOI ESH, 1994, J NEUROSCI RES, V37, P475, DOI 10.1002/jnr.490370407; COX ME, 1991, EXP CELL RES, V195, P423, DOI 10.1016/0014-4827(91)90393-9; HELMKE S, 1995, CELL MOTIL CYTOSKEL, V30, P194, DOI 10.1002/cm.970300304; KHAN MA, 1995, FEBS LETT, V362, P201, DOI 10.1016/0014-5793(95)00250-D; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; MELAMED I, 1995, J EXP MED, V181, P1071, DOI 10.1084/jem.181.3.1071; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SMITH CL, 1994, J NEUROSCI, V14, P384; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653	21	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5957	5960		10.1074/jbc.271.11.5957	http://dx.doi.org/10.1074/jbc.271.11.5957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626373				2022-12-25	WOS:A1996UA36300002
J	Zdanovsky, AG; Zdanovskaia, MV; Strickland, D; Fitzgerald, DJ				Zdanovsky, AG; Zdanovskaia, MV; Strickland, D; Fitzgerald, DJ			Ligand-toxin hybrids directed to the alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein exhibit lower toxicity than native Pseudomonas exotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; ALPHA-2-MACROGLOBULIN RECEPTOR; DIPHTHERIA-TOXIN; ESCHERICHIA-COLI; MEDIATED ENDOCYTOSIS; HIGH-AFFINITY; BINDING; GENE; EXPRESSION; SEQUENCE	Pseudomonas exotoxin (PE) binds the heavy chain of the alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP). To understand the significance of this interaction, novel toxin-derived gene fusions were constructed with two ligands that also bind this receptor. A 39-kDa cellular protein, termed RAP, binds LRP with high affinity and often co-purifies with it. Two RAP toxins were constructed, one with PE and one with diphtheria toxin (DT). RAP, which replaced the toxins binding domains, was combined with each of the corresponding translocating and ADP-ribosylating domains. Both RAP-toxins bound LRP with an apparent higher affinity than native PE. Despite this, RAP-PE and DT-RAP were less toxic than native PE. Apparently, RAP-toxin molecules bound and entered cells but used a pathway that afforded only low efficiency of toxin transport to the cytosol. This was evident because co-internalization with adenovirus increased the toxicity of RAP-toxins by 10-fold. We speculate that the high affinity of RAP binding may not allow the toxin's translocating and ADP-ribosylating domains to reach the cytosol but rather causes the toxin to take another pathway, possibly one that leads to lysosomes. To test this hypothesis, additional RAP-PE fusions were constructed. N-terminal or C-terminal fragments of RAP were joined to PE to produce two novel fusion proteins which were likely to have reduced affinity for LRP. Both of these shorter fusion proteins exhibited greater toxicity than full-length RAP-PE. A second ligand-toxin gene fusion was constructed between plasminogen activator inhibitor type 1 and DT. DT-plasminogen activator inhibitor type I formed a complex with tissue-type plasminogen activator and inhibited its proteolytic activity. However, like the RAP-toxins, this hybrid was less toxic for cells than native PE.	NCI,MOLEC BIOL LAB,DIV CANC BIOL DIAG & CTR,NIH,BETHESDA,MD 20892; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross								ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BACHA P, 1983, J BIOL CHEM, V258, P1565; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GULDIRONTANI C, 1987, MOL BIOL, V1, P67; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NIKJAER A, 1992, J BIOL CHEM, V267, P14543; OGATA M, 1990, J BIOL CHEM, V265, P20678; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; ROLF JM, 1990, J BIOL CHEM, V265, P7331; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; Siegall C B, 1990, Semin Cancer Biol, V1, P345; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TWETEN RK, 1985, J BIOL CHEM, V260, P392; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WRSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; ZDANOVSKY AG, 1992, GENE, V116, P81, DOI 10.1016/0378-1119(92)90632-Y; ZDANOVSKY AG, 1990, MOL GENET MICROBIOL, V7, P27	39	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6122	6128		10.1074/jbc.271.11.6122	http://dx.doi.org/10.1074/jbc.271.11.6122			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626399	hybrid			2022-12-25	WOS:A1996UA36300028
J	Abe, K; Hayashi, H; Malone, PC				Abe, K; Hayashi, H; Malone, PC			Exchange of aspartate and alanine - Mechanism for development of a proton-motive force in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXALOBACTER-FORMIGENES; STREPTOCOCCUS-LACTIS; MALOLACTIC FERMENTATION; ANION-EXCHANGE; ANTIPORT; MEMBRANE; ENERGY; RECONSTITUTION; PHOSPHATE; OXALATE	We examined the idea that aspartate metabolism by Lactobacillus subsp. M3 is organized as a proton-motive metabolic cycle by using reconstitution to monitor the activity of the carrier, termed AspT, expected to carry out the electrogenic exchange of precursor (aspartate) and product (alanine), Membranes of Lactobacillus subsp. M3 were extracted with 1.25% octyl glucoside in the presence of 0.4% Escherichia coli phospholipid and 20% glycerol. The extracts were then used to prepare proteoliposomes loaded with either aspartate or alanine. Aspartate-loaded proteoliposomes accumulated external [H-3]aspartate by exchange with internal substrate; this homologous self-exchange (K-t = 0.4 mM) was insensitive to potassium or proton ionophores and was unaffected by the presence or absence of Na+, K+, or Mg2+. Alanine-loaded proteoliposomes also took up [H-3]aspartate in a heterologous antiport reaction that was stimulated or inhibited by an inside-positive or inside-negative membrane potential, respectively, Several lines of evidence suggest that these homologous and heterologous exchange reactions were catalyzed by the same functional unit, Thus, [H-3]aspartate taken up by AspT during self-exchange was released by a delayed addition of alanine, In addition, the spontaneous loss of AspT activity that occurs when a detergent extract is held at 37 degrees C prior to reconstitution was prevented by the presence of either aspartate (K-D(aspartate) = 0.3 mM) or alanine (K-D(alanine) greater than or equal to 10 mM), indicating that both substrates interact directly with AspT, These findings are consistent with operation of a proton motive metabolic cycle during aspartate metabolism by Lactobacillus subsp. M3.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; KIKKOMAN FOODS INC,NODA,CHIBA 278,JAPAN	Johns Hopkins University; Kikkoman Corporation					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; CHEN CC, 1984, J BIOL CHEM, V259, P150; HAROLD FM, 1977, SCIENCE, V197, P372, DOI 10.1126/science.69317; MALONEY P C, 1975, Journal of Membrane Biology, V25, P285, DOI 10.1007/BF01868580; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1977, J BACTERIOL, V132, P564, DOI 10.1128/JB.132.2.564-575.1977; MALONEY PC, 1987, ESCHERICHIA COLI SAL, P222; MASON PW, 1981, J BIOL CHEM, V256, P1861; MOLENAAR D, 1993, J BACTERIOL, V175, P2864, DOI 10.1128/JB.175.10.2864-2870.1993; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; PAVLASOVA E, 1969, J BACTERIOL, V98, P198, DOI 10.1128/JB.98.1.198-204.1969; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; Postma P.W., 1987, ESCHERICHIA COLI SAL, P127; RAMOS A, 1994, J BACTERIOL, V176, P4899, DOI 10.1128/jb.176.16.4899-4905.1994; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SALEMA M, 1994, EUR J BIOCHEM, V225, P289, DOI 10.1111/j.1432-1033.1994.00289.x; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x	24	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3079	3084		10.1074/jbc.271.6.3079	http://dx.doi.org/10.1074/jbc.271.6.3079			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621704	hybrid			2022-12-25	WOS:A1996TU69100033
J	Aznavoorian, S; Stracke, ML; Parsons, J; McClanahan, J; Liotta, LA				Aznavoorian, S; Stracke, ML; Parsons, J; McClanahan, J; Liotta, LA			Integrin alpha(v)beta(3), mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL TRISPHOSPHATE; VITRONECTIN RECEPTOR; FIBRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; TUMOR-CELLS; GI-PROTEIN	Distinctions between chemotaxis and haptotaxis of cells to extracellular matrix proteins have not been defined in terms of mechanisms or signaling pathways. Migration of A2058 human melanoma cells to soluble (chemotaxis) and substratum-bound (haptotaxis) vitronectin, mediated by alpha(v) beta(3) provided a system with which to address these questions. Both chemotaxis and haptotaxis were completely inhibited by treatment with RGD-containing peptides. Chemotaxis was abolished by a blocking antibody to alpha(v) beta(3) (LM609), whereas haptotaxis was inhibited only by approximately 50%, suggesting involvement of multiple receptors and/or signaling pathways. However, blocking antibodies to alpha(v) beta(3) also present on A2058 cells, did not inhibit. Pertussis toxin treatment of cells inhibited chemotaxis by > 80%, but did not inhibit haptotaxis. Adhesion and spreading over vitronectin induced the phosphorylation of paxillin on tyrosine. In cells migrating over substratum-bound vitronectin, tyrosine phosphorylation of paxillin increased 5-fold between 45 min and 5 h. Dilutions of anti-alpha(v) beta(3) that inhibited haptotaxis also inhibited phosphorylation of paxillin (by alpha 50%) and modestly reduced cell spreading. In contrast, soluble vitronectin (50-100 mu g/ ml) did not induce tyrosine phosphorylation of paxillin. The data suggest that soluble vitronectin stimulates chemotaxis predominantly through a G protein-mediated pathway that is functionally linked to alpha(v) beta(3). Haptotaxis is analogous to directional cell spreading and requires alpha v beta 3-mediated tyrosine phosphorylation of paxillin.			Aznavoorian, S (corresponding author), NCI, PATHOL LAB, NIH, BLDG 10, RM 2A33, BETHESDA, MD 20892 USA.							ALBELDA SM, 1990, CANCER RES, V50, P6757; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BHATTACHARYA S, 1995, J BIOL CHEM, V270, P16781, DOI 10.1074/jbc.270.28.16781; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BRANDO C, 1995, J IMMUNOL, V154, P2005; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; JENNE D, 1985, THROMB RES, V38, P401, DOI 10.1016/0049-3848(85)90138-0; KIM JP, 1994, J BIOL CHEM, V269, P26926; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1988, EXP CELL RES, V174, P1, DOI 10.1016/0014-4827(88)90136-X; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; MARSHALL JF, 1991, INT J CANCER, V49, P924, DOI 10.1002/ijc.2910490621; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NABI IR, 1992, CANCER METAST REV, V11, P5, DOI 10.1007/BF00047599; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RABINOWICH H, 1995, J IMMUNOL, V154, P1124; RANKIN S, 1994, J BIOL CHEM, V269, P704; RECORD RD, 1993, EXP CELL RES, V206, P36, DOI 10.1006/excr.1993.1117; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SCZEKAN MM, 1990, J CELL PHYSIOL, V142, P574, DOI 10.1002/jcp.1041420317; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; SWERLICK RA, 1992, J INVEST DERMATOL, V99, P715, DOI 10.1111/1523-1747.ep12614207; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454; ZIGMOND SH, 1989, AM J RESP CELL MOL, V1, P451, DOI 10.1165/ajrcmb/1.6.451	67	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3247	3254		10.1074/jbc.271.6.3247	http://dx.doi.org/10.1074/jbc.271.6.3247			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621727	hybrid			2022-12-25	WOS:A1996TU69100056
J	Dent, P; Reardon, DB; Wood, SL; Lindorfer, MA; Graber, SG; Garrison, JC; Brautigan, DL; Sturgill, TW				Dent, P; Reardon, DB; Wood, SL; Lindorfer, MA; Graber, SG; Garrison, JC; Brautigan, DL; Sturgill, TW			Inactivation of Raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by G(alpha i/o) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANES; CELLS	A membrane associated form of Raf-1 in v-Ras transformed NIH 3T3 cells can be inactivated by protein phosphatases regulated by GTP. Herein, a distinct protein-tyrosine phosphatase (PTPase) in membrane preparations from v-Ras transformed NiH 3T3 cells was found to be activated by guanyl 5'-yl imidodiphosphate (GMPPNP) and was identified as an effector for pertussis toxin (PTx)-sensitive G-protein alpha subunits. PTPase activation was blocked by prior treatment of cells with PTx. PTPase activation by GTP, but not GMPPNP, was transient. A GMPPNP-stimulated PTPase (PTPase-G) co-purified with G(alpha i/o) subunits during Superose 6 and Mono Q chromatography. PTPase-G; activity in Superose 6 fractions from GDP-treated membranes was reconstituted by activated G(alpha i/o) but not G(beta gamma), subunits. PTPase-G; may contribute to GMPPNP-stimulated inactivation of Raf-1 in v-Ras cell membranes because Raf-1 inactivation was PTx-sensitive and PTPase-G inactivated exogenous Raf-1.	UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; W VIRGINIA UNIV,DEPT PHARMACOL,MORGANTOWN,WV 26506	Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; West Virginia University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077, R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035266] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19952, DK41077] Funding Source: Medline; NIGMS NIH HHS [GM35266] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0	21	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3119	3123		10.1074/jbc.271.6.3119	http://dx.doi.org/10.1074/jbc.271.6.3119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621710	hybrid			2022-12-25	WOS:A1996TU69100039
J	Eytan, GD; Regev, R; Assaraf, YG				Eytan, GD; Regev, R; Assaraf, YG			Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG TRANSPORTER; PROTEIN	We have recently described an ATP-driven, valinomycin-dependent Rb-86(+) uptake into proteoliposomes reconstituted with mammalian P-glycoprotein (Eaten, G. D., Borgnia, M. J., Regev, R., and Assaraf, Y. G. (1994) J. Biol. Chem, 269, 26058-26065), P-glycoprotein mediated the ATP-dependent uptake of Rb-86(+)-ionophore complex into the proteoliposomes, where the radioactive cation was accumulated, thus, circumventing the obstacle posed by the hydrophobicity of P-glycoprotein substrates in transport studies, Taking advantage of this assay and of the high levels of P-glycoprotein expression in multi-drug-resistant Chinese hamster ovary cells, we measured simultaneously both the ATPase and transport activities of P-glycoprotein under identical conditions and observed 0.5-0.8 ionophore molecules transported/ATP molecule hydrolyzed, The amount of Rb-86(+) ions transported within 1 min via the ATP and valinomycin-dependent P-glycoprotein was equivalent to an intravesicular cation concentration of 8 mM. Thus, this stoichiometry and transport capacity of P-glycoprotein resemble various ion-translocating ATPases, that handle millimolar substrate concentrations. This constitutes the first demonstration of comparable rates of P-glycoprotein-catalyzed substrate transport and ATP hydrolysis.			Eytan, GD (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.			Assaraf, Yehuda G./0000-0001-6692-8221				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ASSARAF YG, 1994, EUR J BIOCHEM, V222, P813, DOI 10.1111/j.1432-1033.1994.tb18928.x; BENZ R, 1976, J MEMBRANE BIOL, V27, P1441; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; BROXTERMAN HJ, 1988, FASEB J, V2, P2278, DOI 10.1096/fasebj.2.7.3350243; BROXTERMAN HJ, 1989, FEBS LETT, V247, P405, DOI 10.1016/0014-5793(89)81380-8; CHABNER BA, 1990, CANCER CHEMOTHERAPY; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; ESEN A, 1978, ANAL BIOCHEM, V89, P264, DOI 10.1016/0003-2697(78)90749-2; EYTAN GD, 1994, J BIOL CHEM, V269, P26058; FREI E, 1985, CANCER RES, V45, P6523; GARTY H, 1989, METHOD ENZYMOL, V172, P155; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008	23	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3172	3178		10.1074/jbc.271.6.3172	http://dx.doi.org/10.1074/jbc.271.6.3172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621717	hybrid			2022-12-25	WOS:A1996TU69100046
J	Nishino, S; Kuroyanagi, H; Terada, T; Inoue, Y; Troy, FA; Kitajima, K				Nishino, S; Kuroyanagi, H; Terada, T; Inoue, Y; Troy, FA; Kitajima, K			Induction, localization, and purification of a novel sialidase, deaminoneuraminidase (KDNase), from Sphingobacterium multivorum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; LINKED GLYCAN CHAINS; RAINBOW-TROUT EGGS; RICH GLYCOPROTEIN; 3-DEOXY-D-GLYCERO-D-GALACTO-NONULOSONIC ACID; VITELLINE ENVELOPE; JELLY COAT; POLYSIALOGLYCOPROTEIN; DETERMINANTS	Recently, we reported the discovery of a new type of sialidase, KDNase, which specifically hydrolyzes the ketosidic linkages of 2-keto-3-deoxy-D-glycero-D-galactonononic acid (KDN), but not N-acylneuraminyl linkages. We now report that this enzyme, designated KDNase SM, is an inducible enzyme that is localized in the periplasm of Sphingobacterium multivorum. Growth of S. multivorum in the presence of KDN-containing oligosaccharide alditols, KDN alpha 2-->3Gal beta 1-->3GalNAc alpha 1-->3[KDN alpha 2-->(8KDN alpha 2-->)(n)-->6]GalNAcol, as a sole carbon source induced KDNase SM activity 15-40-fold, compared with growth in the absence of inducer, KDN, Neu5Ac, or Neu5Ac oligomers were ineffective as inducers. The enzyme was released from the periplasm of induced cells by cold osmotic shock and purified 700-fold to homogeneity. The specific activity of the pure enzyme was 82,100 units/mg of protein, KDNase SM activity resided in a single polypeptide chain with an estimated molecular weight of approximately 47,500. Enzyme activity was maximal at near neutral pH. The availability of pure KDNase will now make it possible to study the structure and functional role of KDN-glycoconjugates and to determine the molecular mechanism whereby the enzyme can discriminate between KDN and N-acylneuraminic acid.	UNIV TOKYO, GRAD SCH SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN; UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of Tokyo; Showa University; University of California System; University of California Davis								ANGATA T, 1994, GLYCOBIOLOGY, V4, P517, DOI 10.1093/glycob/4.4.517; ANRAKU Y, 1967, J BIOL CHEM, V242, P2561; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; SONG Y, 1993, BIOCHEMISTRY-US, V32, P9221, DOI 10.1021/bi00086a030; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; TEZUKA T, 1994, BIOCHEMISTRY-US, V33, P6495, DOI 10.1021/bi00187a016; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014; YE J, 1994, METHOD ENZYMOL, V230, P460	24	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2909	2913		10.1074/jbc.271.6.2909	http://dx.doi.org/10.1074/jbc.271.6.2909			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621679	hybrid			2022-12-25	WOS:A1996TU69100008
J	Scarpati, EM; DiCorleto, PE				Scarpati, EM; DiCorleto, PE			Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; SIMIAN SARCOMA-VIRUS; RNA POLYMERASE-II; TRANSCRIPTION FACTOR SP1; REGULATORY ELEMENTS; BINDING-FACTOR; GENE; EXPRESSION; PDGF; ACTIVATION	Thrombin is a coagulation system protease that also serves as a potent stimulator of gene expression in several cell types, including endothelial cells (EC). We and others have previously demonstrated that the transcription of platelet-derived growth factor (PDGF) B-chain (c-sis) by EC is stimulated severalfold by thrombin. Here we examine the molecular mechanism of this regulatory process using bovine aortic EC transiently transfected with a vector containing the chloramphenicol acetyltransferase (CAT) gene under the control of a 400-base pair fragment of the human PDGF B-chain promoter. Thrombin treatment of these cells caused a severalfold increase in CAT expression, Deletion analysis and site-directed mutagenesis revealed that the region spanning nucleotides -61 to -53 from the transcription initiation site (referred to as the thrombin response, or ThR, region) was critical for the transcriptional response to thrombin, Electrophoretic mobility shift assays with an oligonucleotide corresponding to the region -64 to -44, which contained the ThR region, led to the identification of a thrombin-inducible nuclear factor (TINF) in extracts from thrombin-treated, but not control, EC, TINF was formed as early as 40 min post thrombin treatment, persisted for at least 7 h, but was no longer present after 24 h, TINF appeared in the absence of de novo protein synthesis, The ThR region consists of a repeat of a CCACCC element in an ABBA configuration, which, based on mutation analysis and transfection assays, appears to be critical in mediating thrombin stimulation of the PDGF B-chain gene. The conservation of the ThR region in the promoter of the PDGF B-chain among three species (human, feline, and murine) further supports the importance of this region as a cis-acting regulatory element.	CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NHLBI NIH HHS [HL-29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONIADES HN, 1983, FED PROC, V42, P2630; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BONTHRON DT, 1991, GENOMICS, V10, P287, DOI 10.1016/0888-7543(91)90515-G; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DEUEL TF, 1983, PROGR HEMATOLOGY, V13; DICORLETO PE, 1989, BIOCHEM J, V264, P71, DOI 10.1042/bj2640071; DICORLETO PE, 1988, ENDOTHELIAL CELLS, V2, P51; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; DIRKS RPH, 1993, EUR J BIOCHEM, V211, P509, DOI 10.1111/j.1432-1033.1993.tb17577.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FARNHAM PJ, 1991, GENE EXPRESSION, V1, P137; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GUMUCIO DL, 1991, BLOOD, V78, P1853; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LEVIN EG, 1984, J CLIN INVEST, V74, P1988, DOI 10.1172/JCI111620; LEVINE JD, 1982, BLOOD, V60, P531; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MORGAN WD, 1989, MOL CELL BIOL, V9, P4099, DOI 10.1128/MCB.9.9.4099; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1989, LANCET, V1, P1179; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; SHULTZ PJ, 1988, AM J PHYSIOL, V255, pF674, DOI 10.1152/ajprenal.1988.255.4.F674; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; VANDENOUWELAND AMW, 1986, NUCLEIC ACIDS RES, V14, P765; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; YU CY, 1991, J BIOL CHEM, V266, P8907	54	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3025	3032		10.1074/jbc.271.6.3025	http://dx.doi.org/10.1074/jbc.271.6.3025			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621696	hybrid			2022-12-25	WOS:A1996TU69100025
J	Yang, X; Goncalves, J; Gabuzda, D				Yang, X; Goncalves, J; Gabuzda, D			Phosphorylation of Vif and its role in HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE-C; GAG GENE-PRODUCTS; REV PROTEIN; ANTIRETROVIRAL ACTIVITY; INFECTED-CELLS; DNA-SYNTHESIS; VPU-PROTEIN; CEM CELLS; SOR GENE	Vif is a 23-kDa protein encoded by human immunodeficiency virus, type 1 (HIV-1) which is important for virion infectivity. Here, we describe the phosphorylation of HIV-1 Vif and its role in HIV-1 replication. In vivo studies demonstrated that Vif is highly phosphorylated on serine and threonine residues. To identify phosphorylation sites and characterize the Vif kinase(s), Vif was expressed in Escherichia coli and purified for use as a substrate in in vitro kinase assays. The purified Vif protein was phosphorylated in vitro on serine and threonine residues by a kinase(s) present in both cytosol and membrane fractions. Phosphorylation of Vif was stimulated by phorbol 12-myristate 13-acetate and inhibited by staurosporine and hypericin, a drug with potent anti-HIV activity. The Vif kinase(s) was resistant to inhibitors of protein kinase C, cAMP-dependent kinase, and cGMP-dependent kinase, suggesting that it is distinct from these enzymes. To identify the phosphorylation sites, P-32-labeled Vif was digested by V8 protease and the peptides were resolved by reverse-phase high performance liquid chromatography. Radioactive peptide sequencing identified three phosphorylation sites within the C terminus, Ser(144), Thr(155), and Thr(188). Two-dimensional tryptic phosphopeptide mapping indicated that these sites are also phosphorylated in vivo. Both Ser(144) and Thr(188) are contained in the recognition motifs (R/KXXS*/T* and R/KXXXS*/T*) used by serine/threonine protein kinases such as cGMP-dependent kinase and PKC. Ser(144) is present in the motif SLQXLA, which is the most highly conserved sequence among all lentivirus Vif proteins. Mutation of Ser(144) to alanine resulted in loss of Vif activity and >90% inhibition of HIV-1 replication. These studies suggest that phosphorylation of Vif by a serine/threonine protein kinase(s) plays an important role in regulating HIV-1 replication and infectivity.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV HUMAN RETROVIROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			iMed.ULisboa, M2B/B-5277-2014; Goncalves, Joao/B-2013-2008	iMed.ULisboa, M2B/0000-0002-1245-3715; Goncalves, Joao/0000-0002-1245-3715	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033837, R01AI036186, P30AI028691] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36186, AI33837, AI28691] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDRES JC, 1994, VIROLOGY, V201, P157, DOI 10.1006/viro.1994.1278; BLANC D, 1993, VIROLOGY, V193, P186, DOI 10.1006/viro.1993.1114; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1989, J VIROL, V63, P4438, DOI 10.1128/JVI.63.10.4438-4440.1989; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; DEGAR S, 1992, AIDS RES HUM RETROV, V8, P1929, DOI 10.1089/aid.1992.8.1929; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FORD CE, 1994, J BIOL CHEM, V269, P30378; FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; GUY B, 1991, J VIROL, V65, P1325, DOI 10.1128/JVI.65.3.1325-1331.1991; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAUBER J, 1988, J VIROL, V62, P4801, DOI 10.1128/JVI.62.12.4801-4804.1988; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAURENT AG, 1990, J GEN VIROL, V71, P2273, DOI 10.1099/0022-1317-71-10-2273; LAVIE G, 1989, P NATL ACAD SCI USA, V86, P5963, DOI 10.1073/pnas.86.15.5963; LENARD J, 1993, P NATL ACAD SCI USA, V90, P158, DOI 10.1073/pnas.90.1.158; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MICHAELS FH, 1993, AIDS RES HUM RETROV, V9, P1025, DOI 10.1089/aid.1993.9.1025; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MYERS G, 1988, HUMAN RETROVIRUSES A; OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760; OVERTON HA, 1989, VIROLOGY, V170, P107, DOI 10.1016/0042-6822(89)90357-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SCHUBERT U, 1992, EUR J BIOCHEM, V204, P875, DOI 10.1111/j.1432-1033.1992.tb16707.x; SIMM M, 1995, J VIROL, V69, P4582, DOI 10.1128/JVI.69.7.4582-4586.1995; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792	55	97	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10121	10129		10.1074/jbc.271.17.10121	http://dx.doi.org/10.1074/jbc.271.17.10121			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626571	hybrid			2022-12-25	WOS:A1996UG25700043
J	Denbow, CJ; Lang, S; Cramer, CL				Denbow, CJ; Lang, S; Cramer, CL			The N terminal domain of tomato 3-hydroxy-3-methylglutaryl-CoA reductases - Sequence, microsomal targeting, and glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; MEMBRANE DOMAIN; REGULATED DEGRADATION; ARABIDOPSIS-THALIANA; CDNA; INDUCTION; ELICITOR; PROTEINS	The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) catalyzes the conversion of 3-hydroxy-3-methylglutaryl-CoA to mevalonic acid, considered the rate-limiting step in isoprenoid biosynthesis. In plants, isoprenoid compounds play important roles in mediating plant growth and development, electron transport, photosynthesis, and disease resistance. Sequence comparisons of plant HMGR proteins with those from yeast and mammalian systems reveal high levels of sequence identity within the catalytic domain but significant divergence in the membrane domain. Mammalian HMGRs are integral membrane proteins of the endoplasmic reticulum with eight membrane-spanning regions. In contrast, the membrane domain of plant HMGRs is predicted to contain only one to two transmembrane spans. We have isolated and sequenced a clone (pCD4) encoding exon 1 of tomato hmg1. The membrane domain structures of two differentially regulated tomato HMGR isoforms, HMG1 and HMG2, were analyzed using in vitro transcription and translation systems. Microsomal membrane insertion of the tomato HMGRs is co-translational and does not involve cleavage of an N-terminal targeting peptide, HMGR membrane topography was established by protease protection studies of the HMG1 membrane domain and an analogous region of HMG2 engineered to contain a c-myc epitope tag, The data indicate that both tomato HMGRs span the membrane two times with both the C and N termini located in the cytosol, Lumenal localization of the short peptide predicted to lie within the endoplasmic reticulum was further confirmed by in vitro glycosylation of an asparagine-linked glycosylation site present in HMG2.	VIRGINIA POLYTECH INST & STATE UNIV, FRALIN BIOTECHNOL CTR, DEPT PLANT PATHOL PHYSIOL & WEED SCI, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039549] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29-GM39549] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; BACH TJ, 1991, LIPIDS, V26, P637, DOI 10.1007/BF02536429; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CAMPOS N, 1988, J BIOL CHEM, V263, P9646; CHAPPELL J, 1991, PLANT PHYSIOL, V97, P693, DOI 10.1104/pp.97.2.693; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHOI D, 1994, P NATL ACAD SCI USA, V91, P2329, DOI 10.1073/pnas.91.6.2329; CHOI D, 1992, PLANT CELL, V4, P1333, DOI 10.1105/tpc.4.10.1333; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; CRAMER CL, 1993, J NEMATOL, V25, P507; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENJUTO M, 1994, P NATL ACAD SCI USA, V91, P927, DOI 10.1073/pnas.91.3.927; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gal S, 1993, CURR OPIN CELL BIOL, V5, P636, DOI 10.1016/0955-0674(93)90133-B; GENSCHIK P, 1992, PLANT MOL BIOL, V20, P337, DOI 10.1007/BF00014504; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GILLASPY G, 1993, PLANT CELL, V5, P1439, DOI 10.1105/tpc.5.10.1439; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAFFNER MH, 1978, CAN J BIOCHEM, V56, P7229; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LISCUM L, 1985, J BIOL CHEM, V260, P522; MALDONADOMENDOZA IE, 1992, PLANT PHYSIOL, V100, P1613, DOI 10.1104/pp.100.3.1613; MONFAR M, 1990, RECENT ADV PHYTOCHEM, V24, P83; NARITA JO, 1989, PLANT CELL, V1, P181, DOI 10.1105/tpc.1.2.181; NARITA JO, 1991, J CELL BIOCHEM, V15, pA447; NELSON AJ, 1994, PLANT MOL BIOL, V25, P401, DOI 10.1007/BF00043869; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PARK H, 1992, PLANT MOL BIOL, V20, P327, DOI 10.1007/BF00014502; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SNYDER BA, 1990, SCIENCE, V248, P1637, DOI 10.1126/science.248.4963.1637; STERMER BA, 1987, PLANT PHYSIOL, V84, P404, DOI 10.1104/pp.84.2.404; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; WEISSENBORN DL, 1995, PHYSIOL PLANTARUM, V93, P393, DOI 10.1111/j.1399-3054.1995.tb02244.x; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411	47	38	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9710	9715		10.1074/jbc.271.16.9710	http://dx.doi.org/10.1074/jbc.271.16.9710			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621648	hybrid			2022-12-25	WOS:A1996UG04400079
J	Schmid, E; Koziol, JA; Babior, BM				Schmid, E; Koziol, JA; Babior, BM			Enhancement of protein kinase C-dependent O-2(-center dot) production in Epstein-Barr virus-transformed B lymphocytes by p120(Ras-GAP) antisense oligonucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; TYROSINE PHOSPHORYLATION; SUBCELLULAR-DISTRIBUTION; NADPH OXIDASE; RAS; SRC; GROWTH	The mammalian Ras GTPase-activating protein (p120(Ras-GAP)) interacts with activated members of the Ras superfamily of GTP-binding proteins to accelerate their deactivation by sharply increasing their rates of GTP hydrolysis. Among the Ras-family proteins interacting with p120(Ras-GAP) is Rap1A/Krev1, whose activity is not affected by p120(Ras-GAP) but which competes with Ras for p120(Ras-GAP). A second protein that interacts with p120(Ras-GAP) is p190(Rac-GAP), which activates the GTPase of guanine nucleotide-binding proteins of the Rho family (including Rac1 and Rac2). Both these p120(Ras-GAP)- binding proteins are of interest in connection with the regulation of the respiratory burst oxidase, Rap1A/Krev1 because it copurifies with cytochrome b(558), and p190(Rac-GAP) because it inhibits the Rac2-dependent activation of the respiratory burst oxidase in a cell-free system, Using an 18-mer antisense oligonucleotide, we were able to decrease the expression of p120(Ras-GAP) in Epstein-Barr virus-transformed B lymphocytes. Under conditions where p120(Ras-GAP) expression was significantly depressed by antisense oligonucleotides, we observed a 40% increase in protein kinase C-dependent but not receptor-dependent O-2(radical anion) production. In contrast, sense and scrambled oligonucleotides had no effect on either p120(Ras-GAP) expression or O-2(radical anion) production Our results suggest a role for p120(Ras-GAP) as a negative regulator in the protein kinase C-mediated activation of the respiratory burst oxidase.			Schmid, E (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI-24227, AI-28479] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024227, R01AI024227, R21AI128479, R01AI028479] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHANOCK SJ, 1992, P NATL ACAD SCI USA, V89, P10174, DOI 10.1073/pnas.89.21.10174; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLD MR, 1993, J IMMUNOL, V150, P377; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MALY FE, 1994, J BIOL CHEM, V269, P18743; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARK S, 1992, J BIOL CHEM, V267, P17194; PARK S, 1993, J BIOL CHEM, V268, P25728; PATERSON BM, 1977, P NATL ACAD SCI USA, V74, P4370, DOI 10.1073/pnas.74.10.4370; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; PRONK GJ, 1992, ONCOGENE, V7, P389; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; QUINN MT, 1992, BLOOD, V79, P1563; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; THRASHER A, 1992, BLOOD, V80, P1125; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	55	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9320	9325		10.1074/jbc.271.16.9320	http://dx.doi.org/10.1074/jbc.271.16.9320			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621595	hybrid			2022-12-25	WOS:A1996UG04400026
J	Zal, F; Lallier, FH; Green, BN; Vinogradov, SN; Toulmond, A				Zal, F; Lallier, FH; Green, BN; Vinogradov, SN; Toulmond, A			The multi-hemoglobin system of the hydrothermal vent tube worm Riftia pachyptila .2. Complete polypeptide chain composition investigated by maximum entropy analysis of mass spectra	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIANT EXTRACELLULAR HEMOGLOBIN; SODIUM DODECYL-SULFATE; AMINO-ACID-SEQUENCE; POLYCHAETE TYLORRHYNCHUS-HETEROCHAETUS; LUMBRICUS-TERRESTRIS; QUATERNARY STRUCTURE; FUNCTIONAL-PROPERTIES; EARTHWORM HEMOGLOBIN; ANNELID HEMOGLOBIN; SUBUNIT	The deep-sea tube worm Riftia pachyptila Jones possesses a complex of three extracellular Hbs: two in the vascular compartment, V1 (similar to 3500 kDa) and V2 (similar to 400 kDa), and one in the coelomic cavity, C1 (similar to 400 kDa). These native Hbs, their dissociation products and derivatives were subjected to electrospray ionization mass spectrometry (ESI-MS). The data were analyzed by the maximum entropy deconvolution system. We identified three groups of peaks for V1 Hb, at similar to 16, 23-27, and 30 kDa, corresponding to (i) two monomeric globin chains, b (M(r) 16,133.5) and c (M(r) 16,805.9); (ii) four linker subunits, L1-L4 (M(r) 23,505.2, 23,851.4, 26,342.4, and 27,425.8, respectively); and (iii) one disulfide-bonded dimer D1 (M(r) 31,720.7) composed of globin chains d (M(r) 15,578.5) and e (M(r) 16,148.3), V2 and C1 Hbs had no linkers and contained a glycosylated monomeric globin chain, a (M(r) 15,933.4) and a second dimer D2 (M(r) 32,511.7) composed of chains e and f (M(r) 16,368.1). The dimer D1 was absent from C1 Hb, clearly differentiating V2 and C1 Hbs. These Hbs were also subjected to SDS-PAGE analysis for comparative purposes, The following models are proposed ((cD1)(bD1)(3)) for the one-twelfth protomer of V1 Hb, ((cD)(bD)(6)(aD)) (D corresponding to either D1 or D2) for V2 and C1 Hbs. HBL V1 Hb would be composed of 180 polypeptide chains with 144 globin chains and 36 linker chains, each twelfth being in contact with three linker subunits, providing a total molecular mass = 3285 kDa. V2 and C1 would be composed of 24 globin chains providing a total molecular mass = 403 kDa and 406 kDa, respectively. These results are in excellent agreement with experimental M(r) determined by STEM mass mapping and MALLS (8).	VG ORGAN, ALTRINCHAM WA14 5RZ, ENGLAND; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Wayne State University	Zal, F (corresponding author), UPM, CNRS,INSU,EQUIPE ECOPHYSIOL,STN BIOL, PL GEORGES TEISSIER, BP 74, F-29682 ROSCOFF, FRANCE.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38674] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARP AJ, 1987, J EXP BIOL, V128, P139; ASHTON DS, 1994, FEBS LETT, V342, P1, DOI 10.1016/0014-5793(94)80572-5; CHUNG MCM, 1979, PROG BIOPHYS MOL BIO, V35, P53; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; FERRIGE AG, 1991, RAPID COMMUN MASS SP, V5, P374, DOI 10.1002/rcm.1290050810; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FISH WW, 1970, J BIOL CHEM, V245, P5166; FISHER CR, 1990, SCIENCE, V247, P1094, DOI 10.1126/science.247.4946.1094; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1988, P NATL ACAD SCI USA, V85, P9461, DOI 10.1073/pnas.85.24.9461; GARLICK RL, 1982, J BIOL CHEM, V257, P9005; GREEN BN, 1995, J BIOL CHEM, V270, P18209, DOI 10.1074/jbc.270.31.18209; KAPP OH, 1990, J MOL BIOL, V213, P141, DOI 10.1016/S0022-2836(05)80127-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBIN P, 1979, ANAL BIOCHEM, V98, P160, DOI 10.1016/0003-2697(79)90721-8; LAMBIN P, 1976, ANAL BIOCHEM, V74, P567, DOI 10.1016/0003-2697(76)90239-6; MARTIN BM, 1991, TECHNIQUES PROTEIN C, V2, P191; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; QABAR AN, 1991, J MOL BIOL, V222, P1109, DOI 10.1016/0022-2836(91)90596-X; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; Rossi-Fanelli A., 1958, BIOCHIM BIOPHYS ACTA, V30, P608; SUZUKI T, 1989, ZOOL SCI, V6, P915; SUZUKI T, 1988, BIOCHEM J, V255, P541; SUZUKI T, 1986, J BIOL CHEM, V261, P9257; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; SUZUKI T, 1990, J BIOL CHEM, V265, P1551; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TERWILLIGER R, 1985, BIOCHIM BIOPHYS ACTA, V829, P27, DOI 10.1016/0167-4838(85)90064-0; TERWILLIGER RC, 1980, COMP BIOCHEM PHYS B, V65, P531, DOI 10.1016/0305-0491(80)90307-7; TOULMOND A, 1994, DEEP-SEA RES PT I, V41, P1447, DOI 10.1016/0967-0637(94)90054-X; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1980, COMP BIOCHEM PHYS B, V67, P1, DOI 10.1016/0305-0491(80)90262-X; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; Zal F, 1996, J BIOL CHEM, V271, P8869, DOI 10.1074/jbc.271.15.8869; 1993, J PHYS CHEM REF DATA, V22, P1571	42	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8875	8881		10.1074/jbc.271.15.8875	http://dx.doi.org/10.1074/jbc.271.15.8875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621529	hybrid			2022-12-25	WOS:A1996UE73000060
J	Grahame, DA; DeMoll, E				Grahame, DA; DeMoll, E			Partial reactions catalyzed by protein components of the acetyl-CoA decarbonylase synthase enzyme complex from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; METHANOTHRIX-SOEHNGENII; CLOSTRIDIUM-THERMOACETICUM; COENZYME-A; PURIFICATION; CLEAVAGE; THERMOPHILA; CENTERS	In methanogens, the acetyl-CoA decarbonylase synthase (ACDS) complex, which has five different subunits, catalyzes synthesis and cleavage of acetyl-CoA according to the reaction: CO2 + 2H(+) + 2e(-) + CH3-H4SPt + CoA reversible arrow acetyl-CoA + H4SPt + H2O, where H4SPt and CH3-H4SPt are tetrahydrosarcinapterin and N-5-methyl-tetrahydrosarcinapterin, respectively. We have dissociated the ACDS complex into three protein components by limited proteolytic digestion, Catalysis of acetyl-CoA synthesis was lost in parallel with the loss of the intact beta subunit; however, no decrease in activity was detected in any of three partial reactions found to be catalyzed by distinct protein components of the proteolyzed ACDS complex: (a) CO dehydrogenase, catalyzed by the alpha epsilon component, (b) CH3-H(4)pteridine:cob(I)amide-protein methyltransferase, catalyzed by the intact gamma subunit and fragments of the delta subunit, and (c) acetyltransferase, catalyzed by a truncated form of the beta subunit. The results indicated that the beta subunit is responsible for binding CoA and acetyl-CoA and suggested that acetylenzyme formation occurs on the beta subunit. A value of 5.5 x [H+](-1) M(-1) was determined for the equilibrium constant of the following reaction at pH 7.5 and 25 degrees C: CH3-H4SPt + cob(I)amide-protein + H+ reversible arrow H4SPt + CH3-cob(III)amide-protein.	UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky	Grahame, DA (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814, USA.							ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMOLL E, 1987, J BACTERIOL, V169, P3916, DOI 10.1128/jb.169.9.3916-3920.1987; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; GRAHAME DA, 1995, BIOCHEMISTRY-US, V34, P4617, DOI 10.1021/bi00014a015; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; GRAHAME DA, 1993, BIOCHEMISTRY-US, V32, P10786, DOI 10.1021/bi00091a033; HU SI, 1984, J BIOL CHEM, V259, P8892; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; JETTEN MSM, 1991, EUR J BIOCHEM, V195, P385, DOI 10.1111/j.1432-1033.1991.tb15717.x; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU WP, 1991, J BIOL CHEM, V266, P3554; PEZACKA E, 1986, J BIOL CHEM, V261, P1609; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; ROBERTS DL, 1994, J BACTERIOL, V176, P6127, DOI 10.1128/jb.176.19.6127-6130.1994; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; VANBEELEN P, 1984, EUR J BIOCHEM, V139, P359	20	57	64	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8352	8358		10.1074/jbc.271.14.8352	http://dx.doi.org/10.1074/jbc.271.14.8352			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626532	hybrid			2022-12-25	WOS:A1996UD60000072
J	Lepier, A; Graf, R; Azuma, M; Merzendorfer, H; Harvey, WR; Wieczorek, H				Lepier, A; Graf, R; Azuma, M; Merzendorfer, H; Harvey, WR; Wieczorek, H			The peripheral complex of the tobacco hornworm V-ATPase contains a novel 13-kDa subunit G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; TRANSPORTING PLASMA-MEMBRANES; MANDUCA-SEXTA MIDGUT; SECONDARY-STRUCTURE; NEUROSPORA-CRASSA; RECONSTITUTION; PURIFICATION; PREDICTION; EXPRESSION	A prominent 16-kDa protein copurifies with the V-ATPase isolated from both posterior midgut and Malpighian tubules of Manduca sexta larvae and thus was believed to represent a V-ATPase subunit. [C-14]N,N'-dicyclohexylcarbodiimide labeling and its position on SDS-electrophoresis gels revealed that this protein was different from the 17-kDa proteolipid. A cDNA clone encoding a highly hydrophilic protein with a calculated molecular mass of 13,692 Da was obtained by immunoscreening. Monospecific antibodies, affinity-purified to the 13-kDa recombinant protein expressed in Escherichia coli, specifically recognized the 16-kDa protein of the purified V-ATPase, confirming that a cDNA encoding this protein had been cloned. In vitro translation of the cRNA showed that the cloned 13-kDa subunit behaved like a 16-kDa protein on SDS-electrophoresis gels. The cloned protein showed 37% amino acid sequence identity to the 13-kDa V-ATPase subunit Vma10p recently cloned from yeast and some similarity to subunit b of bacterial F-ATPases. In contrast to the Vma10p protein, which behaved like a V-0 subunit, the M. serta 13-kDa protein behaved like a V-1 subunit, since it could be stripped from the membrane by treatment with the chaotropic salt KI and by cold inactivation. When KI dissociated V-ATPase subunits were reassociated by dialysis that removed the KI, a soluble, 450-kDa complex of the M. serta V-ATPase could be purified by gel chromatography. This V-1 complex consisted of subunits A, B, E, and the 13-kDa subunit, confirming that the cloned protein is a new V-ATPase subunit and a member of the peripheral V-1 complex of the V-ATPase. We designate this new V-1 component subunit G.	UNIV MUNICH,INST ZOOL,D-80021 MUNICH,GERMANY; TEMPLE UNIV,DEPT BIOL,PHILADELPHIA,PA 19122	University of Munich; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			/AAU-6215-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022444] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22444] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1988, J BIOL CHEM, V263, P8796; AZUMA M, 1995, FEBS LETT, V361, P153, DOI 10.1016/0014-5793(95)00146-Z; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BERTRAM G, 1991, J INSECT PHYSIOL, V37, P201, DOI 10.1016/0022-1910(91)90070-G; Booth A G, 1974, Biochem J, V142, P575; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DECKERSHEBESTREIT G, 1992, J EXP BIOL, V172, P451; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FINBOW ME, 1993, J CELL SCI, V106, P463; GIORDANA B, 1994, J EXP BIOL, V196, P145; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GLUCK SL, 1992, J EXP BIOL, V172, P219; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; GRAF R, 1995, P GER ZOOL SOC, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GUO Y, 1996, IN PRESS GENE AMST; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; HARVEY WR, 1992, J EXP BIOL, V172, P1; KATAYAMA C, 1990, STRATEGIES MOL BIOL, V4, P56; KLEIN U, 1991, J EXP BIOL, V161, P61; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPIER A, 1994, J EXP BIOL, V196, P361; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MARTIN FG, 1994, J EXP BIOL, V196, P77; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON N, 1992, J EXP BIOL, V172, P19; NICOLSON SW, 1993, J INSECT PHYSIOL, V39, P451, DOI 10.1016/0022-1910(93)90076-4; NISHIKAWA K, 1983, BIOCHIM BIOPHYS ACTA, V748, P285, DOI 10.1016/0167-4838(83)90306-0; NOEL J, 1993, BIOCHEM CELL BIOL, V71, P390, DOI 10.1139/o93-057; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; ONKEN H, 1995, J EXP BIOL, V198, P767; PEREZCASTINEIRA JR, 1990, BIOCHEM J, V271, P127, DOI 10.1042/bj2710127; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; RUSSELL VEW, 1992, J EXP BIOL, V166, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; VANKERKHOVE E, 1994, BELG J ZOOL, V124, P73; WARD JM, 1992, PLANT PHYSIOL, V99, P925, DOI 10.1104/pp.99.3.925; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335; WIECZOREK H, 1986, BIOCHIM BIOPHYS ACTA, V857, P271, DOI 10.1016/0005-2736(86)90356-1; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; XIE XS, 1988, J BIOL CHEM, V263, P9859	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8502	8508		10.1074/jbc.271.14.8502	http://dx.doi.org/10.1074/jbc.271.14.8502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626552	hybrid			2022-12-25	WOS:A1996UD60000092
J	Mu, D; Hsu, DS; Sancar, A				Mu, D; Hsu, DS; Sancar, A			Reaction mechanism of human DNA repair excision nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; POLYMERASE-I; HELICASE-II; GROUP-C; GENE; PROTEIN; PURIFICATION; PSORALEN	Nucleotide excision repair consists of removal of the damaged nucleotide(s) from DNA by dual incision of the damaged strand on both sides of the lesion, followed by filling of the resulting gap and ligation. In humans, 14-16 polypeptides are required for the dual incision step. We have purified the required proteins to homogeneity and reconstituted the dual incision activity (excision nuclease) in a defined enzyme/substrate system. The system was highly efficient, removing >30% of the thymine dimers under optimal conditions. All of the six fractions that constitute the excision nuclease were required for dual incision of the thymine dimer substrate. However, when a cholesterol-substituted oligonucleotide was used as substrate, excision occurred in the absence of the XPC-HHR23B complex, reminiscent of transcription-coupled repair in the XP-C mutant cell line. Replication protein A is absolutely required for both incisions. The XPG subunit is essential to the formation of the preincision complex, but the repair complex can assemble and produce normal levels of 3'-incision in the absence of XPF-ERCC1. Kinetic experiments revealed that the 3'-incision precedes the 5'-incision. Consistent with the kinetic data, uncoupled 5'-incision was never observed in the reconstituted system. Two forms of TFIIH were used in the reconstitution reaction, one containing the CDK7-cyclin H pair and one lacking it. Both forms were equally active in excision. The excised oligomer dissociated from the gapped DNA in a nucleoprotein complex. In total, these results provide a detailed account of the reactions occurring during damage removal by human excision nuclease.			Mu, D (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.		Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NIGMS NIH HHS [GM 32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FRIEDBERG EC, 1995, DNA REPAIR; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUANG JC, 1994, J BIOL CHEM, V269, P19034; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; ORREN DK, 1992, J BIOL CHEM, V267, P780; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH S, 1993, ANNU REV GENET, V263, P12228; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHI YB, 1987, NUCLEIC ACIDS RES, V15, P6843, DOI 10.1093/nar/15.17.6843; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	62	340	345	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8285	8294		10.1074/jbc.271.14.8285	http://dx.doi.org/10.1074/jbc.271.14.8285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626523	Green Published, hybrid			2022-12-25	WOS:A1996UD60000063
J	Gao, C; Arlinghaus, RB; Singh, B				Gao, C; Arlinghaus, RB; Singh, B			Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells	ONCOGENE			English	Article						c-mos expression; transcriptional regulation; cell cycle control	PROTO-ONCOGENE; SARCOMA-VIRUS; MEIOTIC MATURATION; MOUSE-TISSUES; IDENTIFICATION; SEQUENCES; RNA; UPSTREAM; PRODUCT; CLONING	The mouse c-mos proto-oncogene is primarily expressed in germ cells. Our previous studies demonstrated c-mos RNA expression in mouse somatic cells, with the highest level present in the G(2) phase of the cell cycle (Tsui et al., 1993). We have identified the transcription start site of this G(2) specific c-mos transcript to be located about 1580 bp upstream from the open reading frame based on RT-PCR and RNase protection experiments. Upstream sequences containing this transcription start site directed highest expression of the luciferase reporter gene in M phase of the cell cycle. These results suggest that c-mos transcripts are produced in G, phase and that c-Mos protein albeit at extremely low levels would accumulate in M phase.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; NASH M, 1984, J VIROL, V50, P478, DOI 10.1128/JVI.50.2.478-488.1984; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TSUI L, 1993, THESIS U TEXAS GRADU; TSUI LV, 1993, INT J ONCOL, V2, P493; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZINKEL SS, 1992, MOL CELL BIOL, V12, P2029, DOI 10.1128/MCB.12.5.2029	23	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1571	1576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622874				2022-12-25	WOS:A1996UF07600022
J	Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B				Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B			SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin	ONCOGENE			English	Article						vav; SH3; zyxin; focal adhesions	C-SRC ACTIVITY; TYROSINE; BINDING; KINASE; RAS; GTPASE; CELLS	Scr homology 3 (SH3) domain-mediated protein-protein interactions have been implicated in the localization of proteins to specific sites within the cell. We present evidence that the product of the vav proto-oncogene, p95(vav), interacts specifically with the focal adhesion protein zyxin both in vitro and in yeast two hybrid system. Solution binding and two-hybrid system experiments demonstrate that association of Vav with the LIM domain protein zyxin is mediated by the C-terminal SH3 domain of Vav and involves the proline-rich N-terminus of zyxin. The interaction appears to be selective, since no binding of the proline-rich N-terminus of zyxin with other SH3 domain-containing proteins such as GRB-2, phospholipase C gamma, GTPase-activating protein, or p85 was detected.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Max Planck Society; Utah System of Higher Education; University of Utah				Hobert, Oliver/0000-0002-7634-2854				ADAMS JM, 1992, ONCOGENE, V7, P611; BAGSAGI D, 1993, CELL, V79, P83; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; EVANS GA, 1993, BIOCHEM J, V294, P399; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN R, 1989, BLOOD, V74, P1196; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MERILAINEN J, 1993, J CELL SCI, V105, P647; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSSACCHIO A, 1992, FEBS LETT, V307, P55; OKADA M, 1993, J BIOL CHEM, V268, P18070; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	50	76	76	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1577	1581						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622875				2022-12-25	WOS:A1996UF07600023
J	LeCouter, JE; Whyte, PFM; Rudnicki, MA				LeCouter, JE; Whyte, PFM; Rudnicki, MA			Cloning and expression of the Rb-related mouse p130 mRNA	ONCOGENE			English	Article						p130; cDNA; mouse	RETINOBLASTOMA GENE FAMILY; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; PROTEIN; DIFFERENTIATION; INTERACTS; CONTAINS; MUTATION; PRODUCT; MEMBER	The mouse p130 cDNA was cloned from a thymus-derived library using the human p130 cDNA as a probe. The 4515-bp mouse cDNA encodes a putative 1092 aa protein with predicted molecular mass of 123kD. Comparison of mouse and human sequences reveals the mouse protein lacks 43 aa in a conserved domain, relative to the human sequence, located amino-terminal to the pocket region. Northern analysis of P19 embryonal carcinoma (EC) and RA-induced P19 cultures indicates p130 mRNA is not expressed at detectable levels in undifferentiated stem cells and is strongly upregulated after post-mitotic neurons begin to accumulate. Northern analysis of adult mouse tissues indicated that the 4.8 kb p130 mRNA is expressed ubiquitously, however, a putative 9-truncated 1.7 kb isoform is detected solely in testis. Forced expression of mouse p130 induced growth suppression of P19 EC cells and Western analysis of transfected P19 cells suggested the cloned cDNA encodes the full-length p130 protein.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8S 4K1,CANADA	McMaster University								ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2366; HARLOW E, 1988, ANTIBODIES LAB MANUA, P483; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KAWASAKI E, 1990, PCR PROTOCOLS GUIDE, P22; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Maniatis T., 1982, MOL CLONING; MAYOL X, 1993, ONCOGENE, V8, P2561; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; RUDNICKI MA, 1987, TERATOCARCINOMAS EMB, P32; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x	42	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1433	1440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622859				2022-12-25	WOS:A1996UF07600007
J	Cleutjens, KBJM; vanEekelen, CCEM; vanderKorput, HAGM; Brinkmann, AO; Trapman, J				Cleutjens, KBJM; vanEekelen, CCEM; vanderKorput, HAGM; Brinkmann, AO; Trapman, J			Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLANDULAR KALLIKREIN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; BINDING-PROTEIN; C3(1) GENE; ELEMENT; DNA; SITE; LOCALIZATION; EXPRESSION	Transcription of the prostate-specific antigen (PSA) gene is androgen regulated, The PSA promoter contains at position -170 the sequence AGAACAgcaAGTGCT, which is closely related to the ARE (androgen response element) consensus sequence GGTACAnnnTGTTCT. This sequence is a high affinity androgen receptor (AR) binding site and acts as a functional ARE in transfected LNCaP cells. A 35-base pair segment starting at -400 (ARR: androgen response region; GTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG) cooperates with the ARE in androgen induction of the PSA promoter. A construct with three ARR copies linked to a minimal PSA promoter showed a strong (104-fold) androgen induced activity. The ARR was also able to confer androgen responsiveness to a minimal thymidine kinase promoter. Both AR binding and transcriptional activity resided in a 20-base pair ARR subfragment: CAGGGATCAGGGAGTCTCAC (2S), Mutational analysis indicated that the sequence GGATCAgggAGTCTC in the 2S fragment is a functionally active, low affinity AR binding site. Like AR, the glucocorticoid receptor was able to stimulate PSA promoter activity. Both the ARE and ARR art: involved in dexamethasone regulation of the PSA promoter, Both the AR and glucocorticoid receptor were 20-100 fold more active on ARR-PSA and ARR-thymidine kinase promoter constructs in LNCaP cells than in other cell types (COS, HeLa, Hep3B, and T47D cells), indicating (prostate) cell specificity.	ERASMUS UNIV ROTTERDAM, DEPT ENDOCRINOL & REPROD, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	Cleutjens, KBJM (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PATHOL, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS BA, 1988, BIOCHEMISTRY-US, V27, P3124, DOI 10.1021/bi00409a003; FABRE S, 1994, J BIOL CHEM, V269, P5857; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HO KC, 1993, J BIOL CHEM, V268, P27226; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KASPER S, 1994, J BIOL CHEM, V269, P31763; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUIPER GGJM, 1993, BIOCHEM J, V296, P161, DOI 10.1042/bj2960161; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SCHONK D, 1990, CYTOGENET CELL GENET, V54, P15; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAN JA, 1992, J BIOL CHEM, V267, P4456; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	44	331	342	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6379	6388		10.1074/jbc.271.11.6379	http://dx.doi.org/10.1074/jbc.271.11.6379			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626436	Green Published, hybrid			2022-12-25	WOS:A1996UA36300065
J	Cullen, PJ; Bowman, WC; Kranz, RG				Cullen, PJ; Bowman, WC; Kranz, RG			In vitro reconstitution and characterization of the Rhodobacter capsulatus NtrB and NtrC two-component system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN REGULATOR-I; BINDING-PROTEIN NTRC; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RHODOPSEUDOMONAS-CAPSULATA; GLNA TRANSCRIPTION; ACTIVATOR PROTEIN; ENTERIC BACTERIA; ATPASE ACTIVITY; RNA-POLYMERASE	Enhancer-dependent transcription in enteric bacteria depends upon an activator protein that binds DNA far upstream from the promoter and an alternative sigma factor (sigma(54)) that binds with the core RNA polymerase at the promoter. In the photosynthetic bacterium Rhodobacter capsulatus, the NtrB and NtrC proteins (RcNtrB and RcNtrC) are putative members of a two-component system that is novel because the enhancer-binding RcNtrC protein activates transcription of sigma(54)-independent promoters. To reconstitute this putative two-component system in vitro, the RcNtrB protein was overexpressed in Escherichia coli and purified as a maltose-binding protein fusion (MBP-RcNtrB). MBP-RcNtrB autophosphorylates in vitro to the same steady state level and with the same stability as the Salmonella typhimurium NtrB (StNtrB) protein but at a lower initial rate. MBP-RcNtrB similar to P phosphorylates the S.typhimurium NtrC (St-NtrC) and RcNtrC proteins in vitro. The enteric NtrC protein is also phosphorylated in vivo by RcNtrB because plasmids that encode either RcNtrB or MBP-RcNtrB activate transcription of an NtrC-dependent nifL-lacZ fusion. The rate of phosphotransfer to RcNtrC and autophosphatase activity of phosphorylated RcNtrC (RcNtrC similar to P) are comparable to the StNtrC protein. However, the RcNtrC protein appears to be a specific RcNtrB similar to P phosphatase since RcNtrC is not phosphorylated by small molecular weight phosphate compounds or by the StNtrB protein, RcNtrC forms a dimer in solution, and RcNtrC similar to P binds the upstream tandem binding sites of the glnB promoter 4-fold better than the unphosphorylated RcNtrC protein, presumably due to oligomerization of RcNtrC similar to P. Therefore, the R. capsulatus NtrB and NtrC proteins form a two-component system similar to other NtrC-like systems, where specific RcNtrB phosphotransfer to the RcNtrC protein results in increased oligomerization at the enhancer but with subsequent activation of a sigma(54)-independent promoter.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								AMES GFL, 1985, EMBO J, V4, P539, DOI 10.1002/j.1460-2075.1985.tb03662.x; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; AVTGES P, 1985, MOL GEN GENET, V201, P363, DOI 10.1007/BF00331324; BALDWIN T, 1984, FOCUS, V6, P4; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; CULLEN PJ, 1994, MOL MICROBIOL, V11, P51, DOI 10.1111/j.1365-2958.1994.tb00289.x; DERETIC V, 1992, MOL MICROBIOL, V6, P2761, DOI 10.1111/j.1365-2958.1992.tb01455.x; DIXON R, 1991, MOL MICROBIOL, V5, P1657, DOI 10.1111/j.1365-2958.1991.tb01913.x; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; FOSTERHARTNETT D, 1992, MOL MICROBIOL, V6, P1049, DOI 10.1111/j.1365-2958.1992.tb02170.x; FOSTERHARTNETT D, 1994, J BACTERIOL, V176, P6175, DOI 10.1128/jb.176.20.6175-6187.1994; FOSTERHARTNETT D, 1993, MOL MICROBIOL, V8, P903, DOI 10.1111/j.1365-2958.1993.tb01636.x; FOSTERHARTNETT D, 1994, J BACTERIOL, V176, P5171, DOI 10.1128/jb.176.16.5171-5176.1994; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; HUBNER P, 1991, J BACTERIOL, V173, P2993; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; JONES R, 1989, MOL GEN GENET, V215, P507, DOI 10.1007/BF00427050; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KRANZ RG, 1990, J BACTERIOL, V172, P53, DOI 10.1128/JB.172.1.53-62.1990; KRANZ RG, 1990, MOL MICROBIOL, V4, P1793, DOI 10.1111/j.1365-2958.1990.tb02027.x; KRANZ RG, 1985, GENE, V40, P203, DOI 10.1016/0378-1119(85)90043-5; KRANZ RG, 1995, REGULATION NITROGEN, P1191; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MANTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MERTKE I, 1995, J BACTERIOL, V177, P5056; MOFFATT BA, 1988, J BACTERIOL, V170, P2095, DOI 10.1128/jb.170.5.2095-2105.1988; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1991, J BIOL CHEM, V266, P6888; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; OW DW, 1983, NATURE, V301, P307, DOI 10.1038/301307a0; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHNEIDER BL, 1991, J BACTERIOL, V173, P6355, DOI 10.1128/jb.173.20.6355-6363.1991; Sheridan R. C., 2007, INORG SYN, P23; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEDEL A, 1995, GENE DEV, V9, P2024; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	62	22	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6530	6536		10.1074/jbc.271.11.6530	http://dx.doi.org/10.1074/jbc.271.11.6530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626457				2022-12-25	WOS:A1996UA36300086
J	Johnson, AC				Johnson, AC			Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristate 13-acetate is mediated by activator protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTING FACTOR; HUMAN-BRAIN TUMORS; CANCER CELL-LINE; EGF-RECEPTOR; MESSENGER-RNA; ENHANCED EXPRESSION; HUMAN-FIBROBLASTS; CARCINOMA-CELLS; BINDING-SITES; OWN RECEPTOR	The response of the epidermal growth factor (EGF) receptor gene to phorbol 12-myristate 13-acetate (PMA) was analyzed using nuclei and nuclear extracts prepared from PMA-treated KB cells. Transient transfection assays and nuclear run-off experiments showed that PMA increased EGF receptor gene transcription. Cell-free transcription with promoter mutants revealed that the region of the promoter containing nucleotides -150 to -16 was sufficient for PMA inducibility. A promoter fragment containing nucleotides -167 to -105 showed increased binding of a factor present in extracts prepared from PMA-treated cells. When this factor was partially purified by column chromatography, it showed specific PIMA-dependent binding to an EGF receptor promoter fragment. This binding was competed by an SV40 fragment containing binding sites for Sp1, AP1, and AP2. Purified AP2 was used in DNase I footprinting experiments to show that this factor can bind to the EGF receptor promoter. Oligonucleotides corresponding to the AP2 binding sites found in the EGF receptor promoter showed the ability to bind AP2 and compete for the binding of a factor induced by PMA treatment. The addition of AP2 to nuclear extract resulted in increased transcription from the EGF receptor promoter. These results demonstrate that AP2 can activate EGF receptor gene expression and may mediate the PMA response of this gene.			Johnson, AC (corresponding author), NCI, MOLEC BIOL LAB,DIV BASIC SCI,NIH,37-2D18, 37 CONVENT DR, MSC 4255, BETHESDA, MD 20892 USA.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COHEN S, 1982, J BIOL CHEM, V257, P1523; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEB SP, 1994, ONCOGENE, V9, P1341; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EARP HS, 1986, J BIOL CHEM, V261, P4777; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALEY J, 1987, ONCOGENE RES, V1, P375; Hendler F J, 1985, Trans Assoc Am Physicians, V98, P189; HOU XY, 1994, J BIOL CHEM, V269, P4307; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JETTEN AM, 1980, NATURE, V284, P626, DOI 10.1038/284626a0; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JOHNSON AC, 1988, BIOCHEM BIOPH RES CO, V150, P412, DOI 10.1016/0006-291X(88)90536-0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIBERMANN TA, 1984, CANCER RES, V44, P753; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MUKKU VR, 1985, J BIOL CHEM, V260, P9820; MUKKU VR, 1984, J BIOL CHEM, V259, P6543; QUINN JP, 1995, BBA-GENE STRUCT EXPR, V1263, P25, DOI 10.1016/0167-4781(95)00071-N; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; XU J, 1993, J BIOL CHEM, V268, P16065; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, CANCER RES, V46, P414	52	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3033	3038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621697				2022-12-25	WOS:A1996TU69100026
J	Jakob, U; Scheibel, T; Bose, S; Reinstein, J; Buchner, J				Jakob, U; Scheibel, T; Bose, S; Reinstein, J; Buchner, J			Assessment of the ATP binding properties of Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-SUBUNITS	Hsp90, one of the most prominent proteins in eucaryotic cells under physiological and stress conditions, chaperones protein folding reactions in an ATP-independent way. Surprisingly, ATP binding and ATPase activity of Hsp90 has been reported by several groups. To clarify this important issue, we have reinvestigated the potential ATP binding properties and ATPase activity of highly purified Hsp90 using a number of different techniques. Hsp90 was compared to the well characterized ATP-binding chaperone Hsc70 and to two control proteins, immunoglobulin G and bovine serum albumin, that are known to not bind ATP. Hsp90 behaved very similarly to the non-ATP-binding proteins and very differently from the ATP-binding protein Hsc70. Like bovine serum albumin and immunoglobulin G, Hsp90 (i) did not bind to immobilized ATP, (ii) could not be specifically photocross-linked with azido-ATP, (iii) failed to exhibit significant changes in intrinsic protein fluorescence upon ATP addition, and (iv) did not bind to three fluorescent ADP analogues. In contrast, Hsc70 strongly bound ATP and ADP, specifically cross-linked with azido-ATP, and exhibited major shifts in fluorescence upon addition of ATP. Finally, reexamination of the amino acid sequence of Hsp90 failed to reveal any significant homologies to known ATP-binding motifs. Taken together, we conclude that highly purified Hsp90 does not bind ATP. Weak ATPase activities associated with Hsp90 preparations may be due to minor impurities or kinases copurifying with Hsp90.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Regensburg; Max Planck Society			Buchner, Johannes/A-2651-2010; Scheibel, Thomas/I-1170-2014	Scheibel, Thomas/0000-0002-0457-2423; Buchner, Johannes/0000-0003-1282-7737				BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; HOLLNEUGEBAUER B, 1992, BIOCHEMISTRY-US, V30, P16009; INANO K, 1994, J BIOCHEM-TOKYO, V116, P759, DOI 10.1093/oxfordjournals.jbchem.a124593; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; KELLERMAYER MSZ, 1995, BIOCHEM BIOPH RES CO, V211, P166, DOI 10.1006/bbrc.1995.1792; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MORIMOTO RI, 1994, STRESS PROTEINS BIOL; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NADEAU K, 1992, PROTEIN SCI, V1, P970, DOI 10.1002/pro.5560010802; NARDAI G, 1996, IN PRESS J BIOSCI; NOVER L., 1991, HEAT SHOCK RESPONSE; OLSSON H, 1995, FEBS LETT, V361, P282, DOI 10.1016/0014-5793(95)00194-E; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SHUE GL, 1994, J BIOL CHEM, V269, P2707; SMITH DF, 1993, STEROID HORMONE RECE, P247; SPARRER H, 1996, IN PRESS J MOL BIOL; TODD MJ, 1995, FEBS LETT, V359, P123, DOI 10.1016/0014-5793(95)00021-Z; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	37	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10035	10041		10.1074/jbc.271.17.10035	http://dx.doi.org/10.1074/jbc.271.17.10035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626558	hybrid			2022-12-25	WOS:A1996UG25700030
J	Gallagher, MJ; Huang, H; Pritchett, DB; Lynch, DR				Gallagher, MJ; Huang, H; Pritchett, DB; Lynch, DR			Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYAMINE-SENSITIVE SITE; AMINO-ACID RECEPTORS; H-3 MK-801 BINDING; PROTEIN-KINASE-C; NMDA RECEPTOR; RAT-BRAIN; MOLECULAR DIVERSITY; GLUTAMATE RECEPTORS; I-125 IFENPRODIL; CHANNEL	Ifenprodil is an atypical noncompetitive modulator of the N-methyl-D-aspartate (NMDA) receptor (NR) which demonstrates a 140-fold preference for NR2B over NR2A subunits, although the molecular basis for this subunit specificity is unknown. We have made chimeric receptors by fusing the murine forms of NR2A (epsilon(1)) and NR2B (epsilon(2)) to localize the high affinity determinants of ifenprodil inhibition on the 2B subunit. Binding experiments with I-125-MK-801 implicated the region between amino acids 198 and 356 of NR2B for high affinity ifenprodil interaction. Site-directed mutants at Arg-337 showed that this residue is absolutely required for high affinity ifenprodil inhibition. Polyamines also modulate the NMDA receptor with a preference for NR2B subunits, and the pharmacology of these agents overlaps with ifenprodil. Although the determinants of the polyamine enhancement of iodo-MK-801 binding also localize to the NH2 terminus of NR2B, the point mutants at Arg-337 form receptors that are polyamine-stimulated at wild type levels. In addition, polyamine stimulation depends on the expression of NR1 splice variants, whereas high affinity ifenprodil inhibition is independent of NR1 isoform expression. These studies provide evidence that ifenprodil and polyamines interact at discrete sites on the NR2B subunit.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005675] Funding Source: NIH RePORTER; NIDA NIH HHS [NIDA DAO7130, 1F32-DAO5675] Funding Source: Medline; NINDS NIH HHS [CIDA NS01789-01] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANEGAWA NJ, 1995, J NEUROCHEM, V64, P2004; BEART PM, 1991, NEUROSCI LETT, V124, P187, DOI 10.1016/0304-3940(91)90090-G; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BONHAUS DW, 1988, MOL PHARMACOL, V34, P250; BROSE N, 1993, J BIOL CHEM, V268, P22663; CARPER DA, 1995, BBA-PROTEIN STRUCT M, V1246, P67, DOI 10.1016/0167-4838(94)00182-G; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CARTER C, 1991, EXCITATORY AMINO ACI, P130; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DANYSZ W, 1989, MOL PHARMACOL, V36, P912; DERST C, 1994, EUR J BIOCHEM, V224, P533, DOI 10.1111/j.1432-1033.1994.00533.x; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FERSHT AR, 1986, TRENDS BIOCHEM SCI, V11, P321, DOI 10.1016/0968-0004(86)90289-6; GOLDBERG JM, 1993, BIOCHEMISTRY-US, V32, P8092, DOI 10.1021/bi00083a006; GRIMWOOD S, 1995, J NEUROCHEM, V64, P525; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; KLOOG Y, 1988, FEBS LETT, V230, P167, DOI 10.1016/0014-5793(88)80664-1; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LEGENDRE P, 1991, MOL PHARMACOL, V40, P289; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MERCER LD, 1993, J NEUROCHEM, V61, P120, DOI 10.1111/j.1471-4159.1993.tb03545.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NICOLAS C, 1994, J NEUROCHEM, V63, P2248; OTOMO E, 1985, CURR THER RES CLIN E, V37, P811; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; RANSOM RW, 1991, EUR J PHARM-MOLEC PH, V208, P67, DOI 10.1016/0922-4106(91)90052-J; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; SAKURAI SY, 1993, J NEUROCHEM, V60, P1344, DOI 10.1111/j.1471-4159.1993.tb03295.x; SCHOEMAKER H, 1990, EUR J PHARMACOL, V176, P249, DOI 10.1016/0014-2999(90)90539-I; SCHOEMAKER H, 1990, British Journal of Pharmacology, V100, p316P; TAMURA Y, 1993, J PHARMACOL EXP THER, V265, P1017; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WILLIAMS K, 1994, MOL PHARMACOL, V45, P803; WILLIAMS K, 1992, MOL PHARMACOL, V42, P147; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; ZHAO QJ, 1995, BIOCHEMISTRY-US, V34, P6562, DOI 10.1021/bi00019a038; ZHENG X, 1994, NEURON, V12, P811	58	127	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9603	9611		10.1074/jbc.271.16.9603	http://dx.doi.org/10.1074/jbc.271.16.9603			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621635	hybrid			2022-12-25	WOS:A1996UG04400066
J	Hiwasa, T; Sawada, T; Sakiyama, S				Hiwasa, T; Sawada, T; Sakiyama, S			Synergistic induction of anchorage-independent growth of NIH3T3 mouse fibroblasts by cysteine proteinase inhibitors and a tumor promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS GENE-PRODUCTS; CYSTATIN SUPERFAMILY; CATHEPSIN-L; ACTIVATION; ONCOGENE; MUTANTS; BINDING; GTPASE; REGION; RAF-1	We have previously reported that Ras protein is a potent cysteine proteinase inhibitor. In order to examine whether the cysteine proteinase-inhibitory activity of Ras is involved in carcinogenesis, the effects of the following probes were investigated, Cystatin alpha is a cysteine proteinase-specific inhibitor and has some amino acid sequence homology with Ras. Ras has a CAAX motif (C, cysteine; A, aliphatic amino acid; X, any amino acid) at the carboxyl terminus, which is indispensable for the biological activity. Thus, cystatin alpha carrying a CAAX motif (cystatin alpha-CVLS) was examined. A v-Ha-Ras deletion mutant, Ras Delta 42-49, has undetectable GTP binding activity, yet it retains a similar protease inhibitory activity to that of wild-type v-Ras. These genes were inserted into a eukaryotic inducible expression vector and transfected into NIH3T3 cells, The expression was effectively induced by treatment with a glucocorticoid hormone, dexamethasone. The expression of cystatin alpha-CVLS or Ras Delta 42-49 alone induced neither transformation nor morphological changes. However, when their expression was induced in the presence of a tumor-promoting phorbol ester, a remarkable increase in the anchorage-independent growth was observed in cystatin alpha-CVLS- and Ras Delta 42-49-transfected clones. These results suggest that cysteine proteinase inhibitors and a tumor promoter synergistically transformed NIH3T3 cells. It is thus possible that the cysteine proteinase-inhibitory activity of Ras might play a key role in the early stage of carcinogenesis.			Hiwasa, T (corresponding author), CHIBA CANC CTR RES INST,DIV BIOCHEM,CHUO KU,666-2 NITONA CHO,CHIBA 260,JAPAN.							BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Berenblum I, 1941, CANCER RES, V1, P44; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERSCHMAN HR, 1986, SCIENCE, V234, P1385, DOI 10.1126/science.3787250; HIWASA T, 1987, FEBS LETT, V211, P23, DOI 10.1016/0014-5793(87)81266-8; HIWASA T, 1987, BIOCHEM BIOPH RES CO, V146, P731, DOI 10.1016/0006-291X(87)90590-0; HIWASA T, 1987, CANCER RES, V47, P953; HIWASA T, 1995, PROTEASES INVOLVED IN CANCER, P153; HIWASA T, 1991, BIOMED BIOCHIM ACTA, V50, P579; HIWASA T, 1995, BIOCH FUNCT, V13, P293; KATUNUMA N, 1988, FEBS LETT, V238, P116, DOI 10.1016/0014-5793(88)80238-2; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORDAN LJ, 1983, CANCER RES, V43, P4062; NIKAWA T, 1989, FEBS LETT, V255, P309, DOI 10.1016/0014-5793(89)81112-3; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SAWADA T, 1995, PROTEASES INVOLVED IN CANCER, P177; TAKEDA A, 1983, J BIOCHEM, V94, P811, DOI 10.1093/oxfordjournals.jbchem.a134423; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0	31	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9181	9184		10.1074/jbc.271.16.9181	http://dx.doi.org/10.1074/jbc.271.16.9181			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621572	hybrid			2022-12-25	WOS:A1996UG04400003
J	Park, A; Baichwal, VR				Park, A; Baichwal, VR			Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1-associated protein TRADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Tumor necrosis factor receptor 1 (TNF-R1) mediates most of the biological properties of TNF including activation of the transcription factor NF-kappa B and programmed cell death, An similar to 80 amino acid region within the intracellular domain of the receptor, termed the death domain, is required for signaling NF-kappa B activation and cytotoxicity, A TNF-R1-associated protein TRADD has been discovered that interacts with the death domain of the receptor, Elevated expression of TRADD in cells triggers both NF-kappa B activation and programmed cell death pathways, The biological activities of TRADD have been mapped to a 111-amino acid region within the carboxyl-terminal half of the protein, This region shows sequence similarity to the death domain of TNF-R1 and can self-associate and bind to the TNF-R1 death domain, We have performed an alanine scanning mutagenesis of TRADD's death domain to explore the relationship among its various functional properties, Mutations affecting the different activities of TRADD do not map to discrete regions but rather are spread over the entire death domain, suggesting that the death domain is a multifunctional unit, A mutant that separates cell killing from NF-kappa B activation by the TRADD death domain has been identified indicating that these two signaling pathways diverge with TRADD. Additionally, one of the TRADD mutants that fails to activate NF-KB was found to act as dominant negative mutant capable of preventing induction of NF-kappa B by TNF alpha. Such observations provide evidence that TRADD performs an obligate role in TNF-induced NF-kappa B activation.			Park, A (corresponding author), TULARIK INC,S SAN FRANCISCO,CA 94080, USA.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SONG HY, 1995, J BIOL CHEM, V270, P3474; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1	27	65	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9858	9862		10.1074/jbc.271.16.9858	http://dx.doi.org/10.1074/jbc.271.16.9858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621670	hybrid			2022-12-25	WOS:A1996UG04400101
J	Thinakaran, G; Teplow, DB; Siman, R; Greenberg, B; Sisodia, SS				Thinakaran, G; Teplow, DB; Siman, R; Greenberg, B; Sisodia, SS			Metabolism of the ''Swedish'' amyloid precursor protein variant in neuro2a (N2a) cells - Evidence that cleavage at the ''beta-secretase'' site occurs in the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MAMMALIAN-CELLS; PEPTIDE; PATHWAY; IDENTIFICATION; COMPARTMENT; TRANSPORT	The 4-kDa beta-amyloid peptide (A beta), a principal component of parenchymal amyloid deposits in Alzheimer's disease, is derived from amyloid precursor proteins (APP). To identify potential intracellular compartments involved in A beta production, we expressed human APP-695 (APPwt) and APP-695 harboring the Swedish double mutation (APPswe) associated with familial early-onset Alzheimer's disease, in mouse N2a cells. We demonstrate that cells expressing APPswe secrete high levels of A beta peptides and beta-secretase-generated soluble APP derivatives (APP(s beta)) relative to cells expressing APPwt. In addition, we observed a concomitant diminution in the levels of alpha-secretase-generated soluble APP derivatives (APP(s alpha)). Our interpretation of these findings is that beta-secretase cleavage occurs in an intracellular compartment and disables those substrates which would normally be cleaved by alpha-secretase. As anticipated, the levels of APPswe are diminished relative to the steady-state levels of surface-bound APPwt; moreover, surface-bound APPswe and APPwt molecules are released from the plasma membrane after cleavage by alpha-secretase, but not by beta-secretase. Finally, by examining the rate of appearance of specific APP metabolites generated by beta-secretase, we now unequivocally demonstrate that beta-secretase cleavage of APPswe occurs within the Golgi apparatus, as early as the medial compartment.	JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BIOPOLYMER LAB, BOSTON, MA 02115 USA; CEPHALON INC, W CHESTER, PA 19380 USA	Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Teva Pharmaceutical Industries; Cephalon Inc.	Thinakaran, G (corresponding author), JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, 558 ROSS RES BLDG, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.				NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG TT, 1994, INT J EXP CLIN INVES, V1, P30; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FELSENSTEIN KM, 1994, NAT GENET, V6, P251, DOI 10.1038/ng0394-251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HASS C, 1995, J CELL BIOL, V128, P537; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LO ACY, 1994, J BIOL CHEM, V269, P30966; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIEMERS KA, 1993, SCIENCE, V260, P554, DOI 10.1126/science.260.5107.554; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; VANNOSTRAND WE, 1989, NATURE, V341, P543; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	47	275	281	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9390	9397		10.1074/jbc.271.16.9390	http://dx.doi.org/10.1074/jbc.271.16.9390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621605				2022-12-25	WOS:A1996UG04400036
J	Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD				Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD			A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn	ONCOGENE			English	Article						Sek; Eph-like receptors; p59fyn; SH2-binding motif; autophosphorylation sites	GROWTH-FACTOR RECEPTOR; GLUTATHIONE-S-TRANSFERASE; SH2 DOMAINS; SRC FAMILY; PHOSPHORYLATION SITES; ESCHERICHIA-COLI; PDGF RECEPTOR; BETA-RECEPTOR; PROTEINS; BINDING	The large subfamily of receptor tyrosine kinases (RTKs) for which Eph is the prototype have likely roles in intercellular communication during normal mammalian development, but the biochemical signalling pathways utilised by this family are poorly characterised, We have now identified two in vitro autophosphorylation sites within the juxtamembrane domain of the Eph family member Sek, and a candidate binding protein for the activated Sek kinase, Specific antibodies defined Sek as a 130 kDa glycoprotein with protein kinase activity expressed in keratinocytes, whilst a bacterially expressed gst-Sek kinase domain fusion protein autophosphorylated exclusively on tyrosine residues, confirming that Sek encodes an authentic protein tyrosine kinase, Two dimensional phosphopeptide mapping and site-directed mutagenesis defined juxtamembrane residue Y602 as a major site of in vitro autophosphorylation in Sek, whilst Y596 was phosphorylated to a lower stoichiometry. Complementary approaches of in vitro binding assays and BIAcore analysis revealed a high affinity association between the Y602 Sek autophosphorylation site and the cytoplasmic tyrosine kinase p59fyn, an interaction mediated through the SH2 domain of this intracellular signalling molecule, Moreover, these data identify the novel phosphotyrosyl motif pYEDP as mediating high affinity association with fyn-SH2, extending the previously defined consensus motif for this interaction, The extensive conservation of this fyn-binding motif within the juxtamembrane domain of Eph family RTKs suggests that signalling through fyn, or fyn-related, tyrosine kinases may be utilised by many members of this large subclass of transmembrane receptors.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARE DJ, 1993, ONCOGENE, V8, P1429; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LUO K, 1990, ONCOGENE, V5, P921; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1990, ONCOGENE, V5, P445; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	99	107	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1727	1736						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622893				2022-12-25	WOS:A1996UG45800015
J	Leung, HY; Dickson, C; Robson, CN; Neal, DE				Leung, HY; Dickson, C; Robson, CN; Neal, DE			Over-expression of fibroblast growth factor-8 in human prostate cancer	ONCOGENE			English	Article						fibroblast growth factor-8, FGF-8; androgen induced growth factor; prostate cancer; in situ hybridisation			IMPERIAL CANC RES FUND,VIRAL CARCINOGENESIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				DEARNALEY DP, 1994, BRIT MED J, V308, P780, DOI 10.1136/bmj.308.6931.780; LEUNG HY, 1994, INT J ONCOL, V4, P1219; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928	8	72	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1833	1835						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622905				2022-12-25	WOS:A1996UG45800027
J	Killian, CE; Wilt, FH				Killian, CE; Wilt, FH			Characterization of the proteins comprising the integral matrix of Strongylocentrotus purpuratus embryonic spicules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYO; ORGANIC MATRIX; ENHANCED CHEMILUMINESCENCE; MINERALIZED TISSUES; POLYACRYLAMIDE GELS; MESSENGER-RNA; GENE; EXPRESSION; ELECTROPHORESIS; ORGANIZATION	In the present study, we enumerate and characterize the proteins that comprise the integral spicule matrix of the Strongylocentrotus purpuratus embryo, Two-dimensional gel electrophoresis of [S-35]methionine radiolabeled spicule matrix proteins reveals that there are 12 strongly radiolabeled spicule matrix proteins and approximately three dozen less strongly radiolabeled spicule matrix proteins, The majority of the proteins have acidic isoelectric points; however, there are several spicule matrix proteins that have more alkaline isoelectric points. Western blotting analysis indicates that SM50 is the spicule matrix protein with the most alkaline isoelectric point, In addition, two distinct SM30 proteins are identified in embryonic spicules, and they have apparent molecular masses of approximately 43 and 46 kDa. Comparisons between embryonic spicule matrix proteins and adult spine integral matrix proteins suggest that the embryonic 43-kDa SM30 protein is an embryonic isoform of SM30, An adult 49-kDa spine matrix protein is also identified as a possible adult isoform of SM30. Analysis of the SM30 amino acid sequences indicates that a portion of SM30 proteins is very similar to the carbohydrate recognition domain of C-type lectin proteins.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV CELL & DEV BIOL, LIFE SCI ADDIT, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NICHD NIH HHS [HD 15043] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD015043, R01HD015043] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIZENBERG J, 1995, FASEB J, V9, P262, DOI 10.1096/fasebj.9.2.7781928; AKASAKA K, 1994, J BIOL CHEM, V269, P20592; BENSON S, 1990, EXP CELL RES, V188, P141, DOI 10.1016/0014-4827(90)90289-M; BENSON S, 1987, DEV BIOL, V120, P499, DOI 10.1016/0012-1606(87)90253-3; BENSON S, 1983, EXP CELL RES, V148, P249, DOI 10.1016/0014-4827(83)90204-5; BENSON SC, 1986, J CELL BIOL, V102, P1878, DOI 10.1083/jcb.102.5.1878; Benson Stephen C., 1992, P157; BERMAN A, 1993, SCIENCE, V259, P776, DOI 10.1126/science.259.5096.776; BERMAN A, 1990, SCIENCE, V250, P664, DOI 10.1126/science.250.4981.664; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; BETTLER B, 1992, J BIOL CHEM, V267, P185; Dagorn J. C., 1993, P253; DECKER GL, 1988, DEVELOPMENT, V103, P231; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EMLET RB, 1982, BIOL BULL, V163, P264, DOI 10.2307/1541265; ETTENSOHN CA, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P175; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FRUDAKIS TN, 1965, DEV BIOL, V172, P230; GEORGE NC, 1991, DEV BIOL, V147, P334, DOI 10.1016/0012-1606(91)90291-A; HARKEY MA, 1983, DEV BIOL, V100, P12, DOI 10.1016/0012-1606(83)90196-3; HARKEY MA, 1995, DEV BIOL, V168, P549, DOI 10.1006/dbio.1995.1101; Harlow E., 1988, ANTIBODIES LAB MANUA; KATOHFUKUI Y, 1991, DEV BIOL, V145, P201, DOI 10.1016/0012-1606(91)90226-S; KILLIAN CE, 1989, DEV BIOL, V133, P148, DOI 10.1016/0012-1606(89)90306-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIVINGSTON BT, 1991, DEV BIOL, V148, P473, DOI 10.1016/0012-1606(91)90265-5; MAKABE KW, 1995, DEVELOPMENT, V121, P1957; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NG NFL, 1992, J BIOL CHEM, V267, P16069; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAZAKI K, 1975, AM ZOOL, V15, P567; OKAZAKI K, 1976, DEV GROWTH DIFFER, V18, P413; Okazaki K., 1980, MECHANISMS BIOMINERA, P159; Raup D. M., 1966, P379; RICHARDSON W, 1989, DEV BIOL, V132, P266, DOI 10.1016/0012-1606(89)90222-4; SARLES H, 1990, GASTROENTEROLOGY, V99, P900, DOI 10.1016/0016-5085(90)90999-H; SHARON N, 1975, COMPLEX CARBOHYDRATE, P73; SUCOV HM, 1987, DEV BIOL, V120, P507, DOI 10.1016/0012-1606(87)90254-5; SUCOV HM, 1988, GENE DEV, V2, P1238, DOI 10.1101/gad.2.10.1238; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKATESAN M, 1986, EXP CELL RES, V166, P259, DOI 10.1016/0014-4827(86)90526-4; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, AM ZOOL, V24, P945; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEWER UM, 1994, J CELL BIOL, V127, P1767, DOI 10.1083/jcb.127.6.1767; WILT FH, 1993, CHEM BIOL MINERALIZE, P85	52	90	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9150	9159		10.1074/jbc.271.15.9150	http://dx.doi.org/10.1074/jbc.271.15.9150			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621567	hybrid			2022-12-25	WOS:A1996UE73000098
J	Salgado, AP; Silva, AM; Santos, RM; Rosario, LM				Salgado, AP; Silva, AM; Santos, RM; Rosario, LM			Multiphasic action of glucose and alpha-ketoisocaproic acid on the cytosolic pH of pancreatic beta-cells - Evidence for an acidification pathway linked to the stimulation of Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; BURSTING ELECTRICAL-ACTIVITY; INTRACELLULAR PH; B-CELLS; CYTOPLASMIC PH; ISLET CELLS; HEXOSE METABOLISM; CA2+-DEPENDENT ACTIVATION; NUTRIENT SECRETAGOGUES; CA-2+ CONCENTRATION	Glucose stimulation raises the pH(i) of pancreatic beta-cells, but the underlying mechanisms are not web understood, We have now investigated the acute effects of metabolizable (glucose and the mitochondrial substrate alpha-ketoisocaproic acid, KIC) and nonmetabolizable (high K+ and the K-ATP channel blocker tolbutamide) insulin secretagogues on the pH(i) of pancreatic beta-cells isolated from normal mice, as assessed by BCECF fluorescence from single cells or islets in the presence of external bicarbonate, The typical acute effect of glucose (22-30 mM) 0.11 the pH(i) was a fast alkalinization of approximately 0.11 unit, followed by a slower acidification, The relative expression of the alkalinizing and acidifying components was variable, with some cells and islets displaying a predominant alkalinization, others a predominant acidification, and others yet a mixed combination of the two, The initial alkalinization preceded the [Ca2+](i) rise associated with the activation of voltage-sensitive Ca2+ channels, There was a significant overlap between the glucose-evoked [Ca2+](i) rise and the development of the secondary acidification, Depolarization with 30 mM K+ and tolbutamide evoked pronounced [Ca2+](i) rises and concomitant cytosolic acidifications, Blocking glucose-induced Ca2+ influx (with 0 Ca2+, nifedipine, or the K-ATP channel agonist diazoxide) suppressed the secondary acidification while having variable effects (potentiation or slight attenuation) on the initial alkalinization, KIC exerted glucose-like effects on the pH(i) and [Ca2+](i), but the amplitude of the initial alkalinization was about twice as large for KIC relative to glucose, It is concluded that the acute effect of glucose on the pH(i) of pancreatic beta-cells is biphasic, While the initial cytosolic alkalinization is an immediate consequence of the activation of H+-consuming metabolic steps in the mitochondria, the secondary acidification appears to originate from enhanced Ca2+ turnover in the cytoplasm, The degree of coupling between glucose metabolism and Ca2+ influx as well as the relative efficacies of these processes determines whether the acute pH(i), response of a beta-cell (or of a tightly coupled multicellular system such as an islet of Langerhans) is predominantly an alkalinization, an acidification, or a mixed proportion of the two.	UNIV COIMBRA,CTR NEUROSCI,DEPT ZOOL,P-3049 COIMBRA,PORTUGAL; UNIV COIMBRA,FAC SCI & TECHNOL,DEPT BIOCHEM,P-3049 COIMBRA,PORTUGAL	Universidade de Coimbra; Universidade de Coimbra			Silva, Amélia M/J-7128-2013	Silva, Amélia M/0000-0002-7524-9914; Rosario, Luis/0000-0001-8329-2333; Santos, Rosa/0000-0002-1577-1663				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJH, 1994, DIABETOLOGIA, V37, pS21, DOI 10.1007/BF00400822; BARBOSA RM, 1993, FEBS LETT, V332, P9, DOI 10.1016/0014-5793(93)80471-6; BERK BC, 1987, J BIOL CHEM, V262, P5065; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; BUSA WB, 1986, ANNU REV PHYSIOL, V48, P389; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; CASTRO E, 1994, PFLUG ARCH EUR J PHY, V426, P524, DOI 10.1007/BF00378530; CASTRO E, 1995, J BIOL CHEM, V270, P5098, DOI 10.1074/jbc.270.10.5098; DELEERS M, 1984, RES COMMUN CHEM PATH, V44, P83; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; DELEERS M, 1983, FEBS LETT, V154, P97, DOI 10.1016/0014-5793(83)80882-5; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRILL V, 1978, J CLIN INVEST, V61, P1034, DOI 10.1172/JCI109002; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; Grodsky G M, 1970, Vitam Horm, V28, P37; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1988, J BIOL CHEM, V263, P13750; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HELLMAN B, 1992, BIOCHIM BIOPHYS ACTA, V1113, P295, DOI 10.1016/0304-4157(92)90003-S; HELLMAN B, 1984, Q J EXP PHYSIOL CMS, V69, P867, DOI 10.1113/expphysiol.1984.sp002874; HENQUIN JC, 1975, BIOCHIM BIOPHYS ACTA, V381, P437, DOI 10.1016/0304-4165(75)90251-2; HENQUIN JC, 1988, BIOCHEM BIOPH RES CO, V156, P769, DOI 10.1016/S0006-291X(88)80910-0; HERCHUELZ A, 1991, CELL CALCIUM, V12, P577, DOI 10.1016/0143-4160(91)90076-Q; HUTTON JC, 1980, J BIOL CHEM, V255, P7340; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; JUNTTIBERGGREN L, 1994, INSULIN SECRETION PA, P145; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P647, DOI 10.1085/jgp.103.4.647; LEBRUN P, 1986, BIOCHIM BIOPHYS ACTA, V886, P448, DOI 10.1016/0167-4889(86)90181-3; LENZEN S, 1978, DIABETES, V27, P27, DOI 10.2337/diab.27.1.27; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; LINDSTROM P, 1986, BIOCHEM J, V239, P199, DOI 10.1042/bj2390199; LYNCH A, 1990, BIOCHEM PHARMACOL, V40, P411, DOI 10.1016/0006-2952(90)90537-U; LYNCH AM, 1989, BIOCHIM BIOPHYS ACTA, V1012, P166, DOI 10.1016/0167-4889(89)90091-8; MALAISSE WJ, 1994, NUTRIENT REGULATION, P83; MALAISSELAGAE F, 1984, BIOCHEM BIOPH RES CO, V123, P1062, DOI 10.1016/S0006-291X(84)80241-7; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; PACE CS, 1983, J MEMBRANE BIOL, V73, P39, DOI 10.1007/BF01870339; PACE CS, 1983, AM J PHYSIOL, V244, pE3, DOI 10.1152/ajpendo.1983.244.1.E3; PACE CS, 1984, FED PROC, V43, P2379; PANTEN U, 1974, DIABETOLOGIA, V10, P149, DOI 10.1007/BF01219672; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PROKS P, 1994, J PHYSIOL-LONDON, V475, P33, DOI 10.1113/jphysiol.1994.sp020047; RASSCHAERT J, 1991, BIOCHEM J, V278, P335, DOI 10.1042/bj2780335; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROSARIO LM, 1986, FEBS LETT, V200, P203, DOI 10.1016/0014-5793(86)80539-7; ROSARIO LM, 1991, NEUROSCIENCE, V41, P269, DOI 10.1016/0306-4522(91)90215-A; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SANTOS RM, 1996, PHYSL PATHOPHYSIOLOG; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1987, BIOCHEM J, V246, P89, DOI 10.1042/bj2460089; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; SENER A, 1992, J BIOL CHEM, V267, P13251; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; SHEPHERD RM, 1992, AM J PHYSIOL, V262, pC182, DOI 10.1152/ajpcell.1992.262.1.C182; SILVA AM, 1994, J BIOL CHEM, V269, P17095; SMITH JS, 1983, DIABETES, V32, P61, DOI 10.2337/diabetes.32.1.61; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; VAGUE P, 1977, HORM METAB RES, V9, P453, DOI 10.1055/s-0028-1093499; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WESSLEN N, 1987, ACTA PHYSIOL SCAND, V131, P230, DOI 10.1111/j.1748-1716.1987.tb08231.x; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WOLLHEIM CB, 1990, METHOD ENZYMOL, V192, P188; YAMAKAGE M, 1995, AM J PHYSIOL-LUNG C, V268, pL642, DOI 10.1152/ajplung.1995.268.4.L642	70	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8738	8746		10.1074/jbc.271.15.8738	http://dx.doi.org/10.1074/jbc.271.15.8738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621508	Green Published, hybrid			2022-12-25	WOS:A1996UE73000039
J	Vu, TH; Hoffman, AR				Vu, TH; Hoffman, AR			Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF2 GENE; H19 GENE; RNA; RELAXATION	The human IGP2 gene, which encodes a mitogenic peptide required for normal fetal development, is overexpressed in many types of tumors. IGF2 is transcribed from four promoters (P1-P4), and in most tissues, the gene is imprinted. In this study, we have analyzed IGF2 promoter usage and determined the allelic expression from each promoter in 19 ApaI- and 22 AluI-heterozygous Wilms' tumors. Loss of IGF2 imprinting (LOI) was observed in 8 ApaI-informative tumors. In these tumors, each parental allele was expressed in equal abundance, indicating that there was complete relaxation of IGF2 imprinting. In each LOI tumor, expression from promoter P1 as well as from the normally imprinted promoters P2-P4 was biallelic. In the 11 ApaI-informative tumors which maintained IGF2 imprinting (maintenance of imprinting), transcription from promoters P2-P4 was always monoallelic, while transcripts from P1 were derived from either one or both alleles, The lack of consistency of IGF2 imprinting of promoter P1 in maintenance of imprinting tumors was also observed in normal fetal tissues of 6-12 weeks gestation, suggesting a similarity in IGF2 regulation between Wilms' tumors and embryonic tissue development. These data suggest that the increased expression of IGF2 in Wilms' tumor may be caused either by biallelic gene expression in LOI tumors from promoters P2-P4 and/or by a reversion to an earlier stage of development which is characterized by increased synthesis of this fetal growth factor.	VET ADM MED CTR,MED SERV 111,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEPAGTERHOLTHUIZEN P, 1987, FEBS LETT, V214, P259, DOI 10.1016/0014-5793(87)80066-2; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKSBERG R, 1993, NAT GENET, V5, P143; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HOBAN PR, 1990, NUCLEIC ACIDS RES, V19, P1164; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JACOB F, 1993, BIOMED PHARMACOTHER, V47, P127, DOI 10.1016/0753-3322(93)90002-3; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; PHILLIPS LS, 1993, METABOLISM, V42, P1093, DOI 10.1016/0026-0495(93)90265-P; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUSSENBACH JS, 1992, GROWTH REGULAT, V3, P1; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; ZUMSTEIN PP, 1985, P NATL ACAD SCI USA, V82, P3169, DOI 10.1073/pnas.82.10.3169	35	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9014	9023		10.1074/jbc.271.15.9014	http://dx.doi.org/10.1074/jbc.271.15.9014			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621549	hybrid			2022-12-25	WOS:A1996UE73000080
J	Bottner, B; Schrauber, H; Bernhardt, R				Bottner, B; Schrauber, H; Bernhardt, R			Engineering a mineralocorticoid- to a glucocorticoid-synthesizing cytochrome P450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; STEROID 11-BETA-HYDROXYLASE; ALDOSTERONE SYNTHASE; CRYSTAL-STRUCTURE; AMINO-ACID; ENZYMES; SPECIFICITY; BIOSYNTHESIS; P-45011-BETA; GLOMERULOSA	Site-directed mutagenesis of a domain (amino acids 299-338) aligning to the I-helix region of P450(cam) P450(BM3), and P450(terp) was used to investigate the different regioselectivities displayed in the hydroxylation reactions performed by human aldosterone synthase (P450(aldo)) and 11 beta-hydroxylase (P450(11 beta)). The two enzymes are 93% identical and are essential for the synthesis of mineralocorticoids and glucocorticoids in the human adrenal gland. Single replacement of P450(aldo) residues for P450(11 beta)-specific residues at positions 296, 301, 302, 320, and 335 only gave rise to slightly increased 11 beta-hydroxylase activities. However, a L301P/A320V double substitution increased 11 beta-hydroxylase activity to 60% as compared with that of P450(11 beta). Additionally substituting Ala 320 for Val-320 of P450(11 beta) further enhanced this activity to 85%. The aldosterone synthase activities of the mutant P450(aldo) proteins were suppressed to a varying degree, with triple replacement mutant L301P/E302D/A320V retaining only 10% and double replacement mutant L301P/A320V retaining only 13% of the P450(aldo) wild type activity. These results demonstrate a switch in regio- and stereoselectivities of the engineered P450(aldo) enzyme due to manipulation of residues at three critical positions, and we attribute the determination of these features in P450(aldo) to the structure of a region analogous to the I-helix in P450(cam).	MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY; UNIV SAARLAND, D-66041 SAARBRUCKEN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Saarland University								AGUILERA G, 1993, J STEROID BIOCHEM, V45, P147, DOI 10.1016/0960-0760(93)90134-I; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; Bernhardt R, 1996, REV PHYSIOL BIOCH P, V127, P137, DOI 10.1007/BFb0048267; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DENNER K, 1995, PHARMACOGENETICS, V5, P89, DOI 10.1097/00008571-199504000-00005; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRAHAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; KAWAMOTO T, 1992, P NATL ACAD SCI USA, V89, P1458, DOI 10.1073/pnas.89.4.1458; KHALIL MW, 1985, J ENDOCRINOL, V107, P375, DOI 10.1677/joe.0.1070375; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MATSUKAWA N, 1990, BIOCHEM BIOPH RES CO, V169, P245, DOI 10.1016/0006-291X(90)91460-A; MORNET E, 1989, J BIOL CHEM, V264, P20961; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NONAKA Y, 1995, EUR J BIOCHEM, V229, P249, DOI 10.1111/j.1432-1033.1995.tb20462.x; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; PARKER KL, 1993, TRENDS ENDOCRIN MET, V4, P46, DOI 10.1016/S1043-2760(05)80014-1; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P8327, DOI 10.1073/pnas.89.17.8327; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RAMARAO MK, 1995, J BIOL CHEM, V270, P1873, DOI 10.1074/jbc.270.4.1873; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUB P, 1994, BIOCHEMISTRY-US, V33, P8029, DOI 10.1021/bi00192a006; WADA A, 1985, J BIOCHEM-TOKYO, V98, P245, DOI 10.1093/oxfordjournals.jbchem.a135264; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P3556; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	43	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8028	8033						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626485				2022-12-25	WOS:A1996UD60000025
J	Bourdais, J; Biondi, R; Sarfati, S; Guerreiro, C; Lascu, I; Janin, J; Veron, M				Bourdais, J; Biondi, R; Sarfati, S; Guerreiro, C; Lascu, I; Janin, J; Veron, M			Cellular phosphorylation of Anti-HIV nucleosides - Role of nucleoside diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; MYXOCOCCUS-XANTHUS; NM23; CLONING; GENE	Nucleotide analogs are widely used in antiviral therapy and particularly against AIDS. Delivered to the cell as nucleosides, they are phosphorylated into their active triphospho derivative form by cellular kinases from the host. The last step in this series of phosphorylations is performed by nucleoside diphosphate (NDP) kinase, an enzyme that can use both purine or pyrimidine and oxy- or deoxynucleotides as substrates. Using pure recombinant human NDP kinase type B (product of the gene nm23-H2), we have characterized the kinetic parameters of several nucleotide analogs for this enzyme. Contrary to what is generally assumed, diphospho- and triphospho- derivatives of azidothymidine as well as of dideoxyadenosine and dideoxythymidine are very poor substrates for NDP kinase. The rate of phosphorylation of these analogs varies between 0.05% and 0.5%, as compared to the corresponding natural nucleotide, a result that is not due to the inability of the analogs to bind to the enzyme. Using the data from the high resolution crystal structure of NDP kinase, we provide an interpretation of these results based on the crucial role played by the 3'-OH moiety of the nucleotide in catalysis.	INST PASTEUR,UNITE REGULAT ENZYMAT ACTIV CELLULAIRES,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75724 PARIS 15,FRANCE; UNIV BORDEAUX 2,IBC,CNRS,F-33077 BORDEAUX,FRANCE; CNRS,LAB BIOL STRUCT,F-91198 GIF SUR YVETTE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Janin, Joel/I-2958-2012	Biondi, Ricardo/0000-0002-8873-7167				BALZARINI J, 1989, J BIOL CHEM, V264, P6127; BLAKLEY RL, 1990, MOL PHARMACOL, V37, P328; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; STAHL JA, 1991, CANCER RES, V51, P445; TENER GM, 1961, J AM CHEM SOC, V83, P159, DOI 10.1021/ja01462a032; TEPPER A, 1994, J BIOL CHEM, V269, P3215; TORNEVIK Y, 1995, BIOCHEM PHARMACOL, V49, P829, DOI 10.1016/0006-2952(94)00453-S; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	25	79	82	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7887	7890		10.1074/jbc.271.14.7887	http://dx.doi.org/10.1074/jbc.271.14.7887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626464	hybrid			2022-12-25	WOS:A1996UD60000004
J	Civil, A; Bakker, A; Rensink, I; Doerre, S; Aarden, LA; Verweij, CL				Civil, A; Bakker, A; Rensink, I; Doerre, S; Aarden, LA; Verweij, CL			Nuclear appearance of a factor that binds the CD28 response element within the interleukin-2 enhancer correlates with interleukin-2 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; NF-KAPPA-B; ACCESSORY MOLECULE CD28; CYCLOSPORINE-A; GENE-TRANSCRIPTION; ANTIGEN RECEPTOR; CLONAL ANERGY; LYMPHOCYTES; EXPRESSION; SIGNALS	Activation of T lymphocytes requires the combined signaling of the T cell receptor and costimulatory molecules such as CD28. The ability of T cells to produce interleukin-2 (IL-2) is a critical control point in T lymphocyte activation. The IL-2 enhancer contains a functional motif named CD28 response element (CD28RE) that serves a role as a target for mitogenic T cell activation signals. The CD28RE sequence reveals similarity to the consensus kappa B binding motif. Here we demonstrate that CD28RE binds an inducible protein with a molecular mass of approximately 35 kDa called nuclear factor of mitogenic-activated T cells (NF-MATp35) that is clearly different from the known NF-kappa B/Rel family members. Induction of NF-MATp35 was shown to depend on de novo protein synthesis and was restricted to T cells that received a mitogenic combination of T cell stimuli, not necessarily including CD28 signaling. Nonmitogenic T cell stimulation did not result in appearance of NF-MATp35. These results indicate that mitogenic combinations of T cell activation signals are integrated at the level of NF-MATp35 induction. Similar to its effect on IL-2 production, cyclosporin A inhibited the induction of NF-MATp35. Taken together, these data demonstrate that the nuclear appearance of NF-MATp35 shows excellent correlation with IL-2 production, which is a unique characteristic among nuclear factors implicated in the control of IL-2 gene expression.	ACAD HOSP LEIDEN,DEPT RHEUMATOL,2300 RC LEIDEN,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,1066 CX AMSTERDAM,NETHERLANDS; BOSTON UNIV,DEPT MICROBIOL,BOSTON,MA 02118	Leiden University; Leiden University Medical Center (LUMC); Boston University			Bakker, Arnold B./F-8494-2010	Bakker, Arnold B./0000-0003-1489-1847				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BLOEMENA E, 1989, EUR J IMMUNOL, V19, P943, DOI 10.1002/eji.1830190524; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CIVIL A, 1992, EUR J IMMUNOL, V22, P3041, DOI 10.1002/eji.1830221142; CIVIL A, 1995, RES IMMUNOL, V146, P158, DOI 10.1016/0923-2494(96)80250-1; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; HANSEN JA, 1980, IMMUNOGENETICS, V10, P247, DOI 10.1007/BF01561573; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WEAVER CT, 1990, IMMUNOL TODAY, V11, P49	46	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8321	8327		10.1074/jbc.271.14.8321	http://dx.doi.org/10.1074/jbc.271.14.8321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626528	hybrid			2022-12-25	WOS:A1996UD60000068
J	Ghosh, S; Strum, JC; Sciorra, VA; Daniel, L; Bell, RM				Ghosh, S; Strum, JC; Sciorra, VA; Daniel, L; Bell, RM			Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid - Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THREONINE PROTEIN-KINASE; PHOSPHOLIPASE-D; SIGNAL-TRANSDUCTION; CYTOCHROME-OXIDASE; HUMAN NEUTROPHILS; C ACTIVATION; HA-RAS; ASSOCIATION; MEMBRANES; PHOSPHATIDYLCHOLINE	Previous studies demonstrated that the cysteine-rich amino-terminal domain of Raf-1 kinase interacts selectively with phosphatidylserine (Ghosh, S., Xie, W. Q., Quest, A. F. G., Mabrouk, G. M., Strum, J. C., and Bell, R. M. (1994) J. Biol. Chem. 269, 10000-10007). Further analysis showed that full-length Raf-1 bound to both phosphatidylserine and phosphatidic acid (PA). Specifically, a carboxyl-terminal domain of Raf-1 kinase (RafC; residues 295-648 of human Raf-1) interacted strongly with phosphatidic acid. The binding of RafC to PA displayed positive cooperativity with Hill numbers between 3.3 and 6.2; the apparent K-d ranged from 4.9 +/- 0.6 to 7.8 +/- 0.9 mol % PA. The interaction of RafC with PA displayed a pH dependence distinct from the interaction between the cysteine-rich domain of Raf-1 and PA Also, the RafC-PA interaction was unaffected at high ionic strength. Of all the lipids tested, only PA and cardiolipin exhibited high affinity binding; other acidic lipids were either ineffective or weakly effective. By deletion mutagenesis, the PA binding site within RafC was narrowed down to a 35-amino acid segment between residues 389 and 423. RafC did not bind phosphatidyl alcohols; also, inhibition of PA formation in Madin-Darby canine kidney cells by treatment with 1% ethanol significantly reduced the translocation of Raf-1 from the cytosol to the membrane following stimulation with 12-O-tetradecanoylphorbol-13-acetate. These results suggest a potential role of the lipid second messenger, PA, in the regulation of translocation and subsequent activation of Raf-1 in vivo.	GLAXO WELLCOME INC,RES TRIANGLE PK,NC 27709; DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	GlaxoSmithKline; Duke University; Wake Forest University; Wake Forest Baptist Medical Center			GHOSH, SUJOY/I-3729-2017	GHOSH, SUJOY/0000-0002-7601-165X	NATIONAL CANCER INSTITUTE [R01CA048995, R01CA043297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43297, CA-48995] Funding Source: Medline; NIGMS NIH HHS [GM-38737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONI LT, 1985, J BIOL CHEM, V260, P819; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GENNIS RB, 1988, BIOMEMBRANES MOL STR, P21; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH S, 1995, ANAL BIOCHEM, V225, P376, DOI 10.1006/abio.1995.1176; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HUANG CF, 1992, J BIOL CHEM, V267, P16859; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSOIR M, 1993, BIOCHEMISTRY-US, V32, P66; MOSOIR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PARADIES G, 1994, BBA-MOL BASIS DIS, V1225, P165, DOI 10.1016/0925-4439(94)90074-4; PARADIES G, 1993, ARCH BIOCHEM BIOPHYS, V307, P91, DOI 10.1006/abbi.1993.1565; POWELL GL, 1987, BIOCHEMISTRY-US, V26, P8138, DOI 10.1021/bi00399a018; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	64	367	372	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8472	8480		10.1074/jbc.271.14.8472	http://dx.doi.org/10.1074/jbc.271.14.8472			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626548	hybrid			2022-12-25	WOS:A1996UD60000088
J	Mages, GJ; Feldmann, HM; Winnacker, EL				Mages, GJ; Feldmann, HM; Winnacker, EL			Involvement of the Saccharomyces cerevisiae HDF1 gene in DNA double-strand break repair and recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AUTOANTIGEN KU; PROTEIN-KINASE; MEIOTIC RECOMBINATION; V(D)J RECOMBINATION; RAD52 GENE; MAT LOCUS; BLEOMYCIN; YEAST; MECHANISM; ANTIGEN	The HDF1 protein of Saccharomyces cerevisiae shares biochemical properties and structural homology with the 70 kDa subunit of the human autoantigen Ku. The Ku protein, a heterodimer composed of a 70-kDa subunit and an 80-kDa subunit, has been identified as the regulatory subunit of the DNA-dependent protein kinase, This enzyme has recently been shown to be involved in DNA repair and recombination processes in mammalian cells. Here we show that hdf1-disrupted S. cerevisiae strains are strongly sensitive toward the radiomimetic antibiotic bleomycin. In addition, mating-type switching and rates of spontaneous mitotic recombination are strongly reduced. This phenotype is similar to that of mammalian cells lacking components of the DNA-de pendent protein kinase holoenzyme, suggesting that HDF1 participates in and exerts equivalent functions in S. cerevisiae.	UNIV MUNICH,INST BIOCHEM,D-81375 MUNICH,GERMANY	University of Munich								ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; GAME JC, 1980, GENETICS, V94, P51; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GILONI L, 1981, J BIOL CHEM, V256, P8608; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENDRICKSON EA, 1988, GENE DEV, V2, P817, DOI 10.1101/gad.2.7.817; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOLODKIN AL, 1986, CELL, V46, P733, DOI 10.1016/0092-8674(86)90349-1; KRESZENMAN DJ, 1992, J BACTERIOL, V174, P3125; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALONE RE, 1983, MOL GEN GENET, V189, P405, DOI 10.1007/BF00325902; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE CW, 1991, J BACTERIOL, V173, P3605, DOI 10.1128/jb.173.11.3605-3608.1991; MOORE CW, 1982, CANCER RES, V42, P929; MOORE CW, 1978, MUTAT RES, V51, P165, DOI 10.1016/S0027-5107(78)80016-5; MURUGESAN N, 1985, BIOCHEMISTRY-US, V24, P5735, DOI 10.1021/bi00342a008; NICKOLOFF JA, 1986, P NATL ACAD SCI USA, V83, P7831, DOI 10.1073/pnas.83.20.7831; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PRAKASH S, 1980, GENETICS, V94, P31; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; RESNICK MA, 1975, MOL MECHANISMS REPAI, P549; SHERMAN F, 1983, METHODS YEAST GENETI, P163; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA H, 1985, J AM CHEM SOC, V107, P4104, DOI 10.1021/ja00299a072; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WOLF K, 1973, MOL GEN GENET, V125, P53, DOI 10.1007/BF00292983; YANEVA M, 1989, J BIOL CHEM, V264, P13407	61	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7910	7915		10.1074/jbc.271.14.7910	http://dx.doi.org/10.1074/jbc.271.14.7910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626469	hybrid			2022-12-25	WOS:A1996UD60000009
J	Munoz, P; Mora, S; Sevilla, L; Kaliman, P; Tomas, E; Guma, A; Testar, X; Palacin, M; Zorzano, A				Munoz, P; Mora, S; Sevilla, L; Kaliman, P; Tomas, E; Guma, A; Testar, X; Palacin, M; Zorzano, A			Expression and insulin-regulated distribution of caveolin in skeletal muscle - Caveolin does not colocalize with GLUT4 in intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; RAT ADIPOCYTES; SUBCELLULAR-DISTRIBUTION; PROTEINS; VESICLES; COMPONENT; BINDING; CELLS; DIFFERENTIATION; TRANSLOCATION	Caveolin is believed to play an important role in sorting processes, vesicular trafficking, transmembrane signaling, and molecular transport across membranes, In this study we have evaluated the expression and distribution of caveolin in skeletal muscle and its interaction with GLUT4 glucose carriers, Caveolin was expressed to substantial levels in muscle and its expression was regulated in muscle; aging and high fat diet enhanced caveolin expression in skeletal muscle and inversely, myogenesis down-regulated caveolin in L6E9 cells. Under fasting conditions, most of caveolin was found in intracellular membranes and the caveolin present in the cell surface was found in both sarcolemma and T-tubules, Insulin administration led to a redistribution of caveolin from intracellular high density membrane fractions to intracellular lighter density fractions and to the cell surface; this pattern of insulin-induced redistribution was different to what was shown by GLUT4. These results suggests that caveolin is a component of an insulin-regulated machinery of vesicular transport in muscle. Quantitative immunoisolation of GLUT4 vesicles obtained from different intracellular GLUT4 populations revealed the absence of caveolin which substantiates the lack of colocalization of intracellular GLUT4 and caveolin, This indicates that caveolin is not involved in intracellular GLUT4 trafficking in skeletal muscle.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & BIOL MOLEC,E-08028 BARCELONA,SPAIN	University of Barcelona			Palacín, Manuel/G-9786-2015; Gumà, Anna/C-5165-2017; Mora, Silvia/Y-3131-2019; Zorzano, Antonio/R-5479-2018	Gumà, Anna/0000-0001-9390-5252; Mora, Silvia/0000-0002-8473-1497; Palacin, Manuel/0000-0002-8670-293X				BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BROZINICK JT, 1994, BIOCHEM J, V297, P539, DOI 10.1042/bj2970539; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CAMPS M, 1994, ENDOCRINOLOGY, V134, P924, DOI 10.1210/en.134.2.924; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHARUK JHM, 1989, BIOCHEM J, V264, P885, DOI 10.1042/bj2640885; CHAUDRY IH, 1969, BIOCHIM BIOPHYS ACTA, V177, P527, DOI 10.1016/0304-4165(69)90315-8; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DUDEK RW, 1994, FEBS LETT, V339, P205, DOI 10.1016/0014-5793(94)80416-8; EZAKI O, 1992, DIABETES, V41, P920, DOI 10.2337/diabetes.41.8.920; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOODMAN MN, 1983, AM J PHYSIOL, V244, pE93, DOI 10.1152/ajpendo.1983.244.1.E93; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE795, DOI 10.1152/ajpendo.1991.261.6.E795; GUMA A, 1992, FEBS LETT, V310, P51, DOI 10.1016/0014-5793(92)81144-B; HIDALGO C, 1983, J BIOL CHEM, V258, P3937; HOLLOSZY JO, 1965, J BIOL CHEM, V240, P3493; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAHN BB, 1993, ENDOCRINOLOGY, V132, P13, DOI 10.1210/en.132.1.13; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LIN JL, 1991, DIABETOLOGIA, V34, P477, DOI 10.1007/BF00403283; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MARETTE A, 1992, DIABETES, V41, P1562, DOI 10.2337/diabetes.41.12.1562; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MUNOZ P, 1995, BIOCHEM J, V307, P273, DOI 10.1042/bj3070273; MUNOZ P, 1995, BIOCHEM J, V312, P393, DOI 10.1042/bj3120393; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NARAHARA HT, 1963, J BIOL CHEM, V238, P40; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PARK CR, 1968, J GEN PHYSIOL, V52, pS296, DOI 10.1085/jgp.52.1.296; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PUJADES C, 1992, J CELL SCI, V102, P815; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHMID A, 1986, BIOCHEMISTRY-US, V25, P3492, DOI 10.1021/bi00360a002; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; STORLIEN LH, 1986, AM J PHYSIOL, V251, pE576, DOI 10.1152/ajpendo.1986.251.5.E576; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; TAKATA K, 1992, ACTA HISTOCHEM CYTOC, V25, P689, DOI 10.1267/ahc.25.689; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; Zorzano A, 1996, DIABETES, V45, pS70, DOI 10.2337/diab.45.1.S70; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	66	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8133	8139		10.1074/jbc.271.14.8133	http://dx.doi.org/10.1074/jbc.271.14.8133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626501	hybrid, Green Published			2022-12-25	WOS:A1996UD60000041
J	Peppelenbosch, MP; Tertoolen, LGJ; deVriesSmits, AMM; Qiu, RG; MRabet, L; Symons, MH; deLaat, SW; Bos, JL				Peppelenbosch, MP; Tertoolen, LGJ; deVriesSmits, AMM; Qiu, RG; MRabet, L; Symons, MH; deLaat, SW; Bos, JL			Rac-dependent and -independent pathways mediate growth factor-induced Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; GTP-BINDING-PROTEIN; GUANINE-NUCLEOTIDES; ADP-RIBOSYLATION; TYROSINE KINASE; CELLS; TRANSDUCTION; CALCIUM; ACTIVATION; RHO	We report that expressing interfering mutants of the small Ras-related GTPase Rac, using either recombinant vaccinia virus or stable DNA transfection, eliminates epidermal growth factor-induced Ca2+ signaling, without affecting Ca2+ mobilization or influx from G protein-coupled receptors. Platelet-derived growth factor-dependent Ca2+ influx, however, is only partly sensitive to dominant negative Rac proteins. Thus, whereas epidermal growth factor-induced Ca2+ influx is completely mediated by Rac proteins, platelet-derived growth factor-induced Ca2+ influx involves Rac-dependent and -independent signaling pathways.	UNIV UTRECHT,PHYSIOL CHEM LAB,3584 CG UTRECHT,NETHERLANDS; NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; ONYX PHARMACEUT,RICHMOND,CA 94806	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)				Peppelenbosch, Maikel/0000-0001-9112-6028				BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; MACARA IG, 1985, J BIOL CHEM, V261, P9321; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MELDOLESI J, 1995, NAT MED, V1, P512, DOI 10.1038/nm0695-512; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORII N, 1992, J BIOL CHEM, V267, P20921; MOZAHEYEVA GN, 1991, J MEMBRANE BIOL, V124, P113; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1992, CELL, V70, P701; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TILLY BC, 1990, FEBS LETT, V265, P80, DOI 10.1016/0014-5793(90)80888-P; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	36	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7883	7886		10.1074/jbc.271.14.7883	http://dx.doi.org/10.1074/jbc.271.14.7883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626463	hybrid			2022-12-25	WOS:A1996UD60000003
J	Qiu, WQ; Borth, W; Ye, Z; Haass, C; Teplow, DB; Selkoe, DJ				Qiu, WQ; Borth, W; Ye, Z; Haass, C; Teplow, DB; Selkoe, DJ			Degradation of amyloid beta-protein by a serine protease-alpha(2)-macroglobulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; HUMAN ALPHA-2-MACROGLOBULIN; INHIBITORS; PRECURSOR; RECEPTOR; PEPTIDE; CELLS	Progressive cerebral deposition of the amyloid beta-peptide (A beta) is an early and constant feature of Alzheimer's disease. A beta is derived by proteolysis from the beta-amyloid precursor protein. beta-Amyloid precursor protein processing and the generation of A beta have been extensively characterized, but little is known about the mechanisms of degradation of this potentially neurotoxic peptide. We identified and purified a proteolytic activity in culture medium that can degrade secreted A beta but not larger proteins in the medium. Detection of the activity in conditioned medium required the presence of fetal bovine serum and the passage of the cells with a pancreatic trypsin preparation. Its inhibitor profile showed that the activity was a serine protease other than trypsin or chymotrypsin. The protease occurs as a stable similar to 700-kDa complex with the inhibitor, alpha(2)-macroglobulin (alpha(2)M), that retains activity against small substrates such as A beta. Its NH2-terminal sequence suggests that the protease is previously unidentified. Our results indicate that the A beta-degrading protease we have detected is a non-trypsin component of a pancreatic trypsin preparation or else derives from a zymogen in serum that is activated by a protease in the latter preparation. Because A beta-bearing plaques in Alzheimer's disease brain contain both alpha(2)M and receptors of alpha(2)M-protease complexes, the same or a similar alpha(2)M-protease complex could arise in vivo and play a role in A beta clearance.	BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; MT SINAI MED CTR,DEPT HEMATOL,NEW YORK,NY 10029	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Icahn School of Medicine at Mount Sinai				Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410	NATIONAL INSTITUTE ON AGING [RF1AG006173, R37AG006173, R01AG012749, R01AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06173, AG 12749] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BEYNON RJ, 1993, PROTEOLYTIC ENZYMES, P241; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOOL DV, 1993, NEUROBIOL AGING, V14, P233; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HYMAN BT, 1995, ARCH NEUROL-CHICAGO, V52, P373, DOI 10.1001/archneur.1995.00540280059019; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MCCONNELL DJ, 1972, J CLIN INVEST, V51, P1611, DOI 10.1172/JCI106962; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; RESNICK NM, 1991, CELL, V66, P541, DOI 10.1016/0092-8674(81)90017-9; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWEENEY PJ, 1993, ANAL BIOCHEM, V212, P179, DOI 10.1006/abio.1993.1310; TSUJI A, 1989, J BIOL CHEM, V264, P16093; TSUJI A, 1991, BIOCHIM BIOPHYS ACTA, V1078, P85, DOI 10.1016/0167-4838(91)90096-I; UCHINO T, 1993, J BIOL CHEM, V268, P527; VANLEUVEN F, 1988, J BIOL CHEM, V263, P468; VOGT W, 1976, N-S ARCH PHARMACOL, V294, P75, DOI 10.1007/BF00692787	35	85	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8443	8451		10.1074/jbc.271.14.8443	http://dx.doi.org/10.1074/jbc.271.14.8443			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626544				2022-12-25	WOS:A1996UD60000084
J	Tong, YH; Zull, J; Yu, L				Tong, YH; Zull, J; Yu, L			Functional expression and signaling properties of cloned human parathyroid hormone receptor in Xenopus oocytes - Evidence for a novel signalling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; OSTEOBLAST-LIKE CELLS; CYCLIC ADP-RIBOSE; PROTEIN-KINASE-C; OSTEOSARCOMA CELLS; ADENYLATE-CYCLASE; INOSITOL TRISPHOSPHATE; PEPTIDE RECEPTORS; LAEVIS OOCYTES; TUBULAR CELLS	Expression of human parathyroid hormone receptor (hPTHR) was obtained in Xenopus oocytes. Receptor function was detected by hormone stimulation of endogenous Ca2+-activated Cl- current. This current was blocked by injected, but not by extracellular. EGTA, confirming that the hPTHR activates cytosolic Ca2+ signaling pathways. PTH responses were acutely desensitized but were regained in 6-12 h. Injection of cAMP or analogues had no effect on either responsiveness or desensitization to hPTH. The hPTH response was more sluggish than seen with serotonin 5-hydroxytryptamine (5-HT2C) receptor. In oocytes co-expressing both hPTHR and 5-HT2C receptors, homologous desensitization was seen, but cross-desensitization was not observed. Injection of inositol 1,4,5-trisphosphate (InsP(3)) elicited a fast inward current similar to that induced by serotonin, and complete cross-desensitization occurred between the InsP(3) and 5-HT2C responses. Desensitization by hPTH did not affect responses to either InsP(3) or serotonin, but cells desensitized to injected InsP(3) still responded strongly to PTH. Oocytes did not respond to either cADPR or NAADP(+), but NADP(+) and analogues were found to be potent inhibitors of PTH signaling. We suggest that PTH cytosolic Ca2+ signaling in oocytes either involves a novel signaling system or proceeds through a Ca2+ compartment whose responsiveness is regulated in a novel way.	CASE WESTERN RESERVE UNIV, DEPT BIOL, CLEVELAND, OH 44106 USA; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA	Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028190, K04NS001557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009116] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09116] Funding Source: Medline; NINDS NIH HHS [NS28190, NS01557] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BABICH M, 1991, ENDOCRINOLOGY, V129, P1463, DOI 10.1210/endo-129-3-1463; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDWELL JP, 1991, ENDOCRINOLOGY, V128, P1021, DOI 10.1210/endo-128-2-1021; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CHESNOYMARCHAIS D, 1989, PFLUG ARCH EUR J PHY, V415, P104, DOI 10.1007/BF00373147; CIVITELLI R, 1994, J BONE MINER RES, V9, P1407; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CIVITELLI R, 1992, ENDOCRINOLOGY, V130, P2392, DOI 10.1210/en.130.4.2392; COLEMAN DT, 1990, J BONE MINER RES, V5, P299, DOI 10.1002/jbmr.5650050314; DASCAL N, 1985, J PHYSIOL-LONDON, V366, P299, DOI 10.1113/jphysiol.1985.sp015799; DASCAL N, 1986, MOL BRAIN RES, V1, P201, DOI 10.1016/0169-328X(86)90026-4; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOLTZMAN D, 1980, J CLIN INVEST, V65, P1309, DOI 10.1172/JCI109794; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; HORIUCHI T, 1991, J BIOL CHEM, V266, P4700; HRUSKA KA, 1987, J CLIN INVEST, V79, P230, DOI 10.1172/JCI112788; HUDSON PL, 1994, J BIOL CHEM, V269, P21885; IKEDA K, 1991, ENDOCRINOLOGY, V128, P2901, DOI 10.1210/endo-128-6-2901; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LIN LH, 1993, MOL PHARMACOL, V43, P941; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MCINTOSH RP, 1987, P NATL ACAD SCI USA, V84, P9045, DOI 10.1073/pnas.84.24.9045; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo-126-5-2650; NISSENSON RA, 1987, BIOCHEMISTRY-US, V26, P1874, DOI 10.1021/bi00381a013; PAUSOVA Z, 1994, GENOMICS, V20, P20, DOI 10.1006/geno.1994.1122; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; ROSENBLATT M, 1989, ENDOCRINOLOGY, P848; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SCHNEIDER H, 1993, EUR J PHARM-MOLEC PH, V246, P149, DOI 10.1016/0922-4106(93)90092-N; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SHAPIRA H, 1990, BIOPHYS J, V57, P1281, DOI 10.1016/S0006-3495(90)82646-1; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WHITFIELD JF, 1992, J CELL PHYSIOL, V150, P299, DOI 10.1002/jcp.1041500212; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; YOSHII K, 1987, J GEN PHYSIOL, V90, P553, DOI 10.1085/jgp.90.4.553; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8183	8191		10.1074/jbc.271.14.8183	http://dx.doi.org/10.1074/jbc.271.14.8183			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626509	hybrid			2022-12-25	WOS:A1996UD60000049
J	Perez, JL; Jing, SQ; Wong, TW				Perez, JL; Jing, SQ; Wong, TW			Identification of two isoforms of the Cak receptor kinase that are coexpressed in breast tumor cell lines	ONCOGENE			English	Article						receptor kinases; cell adhesion; receptor isoforms	GROWTH-FACTOR; FACTOR-VIII; TYROSINE; SURFACE; DNA	The Cak receptor kinase is a member of a novel family of receptors that are characterized by the unique structure of the ectodomains. We have identified a new isoform of Cak that differs from the original isolate by the deletion of 37 amino acids in the cytoplasmic juxtamembrane sequence. Analysis of the genomic sequence suggests that the two isoforms arise by exon skipping. The isoform-specific insert contains the motif NPXY, which was previously shown to be involved in diverse signaling function in a number of receptors. By RNase protection analyses, we found that the long isoform, Cak I is expressed at three- to sevenfold the abundance of the short isoform (Cak II). By Western blotting, Cak I receptor was found to be expressed in mouse embryos and in adult brain. Cak II protein was not detected in mouse embryos or adult tissues, but is abundantly expressed in some breast tumor cell lines. The expression profile of Cak suggests that its primary function is likely to be in developmental regulation. The coexpression of the Cak isoforms in some epithelial cell lines suggests that heterodimer formation may be a key feature in the function of the rectpror	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; AMGEN INC,THOUSAND OAKS,CA 91320	Rutgers State University New Brunswick; Rutgers State University Medical Center; Amgen					NIGMS NIH HHS [1 F31 GM16363-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVES R, 1995, ONCOGENE, V10, P610; BARBACID M, 1993, ONCOGENE, V8, P2033; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREPARO A, 1995, J BIOL CHEM, V270, P15639; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KARN T, 1993, ONCOGENE, V8, P3277; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAI C, 1994, ONCOGENE, V8, P877; PEREZ JL, 1994, ONCOGENE, V9, P211; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZHOU S, 1995, J BIOL CHEM, V270, P14863	28	40	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1469	1477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622863				2022-12-25	WOS:A1996UF07600011
J	Antle, VD; Liu, DS; McKellar, BR; Caperelli, CA; Hua, M; Vince, R				Antle, VD; Liu, DS; McKellar, BR; Caperelli, CA; Hua, M; Vince, R			Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENOVO PURINE BIOSYNTHESIS; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; INHIBITORS; REAGENT; ANALOG	Several glycinamide ribonucleotide analogs have been prepared and evaluated as substrates and/or inhibitors of glycinamide ribonucleotide transformylase from chicken liver. The side chain modified analogs, in which the glycine side chain, R = CH2NH2, has been replaced by R = CH2NHCH3 and R = CH2CH2NH2, are substrates, with V/K (relative intensity) of 2.4% and 16.3%, respectively. Several carbocyclic analogs of glycinamide ribonucleotide, including the phosphonate derivative of carbocyclic glycinamide ribonucleotide, did not serve as substrates, but were inhibitors of the enzyme, competitive against glycinamide ribonucleotide, with K-i values ranging from 7.4 to 23.6 times the K-m for glycinamide ribonucleotide. However, the O-phosphonate analog of carbocyclic glycinamide ribonucleotide did support enzymatic activity, with V/K (relative intensity) of 0.8%. In addition, glycinamide ribonucleoside was neither a substrate for, nor an inhibitor of, glycinamide ribonucleotide transformylase. Furthermore, alpha-glycinamide ribonucleotide had no effect on enzyme activity. These studies have begun to define the structural features of the nucleotide substrate required to support enzymatic activity.	UNIV CINCINNATI,MED CTR,COLL PHARM,DIV PHARMACEUT SCI,CINCINNATI,OH 45267; UNIV MINNESOTA,COLL PHARM,DEPT MED CHEM,MINNEAPOLIS,MN 55455	University of Cincinnati; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R01CA023263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042663, R01GM046243] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA23263] Funding Source: Medline; NIGMS NIH HHS [R01GM42663, R01GM46243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P197; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1988, ARCH BIOCHEM BIOPHYS, V264, P340, DOI 10.1016/0003-9861(88)90602-9; CAPERELLI CA, 1992, J BIOL CHEM, V267, P9783; CAPERELLI CA, 1991, BIOORG CHEM, V19, P40, DOI 10.1016/0045-2068(91)90042-N; CHETTUR G, 1977, CARBOHYD RES, V56, P75, DOI 10.1016/S0008-6215(00)84238-X; Cleland W W, 1979, Methods Enzymol, V63, P103; HIMMELSBACH F, 1987, HELV CHIM ACTA, V70, P1286, DOI 10.1002/hlca.19870700508; IKBAL M, 1989, EUR J MED CHEM, V24, P415, DOI 10.1016/0223-5234(89)90086-X; INGLESE J, 1991, TETRAHEDRON, V47, P2351, DOI 10.1016/S0040-4020(01)81773-7; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LIU DH, 1991, J BIOL CHEM, V266, P16699; MORAN RG, 1989, J BIOL CHEM, V264, P21047; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; OLAH GA, 1979, J ORG CHEM, V44, P1247, DOI 10.1021/jo01322a012; SCHENDEL FJ, 1986, BIOCHEMISTRY-US, V25, P2256, DOI 10.1021/bi00356a061; Smith M., 1961, BIOCH PREP, V8, P130; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; VINCE R, 1990, J MED CHEM, V33, P17, DOI 10.1021/jm00163a004; YOUNG M, 1984, BIOCHEMISTRY-US, V23, P3979, DOI 10.1021/bi00312a027	22	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6045	6049		10.1074/jbc.271.11.6045	http://dx.doi.org/10.1074/jbc.271.11.6045			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626389				2022-12-25	WOS:A1996UA36300018
J	Banecki, B; Zylicz, M				Banecki, B; Zylicz, M			Real time kinetics of the DnaK DnaJ GrpE molecular chaperone machine action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ATP HYDROLYSIS; UNCOATING ATPASE; RNA-POLYMERASE; REPLICATION; INITIATION; HSP70; BACTERIOPHAGE; PURIFICATION	Applying stopped-flow fluorescence spectroscopy for measuring conformational changes of the UnaK molecular chaperone (bacterial Hsp70 homologue) and its binding to target peptide, we found that after ATP hydrolysis, DnaK is converted to the DnaK*(ADP) conformation, which possesses limited affinity for peptide substrates and the GrpE cochaperone but efficiently binds the DnaJ chaperone. In the presence of DnaJ (bacterial Hsp40 homologue), the DnaK*(ADP) form is converted back to the DnaK conformation, and the resulting DnaJ . DnaK(ADP) complex binds to peptide substrates more tightly. Formation of the DnaJ(substrate-DnaK(ADP)) complex is a rate-limiting reaction. The presence of GrpE and ATP hydrolysis promotes the fast release of the peptide substrate from the chaperone complex and converts DnaK to the DnaK*(ADP) conformation. We conclude that in the presence of DnaJ and GrpE, the binding-release cycle of DnaK is stoichiometrically coupled to the adenosine triphosphatase activity of DnaK.	UNIV GDANSK,DEPT MOLEC BIOL,DIV BIOPHYS,PL-80822 GDANSK,POLAND	Fahrenheit Universities; University of Gdansk								ALFANO C, 1989, J BIOL CHEM, V264, P10709; BANECKI B, 1992, J BIOL CHEM, V267, P25051; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GAO BC, 1993, J BIOL CHEM, V268, P8507; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1992, EMBO J, V11, P71; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	42	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6137	6143		10.1074/jbc.271.11.6137	http://dx.doi.org/10.1074/jbc.271.11.6137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626401				2022-12-25	WOS:A1996UA36300030
J	Scott, VES; DeWaard, M; Liu, HY; Gurnett, CA; Venzke, DP; Lennon, VA; Campbell, KP				Scott, VES; DeWaard, M; Liu, HY; Gurnett, CA; Venzke, DP; Lennon, VA; Campbell, KP			beta Subunit heterogeneity in N-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; PERIPHERAL NEURONS; SKELETAL-MUSCLE; BRAIN; SENSITIVITY; RECEPTOR; CLONING; ALPHA-1	The beta subunit of the voltage-dependent Ca2+ channel is a cytoplasmic protein that interacts directly with an alpha(1) subunit, thereby modulating the biophysical properties of the channel. Herein, we demonstrate that the alpha(1) subunit of the N-type Ca2+ channel associates with several different beta subunits, Polyclonal antibodies specific for three different beta subunits immunoprecipitated I-125-omega-conotoxin GVIA binding from solubilized rabbit brain membranes, Enrichment of the N-type Ca2+ channels with an alpha(1B) subunit-specific monoclonal antibody showed the association of beta(1b), beta(3), and beta(4), subunits. Protein sequencing of tryptic peptides of the 57-kDa component of the purified N-type Ca2+ channel confirmed the presence of the beta(3) and beta(4) subunits. Each of the beta subunits bound to the alpha(1B) subunit interaction domain with similar high affinity. Thus, our data demonstrate important heterogeneity in the beta subunit composition of the N-type Ca2+ channels, which may be responsible for some of the diverse kinetic properties recorded from neurons.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,PROGRAM NEUROSCI,IOWA CITY,IA 52242; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,NEUROIMMUNOL LAB,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Mayo Clinic; Mayo Clinic			Tuluc, Petronel/C-2527-2011; De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Venzke, David/0000-0001-8180-9562; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889	NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LENNON VA, 1995, SOC NEUR ABST, V21; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LIU H, 1995, SOC NEUR ABST; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088	30	116	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					3207	3212		10.1074/jbc.271.6.3207	http://dx.doi.org/10.1074/jbc.271.6.3207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621722	hybrid			2022-12-25	WOS:A1996TU69100051
J	Hitomi, M; Shu, JY; Strom, D; Hiebert, SW; Harter, ML; Stacey, DW				Hitomi, M; Shu, JY; Strom, D; Hiebert, SW; Harter, ML; Stacey, DW			Prostaglandin A(2) blocks the activation of G(1) phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH-INHIBITION; MESSENGER-RNA; RAS; CELLS; PHOSPHORYLATION; EXPRESSION; TRANSACTIVATION; NIH-3T3-CELLS	Prostaglandin A(2) (PGA(2)) reversibly blocked the cell cycle progression of NIH 3T3 cells at G(1) and G(2)/M phase, When it was applied to cells synchronized in G(0) or S phase, cells were blocked at G(1) and G(2)/M, respectively, The G(2)/M blockage was transient, Microinjected oncogenic leucine 61 Ras protein could not override the PGA(2) induced G(1) blockage, nor could previous transformation with the v-raf oncogene, The serum-induced activation of mitogen-activated protein kinase was not inhibited by PGA(2) treatment, These data suggest that PGA(2) blocks cell cycle progression without interfering with the cytosolic proliferative signaling pathway, Combined microinjection of E2F-1 and DP-1 proteins or microinjected adenovirus E1A protein, however, could induce S phase in cells arrested in G(1) by PGA(2), indicating that PGA(2) does not directly inhibit the process of DNA synthesis, In quiescent cells, PGA(2) blocked the normal hyperphosphorylation of the retinoblastoma susceptible gene product and the activation of cyclin-dependent kinase (CDK) 2 and CDK4, in response to serum stimulation, PGA(2) treatment elevated the p21(Waf1/Cip1/Sdi1) protein expression level, These data indicate that PGA(2) may arrest the cell cycle in G(1) by interfering with the activation of G(1) phase CDKs.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Hitomi, M (corresponding author), CLEVELAND CLIN FDN, DEPT MOLEC BIOL, NC2-150, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER; NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HARPER JW, 1993, CELL, V75, P805; HASHIDA T, 1988, FATTY ACIDS, V33, P61; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KATO J, 1993, GENE DEV, V7, P331; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MITRA G, 1993, CELL MOL BIOL RES, V39, P517; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; OHNO K, 1988, J PHARMACOL EXP THER, V245, P294; OHNO K, 1993, BIOCHEM PHARMACOL, V46, P661, DOI 10.1016/0006-2952(93)90552-8; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHULZE A, 1994, ONCOGENE, V9, P3475; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; TERRAGNO A, 1981, PROSTAGLANDINS, V21, P101, DOI 10.1016/0090-6980(81)90200-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAN M, 1994, NATURE, V372, P498	54	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9376	9383		10.1074/jbc.271.16.9376	http://dx.doi.org/10.1074/jbc.271.16.9376			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621603	hybrid			2022-12-25	WOS:A1996UG04400034
J	Ho, GY; Toomey, JR; Broze, GJ; Schwartz, AL				Ho, GY; Toomey, JR; Broze, GJ; Schwartz, AL			Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; BINDING; DOMAINS; IDENTIFICATION; LOCALIZATION; COMPLEXES; PROTEIN; SECRETE; ANTIGEN; HEPARIN	Coagulation factor Xa is a plasma serine protease that catalyzes prothrombin to thrombin conversion, which, in turn, leads to the generation of the fibrin clot. Of the several parameters that govern the plasma level of factor Xa, control of its catabolism is of crucial importance. However, little is known regarding the mechanisms by which factor Xa is catabolized. In the present study we examine the cellular basis for the uptake and degradation of factor Xa. I-125-Factor Xa was degraded by hepatoma cells and embryonic fibroblasts via a process which required cell surface-bound tissue factor pathway inhibitor (TFPI), a potent inhibitor of factor Xa. Uptake and degradation of cell surface-bound I-125-TFPI was also markedly stimulated in response to factor Xa binding. The intracellular kinetics of I-125-factor Xa and cell surface-bound I-125-TFPI display a strikingly similar pattern, suggesting that factor Xa and cell surface-bound TFPI are taken up as a bimolecular complex. Using cell lines either deficient in low density lipoprotein receptor-related protein, an endocytic receptor that mediates the degradation of uncomplexed TFPI (Warshawsky, I., Broze, G. J., Jr., and Schwartz, A. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6664-6668), or deficient in tissue factor (TF), an integral membrane protein capable of forming quarternary complexes with factor Xa, TFPI, and factor VIIa, we demonstrated that the receptor that mediates the uptake and degradation of factor Xa-TFPI complex was neither low density lipoprotein receptor-related protein nor TF. As the vascular endothelial cell surface retains a substantial pool of TFPI (Sandset, P. M., Alildgaard, U., and Larsen, M. L. (1988) Thromb. Res. 50, 803-813; Novotny, W. F., Brown, S. G., Miletich, J. P., Rader, D. J., and Broze, G. J., Jr. (1991) Blood 78, 387-393), our data suggest that endothelial cell surface TFPI may be actively involved in the clearance of factor Xa from the circulation via mediated uptake and degradation.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, DIV HEMATOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital	Ho, GY (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PEDIAT, BOX 8116, ST LOUIS, MO 63110 USA.							BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; BU GJ, 1992, J BIOL CHEM, V267, P15595; COLMAN RW, 1982, J CLIN INVEST, V69, P844; COLMAN RW, 1987, HEMOSTASIS THROMBOSI, P3; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; FLECK RA, 1990, THROMB RES, V57, P765, DOI 10.1016/0049-3848(90)90034-A; GEMMELL CH, 1990, BLOOD, V76, P2266; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KAZAMA Y, 1993, BLOOD, V81, P676; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P373, DOI 10.1021/bi00647a021; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; NOVOTNY WF, 1989, BLOOD S, V74, P780; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, METHOD CELL BIOL, V32, P305; PRATT CW, 1986, ARCH BIOCHEM BIOPHYS, V248, P587, DOI 10.1016/0003-9861(86)90512-6; SAKAI T, 1990, J BIOL CHEM, V265, P9105; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; UNDERHILL DM, 1992, BLOOD, V80, P2746; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WARSHAWSKY I, 1995, J CLIN INVEST, V95, P1773, DOI 10.1172/JCI117855; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WESSELSCHMIDT R, 1993, BLOOD COAGUL FIBRIN, V4, P661, DOI 10.1097/00001721-199304050-00001; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILLNOW TE, 1994, J CELL SCI, V107, P719; WUN TC, 1988, J BIOL CHEM, V263, P6001	34	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9497	9502		10.1074/jbc.271.16.9497	http://dx.doi.org/10.1074/jbc.271.16.9497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621621	hybrid			2022-12-25	WOS:A1996UG04400052
J	Yoon, YS; Kim, JW; Kang, KW; Kim, YS; Choi, KH; Joe, CO				Yoon, YS; Kim, JW; Kang, KW; Kim, YS; Choi, KH; Joe, CO			Poly(ADP-ribosyl)ation of histone H1 correlates with internucleosomal DNA fragmentation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; NICOTINAMIDE ADENINE-DINUCLEOTIDE; ADP-RIBOSYLATION; CELL-DEATH; INTERPHASE DEATH; TOPOISOMERASE-I; POLYMERASE-BETA; STRAND-BREAKS; TUMOR-CELLS; INHIBITION	The biochemical role of poly(ADP-ribosyl)ation on internucleosomal DNA fragmentation associated with apoptosis was investigated in HL 60 human premyelocytic leukemia cells. It was found that UV light and chemotherapeutic drugs including adriamycin, mitomycin C, and cisplatin increased poly(ADP-ribosyl)ation of nuclear proteins, particularly histone H1. A poly(ADP-ribose) polymerase inhibitor, 3-aminobenzamide, prevented both internucleosomal DNA fragmentation and histone H1 poly(ADP-ribosyl)ation in cells treated with the apoptosis inducers, When nuclear chromatin was made accessible to the exogenous nuclease in a permeabilized cell system, chromatin of W-treated cells was more susceptible to micrococcal nuclease than the chromatin of control cells. Suppression of histone H1 poly(ADP-ribosyl)ation by 3-aminobenzamide reduced the micrococcal nuclease digestibility of internucleosomal chromatin in UV-treated cells, These results suggest that the poly(ADP-ribosyl)ation of histone H1 correlates with the internucleosomal DNA fragmentation during apoptosis mediated by DNA damaging agents, This suggestion is supported by the finding that xeroderma pigmentosum cells which are defective in introducing incision at the site of DNA damage, failed to induce DNA fragmentation as well as histone H1 poly(ADP-ribosyl)ation after UV irradiation, We propose that poly(ADP-ribosyl)ation of histone H1 protein in the early stage of apoptosis facilitates internucleosomal DNA fragmentation by increasing the susceptibility of chromatin to cellular endonuclease.	KOREA ADV INST SCI & TECHNOL, DEPT SCI BIOL, TAEJON 305701, SOUTH KOREA; CHUNGNAM NATL UNIV, DEPT BIOCHEM, TAEJON 305764, SOUTH KOREA; CHUNG ANG UNIV, DEPT BIOL, SEOUL 156756, SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Chungnam National University; Chung Ang University			KIM, JIN WOO/C-1655-2011; Joe, Cheol O/C-1917-2011	KIM, JIN WOO/0000-0003-0767-1918; 				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; AUBIN RJ, 1983, EMBO J, V2, P1685, DOI 10.1002/j.1460-2075.1983.tb01643.x; BERGER NA, 1978, BIOCHIM BIOPHYS ACTA, V519, P87, DOI 10.1016/0005-2787(78)90064-3; BERGER NA, 1978, J CLIN INVEST, V62, P111, DOI 10.1172/JCI109094; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BERGER NA, 1978, METHOD CELL BIOL, V20, P326; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; COLE RD, 1989, METHOD ENZYMOL, V170, P524; COTTER TG, 1992, CANCER RES, V52, P997; DADAMIO L, 1992, J IMMUNOL, V149, P3550; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; FERRO AM, 1984, J BIOL CHEM, V259, P547; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; GRUBE K, 1991, ANAL BIOCHEM, V193, P236, DOI 10.1016/0003-2697(91)90015-L; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KREIMEYER A, 1984, J BIOL CHEM, V259, P890; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MARKS DI, 1991, BIOCHEM PHARMACOL, V42, P1859, DOI 10.1016/0006-2952(91)90582-P; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCURRY LS, 1981, J BIOL CHEM, V256, P551; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NELSON PP, 1979, J BIOL CHEM, V254, P9194; NIEDERGANG CP, 1985, EUR J BIOCHEM, V146, P185, DOI 10.1111/j.1432-1033.1985.tb08637.x; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; QUESADA P, 1990, BIOCHEM BIOPH RES CO, V170, P900, DOI 10.1016/0006-291X(90)92176-Z; RANKIN PW, 1980, CANCER RES, V40, P1803; RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHALL S, 1972, FEBS LETT, V24, P1, DOI 10.1016/0014-5793(72)80811-1; SINHA BK, 1995, BBA-MOL BASIS DIS, V1270, P12, DOI 10.1016/0925-4439(94)00065-X; SMETS LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P49, DOI 10.1016/0167-4889(90)90204-Q; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SQUIRES S, 1988, MUTAT RES, V193, P181, DOI 10.1016/0167-8817(88)90048-X; TANAKA Y, 1986, EUR J BIOCHEM, V155, P19, DOI 10.1111/j.1432-1033.1986.tb09453.x; TANIGUCHI T, 1985, BIOCHEM BIOPH RES CO, V127, P526, DOI 10.1016/S0006-291X(85)80191-1; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TANIZAWA A, 1987, BIOCHEM BIOPH RES CO, V144, P1031, DOI 10.1016/S0006-291X(87)80067-0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS JO, 1984, J CELL SCI, P1; TROLL W, 1990, BASIC LIFE SCI, V52, P225; WARING P, 1990, J BIOL CHEM, V265, P14476; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4	56	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					9129	9134		10.1074/jbc.271.15.9129	http://dx.doi.org/10.1074/jbc.271.15.9129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621564	hybrid			2022-12-25	WOS:A1996UE73000095
J	Charest, A; Wagner, J; Jacob, S; McGlade, CJ; Tremblay, ML				Charest, A; Wagner, J; Jacob, S; McGlade, CJ; Tremblay, ML			Phosphotyrosine-independent binding of SHC to the NPLH sequence of murine protein-tyrosine phosphatase-PEST - Evidence for extended phosphotyrosine binding phosphotyrosine interaction domain recognition specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION	The phosphotyrosine binding (PTB) or phosphotyrosine interaction (PI) domain of the proto-oncoprotein p52(SHC) binds to an NPXpY consensus sequence found in several growth factor receptors (Kavanaugh, W. M., Turck, C. W., and Williams, L. T. (1994) Science 268, 1177-1179), The amino terminal region of p52(SHC), which includes the PTB/PI domain, has been previously shown to associate with protein-tyrosine phosphatase-PEST (PTP-PEST) in vivo (Habib, T., Herrera, R., and Decker, S. J. (1994) J. Biol. Chem. 269, 25243-25246). We report here the detailed mapping of this interaction in a murine context using glutathione S-transferase fusion protein binding studies and peptide competition assays. We show that the interaction between murine SHC and murine PTP-PEST is mediated through the PTB/PI domain of murine SHC and an NPLH sequence found in the carboxyl terminus of murine PTP-PEST. Since this interaction is not dependent on the presence of a tyrosine-phosphorylated residue in the target sequence, this reveals that the PTB/PI domain of SHC can recognize both tyrosine-phosphorylated sequences and non-tyrosine-based recognition motifs.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,AMGEN INST,TORONTO,ON M5G 2C1,CANADA	McGill University; University of Toronto; University of Toronto								BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Coligan JE, 1995, CURRENT PROTOCOLS PR; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; HABIB T, 1994, J BIOL CHEM, V269, P25243; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Moore DD, 1995, GLOB MOB SURV; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	26	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8424	8429		10.1074/jbc.271.14.8424	http://dx.doi.org/10.1074/jbc.271.14.8424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626541	hybrid			2022-12-25	WOS:A1996UD60000081
J	Klemm, DJ; Colton, LA; Ryan, S; Routes, JM				Klemm, DJ; Colton, LA; Ryan, S; Routes, JM			Adenovirus E1A proteins regulate phosphoenolpyruvate carboxykinase gene transcription through multiple mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP GENE; RETINOBLASTOMA PROTEIN; PROMOTER ELEMENTS; RESPONSE ELEMENT; BINDING PROTEIN; MESSENGER-RNA; FACTOR FAMILY; IDENTIFICATION; ACTIVATION; DOMAINS	Recently, Kalvakolanu et al. (Kalvakolanu, D. V. R., Liu, J., Hanson, R. W., Harter, M. L., and Sen, G. C. (1992) J. Biol. Chem. 267, 2530-2536) showed that E1A inhibited the basal and cAMP-stimulated transcription of the gene for phosphoenolpyruvate carboxykinase (PEPCK), This inhibition was mediated by the conserved region 1 (CR1) domain of E1A, which has been shown by other laboratories to bind to the cellular transcriptional adaptor proteins, p300 and cAMP response element binding protein (CREB)-binding protein (CBP). The PEPCK gene promoter contains a functional cAMP-response element, through which CREB and, therefore, CBP modulate transcription, and a consensus p300 DNA binding sequence is also present in a distal protein binding site of the promoter, We hypothesized that E1A might inhibit PEPCK gene transcription by binding to p300 and/or CBP, Surprisingly, we found that E1A consistently stimulated basal transcription from the PEPCK promoter in transfection assays in adenovirus (Ad)-infected HepG2 hepatoma cells or E1A-expressing, stably transfected 3T3 fibroblasts and nuclear run-on assays in Ad infected H4IIE hepatoma cells, E1A also enhanced the stimulation of PEPCK gene transcription by Bt(2)cAMP, In transfection assays, wild type Ad5 expressing both 243B and 289R forms of E1A or a mutant virus expressing the 289R form alone stimulated transcription from the PEPCK promoter by approximately 5-fold 20 h postinfection. However, no stimulation was observed in cells infected with a virus expressing either the 243R protein alone or a 289R protein from which conserved region 3 (CR3) was mutated, Mutation or deletion of CR1 of E1A had no significant effect on transcription from the PEPCK promoter, Mutations within conserved region 2 (CR2) of E1A that inhibit the binding of E1A to the retinoblastoma gene product (pRb) further enhanced the stimulation of transcription from the PEPCK promoter by 2-3-fold compared with wild type E1A. These findings suggested that the normal function of pRb is to stimulate PEPCK gene transcription, and that this process is inhibited by the binding of E1A to pRb. This hypothesis was confirmed by overexpressing pRb in HepG2 cells, which stimulated transcription from the PEPCK promoter, Our findings indicate that Ad E1A regulates PEPCK gene transcription through a stimulatory mechanism involving CR3, and by attenuating a stimulatory effect of pRb through CR2.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV ALLERGY & IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Klemm, DJ (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.		Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047117] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32136] Funding Source: Medline; NIGMS NIH HHS [GM47117] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FAHNESTOCK ML, 1989, J VIROL, V63, P1495, DOI 10.1128/JVI.63.4.1495-1504.1989; GEDRICH RW, 1992, J VIROL, V66, P5849, DOI 10.1128/JVI.66.10.5849-5859.1992; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P545; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATIN A, 1994, ONCOGENE, V9, P1333; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROUTES JM, 1993, J IMMUNOL, V150, P4315; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WALTON KM, 1992, MOL ENDOCRINOL, V6, P439; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	49	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8082	8088		10.1074/jbc.271.14.8082	http://dx.doi.org/10.1074/jbc.271.14.8082			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626493	hybrid			2022-12-25	WOS:A1996UD60000033
J	Neault, JF; TajmirRiahi, HA				Neault, JF; TajmirRiahi, HA			Diethylstilbestrol-DNA interaction studied by Fourier transform infrared and Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY; BINDING; COMPLEXES; ACID	The interaction of diethylstilbestrol (DES) with calf thymus DNA was investigated at physiological pH with drug/DNA (phosphate) molar ratios (r) of 1:40, 1:20, 1:10, 1:4, 1:2, and 1. Fourier transform infrared and laser Raman difference spectroscopy were used to establish cor relations between spectral changes and drug binding mode, sequence selectivity, DNA conformation, and structural properties of DES . DNA complexes in aqueous solution. Spectroscopic results indicated that DES is a weak intercalator with affinity for A-T-rich regions. It is also a groove binder with a major interaction with the thymine O-2 atom, At low drug concentration (r = 1:40), the A-T-rich region is the main target of drug intercalation, while at a higher drug content (r > 1:5), external binding to the G-C bases also occurs with a partial helix destabilization. Evidence for this comes from the spectral alterations of the A-T vibrational frequencies at 1661 cm(-1) (Raman) and 1663 and 1609 cm(-1) (IR) and of the G-C vibrations at 1581 and 1491 cm(-1) (Raman) and 1717 and 1492 cm(-1) (TR), Drug intercalation leads to a major reduction of B-DNA structure in favor of A-DNA.	UNIV QUEBEC, DEPT BIOL CHEM, TROIS RIVIERES, PQ G9A 5H7, CANADA	University of Quebec; University of Quebec Trois Rivieres								ALEX S, 1989, INORG CHIM ACTA, V157, P271, DOI 10.1016/S0020-1693(00)80552-6; BHAT HK, 1994, CARCINOGENESIS, V15, P2137, DOI 10.1093/carcin/15.10.2137; BLACKBURN GM, 1976, BIOCHEM J, V158, P643, DOI 10.1042/bj1580643; BROMLEY SD, 1986, NUCLEIC ACIDS RES, V14, P9133, DOI 10.1093/nar/14.22.9133; GLADEK A, 1989, J BIOL CHEM, V264, P16847; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; KIRKMAN HADLEY, 1959, NAIL CANCER INST MONOGR, V1, P1; KRUGLIK SG, 1995, J PHYS CHEM-US, V99, P5732, DOI 10.1021/j100015a066; LANGLAIS M, 1990, BIOPOLYMERS, V30, P743, DOI 10.1002/bip.360300709; LAVERY R, 1985, J BIOMOL STRUCT DYN, V2, P1021, DOI 10.1080/07391102.1985.10507618; LEGAL JM, 1993, CANCER RES, V53, P3681; LIEHR JG, 1985, CARCINOGENESIS, V6, P829, DOI 10.1093/carcin/6.6.829; LOPRETE DM, 1993, BIOCHEMISTRY-US, V32, P4077, DOI 10.1021/bi00066a032; LUTZ WK, 1982, CHEM-BIOL INTERACT, V42, P251, DOI 10.1016/0009-2797(82)90136-3; METZLER M, 1978, BIOCHEM BIOPH RES CO, V85, P874, DOI 10.1016/0006-291X(78)90625-3; METZLER M, 1984, REV BIOCHEM TOXICOL, V6, P191; MORJANI H, 1993, CANCER RES, V53, P4784; MULLER W, 1975, EUR J BIOCHEM, V54, P267, DOI 10.1111/j.1432-1033.1975.tb04137.x; NABIEV I, 1994, J PHYS CHEM-US, V98, P1344, DOI 10.1021/j100055a049; NABIEV I, 1994, BIOCHEMISTRY-US, V33, P9013, DOI 10.1021/bi00196a020; NEAULT JF, 1995, J BIOMOL STRUCT DYN, V13, P387, DOI 10.1080/07391102.1995.10508847; NONAKA Y, 1990, J RAMAN SPECTROSC, V21, P133, DOI 10.1002/jrs.1250210211; SEQUARIS JM, 1984, FEBS LETT, V173, P95, DOI 10.1016/0014-5793(84)81024-8; SMULEVICH G, 1986, J PHYS CHEM-US, V90, P6388, DOI 10.1021/j100281a064; SMULEVICH G, 1988, INDIAN J PURE AP PHY, V26, P207; SPIRO TG, 1987, BIOL APPL RAMAN SPEC, P81; STARIKOV EB, 1991, BIOPOLYMERS, V31, P255, DOI 10.1002/bip.360310302; TAJMIRRIAHI HA, 1995, FEBS LETT, V370, P105, DOI 10.1016/0014-5793(95)00802-G; TAJMIRRIAHI HA, 1988, NUCLEIC ACIDS RES, V16, P751, DOI 10.1093/nar/16.2.751; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; TSUBOI M, 1969, APPL SPECTROSC REV, V3, P45; TUITE E, 1994, J AM CHEM SOC, V116, P7548, DOI 10.1021/ja00096a011; TUITE E, 1995, BIOPOLYMERS, V35, P419, DOI 10.1002/bip.360350502; WARD B, 1986, BIOCHEMISTRY-US, V25, P7827, DOI 10.1021/bi00372a007; WARD B, 1986, BIOCHEMISTRY-US, V25, P6875, DOI 10.1021/bi00370a021; WEINER PK, 1982, P NATL ACAD SCI-BIOL, V79, P3754, DOI 10.1073/pnas.79.12.3754; WHEELER GV, 1995, J BIOMOL STRUCT DYN, V13, P399, DOI 10.1080/07391102.1995.10508848; WIESBURGER JH, 1984, ACS MONOGR SER, V182, P1323	38	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8140	8143		10.1074/jbc.271.14.8140	http://dx.doi.org/10.1074/jbc.271.14.8140			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626502	hybrid			2022-12-25	WOS:A1996UD60000042
J	Thorens, B; Deriaz, N; Bosco, D; DeVos, A; Pipeleers, D; Schuit, F; Meda, P; Porret, A				Thorens, B; Deriaz, N; Bosco, D; DeVos, A; Pipeleers, D; Schuit, F; Meda, P; Porret, A			Protein kinase A-dependent phosphorylation of GLUT2 in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; GLUCOSE-TRANSPORTER; EXPRESSION CLONING; ISLET CELLS; B-CELL; RECEPTOR; SEQUENCE; LIVER; HORMONES; FAMILY	In pancreatic beta cells, cyclic AMP-dependent protein kinase regulates many cellular processes including the potentiation of insulin secretion. The substrates for this kinase, however, have not been biochemically characterized. Here we demonstrate that the glucose transporter GLUT2 is rapidly phosphorylated by protein kinase A following activation of adenylyl cyclase by forskolin or the incretin hormone glucagon-like peptide-1. We show that serines 489 and 501/503 and threonine 510 in the carboxyl-terminal tail of the transporter are the in vitro and in vivo sites of phosphorylation. Stimulation of GLUT2 phosphorylation in beta cells reduces the initial rate of 3-O-methyl glucose uptake by similar to 48% but does not change the Michaelis constant, Similar differences in transport kinetics are observed when comparing the transport activity of GLUT2 mutants stably expressed in insulinoma cell lines and containing glutamates or alanines at the phosphorylation sites. These data indicate that phosphorylation of GLUT2 carboxyl-terminal tail modifies the rate of transport. This lends further support for an important role of the transporter cytoplasmic tail in the modulation of catalytic activity. Finally, because activation of protein kinase A stimulates glucose-induced insulin secretion, we discuss the possible involvement of GLUT2 phosphorylation in the amplification of the glucose signaling process.	UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA,SWITZERLAND; FREE UNIV BRUSSELS,DIABET RES CTR,B-1090 BRUSSELS,BELGIUM	University of Geneva; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Thorens, B (corresponding author), UNIV LAUSANNE,INST PHARMACOL & TOXICOL,27 BUGNON,CH-1005 LAUSANNE,SWITZERLAND.			Bosco, Domenico/0000-0003-3453-9613; Pipeleers, Daniel/0000-0002-6440-2485				ABRAHAMSEN N, 1995, ENDOCRINOLOGY, V136, P1572, DOI 10.1210/en.136.4.1572; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CREUTZFELDT W, 1992, DIABETES METAB REV, V8, P149, DOI 10.1002/dmr.5610080206; DUPRE J, 1991, ENDOCRINE PANCREAS, P253; FERBER S, 1994, J BIOL CHEM, V269, P11523; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GIORDANO E, 1993, AM J PHYSIOL, V265, pC358, DOI 10.1152/ajpcell.1993.265.2.C358; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence John C. Jr., 1994, P473; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; Pipeleers D, 1989, CELL STRUCT FUNCT, P391; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; Reusch Jane E.-B, 1994, P497; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; THORENS B, 1992, INT REV CYTOL, V137A, P209; Thorens Bernard, 1994, P357; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; VALERA A, 1994, J BIOL CHEM, V269, P28543; VANSCHRAVENDIJK CFH, 1985, ENDOCRINOLOGY, V117, P841; WANG JL, 1993, J BIOL CHEM, V268, P7785; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685	45	54	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8075	8081		10.1074/jbc.271.14.8075	http://dx.doi.org/10.1074/jbc.271.14.8075			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626492				2022-12-25	WOS:A1996UD60000032
J	Hooley, R; Yu, CY; Symons, M; Barber, DL				Hooley, R; Yu, CY; Symons, M; Barber, DL			G alpha 13 stimulates Na+-H+ exchange through distinct Cdc42-dependent and RhoA-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-KINASE; INTRACELLULAR PH; CELL-CYCLE; DICTYOSTELIUM-DISCOIDEUM; INDEPENDENT MECHANISM; GENE-EXPRESSION; HL-60 CELLS; ACTIVATION; ANTIPORTER	Activity of the ubiquitously expressed Na+-H+ exchanger subtype NHE1 is stimulated upon activation of receptor tyrosine kinases and G protein-coupled receptors. The intracellular signaling pathways mediating receptor regulation of the exchanger, however, are poorly understood. Using transient expression of dominant interfering and constitutively active alleles in CCL39 fibroblasts, we determined that the GTPases Ha-Ras and G alpha 13 stimulate NHE1 through distinct signaling cascades. Exchange activity stimulated by constitutively active RasV12 occurs through a Raf1- and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase kinase (MEK)-dependent mechanism. Constitutively active G alpha 13QL, recently shown to stimulate the Jun kinase cascade, activates NHE1 through a Cdc42- and MEK kinase (MEKK1)-dependent mechanism that is independent of Rad. Constitutively active Rac1V12 does stimulate NHE1 through a MEKK1-dependent mechanism, but dominant interfering Rac1N17 does not inhibit G alpha 13QL-mediated or constitutively active Cdc42V12-mediated stimulation of the exchanger. Conversely, Cdc42N17 does not inhibit Rac1V17 activation of NHE1, suggesting that Rad and Cdc42 independently regulate a MEKK1-dependent activation of the exchanger. Rapid (<10 min) stimulation of NHE1 with a G alpha 13/G alpha(z) chimera also was inhibited by a kinase-inactive MEKK. G alpha 13QL, but not RasV12, also stimulates NHE1 through a RhoA-dependent pathway that is independent of MEKK, and microinjection of mutationally active G alpha 13 results in a Rho phenotype of increased stress fiber formation. These findings indicate a new target for Rho-like proteins: the regulation of H+ exchange and intracellular pH. Our findings also suggest that a MEKK cascade diverges to regulate effecters other than transcription factors.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; ONYX PHARMACEUT,RICHMOND,CA 94306	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM47413] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AERTS RJ, 1985, CELL, V43, P653, DOI 10.1016/0092-8674(85)90237-5; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FAURE M, 1994, J BIOL CHEM, V269, P7851; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HART MJ, 1994, J BIOL CHEM, V269, P62; HAZAV P, 1989, CANCER RES, V49, P72; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MALY K, 1989, J BIOL CHEM, V264, P11839; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1990, J BIOL CHEM, V265, P1327; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAIRO G, 1992, J BIOL CHEM, V267, P19043; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VANDUIJN B, 1991, P NATL ACAD SCI USA, V88, P4951, DOI 10.1073/pnas.88.11.4951; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798	57	167	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6152	6158		10.1074/jbc.271.11.6152	http://dx.doi.org/10.1074/jbc.271.11.6152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626403	hybrid			2022-12-25	WOS:A1996UA36300032
J	Trotti, D; Rossi, D; Gjesdal, O; Levy, LM; Racagni, G; Danbolt, NC; Volterra, A				Trotti, D; Rossi, D; Gjesdal, O; Levy, LM; Racagni, G; Danbolt, NC; Volterra, A			Peroxynitrite inhibits glutamate transporter subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; RAT-BRAIN; NEUROTOXICITY; EXPRESSION; SUPEROXIDE; MECHANISM; RELEASE; CLONING; SYSTEM; PLASMA	The reuptake of glutamate in neurons and astrocytes terminates excitatory signals and prevents the persistence of excitotoxic levels of glutamate in the synaptic cleft. This process is inhibited by oxygen radicals and hydrogen peroxide (H2O2). Here we show that another biological oxidant, peroxynitrite (ONOO-), formed by combination of superoxide (O-.(2)-) and nitric oxide (NO), potently inhibits glutamate uptake by purified or recombinant high affinity glutamate transporters reconstituted in liposomes. ONOO- reduces selectively the V-max of transport; its action is fast (reaching greater than or equal to 90% within 20 s), dose-dependent (50% inhibition at 50 mu M), persistent upon ONOO- (or by product) removal, and insensitive to the presence of the lipid antioxidant vitamin E in the liposomal membranes. Therefore, it likely depends on direct interaction of ONOO- with the glutamate transporters. Three distinct recombinant glutamate transporters from the rat brain, GLT1, GLAST, and EAAC1, exhibit identical sensitivity to ONOO-. H2O2 also inhibits reconstituted transport, and its action matches that of ONOO- on all respects; however, this is observed only with 5-10 mM H2O2 and after prolonged exposure (10 min) in highly oxygenated buffer. NO, released from NO donors (up to 10 mM), does not modify reconstituted glutamate uptake, although in parallel conditions it promotes cGMP formation in synaptosomal cytosolic fraction. Overall, our results suggest that the glutamate transporters contain conserved sites in their structures conferring vulnerability to ONOO- and other oxidants.	UNIV MILAN,INST PHARMACOL SCI,CTR NEUROPHARMACOL,I-20133 MILAN,ITALY; UNIV OSLO,INST BASIC MED SCI,DEPT ANAT,N-0317 OSLO,NORWAY	University of Milan; University of Oslo			Rossi, Daniela Maria/AAA-3401-2021; Gjesdal, Ola/C-1941-2015; Racagni, Giorgio A./B-5826-2011; Danbolt, Niels Christian/A-1907-2014	Rossi, Daniela Maria/0000-0002-3346-1327; Danbolt, Niels Christian/0000-0003-4227-4520; Volterra, Andrea/0000-0003-1069-1602; Trotti, Davide/0000-0001-6338-6404; Gjesdal, Ola/0000-0003-1913-6445	Telethon [754, 586] Funding Source: Medline	Telethon(Fondazione Telethon)		ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BEAL MF, 1995, J NEUROCHEM, V65, P919; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bjoras M, 1996, MOL BRAIN RES, V36, P163, DOI 10.1016/0169-328X(95)00279-2; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; Bruijn L. I., 1995, Society for Neuroscience Abstracts, V21, P491; CASADO M, 1993, J BIOL CHEM, V268, P27313; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DAWSON VL, 1993, J NEUROSCI, V13, P2651; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEHMANN J, 1982, CLIN CHEM, V28, P1784; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; OHKUMA S, 1995, J NEUROCHEM, V65, P1109; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; RADI R, 1991, J BIOL CHEM, V266, P4244; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SKAPER SD, 1995, J NEUROCHEM, V64, P266; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TROTTI D, 1995, J BIOL CHEM, V270, P9890, DOI 10.1074/jbc.270.17.9890; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433	41	258	264	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					5976	5979		10.1074/jbc.271.11.5976	http://dx.doi.org/10.1074/jbc.271.11.5976			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626378	hybrid			2022-12-25	WOS:A1996UA36300007
J	Kowaltowski, AJ; Castilho, RF; Grijalba, MT; Bechara, EJH; Vercesi, AE				Kowaltowski, AJ; Castilho, RF; Grijalba, MT; Bechara, EJH; Vercesi, AE			Effect of inorganic phosphate concentration on the nature of inner mitochondrial membrane alterations mediated by Ca2+ ions - A proposed model for phosphate-stimulated lipid peroxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; OXIDATIVE STRESS; CYCLOSPORINE-A; PLUS PROOXIDANTS; FREE-RADICALS; OXYGEN; CA-2+; LIPOPEROXIDATION; MODULATION; MECHANISM	Addition of high concentrations (>1 mM) of inorganic phosphate (P-i) or arsenate to Ca2+-loaded mitochondria was followed by increased rates of H2O2 production, membrane lipid peroxidation, and swelling. Mitochondrial swelling was only partially prevented either by butylhydroxytoluene, an inhibitor of lipid peroxidation, or cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. This swelling was totally prevented by the simultaneous presence of these compounds. At lower P-i concentrations (1 mM), mitochondrial swelling is reversible and prevented by cyclosporin A, but not by butylhydroxytoluene. In any case (low or high phosphate concentration) exogenous catalase prevented mitochondrial swelling, suggesting that reactive oxygen species (ROS) participate in these mechanisms. Altogether, the data suggest that, at low P-i concentrations, membrane permeabilization is reversible and mediated by opening of the mitochondrial permeability transition pore, whereas at high P-i concentrations, membrane permeabilization is irreversible because lipid peroxidation also takes place. Under these conditions, lipid peroxidation is strongly inhibited by sorbate, a putative quencher of triplet carbonyl species. This suggests that high P-i or arsenate concentrations stimulate propagation of the peroxidative reactions initiated by mitochondrial-generated ROS because these anions are able to catalyze C-n-aldehyde tautomerization producing enols, which can be oxidized by hemeproteins to yield the lower C-n-1-aldehyde in the triplet state. This proposition was also supported by experiments using a model system consisting of phosphatidyl-choline/dicethylphosphate liposomes and the triplet acetone-generating system isobutanal/horseradish peroxidase, where phosphate and Ca2+ cooperate to increase the yield of thiobarbituric acid-reactive substances.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-05508 SAO PAULO,SP,BRAZIL	Universidade de Sao Paulo	Kowaltowski, AJ (corresponding author), UNIV ESTADUAL CAMPINAS,INST BIOL,DEPT BIOQUIM,CAMPINAS,SP,BRAZIL.		Castilho, Roger F/G-3906-2012; Bechara, Etelvino JH/M-6251-2013; Kowaltowski, Alicia J/H-8698-2012; Bechara, Etelvino JH/AAN-1136-2021; Vercesi, Aníbal E/C-8767-2012	Bechara, Etelvino JH/0000-0001-9526-2529; Bechara, Etelvino JH/0000-0001-9526-2529; Vercesi, Anibal Eugenio/0000-0001-6671-7125; Castilho, Roger/0000-0003-2338-8717				ANTONIO RV, 1991, BIOCHIM BIOPHYS ACTA, V1056, P250, DOI 10.1016/S0005-2728(05)80056-8; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BECHARA EJH, 1979, PHOTOCHEM PHOTOBIOL, V30, P101, DOI 10.1111/j.1751-1097.1979.tb07121.x; BERNARDES CF, 1994, BBA-BIOENERGETICS, V1188, P93, DOI 10.1016/0005-2728(94)90026-4; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Buege J A, 1978, Methods Enzymol, V52, P302; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CASTILHO RF, 1994, ARCH BIOCHEM BIOPHYS, V308, P158, DOI 10.1006/abbi.1994.1022; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P55, DOI 10.1016/0891-5849(94)00098-5; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; DI MASCIO P, 1992, FREE RADICAL BIO MED, V12, P471, DOI 10.1016/0891-5849(92)90100-U; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HERMESLIMA M, 1995, MOL CELL BIOCHEM, V145, P53, DOI 10.1007/BF00925713; Hiemenz PC, 1986, PRINCIPLES COLLOID S, P677; INDIG GL, 1988, PHOTOCHEM PHOTOBIOL, V48, P719, DOI 10.1111/j.1751-1097.1988.tb02886.x; KAMMERMEIER H, 1982, J MOL CELL CARDIOL, V14, P267, DOI 10.1016/0022-2828(82)90205-X; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141, DOI 10.1152/ajpcell.1995.269.1.C141; LANGE LG, 1984, J CLIN INVEST, V73, P1046, DOI 10.1172/JCI111289; LISSI EA, 1988, FREE RADICAL BIO MED, V4, P93, DOI 10.1016/0891-5849(88)90069-X; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MORTARA RA, 1978, BIOCHEM BIOPH RES CO, V81, P1080, DOI 10.1016/0006-291X(78)91246-9; NANTES IL, 1995, PHOTOCHEM PHOTOBIOL, V62, P522, DOI 10.1111/j.1751-1097.1995.tb02378.x; NEPOMUCENO MF, 1991, BRAZ J MED BIOL RES, V24, P833; NOVGORODOV SA, 1990, FEBS LETT, V277, P123, DOI 10.1016/0014-5793(90)80824-3; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PALLER MS, 1994, ANN NY ACAD SCI, V723, P59, DOI 10.1111/j.1749-6632.1994.tb36717.x; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; POOLEWILSON PA, 1984, J MOL CELL CARDIOL, V16, P175, DOI 10.1016/S0022-2828(84)80706-3; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RILEY WW, 1986, J BIOL CHEM, V261, P14018; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; VERCESI AE, 1988, BIOCHEM BIOPH RES CO, V154, P934, DOI 10.1016/0006-291X(88)90229-X; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	42	166	170	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2929	2934		10.1074/jbc.271.6.2929	http://dx.doi.org/10.1074/jbc.271.6.2929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621682	hybrid			2022-12-25	WOS:A1996TU69100011
J	Frederikse, PH; Garland, D; Zigler, JS; Piatigorsky, J				Frederikse, PH; Garland, D; Zigler, JS; Piatigorsky, J			Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (A beta) in mammalian lenses, and A beta has toxic effects on lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; ALZHEIMERS-DISEASE; PHASE-SEPARATION; CATARACT FORMATION; ACTIVATION; MOUSE; OPACIFICATION; FIBROBLASTS; DEPOSITION; MECHANISM	Many amyloid diseases are characterized by protein aggregations linked to oxidative stress. Such diseases including those of the brain, muscle, and blood vessels exhibit plaques containing beta-amyloid (A beta). Here we demonstrate that Alzheimer's precursor protein (beta APP) and A beta are present at low levels in normal lenses and increase in intact cultured monkey lenses treated with H2O2 or UV radiation (known cataractogenic agents), and with phorbol 12-myristate 13-acetate. AP-1 factor binding, shown by others to up-regulate beta APP expression, increased in the monkey lenses treated with H2O2, UV radiation, or phorbol 12-myristate 13-acetate and paralleled the increase in beta APP expression. Rat lenses exposed to oxidative stress showed increased beta APP in the anterior epithelium and cortex. Incubation of cultured rabbit lens N/N1003A epithelial cells with A beta induced inclusions and vacuoles and was cytotoxic. A beta cross-reacting protein was readily detected in the cortex of a cataractous human lens. Our data show that beta APP and A beta increase in mammalian lenses as part of a response to H2O2 or UV radiation and suggest that they may contribute to the mechanism by which oxidative damage leads to lens opacification.	NEI, LAB MECHANISMS OCULAR DIS, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Frederikse, PH (corresponding author), NEI, MOLEC & DEV BIOL LAB, NIH, 6 CTR DR, MSC 2730, BETHESDA, MD 20892 USA.							APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENDICH A, 1995, J AM COLL NUTR, V14, P124; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BRAS A, 1989, OPHTHALMIC PAED GEN, V10, P271, DOI 10.3109/13816818909009882; BRON AJ, 1993, EYE, V7, P260, DOI 10.1038/eye.1993.60; CLARK JI, 1982, INVEST OPHTH VIS SCI, V22, P186; CLARK JI, 1987, P NATL ACAD SCI USA, V84, P122, DOI 10.1073/pnas.84.1.122; CLARK JI, 1980, INVEST OPHTH VIS SCI, V19, P771; CLARK JI, 1983, J GERONTOL, V38, P287, DOI 10.1093/geronj/38.3.287; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GSELL W, 1995, J NEUROCHEM, V64, P1216; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HAYDEN JH, 1980, EXPERIENTIA, V36, P116, DOI 10.1007/BF02004009; HOLLOWS F, 1981, LANCET, V2, P1249; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1992, AM J PATHOL, V140, P345; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1992, BIOCHEMISTRY-US, V31, P12345, DOI 10.1021/bi00164a008; JEDZINIAK JA, 1973, EXP EYE RES, V15, P185, DOI 10.1016/0014-4835(73)90118-8; JEDZINIAK JA, 1978, INVEST OPHTH VIS SCI, V171, P51; JOACHIM CL, 1989, J GERONTOL, V44, pB77, DOI 10.1093/geronj/44.4.B77; Kador P.F., 1994, PRINCIPLES PRACTICE, P146; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUCK JFR, 1983, EXP EYE RES, V36, P351, DOI 10.1016/0014-4835(83)90117-3; LAVER NM, 1993, EXP EYE RES, V57, P493, DOI 10.1006/exer.1993.1151; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; LOTT IT, 1992, PROG CLIN BIOL RES, V379, P1; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MAJOCHA RE, 1994, CELL MOL NEUROBIOL, V14, P425, DOI 10.1007/BF02088829; MARESPERLMAN JA, 1994, OPHTHALMOLOGY, V101, P315; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MAURY CPJ, 1995, LAB INVEST, V72, P4; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MURAKAMI N, 1995, ACTA NEUROPATHOL, V89, P29, DOI 10.1007/BF00294256; NAGATA M, 1989, EXP EYE RES, V48, P667, DOI 10.1016/0014-4835(89)90008-0; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OSGOOD TB, 1986, INVEST OPHTH VIS SCI, V27, P1780; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PITTS DG, 1986, OPTICAL RAD VISUAL H, P5; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; ROBISON WG, 1990, EXP EYE RES, V50, P641, DOI 10.1016/0014-4835(90)90107-6; ROTHSTEIN H, 1982, OPHTHALMIC RES, V14, P215, DOI 10.1159/000265195; RUSSELL P, 1977, INVEST OPHTH VIS SCI, V16, P243; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SKODRAS G, 1993, ANN CLIN LAB SCI, V23, P275; SPECTOR A, 1995, EXP EYE RES, V60, P471, DOI 10.1016/S0014-4835(05)80062-4; SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6; SPECTOR A, 1972, ISRAEL J MED SCI, V8, P1577; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; Spector A, 1990, CLAO J, V16, pS8; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Taylor J. Richard, 1994, Journal of Dermatological Science, V8, P224, DOI 10.1016/0923-1811(94)90059-0; TREJO J, 1994, J BIOL CHEM, V269, P21682; TSUKADA T, 1993, ONCOGENE, V8, P3313; TUMMINIA SJ, 1994, EXP EYE RES, V58, P367, DOI 10.1006/exer.1994.1027; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Worgul B V, 1989, Lens Eye Toxic Res, V6, P559; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZIGLER JS, 1989, INVEST OPHTH VIS SCI, V30, P2195; ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8; ZIGLER JS, 1990, EXP EYE RES, V50, P651, DOI 10.1016/0014-4835(90)90109-8	79	167	175	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10169	10174		10.1074/jbc.271.17.10169	http://dx.doi.org/10.1074/jbc.271.17.10169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626578	hybrid			2022-12-25	WOS:A1996UG25700050
J	Cohen, D; Koh, GY; Nikonova, LN; Porter, JG; Maack, T				Cohen, D; Koh, GY; Nikonova, LN; Porter, JG; Maack, T			Molecular determinants of the clearance function of type C receptors of natriuretic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INTERNALIZATION; CYTOPLASMIC DOMAIN; MUTAGENESIS; EXPRESSION; EFFICIENT; SEQUENCE; SIGNAL; KIDNEY; ACID	Receptor-mediated endocytosis is the cellular mechanism by which type C receptors of natriuretic peptides exert their clearance function. In the present work, performed in recombinant Chinese hamster ovary cells stably transfected with wild type or mutated human kidney C receptors we determined net endocytic rates (ER) of C receptor-ligand complexes, lysosomal hydrolysis of ligand (I-125-labeled native atrial natriuretic factor, ANF(1-28)), and receptor recycling, Equilibrium ligand binding, immunocytochemistry, and immunoprecipitation were performed to characterize the transfected receptors, The net ER of recombinant wild type C receptors was similar to 6% of occupied receptors internalized per min, and C receptor-mediated lysosomal hydrolysis of ligand amounted to similar to 250% of specifically bound I-125-ANF(1-28)/h, with efficient recycling of internalized C receptors to the cell surface. Hypertonic sucrose reduced net ER and lysosomal hydrolysis of I-125-ANF(1-28) more than 10-fold, indicating that endocytosis occurred via clathrin-coated pits. Total deletion of the cytoplasmic domain also reduced net ER and lysosomal hydrolysis of I-125-ANF(1-28) by almost 10-fold whereas deletion of the terminal 28 amino acids of the cytoplasmic tail led to a 4-fold reduction in these parameters, Replacement of cytoplasmic domain Tyr(508) by Ala, or Tyr(508) and Phe(538) by Ala, reduced net endocytosis and lysosomal hydrolysis of I-125-ANF(1-28) by 40-50%. Replacement of extracellular domain Cys(473) by Ala impeded the constitutive formation of homodimers and reduced by similar to 50% the net ER and lysosomal hydrolysis of I-125-ANF(1-28). These results demonstrate that the cytoplasmic domain of C receptors, Tyr(508) within this domain, and constitutive receptor dimerization are the major molecular determinants of the clearance function of C receptors.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; SCIOS NOVA INC,MT VIEW,CA 94043	Cornell University; Scios			Koh, Gou Young/C-1615-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050996] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50996] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMEIDA FA, 1989, AM J PHYSIOL, V256, pR469, DOI 10.1152/ajpregu.1989.256.2.R469; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Harlow E., 1988, ANTIBODIES LAB MANUA; HERZLINGER DA, 1982, J CELL BIOL, V93, P269, DOI 10.1083/jcb.93.2.269; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; JADOT M, 1992, J BIOL CHEM, V267, P11069; KOH GY, 1992, J BIOL CHEM, V267, P11987; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAROVITS J, 1988, CELL, V53, P713; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Maack T, 1992, HDB PHYSL RENAL PHYS, P1577; MAACK T, 1996, IN PRESS KIDNEY INT, V49; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; PORTER JG, 1988, J BIOL CHEM, V263, P18827; PORTER JG, 1990, BIOCHEM BIOPH RES CO, V171, P796, DOI 10.1016/0006-291X(90)91216-F; PORTER JG, 1993, END SOC ABSTR 75 M L, P249; Sambrook J., 2002, MOL CLONING LAB MANU; STULTS JT, 1994, BIOCHEMISTRY-US, V33, P11372, DOI 10.1021/bi00203a036; SUZUKI M, 1987, AM J PHYSIOL, V253, pF917, DOI 10.1152/ajprenal.1987.253.5.F917; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	30	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9863	9869		10.1074/jbc.271.16.9863	http://dx.doi.org/10.1074/jbc.271.16.9863			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621671	hybrid			2022-12-25	WOS:A1996UG04400102
J	Kim, J; Yang, CF; DasSarma, S				Kim, J; Yang, CF; DasSarma, S			Analysis of left-handed Z-DNA formation in short d(CG)(n) sequences in Escherichia coli and Halobacterium halobium plasmids - Stabilization by increasing repeat length and DNA supercoiling but not salinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-Z TRANSITION; RESTRICTION ENDONUCLEASES; RECOMBINANT PLASMIDS; ANTIBODY-BINDING; TRANSCRIPTION; RESOLUTION; ADOPT; CONFORMATION; POLY(DG-DC); REPLICATION	To evaluate the relative importance of alternating d(CG) sequence length, DNA supercoiling, and salt in left-handed Z-DNA formation, plasmids containing short d(CG)(n) sequences (n = 3-17) with the capability of replicating in either Escherichia coli or the halophilic archaeum Halobacterium halobium were constructed. Z-DNA conformation in the d(CG)(n) sequences was assayed by (i) a band shift assay using the Z-DNA-specific Z22 monoclonal antibody (ZIBS assay); (ii) an S1 nuclease cleavage-primer extension assay to map B-Z junctions; and (iii) a BssHII restriction inhibition assay. Using the ZIBS assay on plasmids purified from E. coli, the transition from B-DNA to Z-DNA. occurred from d(CG)(4) to d(CG)(5), with 20% of d(CG)(4) and 90% of d(CG)(5) in Z-DNA conformation, These findings were consistent with the results of S1 nuclease cleavage observed at B-Z junctions flanking d(CG)(4) and d(CG)(5) sequences. Resistance to BssHII restriction endonuclease digestion was observed only in supercoiled plasmids containing d(CG)(8) or longer sequences, indicating that shorter d(CG)(n) sequences are in dynamic equilibrium between B- and Z-DNA conformations. When a plasmid containing d(CG)(4) was isolated from a topA mutant of E. coli, it contained 25% greater linking deficiency and 40% greater Z-DNA conformation in the alternating d(CG) region. In plasmids purified from H. halobium, which showed 30% greater linking deficiency than from E. coli, 20-40% greater Z-DNA formation was found in d(CG)(4-6) sequences. Surprisingly, no significant difference in Z-DNA formation could be detected in d(CG)(3-17) sequences in plasmids from either E. coli or H. halobium in the NaCl concentration range of 0.1-4 M.	UNIV MASSACHUSETTS, DEPT MICROBIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst				DasSarma, Shiladitya/0000-0003-4162-2810	NIGMS NIH HHS [GM41980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON P, 1978, BIOCHEMISTRY-US, V17, P594, DOI 10.1021/bi00597a006; AZORIN F, 1984, P NATL ACAD SCI-BIOL, V81, P5714, DOI 10.1073/pnas.81.18.5714; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CLINE SW, 1987, J BACTERIOL, V169, P1341, DOI 10.1128/jb.169.3.1341-1344.1987; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DasSarma S, 1995, ARCHAEA LAB MANUAL H; ELLISON MJ, 1985, P NATL ACAD SCI USA, V82, P8320, DOI 10.1073/pnas.82.24.8320; FERL RJ, 1992, PLANT MOL BIOL, V18, P1181, DOI 10.1007/BF00047722; HACKETT NR, 1990, NUCLEIC ACIDS RES, V18, P3408, DOI 10.1093/nar/18.11.3408; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; HOHEISEL JD, 1987, J MOL BIOL, V193, P447, DOI 10.1016/0022-2836(87)90259-2; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KILPATRICK MW, 1984, J BIOL CHEM, V259, P7268; KIM JM, 1995, THESIS U MASSACHUSET; KLYSIK J, 1983, J MOL BIOL, V168, P51, DOI 10.1016/S0022-2836(83)80322-2; KLYSIK J, 1981, NATURE, V290, P672, DOI 10.1038/290672a0; KRISHNA P, 1991, BIOCHEM J, V275, P711, DOI 10.1042/bj2750711; LAFER EM, 1985, EMBO J, V4, P3655, DOI 10.1002/j.1460-2075.1985.tb04131.x; LAFER EM, 1981, P NATL ACAD SCI-BIOL, V78, P3546, DOI 10.1073/pnas.78.6.3546; LESNIK EA, 1991, FEBS LETT, V280, P91, DOI 10.1016/0014-5793(91)80211-K; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MOLLER A, 1984, BIOCHEMISTRY-US, V23, P54, DOI 10.1021/bi00296a009; MOORE RL, 1969, J BACTERIOL, V99, P248, DOI 10.1128/JB.99.1.248-254.1969; NG WL, 1993, J BACTERIOL, V175, P4584, DOI 10.1128/JB.175.15.4584-4596.1993; NORDHEIM A, 1982, CELL, V31, P309, DOI 10.1016/0092-8674(82)90124-6; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; NORHEIM A, 1983, P NATL ACAD SCI USA, V80, P1821; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; QUADRIFOGLIO F, 1981, NUCLEIC ACIDS RES, V9, P2195, DOI 10.1093/nar/9.9.2195; REVET B, 1984, EMBO J, V3, P3353, DOI 10.1002/j.1460-2075.1984.tb02303.x; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINGLETON CK, 1983, P NATL ACAD SCI-BIOL, V80, P2447, DOI 10.1073/pnas.80.9.2447; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; STIRDIVANT SM, 1982, J BIOL CHEM, V257, P159; THOMAS MJ, 1990, MOL CELL BIOL, V53, P78; THOMAS TJ, 1988, ANAL BIOCHEM, V168, P358, DOI 10.1016/0003-2697(88)90330-2; THOMAS TJ, 1991, J BIOL CHEM, V266, P6137; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG JC, 1984, J CELL SCI, P21; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; Yang CF, 1996, J BACTERIOL, V178, P840, DOI 10.1128/jb.178.3.840-845.1996	51	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9340	9346		10.1074/jbc.271.16.9340	http://dx.doi.org/10.1074/jbc.271.16.9340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621598				2022-12-25	WOS:A1996UG04400029
J	Shi, JR; Gonzales, RA; Bhattacharyya, MK				Shi, JR; Gonzales, RA; Bhattacharyya, MK			Identification and characterization of an S-adenosyl-L-methionine: Delta(24)-sterol-C-methyltransferase cDNA from soybean	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; STEROL BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; METHYL TRANSFERASE; ZEA-MAYS; MEMBRANE; YEAST; INHIBITION; TRANSFORMATION; COLEOPTILES	In plants, the dominant sterols are 24-alkyl sterols, which play multiple roles in plant growth and development, i.e. as membrane constituents and as precursors to steroid growth regulators such as brassinosteroids. The initial step in the conversion of the phytosterol intermediate cycloartenol to the 24-alkyl sterols is catalyzed by S-adenosyl-L-methionine:Delta(24)-sterol-C-methyl-transferase (SMT), a rate-limiting enzyme for phytosterol biosynthesis. A cDNA clone (SMT1) encoding soybean SMT was isolated from an etiolated hypocotyl cDNA library by immunoscreening using an anti-(plasma membrane) serum. The deduced amino acid sequence of the SMT1 cDNA contained three conserved regions found in S-adenosyl-L-methionine-dependent methyltransferases. The overall structure of the polypeptide encoded by the SMT1 cDNA is most similar to the predicted amino acid sequence of the yeast ERG6 gene, the putative SMT structural gene. The polypeptide encoded by the SMT1 cDNA was expressed as a fusion protein in Escherichia coli and shown to possess SMT activity. The growing soybean vegetative tissues had higher levels of SMT transcript than mature vegetative tissues. Young pods and immature seeds had very low levels of the SMT transcript, The SMT transcript was highly expressed in flowers. The expression of SMT transcript was suppressed in soybean cell suspension cultures treated with yeast elicitor. The transcriptional regulation of SMT in phytosterol biosynthesis is discussed.	SAMUEL ROBERTS NOBLE FDN INC, DIV PLANT BIOL, ARDMORE, OK 73402 USA	Noble Research Institute				Shi, Jinrui/0000-0002-0428-6777				BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BRINDLE PA, 1988, PHYTOCHEMISTRY, V27, P133, DOI 10.1016/0031-9422(88)80603-4; CHAPPELL J, 1995, PLANT PHYSIOL, V109, P1337, DOI 10.1104/pp.109.4.1337; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FANG TY, 1975, BIOCHEM J, V150, P323, DOI 10.1042/bj1500323; FENNER GP, 1986, LIPIDS, V21, P48, DOI 10.1007/BF02534302; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GUO DA, 1995, LIPIDS, V30, P203, DOI 10.1007/BF02537823; HARDWICK KG, 1994, YEAST, V10, P265, DOI 10.1002/yea.320100213; HARTMANNBOUILLON MA, 1978, PHYTOCHEMISTRY, V17, P1037, DOI 10.1016/S0031-9422(00)94275-4; HAUDENSCHILD C, 1995, PHYTOCHEMISTRY, V40, P1117, DOI 10.1016/0031-9422(95)00434-9; HAUGHAN PA, 1988, PHYTOCHEMISTRY, V27, P2491, DOI 10.1016/0031-9422(88)87016-X; Hymowitz T, 1987, SOYBEANS IMPROVEMENT, P23; IKEKAWA N, 1991, PHYSL BIOCH STEROLS, P346; JANSSEN GG, 1992, J BIOL CHEM, V267, P25856; JENNINGS PH, 1970, PLANT PHYSIOL, V45, P634, DOI 10.1104/pp.45.5.634; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KAJIMOTO G, 1982, J JAP SOC FOOD NUTR, V35, P345; KATAYAMA M, 1973, PLANT CELL PHYSIOL, V14, P681; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MCCAMMON MT, 1984, J BACTERIOL, V157, P475, DOI 10.1128/JB.157.2.475-483.1984; MISSO NLA, 1983, PHYTOCHEMISTRY, V22, P2473, DOI 10.1016/0031-9422(83)80143-5; Nes W. David, 1993, P389; NES WD, 1991, BIOCHEM BIOPH RES CO, V177, P566, DOI 10.1016/0006-291X(91)92021-B; NES WD, 1986, ARCH BIOCHEM BIOPHYS, V244, P211, DOI 10.1016/0003-9861(86)90110-4; NES WD, 1991, J BIOL CHEM, V266, P15202; PARKER SR, 1992, ACS SYM SER, V497, P110; RAHIER A, 1984, J BIOL CHEM, V259, P5215; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; RODRIGUEZ RJ, 1983, ARCH BIOCHEM BIOPHYS, V225, P861, DOI 10.1016/0003-9861(83)90099-1; SCHEID F, 1982, PHYTOCHEMISTRY, V21, P1959, DOI 10.1016/0031-9422(82)83023-9; SCHENK RU, 1972, CAN J BOTANY, V50, P199, DOI 10.1139/b72-026; SCHUMACHER HM, 1987, PLANT CELL REP, V6, P410, DOI 10.1007/BF00272770; SHI JR, 1995, P NATL ACAD SCI USA, V92, P4457, DOI 10.1073/pnas.92.10.4457; VANDERHEIJDEN R, 1989, PHYTOCHEMISTRY, V28, P2981, DOI 10.1016/0031-9422(89)80264-X; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; WHITE JL, 1989, J VIROL METHODS, V23, P83, DOI 10.1016/0166-0934(89)90122-5; ZHU T, 1994, MOL GEN GENET, V244, P638, DOI 10.1007/BF00282754; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	42	58	61	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9384	9389		10.1074/jbc.271.16.9384	http://dx.doi.org/10.1074/jbc.271.16.9384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621604	hybrid			2022-12-25	WOS:A1996UG04400035
J	Shibata, H; Omata, W; Suzuki, Y; Tanaka, S; Kojima, I				Shibata, H; Omata, W; Suzuki, Y; Tanaka, S; Kojima, I			A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain inhibits insulin action on glucose transport in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PLASMA-MEMBRANE; ADIPOSE-CELLS; KINASE-C; FAMILY; TRANSLOCATION; RECEPTORS; VESICLES; REDISTRIBUTION; STIMULATION	The present study was conducted to examine the involvement of Rab4, a low molecular weight GTP-binding protein, in the action of insulin on glucose transport, A synthetic peptide corresponding to the Rab4 hypervariable carboxyl-terminal domain, Rab4-(191-210), was successfully transferred into rat adipocytes by electroporation and inhibited insulin-stimulated glucose transport by about 50% without affecting the basal transport activity, In contrast, synthetic peptides corresponding to the Rab3C and Rab3D carboxyl-terminal hypervariable domain had little effect on insulin action on glucose transport, The Rab4-(191-210) peptide also reduced insulin-induced GLUT4 translocation from the intracellular pool to the plasma membrane, Furthermore, the Rab4-(191-210) peptide reduced both insulin-induced glucose transport and GLUT4 translocation in the presence of a major histocompatibility complex class I antigen-derived peptide, D-k-(62-85), which is a potent inhibitor of GLUT4 internalization, suggesting that the peptide inhibited exocytotic recruitment of GLUT4-containing vesicles, The Rab4-(191-210) peptide also inhibited GTP gamma S-stimulated glucose transport, In addition, insulin-stimulated glucose transport was inhibited by the addition of anti-Rab4 antibody, These results suggest that Rab4 protein plays a crucial role in insulin action on GLUT4 translocation, especially in exocytotic recruitment by the hormone of the glucose transporter to the plasma membrane from the intracellular retention pool.			Shibata, H (corresponding author), GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT CELL BIOL,MAEBASHI,GUMMA 371,JAPAN.							ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CORMONT M, 1994, EUR J BIOCHEM, V219, P1081, DOI 10.1111/j.1432-1033.1994.tb18591.x; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DHAR A, 1994, J BIOL CHEM, V269, P9123; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KONO T, 1982, J BIOL CHEM, V257, P942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; PEREZ F, 1994, MOL ENDOCRINOL, V8, P1278, DOI 10.1210/me.8.9.1278; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; SALTIS J, 1991, J BIOL CHEM, V266, P261; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; SHIBATA Y, 1987, BIOCHIM BIOPHYS ACTA, V902, P154, DOI 10.1016/0005-2736(87)90147-7; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; STAGSTED J, 1990, CELL, V62, P297, DOI 10.1016/0092-8674(90)90367-N; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V189, P572, DOI 10.1016/0006-291X(92)91596-I; UPHUES I, 1994, BIOCHEM J, V301, P177, DOI 10.1042/bj3010177; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANO Y, 1993, BIOCHIM BIOPHYS ACTA, V1176, P327, DOI 10.1016/0167-4889(93)90062-T; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	43	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9704	9709		10.1074/jbc.271.16.9704	http://dx.doi.org/10.1074/jbc.271.16.9704			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621647	hybrid			2022-12-25	WOS:A1996UG04400078
J	Shipston, MJ; Kelly, JS; Antoni, FA				Shipston, MJ; Kelly, JS; Antoni, FA			Glucocorticoids block protein kinase a inhibition of calcium-activated potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY CELLS; HORMONE-RELEASE; ATT20 CELLS; K+ CHANNELS; CYCLIC-AMP; ADRENOCORTICOTROPIN; MODULATION; POTENTIALS; SECRETION; SIGNALS	Adrenal corticosteroids have well known and profound effects on neurons and neuroendocrine cells, but the underlying cellular mechanisms are poorly understood, The present study analyzed membrane currents and ACTH release in AtT20 mouse pituitary corticotrope tumor cells, Patch-clamp analysis revealed a significant and selective inhibition of calcium-activated (BK-type) potassium channels upon activation of protein kinase A by corticotropin-releasing factor or 8-chlorophenylthio-cAMP. The synthetic glucocorticoid dexamethasone had no effect on potassium currents evoked by depolarization but prevented the inhibitory effect of protein kinase A activators. The action of dexamethasone had the hallmarks of protein induction, i.e. a lag time and sensitivity to inhibitors of DNA transcription and mRNA translation. In parallel, the specific BK channel blocker iberiotoxin abolished early glucocorticoid inhibition of corticotropin-releasing factor-stimulated ACTH secretion, In summary, the present data show that glucocorticoid-induced proteins render BK-type channels resistant to inhibition by protein kinase A and that this action of the steroid is pivotal for its early inhibitory effect on the secretion of ACTH.	UNIV EDINBURGH,MRC,BRAIN METAB UNIT,EDINBURGH EH8 7NA,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PHARMACOL,EDINBURGH EH8 7NA,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Shipston, Mike/C-7309-2013; Antoni, Ferenc/AAI-7351-2020	Shipston, Mike/0000-0001-7544-582X; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2086, DOI 10.1073/pnas.80.7.2086; ANTONI FA, 1992, J ENDOCRINOL, V133, pR13, DOI 10.1677/joe.0.133R013; CASTELLINO F, 1992, P NATL ACAD SCI USA, V89, P3775, DOI 10.1073/pnas.89.9.3775; CLARK TP, 1994, NEUROENDOCRINOLOGY, V60, P273, DOI 10.1159/000126759; COLBERT RA, 1985, BIOCHIM BIOPHYS ACTA, V826, P49, DOI 10.1016/S0167-4781(85)80007-5; DALLMAN MF, 1987, RECENT PROG HORM RES, V43, P113; DAYANITHI G, 1989, ENDOCRINOLOGY, V125, P308, DOI 10.1210/endo-125-1-308; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DOWD DR, 1991, J BIOL CHEM, V266, P18423; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; JOELS M, 1989, SCIENCE, V245, P1502, DOI 10.1126/science.2781292; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; LEVITAN ES, 1991, MOL ENDOCRINOL, V5, P1903, DOI 10.1210/mend-5-12-1903; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; PENNINGTON AJ, 1994, J NEUROENDOCRINOL, V6, P305, DOI 10.1111/j.1365-2826.1994.tb00587.x; PHILLIPS M, 1982, ENDOCRINOLOGY, V110, P892; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; REISINE T, 1985, P NATL ACAD SCI USA, V82, P8261, DOI 10.1073/pnas.82.23.8261; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; SUPRENANT A, 1982, J CELL BIOL, V95, P559; TAKIMOTO K, 1993, NEURON, V11, P3359; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WONG BS, 1982, BIOPHYS J, V39, P313, DOI 10.1016/S0006-3495(82)84522-0; WOODS MD, 1994, ANN NY ACAD SCI, V746, P456; WOODS MD, 1992, ENDOCRINOLOGY, V131, P2873, DOI 10.1210/en.131.6.2873	31	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9197	9200		10.1074/jbc.271.16.9197	http://dx.doi.org/10.1074/jbc.271.16.9197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621576				2022-12-25	WOS:A1996UG04400007
J	Krane, IM; Leder, P				Krane, IM; Leder, P			NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice	ONCOGENE			English	Article						neu differentiation factor; heregulin; erbB; breast cancer	NEU ONCOGENE; TYROSINE KINASE; POINT MUTATION; TUMOR CELLS; LIGAND; PROTEIN; ACTIVATION; DIFFERENTIATION; GLYCOPROTEIN; ASSOCIATION	Neu differentiation factor (NDF), a member of the neuregulin family of ligands of erbB receptors, induces both differentiative and mitogenic effects on cultured human mammary epithelial cells, Since members of the epidermal growth factor receptor family, including Neu/erbB2, have been implicated in mammary carcinoma, we wished to know whether a potential ligand of this family, NDF, could induce such effects in the mammary gland in vivo, We therefore targeted expression of NDF to the mammary gland of transgenic mice using the mouse mammary tumor virus (MMTV) promoter in a fusion a clear, but subtle effect on adult virgin gland of female transgenic animals, Terminal end bud structures (TEBs), which normally disappear from the mammary gland at the age of similar to 8 weeks in wild type mice, persist in glands of virgin MMTV-NDF transgenic females, suggesting that NDF inhibits signals that normally lead to the terminal differentiation of these structures, Further, female mice, bred continuously to maximize expression of the transgene in the mammary gland,develop mammary adenocarcinomas at a median age of 12 months, Since these tumors arise in a solitary fashion, we infer that NDF is necessary, but not sufficient for their formation, In order to explore the signal transduction pathways potentially activated by NDF, we examined expression of the receptors erbB2, erbB3 and erbB4 in mammary epithelial cells established from induced tumor, All three receptors were though only the erbB3 receptor was phosphorylated, suggesting that overexpression of NDF might operate through this receptor, Additionally, about 50% of MMTV-NDF transgenic mice developed Harderian (lachrymal) gland hyperplasia, a benign tumor that does not progress to frank malignacy.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Daniel CW, 1987, MAMMARY GLAND DEV RE; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RUSSO J, 1995, CANCER LETT, V90, P81, DOI 10.1016/0304-3835(94)03681-8; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; Sambrook J., 2002, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	37	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1781	1788						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622899				2022-12-25	WOS:A1996UG45800021
J	Doolan, CM; Harvey, BJ				Doolan, CM; Harvey, BJ			Modulation of cytosolic protein kinase C and calcium ion activity by steroid hormones in rat distal colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR LEUKOCYTES; SODIUM-PROTON-EXCHANGER; PHOSPHOLIPID DEGRADATION; HUMAN-LYMPHOCYTES; TUMOR PROMOTION; ALDOSTERONE; CELLS; ACTIVATION	Studies from our laboratory have demonstrated rapid (< 1 min) non-genomic activation of Na+-H+ exchange and potassium recycling by mineralocorticoids in human and rat colonic epithelium. It has previously been demonstrated that Na+-H+ exchange may be stimulated by protein kinase C (PKC) activation; therefore, we examined the effect of mineralocorticoids on PKC activity in rat colonic epithelium, Activation (after 15 min of incubation) of basal PKC activity was observed in cytosolic fractions of rat colonic epithelium by aldosterone, fludrocortisone, and deoxycorticosterone acetate, In all instances, PKC activation was inhibited by the PKC inhibitor bisindolylmaleimide (GF109203X), Hydrocortisone failed to activate PKC activity. Stimulation of basal intracellular free calcium [Ca2+](i) was observed, in isolated rat colonic crypts, following aldosterone addition. This stimulatory effect was inhibited by the PKC inhibitor, chelerythrine chloride. Hydrocortisone failed to increase [Ca2+](i), These results indicate that intracellular signaling for aldosterone involves changes in [Ca2+](i) via activation of PKC, Since the stimulation of PKC and increase in [Ca2+](i) are apparent at normal circulating levels of aldosterone, our findings have major implications for the reassessment of mineralocorticoid effects on electrolyte homeostasis.			Doolan, CM (corresponding author), NATL UNIV IRELAND UNIV COLL CORK, DEPT PHYSIOL, WELLCOME TRUST CELLULAR PHYSIOL RES UNIT, CORK, IRELAND.		Harvey, Brian J/A-5120-2010; Harvey, Brian/AAJ-4085-2020	Harvey, Brian J/0000-0002-7388-8034; Harvey, Brian/0000-0002-7388-8034	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; CHRIST M, 1993, J CLIN ENDOCR METAB, V77, P1452, DOI 10.1210/jc.77.6.1452; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; EDMONDS CJ, 1967, J PHYSIOL-LONDON, V193, P589, DOI 10.1113/jphysiol.1967.sp008380; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LOMAX RB, 1994, AM J PHYSIOL, V276, pG485; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maguire Donal D., 1994, Surgical Forum, V45, P195; Maguire Donal D., 1995, Surgical Forum, V46, P203; MCNAMARA B, 1995, SURG FORUM, V81, P560; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; SLOTKI IN, 1990, AM J PHYSIOL, V259, pF666, DOI 10.1152/ajprenal.1990.259.4.F666; Urbach V, 1996, J PHYSIOL-LONDON, V491, P111, DOI 10.1113/jphysiol.1996.sp021200; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V422, P9, DOI 10.1007/BF00381507; WEHLING M, 1989, AM J PHYSIOL, V257, pE170, DOI 10.1152/ajpendo.1989.257.2.E170; WEHLING M, 1994, BIOCHEM BIOPH RES CO, V204, P475, DOI 10.1006/bbrc.1994.2484; WEHLING M, 1991, AM J PHYSIOL, V260, pE719, DOI 10.1152/ajpendo.1991.260.5.E719; WEHLING M, 1987, AM J PHYSIOL, V252, pE505, DOI 10.1152/ajpendo.1987.252.4.E505; WEHLING M, 1989, BIOCHEM BIOPH RES CO, V164, P961, DOI 10.1016/0006-291X(89)91763-4; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5	23	105	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8763	8767		10.1074/jbc.271.15.8763	http://dx.doi.org/10.1074/jbc.271.15.8763			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621511	hybrid			2022-12-25	WOS:A1996UE73000042
J	Xie, RL; Long, GL				Xie, RL; Long, GL			Elements within the first 17 amino acids of human osteonectin are responsible for binding to type V collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; PLATELET OSTEONECTIN; INSITU HYBRIDIZATION; PROTEIN SPARC; MESSENGER-RNA; EXPRESSION; CELLS; BM-40	The region in human osteonectin (ON) responsible for binding to type V collagen has been identified as the first 17 NH2-terminal residues. This conclusion is based upon binding studies with deletion mutants of ON produced in Escherichia coli, in which parts of the first 17 amino acids have been removed. Wild-type ON from E. coli and mammalian cell-derived nonglycosylated ON bind identically to type V collagen and at least twice as effectively as mammalian cell-derived N-glycosylated ON. In previous studies, it was shown that N-glycosylation at residue 99 significantly reduces the capacity of ON to bind to type V collagen. Results reported in this communication demonstrate that the actual binding site on ON for type V collagen is distal from the site of N-glycosylation in terms of amino acid sequence but may be proximal in the folded, fully glycosylated, three-dimensional structure. Consistent with this conclusion is the ability of a synthetic peptide consisting of amino acids 1-17 to specifically inhibit the binding of ON to type V collagen.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NCI NIH HHS [CO6-HL39475] Funding Source: Medline; NIA NIH HHS [P01-AG08777] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J; FRANCKLYN C, 1994, J MOL BIOL, V241, P275, DOI 10.1006/jmbi.1994.1498; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; KAWAMOTO Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P361, DOI 10.1016/0304-4165(90)90101-2; KELM RJ, 1990, BLOOD, V75, P1105; KELM RJ, 1994, J BIOL CHEM, V269, P30147; KELM RJ, 1991, J BIOL CHEM, V266, P9632; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MURATA K, 1986, ATHEROSCLEROSIS, V60, P251, DOI 10.1016/0021-9150(86)90172-3; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OSHIMA A, 1981, SCIENCE, V213, P666; OTSUKA K, 1984, J BIOL CHEM, V259, P9805; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; ROMBERG RW, 1985, J BIOL CHEM, V260, P2728; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; STENNER DD, 1986, P NATL ACAD SCI USA, V83, P6892, DOI 10.1073/pnas.83.18.6892; Swaroop A, 1988, GENOMICS, V2, P37, DOI 10.1016/0888-7543(88)90107-3; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049; VILLARREAL XC, 1991, BLOOD, V78, P1216; WEWER UM, 1988, AM J PATHOL, V132, P345; XIE RL, 1995, J BIOL CHEM, V270, P23212, DOI 10.1074/jbc.270.39.23212; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIATS NP, 1993, J VASC SURG, V17, P710, DOI 10.1016/0741-5214(93)90115-3	33	12	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8121	8125		10.1074/jbc.271.14.8121	http://dx.doi.org/10.1074/jbc.271.14.8121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626499	hybrid			2022-12-25	WOS:A1996UD60000039
J	Zeng, YX; ElDeiry, WS				Zeng, YX; ElDeiry, WS			Regulation of p21(WAF1/CIP1) expression by p53-independent pathways	ONCOGENE			English	Article						p21(WAF1/CIP1); transcription; p53; differentiation; TPA; cell cycle	CELL-CYCLE; P53; SUPPRESSION; GROWTH; GADD45	The CDK-inhibitor p21(WAF1/CIP1) has been implicated as a growth arrest mediator in p53-tumour suppression, cellular senescence and terminal differentiation. Cell type specific differences in p53-independent p21 expression and cell cycle arrest were found following treatment of human tumour cell lines with serum, 12-O-tetra-decanoyl-phorbol-13-acetate (TPA) or okadaic (OA). TPA induced p21 in ML1, K562 and HL60 leukemia cells, whereas OA induced p21 in SW480 and GM4723 carcinoma cells as well as in leukemic cells. In addition, TPA- and serum- but not OA-induced cell cycle arrest was reversed upon return of p21 to basal levels. To further investigate the mechanisms underlying p53-independent regulation of p21, the transcription inhibitor, Actinomycin D (AMD), was used to block p21 expression. The results showed a complete inhibition of p21 mRNA and protein induction by TPA or adriamycin but little effect on p21 mRNA induced by OA in the presence of AMD. These results suggested that TPA-induced p21 expression requires transcription initiation, while a post-transcriptional mechanism may be involved in OA-induction as well. Transient transfection assays with p21 promoter-luciferase reporters and TPA or OA treatment further confirmed that TPA, and to a lesser extent, OA, initiated transcription of p21. Finally, the protein kinase C inhibitor, staurosporine, was found to interfere with p21 induction and prevent cell cycle arrest following treatment with TPA but not OA, suggesting a requirement for PKC in TPA activation of p21 expression.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LAB MOLEC ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BI SC, 1992, LEUKEMIA, V6, P839; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1994, CANCER RES, V54, P5824; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAMA T, 1995, BLOOD, V86, P841; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATIRA A, 1993, CLIN EXP IMMUNOL, V92, P347; LI Y, 1994, ONCOGENE, V9, P2261; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TERADA T, 1995, NATURE, V376, P358; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P704; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	36	273	284	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1557	1564						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622872				2022-12-25	WOS:A1996UF07600020
J	Haas, TA; Plow, EF				Haas, TA; Plow, EF			The cytoplasmic domain of alpha(IIb)beta(3) - A ternary complex of the integrin alpha and beta subunits and a divalent cation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; FLUORESCENCE ENERGY-TRANSFER; MEMBRANE GLYCOPROTEIN-IIB; CELL-ADHESION; GPIIB-IIIA; PLATELET; RECEPTOR; BINDING; CONFORMATION; MODULATION	Peptides corresponding to the cytoplasmic tails of the alpha(IIb) (alpha(IIb)(985-1008)) and beta(3) (beta(3)(713-762)) subunits of the integrin receptor alpha(IIb)beta(3) (glycoprotein IIb-IIIa) were synthesized and used to characterize their interaction with cations and with one another. alpha(IIb)(985-1008) was found to contain a functional cation binding site as assessed by both terbium luminescence and electrospray ionization mass spectroscopy. The binding of Tb3+ to alpha(IIb)(985-1008) was of high affinity (K-d = 8.8 +/- 5.2 nM), occurred with a 1:1 stoichiometry, and was mediated by its acidic carboxyl terminus (alpha(IIb)(999-1008), PLEEDDEEGE). The affinity of this site for divalent cations was in the micromolar range, suggesting that this site would be constitutively occupied in the intracellular environment. Incubation of alpha IIb(999-1008) with beta(3)(713-762) resulted in the formation of a complex, both in the presence and absence of cations. The interactive site for alpha(IIb)(999-1008) in beta(3) was mapped to beta(3)(721-740), and complex formation was associated with a stabilization of secondary structure as assessed by circular dichroism. Both a binary (alpha(IIb)(985-1008).beta(3)(721-740)) and a ternary (Tb3+.alpha(IIb)(999-1008).beta(3)(721-740)) complex were detected by mass spectroscopy, but the distribution and intensity of the mass/charge peaks were distinct. These difference may reflect the involvement of distinct cation coordination sites and the formation of salt bridges in stabilizing the ternary complex. These data demonstrate the formation of a novel entity composed of the cytoplasmic tails of alpha(IIb) and beta(3) and a cation which may constitute a functional intracellular domain.			Haas, TA (corresponding author), CLEVELAND CLIN FDN,DEPT MOLEC BIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL-38292, HL-54924] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054924, R01HL038292] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ANDERSON JS, 1983, BIOPOLYMERS, V22, P2459, DOI 10.1002/bip.360221111; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BCaAE, 1994, TIETZ TXB CLIN CHEM; BENNETT JS, 1990, SEMIN HEMATOL, V27, P186; BRUNO J, 1992, BIOCHEMISTRY-US, V31, P7016, DOI 10.1021/bi00146a002; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CRONET P, 1995, J MOL BIOL, V249, P654, DOI 10.1006/jmbi.1995.0326; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; GANEM B, 1993, AM BIOTECHNOL LAB, V1, P1; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, P1022; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUTCHENS TW, 1992, FEBS LETT, V309, P170, DOI 10.1016/0014-5793(92)81088-4; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KATTA V, 1993, J AM CHEM SOC, V115, P6317, DOI 10.1021/ja00067a054; KUZMIC P, 1992, ANAL BIOCHEM, V205, P65, DOI 10.1016/0003-2697(92)90579-V; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; LOO JA, 1994, BIOL MASS SPECTROM, V23, P6, DOI 10.1002/bms.1200230103; LUK CK, 1971, BIOCHEMISTRY-US, V10, P2838, DOI 10.1021/bi00791a006; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MARGUERIE GA, 1987, PLATELETS BIOL PATHO, V3, P95; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUIR TW, 1995, ANAL BIOCHEM, V224, P100, DOI 10.1006/abio.1995.1013; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEERSCHKE EIB, 1985, SEMIN HEMATOL, V22, P241; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; ROCCO M, 1993, PROTEIN SCI, V2, P2154, DOI 10.1002/pro.5560021215; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VERGELSON JM, 1995, CURR BIOL, V5, P615; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHANG J, 1992, J BIOL CHEM, V267, P4686	66	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6017	6026		10.1074/jbc.271.11.6017	http://dx.doi.org/10.1074/jbc.271.11.6017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626385	hybrid			2022-12-25	WOS:A1996UA36300014
J	Ang, HL; Deltour, L; Hayamizu, TF; ZgombicKnight, M; Duester, G				Ang, HL; Deltour, L; Hayamizu, TF; ZgombicKnight, M; Duester, G			Retinoic acid synthesis in mouse embryos during gastrulation and craniofacial development linked to class IV alcohol dehydrogenase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; HENSEN NODE; VITAMIN-A; RAT; IDENTIFICATION; EMBRYOGENESIS; INHIBITION; INVITRO; ETHANOL; ASSAY	Endogenous retinoic acid (RA) has been observed in vertebrate embryos as early as gastrulation, but the mechanism controlling spatiotemporal synthesis of this important regulatory molecule remains unknown. Some members of the alcohol dehydrogenase (ADH) family catalyze retinol oxidation, the rate-limiting step in RA synthesis. Here we have examined mouse embryos for the presence of endogenous RA and expression of ADH genes. RA was not detected in egg cylinder stage embryos but was detected in late primitive streak stage embryos. Detection of class IV ADH mRNA, but not class I or class III, coincided with the onset of RA synthesis, being absent in egg cylinder embryos but present in the posterior mesoderm of late primitive streak embryos. During neurulation, RA and class IV ADH mRNA were colocalized in the craniofacial region, trunk, and forelimb bud. Class IV ADH mRNA was detected in cranial neural crest cells and craniofacial mesenchyme as well as trunk and forelimb bud mesenchyme. The spatiotemporal expression pattern and enzymatic properties of class TV ADH are thus consistent with a crucial function in RA synthesis during embryogenesis. In addition, the finding of endogenous RA and class IV ADH mRNA in the craniofacial region has implications for the mechanism of fetal alcohol syndrome.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731, R01AA007261] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731, AA07261] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; Blaner William S., 1994, P229; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; DERSCH H, 1993, DEV BIOL, V160, P424, DOI 10.1006/dbio.1993.1318; Duester G., 1994, Vitamin A in health and disease., P343; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; DUESTER G, 1995, DRUG ALCOHOL ABUSE R, V6, P75; Hofmann Clementine, 1994, P387; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; JONES KL, 1973, LANCET, V2, P999; JULIA P, 1986, EXP EYE RES, V42, P305, DOI 10.1016/0014-4835(86)90023-0; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KASTNER P, 1988, VITAMIN A HLTH DIS, P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOHNES D, 1994, DEVELOPMENT, V120, P2723; Maden M., 1994, Vitamin A in health and disease., P289; Mangelsdorf David J., 1994, P319; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SCADDING SR, 1994, DEV BIOL, V162, P608, DOI 10.1006/dbio.1994.1114; SCOTT WJ, 1994, DEV BIOL, V165, P397, DOI 10.1006/dbio.1994.1262; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TWAL W, 1995, DEV BIOL, V168, P225, DOI 10.1006/dbio.1995.1075; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; WEBSTER WS, 1983, TERATOLOGY, V27, P231, DOI 10.1002/tera.1420270211; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868; ZHENG YW, 1993, J BIOL CHEM, V268, P24933	57	146	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9526	9534		10.1074/jbc.271.16.9526	http://dx.doi.org/10.1074/jbc.271.16.9526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621625	hybrid			2022-12-25	WOS:A1996UG04400056
J	Ponton, A; Clement, MV; Stamenkovic, I				Ponton, A; Clement, MV; Stamenkovic, I			The CD95 (APO-1/Fas) receptor activates NF-kappa B independently of its cytotoxic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Engagement of the CD95 (APO-1/Fas) receptor induces apoptosis in a variety of cell types, However, the nature of the cytotoxic signal and the intermediate messenger molecules remain to be elucidated, In an effort to understand CD95-mediated signaling, we assessed possible changes in the DNA binding activity of NF-kappa B as a result of CD95 engagement in various tumor cells, By performing electrophoresis mobility shift assays, we show that CD95 can stimulate the DNA binding activity of NF-kappa B in a variety of cells, irrespective of their sensitivity or resistance to CD95-mediated cytotoxicity, Moreover, deletion of 37 carboxyl-terminal residues from the cytoplasmic domain of CD95, which abrogates CD95-mediated apoptosis, only marginally affects NF-kappa KB activation. Taken together, these observations indicate that CD95 has a function that involves activation of NF-kappa B and that appears to be unrelated to its role as an inducer of apoptotic cell death.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,DEPT PATHOL,MED SCH & PATHOL RES,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA055735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER; NCI NIH HHS [CA55735] Funding Source: Medline; NIGMS NIH HHS [GM/AI48614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; BAUERLE PA, 1988, SCIENCE, V242, P540; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; ITOH N, 1993, J BIOL CHEM, V268, P10932; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PONTON A, 1992, GENE, V116, P187, DOI 10.1016/0378-1119(92)90515-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	23	130	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8991	8995		10.1074/jbc.271.15.8991	http://dx.doi.org/10.1074/jbc.271.15.8991			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621545	hybrid			2022-12-25	WOS:A1996UE73000076
J	Spangler, NJ; Lindahl, PA; Bandarian, V; Ludden, PW				Spangler, NJ; Lindahl, PA; Bandarian, V; Ludden, PW			Spectroelectrochemical characterization of the metal centers in carbon monoxide dehydrogenase (CODH) and nickel-deficient CODH from Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOACETICUM; ACETYL-COA; EPR; ACTIVATION; CYANIDE	Carbon-monoxide dehydrogenase (CODH) from Rhodospirillum rubrum contains two metal centers: a Ni-X-[Fe4S4](2+/1+) cluster (C-center) that serves as the CO-oxidation site and a standard [Fe4S4](2+/1+) cluster (B-center) that mediates electron flow from the C-center to external electron accepters. Four states of the C-center were previously identified in electron paramagnetic resonance (EPR) and Mossbauer studies. In this report, EPR-redox titrations demonstrate that the fully oxidized, diamagnetic form of the C-center (C-ox) undergoes a one-electron reduction to the C-red1 state (g(av) = 1.87) with a midpoint potential of -110 mV. The reduction of C-ox to C-red1 is shown to coincide with the reduction of an [Fe4S4](2+/1+) cluster in redox-titration experiments monitored by UV-visible spectroscopy. Nickel-deficient CODH, which is devoid of nickel yet contains both [Fe4S4](2+/1+) clusters, does not exhibit EPR-active states or reduced Fe4S4 clusters at potentials more positive than -350 mV.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	University of Wisconsin System; University of Wisconsin Madison; Texas A&M University System; Texas A&M University College Station			Lindahl, Paul/B-6137-2015	Lindahl, Paul/0000-0001-8307-9647	NIGMS NIH HHS [GM46441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM046441, R01GM046441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; ANDERSON ME, 1994, BIOCHEMISTRY-US, V33, P1702; BONAM D, 1988, P NATL ACAD SCI USA, V85, P31, DOI 10.1073/pnas.85.1.31; BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; DRAKE HL, 1994, ACETONGENESIS; Dutton P L, 1978, Methods Enzymol, V54, P411; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; FERRY JG, 1992, J BACTERIOL, V174, P5489, DOI 10.1128/JB.174.17.5489-5495.1992; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; KUMAR M, 1993, J AM CHEM SOC, V115, P11646, DOI 10.1021/ja00077a093; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LU WP, 1994, J BIOL CHEM, V269, P9736; MORTON TA, 1991, J BIOL CHEM, V266, P23824; QIU D, 1995, J AM CHEM SOC, V117, P2653, DOI 10.1021/ja00114a032; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; SERAVALLI J, 1995, BIOCHEMISTRY-US, V34, P7879, DOI 10.1021/bi00024a012; SHIN W, 1992, BIOCHEMISTRY-US, V31, P6003, DOI 10.1021/bi00141a007; SMITH ET, 1992, BIOCHEM J, V285, P181, DOI 10.1042/bj2850181; SMITH MR, 1985, J BACTERIOL, V162, P67, DOI 10.1128/JB.162.1.67-71.1985; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; TAN GO, 1992, P NATL ACAD SCI USA, V89, P4427, DOI 10.1073/pnas.89.10.4427	29	26	26	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7973	7977		10.1074/jbc.271.14.7973	http://dx.doi.org/10.1074/jbc.271.14.7973			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626477	hybrid			2022-12-25	WOS:A1996UD60000017
J	Li, FG; Erickson, HP; James, JA; Moore, KL; Cummings, RD; McEver, RP				Li, FG; Erickson, HP; James, JA; Moore, KL; Cummings, RD; McEver, RP			Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID CELLS; IDENTIFICATION; CD62	P-selectin glycoprotein ligand-l (PSGL-1), a sialomucin on human leukocytes, mediates rolling of leukocytes on P-selectin expressed by activated platelets or endothelial cells under shear forces, PSGL-1 requires both tyrosine sulfate and O-linked glycans to bind P-selectin. Electron microscopy of rotary-shadowed PSGL-1 purified from human neutrophils indicated that it is a highly extended molecule with an extracellular domain that is approximate to 50 nm long. Both individual PSGL-1 molecules and rosettes composed of several molecules presumably attached at their transmembrane segments were observed, The extracellular domain of PSGL-1 has 318 residues, including a signal peptide from residues 1-18 and a propeptide from residues 19-41, Using bacterially expressed fusion proteins and synthetic peptides derived from the extracellular domain, we mapped the epitopes for two IgG anti-PSGL-1 monoclonal antibodies, PL1 and PL2, PL2 bound to a region within residues 188-235 that is located in a series of decameric consensus repeats, PL1, which blocks binding of PSGL-1 to P-selectin, recognized an epitope spanning residues 49-62, This sequence overlaps the tyrosine sulfation sites at residues 46, 48, and 51 that have been implicated in binding of PSGL-1 to P-selectin, Our results demonstrate that PSGL-1 is a long, extended molecule and suggest that the P-selectin binding site is located near the N terminus, well above the membrane, This location may facilitate interactions of PSGL-1 with P-selectin under shear stress.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,ARTHRITIS & IMMUNOL PROGRAM,OKLAHOMA CITY,OK 73104; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; Duke University					NCI NIH HHS [R37 CA47056] Funding Source: Medline; NHLBI NIH HHS [P01 HL4804, R29 HL43602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; JAMES JA, 1992, J IMMUNOL, V148, P2074; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; MA L, 1994, J BIOL CHEM, V269, P27739; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; ROSE MC, 1984, J BIOL CHEM, V259, P3167; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCOFIELD RH, 1991, P NATL ACAD SCI USA, V88, P3343, DOI 10.1073/pnas.88.8.3343; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VELDMAN GM, 1995, J BIOL CHEM, V270, P16470, DOI 10.1074/jbc.270.27.16470; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	33	177	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6342	6348		10.1074/jbc.271.11.6342	http://dx.doi.org/10.1074/jbc.271.11.6342			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626430				2022-12-25	WOS:A1996UA36300059
J	AlAbed, Y; Liebich, H; Voelter, W; Bucala, R				AlAbed, Y; Liebich, H; Voelter, W; Bucala, R			Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; IMMUNOCHEMICAL DETECTION; RAT; ENDPRODUCTS; FIBROBLASTS; COMPONENT; INVIVO; ACID	Advanced glycosylation end products (AGEs) have been identified to be present on both the apolipoprotein and lipid components of low density lipoprotein (LDL) and to act to prevent its recognition and uptake by high affinity, tissue LDL receptors. Lipid-linked AGEs form readily in vitro by the covalent addition of glucose to the amine-containing head groups of phospholipids. This process is accompanied by oxidation of the unsaturated fatty acid side chains and occurs in the absence of exogenously added transition metals or free radical generating systems, suggesting that AGE formation may contribute significantly to lipid oxidation in vivo. To assess more precisely the chemical basis of AGE induced oxidative modification, we performed gas chromatography-mass spectrometry analysis of the lipid products which form over time during LDL-advanced glycosylation in vitro. Negative ion chemical ionization mass spectroscopy of two major compounds that were identified were consistent with the structures of the fatty acid oxidation products 4-hydroxyhexenal and 4-hydroxynonenal. These data support the concept that AGE formation in close proximity to unsaturated fatty acyl groups leads to lipid oxidation and provide additional evidence that advanced glycosylation is an important pathogenic modification of the LDL particle in vivo.	PICOWER INST MED RES, MANHASSET, NY 11030 USA; UNIV TUBINGEN, D-72076 TUBINGEN, GERMANY	Northwell Health; Eberhard Karls University of Tubingen			Ueno, Hiroshi/C-3301-2009		NIDDK NIH HHS [DK19655-15] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI N, 1992, J BIOL CHEM, V267, P10211; BROWN WV, 1994, MED CLIN N AM, V78, P143, DOI 10.1016/S0025-7125(16)30180-8; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1995, J BIOL CHEM, V270, P10828, DOI 10.1074/jbc.270.18.10828; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P2666, DOI 10.1073/pnas.90.7.2666; BUCALA R, 1994, RES METHODOLOGIES 1, P273; CHAN L, 1992, J BIOL CHEM, V267, P25621; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIRAMATSU K, 1985, DIABETES, V34, P8, DOI 10.2337/diabetes.34.1.8; KIKUGAWA K, 1992, ANAL BIOCHEM, V202, P249, DOI 10.1016/0003-2697(92)90102-D; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LOPESVIRELLA MF, 1982, DIABETOLOGIA, V22, P430, DOI 10.1007/BF00282585; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; MITSUHASHI T, 1993, DIABETES, V42, P826, DOI 10.2337/diabetes.42.6.826; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; NAKAMURA Y, 1993, AM J PATHOL, V143, P1649; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; POKORNY J, 1981, PROG FOOD NUTR SCI, V5, P421; SCHWARTZ CJ, 1993, AM J CARDIOL, V71, pB9, DOI 10.1016/0002-9149(93)90139-4; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VANKUIJK FJGM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P116, DOI 10.1016/0005-2760(90)90118-H; VANKUIJK FJGM, 1986, BIOCHEM BIOPH RES CO, V139, P144, DOI 10.1016/S0006-291X(86)80091-2; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; 1992, 1992 NIH NAT I DIS D	33	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	1996	271	6					2892	2896		10.1074/jbc.271.6.2892	http://dx.doi.org/10.1074/jbc.271.6.2892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TU691	8621676	hybrid			2022-12-25	WOS:A1996TU69100005
J	Frank, S; Madlener, M; Werner, S				Frank, S; Madlener, M; Werner, S			Transforming growth factors beta 1, beta 2, and beta 3 and their receptors are differentially regulated during normal and impaired wound healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; II RECEPTOR; GENE-EXPRESSION; GROWTH-FACTOR-BETA-1; PROLIFERATION; FACTOR-BETA-1; PURIFICATION; MACROPHAGES; INHIBITION; PATTERNS	A series of studies has shown that application of transforming growth factor beta (TGF-beta) to a wound has a beneficial effect, especially in animals with wound healing disorders. In this study we have investigated the regulation of TGF-beta 1, beta 2, and beta 3 and their receptors during the repair process. We found a large induction of all three TGF-beta isoforms and also of TGF-beta types I and II receptors, although the time course of induction and the absolute expression levels were different for these genes. Furthermore, each TGF-beta isoform had distinct sites of expression in the wound. Systemic treatment with glucocorticoids significantly altered the expression levels of TGF-beta s and TGF-beta receptors. Whereas expression of TGF-beta 1, TGF-beta 2, and TGF-beta type II receptor was suppressed by glucocorticoids in normal and wounded skin, expression of TGF-beta 3 and TGF-beta receptor type I mRNA was stimulated. These findings provide an explanation for the beneficial effect of exogenous TGF-beta in the treatment of impaired wound healing in glucocorticoid-treated animals. Furthermore, they suggest that a disturbed balance between the levels of the three TGF-beta isoforms and their receptors might underlie the wound healing defect seen in glucocorticoid-treated animals.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beck LS, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000293; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082; EHRLICH HP, 1968, ANN SURG, V167, P324, DOI 10.1097/00000658-196803000-00004; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; GROTENDORST GR, 1988, GROWTH FACTORS OTHER, P47; KANE CJM, 1991, J CELL PHYSIOL, V148, P157, DOI 10.1002/jcp.1041480119; KLINGBEIL CK, 1991, PROG CLIN BIOL RES, V365, P443; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LEVINE JH, 1993, AM J PATHOL, V143, P368; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; NATH RK, 1994, J PEDIATR SURG, V29, P416, DOI 10.1016/0022-3468(94)90582-7; NORTH RJ, 1971, J EXP MED, V134, P1485, DOI 10.1084/jem.134.6.1485; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; PITTELKOW MR, 1991, PHYSL BIOCH MOL BIOL, P351; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCHMID P, 1993, J PATHOL, V171, P191, DOI 10.1002/path.1711710307; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHULL S, 1995, LUNG, V173, P71, DOI 10.1007/BF02981467; SUZUKI A, 1994, BIOCHEM BIOPH RES CO, V198, P1063, DOI 10.1006/bbrc.1994.1151; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOMODA T, 1994, BIOCHEM BIOPH RES CO, V198, P1054, DOI 10.1006/bbrc.1994.1150; Wahl S, 1989, ANTIINFLAMMATORY STE, P280; WANG JX, 1995, J BIOL CHEM, V270, P2722, DOI 10.1074/jbc.270.36.21326; WEINER FR, 1987, J BIOL CHEM, V262, P6955; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	44	306	318	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10188	10193		10.1074/jbc.271.17.10188	http://dx.doi.org/10.1074/jbc.271.17.10188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626581	hybrid			2022-12-25	WOS:A1996UG25700053
J	Couchman, JR; Kapoor, R; Sthanam, M; Wu, RR				Couchman, JR; Kapoor, R; Sthanam, M; Wu, RR			Perlecan and basement membrane chondroitin sulfate proteoglycan (Bamacan) are two basement membrane chondroitin dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN-RECEPTOR; CELL-ADHESION MOLECULES; EPIDERMAL GROWTH-FACTOR; HEPARAN-SULFATE; MOUSE-TUMOR; IMMUNOLOGICAL CHARACTERIZATION; EXTRACELLULAR-MATRIX; CORE PROTEIN; RAT-TISSUES; LAMININ	The presence of proteoglycans bearing galactosaminoglycan chains has been reported, but none has been identified previously in the matrix of the Engelbreth-Holm-Swarm tumor, which is a source of several basement membrane components, This tumor matrix contains perlecan, a large, low buoyant density heparan sulfate proteoglycan, widespread in many basement membranes and connective tissues. We now identify two distinct proteoglycan species from this tumor source, which are substituted with galactosaminoglycans and which show basement membrane localization by immunohistochemistry. One species is perlecan but, in addition to being present as a heparan sulfate proteoglycan, it is also present as a hybrid molecule, with dermatan sulfate chains, A minor population of perlecan apparently lacks heparan sulfate chains totally, and some of this is substituted with chondroitin sulfate, The second species is immunologically related to basement membrane-chondroitin sulfate proteoglycan (BM-CSPG) and bears chondroitin sulfate chains. No BM-CSPG was detectable which was substituted with heparan sulfate chains. A combination of immunological and molecular approaches, including cDNA cloning, showed that perlecan and BM-CSPG are distinct in core protein structure. Both are, however, basement membrane components, although there are tissue-specific differences in their distribution.	UNIV ALABAMA,CELL ADHES & MATRIX RES CTR,BIRMINGHAM,AL 35294; BECTON DICKINSON CO,COLLABORAT BIOMED PROD,BEDFORD,MA 01730	University of Alabama System; University of Alabama Birmingham; Becton Dickinson	Couchman, JR (corresponding author), UNIV ALABAMA,DEPT CELL BIOL,VH 201C,UNIV BLVD,BIRMINGHAM,AL 35294, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036457] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36457] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; COUCHMAN JR, 1985, J BIOL CHEM, V260, P3755; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; COUCHMAN JR, 1995, J INVEST DERMATOL, V104, P579; COUCHMAN JR, 1995, FASEB J, V9, pA695; COUCHMAN JR, 1987, J CELL BIOL, V105, P1901, DOI 10.1083/jcb.105.4.1901; COUCHMAN JR, 1989, MATRIX, V91, P311; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; EHARA T, 1994, AM J PATHOL, V144, P612; FINE JD, 1989, J INVEST DERMATOL, V92, P611, DOI 10.1111/1523-1747.ep12712151; FUJIWARA S, 1984, EUR J BIOCHEM, V143, P145, DOI 10.1111/j.1432-1033.1984.tb08353.x; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1985, J BIOL CHEM, V260, P8098; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1986, J BIOL CHEM, V261, P6658; ISEMURA M, 1987, J BIOL CHEM, V262, P8926; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KATO M, 1988, J CELL BIOL, V106, P2203, DOI 10.1083/jcb.106.6.2203; KATO M, 1987, J BIOL CHEM, V262, P7180; LJUBIMOV AV, 1996, IN PRESS INVEST OPHT; MCCARTHY KJ, 1994, J HISTOCHEM CYTOCHEM, V42, P473, DOI 10.1177/42.4.8126374; MCCARTHY KJ, 1989, J CELL BIOL, V109, P3187, DOI 10.1083/jcb.109.6.3187; MCCARTHY KJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1479, DOI 10.1177/38.10.2401786; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1993, MOL CELLULAR ASPECTS, P189; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RADA JA, 1991, ANAT REC, V231, P35, DOI 10.1002/ar.1092310106; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WEWER UM, 1985, DIFFERENTIATION, V30, P61, DOI 10.1111/j.1432-0436.1985.tb00514.x; Yurchenco P.D., 1993, MOL CELLULAR ASPECTS, P19; [No title captured]	42	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9595	9602		10.1074/jbc.271.16.9595	http://dx.doi.org/10.1074/jbc.271.16.9595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621634	hybrid			2022-12-25	WOS:A1996UG04400065
J	Jiang, SW; Eberhard, NL				Jiang, SW; Eberhard, NL			TEF-1 transrepression in BeWo cells is mediated through interactions with the TATA-binding protein, TBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; TRANSCRIPTIONAL ENHANCER; GENE-TRANSCRIPTION; ACTIVATION DOMAIN; TFIIB; EXPRESSION; SEQUENCE	Transcription enhancer factor-1 (TEF-1) has been implicated in transactivating a placental enhancer (CSEn) that regulates human chorionic somatomammotropin (hCS) gene activity, We demonstrated that TEF-1 represses hCS promoter activity in choriocarcinoma (BeWo) cells (Jiang, S. W., and Eberhardt, N. L. (1995) J. Biol. Chem. 270, 13609-13915), suggesting that TEF-1 interacts with basal transcription factors. Here we demonstrate that hTEF-1 overexpression inhibits minimal hCS promoters containing TATA and/or initiator elements, Rous sarcoma virus and thymidine kinase promoters in BeWo cells. Cotransfection of TEF-1 antisense oligonucleotides alleviated exogenous TEF-1-mediated repression and increased basal hCS promoter activity, indicating that endogenous TEF-1 exerts repressor activity, GST-TEF-1 fusion peptides fixed to glutathione-Sepharose beads retained in vitro-generated human TATA-binding protein, hTBP. The TEF-1 proline-rich domain was essential for TBP binding, but polypeptides also containing the zinc finger domain bound TBP with higher apparent affinity. TBP supershifted hTEF-GT-IIC DNA complexes, but TEF-1 inhibited in vitro binding of TBP to the TATA motif, Coexpression of TBP and TEF-1 in BeWo cells alleviated TEF-1-mediated transrepression, indicating that the TBP-TEF-1 interaction is functional in vivo. The data indicate that TEF-1 transrepression is mediated by direct interactions with TBP, possibly by inhibiting preinitiation complex formation.	MAYO CLIN,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NIDDK NIH HHS [DK41206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ING NH, 1992, J BIOL CHEM, V267, P17617; INOSTROZA JA, 1992, CELL, V70, P477; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; LENG P, 1995, INT J ONCOL, V6, P251; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; Snedecor G. W., 1980, STATISTICAL METHODS, P116; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XIE W, 1991, BIOTECHNIQUES, V11, P325; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	41	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9510	9518		10.1074/jbc.271.16.9510	http://dx.doi.org/10.1074/jbc.271.16.9510			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621623	hybrid			2022-12-25	WOS:A1996UG04400054
J	Sagami, H; Igarashi, Y; Tateyama, S; Ogura, K; Roos, J; Lennarz, WJ				Sagami, H; Igarashi, Y; Tateyama, S; Ogura, K; Roos, J; Lennarz, WJ			Enzymatic formation of dehydrodolichal and dolichal, new products related to yeast dolichol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; DIPHOSPHATE SYNTHASE; PYROPHOSPHATES; PHOSPHATE; SITE	Two new polyprenyl products in addition to dehydrodolichol and dolichol were detected by two-plate silica gel thin layer chromatography of nonpolar products formed from [1-C-14]isopentenyl diphosphate and farnesyl diphosphate in the reaction with a crude 1,000 x g supernatant of yeast homogenates in the presence of NADPH. The new products were indistinguishable from authentic dehydrodolichal and dolichal. Analyses of the time-dependent and pH-dependent formation of the four products including dehydrodolichal and dolichal suggested that the biosynthetic pathway from dehydrodolichol leading to dolichal is different from that to dolichol, In double-labeled experiments with a combination of [1-C-14]isopentenyl diphosphate and a [4B-H-3]NADPH-generating system, the ratio of H-3- and C-14-derived radioactivities found in dolichal was six times higher than that in dolichol, A small amount of H-3-labeled dehydrodolichol was also detected, Considering the fact that dolichol is synthesized from dehydrodolichol (Sagami, H., Kurisaki, A., and Ogura, K. (1993) J. Biol, Chem. 268, 10109-10113), we propose that dehydrodolichol is a common branch point intermediate in the biosynthetic pathways leading to dolichal and dolichol and that dehydrodolichal is an intermediate in the pathway from dehydrodolichol to dolichal.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sagami, H (corresponding author), TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN.							ADAIR WL, 1984, J BIOL CHEM, V259, P4441; ADAIR WL, 1982, J BIOL CHEM, V257, P8990; ATTENBURROW J, 1952, J CHEM SOC, P1094, DOI 10.1039/jr9520001094; BABA T, 1987, ARCH BIOCHEM BIOPHYS, V252, P440, DOI 10.1016/0003-9861(87)90050-6; CHEN Z, 1988, ARCH BIOCHEM BIOPHYS, V266, P98, DOI 10.1016/0003-9861(88)90240-8; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; COREY EJ, 1979, TETRAHEDRON LETT, P399; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; EKSTROM TJ, 1987, J BIOL CHEM, V262, P4090; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MORAN RG, 1984, ANAL BIOCHEM, V138, P196, DOI 10.1016/0003-2697(84)90788-7; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; SAGAMI H, 1991, J BIOL CHEM, V266, P3458; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; SAGAMI H, 1992, J LIPID RES, V33, P1857; SAGAMI H, 1993, J BIOL CHEM, V268, P10109; STEEN L, 1984, BIOCHIM BIOPHYS ACTA, V796, P294, DOI 10.1016/0005-2760(84)90130-9; Van Dessel Guido, 1994, Acta Biochimica Polonica, V41, P311; WAECHTER CJ, 1976, ANNU REV BIOCHEM, V45, P95, DOI 10.1146/annurev.bi.45.070176.000523; WONG TK, 1982, J BIOL CHEM, V257, P6619	22	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9560	9566		10.1074/jbc.271.16.9560	http://dx.doi.org/10.1074/jbc.271.16.9560			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621629	hybrid			2022-12-25	WOS:A1996UG04400060
J	Semmes, OJ; Barrett, JF; Dang, CV; Jeang, KT				Semmes, OJ; Barrett, JF; Dang, CV; Jeang, KT			Human T-cell leukemia virus type I Tax masks c-myc function through a cAMP-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; PRIMARY HUMAN-LYMPHOCYTES; RECEPTOR GENE-EXPRESSION; PROTEIN-KINASE-A; HTLV-I; CYCLIC-AMP; DNA-BINDING; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION	Human T-cell leukemia virus type I Tax is a pleiotropic gene regulator that functions through CREB/ATF- and NF-kappa B-mediated pathways, In most contexts, Tax is a potent gene activator. Here, we describe an unexpected finding of Myc repression by Tax. In cells that overexpress human T-cell leukemia virus type I Tax, the detection of c-Myc protein in the nucleus by a monoclonal antibody was masked. Tax prevented immunological visualization of a Myc epitope contained within amino acids 45-104, resulting in interference with Myc function in transcription and in anchorage-independent cell growth, Tax did not affect steady-state protein levels since detection of c-Myc with other antibodies was unperturbed. Four observations suggest that this Tax-Myc interaction is mediated through CREB/ATF signal transduction. 1) Tax point mutants, selectively defective for activation of CREB/ATF but not NF-kappa B, failed to mask. c-Myc; 2) masking of Myc was abolished when Tax-expressing cells were treated with protein kinase inhibitor H-9; 3) Tax-specific shielding of Myc is absent in cells (B1R) that are genetically defective for cAMP signaling; and 4) forskolin treatment of cells mimicked Tax in masking the Myc epitope, Considered collectively, these findings suggest a regulation of Myc function at the level of localized protein conformation.	NIAID,MOL VIROL SECT,MOLEC MICROBIOL LAB,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV HEMATOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University			Jeang, Kuan-Teh/A-2424-2008; Dang, Chi/Y-3375-2019; Semmes, Oliver/GQA-5179-2022	Dang, Chi/0000-0002-4031-2522				ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ALBERT T, 1994, ONCOGENE, V9, P759; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOURNE HR, 1975, J CELL PHYSIOL, V85, P611, DOI 10.1002/jcp.1040850313; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CHOU EY, 1995, P NATL ACAD SCI USA, V92, P4417; COFFINO P, 1974, J CELL PHYSL, V85, P603; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ESSEX M, 1992, AIDS RES HUM RETROV, V8, P719; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOHNSON DA, 1995, GENE ANAL TECH, V1, P3; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; KARIN M, 1990, New Biologist, V2, P126; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1992, ONCOGENE, V7, P1463; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; LACOSTE J, 1994, LEUKEMIA, V8, pS71; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUNOZ E, 1994, J VIROL, V68, P8035; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OSAME M, 1993, MED HYPOTHESES, V41, P363, DOI 10.1016/0306-9877(93)90085-5; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RULEY H, 1983, NATURE, V204, P602; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Sherman M P, 1993, Cancer Treat Res, V64, P79; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WILLEMS L, 1992, J VIROL, V66, P766, DOI 10.1128/JVI.66.2.766-772.1992; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	95	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9730	9738		10.1074/jbc.271.16.9730	http://dx.doi.org/10.1074/jbc.271.16.9730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621651	hybrid			2022-12-25	WOS:A1996UG04400082
J	Song, KS; Li, SW; Okamoto, T; Quilliam, LA; Sargiacomo, M; Lisanti, MP				Song, KS; Li, SW; Okamoto, T; Quilliam, LA; Sargiacomo, M; Lisanti, MP			Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains - Detergent-free purification of caveolae membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; EPITHELIAL-CELLS; COMPONENT; VESICLES; SIGNAL; TRANSFORMATION; MOLECULES; TYROSINE	Caveolae are plasma membrane specializations that have been implicated in signal transduction. Caveolin, a 21-24-kDa integral membrane protein, is a principal structural component of caveolae membranes in vivo, G protein alpha subunits are concentrated in purified preparations of caveolae membranes, and caveolin interacts directly with multiple G protein alpha subunits, including G(s), G(o), and G(i2). Mutational or pharmacologic activation of G, subunits prevents the interaction of caveolin with G(alpha) proteins, indicating that inactive G(alpha) subunits preferentially interact with caveolin, Here, we show that caveolin interacts with another well characterized signal transducer, Ras, Using a detergent-free procedure for purification of caveolin-rich membrane domains and a polyhistidine tagged form of caveolin, we find that Has and other classes of lipid-modified signaling molecules co-fractionate and co-elute with caveolin, The association of Ras with caveolin was further evaluated using two distinct in vitro binding assays, Wild-type H-Ras interacted with glutathione S-transferase (GST)-caveolin fusion proteins but not with GST alone. Using a battery of GST fusion proteins encoding distinct regions of caveolin, Ras binding activity was localized to a 41-amino acid membrane proximal region of the cytosolic N-terminal domain of caveolin, In addition, reconstituted caveolin-rich membranes (prepared with purified recombinant caveolin and purified lipids) interacted with a soluble form of wild-type H-Ras but failed to interact with mutationally activated soluble H-Ras (G12V), Thus, a single amino acid change (G12V) that constitutively activates Ras prevents or destabilizes this interaction, These results clearly indicate that (i) caveolin is sufficient to recruit soluble Ras onto lipid membranes and (ii) membrane-bound caveolin preferentially interacts with inactive Ras proteins, In direct support of these in vitro studies, we also show that recombinant overexpression of caveolin in intact cells is sufficient to functionally recruit a nonfarnesylated mutant of Ras (C186S) onto membranes, overcoming the normal requirement for lipid modification of has. Taken together, these observations suggest that caveolin may function as a scaffolding protein to localize or sequester certain caveolin-interacting proteins, such as wild-type Ras, within caveolin-rich microdomains of the plasma membrane.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED,MASSACHUSETTS GEN HOSP, SHRINERS HOSP CRIPPLED CHILDREN,DEPT ANESTHESIA, BOSTON, MA 02114 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Indiana University System; Indiana University-Purdue University Indianapolis			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382; Sargiacomo, Massimo/0000-0003-4040-706X	NCI NIH HHS [CA-63139] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; Kato K, 1992, Semin Cancer Biol, V3, P179; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; PRENDERGAST GC, 1994, BIOESSAYS, V16, P187, DOI 10.1002/bies.950160309; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8	59	922	937	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	1996	271	16					9690	9697		10.1074/jbc.271.16.9690	http://dx.doi.org/10.1074/jbc.271.16.9690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG044	8621645	hybrid			2022-12-25	WOS:A1996UG04400076
J	BenEfraim, I; Shai, Y; Attali, B				BenEfraim, I; Shai, Y; Attali, B			Cytoplasmic and extracellular IsK peptides activate endogenous K+ and Cl- channels in Xenopus oocytes - Evidence for regulatory function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT POTASSIUM CHANNELS; PROTEIN; EXPRESSION; MUTATIONS; CLONING; MINK	IsK is a 14.5-kDa type III membrane glycoprotein which induces slowly activating K+ and Cl- currents when expressed in Xenopus oocytes and HEK 293 cells. Recently, mutagenesis experiments identified amino- and carboxyl-terminal domains of IsK: as critical for induction of Cl- and K+ currents, respectively, This hypothesis was tested by examining effects of synthetic IsK hydrophilic peptides on untreated Xenopus oocytes. In agreement with IsK membrane topology, we show here that peptides derived from carboxyl and amino termini are sufficient to activate slow K+ and Cl- channels whose biophysical and pharmacological characteristics are similar to those exhibited by the native IsK protein. That data provide further evidence that IsK is a regulatory subunit of pre-existing silent channel complexes rather than a channel per se.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BENEFRAIM I, 1994, BIOCHEMISTRY-US, V33, P6966, DOI 10.1021/bi00188a028; BLUMENTHAL EM, 1992, NEUROCHEM RES, V17, P869, DOI 10.1007/BF00993262; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; BUSCH AE, 1995, J BIOL CHEM, V270, P3638, DOI 10.1074/jbc.270.8.3638; FREEMAN LC, 1993, CIRC RES, V73, P958; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HICE RE, 1994, PFLUG ARCH EUR J PHY, V426, P139, DOI 10.1007/BF00374681; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; Hoshi T, 1993, Curr Opin Neurobiol, V3, P283, DOI 10.1016/0959-4388(93)90119-J; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KACZMAREK LK, 1991, NEW BIOL, V3, P315; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SWANSON R, 1993, SEMIN NEUROSCI, V5, P117; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VARNUM MD, 1995, NEURON, V14, P407, DOI 10.1016/0896-6273(95)90296-1; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5	28	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8768	8771		10.1074/jbc.271.15.8768	http://dx.doi.org/10.1074/jbc.271.15.8768			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621512	hybrid			2022-12-25	WOS:A1996UE73000043
J	Hudmon, A; Aronowski, J; Kolb, SJ; Waxham, MN				Hudmon, A; Aronowski, J; Kolb, SJ; Waxham, MN			Inactivation and self-association of Ca2+ calmodulin-dependent protein kinase II during autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ CALMODULIN; RAT-BRAIN; AUTONOMOUS ENZYME; PURIFICATION; ISCHEMIA; PHOSPHORYLATION; TRANSLOCATION; MUTAGENESIS; ACTIVATION; MECHANISM	The time-dependent loss in enzyme activity associated with the autophosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaM-kinase) was altered by both pH and ATP concentration, These parameters also influenced the extent to which soluble CaM-kinase undergoes self-association to form large aggregates of sedimentable enzyme, Specifically, autophosphorylation of CaM-kinase in 0.01 mM ATP at pH 6.5 resulted in the formation of sedimentable enzyme and a 70% loss of enzyme activity, Under similar conditions at pH 7.5, the enzyme lost only 30% of its activity, and no sedimentable enzyme was detected, In contrast to 0.01 mM ATP, autophosphorylation of CaM-kinase at pH 6.5 in 1 mM ATP did not result in a loss of activity or the production of sedimentable enzyme, even though the stoichiometry of autophosphorylation was comparable, Electron microscopy studies of CaM-kinase autophosphorylated at pH 6.5 in 0.01 mM ATP revealed particles 100-300 nm in diameter that clustered into branched complexes. Inactivation and self-association of CaM-kinase were influenced by the conditions of autophosphorylation in vitro, suggesting that both the catalytic and physical properties of the enzyme may be sensitive to fluctuations in ATP concentration and pH in vivo.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77225; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROL,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kolb, Stephen/E-3415-2011	Waxham, M. Neal/0000-0003-4801-1190	NINDS NIH HHS [NS26086, NS01509] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001509, R56NS026086, R01NS026086] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BRONSTEIN J, 1989, BRAIN RES, V495, P83, DOI 10.1016/0006-8993(89)91220-1; BRONSTEIN JM, 1986, FEBS LETT, V196, P135, DOI 10.1016/0014-5793(86)80228-9; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; COLBRAN RJ, 1992, NEUROCHEM INT, V21, P469, DOI 10.1016/0197-0186(92)90080-B; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; DUNKLEY PR, 1991, MOL NEUROBIOL, V5, P179, DOI 10.1007/BF02935545; FOLBERGROVA J, 1990, J NEUROCHEM, V55, P1690, DOI 10.1111/j.1471-4159.1990.tb04957.x; FONG YL, 1989, J BIOL CHEM, V264, P16759; GOLDENRING JR, 1984, J NEUROCHEM, V43, P1669, DOI 10.1111/j.1471-4159.1984.tb06094.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; ISHIDA A, 1994, J BIOCHEM-TOKYO, V115, P1075, DOI 10.1093/oxfordjournals.jbchem.a124460; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KELLY PT, 1987, METHOD ENZYMOL, V139, P690; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; KURET J, 1985, J BIOL CHEM, V260, P6427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LICKTEIG R, 1988, J BIOL CHEM, V263, P19232; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOU LL, 1989, J NEUROSCI, V9, P2020; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; PATTON BL, 1990, J BIOL CHEM, V265, P11204; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROSTAS JAP, 1987, NEUROSCI RES COMMUN, V1, P3; SAHYOUN N, 1985, J BIOL CHEM, V260, P1230; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; SHACKELFORD DA, 1993, J NEUROCHEM, V61, P738; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; WAXHAM MN, 1989, J BIOL CHEM, V264, P7477; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WILLMUND R, 1986, P NATL ACAD SCI USA, V83, P9789, DOI 10.1073/pnas.83.24.9789; YAMAUCHI T, 1985, BIOCHEM BIOPH RES CO, V129, P213, DOI 10.1016/0006-291X(85)91424-X	45	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8800	8808		10.1074/jbc.271.15.8800	http://dx.doi.org/10.1074/jbc.271.15.8800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621518	hybrid			2022-12-25	WOS:A1996UE73000049
J	Turner, RS; Suzuki, N; Chyung, ASC; Younkin, SG; Lee, VMY				Turner, RS; Suzuki, N; Chyung, ASC; Younkin, SG; Lee, VMY			Amyloids beta(40) and beta(42) are generated intracellularly in cultured human neurons and their secretion increases with maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN GENE; HEREDITARY CEREBRAL-HEMORRHAGE; NTERA-2 CELLS; PEPTIDE; MUTATION; DERIVATIVES; TERMINUS; CLEAVAGE; DUTCH	Previous studies have demonstrated the presence of amyloid beta (A beta) in neurons (NT2N) derived from a human embryonal carcinoma cell line (NT2) by steady state metabolic radiolabeling and immunoprecipitation. We show here that A beta is present intracellularly since trypsin digestion of intact NT2N cells at 4 degrees C did not eliminate the A beta recovered in cell lysates, To determine whether both A beta(40) and A beta(42) are produced intracellularly, quantitative sandwich enzyme-linked immunosorbent assay (ELISA) was performed using COOH-terminal end-specific anti=A beta monoclonal antibodies, Sandwich ELISA detected intracellular A beta(40) and A beta(42) in NT2N cell lysates at a ratio of 3:1, whereas secreted A beta(40) and A beta(42) were recovered in medium conditioned by NT2N cells at a ratio of approximately 20:1, Metabolic steady state and pulse-chase labeling studies demonstrated a 2-h delay in the detection of cell-associated A beta(40)/A beta(42) in the medium, suggesting that A beta is generated at a slow rate intracellularly prior to its secretion, Finally, as NT2N cells mature over time in culture, the secretion of A beta(40) and A beta(42) increases more than 5-fold over 7 weeks. This increase in the secretion of A beta(40)/A beta(42) in NT2N cells as a function of time may recapitulate a similar phenomenon in the aging brain.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106	University of Pennsylvania; University of Pennsylvania; Case Western Reserve University			Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NIA NIH HHS [AG06656, AG-09215] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006656, P01AG009215] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916	36	159	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8966	8970		10.1074/jbc.271.15.8966	http://dx.doi.org/10.1074/jbc.271.15.8966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621541	hybrid			2022-12-25	WOS:A1996UE73000072
J	Ni, TC; Savageau, MA				Ni, TC; Savageau, MA			Application of biochemical systems theory to metabolism in human red blood cells - Signal propagation and accuracy of representation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; DICTYOSTELIUM-DISCOIDEUM; HUMAN-ERYTHROCYTES; STEADY-STATE; MATHEMATICAL-ANALYSIS; MULTIENZYME SYSTEMS; VARIANT THEORIES; KINETIC-MODEL; INVIVO STATE; GLYCOLYSIS	Human erythrocytes are among the simplest of cells. Many of their enzymes have been characterized kinetically using steady-state methods in vitro, and several investigators have assembled this kinetic information into mathematical models of the integrated system. However, despite its relative simplicity, the integrated behavior of erythrocyte metabolism is still complex and not well understood. Errors will inevitably be encountered in any such model because of this complexity; thus, the construction of an integrative model must be considered an iterative process of assessment and refinement. In a previous study, we selected a recent model of erythrocyte metabolism as our starting point and took it through three stages of model assessment and refinement using systematic strategies provided by biochemical systems theory. At each stage deficiencies were diagnosed, putative remedies were identified, and modifications consistent with existing experimental evidence were incorporated into the working model. In this paper we address two issues: the propagation of biochemical signals within the metabolic network, and the accuracy of kinetic representation. The analysis of signal propagation reveals the importance of glutathione peroxidase, transaldolase, and the concentration of total glutathione in determining systemic behavior. It also reveals a highly amplified diversion of flux between the pathways of pentose phosphate and nucleotide metabolism. In determining the range of accurate representation based on alternative kinetic formalisms we discovered large discrepancies. These were identified with the behavior of the model represented within the Michaelis-Menten formalism. This model fails to exhibit a nominal steady state when the activity of glutathione peroxidase is decreased by as little as 9%. Our current understanding, as embodied in this working model, is in need of further refinement, and the results presented in this paper suggest areas of the model where such effort might profitably be concentrated.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM-30054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030054] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBE KR, 1992, J BIOL CHEM, V267, P3106; ALBE KR, 1994, J THEOR BIOL, V169, P243, DOI 10.1006/jtbi.1994.1145; ATAULLAKHANOV FI, 1981, EUR J BIOCHEM, V115, P359, DOI 10.1111/j.1432-1033.1981.tb05246.x; Beutler E., 1984, GLUTATHIONE RED CELL; BIRT DF, 1986, ANN NUTR METAB, V30, P233, DOI 10.1159/000177199; BREWER GJ, 1989, RED CELL; BRUMEN M, 1984, BIOSYSTEMS, V17, P155, DOI 10.1016/0303-2647(84)90006-6; CASCANTE M, 1995, MATH BIOSCI, V130, P51, DOI 10.1016/0025-5564(94)00093-F; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; CURTO R, 1995, MATH BIOSCI, V130, P25, DOI 10.1016/0025-5564(94)00092-E; DEAN BM, 1976, BIOCHIM BIOPHYS ACTA, V437, P1, DOI 10.1016/0304-4165(76)90342-1; GALAZZO J, 1991, ENZYME MICROB TECH, V13, P363; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GIERSCH C, 1988, EUR J BIOCHEM, V174, P509, DOI 10.1111/j.1432-1033.1988.tb14128.x; HEINRICH R, 1975, BIOSYSTEMS, V7, P130, DOI 10.1016/0303-2647(75)90050-7; HOLZHUTTER HG, 1985, EUR J BIOCHEM, V149, P101, DOI 10.1111/j.1432-1033.1985.tb08899.x; JOSHI A, 1990, J THEOR BIOL, V142, P69, DOI 10.1016/S0022-5193(05)80013-X; JOSHI A, 1989, J THEOR BIOL, V141, P529, DOI 10.1016/S0022-5193(89)80234-6; JOSHI A, 1990, J THEOR BIOL, V142, P41, DOI 10.1016/S0022-5193(05)80012-8; JOSHI A, 1989, J THEOR BIOL, V141, P515, DOI 10.1016/S0022-5193(89)80233-4; Kadner R. J., 1996, ESCHERICHIA COLI SAL, V2nd; LACHANT NA, 1984, AM J HEMATOL, V17, P237, DOI 10.1002/ajh.2830170304; LEE ID, 1992, COMPUT METH PROG BIO, V38, P195, DOI 10.1016/0169-2607(92)90102-D; MARSHALL WE, 1974, BIOCHIM BIOPHYS ACTA, V354, P1, DOI 10.1016/0304-4165(74)90046-4; MCINTYRE LM, 1989, EUR J BIOCHEM, V180, P399, DOI 10.1111/j.1432-1033.1989.tb14662.x; MILLS GC, 1976, P NATL ACAD SCI USA, V73, P2867, DOI 10.1073/pnas.73.8.2867; NI TC, 1996, IN PRESS J THEOR BIO; NI TC, 1994, METABOLISM HUMAN RED, P1; ORLAND MJ, 1986, MANUAL MED THERAPEUT; PETTERSSON G, 1988, EUR J BIOCHEM, V175, P661, DOI 10.1111/j.1432-1033.1988.tb14242.x; Press W. H., 1992, NUMERICAL RECIPES C, P379; RAPOPORT TA, 1975, BIOSYSTEMS, V7, P120, DOI 10.1016/0303-2647(75)90049-0; RAPOPORT TA, 1976, BIOCHEM J, V154, P449, DOI 10.1042/bj1540449; ROELS JA, 1983, ENERGETICS KINETICS, P287; SALTER M, 1986, BIOCHEM J, V234, P635, DOI 10.1042/bj2340635; Savageau M, 1976, BIOCH SYSTEMS ANAL S; Savageau M. A., 1992, FUNDAMENTALS MED CEL, V3A, P45; SAVAGEAU MA, 1987, MATH BIOSCI, V86, P147, DOI 10.1016/0025-5564(87)90008-3; SAVAGEAU MA, 1991, J THEOR BIOL, V151, P509, DOI 10.1016/S0022-5193(05)80367-4; SAVAGEAU MA, 1992, J THEOR BIOL, V154, P131, DOI 10.1016/S0022-5193(05)80194-8; SAVAGEAU MA, 1969, J THEOR BIOL, V25, P370, DOI 10.1016/S0022-5193(69)80027-5; SAVAGEAU MA, 1971, ARCH BIOCHEM BIOPHYS, V145, P612, DOI 10.1016/S0003-9861(71)80021-8; SAVAGEAU MA, 1996, WORLD C NONL AN 92, V4, P3323; SCHAUER M, 1981, ACTA BIOL MED GER, V40, P1659; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22912; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22926; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SHIRAISHI F, 1993, J BIOL CHEM, V268, P16917; Shiraishi F, 1996, J THEOR BIOL, V178, P219, DOI 10.1006/jtbi.1996.0018; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22919; SORRIBAS A, 1994, BIOCHEM J, V298, P303, DOI 10.1042/bj2980303; SORRIBAS A, 1993, J THEOR BIOL, V162, P81, DOI 10.1006/jtbi.1993.1078; SORRIBAS A, 1995, MATH BIOSCI, V130, P71, DOI 10.1016/0025-5564(94)00094-G; SORRIBAS A, 1989, MATH BIOSCI, V94, P239, DOI 10.1016/0025-5564(89)90066-7; SORRIBAS A, 1989, MATH BIOSCI, V94, P161, DOI 10.1016/0025-5564(89)90064-3; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; Srere PA, 1989, STRUCTURAL ORG ASPEC; STEPHANOPOULOS G, 1991, SCIENCE, V252, P1675, DOI 10.1126/science.1904627; Surgenor DM, 1974, RED BLOOD CELL; THORBURN DR, 1985, EUR J BIOCHEM, V150, P371, DOI 10.1111/j.1432-1033.1985.tb09030.x; VOIT EO, 1987, BIOCHEMISTRY-US, V26, P6869, DOI 10.1021/bi00395a042; WALLACH J, 1986, INTERPRETATION DIAGN; WERNER A, 1985, BIOMED BIOCHIM ACTA, V44, P185; WRIGHT BE, 1992, J BIOL CHEM, V267, P3101; WRIGHT BE, 1994, J BIOL CHEM, V269, P19931	65	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					7927	7941		10.1074/jbc.271.14.7927	http://dx.doi.org/10.1074/jbc.271.14.7927			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626472	hybrid			2022-12-25	WOS:A1996UD60000012
J	Welsh, N				Welsh, N			Interleukin-1 beta-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; NITRIC-OXIDE PRODUCTION; HL-60 CELLS; SPHINGOMYELIN; LANGERHANS; SECRETION; MECHANISMS; INHIBITION; IL-1-BETA; CYCLOOXYGENASE	The aim of this investigation was to study the putative involvement of lipid second messengers, protein kinases, and transcription factors in interleukin-1 beta (IL-1 beta)-induced signal transduction in insulin-producing cells. For this purpose, insulin-producing RINm5F cells were exposed to IL-1 beta (25 units/ml), and the ceramide, ceramide 1-phosphate, sphingomyelin, diacylglycerol, and phosphatidic acid contents of the cells were subsequently determined, It was found that IL-1 beta induced a transient increase (2-5 min) in ceramide and diacylglycerol, which was not paralleled by an increase in ceramide 1-phosphate and phosphatidic acid. A rapid decrease in the sphingomyelin content of the cells was, however, observed. The cell-permeable ceramide analogue N-acetylsphingosine and the phorbol ester phorbol 12-myristate 13-acetate (PMA) both induced the phosphorylation and increased the activities of the protein kinase JNK1 and the transcription factor ATF2. These effects were, however, not as pronounced as those induced by IL-1 beta. The DNA binding activity of transcription factors in nuclear extracts was determined using the electrophoretic mobility shift assay method. Transcription factor binding to the ATF/cAMP-responsive element consensus sequence was increased 4-5-fold by acetylsphingosine, PMA, or IL-1 beta, whereas binding to the CCAAT/enhancer-binding protein and AP-1 elements was found to be only slightly stimulated by these three agents. Binding to the NF-kappa B element was strongly induced by IL-1 beta, but not by acetylsphingosine or PMA. Finally, acetylsphingosine and PMA did not mimic the nitric oxide-inducing effects of IL-1 beta. It is concluded that IL-1 beta-stimulated formation of ceramide and diacylglycerol may contribute to JNK1 and ATF2 transcription factor activation, which may be a necessary (but not sufficient) step in beta-cell nitric-oxide synthase induction.			Welsh, N (corresponding author), UNIV UPPSALA,DEPT MED CELL BIOL,BOX 571,S-75123 UPPSALA,SWEDEN.							BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BENDTZEN K, 1989, AUTOIMMUNITY, V2, P177, DOI 10.3109/08916938909019954; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIGDELI N, 1994, BIOCHEM BIOPH RES CO, V203, P1542, DOI 10.1006/bbrc.1994.2361; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EIZIRIK DL, 1992, FEBS LETT, V308, P249, DOI 10.1016/0014-5793(92)81285-T; EIZIRIK DL, 1995, MOL CELL ENDOCRINOL, V111, P159, DOI 10.1016/0303-7207(95)03561-K; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JOHNS LD, 1994, J IMMUNOL, V152, P5877; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NERUP J, 1988, DIABETES CARE, V11, P16; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SALDEEN J, 1994, BIOCHEM BIOPH RES CO, V203, P149, DOI 10.1006/bbrc.1994.2161; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDLER S, 1989, ENDOCRINOLOGY, V124, P1492, DOI 10.1210/endo-124-3-1492; SANDLER S, 1987, ENDOCRINOLOGY, V121, P1424, DOI 10.1210/endo-121-4-1424; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; SVENSON M, 1988, SCAND J IMMUNOL, V27, P593, DOI 10.1111/j.1365-3083.1988.tb02387.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WELSH N, 1992, BIOCHEM BIOPH RES CO, V182, P333, DOI 10.1016/S0006-291X(05)80149-4; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167; WELSH N, 1994, BIOSCIENCE REP, V14, P43, DOI 10.1007/BF01901637; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689	50	116	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8307	8312		10.1074/jbc.271.14.8307	http://dx.doi.org/10.1074/jbc.271.14.8307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626526	hybrid			2022-12-25	WOS:A1996UD60000066
J	Zhang, YN; Gray, RD				Zhang, YN; Gray, RD			Characterization of folded, intermediate, and unfolded states of recombinant human interstitial collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; CONFORMATIONAL-CHANGES; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; PROTEIN; DENATURATION; STROMELYSIN; ACTIVATION	Recombinant interstitial collagenase (rMMP-1) forms insoluble inclusion bodies when over-expressed in Escherichia coli. We surveyed conditions for renaturation of purified rMMP-1 in 6 M guandine hydrochloride (GdnHCl) and found that optimal folding occurred when the denatured protein was diluted at 4 degrees C in similar to 2 M guanidine HCl, 20% glycerol, 2.5 mM reduced and oxidized glutathione, and 5 mM CaCl2, followed by buffer exchange to remove denaturant and thiols. The circular dichroism spectrum and catalytic constants of the refolded enzyme were similar to those of native MMP-1. The propeptide, which comprises approximately 20% of the mass of proMMP-1, was not required for folding to a functional enzyme. Size exclusion chromatography and spectroscopic measurements at intermediate [GdnHCl] revealed two intermediate folding states. The first, observed at 1 M GdnHCl, had a slightly larger Stokes' radius than the folded protein. CD and fluorescence analysis showed that it contained ordered tryptophan residues with a higher quantum yield than the fully folded state. The second intermediate, which appeared between 2 and 4 M GdnHCl, exhibited properties consistent with the molten globule, including secondary structure, lack of ordered tryptophan, exposed hydrophobic binding sites, and a Stokes' radius between that of the folded and unfolded states.	UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville					NIADDK NIH HHS [AM 39733] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; FISH WW, 1969, J BIOL CHEM, V244, P4989; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; KRUEGER JK, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P189; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIGHT A, 1991, J BIOL CHEM, V266, P7694; LIN YZ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P247, DOI 10.1016/0167-4838(90)90212-X; LOEWENTHAL R, 1991, BIOCHEMISTRY-US, V30, P6775, DOI 10.1021/bi00241a021; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MA YZ, 1991, BIOCHEM J, V277, P207, DOI 10.1042/bj2770207; MACKAY AR, 1992, INVAS METAST, V12, P168; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1992, J BIOL CHEM, V267, P9612; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SELTZER JL, 1977, BIOCHIM BIOPHYS ACTA, V485, P179, DOI 10.1016/0005-2744(77)90205-4; SHALONGO W, 1993, BIOPOLYMERS, V33, P127, DOI 10.1002/bip.360330112; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SPRULINO JC, 1994, PROTEIN-STRUCT FUNCT, V19, P96; STACK MS, 1989, J BIOL CHEM, V264, P4277; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; TERATO K, 1976, BIOCHIM BIOPHYS ACTA, V445, P753, DOI 10.1016/0005-2744(76)90125-X; TOKORO Y, 1972, BIOCHIM BIOPHYS ACTA, V258, P289, DOI 10.1016/0005-2744(72)90986-2; TSOU CL, 1986, TRENDS BIOCHEM SCI, V11, P427, DOI 10.1016/0968-0004(86)90178-7; WANG Z, 1992, PROTEIN SCI, V1, P522; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YAO QZ, 1984, BIOCHEMISTRY-US, V23, P2740, DOI 10.1021/bi00307a032; ZHANG YN, 1993, FASEB J, V7, pA1286	53	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1996	271	14					8015	8021		10.1074/jbc.271.14.8015	http://dx.doi.org/10.1074/jbc.271.14.8015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UD600	8626483	hybrid			2022-12-25	WOS:A1996UD60000023
J	Buday, L; Khwaja, A; Sipeki, S; Farago, A; Downward, J				Buday, L; Khwaja, A; Sipeki, S; Farago, A; Downward, J			Interactions of Cbl with two adaptor proteins, Grb2 and Crk, upon T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; V-CBL; RECEPTOR; ONCOGENE; TRANSFORMATION; GENE; SH2	Several recent studies have demonstrated that Grb2, composed entirely of SH2 and SH3 domains, serves as an adaptor protein in tyrosine kinase signaling pathways. Cbl, the protein product of c-cbl proto-oncogene, has been reported to be phosphorylated on tyrosine residues upon T cell receptor (TCR) engagement. Here we show that in unstimulated Jurkat cells Cbl is co-immunoprecipitated with monoclonal antibody against Grb2. However, in lymphocytes activated through the TCR, Cbl loses its ability to bind to Grb2 precipitated either with anti-Grb2 antibody or with an immobilized tyrosine phosphopeptide, Y1068-P, derived from the epidermal growth factor receptor. In vitro studies confirm that the ability of Cbl to bind to both SH3 domains of Grb2 is strongly reduced in activated T lymphocytes. Investigation of the time course of Cbl dissociation from Grb2 reveals that it is transient and correlates with the kinetics of tyrosine phosphorylation of Cbl. Moreover, Cbl is co-immunoprecipitated with Crk, another SH2/SH3 domain-containing protein, upon TCR stimulation. Tyrosine-phosphorylated Cbl binds exclusively to the SH2 domain of Crk. These results suggest that different adaptor proteins may have different roles in the regulation of c-cbl proto-oncogene product.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Buday, L (corresponding author), SEMMELWEIS UNIV,SCH MED,INST BIOCHEM 1,9 PUSKIN ST,H-1088 BUDAPEST,HUNGARY.		Khwaja, Asim/C-1509-2008	Sipeki, Szabolcs/0000-0002-9678-6743; Downward, Julian/0000-0002-2331-4729				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REIF K, 1994, J BIOL CHEM, V269, P14081; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	33	132	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6159	6163		10.1074/jbc.271.11.6159	http://dx.doi.org/10.1074/jbc.271.11.6159			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626404	hybrid			2022-12-25	WOS:A1996UA36300033
J	FariasEisner, R; Chaudhuri, G; Aeberhard, E; Fukuto, JM				FariasEisner, R; Chaudhuri, G; Aeberhard, E; Fukuto, JM			The chemistry and tumoricidal activity of nitric oxide hydrogen peroxide and the implications to cell resistance susceptibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; ACTIVATED MACROPHAGES; LIPID-PEROXIDATION; SUPEROXIDE; OXYGEN; PEROXYNITRITE; IRON; INHIBITION; GENERATION; OXIDATION	The mechanism of cytotoxicity of the NO donor 3-morpholino-sydnonimine toward a human ovarian cancer cell line (OVCAR) was examined. It was found that the NO-mediated loss of cell viability was dependent on both NO and hydrogen peroxide (H2O2). Somewhat surprisingly, superoxide (O-2(-.)) and its reaction product with NO, peroxynitrite ((OONO)-O--), did not appear to be directly involved in the observed NO-mediated cytotoxicity against this cancer cell line. The toxicity of NO/H2O2 may be due to the production of a potent oxidant formed via a trace metal-, H2O2-, and NO-dependent process. Because the combination of NO and H2O2 was found to be particularly cytotoxic, the effect of NO on cellular defense mechanisms involving H2O2 degradation was investigated. It was found that NO was able to inhibit catalase activity but had no effect on the activity of the glutathione peroxidase (GSHPx)-glutathione reductase system. It might therefore be expected that cells that utilize primarily the GSHPx-glutathione reductase system for degrading H2O2 would be somewhat resistant to the cytotoxic effects of NO. Consistent with this idea, it was found that ebselen, a compound with GSHPx-like activity, was able to protect cells against NO toxicity. Also, lowering endogenous GSHPx activity via selenium depletion resulted in an increased susceptibility of the target cells to NO-mediated toxicity. Thus, a possible NO/H2O2/metal-mediated mechanism for cellular toxicity is presented as well as a possible explanation for cell resistance/susceptibility to this NO-initiated process.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT OBSTET GYNECOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOHN H, 1989, J CARDIOVASC PHARM, V14, pS6, DOI 10.1097/00005344-198914110-00003; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; BROWN GC, 1995, EUR J BIOCHEM, V232, P188, DOI 10.1111/j.1432-1033.1995.tb20798.x; BUSH PA, 1992, BIOCHEM BIOPH RES CO, V185, P960, DOI 10.1016/0006-291X(92)91720-B; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; FARIASEISNER R, 1994, P NATL ACAD SCI USA, V91, P9407, DOI 10.1073/pnas.91.20.9407; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FREEMAN B, 1994, CHEST, V105, pS79, DOI 10.1378/chest.105.3_Supplement.79S; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FUKUTO JM, 1992, BIOCHEM PHARMACOL, V43, P607, DOI 10.1016/0006-2952(92)90584-6; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GWOST D, 1973, INORG CHEM, V12, P2095, DOI 10.1021/ic50127a030; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOCMAN G, 1988, INT J BIOCHEM, V20, P123, DOI 10.1016/0020-711X(88)90475-2; HOSHINO M, 1993, J AM CHEM SOC, V115, P9568, DOI 10.1021/ja00074a023; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Jeffery G. H., 1989, VOGELS TXB QUANTITAT, P394; JULIAN J, 1992, ENDOCRINOLOGY, V130, P68, DOI 10.1210/en.130.1.68; JUN L, 1993, INT J IMMUNOPHARMACO, V15, P429; KAUR H, 1994, METHOD ENZYMOL, V233, P67; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KRONCKE KD, 1993, BIOCHIM BIOPHYS ACTA, V1182, P221, DOI 10.1016/0925-4439(93)90144-P; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEURS R, 1990, EUR J PHARMACOL, V179, P193, DOI 10.1016/0014-2999(90)90418-6; LITTLEJOHN D, 1982, J PHYS CHEM-US, V86, P537, DOI 10.1021/j100393a024; McLafferty FW., 1988, WILEY NBS REGISTRY M, V4; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; NATHAN CF, 1982, FED PROC, V41, P2206; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; ROKUTAN K, 1988, INT ARCH ALLER A IMM, V87, P113, DOI 10.1159/000234660; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SHAW AW, 1977, J CHEM SOC FARAD T 1, V73, P1239, DOI 10.1039/f19777301239; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; VERCELLOTTI GM, 1988, P SOC EXP BIOL MED, V187, P181; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; WEISS SJ, 1982, J CLIN INVEST, V69, P255, DOI 10.1172/JCI110447; Wendel A, 1981, Methods Enzymol, V77, P325; WENDEL A, 1980, ENZYMATIC BASIS DETO, P333, DOI DOI 10.1016/B978-0-12-380001-5.50022-0; WINK DA, 1994, P NATL ACAD SCI USA, V91, P6604, DOI 10.1073/pnas.91.14.6604; WINK DA, 1991, CHEM RES TOXICOL, V4, P510, DOI 10.1021/tx00023a002; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	57	147	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6144	6151		10.1074/jbc.271.11.6144	http://dx.doi.org/10.1074/jbc.271.11.6144			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626402	hybrid			2022-12-25	WOS:A1996UA36300031
J	Kleinert, H; Euchenhofer, C; IhrigBiedert, I; Forstermann, U				Kleinert, H; Euchenhofer, C; IhrigBiedert, I; Forstermann, U			In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of transcription factor NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; SMOOTH-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; DNA-BINDING SUBUNIT; PROTEIN KINASE-A; BACTERIAL LIPOPOLYSACCHARIDE; GLUCOCORTICOIDS INHIBIT; ENDOTHELIAL-CELLS; INTERFERON-GAMMA	Transcription factor NF-kappa B is essential for the induction of nitric oxide synthase (NOS) II (iNOS) by bacterial lipopolysaccharide in murine macrophages (Xie, Q. W., Kashiwabara, Y., and Nathan, C. (1994) J. Biol. Chem. 269, 4705-4708). In 3T3 fibroblasts, agents other than cytokines are efficacious inducers of NOS II expression. In addition to cytokines such as interferon-gamma or tumor necrosis factor-alpha, protein kinase C-stimulating agents such as tetradecanoylphorbol-13-acetate, or cyclic AMP-elevating agents such as forskolin and 8-bromo-cAMP markedly increased NOS II mRNA (measured by S1 nuclease and RNase protection analyses), NOS II protein (determined by Western blotting), and NOS activity (measured by chemiluminescence detection of NO2-). Transforming growth factor-beta 1 (which is an inhibitor of NOS II induction in other cell types) potentiated NOS II mRNA expression produced by all inducing agents listed, whereas dexamethasone, pyrrolidine dithiocarbamate and 3,4-dichloroisocoumarin (inhibitors of NF-kappa B activation) suppressed NOS II mRNA induction in response to all stimulants. In electrophoretic mobility shift assays, nuclear protein extracts from 3T3 cells stimulated with any of the inducing agents significantly slowed the migration of an NF-kappa B-binding oligonucleotide, whereas nuclear extracts from untreated control cells did not. These experiments indicate that NF-kappa B is the key control element for the induction of NOS II in response to at least three different second messenger pathways in 3T3 cells.	UNIV MAINZ,DEPT PHARMACOL,D-55101 MAINZ,GERMANY	Johannes Gutenberg University of Mainz			Kleinert, Hartmut/M-2988-2018	Kleinert, Hartmut/0000-0003-2202-3548				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DING A, 1990, J IMMUNOL, V145, P940; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; EBERHARDT W, 1994, BIOCHEM BIOPH RES CO, V200, P163, DOI 10.1006/bbrc.1994.1429; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILBERT RS, 1993, J CELL PHYSIOL, V157, P128, DOI 10.1002/jcp.1041570117; GILBERT RS, 1993, BIOCHEM BIOPH RES CO, V195, P380, DOI 10.1006/bbrc.1993.2054; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GRILLI M, 1993, INT REV CYTOL, V143, P1; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; IMAI T, 1994, J CLIN INVEST, V93, P543, DOI 10.1172/JCI117005; JUN CD, 1994, J IMMUNOL, V153, P3684; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KLEINERT H, 1996, MOL PHARMACOL, V49, P1; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MESSMER UK, 1994, CELL SIGNAL, V6, P17; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; SALKOWSKI CA, 1992, J IMMUNOL, V149, P4041; SCHINI VB, 1992, EUR J PHARMACOL, V216, P379, DOI 10.1016/0014-2999(92)90434-6; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEISZ A, 1994, J BIOL CHEM, V269, P8324; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	54	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6039	6044		10.1074/jbc.271.11.6039	http://dx.doi.org/10.1074/jbc.271.11.6039			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626388	hybrid			2022-12-25	WOS:A1996UA36300017
J	Steinkuhler, C; Tomei, L; DeFrancesco, R				Steinkuhler, C; Tomei, L; DeFrancesco, R			In vitro activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE NONSTRUCTURAL PROTEINS; NON-B-HEPATITIS; NON-A; POLYPROTEIN; CLEAVAGE; GENOME; ORGANIZATION; PRECURSOR; ENCODES	A recombinant Baculovirus expression system was used for the production of a 20-kDa protein encompassing the hepatitis C virus NS3 protease domain. The protein was purified to apparent homogeneity after detergent extraction of cell homogenates. It was shown to be a monomer in solution and to cleave the in vitro translated precursor proteins NS4A-NS4B and NS5A-N95B, but not the NS4B-NS5A or the NS3-NS4A precursors, The enzyme also cleaved a 20-mer peptide corresponding to the NS4A-NS4B junction with k(cat)/K-m = 174 M(-1) s(-1). Peptides harboring NS4A sequences comprising amino acids 21-54 (Pep4A(21-54)) and 21-34 (Pep4A(21-34)) were found to induce an up to 2.8-fold acceleration of cleavage, Kinetic analysis revealed that this acceleration was due to an increase in k(cat), whereas no significant effect on K-m could be detected, Pep4A(21-54) was also an absolute requirement for cleavage of in vitro translated NS4B-NS5A by the purified protease, From these data we conclude that: (i) the purified protease domain shows substrate specificity and cleavage requirements similar to those previously reported on the basis of transfection experiments, (ii) activation of the purified protease by the NS4A co-factor can be mimicked by synthetic peptide analogs, and (iii) a central hydrophobic region of NS4A with a minimum core of 14 amino acids is responsible for the interaction with NS3.	IST RIC BIOL MOLEC P ANGELETTI POMEZIA,I-00040 ROME,ITALY				De Francesco, Raffaele/J-6003-2012	De Francesco, Raffaele/0000-0001-8754-5123				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DARKE PL, 1994, J BIOL CHEM, V269, P18708; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; DSOUZA EDA, 1995, J GEN VIROL, V76, P1729, DOI 10.1099/0022-1317-76-7-1729; ECKART MR, 1993, BIOCHEM BIOPH RES CO, V192, P399, DOI 10.1006/bbrc.1993.1429; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; KAKIUCHI N, 1995, BIOCHEM BIOPH RES CO, V210, P1059, DOI 10.1006/bbrc.1995.1764; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KOMODA Y, 1994, GENE, V145, P221; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIZZI E, 1994, P NATL ACAD SCI USA, V91, P888, DOI 10.1073/pnas.91.3.888; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; SATOH S, 1995, J VIROL, V69, P4255, DOI 10.1128/JVI.69.7.4255-4260.1995; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993	32	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1996	271	11					6367	6373		10.1074/jbc.271.11.6367	http://dx.doi.org/10.1074/jbc.271.11.6367			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UA363	8626434	hybrid			2022-12-25	WOS:A1996UA36300063
